# Furukawa_2007_Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia.

Cochrane
Library

Cochrane Database of Systematic Reviews

Combined psychotherapy plus antidepressants for panic disorder
with or without agoraphobia (Review)

Furukawa TA, Watanabe N, Churchill R

Furukawa TA, Watanabe N, Churchill R. 
Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia. 
Cochrane Database of Systematic Reviews 2007, Issue 1. Art. No.: CD004364. 
DOI: 10.1002/14651858.CD004364.pub2.

www.cochranelibrary.com

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

T A B L E   O F   C O N T E N T S

HEADER.........................................................................................................................................................................................................
ABSTRACT.....................................................................................................................................................................................................
PLAIN LANGUAGE SUMMARY.......................................................................................................................................................................
BACKGROUND..............................................................................................................................................................................................
OBJECTIVES..................................................................................................................................................................................................
METHODS.....................................................................................................................................................................................................
RESULTS........................................................................................................................................................................................................
Figure 1..................................................................................................................................................................................................
Figure 2..................................................................................................................................................................................................
DISCUSSION..................................................................................................................................................................................................
AUTHORS' CONCLUSIONS...........................................................................................................................................................................
ACKNOWLEDGEMENTS................................................................................................................................................................................
REFERENCES................................................................................................................................................................................................
CHARACTERISTICS OF STUDIES..................................................................................................................................................................
DATA AND ANALYSES....................................................................................................................................................................................
Analysis  1.1.  Comparison  1  PD+/-AGORAPHOBIA:  Psychotherapy+Antidepressant  vs  Antidepressant  alone,  Outcome  1
Response at 2-4 months.......................................................................................................................................................................
Analysis  1.2.  Comparison  1  PD+/-AGORAPHOBIA:  Psychotherapy+Antidepressant  vs  Antidepressant  alone,  Outcome  2
Remission at 2-4 months......................................................................................................................................................................
Analysis 1.3. Comparison 1 PD+/-AGORAPHOBIA: Psychotherapy+Antidepressant vs Antidepressant alone, Outcome 3 Global
severity at 2-4 months..........................................................................................................................................................................
Analysis  1.4.  Comparison  1  PD+/-AGORAPHOBIA:  Psychotherapy+Antidepressant  vs  Antidepressant  alone,  Outcome  4
Frequency of panic attacks at 2-4 months..........................................................................................................................................
Analysis 1.5. Comparison 1 PD+/-AGORAPHOBIA: Psychotherapy+Antidepressant vs Antidepressant alone, Outcome 5 Phobic
avoidance at 2-4 months......................................................................................................................................................................
Analysis 1.6. Comparison 1 PD+/-AGORAPHOBIA: Psychotherapy+Antidepressant vs Antidepressant alone, Outcome 6 General
anxiety at 2-4 months...........................................................................................................................................................................
Analysis  1.7.  Comparison  1  PD+/-AGORAPHOBIA:  Psychotherapy+Antidepressant  vs  Antidepressant  alone,  Outcome  7
Depression at 2-4 months....................................................................................................................................................................
Analysis 1.8. Comparison 1 PD+/-AGORAPHOBIA: Psychotherapy+Antidepressant vs Antidepressant alone, Outcome 8 Social
malfunctioning at 2-4 months.............................................................................................................................................................
Analysis 1.9. Comparison 1 PD+/-AGORAPHOBIA: Psychotherapy+Antidepressant vs Antidepressant alone, Outcome 9 Dropouts
for any reason within 2-4 months.......................................................................................................................................................
Analysis  1.10.  Comparison  1  PD+/-AGORAPHOBIA:  Psychotherapy+Antidepressant  vs  Antidepressant  alone,  Outcome  10
Dropouts due to side effects within 2-4 months................................................................................................................................
Analysis  1.11.  Comparison  1  PD+/-AGORAPHOBIA:  Psychotherapy+Antidepressant  vs  Antidepressant  alone,  Outcome  11
Response/remission on continued treatment....................................................................................................................................
Analysis  1.12.  Comparison  1  PD+/-AGORAPHOBIA:  Psychotherapy+Antidepressant  vs  Antidepressant  alone,  Outcome  12
Global/Avoidance/Panic on continued treatment..............................................................................................................................
Analysis  1.13.  Comparison  1  PD+/-AGORAPHOBIA:  Psychotherapy+Antidepressant  vs  Antidepressant  alone,  Outcome  13
Dropouts for any reason on continued treatment..............................................................................................................................
Analysis  1.14.  Comparison  1  PD+/-AGORAPHOBIA:  Psychotherapy+Antidepressant  vs  Antidepressant  alone,  Outcome  14
Response/remission immediately after treatment discontinuation..................................................................................................
Analysis  1.15.  Comparison  1  PD+/-AGORAPHOBIA:  Psychotherapy+Antidepressant  vs  Antidepressant  alone,  Outcome  15
Global/Avoidance/Panic immediately after treatment discontinuation............................................................................................
Analysis  1.16.  Comparison  1  PD+/-AGORAPHOBIA:  Psychotherapy+Antidepressant  vs  Antidepressant  alone,  Outcome  16
Response/remission 6-24 months after treatment discontinuation..................................................................................................
Analysis  1.17.  Comparison  1  PD+/-AGORAPHOBIA:  Psychotherapy+Antidepressant  vs  Antidepressant  alone,  Outcome  17
Global/Avoidance/Panic 6-24 months after treatment discontinuation...........................................................................................
Analysis 2.1. Comparison 2 PD+/-AGORAPHOBIA: Psychotherapy+Antidepressant vs Psychotherapy alone, Outcome 1 Response
at 2-4 months........................................................................................................................................................................................
Analysis  2.2.  Comparison  2  PD+/-AGORAPHOBIA:  Psychotherapy+Antidepressant  vs  Psychotherapy  alone,  Outcome  2
Remission at 2-4 months......................................................................................................................................................................

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

1
1
2
3
3
3
6
9
11
12
13
14
15
21
43
47

48

49

49

50

51

51

52

53

53

54

55

56

56

57

57

58

61

62

i

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 2.3. Comparison 2 PD+/-AGORAPHOBIA: Psychotherapy+Antidepressant vs Psychotherapy alone, Outcome 3 Global
severity at 2-4 months..........................................................................................................................................................................
Analysis  2.4.  Comparison  2  PD+/-AGORAPHOBIA:  Psychotherapy+Antidepressant  vs  Psychotherapy  alone,  Outcome  4
Frequency of panic attacks at 2-4 months..........................................................................................................................................
Analysis 2.5. Comparison 2 PD+/-AGORAPHOBIA: Psychotherapy+Antidepressant vs Psychotherapy alone, Outcome 5 Phobic
avoidance at 2-4 months......................................................................................................................................................................
Analysis 2.6. Comparison 2 PD+/-AGORAPHOBIA: Psychotherapy+Antidepressant vs Psychotherapy alone, Outcome 6 General
anxiety at 2-4 months...........................................................................................................................................................................
Analysis  2.7.  Comparison  2  PD+/-AGORAPHOBIA:  Psychotherapy+Antidepressant  vs  Psychotherapy  alone,  Outcome  7
Depression at 2-4 months....................................................................................................................................................................
Analysis 2.8. Comparison 2 PD+/-AGORAPHOBIA: Psychotherapy+Antidepressant vs Psychotherapy alone, Outcome 8 Social
malfunctioning at 2-4 months.............................................................................................................................................................
Analysis 2.9. Comparison 2 PD+/-AGORAPHOBIA: Psychotherapy+Antidepressant vs Psychotherapy alone, Outcome 9 Dropouts
for any reason within 2-4 months.......................................................................................................................................................
Analysis  2.10.  Comparison  2  PD+/-AGORAPHOBIA:  Psychotherapy+Antidepressant  vs  Psychotherapy  alone,  Outcome  10
Dropouts due to side effects within 2-4 months................................................................................................................................
Analysis  2.11.  Comparison  2  PD+/-AGORAPHOBIA:  Psychotherapy+Antidepressant  vs  Psychotherapy  alone,  Outcome  11
Response/remission on continued treatment....................................................................................................................................
Analysis  2.12.  Comparison  2  PD+/-AGORAPHOBIA:  Psychotherapy+Antidepressant  vs  Psychotherapy  alone,  Outcome  12
GlobalAvoidance/Panic on continued treatment................................................................................................................................
Analysis  2.13.  Comparison  2  PD+/-AGORAPHOBIA:  Psychotherapy+Antidepressant  vs  Psychotherapy  alone,  Outcome  13
Dropouts for any reason on continued treatment..............................................................................................................................
Analysis  2.14.  Comparison  2  PD+/-AGORAPHOBIA:  Psychotherapy+Antidepressant  vs  Psychotherapy  alone,  Outcome  14
Response/remission 6-24 months after treatment discontinuation..................................................................................................
Analysis 2.15. Comparison 2 PD+/-AGORAPHOBIA: Psychotherapy+Antidepressant vs Psychotherapy alone, Outcome 15 Global/
Avoidance/Panic 6-24 months after treatment discontinuation........................................................................................................
Analysis  3.1.  Comparison  3  PD+/-AGORAPHOBIA:  Psychotherapy+Antidepressant  vs  Psychotherapy+Placebo,  Outcome  1
Response at 2-4 months.......................................................................................................................................................................
Analysis  3.2.  Comparison  3  PD+/-AGORAPHOBIA:  Psychotherapy+Antidepressant  vs  Psychotherapy+Placebo,  Outcome  2
Remission at 2-4 months......................................................................................................................................................................
Analysis 3.3. Comparison 3 PD+/-AGORAPHOBIA: Psychotherapy+Antidepressant vs Psychotherapy+Placebo, Outcome 3 Global
severity at 2-4 months..........................................................................................................................................................................
Analysis  3.4.  Comparison  3  PD+/-AGORAPHOBIA:  Psychotherapy+Antidepressant  vs  Psychotherapy+Placebo,  Outcome  4
Frequency of panic attacks at 2-4 months..........................................................................................................................................
Analysis  3.5.  Comparison  3  PD+/-AGORAPHOBIA:  Psychotherapy+Antidepressant  vs  Psychotherapy+Placebo,  Outcome  5
Phobic avoidance at 2-4 months.........................................................................................................................................................
Analysis  3.6.  Comparison  3  PD+/-AGORAPHOBIA:  Psychotherapy+Antidepressant  vs  Psychotherapy+Placebo,  Outcome  6
General anxiety at 2-4 months.............................................................................................................................................................
Analysis  3.7.  Comparison  3  PD+/-AGORAPHOBIA:  Psychotherapy+Antidepressant  vs  Psychotherapy+Placebo,  Outcome  7
Depression at 2-4 months....................................................................................................................................................................
Analysis 3.8. Comparison 3 PD+/-AGORAPHOBIA: Psychotherapy+Antidepressant vs Psychotherapy+Placebo, Outcome 8 Social
malfunctioning at 2-4 months.............................................................................................................................................................
Analysis  3.9.  Comparison  3  PD+/-AGORAPHOBIA:  Psychotherapy+Antidepressant  vs  Psychotherapy+Placebo,  Outcome  9
Dropouts for any reason within 2-4 months.......................................................................................................................................
Analysis  3.10.  Comparison  3  PD+/-AGORAPHOBIA:  Psychotherapy+Antidepressant  vs  Psychotherapy+Placebo,  Outcome  10
Dropouts due to side effects within 2-4 months................................................................................................................................
Analysis  3.11.  Comparison  3  PD+/-AGORAPHOBIA:  Psychotherapy+Antidepressant  vs  Psychotherapy+Placebo,  Outcome  11
Response/remission on continued treatment....................................................................................................................................
Analysis  3.12.  Comparison  3  PD+/-AGORAPHOBIA:  Psychotherapy+Antidepressant  vs  Psychotherapy+Placebo,  Outcome  12
Global/Avoidance/Panic on continued treatment..............................................................................................................................
Analysis  3.13.  Comparison  3  PD+/-AGORAPHOBIA:  Psychotherapy+Antidepressant  vs  Psychotherapy+Placebo,  Outcome  13
Dropouts for any reason on continued treatment..............................................................................................................................
Analysis  3.14.  Comparison  3  PD+/-AGORAPHOBIA:  Psychotherapy+Antidepressant  vs  Psychotherapy+Placebo,  Outcome  14
Response/remission 6-24 months after treatment discontinuation..................................................................................................
Analysis  3.15.  Comparison  3  PD+/-AGORAPHOBIA:  Psychotherapy+Antidepressant  vs  Psychotherapy+Placebo,  Outcome  15
Global/Avoidance/Panic 6-24 months after treatment discontinuation...........................................................................................

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

63

63

64

64

65

65

66

66

67

67

68

68

69

72

73

74

74

75

76

76

77

78

78

79

80

80

81

81

ii

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis  4.1.  Comparison  4  PD+/-AGORAPHOBIA:  Psychotherapy+Antidepressant  vs  Psychotherapy  alone  or  +Placebo,
Outcome 1 Response at 2-4 months...................................................................................................................................................
Analysis  4.2.  Comparison  4  PD+/-AGORAPHOBIA:  Psychotherapy+Antidepressant  vs  Psychotherapy  alone  or  +Placebo,
Outcome 2 Remission at 2-4 months..................................................................................................................................................
Analysis  4.3.  Comparison  4  PD+/-AGORAPHOBIA:  Psychotherapy+Antidepressant  vs  Psychotherapy  alone  or  +Placebo,
Outcome 3 Global severity at 2-4 months..........................................................................................................................................
Analysis  4.4.  Comparison  4  PD+/-AGORAPHOBIA:  Psychotherapy+Antidepressant  vs  Psychotherapy  alone  or  +Placebo,
Outcome 4 Frequency of panic attacks at 2-4 months......................................................................................................................
Analysis  4.5.  Comparison  4  PD+/-AGORAPHOBIA:  Psychotherapy+Antidepressant  vs  Psychotherapy  alone  or  +Placebo,
Outcome 5 Phobic avoidance at 2-4 months......................................................................................................................................
Analysis  4.6.  Comparison  4  PD+/-AGORAPHOBIA:  Psychotherapy+Antidepressant  vs  Psychotherapy  alone  or  +Placebo,
Outcome 6 General anxiety at 2-4 months.........................................................................................................................................
Analysis  4.7.  Comparison  4  PD+/-AGORAPHOBIA:  Psychotherapy+Antidepressant  vs  Psychotherapy  alone  or  +Placebo,
Outcome 7 Depression at 2-4 months.................................................................................................................................................
Analysis  4.8.  Comparison  4  PD+/-AGORAPHOBIA:  Psychotherapy+Antidepressant  vs  Psychotherapy  alone  or  +Placebo,
Outcome 8 Social malfunctioning at 2-4 months...............................................................................................................................
Analysis  4.9.  Comparison  4  PD+/-AGORAPHOBIA:  Psychotherapy+Antidepressant  vs  Psychotherapy  alone  or  +Placebo,
Outcome 9 Dropouts for any reason within 2-4 months....................................................................................................................
Analysis  4.10.  Comparison  4  PD+/-AGORAPHOBIA:  Psychotherapy+Antidepressant  vs  Psychotherapy  alone  or  +Placebo,
Outcome 10 Dropouts due to side effects within 2-4 months...........................................................................................................
Analysis  4.11.  Comparison  4  PD+/-AGORAPHOBIA:  Psychotherapy+Antidepressant  vs  Psychotherapy  alone  or  +Placebo,
Outcome 11 Response/remission on continued treatment...............................................................................................................
Analysis  4.12.  Comparison  4  PD+/-AGORAPHOBIA:  Psychotherapy+Antidepressant  vs  Psychotherapy  alone  or  +Placebo,
Outcome 12 Global/Avoidance/Panic on continued treatment.........................................................................................................
Analysis  4.13.  Comparison  4  PD+/-AGORAPHOBIA:  Psychotherapy+Antidepressant  vs  Psychotherapy  alone  or  +Placebo,
Outcome 13 Dropouts for any reason on continued treatment........................................................................................................
Analysis  4.14.  Comparison  4  PD+/-AGORAPHOBIA:  Psychotherapy+Antidepressant  vs  Psychotherapy  alone  or  +Placebo,
Outcome 14 Response/remission 6-24 months after treatment discontinuation.............................................................................
Analysis  4.15.  Comparison  4  PD+/-AGORAPHOBIA:  Psychotherapy+Antidepressant  vs  Psychotherapy  alone  or  +Placebo,
Outcome 15 Global/Avoidance/Panic 6-24 months after treatment discontinuation......................................................................
Analysis 5.1. Comparison 5 SUBGROUP2: TCA: Psychotherapy+Antidepressant vs Antidepressant alone, Outcome 1 Response
at 2-4 months........................................................................................................................................................................................
Analysis 5.2. Comparison 5 SUBGROUP2: TCA: Psychotherapy+Antidepressant vs Antidepressant alone, Outcome 2 Remission
at 2-4 months........................................................................................................................................................................................
Analysis  5.3.  Comparison  5  SUBGROUP2:  TCA:  Psychotherapy+Antidepressant  vs  Antidepressant  alone,  Outcome  3  Global
severity at 2-4 months..........................................................................................................................................................................
Analysis 5.4. Comparison 5 SUBGROUP2: TCA: Psychotherapy+Antidepressant vs Antidepressant alone, Outcome 4 Frequency
of panic attacks at 2-4 months............................................................................................................................................................
Analysis  5.5.  Comparison  5  SUBGROUP2:  TCA:  Psychotherapy+Antidepressant  vs  Antidepressant  alone,  Outcome  5  Phobic
avoidance at 2-4 months......................................................................................................................................................................
Analysis 5.6. Comparison 5 SUBGROUP2: TCA: Psychotherapy+Antidepressant vs Antidepressant alone, Outcome 6 General
anxiety at 2-4 months...........................................................................................................................................................................
Analysis 5.7. Comparison 5 SUBGROUP2: TCA: Psychotherapy+Antidepressant vs Antidepressant alone, Outcome 7 Depression
at 2-4 months........................................................................................................................................................................................
Analysis  5.8.  Comparison  5  SUBGROUP2:  TCA:  Psychotherapy+Antidepressant  vs  Antidepressant  alone,  Outcome  8  Social
functioning at 2-4 months....................................................................................................................................................................
Analysis 5.9. Comparison 5 SUBGROUP2: TCA: Psychotherapy+Antidepressant vs Antidepressant alone, Outcome 9 Dropouts
for any reason within 2-4 months.......................................................................................................................................................
Analysis 5.10. Comparison 5 SUBGROUP2: TCA: Psychotherapy+Antidepressant vs Antidepressant alone, Outcome 10 Dropouts
due to side effects within 2-4 months.................................................................................................................................................
Analysis  5.11.  Comparison  5  SUBGROUP2:  TCA:  Psychotherapy+Antidepressant  vs  Antidepressant  alone,  Outcome  11
Response/remission on continued treatment....................................................................................................................................
Analysis 5.12. Comparison 5 SUBGROUP2: TCA: Psychotherapy+Antidepressant vs Antidepressant alone, Outcome 12 Global/
Avoidance/Panic on continued treatment..........................................................................................................................................
Analysis 5.13. Comparison 5 SUBGROUP2: TCA: Psychotherapy+Antidepressant vs Antidepressant alone, Outcome 13 Dropouts
for any reason on continued treatment..............................................................................................................................................

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

84

85

86

87

88

88

89

90

91

91

92

93

93

94

95

99

100

101

101

102

103

103

104

104

105

106

107

107

iii

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis  5.16.  Comparison  5  SUBGROUP2:  TCA:  Psychotherapy+Antidepressant  vs  Antidepressant  alone,  Outcome  16
Response/remission 6-24 months after treatment discontinuation..................................................................................................
Analysis 5.17. Comparison 5 SUBGROUP2: TCA: Psychotherapy+Antidepressant vs Antidepressant alone, Outcome 17 Global/
Avoidance/Panic 6-24 months after treatment discontinuation........................................................................................................
Analysis 6.1. Comparison 6 SUBGROUP2: TCA: Psychotherapy+Antidepressant vs Psychotherapy alone or +Placebo, Outcome
1 Response at 2-4 months....................................................................................................................................................................
Analysis 6.2. Comparison 6 SUBGROUP2: TCA: Psychotherapy+Antidepressant vs Psychotherapy alone or +Placebo, Outcome
2 Remission at 2-4 months...................................................................................................................................................................
Analysis 6.3. Comparison 6 SUBGROUP2: TCA: Psychotherapy+Antidepressant vs Psychotherapy alone or +Placebo, Outcome
3 Global severity at 2-4 months...........................................................................................................................................................
Analysis 6.4. Comparison 6 SUBGROUP2: TCA: Psychotherapy+Antidepressant vs Psychotherapy alone or +Placebo, Outcome
4 Frequency of panic attacks at 2-4 months.......................................................................................................................................
Analysis 6.5. Comparison 6 SUBGROUP2: TCA: Psychotherapy+Antidepressant vs Psychotherapy alone or +Placebo, Outcome
5 Phobic avoidance at 2-4 months......................................................................................................................................................
Analysis 6.6. Comparison 6 SUBGROUP2: TCA: Psychotherapy+Antidepressant vs Psychotherapy alone or +Placebo, Outcome
6 General anxiety at 2-4 months..........................................................................................................................................................
Analysis 6.7. Comparison 6 SUBGROUP2: TCA: Psychotherapy+Antidepressant vs Psychotherapy alone or +Placebo, Outcome
7 Depression at 2-4 months.................................................................................................................................................................
Analysis 6.8. Comparison 6 SUBGROUP2: TCA: Psychotherapy+Antidepressant vs Psychotherapy alone or +Placebo, Outcome
8 Social malfunctioning at 2-4 months...............................................................................................................................................
Analysis 6.9. Comparison 6 SUBGROUP2: TCA: Psychotherapy+Antidepressant vs Psychotherapy alone or +Placebo, Outcome
9 Dropouts for any reason within 2-4 months....................................................................................................................................
Analysis 6.10. Comparison 6 SUBGROUP2: TCA: Psychotherapy+Antidepressant vs Psychotherapy alone or +Placebo, Outcome
10 Dropouts due to side effects within 2-4 months...........................................................................................................................
Analysis 6.11. Comparison 6 SUBGROUP2: TCA: Psychotherapy+Antidepressant vs Psychotherapy alone or +Placebo, Outcome
11 Response/remission on continued treatment...............................................................................................................................
Analysis 6.12. Comparison 6 SUBGROUP2: TCA: Psychotherapy+Antidepressant vs Psychotherapy alone or +Placebo, Outcome
12 Global/Avoidance/Panic on continued treatment.........................................................................................................................
Analysis 6.13. Comparison 6 SUBGROUP2: TCA: Psychotherapy+Antidepressant vs Psychotherapy alone or +Placebo, Outcome
13 Dropouts for any reason on continued treatment.........................................................................................................................
Analysis 6.18. Comparison 6 SUBGROUP2: TCA: Psychotherapy+Antidepressant vs Psychotherapy alone or +Placebo, Outcome
18 Response 6-24 months after treatment discontinuation..............................................................................................................
Analysis 6.19. Comparison 6 SUBGROUP2: TCA: Psychotherapy+Antidepressant vs Psychotherapy alone or +Placebo, Outcome
19 Global/Avoidance/Panic 6-24 months after treatment discontinuation.......................................................................................
Analysis 7.1. Comparison 7 SUBGROUP2: SSRI: Psychotherapy+Antidepressant vs Antidepressant alone, Outcome 1 Response
at 2-4 months........................................................................................................................................................................................
Analysis 7.2. Comparison 7 SUBGROUP2: SSRI: Psychotherapy+Antidepressant vs Antidepressant alone, Outcome 2 Remission
at 2-4 months........................................................................................................................................................................................
Analysis  7.3.  Comparison  7  SUBGROUP2:  SSRI:  Psychotherapy+Antidepressant  vs  Antidepressant  alone,  Outcome  3  Global
severity at 2-4 months..........................................................................................................................................................................
Analysis 7.4. Comparison 7 SUBGROUP2: SSRI: Psychotherapy+Antidepressant vs Antidepressant alone, Outcome 4 Frequency
of panic attacks at 2-4 months............................................................................................................................................................
Analysis  7.5.  Comparison  7  SUBGROUP2:  SSRI:  Psychotherapy+Antidepressant  vs  Antidepressant  alone,  Outcome  5  Phobic
avoidance at 2-4 months......................................................................................................................................................................
Analysis 7.6. Comparison 7 SUBGROUP2: SSRI: Psychotherapy+Antidepressant vs Antidepressant alone, Outcome 6 General
anxiety at 2-4 months...........................................................................................................................................................................
Analysis 7.7. Comparison 7 SUBGROUP2: SSRI: Psychotherapy+Antidepressant vs Antidepressant alone, Outcome 7 Depression
at 2-4 months........................................................................................................................................................................................
Analysis  7.8.  Comparison  7  SUBGROUP2:  SSRI:  Psychotherapy+Antidepressant  vs  Antidepressant  alone,  Outcome  8  Social
functioning at 2-4 months....................................................................................................................................................................
Analysis 7.9. Comparison 7 SUBGROUP2: SSRI: Psychotherapy+Antidepressant vs Antidepressant alone, Outcome 9 Dropouts
for any reason within 2-4 months.......................................................................................................................................................
Analysis 7.10. Comparison 7 SUBGROUP2: SSRI: Psychotherapy+Antidepressant vs Antidepressant alone, Outcome 10 Dropouts
due to side effects within 2-4 months.................................................................................................................................................
Analysis  7.11.  Comparison  7  SUBGROUP2:  SSRI:  Psychotherapy+Antidepressant  vs  Antidepressant  alone,  Outcome  11
Response/remission on continued treatment....................................................................................................................................

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

108

109

112

113

113

114

114

115

116

116

117

118

118

119

119

120

121

125

126

126

127

128

128

129

129

130

131

131

iv

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 7.12. Comparison 7 SUBGROUP2: SSRI: Psychotherapy+Antidepressant vs Antidepressant alone, Outcome 12 Global/
Avoidance/Panic on continued treatment..........................................................................................................................................
Analysis  7.14.  Comparison  7  SUBGROUP2:  SSRI:  Psychotherapy+Antidepressant  vs  Antidepressant  alone,  Outcome  14
Response/remission immediately after treatment discontinuation..................................................................................................
Analysis 7.15. Comparison 7 SUBGROUP2: SSRI: Psychotherapy+Antidepressant vs Antidepressant alone, Outcome 15 Global/
Avoidance/Panic immediately after treatment discontinuation........................................................................................................
Analysis  7.16.  Comparison  7  SUBGROUP2:  SSRI:  Psychotherapy+Antidepressant  vs  Antidepressant  alone,  Outcome  16
Response/remission 6-24 months after treatment discontinuation..................................................................................................
Analysis 8.1. Comparison 8 SUBGROUP2: SSRI: Psychotherapy+Antidepressant vs Psychotherapy alone or +Placebo, Outcome
1 Response at 2-4 months....................................................................................................................................................................
Analysis 8.2. Comparison 8 SUBGROUP2: SSRI: Psychotherapy+Antidepressant vs Psychotherapy alone or +Placebo, Outcome
2 Remission at 2-4 months...................................................................................................................................................................
Analysis 8.3. Comparison 8 SUBGROUP2: SSRI: Psychotherapy+Antidepressant vs Psychotherapy alone or +Placebo, Outcome
3 Global severity at 2-4 months...........................................................................................................................................................
Analysis 8.4. Comparison 8 SUBGROUP2: SSRI: Psychotherapy+Antidepressant vs Psychotherapy alone or +Placebo, Outcome
4 Frequency of panic attacks at 2-4 months.......................................................................................................................................
Analysis 8.5. Comparison 8 SUBGROUP2: SSRI: Psychotherapy+Antidepressant vs Psychotherapy alone or +Placebo, Outcome
5 Phobic avoidance at 2-4 months......................................................................................................................................................
Analysis 8.6. Comparison 8 SUBGROUP2: SSRI: Psychotherapy+Antidepressant vs Psychotherapy alone or +Placebo, Outcome
6 General anxiety at 2-4 months..........................................................................................................................................................
Analysis 8.7. Comparison 8 SUBGROUP2: SSRI: Psychotherapy+Antidepressant vs Psychotherapy alone or +Placebo, Outcome
7 Depression at 2-4 months.................................................................................................................................................................
Analysis 8.8. Comparison 8 SUBGROUP2: SSRI: Psychotherapy+Antidepressant vs Psychotherapy alone or +Placebo, Outcome
8 Social malfunctioning at 2-4 months...............................................................................................................................................
Analysis 8.9. Comparison 8 SUBGROUP2: SSRI: Psychotherapy+Antidepressant vs Psychotherapy alone or +Placebo, Outcome
9 Dropouts for any reason within 2-4 months....................................................................................................................................
Analysis 8.10. Comparison 8 SUBGROUP2: SSRI: Psychotherapy+Antidepressant vs Psychotherapy alone or +Placebo, Outcome
10 Dropouts due to side effects within 2-4 months...........................................................................................................................
Analysis 8.13. Comparison 8 SUBGROUP2: SSRI: Psychotherapy+Antidepressant vs Psychotherapy alone or +Placebo, Outcome
13 Dropouts for any reason on continued treatment.........................................................................................................................
Analysis 8.18. Comparison 8 SUBGROUP2: SSRI: Psychotherapy+Antidepressant vs Psychotherapy alone or +Placebo, Outcome
18 Response 6-24 months after treatment discontinuation..............................................................................................................
Analysis 8.19. Comparison 8 SUBGROUP2: SSRI: Psychotherapy+Antidepressant vs Psychotherapy alone or +Placebo, Outcome
19 Global/Avoidance/Panic 6-24 months after treatment discontinuation.......................................................................................
Analysis  9.1.  Comparison  9  SUBGROUP3:  100%agoraphobia:  Psychotherapy+Antidepressant  vs  Antidepressant  alone,
Outcome 1 Response at 2-4 months...................................................................................................................................................
Analysis  9.2.  Comparison  9  SUBGROUP3:  100%agoraphobia:  Psychotherapy+Antidepressant  vs  Antidepressant  alone,
Outcome 2 Remission at 2-4 months..................................................................................................................................................
Analysis  9.3.  Comparison  9  SUBGROUP3:  100%agoraphobia:  Psychotherapy+Antidepressant  vs  Antidepressant  alone,
Outcome 3 Global severity at 2-4 months..........................................................................................................................................
Analysis  9.4.  Comparison  9  SUBGROUP3:  100%agoraphobia:  Psychotherapy+Antidepressant  vs  Antidepressant  alone,
Outcome 4 Frequency of panic attacks at 2-4 months......................................................................................................................
Analysis  9.5.  Comparison  9  SUBGROUP3:  100%agoraphobia:  Psychotherapy+Antidepressant  vs  Antidepressant  alone,
Outcome 5 Phobic avoidance at 2-4 months......................................................................................................................................
Analysis  9.6.  Comparison  9  SUBGROUP3:  100%agoraphobia:  Psychotherapy+Antidepressant  vs  Antidepressant  alone,
Outcome 6 General anxiety at 2-4 months.........................................................................................................................................
Analysis  9.7.  Comparison  9  SUBGROUP3:  100%agoraphobia:  Psychotherapy+Antidepressant  vs  Antidepressant  alone,
Outcome 7 Depression at 2-4 months.................................................................................................................................................
Analysis  9.8.  Comparison  9  SUBGROUP3:  100%agoraphobia:  Psychotherapy+Antidepressant  vs  Antidepressant  alone,
Outcome 8 Social functioning at 2-4 months.....................................................................................................................................
Analysis  9.9.  Comparison  9  SUBGROUP3:  100%agoraphobia:  Psychotherapy+Antidepressant  vs  Antidepressant  alone,
Outcome 9 Dropouts for any reason within 2-4 months....................................................................................................................
Analysis  9.10.  Comparison  9  SUBGROUP3:  100%agoraphobia:  Psychotherapy+Antidepressant  vs  Antidepressant  alone,
Outcome 10 Dropouts due to side effects within 2-4 months...........................................................................................................
Analysis  9.11.  Comparison  9  SUBGROUP3:  100%agoraphobia:  Psychotherapy+Antidepressant  vs  Antidepressant  alone,
Outcome 11 Response/remission on continued treatment...............................................................................................................

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

132

132

133

134

137

138

138

139

139

140

140

141

141

142

143

143

144

148

149

150

150

151

152

152

153

153

154

155

v

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis  9.12.  Comparison  9  SUBGROUP3:  100%agoraphobia:  Psychotherapy+Antidepressant  vs  Antidepressant  alone,
Outcome 12 Global/Avoidance/Panic on continued treatment.........................................................................................................
Analysis  9.13.  Comparison  9  SUBGROUP3:  100%agoraphobia:  Psychotherapy+Antidepressant  vs  Antidepressant  alone,
Outcome 13 Dropouts for any reason on continued treatment........................................................................................................
Analysis  9.16.  Comparison  9  SUBGROUP3:  100%agoraphobia:  Psychotherapy+Antidepressant  vs  Antidepressant  alone,
Outcome 16 Response/remission 6-24 months after treatment discontinuation.............................................................................
Analysis  10.1.  Comparison  10  SUBGROUP3:  100%agoraphobia:  Psychotherapy+Antidepressant  vs  Psychotherapy  alone  or
+Placebo, Outcome 1 Response at 2-4 months..................................................................................................................................
Analysis  10.2.  Comparison  10  SUBGROUP3:  100%agoraphobia:  Psychotherapy+Antidepressant  vs  Psychotherapy  alone  or
+Placebo, Outcome 2 Remission at 2-4 months.................................................................................................................................
Analysis  10.3.  Comparison  10  SUBGROUP3:  100%agoraphobia:  Psychotherapy+Antidepressant  vs  Psychotherapy  alone  or
+Placebo, Outcome 3 Global severity at 2-4 months.........................................................................................................................
Analysis  10.4.  Comparison  10  SUBGROUP3:  100%agoraphobia:  Psychotherapy+Antidepressant  vs  Psychotherapy  alone  or
+Placebo, Outcome 4 Frequency of panic attacks at 2-4 months.....................................................................................................
Analysis  10.5.  Comparison  10  SUBGROUP3:  100%agoraphobia:  Psychotherapy+Antidepressant  vs  Psychotherapy  alone  or
+Placebo, Outcome 5 Phobic avoidance at 2-4 months....................................................................................................................
Analysis  10.6.  Comparison  10  SUBGROUP3:  100%agoraphobia:  Psychotherapy+Antidepressant  vs  Psychotherapy  alone  or
+Placebo, Outcome 6 General anxiety at 2-4 months........................................................................................................................
Analysis  10.7.  Comparison  10  SUBGROUP3:  100%agoraphobia:  Psychotherapy+Antidepressant  vs  Psychotherapy  alone  or
+Placebo, Outcome 7 Depression at 2-4 months...............................................................................................................................
Analysis  10.8.  Comparison  10  SUBGROUP3:  100%agoraphobia:  Psychotherapy+Antidepressant  vs  Psychotherapy  alone  or
+Placebo, Outcome 8 Social malfunctioning at 2-4 months..............................................................................................................
Analysis  10.9.  Comparison  10  SUBGROUP3:  100%agoraphobia:  Psychotherapy+Antidepressant  vs  Psychotherapy  alone  or
+Placebo, Outcome 9 Dropouts for any reason within 2-4 months...................................................................................................
Analysis  10.10.  Comparison  10  SUBGROUP3:  100%agoraphobia:  Psychotherapy+Antidepressant  vs  Psychotherapy  alone  or
+Placebo, Outcome 10 Dropouts due to side effects within 2-4 months..........................................................................................
Analysis  10.11.  Comparison  10  SUBGROUP3:  100%agoraphobia:  Psychotherapy+Antidepressant  vs  Psychotherapy  alone  or
+Placebo, Outcome 11 Response/remission on continued treatment..............................................................................................
Analysis  10.12.  Comparison  10  SUBGROUP3:  100%agoraphobia:  Psychotherapy+Antidepressant  vs  Psychotherapy  alone  or
+Placebo, Outcome 12 Global/Avoidance/Panic on continued treatment........................................................................................
Analysis  10.13.  Comparison  10  SUBGROUP3:  100%agoraphobia:  Psychotherapy+Antidepressant  vs  Psychotherapy  alone  or
+Placebo, Outcome 13 Dropouts for any reason on continued treatment.......................................................................................
Analysis  10.18.  Comparison  10  SUBGROUP3:  100%agoraphobia:  Psychotherapy+Antidepressant  vs  Psychotherapy  alone  or
+Placebo, Outcome 18 Response 6-24 months after treatment discontinuation.............................................................................
Analysis  10.19.  Comparison  10  SUBGROUP3:  100%agoraphobia:  Psychotherapy+Antidepressant  vs  Psychotherapy  alone  or
+Placebo, Outcome 19 Global/Avoidance/Panic 6-24 months after treatment discontinuation.....................................................
Analysis  11.1.  Comparison  11  SUBGROUP3:  0%agoraphobia:  Psychotherapy+Antidepressant  vs  Psychotherapy  alone  or
+Placebo, Outcome 1 Response at 2-4 months..................................................................................................................................
Analysis  11.2.  Comparison  11  SUBGROUP3:  0%agoraphobia:  Psychotherapy+Antidepressant  vs  Psychotherapy  alone  or
+Placebo, Outcome 2 Remission at 2-4 months.................................................................................................................................
Analysis  11.3.  Comparison  11  SUBGROUP3:  0%agoraphobia:  Psychotherapy+Antidepressant  vs  Psychotherapy  alone  or
+Placebo, Outcome 3 Global severity at 2-4 months.........................................................................................................................
Analysis  11.9.  Comparison  11  SUBGROUP3:  0%agoraphobia:  Psychotherapy+Antidepressant  vs  Psychotherapy  alone  or
+Placebo, Outcome 9 Dropouts for any reason within 2-4 months...................................................................................................
Analysis  11.10.  Comparison  11  SUBGROUP3:  0%agoraphobia:  Psychotherapy+Antidepressant  vs  Psychotherapy  alone  or
+Placebo, Outcome 10 Dropouts due to side effects within 2-4 months..........................................................................................
Analysis  11.11.  Comparison  11  SUBGROUP3:  0%agoraphobia:  Psychotherapy+Antidepressant  vs  Psychotherapy  alone  or
+Placebo, Outcome 11 Response/remission on continued treatment..............................................................................................
Analysis  11.12.  Comparison  11  SUBGROUP3:  0%agoraphobia:  Psychotherapy+Antidepressant  vs  Psychotherapy  alone  or
+Placebo, Outcome 12 Global/Avoidance/Panic on continued treatment........................................................................................
Analysis  11.13.  Comparison  11  SUBGROUP3:  0%agoraphobia:  Psychotherapy+Antidepressant  vs  Psychotherapy  alone  or
+Placebo, Outcome 13 Dropouts for any reason on continued treatment.......................................................................................
Analysis  11.18.  Comparison  11  SUBGROUP3:  0%agoraphobia:  Psychotherapy+Antidepressant  vs  Psychotherapy  alone  or
+Placebo, Outcome 18 Response 6-24 months after treatment discontinuation.............................................................................
Analysis  11.19.  Comparison  11  SUBGROUP3:  0%agoraphobia:  Psychotherapy+Antidepressant  vs  Psychotherapy  alone  or
+Placebo, Outcome 19 Global/Avoidance/Panic 6-24 months after treatment discontinuation.....................................................

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

156

156

157

160

161

162

162

163

163

164

165

165

166

167

167

168

168

169

172

173

173

174

174

175

175

176

176

177

vi

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis  12.1.  Comparison  12  SUBGROUP4:  without  comorbidity:  Psychotherapy+Antidepressant  vs  Antidepressant  alone,
Outcome 1 Response at 2-4 months...................................................................................................................................................
Analysis  12.2.  Comparison  12  SUBGROUP4:  without  comorbidity:  Psychotherapy+Antidepressant  vs  Antidepressant  alone,
Outcome 2 Remission at 2-4 months..................................................................................................................................................
Analysis  12.3.  Comparison  12  SUBGROUP4:  without  comorbidity:  Psychotherapy+Antidepressant  vs  Antidepressant  alone,
Outcome 3 Global severity at 2-4 months..........................................................................................................................................
Analysis  12.4.  Comparison  12  SUBGROUP4:  without  comorbidity:  Psychotherapy+Antidepressant  vs  Antidepressant  alone,
Outcome 4 Frequency of panic attacks at 2-4 months......................................................................................................................
Analysis  12.5.  Comparison  12  SUBGROUP4:  without  comorbidity:  Psychotherapy+Antidepressant  vs  Antidepressant  alone,
Outcome 5 Phobic avoidance at 2-4 months......................................................................................................................................
Analysis  12.6.  Comparison  12  SUBGROUP4:  without  comorbidity:  Psychotherapy+Antidepressant  vs  Antidepressant  alone,
Outcome 6 General anxiety at 2-4 months.........................................................................................................................................
Analysis  12.7.  Comparison  12  SUBGROUP4:  without  comorbidity:  Psychotherapy+Antidepressant  vs  Antidepressant  alone,
Outcome 7 Depression at 2-4 months.................................................................................................................................................
Analysis  12.8.  Comparison  12  SUBGROUP4:  without  comorbidity:  Psychotherapy+Antidepressant  vs  Antidepressant  alone,
Outcome 8 Social functioning at 2-4 months.....................................................................................................................................
Analysis  12.9.  Comparison  12  SUBGROUP4:  without  comorbidity:  Psychotherapy+Antidepressant  vs  Antidepressant  alone,
Outcome 9 Dropouts for any reason within 2-4 months....................................................................................................................
Analysis 12.10. Comparison 12 SUBGROUP4: without comorbidity: Psychotherapy+Antidepressant vs Antidepressant alone,
Outcome 10 Dropouts due to side effects within 2-4 months...........................................................................................................
Analysis 12.11. Comparison 12 SUBGROUP4: without comorbidity: Psychotherapy+Antidepressant vs Antidepressant alone,
Outcome 11 Response/remission on continued treatment...............................................................................................................
Analysis 12.12. Comparison 12 SUBGROUP4: without comorbidity: Psychotherapy+Antidepressant vs Antidepressant alone,
Outcome 12 Global/Avoidance/Panic on continued treatment.........................................................................................................
Analysis 12.13. Comparison 12 SUBGROUP4: without comorbidity: Psychotherapy+Antidepressant vs Antidepressant alone,
Outcome 13 Dropouts for any reason on continued treatment........................................................................................................
Analysis 12.16. Comparison 12 SUBGROUP4: without comorbidity: Psychotherapy+Antidepressant vs Antidepressant alone,
Outcome 16 Response/remission 6-24 months after treatment discontinuation.............................................................................
Analysis 13.1. Comparison 13 SUBGROUP4: without comorbidity: Psychotherapy+Antidepressant vs Psychotherapy alone or
+Placebo, Outcome 1 Response at 2-4 months..................................................................................................................................
Analysis 13.2. Comparison 13 SUBGROUP4: without comorbidity: Psychotherapy+Antidepressant vs Psychotherapy alone or
+Placebo, Outcome 2 Remission at 2-4 months.................................................................................................................................
Analysis 13.3. Comparison 13 SUBGROUP4: without comorbidity: Psychotherapy+Antidepressant vs Psychotherapy alone or
+Placebo, Outcome 3 Global severity at 2-4 months.........................................................................................................................
Analysis 13.4. Comparison 13 SUBGROUP4: without comorbidity: Psychotherapy+Antidepressant vs Psychotherapy alone or
+Placebo, Outcome 4 Frequency of panic attacks at 2-4 months.....................................................................................................
Analysis 13.5. Comparison 13 SUBGROUP4: without comorbidity: Psychotherapy+Antidepressant vs Psychotherapy alone or
+Placebo, Outcome 5 Phobic avoidance at 2-4 months....................................................................................................................
Analysis 13.6. Comparison 13 SUBGROUP4: without comorbidity: Psychotherapy+Antidepressant vs Psychotherapy alone or
+Placebo, Outcome 6 General anxiety at 2-4 months........................................................................................................................
Analysis 13.7. Comparison 13 SUBGROUP4: without comorbidity: Psychotherapy+Antidepressant vs Psychotherapy alone or
+Placebo, Outcome 7 Depression at 2-4 months...............................................................................................................................
Analysis 13.8. Comparison 13 SUBGROUP4: without comorbidity: Psychotherapy+Antidepressant vs Psychotherapy alone or
+Placebo, Outcome 8 Social functioning at 2-4 months....................................................................................................................
Analysis 13.9. Comparison 13 SUBGROUP4: without comorbidity: Psychotherapy+Antidepressant vs Psychotherapy alone or
+Placebo, Outcome 9 Dropouts for any reason within 2-4 months...................................................................................................
Analysis 13.10. Comparison 13 SUBGROUP4: without comorbidity: Psychotherapy+Antidepressant vs Psychotherapy alone or
+Placebo, Outcome 10 Dropouts due to side effects within 2-4 months..........................................................................................
Analysis 13.11. Comparison 13 SUBGROUP4: without comorbidity: Psychotherapy+Antidepressant vs Psychotherapy alone or
+Placebo, Outcome 11 Response/remission on continued treatment..............................................................................................
Analysis 13.12. Comparison 13 SUBGROUP4: without comorbidity: Psychotherapy+Antidepressant vs Psychotherapy alone or
+Placebo, Outcome 12 Global/Avoidance/Panic on continued treatment........................................................................................
Analysis 13.13. Comparison 13 SUBGROUP4: without comorbidity: Psychotherapy+Antidepressant vs Psychotherapy alone or
+Placebo, Outcome 13 Dropouts for any reason on continued treatment.......................................................................................
Analysis 13.14. Comparison 13 SUBGROUP4: without comorbidity: Psychotherapy+Antidepressant vs Psychotherapy alone or
+Placebo, Outcome 14 Response/remission 6 months after treatment discontinuation.................................................................

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

181

182

183

183

184

185

185

186

186

187

188

189

189

190

193

194

195

195

196

197

197

198

199

199

200

200

201

201

vii

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 13.15. Comparison 13 SUBGROUP4: without comorbidity: Psychotherapy+Antidepressant vs Psychotherapy alone or
+Placebo, Outcome 15 Global/Avoidance/Panic 6 months after treatment discontinuation...........................................................
Analysis 13.16. Comparison 13 SUBGROUP4: without comorbidity: Psychotherapy+Antidepressant vs Psychotherapy alone or
+Placebo, Outcome 16 Response/remission 18-24 months after treatment discontinuation..........................................................
Analysis 13.17. Comparison 13 SUBGROUP4: without comorbidity: Psychotherapy+Antidepressant vs Psychotherapy alone or
+Placebo, Outcome 17 Global/Avoidance/Panic 18-24 months after treatment discontinuation...................................................
Analysis 14.1. Comparison 14 SENSITIVITY1: blinded rater: Psychotherapy+Antidepressant vs Antidepressant alone, Outcome
1 Response at 2-4 months....................................................................................................................................................................
Analysis 14.2. Comparison 14 SENSITIVITY1: blinded rater: Psychotherapy+Antidepressant vs Antidepressant alone, Outcome
2 Remission at 2-4 months...................................................................................................................................................................
Analysis 14.3. Comparison 14 SENSITIVITY1: blinded rater: Psychotherapy+Antidepressant vs Antidepressant alone, Outcome
3 Global severity at 2-4 months...........................................................................................................................................................
Analysis 14.4. Comparison 14 SENSITIVITY1: blinded rater: Psychotherapy+Antidepressant vs Antidepressant alone, Outcome
4 Frequency of panic attacks at 2-4 months.......................................................................................................................................
Analysis 14.5. Comparison 14 SENSITIVITY1: blinded rater: Psychotherapy+Antidepressant vs Antidepressant alone, Outcome
5 Phobic avoidance at 2-4 months......................................................................................................................................................
Analysis 14.6. Comparison 14 SENSITIVITY1: blinded rater: Psychotherapy+Antidepressant vs Antidepressant alone, Outcome
6 General anxiety at 2-4 months..........................................................................................................................................................
Analysis 14.7. Comparison 14 SENSITIVITY1: blinded rater: Psychotherapy+Antidepressant vs Antidepressant alone, Outcome
7 Depression at 2-4 months.................................................................................................................................................................
Analysis 14.8. Comparison 14 SENSITIVITY1: blinded rater: Psychotherapy+Antidepressant vs Antidepressant alone, Outcome
8 Social functioning at 2-4 months.....................................................................................................................................................
Analysis 14.9. Comparison 14 SENSITIVITY1: blinded rater: Psychotherapy+Antidepressant vs Antidepressant alone, Outcome
9 Dropouts for any reason within 2-4 months....................................................................................................................................
Analysis 14.10. Comparison 14 SENSITIVITY1: blinded rater: Psychotherapy+Antidepressant vs Antidepressant alone, Outcome
10 Dropouts due to side effects within 2-4 months...........................................................................................................................
Analysis 14.11. Comparison 14 SENSITIVITY1: blinded rater: Psychotherapy+Antidepressant vs Antidepressant alone, Outcome
11 Response/remission on continued treatment...............................................................................................................................
Analysis 14.12. Comparison 14 SENSITIVITY1: blinded rater: Psychotherapy+Antidepressant vs Antidepressant alone, Outcome
12 Global/Avoidance/Panic on continued treatment.........................................................................................................................
Analysis 14.13. Comparison 14 SENSITIVITY1: blinded rater: Psychotherapy+Antidepressant vs Antidepressant alone, Outcome
13 Dropouts for any reason on continued treatment.........................................................................................................................
Analysis 14.16. Comparison 14 SENSITIVITY1: blinded rater: Psychotherapy+Antidepressant vs Antidepressant alone, Outcome
16 Response/remission 6-24 months after treatment discontinuation.............................................................................................
Analysis 14.17. Comparison 14 SENSITIVITY1: blinded rater: Psychotherapy+Antidepressant vs Antidepressant alone, Outcome
17 Global/Avoidance/Panic 6-24 months after treatment discontinuation.......................................................................................
Analysis 15.1. Comparison 15 SENSITIVITY1: blinded rater: Psychotherapy+Antidepressant vs Psychotherapy alone or +Placebo,
Outcome 1 Response at 2-4 months...................................................................................................................................................
Analysis 15.2. Comparison 15 SENSITIVITY1: blinded rater: Psychotherapy+Antidepressant vs Psychotherapy alone or +Placebo,
Outcome 2 Remission at 2-4 months..................................................................................................................................................
Analysis 15.3. Comparison 15 SENSITIVITY1: blinded rater: Psychotherapy+Antidepressant vs Psychotherapy alone or +Placebo,
Outcome 3 Global severity at 2-4 months..........................................................................................................................................
Analysis 15.4. Comparison 15 SENSITIVITY1: blinded rater: Psychotherapy+Antidepressant vs Psychotherapy alone or +Placebo,
Outcome 4 Frequency of panic attacks at 2-4 months......................................................................................................................
Analysis 15.5. Comparison 15 SENSITIVITY1: blinded rater: Psychotherapy+Antidepressant vs Psychotherapy alone or +Placebo,
Outcome 5 Phobic avoidance at 2-4 months......................................................................................................................................
Analysis 15.6. Comparison 15 SENSITIVITY1: blinded rater: Psychotherapy+Antidepressant vs Psychotherapy alone or +Placebo,
Outcome 6 General anxiety at 2-4 months.........................................................................................................................................
Analysis 15.7. Comparison 15 SENSITIVITY1: blinded rater: Psychotherapy+Antidepressant vs Psychotherapy alone or +Placebo,
Outcome 7 Depression at 2-4 months.................................................................................................................................................
Analysis 15.8. Comparison 15 SENSITIVITY1: blinded rater: Psychotherapy+Antidepressant vs Psychotherapy alone or +Placebo,
Outcome 8 Social functioning at 2-4 months.....................................................................................................................................
Analysis 15.9. Comparison 15 SENSITIVITY1: blinded rater: Psychotherapy+Antidepressant vs Psychotherapy alone or +Placebo,
Outcome 9 Dropouts for any reason within 2-4 months....................................................................................................................
Analysis  15.10.  Comparison  15  SENSITIVITY1:  blinded  rater:  Psychotherapy+Antidepressant  vs  Psychotherapy  alone  or
+Placebo, Outcome 10 Dropouts due to side effects within 2-4 months..........................................................................................

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

202

203

203

207

208

209

209

210

210

211

212

212

213

214

215

215

216

217

220

221

222

223

224

224

225

226

227

228

viii

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis  15.11.  Comparison  15  SENSITIVITY1:  blinded  rater:  Psychotherapy+Antidepressant  vs  Psychotherapy  alone  or
+Placebo, Outcome 11 Response/remission on continued treatment..............................................................................................
Analysis  15.12.  Comparison  15  SENSITIVITY1:  blinded  rater:  Psychotherapy+Antidepressant  vs  Psychotherapy  alone  or
+Placebo, Outcome 12 Global/Avoidance/Panic on continued treatment........................................................................................
Analysis  15.13.  Comparison  15  SENSITIVITY1:  blinded  rater:  Psychotherapy+Antidepressant  vs  Psychotherapy  alone  or
+Placebo, Outcome 13 Dropouts for any reason on continued treatment.......................................................................................
Analysis  15.14.  Comparison  15  SENSITIVITY1:  blinded  rater:  Psychotherapy+Antidepressant  vs  Psychotherapy  alone  or
+Placebo, Outcome 14 Response/remission 6-24 months after treatment discontinuation............................................................
Analysis  15.15.  Comparison  15  SENSITIVITY1:  blinded  rater:  Psychotherapy+Antidepressant  vs  Psychotherapy  alone  or
+Placebo, Outcome 15 Global/Avoidance/Panic 6-24 months after treatment discontinuation.....................................................
Analysis  16.1.  Comparison  16  SENSITIVITY2:  demonstrated  effectiveness:  Psychotherapy+Antidepressant  vs  Antidepressant
alone, Outcome 1 Response at 2-4 months........................................................................................................................................
Analysis  16.2.  Comparison  16  SENSITIVITY2:  demonstrated  effectiveness:  Psychotherapy+Antidepressant  vs  Antidepressant
alone, Outcome 2 Remission at 2-4 months.......................................................................................................................................
Analysis  16.3.  Comparison  16  SENSITIVITY2:  demonstrated  effectiveness:  Psychotherapy+Antidepressant  vs  Antidepressant
alone, Outcome 3 Global severity at 2-4 months...............................................................................................................................
Analysis  16.4.  Comparison  16  SENSITIVITY2:  demonstrated  effectiveness:  Psychotherapy+Antidepressant  vs  Antidepressant
alone, Outcome 4 Frequency of panic attacks at 2-4 months...........................................................................................................
Analysis  16.5.  Comparison  16  SENSITIVITY2:  demonstrated  effectiveness:  Psychotherapy+Antidepressant  vs  Antidepressant
alone, Outcome 5 Phobic avoidance at 2-4 months..........................................................................................................................
Analysis  16.6.  Comparison  16  SENSITIVITY2:  demonstrated  effectiveness:  Psychotherapy+Antidepressant  vs  Antidepressant
alone, Outcome 6 General anxiety at 2-4 months..............................................................................................................................
Analysis  16.7.  Comparison  16  SENSITIVITY2:  demonstrated  effectiveness:  Psychotherapy+Antidepressant  vs  Antidepressant
alone, Outcome 7 Depression at 2-4 months.....................................................................................................................................
Analysis  16.8.  Comparison  16  SENSITIVITY2:  demonstrated  effectiveness:  Psychotherapy+Antidepressant  vs  Antidepressant
alone, Outcome 8 Social functioning at 2-4 months..........................................................................................................................
Analysis  16.9.  Comparison  16  SENSITIVITY2:  demonstrated  effectiveness:  Psychotherapy+Antidepressant  vs  Antidepressant
alone, Outcome 9 Dropouts for any reason within 2-4 months.........................................................................................................
Analysis 16.10. Comparison 16 SENSITIVITY2: demonstrated effectiveness: Psychotherapy+Antidepressant vs Antidepressant
alone, Outcome 10 Dropouts due to side effects within 2-4 months................................................................................................
Analysis 16.11. Comparison 16 SENSITIVITY2: demonstrated effectiveness: Psychotherapy+Antidepressant vs Antidepressant
alone, Outcome 11 Response/remission on continued treatment....................................................................................................
Analysis 16.12. Comparison 16 SENSITIVITY2: demonstrated effectiveness: Psychotherapy+Antidepressant vs Antidepressant
alone, Outcome 12 Global/Avoidance/Panic on continued treatment..............................................................................................
Analysis 16.13. Comparison 16 SENSITIVITY2: demonstrated effectiveness: Psychotherapy+Antidepressant vs Antidepressant
alone, Outcome 13 Dropouts for any reason on continued treatment.............................................................................................
Analysis 16.16. Comparison 16 SENSITIVITY2: demonstrated effectiveness: Psychotherapy+Antidepressant vs Antidepressant
alone, Outcome 16 Response/remission 6-24 months after treatment discontinuation.................................................................
Analysis 16.17. Comparison 16 SENSITIVITY2: demonstrated effectiveness: Psychotherapy+Antidepressant vs Antidepressant
alone, Outcome 17 Global/Avoidance/Panic 6-24 months after treatment discontinuation...........................................................
Analysis  17.1.  Comparison  17  SENSITIVITY2:  demonstrated  effectiveness:  Psychotherapy+Antidepressant  vs  Psychotherapy
alone or +Placebo, Outcome 1 Response at 2-4 months...................................................................................................................
Analysis  17.2.  Comparison  17  SENSITIVITY2:  demonstrated  effectiveness:  Psychotherapy+Antidepressant  vs  Psychotherapy
alone or +Placebo, Outcome 2 Remission at 2-4 months..................................................................................................................
Analysis  17.3.  Comparison  17  SENSITIVITY2:  demonstrated  effectiveness:  Psychotherapy+Antidepressant  vs  Psychotherapy
alone or +Placebo, Outcome 3 Global severity at 2-4 months..........................................................................................................
Analysis  17.4.  Comparison  17  SENSITIVITY2:  demonstrated  effectiveness:  Psychotherapy+Antidepressant  vs  Psychotherapy
alone or +Placebo, Outcome 4 Frequency of panic attacks at 2-4 months.......................................................................................
Analysis  17.5.  Comparison  17  SENSITIVITY2:  demonstrated  effectiveness:  Psychotherapy+Antidepressant  vs  Psychotherapy
alone or +Placebo, Outcome 5 Phobic avoidance at 2-4 months......................................................................................................
Analysis  17.6.  Comparison  17  SENSITIVITY2:  demonstrated  effectiveness:  Psychotherapy+Antidepressant  vs  Psychotherapy
alone or +Placebo, Outcome 6 General anxiety at 2-4 months.........................................................................................................
Analysis  17.7.  Comparison  17  SENSITIVITY2:  demonstrated  effectiveness:  Psychotherapy+Antidepressant  vs  Psychotherapy
alone or +Placebo, Outcome 7 Depression at 2-4 months.................................................................................................................
Analysis  17.8.  Comparison  17  SENSITIVITY2:  demonstrated  effectiveness:  Psychotherapy+Antidepressant  vs  Psychotherapy
alone or +Placebo, Outcome 8 Social functioning at 2-4 months.....................................................................................................

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

229

229

230

230

231

235

236

236

237

238

238

239

239

240

241

241

242

242

243

244

248

248

249

250

250

251

252

252

ix

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis  17.9.  Comparison  17  SENSITIVITY2:  demonstrated  effectiveness:  Psychotherapy+Antidepressant  vs  Psychotherapy
alone or +Placebo, Outcome 9 Dropouts for any reason within 2-4 months....................................................................................
Analysis 17.10. Comparison 17 SENSITIVITY2: demonstrated effectiveness: Psychotherapy+Antidepressant vs Psychotherapy
alone or +Placebo, Outcome 10 Dropouts due to side effects within 2-4 months............................................................................
Analysis 17.11. Comparison 17 SENSITIVITY2: demonstrated effectiveness: Psychotherapy+Antidepressant vs Psychotherapy
alone or +Placebo, Outcome 11 Response/remission on continued treatment...............................................................................
Analysis 17.12. Comparison 17 SENSITIVITY2: demonstrated effectiveness: Psychotherapy+Antidepressant vs Psychotherapy
alone or +Placebo, Outcome 12 Global/Avoidance/Panic on continued treatment.........................................................................
Analysis 17.13. Comparison 17 SENSITIVITY2: demonstrated effectiveness: Psychotherapy+Antidepressant vs Psychotherapy
alone or +Placebo, Outcome 13 Dropouts for any reason on continued treatment.........................................................................
Analysis 17.14. Comparison 17 SENSITIVITY2: demonstrated effectiveness: Psychotherapy+Antidepressant vs Psychotherapy
alone or +Placebo, Outcome 14 Response/remission 6-24 months after treatment discontinuation.............................................
Analysis 17.15. Comparison 17 SENSITIVITY2: demonstrated effectiveness: Psychotherapy+Antidepressant vs Psychotherapy
alone or +Placebo, Outcome 15 Global/Avoidance/Panic 6-24 months after treatment discontinuation.......................................
Analysis 18.1. Comparison 18 SENSITIVITY3: operationalised criteria: Psychotherapy+Antidepressant vs Antidepressant alone,
Outcome 1 Response at 2-4 months...................................................................................................................................................
Analysis 18.2. Comparison 18 SENSITIVITY3: operationalised criteria: Psychotherapy+Antidepressant vs Antidepressant alone,
Outcome 2 Remission at 2-4 months..................................................................................................................................................
Analysis 18.3. Comparison 18 SENSITIVITY3: operationalised criteria: Psychotherapy+Antidepressant vs Antidepressant alone,
Outcome 3 Global severity at 2-4 months..........................................................................................................................................
Analysis 18.4. Comparison 18 SENSITIVITY3: operationalised criteria: Psychotherapy+Antidepressant vs Antidepressant alone,
Outcome 4 Frequency of panic attacks at 2-4 months......................................................................................................................
Analysis 18.5. Comparison 18 SENSITIVITY3: operationalised criteria: Psychotherapy+Antidepressant vs Antidepressant alone,
Outcome 5 Phobic avoidance at 2-4 months......................................................................................................................................
Analysis 18.6. Comparison 18 SENSITIVITY3: operationalised criteria: Psychotherapy+Antidepressant vs Antidepressant alone,
Outcome 6 General anxiety at 2-4 months.........................................................................................................................................
Analysis 18.7. Comparison 18 SENSITIVITY3: operationalised criteria: Psychotherapy+Antidepressant vs Antidepressant alone,
Outcome 7 Depression at 2-4 months.................................................................................................................................................
Analysis 18.8. Comparison 18 SENSITIVITY3: operationalised criteria: Psychotherapy+Antidepressant vs Antidepressant alone,
Outcome 8 Social functioning at 2-4 months.....................................................................................................................................
Analysis 18.9. Comparison 18 SENSITIVITY3: operationalised criteria: Psychotherapy+Antidepressant vs Antidepressant alone,
Outcome 9 Dropouts for any reason within 2-4 months....................................................................................................................
Analysis 18.10. Comparison 18 SENSITIVITY3: operationalised criteria: Psychotherapy+Antidepressant vs Antidepressant alone,
Outcome 10 Dropouts due to side effects within 2-4 months...........................................................................................................
Analysis 18.11. Comparison 18 SENSITIVITY3: operationalised criteria: Psychotherapy+Antidepressant vs Antidepressant alone,
Outcome 11 Response/remission on continued treatment...............................................................................................................
Analysis 18.12. Comparison 18 SENSITIVITY3: operationalised criteria: Psychotherapy+Antidepressant vs Antidepressant alone,
Outcome 12 Global/Avoidance/Panic on continued treatment.........................................................................................................
Analysis 18.13. Comparison 18 SENSITIVITY3: operationalised criteria: Psychotherapy+Antidepressant vs Antidepressant alone,
Outcome 13 Dropouts for any reason on continued treatment........................................................................................................
Analysis 18.16. Comparison 18 SENSITIVITY3: operationalised criteria: Psychotherapy+Antidepressant vs Antidepressant alone,
Outcome 16 Response/remission 6-24 months after treatment discontinuation.............................................................................
Analysis 18.17. Comparison 18 SENSITIVITY3: operationalised criteria: Psychotherapy+Antidepressant vs Antidepressant alone,
Outcome 17 Global/Avoidance/Panic 6-24 months after treatment discontinuation......................................................................
Analysis 19.1. Comparison 19 SENSITIVITY3: operationalised criteria: Psychotherapy+Antidepressant vs Psychotherapy alone
or +Placebo, Outcome 1 Response at 2-4 months.............................................................................................................................
Analysis 19.2. Comparison 19 SENSITIVITY3: operationalised criteria: Psychotherapy+Antidepressant vs Psychotherapy alone
or +Placebo, Outcome 2 Remission at 2-4 months............................................................................................................................
Analysis 19.3. Comparison 19 SENSITIVITY3: operationalised criteria: Psychotherapy+Antidepressant vs Psychotherapy alone
or +Placebo, Outcome 3 Global severity at 2-4 months.....................................................................................................................
Analysis 19.4. Comparison 19 SENSITIVITY3: operationalised criteria: Psychotherapy+Antidepressant vs Psychotherapy alone
or +Placebo, Outcome 4 Frequency of panic attacks at 2-4 months.................................................................................................
Analysis 19.5. Comparison 19 SENSITIVITY3: operationalised criteria: Psychotherapy+Antidepressant vs Psychotherapy alone
or +Placebo, Outcome 5 Phobic avoidance at 2-4 months................................................................................................................
Analysis 19.6. Comparison 19 SENSITIVITY3: operationalised criteria: Psychotherapy+Antidepressant vs Psychotherapy alone
or +Placebo, Outcome 6 General anxiety at 2-4 months....................................................................................................................

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

253

254

254

255

256

256

257

261

262

262

263

264

264

265

266

266

267

268

268

269

270

270

274

275

276

276

277

278

x

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 19.7. Comparison 19 SENSITIVITY3: operationalised criteria: Psychotherapy+Antidepressant vs Psychotherapy alone
or +Placebo, Outcome 7 Depression at 2-4 months...........................................................................................................................
Analysis 19.8. Comparison 19 SENSITIVITY3: operationalised criteria: Psychotherapy+Antidepressant vs Psychotherapy alone
or +Placebo, Outcome 8 Social functioning at 2-4 months...............................................................................................................
Analysis 19.9. Comparison 19 SENSITIVITY3: operationalised criteria: Psychotherapy+Antidepressant vs Psychotherapy alone
or +Placebo, Outcome 9 Dropouts for any reason within 2-4 months..............................................................................................
Analysis 19.10. Comparison 19 SENSITIVITY3: operationalised criteria: Psychotherapy+Antidepressant vs Psychotherapy alone
or +Placebo, Outcome 10 Dropouts due to side effects within 2-4 months......................................................................................
Analysis 19.11. Comparison 19 SENSITIVITY3: operationalised criteria: Psychotherapy+Antidepressant vs Psychotherapy alone
or +Placebo, Outcome 11 Response/remission on continued treatment.........................................................................................
Analysis 19.12. Comparison 19 SENSITIVITY3: operationalised criteria: Psychotherapy+Antidepressant vs Psychotherapy alone
or +Placebo, Outcome 12 Global/Avoidance/Panic on continued treatment...................................................................................
Analysis 19.13. Comparison 19 SENSITIVITY3: operationalised criteria: Psychotherapy+Antidepressant vs Psychotherapy alone
or +Placebo, Outcome 13 Dropouts for any reason on continued treatment...................................................................................
Analysis 19.14. Comparison 19 SENSITIVITY3: operationalised criteria: Psychotherapy+Antidepressant vs Psychotherapy alone
or +Placebo, Outcome 14 Response/remission 6-24 months after treatment discontinuation.......................................................
Analysis 19.15. Comparison 19 SENSITIVITY3: operationalised criteria: Psychotherapy+Antidepressant vs Psychotherapy alone
or +Placebo, Outcome 15 Global/Avoidance/Panic 6-24 months after treatment discontinuation.................................................
Analysis 20.1. Comparison 20 SENSITIVITY5: without benzo: Psychotherapy+Antidepressant vs Antidepressant alone, Outcome
1 Response at 2-4 months....................................................................................................................................................................
Analysis 20.2. Comparison 20 SENSITIVITY5: without benzo: Psychotherapy+Antidepressant vs Antidepressant alone, Outcome
2 Remission at 2-4 months...................................................................................................................................................................
Analysis 20.3. Comparison 20 SENSITIVITY5: without benzo: Psychotherapy+Antidepressant vs Antidepressant alone, Outcome
3 Global severity at 2-4 months...........................................................................................................................................................
Analysis 20.4. Comparison 20 SENSITIVITY5: without benzo: Psychotherapy+Antidepressant vs Antidepressant alone, Outcome
4 Frequency of panic attacks at 2-4 months.......................................................................................................................................
Analysis 20.5. Comparison 20 SENSITIVITY5: without benzo: Psychotherapy+Antidepressant vs Antidepressant alone, Outcome
5 Phobic avoidance at 2-4 months......................................................................................................................................................
Analysis 20.6. Comparison 20 SENSITIVITY5: without benzo: Psychotherapy+Antidepressant vs Antidepressant alone, Outcome
6 General anxiety at 2-4 months..........................................................................................................................................................
Analysis 20.7. Comparison 20 SENSITIVITY5: without benzo: Psychotherapy+Antidepressant vs Antidepressant alone, Outcome
7 Depression at 2-4 months.................................................................................................................................................................
Analysis 20.8. Comparison 20 SENSITIVITY5: without benzo: Psychotherapy+Antidepressant vs Antidepressant alone, Outcome
8 Social functioning at 2-4 months.....................................................................................................................................................
Analysis 20.9. Comparison 20 SENSITIVITY5: without benzo: Psychotherapy+Antidepressant vs Antidepressant alone, Outcome
9 Dropouts for any reason within 2-4 months....................................................................................................................................
Analysis  20.10.  Comparison  20  SENSITIVITY5:  without  benzo:  Psychotherapy+Antidepressant  vs  Antidepressant  alone,
Outcome 10 Dropouts due to side effects within 2-4 months...........................................................................................................
Analysis  20.16.  Comparison  20  SENSITIVITY5:  without  benzo:  Psychotherapy+Antidepressant  vs  Antidepressant  alone,
Outcome 16 Response/remission 6-24 months after treatment discontinuation.............................................................................
Analysis  21.1.  Comparison  21  SENSITIVITY5:  without  benzo:  Psychotherapy+Antidepressant  vs  Psychotherapy  alone  or
+Placebo, Outcome 1 Response at 2-4 months..................................................................................................................................
Analysis  21.2.  Comparison  21  SENSITIVITY5:  without  benzo:  Psychotherapy+Antidepressant  vs  Psychotherapy  alone  or
+Placebo, Outcome 2 Remission at 2-4 months.................................................................................................................................
Analysis  21.3.  Comparison  21  SENSITIVITY5:  without  benzo:  Psychotherapy+Antidepressant  vs  Psychotherapy  alone  or
+Placebo, Outcome 3 Global severity at 2-4 months.........................................................................................................................
Analysis  21.4.  Comparison  21  SENSITIVITY5:  without  benzo:  Psychotherapy+Antidepressant  vs  Psychotherapy  alone  or
+Placebo, Outcome 4 Frequency of panic attacks at 2-4 months.....................................................................................................
Analysis  21.5.  Comparison  21  SENSITIVITY5:  without  benzo:  Psychotherapy+Antidepressant  vs  Psychotherapy  alone  or
+Placebo, Outcome 5 Phobic avoidance at 2-4 months....................................................................................................................
Analysis  21.6.  Comparison  21  SENSITIVITY5:  without  benzo:  Psychotherapy+Antidepressant  vs  Psychotherapy  alone  or
+Placebo, Outcome 6 General anxiety at 2-4 months........................................................................................................................
Analysis  21.7.  Comparison  21  SENSITIVITY5:  without  benzo:  Psychotherapy+Antidepressant  vs  Psychotherapy  alone  or
+Placebo, Outcome 7 Depression at 2-4 months...............................................................................................................................
Analysis  21.8.  Comparison  21  SENSITIVITY5:  without  benzo:  Psychotherapy+Antidepressant  vs  Psychotherapy  alone  or
+Placebo, Outcome 8 Social functioning at 2-4 months....................................................................................................................

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

279

279

280

281

282

282

283

283

284

288

289

289

290

290

291

292

292

293

293

294

298

299

299

300

300

301

302

303

xi

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis  21.9.  Comparison  21  SENSITIVITY5:  without  benzo:  Psychotherapy+Antidepressant  vs  Psychotherapy  alone  or
+Placebo, Outcome 9 Dropouts for any reason within 2-4 months...................................................................................................
Analysis  21.10.  Comparison  21  SENSITIVITY5:  without  benzo:  Psychotherapy+Antidepressant  vs  Psychotherapy  alone  or
+Placebo, Outcome 10 Dropouts due to side effects within 2-4 months..........................................................................................
Analysis  21.14.  Comparison  21  SENSITIVITY5:  without  benzo:  Psychotherapy+Antidepressant  vs  Psychotherapy  alone  or
+Placebo, Outcome 14 Response/remission 6-24 months after treatment discontinuation............................................................
Analysis  21.15.  Comparison  21  SENSITIVITY5:  without  benzo:  Psychotherapy+Antidepressant  vs  Psychotherapy  alone  or
+Placebo, Outcome 15 Global/Avoidance/Panic 6-24 months after treatment discontinuation.....................................................
Analysis 22.1. Comparison 22 SENSITIVITY5: allowed benzo: Psychotherapy+Antidepressant vs Antidepressant alone, Outcome
1 Response at 2-4 months....................................................................................................................................................................
Analysis 22.2. Comparison 22 SENSITIVITY5: allowed benzo: Psychotherapy+Antidepressant vs Antidepressant alone, Outcome
2 Remission at 2-4 months...................................................................................................................................................................
Analysis 22.3. Comparison 22 SENSITIVITY5: allowed benzo: Psychotherapy+Antidepressant vs Antidepressant alone, Outcome
3 Global severity at 2-4 months...........................................................................................................................................................
Analysis 22.4. Comparison 22 SENSITIVITY5: allowed benzo: Psychotherapy+Antidepressant vs Antidepressant alone, Outcome
4 Frequency of panic attacks at 2-4 months.......................................................................................................................................
Analysis 22.5. Comparison 22 SENSITIVITY5: allowed benzo: Psychotherapy+Antidepressant vs Antidepressant alone, Outcome
5 Phobic avoidance at 2-4 months......................................................................................................................................................
Analysis 22.6. Comparison 22 SENSITIVITY5: allowed benzo: Psychotherapy+Antidepressant vs Antidepressant alone, Outcome
6 General anxiety at 2-4 months..........................................................................................................................................................
Analysis 22.7. Comparison 22 SENSITIVITY5: allowed benzo: Psychotherapy+Antidepressant vs Antidepressant alone, Outcome
7 Depression at 2-4 months.................................................................................................................................................................
Analysis 22.8. Comparison 22 SENSITIVITY5: allowed benzo: Psychotherapy+Antidepressant vs Antidepressant alone, Outcome
8 Social functioning at 2-4 months.....................................................................................................................................................
Analysis 22.9. Comparison 22 SENSITIVITY5: allowed benzo: Psychotherapy+Antidepressant vs Antidepressant alone, Outcome
9 Dropouts for any reason within 2-4 months....................................................................................................................................
Analysis  22.10.  Comparison  22  SENSITIVITY5:  allowed  benzo:  Psychotherapy+Antidepressant  vs  Antidepressant  alone,
Outcome 10 Dropouts due to side effects within 2-4 months...........................................................................................................
Analysis  22.11.  Comparison  22  SENSITIVITY5:  allowed  benzo:  Psychotherapy+Antidepressant  vs  Antidepressant  alone,
Outcome 11 Response/remission on continued treatment...............................................................................................................
Analysis  22.12.  Comparison  22  SENSITIVITY5:  allowed  benzo:  Psychotherapy+Antidepressant  vs  Antidepressant  alone,
Outcome 12 Global/Avoidance/Panic on continued treatment.........................................................................................................
Analysis  22.13.  Comparison  22  SENSITIVITY5:  allowed  benzo:  Psychotherapy+Antidepressant  vs  Antidepressant  alone,
Outcome 13 Dropouts for any reason on continued treatment........................................................................................................
Analysis  22.14.  Comparison  22  SENSITIVITY5:  allowed  benzo:  Psychotherapy+Antidepressant  vs  Antidepressant  alone,
Outcome 14 Response/remission immediately after treatment discontinuation.............................................................................
Analysis  22.15.  Comparison  22  SENSITIVITY5:  allowed  benzo:  Psychotherapy+Antidepressant  vs  Antidepressant  alone,
Outcome 15 Global/Avoidance/Panic immediately after treatment discontinuation......................................................................
Analysis  22.16.  Comparison  22  SENSITIVITY5:  allowed  benzo:  Psychotherapy+Antidepressant  vs  Antidepressant  alone,
Outcome 16 Response/remission 6-24 months after treatment discontinuation.............................................................................
Analysis  22.17.  Comparison  22  SENSITIVITY5:  allowed  benzo:  Psychotherapy+Antidepressant  vs  Antidepressant  alone,
Outcome 17 Global/Avoidance/Panic 6-24 months after treatment discontinuation......................................................................
Analysis  23.1.  Comparison  23  SENSITIVITY5:  allowed  benzo:  Psychotherapy+Antidepressant  vs  Psychotherapy  alone  or
+Placebo, Outcome 1 Response at 2-4 months..................................................................................................................................
Analysis  23.2.  Comparison  23  SENSITIVITY5:  allowed  benzo:  Psychotherapy+Antidepressant  vs  Psychotherapy  alone  or
+Placebo, Outcome 2 Remission at 2-4 months.................................................................................................................................
Analysis  23.3.  Comparison  23  SENSITIVITY5:  allowed  benzo:  Psychotherapy+Antidepressant  vs  Psychotherapy  alone  or
+Placebo, Outcome 3 Global severity at 2-4 months.........................................................................................................................
Analysis  23.4.  Comparison  23  SENSITIVITY5:  allowed  benzo:  Psychotherapy+Antidepressant  vs  Psychotherapy  alone  or
+Placebo, Outcome 4 Frequency of panic attacks at 2-4 months.....................................................................................................
Analysis  23.5.  Comparison  23  SENSITIVITY5:  allowed  benzo:  Psychotherapy+Antidepressant  vs  Psychotherapy  alone  or
+Placebo, Outcome 5 Phobic avoidance at 2-4 months....................................................................................................................
Analysis  23.6.  Comparison  23  SENSITIVITY5:  allowed  benzo:  Psychotherapy+Antidepressant  vs  Psychotherapy  alone  or
+Placebo, Outcome 6 General anxiety at 2-4 months........................................................................................................................
Analysis  23.7.  Comparison  23  SENSITIVITY5:  allowed  benzo:  Psychotherapy+Antidepressant  vs  Psychotherapy  alone  or
+Placebo, Outcome 7 Depression at 2-4 months...............................................................................................................................

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

303

304

305

305

309

310

311

311

312

313

313

314

314

315

316

316

317

318

318

319

320

323

323

324

325

325

326

326

xii

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis  23.9.  Comparison  23  SENSITIVITY5:  allowed  benzo:  Psychotherapy+Antidepressant  vs  Psychotherapy  alone  or
+Placebo, Outcome 9 Dropouts for any reason within 2-4 months...................................................................................................
Analysis  23.10.  Comparison  23  SENSITIVITY5:  allowed  benzo:  Psychotherapy+Antidepressant  vs  Psychotherapy  alone  or
+Placebo, Outcome 10 Dropouts due to side effects within 2-4 months..........................................................................................
Analysis  23.11.  Comparison  23  SENSITIVITY5:  allowed  benzo:  Psychotherapy+Antidepressant  vs  Psychotherapy  alone  or
+Placebo, Outcome 11 Response/remission on continued treatment..............................................................................................
Analysis  23.12.  Comparison  23  SENSITIVITY5:  allowed  benzo:  Psychotherapy+Antidepressant  vs  Psychotherapy  alone  or
+Placebo, Outcome 12 Global/Avoidance/Panic on continued treatment........................................................................................
Analysis  23.13.  Comparison  23  SENSITIVITY5:  allowed  benzo:  Psychotherapy+Antidepressant  vs  Psychotherapy  alone  or
+Placebo, Outcome 13 Dropouts for any reason on continued treatment.......................................................................................
Analysis  23.14.  Comparison  23  SENSITIVITY5:  allowed  benzo:  Psychotherapy+Antidepressant  vs  Psychotherapy  alone  or
+Placebo, Outcome 14 Response/remission 6-24 months after treatment discontinuation............................................................
Analysis  23.15.  Comparison  23  SENSITIVITY5:  allowed  benzo:  Psychotherapy+Antidepressant  vs  Psychotherapy  alone  or
+Placebo, Outcome 15 Global/Avoidance/Panic 6-24 months after treatment discontinuation.....................................................
WHAT'S NEW.................................................................................................................................................................................................
HISTORY........................................................................................................................................................................................................
CONTRIBUTIONS OF AUTHORS...................................................................................................................................................................
DECLARATIONS OF INTEREST.....................................................................................................................................................................
SOURCES OF SUPPORT...............................................................................................................................................................................
INDEX TERMS...............................................................................................................................................................................................

327

327

328

328

329

329

330

330
331
331
331
331
331

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

xiii

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

[Intervention Review]

Cochrane Database of Systematic Reviews

Combined psychotherapy plus antidepressants for panic disorder with
or without agoraphobia

Toshi A Furukawa1, Norio Watanabe1, Rachel Churchill2

1Department of Psychiatry & Cognitive-Behavioral Medicine, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
2Academic Unit of Psychiatry, Community Based Medicine, University of Bristol, Bristol, UK

Contact address: Toshi A Furukawa, Department of Psychiatry & Cognitive-Behavioral Medicine, Nagoya City University Graduate School
of Medical Sciences, Mizuho-cho, Mizuho-ku, Nagoya, Aichi, 467-8601, Japan. furukawa@med.nagoya-cu.ac.jp.

Editorial group: Cochrane Common Mental Disorders Group
Publication status and date: Edited (no change to conclusions), published in Issue 1, 2010.

Citation: Furukawa TA, Watanabe N, Churchill R. Combined psychotherapy plus antidepressants for panic disorder with or without
agoraphobia. Cochrane Database of Systematic Reviews 2007, Issue 1. Art. No.: CD004364. DOI: 10.1002/14651858.CD004364.pub2.

Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Background

A B S T R A C T

Panic disorder can be treated with pharmacotherapy, psychotherapy or in combination, but the relative merits of combined therapy have
not been well established.

Objectives

To review evidence concerning short- and long-term advantages and disadvantages of combined psychotherapy plus antidepressant treat-
ment for panic disorder with or without agoraphobia, in comparison with either therapy alone.

Search methods

The Cochrane Collaboration Depression, Anxiety and Neurosis Controlled Trials Registers (CCDANCTR-Studies and CCDANCTR-References)
were searched on 11/10/2005, together with a complementary search of the Cochrane Central Register of Controlled Trials and MEDLINE,
using the keywords antidepressant and panic. A reference search, SciSearch and personal contact with experts were carried out.

Selection criteria

Two independent review authors identified randomised controlled trials comparing the combined therapy against either of the monother-
apies among adult patients with panic disorder with or without agoraphobia.

Data collection and analysis

Two independent review authors extracted data using predefined data formats, including study quality indicators. The primary outcome
was relative risk (RR) of "response" i.e. substantial overall improvement from baseline as defined by the original investigators. Secondary
outcomes included standardised weighted mean differences in global severity, panic attack frequency, phobic avoidance, general anxiety,
depression and social functioning and relative risks of overall dropouts and dropouts due to side effects.

Main results

We identified 23 randomised comparisons (representing 21 trials, 1709 patients), 21 of which involved behaviour or cognitive-behaviour
therapies. In the acute phase treatment, the combined therapy was superior to antidepressant pharmacotherapy (RR 1.24, 95% confidence
interval (CI) 1.02 to 1.52) or psychotherapy (RR 1.17, 95% CI 1.05 to 1.31). The combined therapy produced more dropouts due to side effects
than psychotherapy (number needed to harm (NNH) around 26). After the acute phase treatment, as long as the drug was continued,
the superiority of the combination over either monotherapy appeared to persist. After termination of the acute phase and continuation

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

1

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

treatment, the combined therapy was more effective than pharmacotherapy alone (RR 1.61, 95% CI 1.23 to 2.11) and was as effective as
psychotherapy (RR 0.96, 95% CI 0.79 to 1.16).

Authors' conclusions

Either combined therapy or psychotherapy alone may be chosen as first line treatment for panic disorder with or without agoraphobia,
depending on patient preference.

P L A I N   L A N G U A G E   S U M M A R Y

Psychotherapy combined with antidepressants for panic disorder

Psychotherapy plus antidepressant treatment were compared with each of the two individual treatments alone for panic disorder. At
the end of the acute phase treatment, the combined therapy was superior to psychotherapy or antidepressant treatment alone. After
termination of active treatment, the combined therapy was superior to antidepressants alone and was as effective as psychotherapy alone.
Either combined therapy or psychotherapy alone may be chosen as first line treatment for panic disorder with or without agoraphobia,
depending on patient preference.

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

2

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

B A C K G R O U N D

Panic disorder is characterised by recurrent, unexpected panic at-
tacks and persistent concern about having an additional attack, or
worry about the implications of an attack or its consequences. It is
estimated to affect around 2% of the population for any one year
and around 2% to 5% of the population sometime during their life-
time (Kessler 2006; Carlbring 2002). One third to one half of indi-
viduals diagnosed with panic disorder in community samples also
have agoraphobia, although a much higher rate of agoraphobia is
encountered in clinical samples (Weissman 1997). It is estimated
to account for 0.5% of the global burden of disease for humankind
in 2002, a percentage figure as great as epilepsy and greater than
breast cancer, for example (WHO 2004).

Two broad categories of treatment have been shown to be effec-
tive in treating panic disorder with or without agoraphobia; one is
psychotherapy and cognitive-behaviour therapy in particular, and
the other is pharmacotherapy with antidepressants and benzodi-
azepines (Nathan 2002; APA 1998). It remains to be seen, howev-
er, whether combining these two effective forms of treatment con-
fers any additional benefit over and above either of the treatments
alone, especially with regard to long-term outcomes.

It is important to examine this issue for many reasons. Firstly, typi-
cal response rates for these two effective therapies are only in the
range of 50% to 70% at the end of acute phase treatment. More-
over, it is now increasingly recognised that pharmacotherapy alone
tends to result in substantial relapse rates, not only when discon-
tinued (Mavissakalian 2002; Pecknold 1988), but even when main-
tained at adequate dosage (Simon 2002; Toni 2000). Cognitive-be-
haviour therapy may not always be able to prevent relapses over
the  long  term  either  (Burns  1986;  Fava  2001).  We  are  therefore
in  need  of  "stronger"  treatment.  Secondly,  combination  therapy
appears  to  be  practiced  very  frequently  in  the  real  world,  possi-
bly  because  of  the  above-mentioned  inadequacy  of  either  of  the
monotherapies. For example, Schmidt et al reported that, at their
research  laboratory,  75%  of  patients  with  panic  disorder  had  re-
ceived at least one medication and 65% were receiving medication
at the time of their initial assessment (Schmidt 2001).

However, the evidence regarding the incremental effectiveness of
combined  therapy  remains  inconclusive.  Several  reviews  can  be
found  in  the  literature  but  their  conclusions  have  been  variable,
with some favouring the combination therapy (Mattick 1990; van
Balkom 1997; Pollack 2003), some favouring monotherapy (Taylor
2000;  Westra  1998;  Gould  1995)  and  others  with  mixed  or  guard-
ed  conclusions  (Clum  1993;  Telch  1994;  APA  1998;  Schmidt  1999;
Schmidt 2001). Unfortunately most of these reviews have been ei-
ther unsystematic or narrative only (Schmidt 1999; Schmidt 2001;
Taylor 2000; APA 1998) or, where meta-analytic summary was es-
sayed,  did  not  focus  on  head-to-head  comparisons  (van  Balkom
1997;  Gould  1995;  Clum  1993;  Mattick  1990).  The  precariousness
of comparing different treatment conditions by way of their with-
in-group effect sizes or between-group effect sizes against place-
bo conditions has been well documented (Bucher 1997; Klein 2000;
Song 2003).

Cochrane Database of Systematic Reviews

and detract from cognitive-behavioural interventions (van Balkom
1996; Brown 1995; Otto 1996; Westra 1998). We do not yet know if
the same applies to the other form of pharmacotherapy, i.e. antide-
pressant medication, although there are some suggestive findings
(Barlow 2000).

Therefore, the primary objective of this systematic review is to eval-
uate  and  synthesise  evidence  from  randomised  controlled  trials
that examined effectiveness and adverse effects of combined treat-
ment by psychotherapy and antidepressants in comparison with ei-
ther therapy alone in the treatment of panic disorder with or with-
out  agoraphobia.  This  review  focuses  on  antidepressants,  and  a
separate companion review focuses on benzodiazepines (Watan-
abe 2005).

O B J E C T I V E S

The primary objective of the present systematic review is to eval-
uate  evidence  from  randomised  controlled  trials  that  examined
effectiveness and adverse effects of combined treatment by psy-
chotherapy and antidepressants in comparison with either therapy
alone in the treatment of panic disorder with or without agorapho-
bia.

M E T H O D S

Criteria for considering studies for this review

Types of studies

All relevant randomised controlled trials (RCTs). Quasi-randomised
trials, such as those allocated by using alternate days of the week,
were excluded. For trials using a cross-over design, we used the first
comparative phase only.

Types of participants

Adult  patients  with  panic  disorder  with  or  without  agoraphobia,
diagnosed according to any of the following criteria: Feighner cri-
teria,  Research  Diagnostic  Criteria,  DSM-III,  DSM-III-R,  DSM-IV  or
ICD-10. When the study eligibility focused on agoraphobia, rather
than panic disorder, and was operationally diagnosed according to
the above-named criteria and when it could be safely assumed that
at least some of the patients were suffering from panic disorder as
defined by the above criteria, such a study could still be included.
An informed estimate tells us that over 95% of patients with agora-
phobia seen clinically suffer from panic disorder as well (Goisman
1995). However, the effect of their inclusion was examined in a sen-
sitivity analysis.
The patients had to be 18 years old or older.
Patients with comorbid physical or mental disorders were not ex-
cluded but the effect of including these patients was examined in
sensitivity analyses.

Types of interventions

Trials were included if they compared the combined psychother-
apy and antidepressant pharmacotherapy against either of these
single approaches for at least one week.

Not only does the incremental effectiveness remain unproven, but
there is a possibility that combination harms. Several reports have
suggested that benzodiazepines are not only associated with sever-
al disadvantages including sedation, reduced coordination and de-
velopment of dependence but that they may actually interfere with

The following individual, group, extensive or intensive psychologi-
cal treatments were included:
(i) Behaviour therapy that used some kind of exposure.
(ii) Cognitive therapy that used some kind of cognitive restructur-
ing.

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

3

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

(iii) Cognitive-behaviour therapy that contained both cognitive and
behavioural therapy elements.
(iv)  Psychodynamic  therapy  that  used  interpretation  of  current
maladaptive  patterns  as  repetition  of  earlier  childhood  experi-
ences.
(v)  Any  other  psychological  approach,  such  as  Rogerian  therapy,
Morita therapy or Eye Movement and Desensitisation Reprocessing
(EMSR).

(TCA): 

The following antidepressants were included:
(i)  Tricyclic  antidepressants 
imipramine,  amitripty-
line,  clomipramine,  desipramine,  nortryptiline,  doxepin,  do-
sulepin/dothiepin, trimipramine, lofepramine.
(ii) Selective serotonin reuptake inhibitors (SSRI): fluoxetine, ser-
traline, paroxetine, citalopram, fluvoxamine, escitalopram.
(iii) Monoamine oxidase inhibitors (MAOI): phenelzine, isocarbox-
azide, tranylcipromine, moclobemide, brofaromine.
(iv) Serotonin-noradrenaline reuptake inhibitors (SNRI): venlafax-
ine, milnacipran.
(v) Others: bupropion, trazodone, nefazodone, mianserin, mapro-
tilin, mirtazapine.

Studies  where  irregular  use  of  benzodiazepines  took  place  were
included.  Excluding  such  studies  would  be  meaningless  because
it  has  been  documented  that  a  minority  of  patients  take  ben-
zodiazepines  and  antidepressants  surreptitiously  when  they  are
prohibited  by  the  protocol  (Clark  1990).  Studies  where  benzodi-
azepines  were  regularly  administered  at  a  constant  dosage  for
long-time users were also included but the effect of this decision
was  examined  in  a  sensitivity  analysis.  Studies  where  benzodi-
azepines were regularly administered as part of the study medica-
tion were excluded.

The value of psychotherapy in helping medication discontinuation
is not the focus of this review and, therefore, such trials were not
included.

Types of outcome measures

(A) Effectiveness

(1) Short-term, i.e. during the acute phase treatment which normal-
ly would last 2 to 4 months

(i) Our primary outcome was the rate of "response", i.e. substan-
tial improvement from baseline as defined by the original investi-
gators. Examples would be "very much or much improved" accord-
ing to the Clinical Global Impression Change Scale, more than 40%
reduction in the Panic Disorder Severity Scale score, and more than
50% reduction in the Fear Questionnaire Agoraphobia Subscale.
(ii)  Rate  of  "remission",  i.e.  satisfactory  end-state  as  defined  by
global judgement of the original investigators. Examples would be
"panic free" and "no or minimal symptom" according to the Clini-
cal Global Impression Severity Scale.
(iii) Global judgement on a continuous scale. Examples would be
Panic  Disorder  Severity  Scale  total  score  (0  to  28),  Clinical  Glob-
al  Impression  Severity  Scale  (1  to  7),  Clinical  Global  Impression
Change Scale (1 to 7), etc. When multiple measures were used, pref-
erence was given in the order as above, and the actual measure en-
tered into meta-analysis was indicated at the top of the listings in
the Table of Included Studies.
(iv) Frequency of panic attacks, as recorded, for example, by a panic
diary.

Cochrane Database of Systematic Reviews

(v) Agoraphobia, as measured, for example, by Fear Questionnaire,
Mobility Inventory, behavioural avoidance test etc.
(vi) General anxiety, as measured, for example, by Hamilton Rating
Scale for Anxiety, Beck Anxiety Inventory, State-Trait Anxiety Index,
Sheehan Patient-Rated Anxiety Scale, Anxiety Subscale of SCL-90-
R etc.
(vii)  Depression,  as  measured,  for  example,  by  Hamilton  Rating
Scale for Depression, Beck Depression Inventory, Depression Sub-
scale of SCL-90-R etc.
(viii) Social functioning, as measured, for example, by Sheehan Dis-
ability  Scale,  Global  Assessment  Scale,  Social  Adjustment  Scale-
Self Report etc.
(ix) Quality of life, as measured for example by SF-36, SF-12 etc.
(x) Patient satisfaction with treatment.
(xi) Economic costs.

(2) Long-term, i.e. after the acute phase treatment

(2.1) On continued treatment

(i) Response/remission on continued treatment.
Although some studies reported on remission but not on response,
we also pooled such studies under the outcome "response/remis-
sion", in order to increase statistical power.
(ii) Quality of life.
(iii) Patient satisfaction.

(2.2) On treatment discontinuation

(i) Withdrawal symptoms on treatment discontinuation within one
month.
(ii) Response/remission after treatment discontinuation at 6 to 24
months.
Although some studies reported on remission but not on response,
we pooled such studies as well under the outcome "response/re-
mission" in order to increase statistical power.

(B) Adverse effects

(i) Total number of dropouts for any reason as a proxy measure of
treatment acceptability.
(ii) Number of dropouts due to adverse effects.
(iii) Number of patients experiencing at least one adverse effect.

Search methods for identification of studies

1. Electronic search
We searched the Cochrane Collaboration Depression, Anxiety and
Neurosis  Controlled  Trials  Registers  (CCDANCTR-Studies  and  CC-
DANCTR-References),  a  study-based  register  of  randomised  tri-
als incorporating results of group searches of MEDLINE (1966 on-
wards), EMBASE (1980 onwards), CINAHL (1982 onwards), PsycIN-
FO (1974 onwards), PSYNDEX (1977 onwards) and LILACS (1982 to
1999), and conducted handsearches of major psychiatric and med-
ical journals (see Collaborative Review Group Search Strategy). Be-
cause the concomitant administration of psychotherapy was often
either not mentioned in the abstract or indexed in the database,
we used the following simple search terms: panic AND antidepres-
sants, which included:

CCDANCTR-Studies (searched on 11/10/2005)
Diagnosis = Panic
and

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

4

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Free-text  =  "Antidepressive  Agents"  or  "Monoamine  Oxidase  In-
hibitors" or "Selective Serotonin Reuptake Inhibitors" or "Tricyclic
Drugs"  or  Acetylcarnitine  or  Alaproclate  or  Amersergide  or  Ami-
flamine  or  Amineptine  or  Amitriptyline  or  Amoxapine  or  Beflox-
atone  or  Benactyzine  or  Brofaromine  or  Bupropion  or  Butripty-
line or Caroxazone or Chlorpoxiten or Cilosamine or Cimoxatone
or  Citalopram  or  Clomipramine  or  Clorgyline  or  Clorimipramine
or  Clovoxamine  or  Deanol  or  Demexiptiline  or  Deprenyl  or  De-
sipramine or Dibenzipin or Diclofensine or Dothiepin or Doxepin or
Duloxetine or Escitalopram or Etoperidone or Femoxetine or Flu-
otracen  or  Fluoxetine  or  Fluparoxan  or  Fluvoxamine  or  Idazoxan
or Imipramine or Iprindole or Iproniazid or isocarboxazid or Litox-
etine or Lofepramine or Maprotiline or Medifoxamine or Melitracen
or  Metapramine  or  Mianserin  or  Milnacipran  or  Minaprine  or  Mir-
tazapine or Moclobemide or Nefazodone or Nialamide or Nomifen-
sine or Nortriptyline or Noxiptiline or Opipramol or Oxaflozane or
Oxaprotiline or Pargyline or Paroxetine or Phenelzine or Piribedil
or Pirlindole or Pivagabine or Prosulpride or Protriptyline or Quin-
upramine or Reboxetine or Rolipram or Sertraline or Setiptiline or
Teniloxine or Tetrindole or Thiazesim or Thozalinone or Tianeptine
or Toloxatone or Tomoxetine or Tranylcypromine or Trazodone or
Trimipramine or Venlafaxine or Viloxazine or Viqualine or Zimeldine

CCDANCTR-References (searched on 11/10/2005)
Keyword = Panic
and
Free-text  =  "Antidepressive  Agents"  or  "Monoamine  Oxidase  In-
hibitors" or "Selective Serotonin Reuptake Inhibitors" or "Tricyclic
Drugs"  or  Acetylcarnitine  or  Alaproclate  or  Amersergide  or  Ami-
flamine  or  Amineptine  or  Amitriptyline  or  Amoxapine  or  Beflox-
atone  or  Benactyzine  or  Brofaromine  or  Bupropion  or  Butripty-
line  or  Caroxazone  or  Chlorpoxiten  or  Cilosamine  or  Cionotome
or Citalopram or Clomipramine or Clorgyline or Chlormerodrin or
Scopolamine or Deanol or Demerit or Deprenyl or Desipramine or
Dibenzyline  or  Diclofenac  or  Dothiepin  or  Doxepin  or  Sulbentine
or Sialograms or Metroperitoneal or Entoretina or Fluorescent or
Fluoxetine or Guaroa or Fluvoxamine or Midrazolam or Imipramine
or Iprindole or Iproniazid or isocarboxazid or Alloxanthine or Lo-
belamine or Maprotiline or Etidocaine or Melitracen or Metathrom-
bin  or  Mianserin  or  Mulaire  or  Inapsine  or  Oracaine  or  Moclobe-
mide or Nefazodone or Nialamide or Nomifensine or Nortriptyline
or Mexitil or Opipramol or Oxaflozane or Oxaprotiline or Pargyline
or Paroxetine or Phenelzine or Piribedil or Pirlindole or Pivagabine
or Prosulpride or Protriptyline or Quinupramine or Reboxetine or
Rolipram or Sertraline or Setiptiline or Teniloxine or Tetrindole or
Thiazesim or Thozalinone or Tianeptine or Toloxatone or Tomoxe-
tine or Tranylcypromine or Trazodone or Trimipramine or Venlafax-
ine or Viloxazine or Viqualine or Zimeldine
We therefore sought all randomised controlled trials with antide-
pressants for panic disorder and manually checked to ascertain if
they had co-administered any credible psychotherapy. The search-
es were conducted with the assistance of the Depression, Anxiety
and Neurosis Review Group.

Two  complementary  searches  for  additional  relevant  trials  were
conducted on the Cochrane Central Controlled Trials Register with
the  search  terms:  panic  AND  antidepress*,  and  on  MEDLINE  us-
ing  the  search  terms:  panic  disorder  [MeSH]  AND  psychotherapy
[MeSH] limited to Randomized Controlled Trial [Publication type].
No language restriction was imposed.

2. Reference search

Cochrane Database of Systematic Reviews

The references of all selected studies were inspected for more pub-
lished reports and citations of unpublished research. In addition,
relevant review papers, both systematic and traditional ones, were
checked (Schmidt 2001; Taylor 2000; Schmidt 1999; APA 1998; van
Balkom 1997; Gould 1995; Telch 1994; Mavissakalian 1993; Mattick
1990).

3. SciSearch
All the selected studies were sought as a citation in the SciSearch
database in order to identify more studies.

4. Personal communication
To ensure that all RCTs were identified, the authors of significant
papers and other experts in the field were contacted (Isaac Marks
and authors of included trials).

Data collection and analysis

1. Selection of trials
Two review authors (TAF and NW) examined titles and abstracts of
references identified by the electronic search strategies described
above to check whether the study was likely to be relevant. Full ar-
ticles of all the studies identified by either of the two review authors
were then obtained and inspected by the same two review authors
for trials meeting the following broad and simple criteria:
(1) Randomised trial.
(2) Panic disorder as diagnosed by operationalised criteria.
(3) Combination of any form of psychotherapy plus antidepressant
versus either of these treatments.
Two independent review authors (TAF and NW) then examined the
strict eligibility of these broadly defined trials. The eligibility crite-
ria consisted of five items which operationalised the above-listed
criteria for considering studies. The inter-rater reliability of these
judgements was evaluated by means of weighted kappas.

2. Quality assessment
Two  independent  review  authors  (TAF  and  NW)  assessed  the
methodological quality of the selected studies.
The criteria for the quality assessment were based on the recom-
mendations of the Cochrane Reviewers' Handbook (Clark & Oxman
2000). Firstly, on the basis of explicit criteria (available from the au-
thors upon request), quality of randomisation in treatment condi-
tions  was  assessed,  and  trials  were  assigned  to  one  of  the  three
categories: A: adequate concealment, B: unclear concealment, and
C: inadequate concealment. There is empirical evidence that qual-
ity of randomisation can produce biased results (Schulz 1995, Mo-
her 1998, Chalmers 1983, Egger 2003). Secondly, we also rated the
study  as  'blinded'  when  at  least  one  outcome  measure  was  as-
sessed by an independent assessor blind to treatment allocation
and  'unblinded'  when  the  outcomes  were  assessed  by  someone
who was aware of the allocated treatment. There is some evidence
to suggest that trials that are not double blind yield biased results
(Schulz 1995, Coldiz 1989).
In addition to the methodological quality assessment of the select-
ed trials, we assessed the adequacy of the psychotherapy accord-
ing to the following criteria. We determined the quality of the ad-
ministered  psychotherapy  according  to  the  following  criteria:  A,
when the psychotherapy alone arm was shown to be superior to
the placebo arm in the same trial or when the same group of inves-
tigators  had  proved  effectiveness  in  a  separate  randomised  con-
trolled trial; B, when the conduct of psychotherapy was examined
by a third reviewer through audiotapes etc; and C, when the authors
gave sufficiently detailed descriptions of the therapy procedure. We

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

5

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

did not include trials which did not give detailed descriptions of the
psychotherapies they administered.
The effect of including studies with lower quality ("unblinded" for
blinding, and C on adequacy of psychotherapy) was examined in a
sensitivity analysis.

3. Data extraction
Two  review  authors  (RC  and  NW)  independently  extracted  data
from the original reports using data extraction forms. Any disagree-
ment was resolved by consensus between the two or, where neces-
sary, between all three review authors.
Some studies did not provide response rates but reported the base-
line and endpoint means and standard deviations (SD) of their glob-
al severity, agoraphobia and/or panic frequency measures. In such
instances, response rates can be imputed by calculating the per-
centage  of  subjects  scoring  less  than  half  of  the  baseline  score
from the endpoint mean and SD. This imputation method has been
shown to work excellently when imputing response in depression
trials, the agreement between the imputed and actual values being
an ANOVA ICC of 0.97 (95% CI 0.95 to 0.98) (Furukawa 2005).

4. Data synthesis
Data were entered into Review Manager 4.2 and double-checked for
accuracy by TAF.
For dichotomous outcomes, relative risks and their 95% confidence
intervals were calculated using a random-effects model. The ran-
dom-effects  model's  relative  risk  has  been  shown  to  be  superi-
or in clinical interpretation and external generalisation compared
to  fixed-effects  models  and  odds  ratios  or  risk  differences  (Fu-
rukawa 2002). For dichotomous outcomes, we used intention-to-
treat (ITT) analyses according to the following principle. When da-
ta on dropouts were carried forward and included in the efficacy
evaluation  by  the  last-observation-carried-forward  (LOCF)  in  the
original reports, they were included as such. When drop outs were
excluded  from  any  assessment  in  the  primary  studies  (for  exam-
ple, those who never returned for assessment after randomisation),
they were considered to be non-responders in both active and com-
parison groups. The same principles applied to outcomes at or af-
ter end of maintenance treatment, because we were interested in
the percentage of patients remaining well among those who had
entered the trials at all, and not among those who successfully en-
tered and/or finished the maintenance treatment phase.
For continuous outcomes, the standardised weighted mean differ-
ence (WMD) and their 95% confidence intervals were calculated us-
ing a random-effects model. When the study failed to report SD, it
was imputed from the other studies in this review that employed
the same scale (Furukawa 2006). The ITT approach was not feasi-
ble as studies only perform LOCF or endpoint analyses. Therefore,
continuous outcomes were analysed on an endpoint basis, includ-
ing only patients with a final assessment or with a last observation
carried forward to the final assessment.

5. Assessment of heterogeneity
Heterogeneity between studies was assessed by the I-squared sta-
tistic, the Q statistic and by visual inspection of the results. If sig-
nificant  heterogeneity  was  noted,  sources  were  investigated  (I-
squared > 50% was taken to be indicative of moderate heterogene-
ity (Higgins 2003); due to the known low sensitivity of the Q statis-
tic, P < 0.10 was taken to be suggestive of heterogeneity).

6. Funnel plot analysis
Funnel plot analysis was performed to check for small study effects,
including publication bias.

Cochrane Database of Systematic Reviews

7. Subgroup analyses
Subgroup analyses should be performed and interpreted with cau-
tion because multiple analyses lead to false positive conclusions
(Oxman  1992).  However,  we  performed  the  following  subgroups
analyses, where possible, for the following a priori reasons:
(1) For each type of psychotherapy separately (behaviour therapy,
cognitive therapy, cognitive-behaviour therapy and psychodynam-
ic  therapy  and  others),  because  they  may  not,  a  priori,  have  the
same degree of effectiveness when administered alone or the same
degree of combinability with pharmacotherapy.
(2) For classes of antidepressants, such as tricylic antidepressants,
selective serotonin reuptake inhibitors, and others.
(3) For patients with agoraphobia and for those without agorapho-
bia, because the same treatment may have differential effective-
ness with regard to panic and agoraphobia.
(4) For patients with and without depressive disorder, because it is
likely that antidepressants may confer more benefit for those pa-
tients with panic disorder comorbid with depression.

8. Sensitivity analyses
The following sensitivity analyses were planned a priori. By limiting
the studies for inclusion to those with higher quality, we examined
if the results changed and aimed to check for the robustness of the
observed findings by limiting to:
(1) Randomised controlled trials where at least one measure was
assessed  by  an  independent  assessor  blind  to  treatment  alloca-
tion.
(2)  Randomised  controlled  trials  where  the  administered  psy-
chotherapy had a demonstrated effectiveness rating of A or B ac-
cording to the above criteria.
(3) Randomised controlled trials which used operational diagnostic
criteria for panic disorder with or without agoraphobia.
(4) Studies whose participants were clearly without significant psy-
chiatric or physical comorbidities including primary or secondary
depressive disorders.
(5) Studies whose protocols explicitly prohibited concomitant use
of benzodiazepines. According to Clark 1990, 10% to 20% of those
assigned  to  placebo  or  imipramine  arms  in  a  randomised  con-
trolled trial took explicitly prohibited anxiolytic medication.

R E S U L T S

Description of studies

The electronic search identified 139 studies from the CCDANCTR,
an additional 164 from the CCCTR and 35 from MEDLINE. Browsing
their titles and abstracts, 135 articles were identified by either of
the two independent review authors (TAF and NW) as possible can-
didates, and their full copies were obtained. The inter-rater relia-
bility of the two raters with regard to the first-stage broad criteria
was percentage agreement = 91% and kappa = 0.79 (95% CI 0.68
to 0.90). Discrepancies were resolved by consensus. Two indepen-
dent review authors (TAF and NW) then examined the strict eligibili-
ty of these 42 papers, representing 20 RCTs. The inter-rater reliabili-
ty of these strict eligibility criteria was percentage agreement = 94%
(weighted kappa = 0.35, 95% CI 0.06 to 0.64). Disagreement was re-
solved by consensus between the two review authors. Ba 1999 was
excluded because the investigators prescribed both an antidepres-
sant and alprazolam at the same time as a pharmacological inter-
vention. Therefore we arrived at 19 studies that compared the com-
bined therapy against monotherapy.

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

6

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Once  this  preliminary  list  of  selected  studies  became  available,
their references, along with references of other relevant review pa-
pers, were checked by TAF for further reports and four additional
studies were identified (Agras 1991; Sheehan 1980a; Solyom 1981;
Lipsedge 1973). All the selected studies were sought as a citation
in the SciSearch database; seven additional articles reported on al-
ready identified trials, and one new trial was identified (Johnston
1995). Authors of significant papers and other experts in the field
were contacted, who were able to identify no further studies. When
the  five  additional  studies  were  examined  for  their  strict  eligibil-
ity,  Agras  1991  reported  that  their  randomisation  procedure  was
flawed and they could not obtain groups with comparable baseline
characteristics (personal communication). Solyom 1981 did not re-
port separate results for their social phobia and agoraphobia pa-
tients; the original author was contacted by telephone but could
not provide suitable data. Lipsedge 1973 did not use operational di-
agnostic criteria; moreover, they used iproniazid, which has some
MAO inhibiting effect, but which is not a widely recognised antide-
pressant.

All total, we identified 21 studies which satisfied the strict eligibil-
ity  and  validity  criteria.  Because  two  studies  provided  two  com-
parisons each (Mavissakalian 1986a; Mavissakalian 1986b; Sheehan
1980a; Sheehan 1980b), we had 23 comparisons from the 21 stud-
ies, comprising 1709 participants altogether.

1. Participants
For diagnostic criteria, four studies used DSM-IV panic disorder with
or without agoraphobia, nine studies used DSM-III-R panic disorder
with or without agoraphobia and three studies used DSM-III agora-
phobia with panic disorder. Seven studies (Johnston 1995; Marks
1983;  Mavissakalian  1983;  Sheehan  1980a;  Sheehan  1980b;  Zitrin
1980; Zitrin 1983) focused on agoraphobia, but contained descrip-
tions indicating that the participants were suffering from panic at-
tacks as well (e.g., moderate to high scores on measures of panic
attacks); they were therefore included in the present meta-analysis.

Only one study (Barlow 2000) focused on patients with panic disor-
der without agoraphobia. On the other hand, 13 studies (de Beurs
1995; Fava 1997; Johnston 1995; Loerch 1999; Marks 1983; Mavis-
sakalian 1983; Mavissakalian 1986a; Mavissakalian 1986b; Sheehan
1980a; Sheehan 1980b; Telch 1985; Zitrin 1980; Zitrin 1983) focused
on patients with panic disorder with agoraphobia. In the remain-
ing studies, either the percentage of participants with agoraphobia
was not specified or, when it was given, between 42% and 85% of
participants suffered from agoraphobia.

Typically, the majority of the participants were women, and their
average age was in the 30s. They had suffered from panic disorder
for 5 to 10 years.

Eleven studies explicitly limited their participants to those without
significant comorbid psychiatric (including depressive) and med-
ical comorbidities (Loerch 1999; Marks 1983; Mavissakalian 1986a;
Mavissakalian 1986b; Sharp 1996; Zitrin 1983; Oehrberg 1995; Spin-
hoven 1996; Stein 2000; Telch 1985; Zitrin 1980). The other studies
included patients with major depression (primary or secondary to
panic disorder) or personality disorders. No study focused on pa-
tients with comorbid panic disorder and depression, or reported re-
sults separately for such a sub-population.

Cochrane Database of Systematic Reviews

Twelve studies administered behaviour therapy that consisted of
exposure  and/or  breathing  retraining  and/or  relaxation  exercis-
es (de Beurs 1995; Fava 1997; Johnston 1995; Marks 1983; Mavis-
sakalian  1983;  Mavissakalian  1986a;  Mavissakalian  1986b;  Shee-
han  1980a;  Sheehan  1980b;  Telch  1985;  Zitrin  1980;  Zitrin  1983).
No study used narrowly-defined cognitive therapy relying only on
cognitive  restructuring.  Nine  studies  administered  cognitive-be-
haviour therapy consisting of both behaviour and cognitive thera-
py elements (Azhar 2000; Barlow 2000; Fahy 1992; Kampman 2002;
Loerch  1999;  Oehrberg  1995;  Sharp  1996;  Spinhoven  1996;  Stein
2000). For two studies, their psychotherapies were classified in the
"psychodynamic and others" category: Berger 2004 administered
cognitive-interpersonal group therapy, involving elements of cog-
nitive-behaviour therapy and interpersonal psychotherapy; Wiborg
1996 used brief dynamic psychotherapy without encouraging ex-
posure.

Six  studies  used  a  psychotherapy  alone  arm  (de  Beurs  1995;  Fa-
va  1997;  Azhar  2000;  Barlow  2000;  Sharp  1996;  Spinhoven  1996),
whereas  17  studies  used  a  psychotherapy  plus  placebo  arm  (de
Beurs  1995;  Johnston  1995;  Marks  1983;  Mavissakalian  1986a;
Mavissakalian 1986b; Sheehan 1980a; Sheehan 1980b; Telch 1985;
Zitrin 1980; Zitrin 1983; Barlow 2000; Fahy 1992; Kampman 2002;
Loerch 1999; Oehrberg 1995; Sharp 1996; Stein 2000).

With  regard  to  medications,  14  studies  used  tricyclic  antidepres-
sants  (imipramine  in  ten,  clomipramine  in  three,  trazodone  in
one  study),  seven  studies  used  selective  serotonin-reuptake  in-
hibitors  (paroxetine  in  four,  fluvoxamine  in  three),  and  two  oth-
er studies used monoamine oxidase inhibitors (moclobemide and
phenelzine).

The typical length of the acute phase active treatment was between
8 and 12 weeks; two studies were shorter (Fahy 1992 and Spinhoven
1996 lasted six weeks only), and two studies were much longer (20
weeks for Berger 2004 and 26 weeks for Zitrin 1983). Seven stud-
ies took explicit caution for the study participants not to take ben-
zodiazepines during the trial (Fahy 1992; Loerch 1999; Marks 1983;
Mavissakalian  1983;  Oehrberg  1995;  Sharp  1996;  Sheehan  1980a;
Sheehan  1980b;  Stein  2000).  Three  studies  (Oehrberg  1995;  Stein
2000;  Barlow  2000)  screened  the  urine  for  surreptitious  benzodi-
azepine use but in the others the success of this prohibition was not
ascertained.

Five  studies  provided  continuation  treatment,  in  which  the  drug
regimen  of  the  acute  phase  treatment  was  continued  (Johnston
1995; Marks 1983; Telch 1985; Wiborg 1996; Zitrin 1980). It was ex-
tremely important to know the outcomes of patients after the ac-
tive treatment phases consisting of acute phase treatment and, in
some cases, continuation treatment. Eleven studies provided fol-
low-up data for the study participants after discontinuation of ac-
tive  treatments  (Barlow  2000;  Berger  2004;  de  Beurs  1995;  Fava
1997; Loerch 1999; Marks 1983; Mavissakalian 1986a; Mavissakalian
1986b;  Sharp  1996;  Wiborg  1996;  Zitrin  1983).  The  patients  were
mostly free to seek further treatment between trial termination and
follow-up  assessment.  Of  the  originally  randomised  cohorts,  be-
tween 33% to 100% were successfully followed up at 6 to 24 months
after termination of active treatment, and between 30% and 77% of
these participants are reported to have received further treatment
in the interim.

2. Interventions

3. Outcomes

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

7

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Among the 21 included studies, there was no standard measure-
ment instrument for panic disorder or no agreed-upon definition of
response or remission. We therefore used the following scale scores
for meta-analyses:
Global  severity  of  panic  disorder  was  measured  with  PDSS  (Bar-
low  2000),  with  CGI  Severity  and/or  Change  (Fahy  1992;  Loerch
1999;  Sharp  1996;  Zitrin  1980;  Zitrin  1983),  or  with  the  authors'
original scales (de Beurs 1995; Mavissakalian 1983; Mavissakalian
1986a; Mavissakalian 1986b; Sheehan 1980a; Sheehan 1980b; Wi-
borg 1996).
Panic  attack  frequency/severity  was  measured  by  counting  the
number  of  panic  attacks  for  a  certain  time  period  preceding  as-
sessment (Azhar 2000; Berger 2004; de Beurs 1995; Johnston 1995;
Marks  1983;  Oehrberg  1995;  Spinhoven  1996;  Stein  2000;  Telch
1985) or with the authors' original scales (Fava 1997; Mavissakalian
1986a; Mavissakalian 1986b; Wiborg 1996; Zitrin 1980; Zitrin 1983).
Agoraphobia  was  assessed  with  FQ  Agoraphobia  subscale  (Fa-
va  1997;  Johnston  1995;  Loerch  1999;  Marks  1983;  Mavissakalian
1983; Mavissakalian 1986a; Mavissakalian 1986b; Sharp 1996; Stein
2000;  Telch  1985),  Mobility  Inventory  (Kampman  2002),  Fear  Sur-
vey Schedule (Sheehan 1980a; Sheehan 1980b) or with the authors'
original scales (Berger 2004; de Beurs 1995; Fahy 1992; Spinhoven
1996; Wiborg 1996; Zitrin 1980; Zitrin 1983).
General anxiety was measured with HAM-A (Azhar 2000; Fahy 1992;
Loerch  1999;  Sharp  1996;  Wiborg  1996),  Beck  Anxiety  Inventory
(Stein  2000),  Zung  Self-Rating  Anxiety  Scale  (Mavissakalian  1983;
Mavissakalian  1986a;  Mavissakalian  1986b;  Oehrberg  1995),  SCL
Anxiety subscale (Sheehan 1980a; Sheehan 1980b), Taylor Manifest
Anxiety ( Zitrin 1983), FQ General Anxiety (Kampman 2002) or with
the authors' original scales (Berger 2004; de Beurs 1995; Fava 1997;
Marks 1983).
Depression was measured with HAM-D (Azhar 2000; Fahy 1992; Lo-
erch 1999; Marks 1983; Mavissakalian 1983; Wiborg 1996), MADRS
(Sharp  1996),  Beck  Depression  Inventory  (Mavissakalian  1986a;
Mavissakalian 1986b; Stein 2000; Telch 1985), SCL Depression sub-
scale (Johnston 1995), Zung Self-Rating Depression Scale (Sheehan
1980a; Sheehan 1980b; Spinhoven 1996 or with the authors' origi-
nal scales (de Beurs 1995; Fava 1997; Zitrin 1983).
Social functioning was reported in 13 studies; they used Sheehan
Disability  Scale  (Berger  2004;  Loerch  1999;  Sharp  1996;  Sheehan
1980a;  Sheehan  1980b;  Stein  2000;  Wiborg  1996),  SAS-SR  (John-
ston 1995) and some ad hoc measures (Mavissakalian 1983; Mavis-
sakalian 1986a; Mavissakalian 1986b; Zitrin 1980; Zitrin 1983).

The  definition  of  response  and  remission  varied  from  study  to
study. We therefore sought to re-define "response" as substantial
improvement  from  baseline,  and  "remission"  as  satisfactory  end
state.  The  operational  definition  of  "response"  then  correspond-
ed  with  "very  much  or  much  improved"  on  CGI  Change  (Berger
2004; Loerch 1999; Sharp 1996; Stein 2000; Zitrin 1980; Zitrin 1983),
more  than  40%  reduction  in  the  PDSS  (Barlow  2000),  more  than
50% reduction in self-rated severity of phobia (Mavissakalian 1983),
more  than  50%  reduction  in  panic  frequency  (Oehrberg  1995)  or
some  other  original  definitions  by  the  authors  (Kampman  2002;
Marks 1983; Sheehan 1980a; Sheehan 1980b). In addition, we im-
puted response rates by the method described above in the Meth-
ods section by defining response as more than 40% reduction in
the CGI Severity (Fahy 1992) or an ad hoc global severity scale (Wi-
borg 1996), more than 50% reduction in the FQ Agoraphobia sub-
scale (de Beurs 1995; Johnston 1995; Telch 1985), more than 50%
reduction in the self-rated severity of phobia (Mavissakalian 1986a;
Mavissakalian 1986b), or more than 50% reduction in the frequen-

Cochrane Database of Systematic Reviews

cy  of  panic  attacks  (Azhar  2000;  Spinhoven  1996).  The  validity  of
this imputation method was confirmed because the agreement be-
tween the actual values and the imputed values, when both were
given in the original reports, was an ANOVA ICC of 0.93 (one-way
random, single rater, 95% CI 0.83 to 0.99). "Remission" was opera-
tionally defined as "panic free" (Berger 2004; de Beurs 1995; Fahy
1992;  Fava  1997;  Kampman  2002;  Mavissakalian  1983;  Oehrberg
1995; Sharp 1996; Stein 2000; Wiborg 1996), "no or minimal symp-
tom"  according  to  the  Clinical  Global  Impression  Severity  Scale
(Barlow 2000; Loerch 1999) or some other original definitions by the
authors  (Marks  1983;  Mavissakalian  1986a;  Mavissakalian  1986b;
Sheehan 1980a; Sheehan 1980b; Zitrin 1980; Zitrin 1983).

No  study  reported  on  the  quality  of  life,  patient  satisfaction  and
economic costs during the acute phase treatment or continuation
treatment.  Some  studies  reported  the  number  of  patients  who
dropped out due to side effects, but no study reported on the to-
tal number of patients reporting side effects or on the withdraw-
al symptoms upon discontinuation of treatment. Total number of
dropouts  during  the  acute  phase  treatment  were  in  the  range  of
0%  to  9%  (Fava  1997;  Stein  2000;  Wiborg  1996),  10%  to  19%  (de
Beurs 1995; Spinhoven 1996; Mavissakalian 1983; Kampman 2002;
Oehrberg 1995), 20% to 29% (Telch 1985; Zitrin 1983; Azhar 2000;
Spinhoven  1996;  Berger  2004;  Barlow  2000;  Loerch  1999;  Sharp
1996;  Sheehan  1980a;  Sheehan  1980b)  and  over  30%  (Johnston
1995; Marks 1983).

4. Commercial involvement
Four studies acknowledged financial support from pharmaceutical
companies (de Beurs 1995; Fahy 1992; Loerch 1999; Sharp 1996);
these companies marketed the drugs involved in the trials. Sharp
1996 had some drug company employees as co-authors. Oehrberg
1995 did not acknowledge financial support from a drug company
but three of the co-authors were company employees.

See Tables of Excluded Studies and Included Studies for further de-
tails.

Risk of bias in included studies

With regard to validity, based on information from published ma-
terials, all but two (Mavissakalian 1986a; Mavissakalian 1986b) of
the 23 comparisons scored B for allocation concealment. Person-
al contact with the original authors revealed two more trials with
adequate  concealment  (Berger  2004;  Wiborg  1996).  Nineteen  tri-
als conducted blind outcome assessments, and four trials were un-
blinded (Azhar 2000; Berger 2004; Mavissakalian 1983; Spinhoven
1996).  The  inter-rater  reliability  of  these  two  validity  criteria  was
a percentage agreement of 94% (kappa was incalculable because
one rater's ratings were constant) for allocation concealment and
83% (weighted kappa = 0.51, 95% CI 0.16 to 0.87) for blinding; any
disagreement was resolved by consensus between the two raters.

With regard to quality of the psychotherapies provided, only three
studies scored A, i.e. provided direct evidence of operationalising
an  effective  psychotherapy  compared  with  a  drug  placebo  arm;
these were Barlow 2000, Loerch 1999 and Sharp 1996. Four more
studies  scored  B,  i.e.  examined  the  adequacy  of  the  psychother-
apies  through  audiotapes;  these  were  Kampman  2002,  de  Beurs
1995, Fava 1997 and Zitrin 1983.

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

8

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Effects of interventions

1.  Psychotherapy  plus  antidepressant  versus  antidepressant
alone

(1.1) Acute phase treatment
Combining 322 patients in the psychotherapy plus antidepressant
arm and 347 patients in the antidepressant alone arm from 11 stud-
ies, the combination arm was 1.24 (95% CI 1.02 to 1.52) times more
likely  to  produce  response  at  the  end  of  two  to  four  months  of
acute phase treatment than the antidepressant alone arm. The test
for heterogeneity was significant with p = 0.05, and moderate with

I-squared  at  44.9%.  Furthermore,  the  funnel  plot  (Figure  1)  was
suggestive of some publication bias, with one small study report-
ing an extreme result (Telch 1985). When we omitted this outlying
study and studies which used "psychodynamic and other" thera-
pies  (Berger  2004;  Wiborg  1996),  thus  limiting  the  included  stud-
ies to those employing behaviour or cognitive-behaviour therapies,
the  RR  was  similar  (RR  1.28,  95%  CI  1.08  to  1.52)  and  there  was
no longer statistical heterogeneity (p = 0.18, I-squared = 30.5%) or
funnel plot asymmetry. The superiority of the combination therapy
was no longer apparent, though, when we looked at the remission
rates rather than the response rates (RR 1.12, 95% CI 0.84 to 1.48),
possibly because of the smaller number of included studies (seven
instead of 11 studies).

Figure 1.   Funnel plot for response at 2-4 months on PT+AD vs AD alone

The  superiority  of  the  combination  therapy  was  corroborated  by
secondary analyses employing continuous data. The combination
arm decreased global severity of the disorder (SMD -0.36, 95% CI
-0.60 to -0.11), depression (SMD -0.52, 95% CI -0.76 to -0.28), and
social malfunctioning (SMD -0.47, 95% CI -0.89 to -0.05). Non-signif-
icant trends in favour of the combination therapy were noted for
panic frequency (SMD -0.20, 95% CI -0.56 to 0.16), phobic avoidance
(SMD -0.32, 95% CI -0.68 to 0.05) and general anxiety (SMD -0.43,
95% CI -0.88 to 0.03). Limiting the studies to those administering be-
haviour and cognitive-behaviour therapies decreased heterogene-
ity but did not materially affect the overall effect estimates.

There was no difference in overall dropouts, or in dropouts due to
side effects.

(1.2) Continued treatment
There was strong heterogeneity (p = 0.005, I-squared = 76.8%). Lim-
iting the studies to behaviour and cognitive-behaviour therapies,
heterogeneity disappeared (p = 0.55, I-squared = 0%), and the com-
bination therapy was 1.63 (95% CI 1.21 to 2.19) times more likely to
produce response/remission than the antidepressant alone treat-
ment. The effect size in reducing global/avoidance/panic severity
was also statistically significant in favour of the combination ther-
apy (SMD -0.60, 95% CI -1.00 to -0.19).

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

9

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

(1.3) After treatment discontinuation
There was only one study that reported outcomes immediately af-
ter tapering paroxetine over four weeks (Berger 2004): no statisti-
cally significant difference was noted for dichotomous or continu-
ous measures.

Five studies reported outcomes after 6 to 24 months of naturalis-
tic follow-up. Combining outcomes based on 376 participants, the
combination therapy was still superior to antidepressants alone in
terms of response/remission (RR 1.61, 95% CI 1.23 to 2.11). No het-
erogeneity was noted (p = 0.50, I-squared = 0%). This advantage was
not apparent on a continuous measure, probably because of the
smaller number of trials reporting such outcomes.

None of these meta-analytic comparisons were heterogeneous; un-
fortunately,  there  were  too  few  studies  for  the  funnel  plot  to  be
meaningful.

The two arms did not differ in terms of dropouts for any reason, but
dropouts due to side effects were more frequent in the combination
arm (RR 7.46, 95% CI 1.73 to 32.26).

(2.2) Continuation treatment
There was only one study which examined the effect of continued
treatment (Barlow 2000). Again, the advantage of the combination
therapy appeared to continue as long as the treatments were con-
tinued. Only the SMD was significant (-0.46, 95% CI -0.80 to -0.13).

2.  Psychotherapy  plus  antidepressant  versus  psychotherapy
alone
Although the comparison psychotherapy plus antidepressant ver-
sus  psychotherapy  alone  is  theoretically  different  from  the  com-
parison psychotherapy plus antidepressant versus psychotherapy
plus  placebo  (Hollon  1981),  our  meta-analytic  summaries  for  the
former comparison were surprisingly in accordance with those for
the latter comparison, save for the fact that the former comparison
had a smaller number of studies and produced a smaller number
of statistically significant results.

(2.1) Acute phase treatment
Five studies compared, in total, 169 participants in the combination
arm  and  183  participants  in  the  psychotherapy  alone  arm.  None
of the comparisons of effectiveness between these two arms were
statistically significant, but their point estimates were very similar
to those between psychotherapy plus antidepressant versus psy-
chotherapy  plus  placebo.  For  example,  RR  of  response  was  1.09
(95%  CI  0.91  to  1.32),  that  of  remission  was  1.22  (95%  CI  0.99  to
1.51), and SMR for global severity was -0.31 (95% CI -0.63 to 0.02).

(2.3) After treatment discontinuation
Two  hundred  and  seventy  two  patients  were  assessed  at  6  to
24 months after treatment discontinuation. Any advantage of the
combination therapy seemed to disappear (RR 0.97, 95% CI 0.71 to
1.33).

3.  Psychotherapy  plus  antidepressant  versus  psychotherapy
plus placebo

(3.1) Acute phase treatment
Comparing 550 patients in the psychotherapy plus antidepressant
arm and 482 patients in the psychotherapy plus placebo arm from
17 studies, the former was 1.17 (95% CI 1.04 to 1.32) times more
likely to produce response at the end of two to four months of acute
phase treatment than the latter. The test for heterogeneity was not
significant, with I-squared of 12.0%. Funnel plot of response (Fig-
ure 2) was somewhat suggestive of publication bias, with one small
study reporting results much in favour of the combination therapy
(Telch 1985). Excluding it reduced heterogeneity further, and the RR
was unaffected.

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

10

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Figure 2.

Cochrane Database of Systematic Reviews

The same tendencies in favour of the combined therapy were noted
for the remission rate (RR 1.30, 95% CI 1.10 to 1.54) and global sever-
ity (SMD -0.45, 95% CI -0.63 to -0.26). Looking at different aspects of
panic disorder, although no statistically significant difference was
found for frequency of panic attacks, the combination therapy was
again significantly superior in terms of reduction in phobic avoid-
ance, general anxiety, depression and social functioning.

Although  the  two  arms  did  not  differ  in  overall  dropout  rates,
dropouts due to side effects were more frequent in the combined
therapy arm than the psychotherapy plus placebo arm (random ef-
fects RR 2.43, 95% CI 1.23 to 4.81).

(3.2) Continuation treatment
As  long  as  the  treatments  were  continued,  the  advantage  of  the
combination therapy appeared to continue, as the response rate at
the end of continuation treatment was non-significantly in favour
of the combination therapy (RR 1.29, 95% CI 1.03 to 1.62) and the
global severity was significantly lower in the combination arm (SMD
-0.65,  95%  CI  -0.97  to  -0.33).  The  test  for  heterogeneity  was  not
significant  for  either  of  these  two  meta-analyses,  although  the  I-
squared was 52.7% for the global severity; for the response rate, it
was only 3.1%. During the continuation treatment, there were no
differential dropout rates between the two arms.

(3.3) After treatment discontinuation
In total, 658 patients were assessed at 6-24 months after discontin-
uing treatment. Any advantage of the combination therapy seems

to  disappear,  because  neither  the  response  rate  (RR  0.96,  95%CI
0.79 to 1.16) nor the global severity measures were significantly dif-
ferent between the two arms. The test for heterogeneity was signif-
icant for neither of these meta-analyses.

4.  Psychotherapy  plus  antidepressant  versus  psychotherapy
alone or plus placebo
Here  and  in  the  following  subgroup  and  sensitivity  analyses,  we
examine the aggregate results of trials comparing psychotherapy
plus antidepressant with psychotherapy alone and those compar-
ing  the  former  with  psychotherapy  plus  placebo.  Although  these
two types of comparisons are theoretically different from one an-
other (Hollon 1981), our meta-analytical summaries were remark-
ably  similar  for  the  acute  phase  and  follow-up  evaluations.  We
therefore made a post hoc (i.e. after the data were collected) deci-
sion to increase the statistical power by combining them. When one
study contributed both comparisons, i.e. one between the combi-
nation versus psychotherapy alone and another between the com-
bination versus psychotherapy plus placebo, the name of the study
was automatically given a suffix of i or ii; such was the case with
Barlow 2000, de Beurs 1995 and Sharp 1996.
We will here briefly summarize the combined results.

(4.1) Acute phase treatment
Comparing 599 patients in the psychotherapy+antidepressant arm
and 672 patients in the psychotherapy alone or +placebo arm from
23 studies, the former was 1.17 (95% CI: 1.05 to 1.31) times more
likely to produce response at the end of 2-4 months of acute phase

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

11

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

treatment than the latter. The test for heterogeneity was not signif-
icant, with I-squared of 12.6%.

The same tendencies in favour of the combined therapy were noted
for the remission rate (RR1.26, 95%CI 1.10 to 1.44) and global sever-
ity (SMD -0.43, 95%CI -0.60 to -0.26). Looking at different aspects of
panic disorder, although no statistically significant difference was
found for frequency of panic attacks, the combination therapy was
again significantly superior in terms of reduction in phobic avoid-
ance, general anxiety, depression and social dysfunction.

Although  the  two  arms  did  not  differ  in  overall  dropout  rates,
dropouts due to side effects were more frequent in the combined
therapy  arm  than  the  psychotherapy  alone  or  +placebo  arm  (RR
3.01, 95%CI 1.61 to 5.63).

Because there was no study that focused on patients with comor-
bid panic disorder and depressive disorder, and no study reported
results for depressed and non-depressed participants separately,
it was not possible to examine if the effect sizes were comparable
when the participants suffered from depression or when they did
not. We therefore performed a separate subgroup meta-analysis of
12 studies which explicitly excluded subjects with comorbid psychi-
atric (including depressive) and medical conditions. The pooled es-
timates of effectiveness from those studies focusing on pure panic
disorder patients were again largely in accordance with the overall
estimates. In two out of 15 comparisons, the point estimates were
qualitatively different, but the confidence intervals overlapped be-
tween those focusing on patients without comorbidities and those
including all the trials found for this systematic review.

5. Subgroup analyses

6. Sensitivity analyses

(5.1) Types of psychotherapy
For all the outcomes during the acute phase or continuation treat-
ments  or  after  treatment  discontinuation,  the  confidence  inter-
vals of the pooled estimates of the effectiveness of behaviour ther-
apy  and  cognitive-behaviour  therapy  overlapped  to  a  significant
degree. Pooling these two kinds of psychotherapies together sel-
dom resulted in statistically significant (p < 0.10) or substantive (I-
squared > 30%) heterogeneity.

The only exceptions were "Psychodynamic psychotherapy and oth-
ers" category for the comparison psychotherapy plus antidepres-
sant versus antidepressant alone. Berger 2004 administered what
the authors called cognitive-interpersonal group therapy for pan-
ic disorder, adapted from cognitive therapy and interpersonal psy-
chotherapy. Wiborg 1996 administered brief dynamic psychother-
apy,  developed  from  concepts  and  techniques  from  Davanloo,
Malan and Strupp. The results from these two studies were often
qualitatively different not only from one another but also from the
other studies administering behaviour or cognitive-behaviour ther-
apies, and combining them altogether often resulted in significant
and substantive heterogeneity.

(5.2) Classes of antidepressants
We  performed  a  meta-analysis  of  14  studies  that  used  TCAs  and
seven studies that used SSRIs as antidepressants. The pooled esti-
mates of effect size of these two meta-analyses were very similar
to each other, and to the overall results. For the TCA meta-analysis,
only one out of 15 major outcomes had a qualitatively different es-
timate than the overall results; for the SSRI meta-analysis, only two
had such. In all these instances, the 95% confidence intervals were
rather wide and overlapped significantly with the overall results.

(5.3) Panic disorder with agoraphobia versus panic disorder with-
out agoraphobia
We performed a meta-analysis of 13 studies which focused on pa-
tients with agoraphobia only and compared their response/remis-
sion rates and changes in global severity. The point estimates of the
pooled effectiveness were qualitatively different from those of the
only study which focused on patients without agoraphobia (Barlow
2000) in only two out of 15 comparisons; in either case, the con-
fidence  intervals  were  very  wide  and  there  was  overlap  between
those for agoraphobic patients and those for non-agoraphobic pa-
tients.

(5.4) Patients without depression

(6.1) Limited to RCTs where at least one measure was assessed by
an independent rater blind to treatment allocation.
Nineteen studies were included. The pooled estimates were virtu-
ally identical to and qualitatively no different from the overall re-
sults.

(6.2) Limited to RCTs where the administered psychotherapy had
a demonstrated effectiveness rating of A or B.
Seven studies were included. Again the pooled estimates were vir-
tually identical to and qualitatively no different from the overall re-
sults.

(6.3) Limited to RCTs that used operationalised diagnostic criteria
for panic disorder with or without agoraphobia.
Sixteen studies were included. Again the pooled estimates were vir-
tually identical to and qualitatively no different from the overall re-
sults.

(6.4) Limited to studies whose participants were explicitly with-
out significant psychiatric or medical comorbidities.
Please see the subgroup analysis 5.4 above.

(6.5) Limited to studies whose protocols explicitly prohibited con-
comitant use of benzodiazepines.
Nine studies could be included. There were three point estimates of
effectiveness that were qualitatively different from the overall esti-
mates out of 15 comparisons we made, but the small number of tri-
als included allowed wide confidence intervals which overlapped
significantly with those from the overall estimates. Otherwise the
pooled point estimates were very similar between the overall re-
sults and those which prohibited benzodiazepines.

D I S C U S S I O N

The  combined  psychotherapy  plus  antidepressant  treatment
turned out to be robustly superior to either monotherapy for the
acute phase treatment of panic disorder with or without agorapho-
bia. Taking the average response rates of between 50% to 70% for
monotherapy,  the  pooled  RR  of  1.2  for  the  combination  therapy
was translated into NNTs between seven and ten. During the acute
phase treatment, combination therapy resulted in more drop-outs
due  to  side  effects  than  psychotherapy  alone,  and  the  NNH  was
around 26.
The  superiority  of  the  combination  appeared  to  hold  as  long  as
the antidepressant treatment was continued. There was, however,
a  differential  advantage  to  the  combination  therapy  vis-a-vis  an-

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

12

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

tidepressant alone or psychotherapy alone after the acute phase
and  continuation  treatments  were  discontinued.  The  naturalistic
follow-up of the included RCTs demonstrated the sustained advan-
tage  of  the  combination  therapy  over  antidepressant  alone  for  6
to  24  months  but  no  differential  effectiveness  over  psychothera-
py alone at 6 to 24 months. At 6 to 24 months after treatment dis-
continuation, the combined therapy still showed an NNT around
six over antidepressant pharmacotherapy alone. With regard to the
comparison between the combination therapy and psychotherapy,
there was no evidence of long-term benefit of the former compared
with the latter. In this respect, it is important to note that, despite
recent admonitions from several experts (Foa 2002; Schmidt 2001;
Taylor 2000), no disadvantage was observed for the combination
therapy in the long term.
These results were robust against several sensitivity analyses. We
observed  similar  effectiveness  for  three  of  the  four  a  priori  de-
fined subgroup analyses, namely for TCAs and SSRIs, for patients
with agoraphobia and those without, and for patients without co-
morbid depression. In terms of differential effectiveness of various
forms of psychotherapy, however, only behaviour therapy and cog-
nitive-behaviour therapy were homogeneously effective; the oth-
er two therapy modalities, brief psychodynamic therapy and cog-
nitive-interpersonal therapy, produced mixed results which lead to
increased heterogeneity. Funnel plot analyses were suggestive of
some publication bias. However, excluding outliers and limiting to
behaviour and cognitive-behaviour therapies, we were able to ar-
rive  at  effect  estimates  which  were  more  homogeneous,  and  yet
materially no different from the overall results.

The major strengths of the present systematic review may be as fol-
lows:
(1) We performed a systematic and comprehensive search of the
relevant  trials:  we  identified  23  comparisons  from  21  studies,
whereas the previous reviews were able to include a maximum of
11 to 13 studies (Telch 1994; Taylor 2000; Schmidt 2001).
(2)  We  contacted  the  original  authors  for  missing  data  and  ap-
plied empirically validated imputation methods (Furukawa 2005;
Furukawa 2006) to represent the identified trials in the meta-ana-
lytic summary as much as possible.
(3)  We  abode  by  the  ITT  principle  when  meta-analysing  dichoto-
mous outcomes by counting all the dropouts as non-responders.
This  policy  is  especially  pertinent  when  considering  the  relative
merits of the combination therapy over monotherapy in the long
term, because we were interested in the number of patients doing
well out of those who started the acute phase therapy, and not out
of those who successfully completed it.
(4) The a priori planned sensitivity analyses and subgroup analyses
confirmed the overall findings.

Several  possible  weaknesses  of  the  present  study  must  also  be
highlighted:
(1) Firstly, the funnel plot analyses suggested the possibility of pub-
lication bias among the identified trials. Excluding outliers, howev-
er, did not affect the pooled estimates.
(2) Secondly, generalisability of the present findings beyond spe-
cialist  psychiatric  settings  is  not  straightforward.  Only  one  study
(Sharp 1996) was conducted in the primary care setting but in this
study patients were seen in their local GP clinics but by qualified
clinical  psychologists.  Only  two  studies  in  this  review  assessed  a
psychological approach other than CBT. Where CBT therapists were
not available, the research evidence, as accumulated and present-

Cochrane Database of Systematic Reviews

ed in this systematic review, would not be readily applicable to clin-
ical practices.
(3) Up until recently, there have not been widely accepted and vali-
dated rating scales for panic disorder, and many studies included in
this systematic review used the authors' original scales. One study
has indicated that rating scales which have not been validated or
standardised are more likely to report statistically significant find-
ings than those which are validated (Marshall 2000). Due to this lack
of accepted assessment methods for panic disorder, the definition
of "response" (our primary outcome) had to be operationalised by
a variety of measures. However, these overall results were corrobo-
rated by analyses that focused on specific aspects of the symptoms
of panic disorder.
(4) Last, but most importantly, the comparability of the treatment
arms after termination of acute phase and continuation treatments
may have been compromised by the naturalistic nature of the fol-
low-ups. Except for Sharp 1996, which explicitly required patients
not to receive any psychotropic drugs or psychotherapies, partici-
pants were free to seek further treatment between treatment ter-
mination and follow-up assessments, and 30% to 77% did receive
additional therapies. This does not necessarily undermine the com-
parability  of  the  treatment  arms  per  se;  had  the  published  stud-
ies reported number of patients who did well without further treat-
ment, the interpretation of the relative merits of the combination
versus single therapies would have been more straightforward. It
is also important to note that overall only about half of the acute
phase  treatment  studies  included  long  term  follow  ups  after  the
acute phase (five out of 11 that compared the combined treatment
against  antidepressant  pharmacotherapy,  and  12  out  of  23  that
compared  the  combination  against  psychotherapy  alone  or  psy-
chotherapy plus placebo).

It must be noted that our review does not answer the question of
relative merits of combination versus sequential treatments. How-
ever, this is not, strictly speaking, a weakness of our study, because
we  did  not  plan  our  review  to  answer  such  questions.  Given  the
present findings, some might argue for psychotherapy alone as first
line treatment, and to consider combination therapy only when the
former fails; it appears to be a viable option but remains unproven
as far as the present review is concerned.

In conclusion, the current findings from the best available evidence
suggest that either combined therapy or psychotherapy alone may
be chosen as first line treatment for panic disorder with or without
agoraphobia. Treatment decisions might depend on patient pref-
erence and values. Antidepressant pharmacotherapy alone is not
to be recommended as first line treatment where appropriate re-
sources  are  available.  Although  none  of  the  included  studies  ex-
amined cost issues, economic consideration of years of medication
versus  one-off  psychological  treatment  would  also  favour  inclu-
sion of psychotherapy (Otto 2000). It remains, however, that where
quality psychotherapy is hard to obtain (which unfortunately is the
case for most parts of the world, and which therefore needs to be
remedied through national health policies), antidepressant med-
ication alone will still remain the only treatment accessible.

A U T H O R S '   C O N C L U S I O N S

Implications for practice

Combined therapy is more effective than psychotherapy alone or
antidepressant  pharmacotherapy  alone  in  the  short  term.  Com-
bined therapy is as effective as psychotherapy alone and is more

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

13

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

effective than antidepressant pharmacotherapy alone in the long
term. The strongest evidence existed for behaviour or cognitive-be-
haviour therapy. It therefore follows that either combined cogni-
tive-behaviour and pharmacotherapy or cognitive-behaviour ther-
apy alone may be chosen as first line treatment for panic disorder
with or without agoraphobia, depending on patient preference. An-
tidepressant pharmacotherapy alone is not to be recommended as
first line treatment where appropriate resources are available.

Implications for research

Three lines of inquiry warrant further investigation. Firstly, in the
acute phase treatment, if we adhere to the strict ITT principle, the
remission rates are only slightly above 50% for combination thera-
py and slightly below 50% for psychotherapy alone. We need to de-
velop strategies to deal with partial and non-responders to these
therapies.  Secondly,  for  the  long  term  outcome,  our  review  sug-

gested  that  combined  therapy  does  not  interfere  with  or  detract
from psychotherapy. Further research is necessary to confirm this
finding by counting the number of patients completely recovered,
without further treatment at follow up. Lastly, there are currently
only limited data available on the effects of combining antidepres-
sants with non-cognitive-behavioural therapies, such as psychody-
namic and interpersonal therapies. In this review, the only avail-
able trial that involved psychodynamic therapy showed increased
benefit  when  combined  with  antidepressants.  This  suggests  the
potential value of future trials designed to investigate this type of
combination in the treatment of panic disorder.

A C K N O W L E D G E M E N T S

The review was supported in part by Health and Labour Sciences
Research Grants (Research on Health and Technology Assessment)
H13-018 from the Ministry of Health, Labour and Welfare, Japan.

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

14

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

R E F E R E N C E S

References to studies included in this review

Azhar 2000 {published data only}

Azhar MZ. Comparison of fluvoxamine alone, fluvoxamine
and cognitive psychotherapy and psychotherapy alone in
the treatment of panic disorder in Kelantan--implications for
management by family doctors. Medical Journal of Malaysia
2000;55:402-8.

Barlow 2000 {published data only}

* Barlow DH, Gorman JM, Shear MK, Woods SW. Cognitive-
behavioral therapy, imipramine, or their combination for panic
disorder: A randomized controlled trial. JAMA 2000;283:2529-36.

Gorman JM, Martinez JM, Goetz R, Huppert JD, Ray S,
Barlow DH, et al. The effect of pharmacotherapist
characteristics on treatment outcome in panic disorder.
Depression and Anxiety 2003;17:88-93.

Grilo CM, Money R, Barlow DH, Goddard AW, Gorman JM,
Hofmann SG, et al. Pretreatment patient factors predicting
attrition from a multicenter randomized controlled
treatment study for panic disorder. Comprehensive Psychiatry
1998;39(6):323-32.

Hofmann SG, Barlow DH, Papp LA, Detweiler MF, Ray SE,
Shear MK, et al. Pretreatment attrition in a comparative
treatment outcome study on panic disorder. American Journal
of Psychiatry 1998;155(1):43-7.

Hofmann SG, Shear MK, Barlow DH, Gorman JM, Hershberger D,
Patterson M, et al. Effects of panic disorder treatments on
personality disorder characteristics. Depression and Anxiety
1998;8(1):14-20.

Huppert JD, Bufka LF, Barlow DH, Gorman JM, Shear MK,
Woods SW. Therapists, therapist variables, and cognitive-
behavioral therapy outcome in a multicenter trial for panic
disorder. Journal of Consulting and Clinical Psychology
2001;69:747-55.

Barlow 2000i {published data only}

* Barlow DH, Gorman JM, Shear MK, Woods SW. Cognitive-
behavioral therapy, imipramine, or their combination for panic
disorder: A randomized controlled trial. JAMA 2000;283:2529-36.

Gorman JM, Martinez JM, Goetz R, Huppert JD, Ray S,
Barlow DH, et al. The effect of pharmacotherapist
characteristics on treatment outcome in panic disorder.
Depression and Anxiety 2003;17:88-93.

Grilo CM, Money R, Barlow DH, Goddard AW, Gorman JM,
Hofmann SG, et al. Pretreatment patient factors predicting
attrition from a multicenter randomized controlled treatment
study for panic disorder. Comprrehensive Psychiatry
1998;39(6):323-32.

Hofmann SG, Barlow DH, Papp LA, Detweiler MF, Ray SE,
Shear MK, et al. Pretreatment attrition in a comparative
treatment outcome study on panic disorder. American Journal
of Psychiatry 1998;155(1):43-7.

Hofmann SG, Shear MK, Barlow DH, Gorman JM, Hershberger D,
Patterson M, et al. Effects of panic disorder treatments on
personality disorder characteristics. Depression and Anxiety
1998;8(1):14-20.

Huppert JD, Bufka LF, Barlow DH, Gorman JM, Shear MK,
Woods SW. Therapists, therapist variables, and cognitive-
behavioral therapy outcome in a multicenter trial for panic
disorder. Journal of Consulting and Clinical Psychology
2001;69:747-55.

Barlow 2000ii {published data only}

Barlow DH, Gorman JM, Shear MK, Woods SW. Cognitive-
behavioral therapy, imipramine, or their combination for panic
disorder: A randomized controlled trial. JAMA 2000;283:2529-36.

Gorman JM, Martinez JM, Goetz R, Huppert JD, Ray S,
Barlow DH, et al. The effect of pharmacotherapist
characteristics on treatment outcome in panic disorder.
Depression and Anxiety 2003;17:88-93.

Grilo CM, Money R, Barlow DH, Goddard AW, Gorman JM,
Hofmann SG, et al. Pretreatment patient factors predicting
attrition from a multicenter randomized controlled
treatment study for panic disorder. Comprehensive Psychiatry
1998;39(6):323-32.

Hofmann SG, Barlow DH, Papp LA, Detweiler MF, Ray SE,
Shear MK, et al. Pretreatment attrition in a comparative
treatment outcome study on panic disorder. American Journal
of Psychiatry 1998;155(1):43-7.

Hofmann SG, Shear MK, Barlow DH, Gorman JM, Hershberger D,
Patterson M, et al. Effects of panic disorder treatments on
personality disorder characteristics. Depression and Anxiety
1998;8(1):14-20.

Huppert JD, Bufka LF, Barlow DH, Gorman JM, Shear MK,
Woods SW. Therapists, therapist variables, and cognitive-
behavioral therapy outcome in a multicenter trial for panic
disorder. Journal of Consulting and Clinical Psychology
2001;69:747-55.

Berger 2004 {published and unpublished data}

* Berger P, Sachs G, Amering M, Holzinger A, Bankier B,
Katschnig H. Personality disorder and social anxiety predict
delayed response in drug and behavioral treatment of panic
disorder. Journal of Affective Disorders 2004;80:75-8.

Berger P, Sachs G, Amering M, Holzinger A, Maierhofer D,
Bankier B, et al. Predictors of treatment-response in panic
disorder. 151st Annual Meeting of the American Psychiatric
Association. 1998.

Katschnig H, Berger P, Sachs G, Amering M, Holzinger A,
Maierhofer D, et al. Drugs and psychotherapy in panic disorder:
methodological issues. 151st Annual Meeting of the American
Psychiatric Association. 1998.

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

15

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

de Beurs 1995 {published data only}

* de Beurs E, van Balkom AJ, Lange A, Koele P, van Dyck R.
Treatment of panic disorder with agoraphobia: comparison of
fluvoxamine, placebo, and psychological panic management
combined with exposure and of exposure in vivo alone.
American Journal of Psychiatry 1995;152:683-91.

de Beurs E, van Balkom AJ, Van Dyck R, Lange A. Long-term
outcome of pharmacological and psychological treatment for
panic disorder with agoraphobia: a 2-year naturalistic follow-
up. Acta Psychiatrica Scandinavica 1999;99:59-67.

de Beurs E, van Dyck R, Lange A, van Balkom AJ. Perceived
upbringing and its relation to treatment outcome in
agoraphobia. Clinical Psychology and Psychotherapy
1995;2:78-85.

van Balkom AJ, de Beurs E, Koele P, Lange A, van Dyck R. Long-
term benzodiazepine use is associated with smaller treatment
gain in panic disorder with agoraphobia. Journal of Nervous and
Mental Disease 1996;184(2):133-5.

van Balkom AJ, de Beurs E, van Dyck R, Lange A. Two-year
follow-up after treatment of panic disorder with agoraphobia.
8th European College of Neuropsychopharmacology Congress.
8th European College of Neuropsychopharmacology Congress.
1995.

de Beurs 1995i {published data only}

* de Beurs E, van Balkom AJ, Lange A, Koele P, van Dyck R.
Treatment of panic disorder with agoraphobia: comparison of
fluvoxamine, placebo, and psychological panic management
combined with exposure and of exposure in vivo alone.
American Journal of Psychiatry 1995;152:683-91.

de Beurs E, van Balkom AJ, Van Dyck R, Lange A. Long-term
outcome of pharmacological and psychological treatment for
panic disorder with agoraphobia: a 2-year naturalistic follow-
up. Acta Psychiatrica Scandinavica 1999;99:59-67.

de Beurs E, van Dyck R, Lange A, van Balkom AJ. Perceived
upbringing and its relation to treatment outcome in
agoraphobia. Clinical Psychology and Psychotherapy
1995;2:78-85.

van Balkom AJ, de Beurs E, Koele P, Lange A, van Dyck R. Long-
term benzodiazepine use is associated with smaller treatment
gain in panic disorder with agoraphobia. Journal of Nervous and
Mental Disease 1996;184(2):133-5.

van Balkom AJ, de Beurs E, van Dyck R, Lange A. Two-year
follow-up after treatment of panic disorder with agoraphobia.
8th European College of Neuropsychopharmacology Congress.
8th European College of Neuropsychopharmacology Congress.
1995.

de Beurs 1995ii {published data only}

* de Beurs E, van Balkom AJ, Lange A, Koele P, van Dyck R.
Treatment of panic disorder with agoraphobia: comparison of
fluvoxamine, placebo, and psychological panic management
combined with exposure and of exposure in vivo alone.
American Journal of Psychiatry 1995;152:683-91.

Cochrane Database of Systematic Reviews

de Beurs E, van Balkom AJ, Van Dyck R, Lange A. Long-term
outcome of pharmacological and psychological treatment for
panic disorder with agoraphobia: a 2-year naturalistic follow-
up. Acta Psychiatrica Scandinavica 1999;99:59-67.

de Beurs E, van Dyck R, Lange A, van Balkom AJ. Perceived
upbringing and its relation to treatment outcome in
agoraphobia. Clinical Psychology and Psychotherapy
1995;2:78-85.

van Balkom AJ, de Beurs E, Koele P, Lange A, van Dyck R. Long-
term benzodiazepine use is associated with smaller treatment
gain in panic disorder with agoraphobia. Journal of Nervous and
Mental Disease 1996;184(2):133-5.

van Balkom AJ, de Beurs E, van Dyck R, Lange A. Two-year
follow-up after treatment of panic disorder with agoraphobia.
8th European College of Neuropsychopharmacology Congress.
8th European College of Neuropsychopharmacology Congress.
1995.

Fahy 1992 {published data only}

Fahy TJ, O'Rourke D, Brophy J, Schazmann W, Sciascia S.
The Galway Study of Panic Disorder. I: Clomipramine and
lofepramine in DSM III-R panic disorder: a placebo controlled
trial. Journal of Affective Disorders 1992;25:63-75.

O'Rourke D, Fahy TJ, Brophy J, Prescott P. The Galway study
of panic disorder III: Outcome at 5 to 6 years. British Journal of
Psychiatry 1996;168:462-9.

Fava 1997 {published data only}

Fava GA, Savron G, Zielezny M, Grandi S, Rafanelli C, Conti S.
Overcoming resistance to exposure in panic disorder with
agoraphobia. Acta Psychiatrica Scandinavica 1997;95:306-12.

Johnston 1995 {published and unpublished data}

Johnson DG, Troyer IE, Whitsett SF, Dalby JT. Clomipramine
therapy and behavior therapy with agoraphobic women.
Canadian Journal of Psychiatry - Revue Canadienne De
Psychiatrie 1995;40:192-9.

Kampman 2002 {published data only}

Kampman M, Keijsers GP, Hoogduin CA, Hendriks GJ. A
randomized, double-blind, placebo-controlled study of the
effects of adjunctive paroxetine in panic disorder patients
unsuccessfully treated with cognitive-behavioral therapy alone.
Journal of Clinial Psychiatry 2002;63(9):772-7.

Loerch 1999 {published data only}

Loerch B, Graf-Morgenstern M, Hautzinger M, Schlegel S,
Hain C, Sandmann J, et al. Randomised placebo-controlled
trial of moclobemide, cognitive- behavioural therapy and their
combination in panic disorder with agoraphobia. British Journal
of Psychiatry 1999;174:205-12.

Marks 1983 {published data only}

Cohen SD, Monteiro W, Marks IM. Two-year follow-up of
agoraphobics after exposure and imipramine. British Journal of
Psychiatry 1984;144:276-81.

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

16

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Lelliott PT, Marks IM, Monteiro WO, Tsakiris F, Noshirvani H.
Agoraphobics 5 years after imipramine and exposure. Outcome
and predictors. Journal of Nervous and Mental Disease
1987;175(10):599-605.

* Marks IM, Gray S, Cohen D, Hill R, Mawson D, Ramm E,
et al. Imipramine and brief therapists-aided exposure in
agoraphobics having self-exposure homework. Archives of
General Psychiatry 1983;40(2):153-62.

Mavissakalian 1983 {published data only}

Mavissakalian M, Michelson L, Dealy RS. Pharmacological
treatment of agoraphobia: imipramine versus imipramine
with programmed practice. British Journal of Psychiatry
1983;143:348-55.

Mavissakalian 1986a {published data only}

Mavissakalian M. Combined behavioral-therapy and
pharmacotherapy of agoraphobia. Journal of Psychiatric
Research 1993;27:179-91.

Mavissakalian M, Michelson L. Agoraphobia: behavioral and
pharmacological treatments, preliminary outcome, and process
findings. Psychopharmacology Bulletin 1982;18:91-103.

* Mavissakalian M, Michelson L. Agoraphobia: relative and
combined effectiveness of therapist-assisted in vivo exposure
and imipramine. Journal of Clinical Psychiatry 1986;47:117-22.

Mavissakalian M, Michelson L. Self-directed in vivo exposure
practice in behavioral and pharmacological treatments of
agoraphobia. Behavior Therapy 1983;14:506-19.

Mavissakalian M, Michelson L. Two-year follow-up of exposure
and imipramine treatment of agoraphobia. American Journal of
Psychiatry 1986;143:1106-12.

Mavissakalian M, Perel J. Imipramine in the treatment of
agoraphobia: dose-response relationships. American Journal of
Psychiatry 1985;142:1032-6.

Mavissakalian 1986b {published data only}

Mavissakalian M. Combined behavioral-therapy and
pharmacotherapy of agoraphobia. Journal of Psychiatric
Research 1993;27:179-91.

Mavissakalian M, Michelson L. Agoraphobia: behavioral and
pharmacological treatments, preliminary outcome, and process
findings. Psychopharmacology Bulletin 1982;18:91-103.

Mavissakalian M, Michelson L. Agoraphobia: relative and
combined effectiveness of therapist-assisted in vivo exposure
and imipramine. Journal of Clinial Psychiatry 1986;47:117-22.

Mavissakalian M, Michelson L. Self-directed in vivo exposure
practice in behavioral and pharmacological treatments of
agoraphobia. Behavior Therapy 1983;14:506-19.

Mavissakalian M, Michelson L. Two-year follow-up of exposure
and imipramine treatment of agoraphobia. American Journal of
Psychiatry 1986;143:1106-12.

Cochrane Database of Systematic Reviews

Mavissakalian M, Perel J. Imipramine in the treatment of
agoraphobia: dose-response relationships. American Journal of
Psychiatry 1985;142:1032-6.

Oehrberg 1995 {published data only}

Oehrberg S, Christiansen PE, Behnke K, Borup AL, Severin B,
Soegaard J, et al. Paroxetine in the treatment of panic disorder.
A randomised, double- blind, placebo-controlled study. British
Journal of Psychiatry 1995;167:374-9.

Sharp 1996 {published data only}

Sharp DM, Power KG. Predicting treatment outcome for panic
disorder and agoraphobia in primary care. Clinical Psychology
and Psychotherapy 1999;6(5):336-48.

Sharp DM, Power KG. Psychologist, patient, and general
practitioneer ratings of outcome of pharmacological and
psychological treatments for panic disorder and agoraphobia
in primary care. Behavioural and Cognitive Psychotherapy
1998;26:13-27.

Sharp DM, Power KG. Treatment-outcome research in
panic disorder: Dilemmas in reconciling the demands of
pharmacological and psychological methodologies. Journal of
Psychopharmacology 1997;11(4):373-80.

Sharp DM, Power KG, Simpson RJ, Swanson V, Anstee JA.
Global measures of outcome in a controlled comparison of
pharmacological and psychological treatment of panic disorder
and agoraphobia in primary care. British Journal of General
Practice 1997;47(416):150-5.

* Sharp DM, Power KG, Simpson RJ, Swanson V, Moodie E,
Anstee JA, et al. Fluvoxamine, placebo and cognitive behaviour
therapy used alone and in combination in the treatment of
ppanic disorder and agoraphobia. Journal of Anxiety Disorders
1996;10:219-42. [MEDLINE: ,]

Sharp 1996i {published data only}

Sharp DM, Power KG. Predicting treatment outcome for panic
disorder and agoraphobia in primary care. Clinical Psychology
and Psychotherapy 1999;6(5):336-48.

Sharp DM, Power KG. Psychologist, patient, and general
practitioneer ratings of outcome of pharmacological and
psychological treatments for panic disorder and agoraphobia
in primary care. Behavioural and Cognitive Psychotherapy
1998;26:13-27.

Sharp DM, Power KG. Treatment-outcome research in
panic disorder: Dilemmas in reconciling the demands of
pharmacological and psychological methodologies. Journal of
Psychopharmacology 1997;11(4):373-80.

Sharp DM, Power KG, Simpson RJ, Swanson V, Anstee JA.
Global measures of outcome in a controlled comparison of
pharmacological and psychological treatment of panic disorder
and agoraphobia in primary care. British Journal of General
Practice 1997;47(416):150-5.

* Sharp DM, Power KG, Simpson RJ, Swanson V, Moodie E,
Anstee JA, et al. Fluvoxamine, placebo and cognitive behaviour
therapy used alone and in combination in the treatment of

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

17

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

ppanic disorder and agoraphobia. Journal of Anxiety Disorders
1996;10:219-42.

Sharp 1996ii {published data only}

Sharp DM, Power KG. Predicting treatment outcome for panic
disorder and agoraphobia in primary care. Clinical Psychology
and Psychotherapy 1999;6(5):336-48.

Sharp DM, Power KG. Psychologist, patient, and general
practitioneer ratings of outcome of pharmacological and
psychological treatments for panic disorder and agoraphobia
in primary care. Behavioural and Cognitive Psychotherapy
1998;26:13-27.

Sharp DM, Power KG. Treatment-outcome research in
panic disorder: Dilemmas in reconciling the demands of
pharmacological and psychological methodologies. Journal of
Psychopharmacology 1997;11(4):373-80.

Sharp DM, Power KG, Simpson RJ, Swanson V, Anstee JA.
Global measures of outcome in a controlled comparison of
pharmacological and psychological treatment of panic disorder
and agoraphobia in primary care. British Journal of General
Practice 1997;47(416):150-5.

* Sharp DM, Power KG, Simpson RJ, Swanson V, Moodie E,
Anstee JA, et al. Fluvoxamine, placebo and cognitive behaviour
therapy used alone and in combination in the treatment of
ppanic disorder and agoraphobia. Journal of Anxiety Disorders
1996;10:219-42.

Sheehan 1980a {published data only}

* Sheehan DV, Ballanger J, Jacobsen G. Treatment
of endogenous anxiety with phobic, hysterical, and
hypochondriachal symptoms. Archives of General Psychiatry
1980;37:51-9.

Sheehan 1980b {published data only}

Sheehan DV, Ballanger J, Jacobsen G. Treatment of endogenous
anxiety with phobic, hysterical, and hypochondriachal
symptoms. Archives of General Psychiatry 1980;37:51-9.

Spinhoven 1996 {published data only}

Spinhoven P, Onstein EJ, Klinkhamer RA, der Klein EA. Panic
management, trazodone and a combination of both in
the treatment of panic disorder. Clinical Psychology and
Psychotherapy 1996;3:86-92.

Stein 2000 {published data only}

Stein MB, Ron Norton G, Walker JR, Chartier MJ, Graham R. Do
selective serotonin re-uptake inhibitors enhance the efficacy
of very brief cognitive behavioral therapy for panic disorder? A
pilot study. Psychiatry Research 2000;94:191-200.

Cochrane Database of Systematic Reviews

Wiborg 1996 {published and unpublished data}

Dahl AA, Wiborg IM. Pharmacotherapy and brief dynamic
psychotherapy of panic disorder. 9th European College of
Neuropsychopharmacology Congress. Amsterdam, The
Netherlands, 1996.

* Wiborg IM, Dahl AA. Does brief dynamic psychotherapy
reduce the relapse rate of panic disorder?. Archives of General
Psychiatry 1996;53:689-94.

Wiborg IM, Dahl AA. Pharmacotherapy and brief dynamic
psychotherapy of panic disorder. Xth World Congress of
Psychiatry. Madrid, Spain, 1996.

Zitrin 1980 {published data only}

Zitrin CM. Differential treatment of phobias: Use of imipramine
for panic attacks. Journal of Behavior Therapy and Experimental
Psychiatry 1983;14(1):11-8.

Zitrin CM, Klein DF, Woerner MG. Treatment of agoraphobia
with group exposure in vivo and imipramine. Archives of General
Psychiatry 1980;37:63-72.

Zitrin 1983 {published data only}

Klein DF, Ross DC, Cohen P. Panic and avoidance in
agoraphobia. Application of path analysis to treatment studies.
Archives of General Psychiatry 1987;44(4):377-85.

Klein DF, Zitrin CM, Woerner MG, Ross DC. Treatment of phobias.
II. Behavior therapy and supportive psychotherapy: are there
any specific ingredients?. Archives of General Psychiatry
1983;40(2):139-45.

Lipsitz JD, Mannuzza S, Klein DF, Ross DC, Fyer AJ. Specific
phobia 10-16 years after treatment. Depression and Anxiety
1999;10(3):105-11.

Zitrin CM. Differential treatment of phobias: Use of imipramine
for panic attacks. Journal of Behavior Therapy and Experimental
Psychiatry 1983;14(1):11-8.

Zitrin CM, Klein DF, Lindemann C, Kaplan JH, Ganz VH.
Comparison of short-term treatment regimens in phobic
patients: a preliminary report. In: Spitzer RL, Klein DF editor(s).
Evaluation of Psychological Therapies. Baltimore, MD: Johns
Hopkins Press, 1976:233-250.

Zitrin CM, Klein DF, Woerner MG. Behavior therapy, supportive
psychotherapy, imipramine, and phobias. Archives of General
Psychiatry 1978;35:307-16.

* Zitrin CM, Klein DF, Woerner MG, Ross DC. Treatment of
phobias. I. Comparison of imipramine hydrochloride and
placebo. Archives of General Psychiatry 1983;40:125-38.

Telch 1985 {published data only}

Roth WT, Telch MJ, Taylor CB, Agras WS. Autonomic changes
after treatment of agoraphobia with panic attacks. Psychiatry
Research 1988;24(1):95-107.

Zitrin CM, Woerner MG, Klein DF. Differentiation of panic anxiety
from anticipatory anxiety and avoidance behavior. In: Klein
DF, Rabkin J editor(s). Anxiety: New Research and Changing
Concepts. New York, NY: Raven Press, 1981.

* Telch MJ, Agras WS, Taylor CB, Roth WT, Gallen CC. Combined
pharmacological and behavioral treatment for agoraphobia.
Behavior Research and Therapy 1985;23:325-35.

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

18

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

References to studies excluded from this review

Bucher 1997

Agras 1991 {published data only}

* Agras, WS, Telch, MJ, Taylor, CB, Roth, WT, Brouillard, M.
Imipramine and exposure therapy in agoraphobia: untangling
the actions and interactions. Telch and Lucas (1984).

Ba 1999 {published and unpublished data}

Ba G, Vigano C. Integrated therapy of panic disorder: a
controlled study. 152nd Annual Meeting of the American
Psychiatric Association. Washington DC, USA, 1999.

Ba G, Vigano C. Integrated therapy of panic disorders: a
controlled study. Unpublished manuscript.

Vigano C, Bielli A, Carozzi A, Divino T, Pagliarulo E, Ba G. Panic
disorder: A two-year follow-up of an integrated treatment
approach. [Il disturbo di panico: follow up a due anni di
un modello di trattamento integrato]. Italian Journal of
Psychopathology in press.

Chambless 1979 {published data only}

* Chambless DL, Foa EB, Groves GA, Goldstein AJ. Exposure
and communications training in the treatment of agoraphobia.
Behavior Research and Therapy 1982;20:219-31.

Chambless DL, Foa EB, Groves GA, Goldstein AJ. Flooding with
Brevital in the treatment of agoraphobia: countereffective?.
Behavior Research and Therapy 1979;17(3):243-51.

Cox 1988 {published data only}

Cox DJ, Ballanger JC, Laraia M, Hobbs WR, Peterson GA,
Hucek A. Different rates of improvement of different symptoms
in combined pharmacological and behavioral treatment of
agoraphobia. Journal of Behavior Therapy and Experimental
Psychiatry 1988;19(2):119-26.

Lipsedge 1973 {published data only}

* Lipsedge, MS, Hajioff, J, Huggins, P, Napier, L, Pearce,
J, Pike, et al. The management of severe agoraphobia: a
comparison of ipronizaid and systematic desensitization.
Psychopharmacologia 1973;32(1):67-80.

Solyom 1981 {published data only}

* Solyom, C, Solyom, L, LaPierre, Y, Pecknold, J, Morton, L.
Phenelzine and exposure in the treatment of phobias. Biological
Psychiatry 1981;16(3):239-47.

Additional references

APA 1998

American Psychiatric Association. Practice guideline for the
treatment of patients with panic disorder. American Journal of
Psychiatry 1998;155 Supplement:1-34.

Brown 1995

Brown, TA, Barlow, DH. Long-term outcome in cognitive-
behavioral treatment of panic disorder: clinical predictors and
alternative strategies for assessment. Journal of Consulting and
Clinical Psychology 1995;63:754-65.

Bucher HC, Guyatt GH, Griffith LE, Walter SD. The results of
direct and indirect treatment comparisons in meta-analysis of
randomized controlled trials. Journal of Clinical Epidemiology
1997;50(6):683-91.

Burns 1986

Burns, LE, Thorpe, CL, Cavallaro, LA. Agoraphobia 8 years after
behavioral treatment: a follow-up study with interview, self-
report, and behavioral data. Behavior Therapy 1986;17:580-91.

Carlbring 2002

Carlbring, P, Gustafsson, H, Ekselius, L, Andersson, G. 12-month
prevalence of panic disorder with or without agoraphobia in the
Swedish general population. Social Psychiatry and Psychiatric
Epidemiology 2002;37:207-11.

Chalmers 1983

Chalmers TC, Celano P, Sacks HS, Smith H Jr. Bias in treatment
assignment in controlled clinical trials. New England Journal of
Medicine 1983;309:1358-61.

Clark 1990

Calrk DB, Taylor CB, Roth WT, Hayward C, Ahlers A, Margraf J, et
al. Surreptitious drug use by patients in a panic disorder study.
American Journal of Psychiatry 1990;147:507-9.

Clum 1993

Clum GA, Clum GA, Surls R. A meta-analysis of treatments for
panic disorder. Journal of Consulting and Clinical Psychology
1993;61:317-26.

Coldiz 1989

Coldiz, GA, Miller, JN, Mosteller, F. How study design affects
outcomes in comparisons of therapy. I: medical. Statistics in
Medicine 1989;9:441-54.

Egger 2003

Egger M, Juni P, Bartlett C, Holenstein F, Sterne J. How
important are comprehensive literature searches and the
assessment of trial quality in systematic reviews? Empirical
study. Health Technology Assessment 2003;7(1):1-76.

Fava 2001

Fava, GA, Rafanelli, C, Grandi, S, Conti, S, Ruini, C, Mangelli, L,
et al. Long-term outcome of panic disorder with agoraphobia
treated by exposure. Psychological Medicine 2001;31:891-8.

Foa 2002

Foa EB, Franklin ME, Moser J. Context in the clinic: How well
do cognitive-behavioral therapies and medications work in
combination?. Biological Psychiatry 2002;52:987-97.

Furukawa 2002

Furukawa TA, Guyatt GH, Grifitth LE. Can we individualize the
Number Needed to Treat (NNT)? An empirical study of summary
effect measures in meta-analyses. International Journal of
Epidemiology 2002;31:72-6.

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

19

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Furukawa 2005

Mavissakalian 2002

Furukawa T, Cipriani A, Barbui C, Brambilla P, Watanabe N.
Imputing response rates from means and standard deviations
in meta-analysis. International Clinical Psychopharmacology
2005;20(1):49-52.

Furukawa 2006

Furukawa TA, Barbui C, Cipriani A, Brambilla P, Watanabe N.
Imputing missing standard deviations in meta-analyses can
provide accurate results. Journal of Clinical Epidemiology
2006;59:7-10.

Goisman 1995

Goisman RM, Warshaw MG, Steketee GS, Fierman EJ,
Rogers MP, Goldenberg I, et al. DSM-IV and the disappearnace
of agoraphobia without history of panic disorder: new data
on a controversial diagnosis. American Journal of Psychiatry
1995;152:1438-43.

Gould 1995

Gould RA, Otto MW, Pollack MH. A meta-analysis of treatment
outcome for panic disorder. Clinical Psychology Review
1995;15:819-44.

Higgins 2003

Mavissakalian MR, Perel JM. Duration of imipramine therapy
and relapse in panic disorder with agoraphobia. Journal of
Clinical Psychopharmacology 2002;22:294-9.

Moher 1998

Moher D, Pham B, Jones A, Cook DJ, Jadad AR, Moher M, et al.
Does quality of reports of randomised trials affect estimates
of intervention efficacy reported in meta-analyses?. Lancet
1998;352:609-13.

Nathan 2002

Nathan PE, Gorman JM. A Guide to Treatments that Work. 2nd
Edition. Oxford: Oxford University Press, 2002.

Otto 1996

Otto MW, Pollack MH, Sabatino SA. Maintenance of remission
following cognitive behavior therapy for panic disorder:
possible deleterious effects of concurrent medication
treatment. Behavior Therapy 1996;27:473-82.

Otto 2000

Otto MW, Pollack MH, Maki KM. Empirically supported
treatments for panic disorder: costs, benefits, and stepped care.
Journal of Consulting and Clinical Psychology 2000;68:556-63.

Higgins, JP, Thompson, SG, Deeks, JJ, Altman, DG. Measuring
inconsistency in meta-analyses. BMJ 2003;327(7414):557-60.

Oxman 1992

Hollon 1981

Hollon, SD, DeRubeis, RJ. Placebo-psychotherapy
combinations: inappropriate representations of psychotherapy
in drug-psychotherapy comparative trials. Psychological Bulletin
1981;90:467-77.

Kessler 2006

Kessler RC, Chiu WT, Jin R, Ruscio AM, Shear K, Walters EE. The
epidemiology of panic attacks, panic disorder, and agoraphobia
in the National Comorbidity Survey Replication. Archives of
General Psychiatry 2006;63:415-24.

Klein 2000

Klein DF. Flawed meta-analyses comparing psychotherapy
with pharmacotherapy. American Journal of Psychiatry
2000;157:1204-11.

Marshall 2000

Marshall M, Lockwood A, Bradley C, Adams C, Joy C, Fenton M.
Unpublished rating scales: a major source of bias in randomised
controlled trials of treatments for schizophrenia. British Journal
of Psychiatry 2000;176:249-52.

Mattick 1990

Mattick RP, Andrews G, Hadzi-Pavlovic D, Christensen H.
Treatment of panic and agoraphobia: an integrative review.
Journal of Nervous and Mental Disease 1990;178:567-76.

Mavissakalian 1993

Mavissakalian M. Combined behavioral therapy and
pharmacotherapy of agoraphobia. Journal of Psychiatric
Research 1993;27 Suppl 1:179-91.

Oxman AD, Guyatt GH. A consumer's guide to subgroup
analyses. Annals of Internal Medicine 1992;116:78-84.

Pecknold 1988

Pecknold JC, Swinson RP, Kuch K, Lewis CP. Alprazolam in
panic disorder and agoraphobia: results from a multicenter
trial. III. Discontinuation effects. Archives of General Psychiatry
1988;45:429-36.

Pollack 2003

Pollack MH, Allgulander C, Bandelow B, Cassano GB, Greist JH,
Hollander E, et al. WCA recommendations for the long-term
treatment of panic disorder. CNS Spectrums 2003;8:17-30.

Schmidt 1999

Schmidt NB. Panic disorder: cognitive behavioral and
pharmacological treatment strategies. Journal of Clinical
Psychology in Medical Settings 1999;6:89-111.

Schmidt 2001

Schmidt NB, Koselka M, Woolaway-Bickel K. Combined
treatments for phobic anxiety disorders. In: Sammons, MT,
Schmidt, NB editor(s). Combined Treatments for Mental
Disorders: A Guide to Psychological and Pharmacological
Interventions. Washington, DC: American Psychological
Association, 2001:81-110.

Schulz 1995

Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence
of bias: dimensions of methodological quality associated
with estimates of treatment effects in controlled trials. JAMA
1995;273:408-12.

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

20

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Simon 2002

Simon NM, Safren SA, Otto MW, Sharma SG, Lanka GD,
Pollack MH. Longitudinal outcome with pharmacotherapy in a
naturalistic study of panic disorder. Journal of Affective Disorders
2002;69:201-8.

Song 2003

Song F, Altman DG, Glenny AM, Deeks JJ. Validity of indirect
comparison for estimating efficacy of competing interventions:
empirical evidence from published meta-analyses. BMJ
2003;326(7387):472.

Taylor 2000

Taylor S. Understanding and Treating Panic Disorder.
Chichester: John Wiley & Sons, 2000.

Telch 1994

Telch MJ, Lucas R. A. Combined pharmacological and
psychological tretment of panic disorder: Current status and
future directions.. In: Wolfe BE, Maser JD editor(s). Treatment
of Panic Disorder: A Consensus Development Conference.
Washington, DC: American Psychiatric Press, Inc., 1994:177-97.

Toni 2000

Toni, C, Perugi, G, Frare, F, Mata, B, Vitale, B, Mengali, F, et al.
A prospective naturalistic study of 326 panic-agoraphobic
patients treated with antidepressants. Pharmacopsychiatry
2000;33:121-31.

van Balkom 1996

van Balkom AJ, de Beurs E, Koele P, Lange A, van Dyck R. Long-
term benzodiazepine use is associated with smaller treatment

C H A R A C T E R I S T I C S   O F   S T U D I E S

Characteristics of included studies [ordered by study ID]

Cochrane Database of Systematic Reviews

gain in panic disorder with agoraphobia. Journal of Nervous and
Mental Disease 1996;184(2):133-5.

van Balkom 1997

van Balkom AJ, Bakker A, Spinhoven P, Blaauw BM, Smeenk S,
Ruesink B. A meta-analysis of the treatment of panic
disorder with or without agoraphobia: a comparison
of psychopharmacological, cognitive-behavioral, and
combination treatments. Journal of Nervous and Mental Disease
1997;185:510-6.

Watanabe 2005

Watanabe N, Churchill R, Furukawa TA. Combined
psychotherapy plus benzodiazepines for panic disorder with
or without agoraphobia [Protocol]. Cochrane Database of
Systematic Reviews 2005, Issue 1.

Weissman 1997

Weissman MM, Bland RC, Canino GJ, Faravelli C, Greenwald S,
Hwu HG, et al. The cross-national epidemiology of panic
disorder. Archives of General Psychiatry 1997;54:305-9.

Westra 1998

Westra HA, Stewart SH. Cognitive behavioural therapy and
pharmacotherapy: complementary or contradictory approaches
to the treatment of anxiety?. Clinical Psychology Review
1998;18(3):307-40.

WHO 2004

World Health Report 2004. WHO.

* Indicates the major publication for the study

Azhar 2000 

Methods

Participants

Interventions

ALLOCATION CONCEALMENT: unclear 
BLINDING: not blind

DIAGNOSIS: DSM-IV panic disorder (% agoraphobic unspecified) 
AGE: mean=31.4 to 31.7 years 
SEX: men and women 
HISTORY: - 
PSYCHIATRIC COMORBIDITY: No comorbidity was allowed. 
MEDICAL COMORBIDITY: -

ACUTE PHASE: 9 weeks 
1. fluvoxamine (mean=64 mg/d) + CBT (9 weekly sessions) 
2. fluvoxamine alone (mean=154 mg/d) 
3. CBT alone

ACUTE PHASE CO-INTERVENTION: not specified

MAINTENANCE: None.

FOLLOW-UP: None.

Outcomes

RESPONSE: >=50% reduction in panic frequency [imputed from mean&SD] 

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

21

 
 
 
 
 
Cochrane Database of Systematic Reviews

Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Azhar 2000  (Continued)

REMISSION: - 
GLOBAL: - 
PANIC ATTACK: panic frequency 
AGORAPHOBIA: - 
GENERAL ANXIETY: HAM-A, BAI 
DEPRESSION: HAM-D, BDI 
FUNCTIONING: -

Notes

Risk of bias

Bias

Authors' judgement

Support for judgement

Allocation concealment?

Unclear risk

B - Unclear

Barlow 2000 

Methods

Participants

Interventions

Outcomes

ALLOCATION CONCEALMENT: unclear 
BLINDING: at least one measure was assessed by an independent assessor blind to treatment alloca-
tion

DIAGNOSIS: DSM-III-R panic disorder with mild to no agoraphobia 
AGE: mean=34.1 to 37.8 years 
SEX: 62% women 
HISTORY: mean duration of panic disorder=5.5 to 6.6 years 
During wash-out, up to 10 doses of benzos were allowed during 2 weeks. 
PSYCHIATRIC COMORBIDITY: 27% suffered from current major depression. 
MEDICAL COMORBIDITY: Significant medical illness was excluded.

ACUTE PHASE: 12 weeks 
1. imipramine (mean=214 to 239 mg/d by week 12) + CBT (11sessions during 3 months) 
2. imipramine alone 
3. CBT alone 
4. CBT + placebo 
5. placebo alone (not used in the current meta-analysis)

ACUTE PHASE CO-INTERVENTION: Patients were permitted up to 20 doses of benzo (0.5 mg of alprazo-
lam equivalent) during 3 months after the study started.

MAINTENANCE: 6 months of monthly appointments

MODE OF DISCONTINUATION: Abrupt (?)

FOLLOW-UP: at 6 months after treatment discontinuation. 33% of the original cohort was successfully
followed up.

INTERVENTIONS AFTER TRIAL DISCONTINUATION: described as "no treatment" but more details lack-
ing

RESPONSE: >= 40% reduction on PDSS; "much improved" or better on CGI Improvement and "mild" or
less on CGI Severity 
REMISSION: 2 or better on CGI Severity 
GLOBAL: PDSS, CGI 
PANIC ATTACK: - 
AGORAPHOBIA: - 
GENERAL ANXIETY: - 
DEPRESSION: - 

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

22

 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Barlow 2000  (Continued)

FUNCTIONING: -

Notes

Risk of bias

Bias

Authors' judgement

Support for judgement

Allocation concealment?

Unclear risk

B - Unclear

Cochrane Database of Systematic Reviews

Barlow 2000i 

Methods

Participants

Interventions

Outcomes

Notes

Risk of bias

Bias

Same as (Barlow 2000) but refers only to comparison with psychotherapy + placebo.

Authors' judgement

Support for judgement

Allocation concealment?

Unclear risk

B - Unclear

Barlow 2000ii 

Methods

Participants

Interventions

Outcomes

Notes

Risk of bias

Bias

Same as (Barlow 2000) but refers only to comparison with psychotherapy alone.

Authors' judgement

Support for judgement

Allocation concealment?

Unclear risk

D - Not used

Berger 2004 

Methods

ALLOCATION CONCEALMENT: adequate 
BLINDING:unclear

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

23

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Berger 2004  (Continued)

Participants

Interventions

Outcomes

Notes

Risk of bias

Bias

DIAGNOSIS: DSM-III-R panic disorder with or without agoraphobia (81% with agoraphobia) 
AGE: mean=33.9 
SEX: 66% women 
HISTORY: mean duration of panic disorder=4.8 years 
PSYCHIATRIC COMORBIDITY: 19% with major depression, 27% with social phobia, 16% with simple
phobia, 10% with GAD, 32% with personality disorder. Melancholic depression, bipolar disorder, OCD,
substance abuse/dependence were excluded. 
MEDICAL COMORBIDITY: Concurrent medical illness was excluded.

ACUTE PHASE: 20 weeks 
1. paroxetine (mean=31 mg/d, range: 10-60 mg/d) + cognitive-interpersonal group therapy (2 individual
sessions + 20 weekly group sessions, including elements of CBT and IPT) 
2. paroxetine alone

ACUTE PHASE CO-INTERVENTION: Concomitant p.r.n. intake of alprazolam up to 1 mg/d was allowed.

MAINTENANCE: None.

MODE OF DISCONTINUATION: tapering from week 20 to week 24

FOLLOW-UP: at 24 weeks, i.e. at the end of tapering. 50% of the original cohort were successfully fol-
lowed up.

RESPONSE: Much or very much improved on CGI 
REMISSION: Free of panic attacks 
GLOBAL: - 
PANIC ATTACK: panic frequency 
AGORAPHOBIA: 4-point rating of agoraphobia 
GENERAL ANXIETY: 11-point rating of anticipatory anxiety 
DEPRESSION: - 
FUNCTIONING: Sheehan Disability Scale

Authors' judgement

Support for judgement

Allocation concealment?

Low risk

A - Adequate

de Beurs 1995 

Methods

Participants

ALLOCATION CONCEALMENT: unclear 
BLINDING: at least one measure was assessed by an independent assessor blind to treatment alloca-
tion

DIAGNOSIS: DSM-III-R panic disorder with moderate to severe agoraphobia 
AGE: mean=38.8 
SEX: 75% women 
HISTORY: mean duration of panic disorder=9.4 years 
PSYCHIATRIC COMORBIDITY: Current major depression was included if it developed after panic disor-
der. Patients with psychotic disorders, organic mental disorders, or psychoactive substance use disor-
ders were excluded. 
MEDICAL COMORBIDITY: Patients with severe medical illness, pregnant and lactating women were ex-
cluded.

Interventions

ACUTE PHASE: 12 weeks 

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

24

 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

de Beurs 1995  (Continued)

Cochrane Database of Systematic Reviews

1. fluvoxamine (100-150 mg/day) + exposure (12 weekly sessions) 
2. exposure alone 
3. placebo + exposure 
4. psychological panic management plus exposure (not used in the current meta-analysis)

ACUTE PHASE CO-INTERVENTION: 18 out of 97 patients used benzo during the trial. Concomitant use of
benzo was permitted when patients had been taking benzo for more than 3 months and were willing to
keep use at a constant dosage during the trial.

MAINTENANCE: None.

MODE OF DISCONTINUATION: Continue the drug for the time being

FOLLOW-UP: at 24 months after trial termination. 74% was successfully followed up.

INTERVENTIONS AFTER TRIAL DISCONTINUATION: 77% received additional treatment, equally divided
over four arms

RESPONSE: >=50% reduction in FQ-Ag [imputed from mean&SD] 
REMISSION: panic-free 
GLOBAL: Global outcome (1-9; the larger, the better) 
PANIC ATTACK: panic frequency 
AGORAPHOBIA: Agoraphobia composite, FQ-Ag, Multi-Task Behavioral Avoidence Test 
GENERAL ANXIETY: Somatic Anxeity composite 
DEPRESSION: Depression composite, BDI 
FUNCTIONING: -

Authors' judgement

Support for judgement

Outcomes

Notes

Risk of bias

Bias

Allocation concealment?

Unclear risk

B - Unclear

de Beurs 1995i 

Methods

Same as (de Beurs 1995) but refers only to the comparison with psychotherapy + placebo.

Participants

Interventions

Outcomes

Notes

Risk of bias

Bias

Authors' judgement

Support for judgement

Allocation concealment?

Unclear risk

B - Unclear

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

25

 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

de Beurs 1995ii 

Cochrane Database of Systematic Reviews

Methods

Same as (de Beurs 1995) but refers only to the comparison with psychotherapy alone.

Participants

Interventions

Outcomes

Notes

Risk of bias

Bias

Authors' judgement

Support for judgement

Allocation concealment?

Unclear risk

D - Not used

Fahy 1992 

Methods

Participants

ALLOCATION CONCEALMENT: unclear 
BLINDING: at least one measure was assessed by an independent assessor blind to treatment alloca-
tion

DIAGNOSIS: DSM-III-R panic disorder with or without agoraphobia (42% with moderate or severe agora-
phobia) 
AGE: mean=33.6 to 37.8 years 
SEX: 65% women 
HISTORY: mean duration of panic disorder=4.6 years 
PSYCHIATRIC COMORBIDITY: Major depression was included if it preceded panic. Those with history of
seizures, bipolar or melancholic depression, cyclothymic disorder, obsessive-compulsive disorder or
current drug or alcohol dependence were excluded. 
MEDICAL COMORBIDITY: "In good physical health."

Interventions

ACUTE PHASE: 6 weeks 
1. clomipramine (100 mg/d) or lofepramine (140 mg/d) + CBT (6 one-hour sessions over eight weeks) 
2. placebo + CBT

ACUTE PHASE CO-INTERVENTION: No psychotropic drug was allowed.

MAINTENANCE: None.

MODE OF DISCONTINUATION: -

FOLLOW-UP: None (After 6 weeks, those on placebo received antidepressants and the double-blind
was broken at 8 weeks)

RESPONSE: >=40% reduction in CGI [imputed from mean&SD] 
REMISSION: panic-free 
GLOBAL: CGI Severity, CGI Change 
PANIC ATTACK: - 
AGORAPHOBIA: Fear Inventory 
GENERAL ANXIETY: HAM-A 
DEPRESSION: HAM-D, MADRS, CGI Depression, BDI, Wakefield Self Assessment Depressiion Inventory 
FUNCTIONING: -

Outcomes

Notes

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

26

 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Fahy 1992  (Continued)

Risk of bias

Bias

Authors' judgement

Support for judgement

Allocation concealment?

Unclear risk

B - Unclear

Fava 1997 

Methods

Participants

ALLOCATION CONCEALMENT: unclear 
BLINDING: at least one measure was assessed by an independent assessor blind to treatment alloca-
tion

DIAGNOSIS: DSM-IV panic disorder with agoraphobia 
AGE: mean=29.8 years 
SEX: 52% women 
HISTORY: mean duration of illness=3.5 years before start of first exposure therapy; resistant to twelve
30-minute sessions for exposure 
PSYCHIATRIC COMORBIDITY: Current major depression was excluded. 38% suffered from personality
disorder. 
MEDICAL COMORBIDITY: -

Interventions

ACUTE PHASE: 8 weeks 
1. imipramine (mean=72 mg/d) + behaviour therapy (eight 45-minute sessions) 
2. behaviour therapy alone 
3. behaviour therapy plus congitive therapy (not used in the present meta-analysis)

ACUTE PHASE CO-INTERVENTION: not specifid

MAINTENANCE: None.

MODE OF DISCONTINUATION: naturalistic

FOLLOW-UP: at 24 months after acute phase treatment. 57% was successfully followed up.

INTERVENTIONS AFTER TRIAL DISCONTINUATION: Those who faild to respond received further 16
weeks of exposure with or without imipramine treatments.

RESPONSE: - 
REMISSION: panic-free for a month and 1or 2 on CID-agoraphobia 
GLOBAL: - 
PANIC ATTACK: CID-panic 
AGORAPHOBIA: FQ-Ag, CID-Agoraphobia 
GENERAL ANXIETY: CID-generalized anxiety 
DEPRESSION: CID-depression 
FUNCTIONING: -

Authors' judgement

Support for judgement

Outcomes

Notes

Risk of bias

Bias

Allocation concealment?

Unclear risk

B - Unclear

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

27

 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Johnston 1995 

Methods

Participants

Interventions

Outcomes

Notes

Risk of bias

Bias

ALLOCATION CONCEALMENT: unclear 
BLINDING: at least one measure was assessed by an independent assessor blind to treatment alloca-
tion

DIAGNOSIS: DSM-III agoraphobia 
AGE: mean=37 years 
SEX: 100% women 
HISTORY: mean duration of illness=9.5 years 
PSYCHIATRIC COMORBIDITY: - 
MEDICAL COMORBIDITY: -

ACUTE PHASE: 17 weeks 
1. clomipramine (mean=95 mg/d) + behavior therapy (twice weekly for eight weeks) 
2. clomipramine alone 
3. placebo + behavior therapy 
4. placebo alone

ACUTE PHASE CO-INTERVENTION: not specified

MAINTENANCE: 12 weeks 
On clomipraime or placebo only; no psychological intervention

MODE OF DISCONTINUATION: naturalistic

FOLLOW-UP: -

RESPONSE: >=50% reduction in FQ-AG [imputed from mean&SD] 
REMISSION: - 
GLOBAL: - 
PANIC ATTACK: Number of days per week when panic was reported 
AGORAPHOBIA: FQ-Ag, FSS-III-Ag, BAT 
GENERAL ANXIETY: - 
DEPRESSION: SCL-90-R Depression 
FUNCTIONING: SAS-SR Social Leisure

Authors' judgement

Support for judgement

Allocation concealment?

Unclear risk

B - Unclear

Kampman 2002 

Methods

Participants

ALLOCATION CONCEALMENT: unclear 
BLINDING: at least one measure was assessed by an independent assessor blind to treatment alloca-
tion

DIAGNOSIS: DSM-IV panic disorder with or without agoraphobia (% agoraphobic unspecified) 
AGE: between 18 and 65 
SEX: unspecified 
HISTORY: unresponsive to initial 15 sessions of CBT (51% of the original sample) 
PSYCHIATRIC COMORBIDITY: 16% suffered from mood disorders, 16% from additional anxiety disor-
ders, and 9% suffered from somatoform disorders. 
MEDICAL COMORBIDITY: -

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

28

 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Kampman 2002  (Continued)

Interventions

ACUTE PHASE: 8 weeks 
1. paroxetine (40 mg/d) + CBT (4 sessions over 8 weeks) 
2. placebo + CBT

ACUTE PHASE CO-INTERVENTION: Patients who had been using benzo were asked either to discontinue
their medication under supervision or to adhere to a fixed daily dose throughout the study.

MAINTENANCE: -

MODE OF DISCONTINUATION: -

FOLLOW-UP: -

RESPONSE: 30% improvement in panic frequency, ACQ and ADS 
REMISSION: panic-free 
GLOBAL: - 
PANIC ATTACK: - 
AGORAPHOBIA: MI, (ACQ, BSQ, ADS) 
GENERAL ANXIETY: FQ-general anxiety 
DEPRESSION: - 
FUNCTIONING: -

Authors' judgement

Support for judgement

Outcomes

Notes

Risk of bias

Bias

Allocation concealment?

Unclear risk

B - Unclear

Loerch 1999 

Methods

Participants

Interventions

ALLOCATION CONCEALMENT: unclear 
BLINDING: at least one measure was assessed by an independent assessor blind to treatment alloca-
tion

DIAGNOSIS: DSM-III-R panic disorder with agoraphobia 
AGE: mean=35.1 years 
SEX: 75% women 
HISTORY: mean duration of illness=6.1 years 
PSYCHIATRIC COMORBIDITY: Depressed patients with 19-item HAM-D >=17 were excluded. Patients
with bipolar disorder, obsessive-compulsive disorder, organic mental disorder, schizophrenia, alcohol
or drug dependence during the preceding 12 months, suicidality were excluded. 
MEDICAL COMORBIDITY: Clinically relevant organic diseases, significant laboratory abnormalities,
known allergic reactions to monoamine oxidase inhibitors, pregnancy, lactation period were excluded.

ACUTE PHASE: 8 weeks 
1. moclobemide (mean=551 mg/d) + CBT (nine 50-minute individual sessions + two 6-hour thera-
pist-aided exposure sessions) 
2. moclobemide + clinical management 
3. placebo + CBT 
4. placebo + clinical management (not used in the present meta-analysis)

ACUTE PHASE CO-INTERVENTION: If patiens had been taing benzo, tapering lasted upt to 4 weeks and
withdrawal symptoms had to end at least 1 week prior to treatment.

MAINTENANCE: -

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

29

 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Loerch 1999  (Continued)

Cochrane Database of Systematic Reviews

MODE OF DISCONTINUATION: tapered off over two weeks (from week 8 to week 10). However, 70% of
patients received treatment during follow-up, defined either as at least one intake of a drug such as
benzodiazepine, antidepressant or beta-blocker or ast least one psychosocial treatmetn session.

FOLLOW-UP: at 6 months after treatment discontinuation. 67% was successfully followed-up.

INTERVENTIONS AFTER TRIAL DISCONTINUATION: 70% received at least some treatment after discon-
tinuing moclobemide.

Outcomes

Notes

Risk of bias

Bias

RESPONSE: "Much" or "very much improved" on CGI Improvement 
REMISSION: "Normal" or "borderline mentally ill" on CGI Severity 
GLOBAL: CGI Severity, CGI Improvement 
PANIC ATTACK: - 
AGORAPHOBIA: FQ-Ag, MI 
GENERAL ANXIETY: HAM-A 
DEPRESSION: HAM-D 
FUNCTIONING: Sheehan Disability Scale-work, -leisure, -home life

Authors' judgement

Support for judgement

Allocation concealment?

Unclear risk

B - Unclear

Marks 1983 

Methods

Participants

ALLOCATION CONCEALMENT: unclear 
BLINDING: at least one measure was assessed by an independent assessor blind to treatment alloca-
tion

DIAGNOSIS: approximately DSM-III agoraphobia (96% had spontaneous panic attacks) 
AGE: mean=34 years 
SEX: 84% women 
HISTORY: mean duration of illness=8 years 
PSYCHIATRIC COMORBIDITY: Moderate to severe depression was excluded. 
MEDICAL COMORBIDITY: -

Interventions

ACUTE PHASE: 14 weeks 
1. imipramine (mean=124-158 mg/d) + behavior therapy (six bi-weekly 1-hour sessions; self-exposure +
therapist-guided exposure or + relaxation) 
2. placebo + behavior therapy

ACUTE PHASE CO-INTERVENTION: not specified

MAINTENANCE: 14 weeks

MODE OF DISCONTINUATION: tapered off over 2 weeks (from week 26 to 28)

FOLLOW-UP: at 6 months and at 18 months after treatment discontinuation. 63% and 56% were suc-
cessfully followed up, respectively.

INTERVENTIONS AFTER TRIAL DISCONTINUATION: 47% received some treatment (antidepressant, ben-
zodiazepine, therapist-aided exposure)

Outcomes

RESPONSE: >= 2 points reduction in total phobic targets 
REMISSION: >= 4 points reduction in total phobic targets 
GLOBAL: - 

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

30

 
 
 
 
 
Cochrane Database of Systematic Reviews

Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Marks 1983  (Continued)

PANIC ATTACK: spontaneous panics 
AGORAPHOBIA: FQ-Ag, 4 phobic targets, FQ-Global 
GENERAL ANXIETY: Non-phobic anxiety, FQ-Anxiety-Depression, 
DEPRESSION: HAM-D 
FUNCTIONING: -

Notes

Risk of bias

Bias

Authors' judgement

Support for judgement

Allocation concealment?

Unclear risk

B - Unclear

Mavissakalian 1983 

Methods

Participants

Interventions

Outcomes

Notes

Risk of bias

Bias

ALLOCATION CONCEALMENT: unclear 
BLINDING: not blind

DIAGNOSIS: DSM-III agoraphobia (patients scored, on average, 5.5 on an 0-8 point scale of panic severi-
ty) 
AGE: mean=33.5 years 
SEX: 100% women 
HISTORY: mean duration of illness=7 years 
PSYCHIATRIC COMORBIDITY: Primary affective disorder, schizophrenia, organic brain syndrome and
OCD were excluded. 
MEDICAL COMORBIDITY: Physical illness precluding imipramine was excluded.

ACUTE PHASE: 12 weeks 
1. imipramine (mean=125 mg/d) + programmd practice (self-directed in vivo graded exposure with be-
havioural diary, eight 1-hour sessions) 
2. imipramine + anti-exposure instruction

ACUTE PHASE CO-INTERVENTION: Patients had to be free of all psychotropic medications at least 2
weeks before starting treatment.

MAINTENANCE: -

MODE OF DISCONTINUATION: -

FOLLOW-UP: -

RESPONSE: >=50% reduction on Self-Rated Severity 
REMISSION: no spontaneous panic 
GLOBAL: Self-Rated Panic Overall Severity [0-8] 
PANIC ATTACK: - 
AGORAPHOBIA: FQ-Ag 
GENERAL ANXIETY: Zung Anxiety Scale 
DEPRESSION: HAM-D 
FUNCTIONING: Clinician's Global Assessment [1-5]

Authors' judgement

Support for judgement

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

31

 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Mavissakalian 1983  (Continued)

Allocation concealment?

Unclear risk

B - Unclear

Mavissakalian 1986a 

Methods

Participants

ALLOCATION CONCEALMENT: adequate 
BLINDING: at least one measure was assessed by an independent assessor blind to treatment alloca-
tion

DIAGNOSIS: DSM-III agoraphobia with panic 
AGE: mean=36.5 years 
SEX: 84% women 
HISTORY: mean duration of illness=10.5 years 
PSYCHIATRIC COMORBIDITY: Primary affective disorder or concurrent major depressive episode, schiz-
ophrenia, organic brain syndrome, OCD, somatization disorder, substance abuse, or severe personality
disorder were excluded. 
MEDICAL COMORBIDITY: Physical illness precluding imipramine was excluded.

Interventions

ACUTE PHASE: 12 weeks 
1. imipramine (mean=130 mg/d) + programmed practice (self-directed in vivo graded exposure, twelve
90-min group sessions) 
2. placebo + programmed practice

ACUTE PHASE CO-INTERVENTION: not specified

MAINTENANCE: -

MODE OF DISCONTINUATION: naturalistic

FOLLOW-UP: at 6 months and 24 months after acute phase treatment. 50% and 63% were successfully
followed up, respectively.

INTERVENTIONS AFTER TRIAL DISCONTINUATION: 30% had interim treatment (individual therapy,
group therapy, anxiolytics, antidepressants)

RESPONSE: >=50% reduction in self-rated severity of phobia (imputed from mean & SD) 
REMISSION: High end-state functioning 
GLOBAL: Self-rated Severity of Phobia [0-8] 
PANIC ATTACK: Self-rated Panic Overall Severity [0-8] 
AGORAPHOBIA: FQ-Ag [0-40], Individualized phobic anxiety-avoidance [0-8], Behavioral avoidance-anx-
iety index [0-8] 
GENERAL ANXIETY: Zung Anxiety Scale [20-80] 
DEPRESSION: Beck Depression Inventory [0-63] 
FUNCTIONING: Clinician's Global Assessment [1-5]

Authors' judgement

Support for judgement

Outcomes

Notes

Risk of bias

Bias

Allocation concealment?

Low risk

A - Adequate

Mavissakalian 1986b 

Methods

ALLOCATION CONCEALMENT: adequate 

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

32

 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Mavissakalian 1986b  (Continued)

Cochrane Database of Systematic Reviews

Participants

BLINDING: at least one measure was assessed by an independent assessor blind to treatment alloca-
tion

DIAGNOSIS: DSM-III agoraphobia with panic 
AGE: mean=36.5 years 
SEX: 84% women 
HISTORY: mean duration of illness=10.5 years 
PSYCHIATRIC COMORBIDITY: Primary affective disorder or concurrent major depressive episode, schiz-
ophrenia, organic brain syndrome, OCD, somatization disorder, substance abuse, or severe personality
disorder were excluded. 
MEDICAL COMORBIDITY: Physical illness precluding imipramine was excluded.

Interventions

ACUTE PHASE: 12 weeks 
1. imipramine (mean=130 mg/d) + programmed practice (self-directed in vivo graded exposure) +
flooding twelve 90-min group sessions (twelve 90-min group sessions) 
2. placebo + programmed practice + flooding

ACUTE PHASE CO-INTERVENTION: not specified

MAINTENANCE: -

MODE OF DISCONTINUATION: naturalistic

FOLLOW-UP: at 6 months and 12 months after acute phase treatment. 63% and 55% were successfully
followed up, respectively.

INTERVENTIONS AFTER TRIAL DISCONTINUATION: 30% had interim treatment (individual therapy,
group therapy, anxiolytics, antidepressants)

RESPONSE: >=50% reduction in self-rated severity of phobia (imputed from mean & SD) 
REMISSION: High end-state functioning 
GLOBAL: SElf-rated Severity of Phobia [0-8] 
PANIC ATTACK: Self-rated Panic Overall Severity [0-8] 
AGORAPHOBIA: FQ-Ag [0-40], Individualized phobic anxiety-avoidance [0-8], Behavioral avoidance-anx-
iety index [0-8] 
GENERAL ANXIETY: Zung Anxiety Scale [20-80] 
DEPRESSION: Beck Depression Inventory [0-63] 
FUNCTIONING: Clinician's Global Assessment [1-5]

Authors' judgement

Support for judgement

Outcomes

Notes

Risk of bias

Bias

Allocation concealment?

Low risk

A - Adequate

Oehrberg 1995 

Methods

Participants

ALLOCATION CONCEALMENT: unclear 
BLINDING: at least one measure was assessed by an independent assessor blind to treatment alloca-
tion

DIAGNOSIS: DSM-III-R panic disorder with or without agoraphobia (64% reported moderate to severe
agoraphobia) 
AGE: mean=37.4 years 
SEX: 76% women 
HISTORY: unspecified 

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

33

 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Oehrberg 1995  (Continued)

Cochrane Database of Systematic Reviews

PSYCHIATRIC COMORBIDITY: Primary diagnosis of major depression, generalized anxiety disorder,
schizophrenia, dementia, organic brain disease, alcohol or drug abuse, or concomitant treatment with
psychotropics and anticoagulants were excluded. The baseline 17-item HAM-D had to be 14 or less. 
MEDICAL COMORBIDITY: -

Interventions

ACUTE PHASE: 12 weeks 
1. paroxetine (40-60 mg/d) + CBT (details not given) 
2. placebo + CBT

ACUTE PHASE CO-INTERVENTION: Concomitant use of benzo was prohibited. The urine was screened.

MAINTENANCE: -

MODE OF DISCONTINUATION: -

FOLLOW-UP: -

RESPONSE: >=50% reduction in panic frequency 
REMISSION: "mildly ill" or less on CGI 
GLOBAL: - 
PANIC ATTACK: panic frequency 
AGORAPHOBIA: - 
GENERAL ANXIETY: Zung Anxiety Scale 
DEPRESSION: - 
FUNCTIONING: -

Authors' judgement

Support for judgement

Outcomes

Notes

Risk of bias

Bias

Allocation concealment?

Unclear risk

B - Unclear

Sharp 1996 

Methods

Participants

ALLOCATION CONCEALMENT: unclear 
BLINDING: at least one measure was assessed by an independent assessor blind to treatment alloca-
tion

DIAGNOSIS: DSM-III-R panic disorder with or without agoraphobia (% agoraphobia unclear; however,
the average score for FQ-Ag was around 15, indicating most had at least some agoraphobia) 
AGE: mean=33.2 to 38.8 
SEX: 78% women 
HISTORY: mean duration of panic disorder = 5.1 to 7.3 years 
Patients who had received psychotherapy within 6 months were excluded. 
Drugs were washed out over 4 weeks. 
PSYCHIATRIC COMORBIDITY: Concurrent major depression (defined as MADRS>=21) was excluded.
OCD, paranoid personality disorder, schizophrenia, schizoaffective disorder, manic disorder, other un-
specified psychosis, epilepsy, organic brain disease, alcohol dependence, drug dependence were ex-
cluded. 
MEDICAL COMORBIDITY: Severe concurrent somatic disease and a physical disability that severely re-
stricted mobility were excluded.

Interventions

ACUTE PHASE: 12 weeks 
1. fluvoxamine (100-150 mg/day) + CBT (12 sessions) 
2. fluvoxamine alone 
3. CBT alone 

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

34

 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Sharp 1996  (Continued)

4. CBT + placebo 
5. placebo alone [not included in the present meta-analysis]

ACUTE PHASE CO-INTERVENTION: Patients were required to undergo a 4-week washout from psy-
chotropics before entry into the study.

MAINTENANCE: No maintenance phase

MODE OF DISCONTINUATION: Abrupt

FOLLOW-UP: At 6 months after treatment discontinuation. 79% was successfully followed up.

INTERVENTIONS AFTER TRIAL DISCONTINUATION: Patients were required not to receive any psy-
chotropic drugs or psychotherapies but at least 33% received further treatment.

Outcomes

Notes

Risk of bias

Bias

RESPONSE: "Very much" or "Much improved" on CGI Change 
REMISSION: "Normal" or "borderline" on CGI Severity 
GLOBAL: CGI Severity, CGI Change 
PANIC ATTACK: - 
AGORAPHOBIA: FQ-Ag 
GENERAL ANXIETY: HAM-A 
DEPRESSION: MADRS 
FUNCTIONING: Sheehan Disability Scale-work, -social, -home

Authors' judgement

Support for judgement

Allocation concealment?

Unclear risk

B - Unclear

Sharp 1996i 

Methods

Participants

Interventions

Outcomes

Notes

Risk of bias

Bias

Same as (Sharp 1996) but refers only to the comparison with psychotherapy + placebo.

Authors' judgement

Support for judgement

Allocation concealment?

Unclear risk

B - Unclear

Sharp 1996ii 

Methods

Same as (Sharp 1996) but refers only to the comparison with psychotherapy alone.

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

35

 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Sharp 1996ii  (Continued)

Participants

Interventions

Outcomes

Notes

Risk of bias

Bias

Authors' judgement

Support for judgement

Allocation concealment?

Unclear risk

D - Not used

Sheehan 1980a 

Methods

Participants

Interventions

Outcomes

Notes

Risk of bias

ALLOCATION CONCEALMENT: unclear 
BLINDING: at least one measure was assessed by an independent assessor blind to treatment alloca-
tion

DIAGNOSIS: authors' own criteria, very similar to DSM-IV panic disorder with agoraphobia 
AGE: mean=37.1 years 
SEX: 82% women 
HISTORY: mean duration of panic disorder = 11.5 to 13.5 years. On average, patients had received 4
years of psychoanalysis or behavior therapy. 
PSYCHIATRIC COMORBIDITY: Psychosis was excluded. 
MEDICAL COMORBIDITY: Physicall illness was excluded.

ACUTE PHASE: 12 weeks 
1. imipramine (150 mg/d) + group behavior therapy (1-hour supportive group therapy every two weeks
for three months; Patients were encouraged to gradually reapproach phobic situations and objects,
and were rewarded emotionally when they did so) 
2. placebo + group behavior therapy

ACUTE PHASE CO-INTERVENTION: Patients were required to avoid all psychtropic drugs other than
imipramine and phenelzine.

MAINTENANCE: -

MODE OF DISCONTINUATION: -

FOLLOW-UP: -

RESPONSE: Partial or marked improvement on Symptom Severity and Avoidance Scale 
REMISSION: Marked improvement on Symptom Severity and Phobic Avoidance Scale 
GLOBAL: Symptom Severity and Phobic Avoidacne Scale[1-5] 
PANIC ATTACK: - 
AGORAPHOBIA: Wolpe-Lang FSS 
GENERAL ANXIETY: SCL anxiety 
DEPRESSION: Zung Depression Scale 
FUNCTIONING: Work and Social Disability Scale [1-5]

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

36

 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Sheehan 1980a  (Continued)

Bias

Authors' judgement

Support for judgement

Allocation concealment?

Unclear risk

B - Unclear

Sheehan 1980b 

Methods

Participants

Interventions

Outcomes

Notes

Risk of bias

Bias

ALLOCATION CONCEALMENT: unclear 
BLINDING: at least one measure was assessed by an independent assessor blind to treatment alloca-
tion

DIAGNOSIS: authors' own criteria, very similar to DSM-IV panic disorder with agoraphobia 
AGE: mean=37.1 years 
SEX: 82% women 
HISTORY: mean duration of panci disorder = 13.0 to 13.5 years. On average, patients had received 4
years of psychoanalysis or behavior therapy. 
PSYCHIATRIC COMORBIDITY: Psychosis was excluded. 
MEDICAL COMORBIDITY: Physicall illness was excluded.

ACUTE PHASE: 12 weeks 
1. phenelzine (45 mg/d) + group behavior therapy (1-hour supportive group therapy every two weeks
for three months; Patients were encouraged to gradually reapproach phobic situations and objects,
and were rewarded emotionally when they did so) 
2. placebo + group behavior therapy

ACUTE PHASE CO-INTERVENTION: Patients were required to avoid all psychtropic drugs other than
imipramine and phenelzine.

MAINTENANCE: -

MODE OF DISCONTINUATION: -

FOLLOW-UP: -

RESPONSE: Partial or marked improvement on Symptom Severity and Avoidance Scale 
REMISSION: Marked improvement on Symptom Severity and Phobic Avoidance Scale 
GLOBAL: Symptom Severity and Phobic Avoidacne Scale[1-5] 
PANIC ATTACK: - 
AGORAPHOBIA: Wolpe-Lang FSS 
GENERAL ANXIETY: SCL anxiety 
DEPRESSION: Zung Depression Scale 
FUNCTIONING: Work and Social Disability Scale [1-5]

Authors' judgement

Support for judgement

Allocation concealment?

Unclear risk

B - Unclear

Spinhoven 1996 

Methods

ALLOCATION CONCEALMENT: unclear 
BLINDING: not blind

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

37

 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Spinhoven 1996  (Continued)

Participants

Interventions

Outcomes

Notes

Risk of bias

Bias

DIAGNOSIS: DSM-III-R panic disorder with or without agoraphobia (85% agoraphobic) 
AGE: mean=35.6 years 
SEX: 57% women 
HISTORY: mean duration of illness=6.2 years 
PSYCHIATRIC COMORBIDITY: Psychosis, major depression, alcohol abuse or dependence were exclud-
ed. 
MEDICAL COMORBIDITY: Hyperthyroidism, pheochromocytome, bronchial asthma or angina were ex-
cluded.

ACUTE PHASE: 6 weeks 
1. tranzodone (mean=178 mg/d) + CBT (breathing retraining, progressive relaxation, catastrophic cog-
nitions, voluntary hyperventilation, BUT NO in vivo exposure; 6 sessions) 
2. tranzodone alone 
3. CBT alone

ACUTE PHASE CO-INTERVENTION: 25 out of 60 patients were taking low potency benzo at the start of
the study. They were required to keep the dosage constant throughout the study.

MAINTENANCE: -

MODE OF DISCONTINUATION: -

FOLLOW-UP: -

RESPONSE: >=50% reduction in agoraphobic avoidance [imputed from mean&SD] 
REMISSION: - 
GLOBAL: - 
PANIC ATTACK: panic frequency for two weeks; panic intensity [0-10] 
AGORAPHOBIA: agoraphobic avoidance [0-40]; agoraphobic anxiety [0-40] 
GENERAL ANXIETY: - 
DEPRESSION: Zung Depression Scale [20-80] 
FUNCTIONING: -

Authors' judgement

Support for judgement

Allocation concealment?

Unclear risk

B - Unclear

Stein 2000 

Methods

Participants

ALLOCATION CONCEALMENT: unclear 
BLINDING: at least one measure was assessed by an independent assessor blind to treatment alloca-
tion

DIAGNOSIS: DSM-IV panic disorder with or without agoraphobia (percent agoraphobic not given; how-
ever, the average score for FQ-Ag was around 10.5 and 16.1, indicating most had at least some agora-
phobia) 
AGE: mean=33.8 years 
SEX: 73% women 
HISTORY: None of the enrolled subjects reported taking benzodiazepines. 
PSYCHIATRIC COMORBIDITY: Major depressive disorder with melancholic features, schizophrenia, cur-
rent substance abuse/dependence were excluded. 
MEDICAL COMORBIDITY: Seizure disorder, thyroid disease were excluded.

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

38

 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Stein 2000  (Continued)

Interventions

ACUTE PHASE: 10 weeks 
1. paroxetine (mean=32.4 mg/d) + CBT (2 sessions only, using self-help book, relaxation tape, cognitive
restructuring, breathing control, graded exposure) 
2. placebo + CBT

ACUTE PHASE CO-INTERVENTION: None of the subjected entrolled reported taking benzo.

MAINTENANCE: -

MODE OF DISCONTINUATION: -

FOLLOW-UP: -

RESPONSE: "Much" or "very much improved" on CGI Improvement 
REMISSION: panic free 
GLOBAL: - 
PANIC ATTACK: frequency of panic attacks 
AGORAPHOBIA: FQ-Ag 
GENERAL ANXIETY: Beck Anxiety Inventory 
DEPRESSION: Beck Depression Inventory 
FUNCTIONING: Sheehan Disability Scale

Authors' judgement

Support for judgement

Outcomes

Notes

Risk of bias

Bias

Allocation concealment?

Unclear risk

B - Unclear

Telch 1985 

Methods

Participants

Interventions

ALLOCATION CONCEALMENT: unclear 
BLINDING: at least one measure was assessed by an independent assessor blind to treatment alloca-
tion

DIAGNOSIS: DSM-III agoraphobia with panic attacks 
AGE: mean=41.5 years 
SEX: 92% women 
HISTORY: mean duration of illness=12.2 years 
PSYCHIATRIC COMORBIDITY: None met criteria for major affective disorder. 
MEDICAL COMORBIDITY:

ACUTE PHASE: 8 weeks 
1. imipramine (ca 180 mg/d) + behavior therapy (three 3-hour group sessions + three 1.5-hour individ-
ual sessions) 
2. imipramine (with anti-exposure) 
3. placebo + behavior therapy

ACUTE PHASE CO-INTERVENTION: not specified

MAINTENANCE: 18 weeks

MODE OF DISCONTINUATION: -

FOLLOW-UP: -

Outcomes

RESPONSE: >=50% reduction in FQ-Ag [imputed from mean&SD] 

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

39

 
 
 
 
 
Cochrane Database of Systematic Reviews

Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Telch 1985  (Continued)

REMISSION: 
GLOBAL: - 
PANIC ATTACK: frequency of panic attacks 
AGORAPHOBIA: FQ-Ag; BAT 
GENERAL ANXIETY: - 
DEPRESSION: Beck Depression Inventory 
FUNCTIONING: -

Notes

Risk of bias

Bias

Authors' judgement

Support for judgement

Allocation concealment?

Unclear risk

B - Unclear

Wiborg 1996 

Methods

Participants

Interventions

Outcomes

Notes

ALLOCATION CONCEALMENT: adequate [data provided by the original author] 
BLINDING: at least one measure was assessed by an independent assessor blind to treatment alloca-
tion

DIAGNOSIS: DSM-III-R panic disorder with or without agoraphobia (80% agoraphobic) 
AGE: mean=31.7 years 
SEX: 58% women 
HISTORY: mean duration of illness=3.2 years 
PSYCHIATRIC COMORBIDITY: Personality disorder, primary major depression, psychosis, substance
abuse, eating disorder, agoraphobia with or without panic attacks were excluded. 
MEDICAL COMORBIDITY: Significant medical illness, pregnancy and lactation were excluded.

ACUTE PHASE: 12-15 weeks 
1. clomipramine (mean=108-113 mg/d) + psychodynamic psychotherapy (15 weekly brief dynamic psy-
chotherapy sessions, without encouraging exposure) 
2. clomipramine alone

ACUTE PHASE CO-INTERVENTION: 11 out of 40 took benzo in the first month; 4 used benzo irregularly
for six months.

MAINTENANCE: 33-36 weeks

MODE OF DISCONTINUATION: tapered off over 6 weeks

FOLLOW-UP: at 9 months after treatment discontinuation. 100% follow-up was achieved.

INTERVENTIONS AFTER TRIAL DISCONTINUATION: 
Of 20 patients in the first arm, 4 took effective medication. Of 20 patients in the second arm, 14 took ef-
fective medication and 4 received psychological treatment.

RESPONSE: >=40% reduction in Patient Status Scale [imputed from mean&SD] 
REMISSION: panic free 
GLOBAL: Patient Status Scale 
PANIC ATTACK: Panic Attack and Anxiety Scale 
AGORAPHOBIA: Phobia Scale 
GENERAL ANXIETY: HAM-A 
DEPRESSION: HAM-D 
FUNCTIONING: Sheehan Disability Scale

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

40

 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Wiborg 1996  (Continued)

Risk of bias

Bias

Authors' judgement

Support for judgement

Allocation concealment?

Low risk

A - Adequate

Zitrin 1980 

Methods

Participants

ALLOCATION CONCEALMENT: unclear 
BLINDING: at least one measure was assessed by an independent assessor blind to treatment alloca-
tion

DIAGNOSIS: "agoraphobia" (the average severity being 5.9 to 6.3 on a scale between 1 through 7) with
"spontaneous panic" (again the average severity being 4.1 to 4.9 on a scale between 1 through 7) 
AGE: mean=35.6 years 
SEX: 100% women 
HISTORY: mean duration of illness=8.6 years 
PSYCHIATRIC COMORBIDITY: Schizophrenia and significant current depression were excluded. 
MEDICAL COMORBIDITY: -

Interventions

ACUTE PHASE: 14 weeks 
1. imipramine (ca 200 mg/d) + behavior therapy (group in vivo exposure, ten 3-4-hour sessions) 
2. placebo + behavior therapy

ACUTE PHASE CO-INTERVENTION: not specified

MAINTENANCE: 12 weeks

MODE OF DISCONTINUATION: -

FOLLOW-UP: -

RESPONSE: "moderate" to "marked" improvement on CGI Change by an independent evaluator 
REMISSION: "Marked" improvement on CGI Change by an independent evaluator 
GLOBAL: CGI Change 
PANIC ATTACK: spontaneous panic scale [1-7] 
AGORAPHOBIA: primary phobia scale [1-7] 
GENERAL ANXIETY: - 
DEPRESSION: - 
FUNCTIONING: functioning scale [1-7]

Authors' judgement

Support for judgement

Outcomes

Notes

Risk of bias

Bias

Allocation concealment?

Unclear risk

B - Unclear

Zitrin 1983 

Methods

ALLOCATION CONCEALMENT: unclear 
BLINDING: at least one measure was assessed by an independent assessor blind to treatment alloca-
tion

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

41

 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Zitrin 1983  (Continued)

Participants

Interventions

Outcomes

Notes

Risk of bias

Bias

DIAGNOSIS: authors' own criteria, similar to DSM-III agoraphobia with panic attacks or DSM-IV panic
disorder with moderate to severe agoraphobia 
AGE: mean=35.5 years 
SEX: 65% women 
HISTORY: mean duration of illness=10.6 years 
PSYCHIATRIC COMORBIDITY: Patients rated as more than moderately depressed on BPRS were exclud-
ed. 
MEDICAL COMORBIDITY: not specified

ACUTE PHASE: 26 weeks 
1. imipramine (mean=204 mg/d) + supportive therapy (dynamically oriented and non-directive) + be-
havior therapy (twenty-six 45-minute sessions including relaxation training, imaginary desensitization,
in vivo desensitization, assertiveness training) 
2. imipramine + supportive therapy 
3. placebo + supportive therapy + behavior therapy

ACUTE PHASE CO-INTERVENTION: not specified

MAINTENANCE:-

MODE OF DISCONTINUATION: naturalisitc

FOLLOW-UP: At 24 months after treatment discontinuation. 59% was successfully followed up.

INTERVENTIONS AFTER TRIAL DISCONTINUATION: not specified

RESPONSE: "Moderate" to "marked" improvement on CGI Change by an independent evaluator 
REMISSION: "Marked" improvement on CGI Change by an independent evaluator 
GLOBAL: CGI Severity; CGI Improvement 
PANIC ATTACK: spontaneous panic 
AGORAPHOBIA: primary phobia 
GENERAL ANXIETY: Taylor Manifest Anxiety 
DEPRESSION: Self-rating Symptom Scale depression 
FUNCTIONING: functioning scale

Authors' judgement

Support for judgement

Allocation concealment?

Unclear risk

B - Unclear

ACQ: Agoraphobic Cognitiions Questionnaire
ADS: Anxiety Discomfort Scale
BAI: Beck Anxiety Inventory
BDI: Beck Depression Inventory
BAT: Behavioral Avoidance Test
BPRS: Bief Psychiatric Rating Scale
BSQ: Body Sensations Questionnaire
CGI: Clinical Global Impression
CID: Clinical Interview for Depression
FQ-Ag: Fear Questionnaire Agoraphobia Subscale
FSS: Fear Survey Schedule
HAM-A: Hamilton Rating Scale for Anxiety
HAM-D: Hamilton Rating Scale for Depression
IPT: Interpersonalty Therapy
MADRS: Montgomery-Asberg Depression Rating Scale
MI: Mobility Inventory
PDSS: Panic Disorder Severity Scale

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

42

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

SAS-SR: Social Adjustment Scale-Self Report
SCL-90-R: Symptom Checklist 90 Revised

Characteristics of excluded studies [ordered by study ID]

Study

Agras 1991

Ba 1999

Reason for exclusion

Randomization was flawed and the groups were not comparable (Personal communication from Dr
Agras on Oct 14, 2003).

Although 3 arms had been planned (pharmacotherpay alone, pharmacotherapy plus CBT, pharma-
cotherapy plus CBT plus psychodynamic therapy), only the last two were successfully completed. 
Moreover, pharmacotherapy always consisted of SSRI plus alprazolam.

Chambless 1979

Flooding versus Flooding + barbiturate

Cox 1988

Lipsedge 1973

Solyom 1981

Randomized comparison between high serum level vs low serum level of imipramine, combined
with behavior therapy

No operational diagnostic criteria used. 
Iproniazid, though with MAO inhibiting effect, is not a widely recognized antidepressant.

Although the overall study design appears to satisfy the inclusion criteria of this systematic review,
the authors did not separately report the results for agoraphobia and social phobia. The original
author was contacted but could not provide separate data for patients with agoraphobia.

D A T A   A N D   A N A L Y S E S

Comparison 1.   PD+/-AGORAPHOBIA: Psychotherapy+Antidepressant vs Antidepressant alone

Outcome or subgroup title

No. of
studies

No. of
partici-
pants

Statistical method

Effect size

1 Response at 2-4 months

11

1.1 Behaviour therapy

1.2 Cognitive-behaviour therapy

1.3 Psychodynamic psychotherapy and others

2 Remission at 2-4 months

2.1 Behaviour therapy

2.2 Cognitive-behaviour therapy

4

5

2

7

2

3

669

193

336

140

506

114

252

Risk Ratio (M-H, Random,
95% CI)

1.24 [1.02, 1.51]

Risk Ratio (M-H, Random,
95% CI)

1.06 [0.80, 1.40]

Risk Ratio (M-H, Random,
95% CI)

1.46 [1.05, 2.02]

Risk Ratio (M-H, Random,
95% CI)

1.10 [0.65, 1.85]

Risk Ratio (M-H, Random,
95% CI)

1.12 [0.84, 1.48]

Risk Ratio (M-H, Random,
95% CI)

0.97 [0.62, 1.51]

Risk Ratio (M-H, Random,
95% CI)

1.40 [0.92, 2.14]

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

43

 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of
studies

No. of
partici-
pants

Statistical method

Effect size

2.3 Psychodynamic psychotherapy and others

3 Global severity at 2-4 months

3.1 Behaviour therapy

3.2 Cognitive-behaviour therapy

3.3 Psychodynamic psychotherapy and others

4 Frequency of panic attacks at 2-4 months

4.1 Behaviour therapy

4.2 Cognitive-behaviour therapy

4.3 Psychodynamic psychotherapy and others

5 Phobic avoidance at 2-4 months

5.1 Behaviour therapy

5.2 Cognitive-behaviour therapy

5.3 Psychodynamic psychotherapy and others

6 General anxiety at 2-4 months

6.1 Behaviour therapy

6.2 Cognitive-behaviour therapy

6.3 Psychodynamic psychotherapy and others

7 Depression at 2-4 months

2

5

2

2

1

8

4

3

2

9

4

3

2

7

2

4

2

8

140

336

90

206

40

355

138

125

92

357

138

127

92

356

90

174

92

281

Risk Ratio (M-H, Random,
95% CI)

0.86 [0.28, 2.61]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.36 [-0.60, -0.11]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.51 [-1.45, 0.44]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.30 [-0.57, -0.02]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.69 [-1.33, -0.05]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.20 [-0.56, 0.16]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.15 [-0.49, 0.19]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.46 [-1.42, 0.50]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.03 [-0.53, 0.59]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.32 [-0.68, 0.05]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.53 [-1.01, -0.06]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.25 [-0.94, 0.44]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.01 [-1.15, 1.13]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.43 [-0.88, 0.03]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.19 [-0.60, 0.23]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.51 [-1.20, 0.18]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.45 [-2.12, 1.22]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.52 [-0.76, -0.28]

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

44

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

No. of
studies

No. of
partici-
pants

Statistical method

Effect size

Outcome or subgroup title

7.1 Behaviour therapy

7.2 Cognitive-behaviour therapy

7.3 Psychodynamic psychotherapy and others

8 Social malfunctioning at 2-4 months

8.1 Behavour therapy

8.2 Cognitive-behaviour therapy

8.3 Psychodynamic psychotherapy and others

4

3

1

6

3

2

1

9 Dropouts for any reason within 2-4 months

11

9.1 Behaviour therapy

9.2 Cognitive-behaviour therapy

9.3 Psychodynamic psychotherapy and others

10 Dropouts due to side effects within 2-4
months

10.1 Behaviour therapy

10.2 Cognitive-behaviour therapy

4

5

2

6

2

3

10.3 Psychodynamic psychotherapy and others

1

11 Response/remission on continued treat-
ment

11.1 Behaviour therapy

11.2 Cognitive-behaviour therapy

5

2

1

138

103

40

246

118

88

40

669

193

336

140

345

43

262

40

382

121

148

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.35 [-0.69, -0.01]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.65 [-1.10, -0.20]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.79 [-1.44, -0.14]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.47 [-0.89, -0.05]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.23 [-0.85, 0.39]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.63 [-1.39, 0.12]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.81 [-1.46, -0.16]

Risk Ratio (M-H, Random,
95% CI)

0.96 [0.75, 1.23]

Risk Ratio (M-H, Random,
95% CI)

1.21 [0.78, 1.88]

Risk Ratio (M-H, Random,
95% CI)

0.77 [0.55, 1.08]

Risk Ratio (M-H, Random,
95% CI)

1.30 [0.69, 2.45]

Risk Ratio (M-H, Random,
95% CI)

0.92 [0.45, 1.87]

Risk Ratio (M-H, Random,
95% CI)

0.97 [0.27, 3.58]

Risk Ratio (M-H, Random,
95% CI)

0.81 [0.25, 2.68]

Risk Ratio (M-H, Random,
95% CI)

3.00 [0.13, 69.52]

Risk Ratio (M-H, Random,
95% CI)

1.34 [0.75, 2.40]

Risk Ratio (M-H, Random,
95% CI)

1.94 [1.10, 3.41]

Risk Ratio (M-H, Random,
95% CI)

1.52 [1.07, 2.16]

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

45

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of
studies

No. of
partici-
pants

Statistical method

Effect size

11.3 Psychdynamic psychotherapy and others

12 Global/Avoidance/Panic on continued treat-
ment

12.1 Behaviour therapy

12.2 Cognitive-behaviour therapy

2

5

2

1

12.3 Psychodynamic psychotherapy and others

2

13 Dropouts for any reason on continued treat-
ment

13.1 Behaviour therapy

13.2 Cognitive-behaviour therapy

3

1

1

13.3 Psychodynamic psychotherapy and others

1

14 Response/remission immediately after
treatment discontinuation

14.1 Behaviour therapy

14.2 Cognitive-behaviour therapy

1

0

0

14.3 Psychodynamic psychotherapy and others

1

15 Global/Avoidance/Panic immediately after
treatment discontinuation

15.1 Behaviour therapy

15.2 Cognitive-behaviour therapy

1

0

0

15.3 Psychodynamic psychotherapy and others

1

16 Response/remission 6-24 months after
treatment discontinuation

5

113

286

48

148

90

208

20

148

40

50

0

0

50

50

0

0

50

376

Risk Ratio (M-H, Random,
95% CI)

0.67 [0.44, 1.02]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.48 [-0.98, 0.01]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.91 [-1.51, -0.30]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.41 [-0.74, -0.09]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.20 [-1.45, 1.04]

Risk Ratio (M-H, Random,
95% CI)

0.71 [0.27, 1.90]

Risk Ratio (M-H, Random,
95% CI)

1.0 [0.07, 13.87]

Risk Ratio (M-H, Random,
95% CI)

0.73 [0.22, 2.39]

Risk Ratio (M-H, Random,
95% CI)

0.5 [0.05, 5.08]

Risk Ratio (M-H, Random,
95% CI)

0.85 [0.65, 1.11]

Risk Ratio (M-H, Random,
95% CI)

0.0 [0.0, 0.0]

Risk Ratio (M-H, Random,
95% CI)

0.0 [0.0, 0.0]

Risk Ratio (M-H, Random,
95% CI)

0.85 [0.65, 1.11]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.42 [-0.15, 0.99]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.0 [0.0, 0.0]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.0 [0.0, 0.0]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.42 [-0.15, 0.99]

Risk Ratio (M-H, Random,
95% CI)

1.61 [1.23, 2.11]

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

46

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

16.1 Behaviour therapy

16.2 Cognitive-behaviour therapy

16.3 Other psychotherapies

17 Global/Avoidance/Panic 6-24 months after
treatment discontinuation

17.1 Behaviour therapy

17.2 Cognitive-behaviour therapy

1

3

1

2

0

1

17.3 Psychodynamic psychotherapy and others

1

No. of
studies

No. of
partici-
pants

Statistical method

Effect size

96

240

40

176

0

136

40

Risk Ratio (M-H, Random,
95% CI)

1.49 [0.95, 2.35]

Risk Ratio (M-H, Random,
95% CI)

1.46 [1.00, 2.11]

Risk Ratio (M-H, Random,
95% CI)

3.2 [1.45, 7.05]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.58 [-1.78, 0.63]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.0 [0.0, 0.0]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.0 [-0.34, 0.34]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-1.23 [-1.91, -0.55]

Analysis 1.1.   Comparison 1 PD+/-AGORAPHOBIA: Psychotherapy
+Antidepressant vs Antidepressant alone, Outcome 1 Response at 2-4 months.

PT+AD

n/N

AD

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

Study or subgroup

1.1.1 Behaviour therapy

Johnston 1995

Mavissakalian 1983

Telch 1985

Zitrin 1983

Subtotal (95% CI)

7/28

7/9

5/13

25/43

93

Total events: 44 (PT+AD), 44 (AD)

Heterogeneity: Tau2=0; Chi2=2.86, df=3(P=0.41); I2=0%

Test for overall effect: Z=0.41(P=0.68)

1.1.2 Cognitive-behaviour therapy

Azhar 2000

Barlow 2000

Loerch 1999

Sharp 1996

Spinhoven 1996

Subtotal (95% CI)

14/22

39/65

11/14

26/38

4/20

159

Total events: 94 (PT+AD), 74 (AD)

Heterogeneity: Tau2=0.05; Chi2=6.97, df=4(P=0.14); I2=42.64%

Test for overall effect: Z=2.26(P=0.02)

1.1.3 Psychodynamic psychotherapy and others

5/26

6/9

1/12

32/53

100

5/22

38/83

5/16

21/36

5/20

177

3.31%

7.96%

0.95%

14.46%

26.68%

4.62%

15.46%

5.17%

13.9%

2.62%

41.78%

1.3[0.47,3.59]

1.17[0.65,2.08]

4.62[0.63,34.05]

0.96[0.69,1.35]

1.06[0.8,1.4]

2.8[1.22,6.44]

1.31[0.96,1.78]

2.51[1.16,5.47]

1.17[0.83,1.67]

0.8[0.25,2.55]

1.46[1.05,2.02]

Berger 2004

29/50

34/50

15.61%

0.85[0.63,1.15]

Favours AD

0.2

0.5

1

2

5

Favours PT+AD

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

47

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Study or subgroup

Wiborg 1996

Subtotal (95% CI)

PT+AD

n/N

20/20

70

AD

n/N

14/20

70

Total events: 49 (PT+AD), 48 (AD)

Heterogeneity: Tau2=0.12; Chi2=6.07, df=1(P=0.01); I2=83.51%

Test for overall effect: Z=0.36(P=0.72)

Cochrane Database of Systematic Reviews

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

15.94%

31.55%

1.41[1.05,1.9]

1.1[0.65,1.85]

Total (95% CI)

322

347

100%

1.24[1.02,1.51]

Total events: 187 (PT+AD), 166 (AD)

Heterogeneity: Tau2=0.04; Chi2=17.94, df=10(P=0.06); I2=44.25%

Test for overall effect: Z=2.11(P=0.04)

Test for subgroup differences: Not applicable

Favours AD

0.2

0.5

1

2

5

Favours PT+AD

Analysis 1.2.   Comparison 1 PD+/-AGORAPHOBIA: Psychotherapy
+Antidepressant vs Antidepressant alone, Outcome 2 Remission at 2-4 months.

PT+AD

n/N

AD

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

Study or subgroup

1.2.1 Behaviour therapy

Mavissakalian 1983

Zitrin 1983

Subtotal (95% CI)

6/9

13/43

52

Total events: 19 (PT+AD), 23 (AD)

Heterogeneity: Tau2=0; Chi2=0.02, df=1(P=0.89); I2=0%

Test for overall effect: Z=0.14(P=0.89)

1.2.2 Cognitive-behaviour therapy

Barlow 2000

Loerch 1999

Sharp 1996

Subtotal (95% CI)

Total events: 75 (PT+AD), 62 (AD)

42/65

9/14

24/38

117

Heterogeneity: Tau2=0.07; Chi2=4.73, df=2(P=0.09); I2=57.73%

Test for overall effect: Z=1.56(P=0.12)

1.2.3 Psychodynamic psychotherapy and others

Berger 2004

Wiborg 1996

Subtotal (95% CI)

14/50

20/20

70

Total events: 34 (PT+AD), 41 (AD)

Heterogeneity: Tau2=0.6; Chi2=14.64, df=1(P=0); I2=93.17%

Test for overall effect: Z=0.27(P=0.79)

6/9

17/53

62

40/83

2/16

20/36

135

26/50

15/20

70

10.87%

11.97%

22.85%

1[0.52,1.92]

0.94[0.52,1.72]

0.97[0.62,1.51]

20.57%

3.72%

17.72%

42.01%

1.34[1.01,1.79]

5.14[1.33,19.92]

1.14[0.78,1.66]

1.4[0.92,2.14]

13.88%

21.27%

35.15%

0.54[0.32,0.9]

1.32[1.02,1.72]

0.86[0.28,2.61]

Total (95% CI)

239

267

100%

1.12[0.84,1.48]

Total events: 128 (PT+AD), 126 (AD)

Heterogeneity: Tau2=0.08; Chi2=16, df=6(P=0.01); I2=62.51%

Test for overall effect: Z=0.77(P=0.44)

Test for subgroup differences: Not applicable

Favours AD

0.1

0.2

0.5

1

2

5

10

Favours PT+AD

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

48

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 1.3.   Comparison 1 PD+/-AGORAPHOBIA: Psychotherapy+Antidepressant
vs Antidepressant alone, Outcome 3 Global severity at 2-4 months.

Study or subgroup

PT+AD

AD

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

3.7 (1.6)

3.3 (1)

1.1 (0.8)

2.3 (1.2)

2 (1.1)

1.3.1 Behaviour therapy

Mavissakalian 1983

Zitrin 1983

Subtotal ***

2.2 (0.8)

3.2 (1)

8

34

42

Heterogeneity: Tau2=0.31; Chi2=2.62, df=1(P=0.11); I2=61.84%

Test for overall effect: Z=1.05(P=0.29)

1.3.2 Cognitive-behaviour therapy

Barlow 2000

Sharp 1996

Subtotal ***

0.9 (0.7)

1.7 (1.1)

65

29

94

Heterogeneity: Tau2=0; Chi2=0.68, df=1(P=0.41); I2=0%

Test for overall effect: Z=2.1(P=0.04)

1.3.3 Psychodynamic psychotherapy and others

Wiborg 1996

Subtotal ***

1.4 (0.5)

20

20

Heterogeneity: Not applicable

Test for overall effect: Z=2.11(P=0.03)

7

41

48

83

29

112

20

20

Total ***

156

180

Heterogeneity: Tau2=0.01; Chi2=4.61, df=4(P=0.33); I2=13.19%

Test for overall effect: Z=2.87(P=0)

Test for subgroup differences: Chi2=1.3, df=1 (P=0.52), I2=0%

4.53%

23.69%

28.22%

-1.14[-2.26,-0.02]

-0.14[-0.6,0.31]

-0.51[-1.45,0.44]

40.02%

18.71%

58.73%

-0.22[-0.55,0.1]

-0.48[-1.01,0.04]

-0.3[-0.57,-0.02]

13.05%

13.05%

-0.69[-1.33,-0.05]

-0.69[-1.33,-0.05]

100%

-0.36[-0.6,-0.11]

Favours PT+AD

-4

-2

0

2

4

Favours AD

Analysis 1.4.   Comparison 1 PD+/-AGORAPHOBIA: Psychotherapy+Antidepressant
vs Antidepressant alone, Outcome 4 Frequency of panic attacks at 2-4 months.

Study or subgroup

PT+AD

AD

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

1.4.1 Behaviour therapy

Johnston 1995

Mavissakalian 1983

Telch 1985

Zitrin 1983

Subtotal ***

0.6 (0.9)

1.7 (1.9)

0.6 (1.1)

6 (1.2)

12

8

10

34

64

Heterogeneity: Tau2=0; Chi2=2.22, df=3(P=0.53); I2=0%

Test for overall effect: Z=0.86(P=0.39)

1.4.2 Cognitive-behaviour therapy

Azhar 2000

Berger 2004

Spinhoven 1996

Subtotal ***

4.1 (3.9)

0.6 (1.1)

3 (2.5)

17

20

20

57

16

7

10

41

74

17

32

19

68

0.3 (0.7)

2.1 (1.8)

0.8 (1)

6.4 (1.2)

9.1 (2)

0.6 (1.6)

2.8 (2.3)

11.43%

8.12%

9.73%

16.69%

45.97%

11.02%

14.76%

13.5%

39.28%

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Favours PT+AD

-4

-2

0

2

4

Favours AD

0.35[-0.41,1.1]

-0.22[-1.24,0.8]

-0.14[-1.01,0.74]

-0.32[-0.78,0.14]

-0.15[-0.49,0.19]

-1.59[-2.37,-0.81]

0.03[-0.53,0.59]

0.08[-0.55,0.71]

-0.46[-1.42,0.5]

49

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

PT+AD

AD

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

Heterogeneity: Tau2=0.61; Chi2=13.13, df=2(P=0); I2=84.76%

Test for overall effect: Z=0.94(P=0.35)

1.4.3 Psychodynamic psychotherapy and others

Berger 2004

Wiborg 1996

Subtotal ***

20

20

40

0.6 (1.1)

0 (0)

32

20

52

0.6 (1.6)

0.8 (2.1)

Heterogeneity: Not applicable

Test for overall effect: Z=0.09(P=0.92)

Total ***

161

194

Heterogeneity: Tau2=0.15; Chi2=16.4, df=7(P=0.02); I2=57.3%

Test for overall effect: Z=1.09(P=0.28)

Test for subgroup differences: Chi2=1.05, df=1 (P=0.59), I2=0%

14.76%

0.03[-0.53,0.59]

Not estimable

14.76%

0.03[-0.53,0.59]

100%

-0.2[-0.56,0.16]

Favours PT+AD

-4

-2

0

2

4

Favours AD

Analysis 1.5.   Comparison 1 PD+/-AGORAPHOBIA: Psychotherapy+Antidepressant
vs Antidepressant alone, Outcome 5 Phobic avoidance at 2-4 months.

Study or subgroup

PT+AD

AD

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

1.5.1 Behaviour therapy

Johnston 1995

Mavissakalian 1983

Telch 1985

Zitrin 1983

Subtotal ***

8.5 (8.4)

8.6 (6.2)

17.3 (10.3)

2.7 (1.4)

12

8

10

34

64

Heterogeneity: Tau2=0.09; Chi2=4.73, df=3(P=0.19); I2=36.59%

Test for overall effect: Z=2.19(P=0.03)

1.5.2 Cognitive-behaviour therapy

Loerch 1999

Sheehan 1980a

Spinhoven 1996

Subtotal ***

7 (8.3)

4.7 (7.8)

22.5 (12)

14

29

20

63

Heterogeneity: Tau2=0.26; Chi2=7.1, df=2(P=0.03); I2=71.84%

Test for overall effect: Z=0.7(P=0.48)

1.5.3 Psychodynamic psychotherapy and others

Berger 2004

Wiborg 1996

Subtotal ***

0.5 (1)

1.1 (1.1)

20

20

40

Heterogeneity: Tau2=0.58; Chi2=7.14, df=1(P=0.01); I2=86%

Test for overall effect: Z=0.01(P=0.99)

13.9 (9)

19.4 (12.4)

28.4 (11.2)

2.8 (1.4)

19 (13.2)

5.5 (7.9)

18.7 (13.3)

0.1 (0.3)

2.6 (3.3)

16

7

10

41

74

16

29

19

64

32

20

52

Total ***

167

190

Heterogeneity: Tau2=0.19; Chi2=21.81, df=8(P=0.01); I2=63.32%

Test for overall effect: Z=1.69(P=0.09)

Test for subgroup differences: Chi2=2.83, df=1 (P=0.24), I2=29.39%

10.2%

6.88%

8.33%

14.36%

39.77%

10.15%

13.52%

11.92%

35.6%

-0.6[-1.37,0.17]

-1.07[-2.18,0.04]

-0.99[-1.93,-0.05]

-0.11[-0.56,0.35]

-0.53[-1.01,-0.06]

-1.05[-1.82,-0.28]

-0.1[-0.62,0.41]

0.29[-0.34,0.93]

-0.25[-0.94,0.44]

12.76%

11.88%

24.63%

0.57[-0,1.14]

-0.6[-1.23,0.04]

-0.01[-1.15,1.13]

100%

-0.32[-0.68,0.05]

Favours PT+AD

-4

-2

0

2

4

Favours AD

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

50

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 1.6.   Comparison 1 PD+/-AGORAPHOBIA: Psychotherapy+Antidepressant
vs Antidepressant alone, Outcome 6 General anxiety at 2-4 months.

Study or subgroup

PT+AD

AD

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

1.6.1 Behaviour therapy

Mavissakalian 1983

Zitrin 1983

Subtotal ***

27.3 (4.8)

21.5 (9.9)

8

34

42

Heterogeneity: Tau2=0; Chi2=0.39, df=1(P=0.53); I2=0%

Test for overall effect: Z=0.88(P=0.38)

1.6.2 Cognitive-behaviour therapy

Azhar 2000

Berger 2004

Loerch 1999

Sharp 1996

Subtotal ***

22.9 (4.7)

1.8 (2)

11.4 (11.1)

4.8 (5.7)

17

20

14

29

80

Heterogeneity: Tau2=0.38; Chi2=14.04, df=3(P=0); I2=78.64%

Test for overall effect: Z=1.46(P=0.14)

1.6.3 Psychodynamic psychotherapy and others

Berger 2004

Wiborg 1996

Subtotal ***

1.8 (2)

5.5 (4.7)

20

20

40

Heterogeneity: Tau2=1.35; Chi2=14.05, df=1(P=0); I2=92.88%

Test for overall effect: Z=0.53(P=0.6)

32.3 (13.1)

22.8 (9.9)

28.7 (4.2)

1 (2)

19.9 (9.8)

7.9 (7)

1 (2)

16 (10)

7

41

48

17

32

16

29

94

32

20

52

Total ***

162

194

Heterogeneity: Tau2=0.32; Chi2=29.2, df=7(P=0); I2=76.03%

Test for overall effect: Z=1.85(P=0.07)

Test for subgroup differences: Chi2=0.72, df=1 (P=0.7), I2=0%

9.06%

14.54%

23.59%

-0.49[-1.53,0.54]

-0.13[-0.58,0.33]

-0.19[-0.6,0.23]

11.67%

13.49%

11.65%

13.89%

50.7%

-1.29[-2.03,-0.54]

0.39[-0.18,0.95]

-0.79[-1.54,-0.04]

-0.48[-1,0.04]

-0.51[-1.2,0.18]

13.49%

12.23%

25.71%

0.39[-0.18,0.95]

-1.32[-2.01,-0.63]

-0.45[-2.12,1.22]

100%

-0.43[-0.88,0.03]

Favours PT+AD

-4

-2

0

2

4

Favours AD

Analysis 1.7.   Comparison 1 PD+/-AGORAPHOBIA: Psychotherapy
+Antidepressant vs Antidepressant alone, Outcome 7 Depression at 2-4 months.

Study or subgroup

PT+AD

AD

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

1.7.1 Behaviour therapy

Johnston 1995

Mavissakalian 1983

Telch 1985

Zitrin 1983

Subtotal ***

0.8 (0.5)

2.4 (2)

13.4 (5.7)

1.3 (0.5)

12

8

10

34

64

1 (0.9)

9.1 (7.8)

14.7 (14.1)

1.5 (0.5)

16

7

10

41

74

Heterogeneity: Tau2=0; Chi2=2.28, df=3(P=0.52); I2=0%

Test for overall effect: Z=2.01(P=0.04)

1.7.2 Cognitive-behaviour therapy

10.23%

4.61%

7.52%

27.67%

50.03%

-0.27[-1.02,0.48]

-1.14[-2.26,-0.02]

-0.12[-0.99,0.76]

-0.31[-0.77,0.15]

-0.35[-0.69,-0.01]

Azhar 2000

17

9.2 (1.4)

17

12.2 (4.5)

11.53%

-0.89[-1.6,-0.18]

Favours PT+AD

-4

-2

0

2

4

Favours AD

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

51

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

PT+AD

AD

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

Loerch 1999

Spinhoven 1996

Subtotal ***

5.6 (5.8)

43.5 (8.7)

14

20

51

Heterogeneity: Tau2=0.03; Chi2=2.5, df=2(P=0.29); I2=19.85%

Test for overall effect: Z=2.85(P=0)

1.7.3 Psychodynamic psychotherapy and others

Wiborg 1996

Subtotal ***

3.6 (2.7)

20

20

Heterogeneity: Not applicable

Test for overall effect: Z=2.4(P=0.02)

12 (7.4)

46 (10.8)

7.4 (6.1)

16

19

52

20

20

10.01%

14.56%

36.1%

-0.93[-1.69,-0.17]

-0.25[-0.88,0.38]

-0.65[-1.1,-0.2]

13.87%

13.87%

-0.79[-1.44,-0.14]

-0.79[-1.44,-0.14]

Total ***

135

146

100%

-0.52[-0.76,-0.28]

Heterogeneity: Tau2=0; Chi2=6.77, df=7(P=0.45); I2=0%

Test for overall effect: Z=4.2(P<0.0001)

Test for subgroup differences: Chi2=2, df=1 (P=0.37), I2=0.18%

Favours PT+AD

-4

-2

0

2

4

Favours AD

Analysis 1.8.   Comparison 1 PD+/-AGORAPHOBIA: Psychotherapy+Antidepressant
vs Antidepressant alone, Outcome 8 Social malfunctioning at 2-4 months.

Study or subgroup

PT+AD

AD

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

2.3 (0.7)

2.9 (0.9)

1.1 (0.9)

5.9 (3.5)

2.2 (2.9)

3 (2.7)

1.8.1 Behavour therapy

Johnston 1995

Mavissakalian 1983

Zitrin 1983

Subtotal ***

2.1 (0.6)

1.9 (0.9)

1.2 (0.9)

12

8

34

54

Heterogeneity: Tau2=0.16; Chi2=4.34, df=2(P=0.11); I2=53.91%

Test for overall effect: Z=0.73(P=0.46)

1.8.2 Cognitive-behaviour therapy

Loerch 1999

Sharp 1996

Subtotal ***

2.4 (2.8)

1.4 (2.8)

14

29

43

Heterogeneity: Tau2=0.19; Chi2=2.67, df=1(P=0.1); I2=62.54%

Test for overall effect: Z=1.65(P=0.1)

1.8.3 Psychodynamic psychotherapy and others

Wiborg 1996

Subtotal ***

1.2 (1.5)

20

20

Heterogeneity: Not applicable

Test for overall effect: Z=2.45(P=0.01)

16

7

41

64

16

29

45

20

20

Total ***

117

129

Heterogeneity: Tau2=0.15; Chi2=11.86, df=5(P=0.04); I2=57.83%

Test for overall effect: Z=2.21(P=0.03)

Test for subgroup differences: Chi2=4.85, df=1 (P=0.09), I2=58.74%

15.22%

9.68%

22.21%

47.12%

-0.28[-1.03,0.47]

-1.05[-2.15,0.06]

0.17[-0.29,0.62]

-0.23[-0.85,0.39]

14.78%

20.61%

35.4%

-1.08[-1.85,-0.3]

-0.3[-0.82,0.22]

-0.63[-1.39,0.12]

17.48%

17.48%

-0.81[-1.46,-0.16]

-0.81[-1.46,-0.16]

100%

-0.47[-0.89,-0.05]

Favours PT+AD

-4

-2

0

2

4

Favours AD

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

52

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 1.9.   Comparison 1 PD+/-AGORAPHOBIA: Psychotherapy+Antidepressant
vs Antidepressant alone, Outcome 9 Dropouts for any reason within 2-4 months.

PT+AD

n/N

AD

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

Study or subgroup

1.9.1 Behaviour therapy

Johnston 1995

Mavissakalian 1983

Telch 1985

Zitrin 1983

Subtotal (95% CI)

16/28

1/9

3/13

9/43

93

Total events: 29 (PT+AD), 26 (AD)

Heterogeneity: Tau2=0; Chi2=1.63, df=3(P=0.65); I2=0%

Test for overall effect: Z=0.87(P=0.38)

1.9.2 Cognitive-behaviour therapy

Azhar 2000

Barlow 2000

Loerch 1999

Sharp 1996

Spinhoven 1996

Subtotal (95% CI)

5/22

18/65

3/14

11/38

4/20

159

Total events: 41 (PT+AD), 60 (AD)

Heterogeneity: Tau2=0; Chi2=1.19, df=4(P=0.88); I2=0%

Test for overall effect: Z=1.52(P=0.13)

1.9.3 Psychodynamic psychotherapy and others

Berger 2004

Wiborg 1996

Subtotal (95% CI)

15/50

1/20

70

Total events: 16 (PT+AD), 12 (AD)

Heterogeneity: Tau2=0; Chi2=0.29, df=1(P=0.59); I2=0%

Test for overall effect: Z=0.8(P=0.43)

10/26

2/9

2/12

12/53

100

5/22

32/83

7/16

12/36

4/20

177

12/50

0/20

70

17.84%

1.23%

2.34%

10.35%

31.76%

5.1%

26.54%

4.6%

13.12%

3.94%

53.3%

1.49[0.83,2.66]

0.5[0.05,4.58]

1.38[0.28,6.91]

0.92[0.43,1.99]

1.21[0.78,1.88]

1[0.34,2.97]

0.72[0.45,1.16]

0.49[0.16,1.54]

0.87[0.44,1.71]

1[0.29,3.45]

0.77[0.55,1.08]

14.33%

0.61%

14.94%

1.25[0.65,2.39]

3[0.13,69.52]

1.3[0.69,2.45]

Total (95% CI)

322

347

100%

0.96[0.75,1.23]

Total events: 86 (PT+AD), 98 (AD)

Heterogeneity: Tau2=0; Chi2=6.69, df=10(P=0.75); I2=0%

Test for overall effect: Z=0.31(P=0.76)

Test for subgroup differences: Not applicable

Favours PT+AD

0.1

0.2

0.5

1

2

5

10

Favours AD

Analysis 1.10.   Comparison 1 PD+/-AGORAPHOBIA: Psychotherapy+Antidepressant
vs Antidepressant alone, Outcome 10 Dropouts due to side effects within 2-4 months.

Study or subgroup

1.10.1 Behaviour therapy

Mavissakalian 1983

Telch 1985

Subtotal (95% CI)

PT+AD

n/N

AD

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

1/9

3/13

22

2/9

2/12

21

9.68%

17.54%

27.22%

0.5[0.05,4.58]

1.38[0.28,6.91]

0.97[0.27,3.58]

Favours PT+AD

0.1

0.2

0.5

1

2

5

10

Favours AD

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

53

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

PT+AD

n/N

AD

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

Total events: 4 (PT+AD), 4 (AD)

Heterogeneity: Tau2=0; Chi2=0.53, df=1(P=0.47); I2=0%

Test for overall effect: Z=0.04(P=0.97)

1.10.2 Cognitive-behaviour therapy

Barlow 2000

Sharp 1996

Spinhoven 1996

Subtotal (95% CI)

2/65

5/38

4/20

123

11/83

3/36

3/20

139

Total events: 11 (PT+AD), 17 (AD)

Heterogeneity: Tau2=0.6; Chi2=4.38, df=2(P=0.11); I2=54.39%

Test for overall effect: Z=0.34(P=0.73)

1.10.3 Psychodynamic psychotherapy and others

20.57%

23.72%

23.55%

67.84%

0.23[0.05,1.01]

1.58[0.41,6.13]

1.33[0.34,5.21]

0.81[0.25,2.68]

Wiborg 1996

Subtotal (95% CI)

Total events: 1 (PT+AD), 0 (AD)

Heterogeneity: Not applicable

Test for overall effect: Z=0.69(P=0.49)

1/20

20

0/20

20

4.94%

4.94%

3[0.13,69.52]

3[0.13,69.52]

Total (95% CI)

165

180

100%

0.92[0.45,1.87]

Total events: 16 (PT+AD), 21 (AD)

Heterogeneity: Tau2=0.07; Chi2=5.49, df=5(P=0.36); I2=8.88%

Test for overall effect: Z=0.22(P=0.82)

Test for subgroup differences: Not applicable

Favours PT+AD

0.1

0.2

0.5

1

2

5

10

Favours AD

Analysis 1.11.   Comparison 1 PD+/-AGORAPHOBIA: Psychotherapy+Antidepressant
vs Antidepressant alone, Outcome 11 Response/remission on continued treatment.

Study or subgroup

1.11.1 Behaviour therapy

Telch 1985

Zitrin 1983

Subtotal (95% CI)

Total events: 24 (PT+AD), 14 (AD)

PT+AD

n/N

AD

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

7/13

17/43

56

2/12

12/53

65

12.05%

25.58%

37.62%

3.23[0.83,12.61]

1.75[0.94,3.25]

1.94[1.1,3.41]

Heterogeneity: Tau2=0; Chi2=0.66, df=1(P=0.42); I2=0%

Test for overall effect: Z=2.3(P=0.02)

1.11.2 Cognitive-behaviour therapy

Barlow 2000

Subtotal (95% CI)

Total events: 37 (PT+AD), 31 (AD)

Heterogeneity: Not applicable

Test for overall effect: Z=2.36(P=0.02)

37/65

65

31/83

83

31.98%

31.98%

1.52[1.07,2.16]

1.52[1.07,2.16]

1.11.3 Psychdynamic psychotherapy and others

Berger 2004

16/35

26/38

30.39%

0.67[0.44,1.02]

Favours AD

0.1

0.2

0.5

1

2

5

10

Favours PT+AD

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

54

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Wiborg 1996

Subtotal (95% CI)

Total events: 36 (PT+AD), 46 (AD)

Heterogeneity: Not applicable

Test for overall effect: Z=1.88(P=0.06)

PT+AD

n/N

20/20

55

AD

n/N

20/20

58

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

Not estimable

30.39%

0.67[0.44,1.02]

Total (95% CI)

176

206

100%

1.34[0.75,2.4]

Total events: 97 (PT+AD), 91 (AD)

Heterogeneity: Tau2=0.24; Chi2=12.91, df=3(P=0); I2=76.77%

Test for overall effect: Z=1(P=0.32)

Test for subgroup differences: Not applicable

Favours AD

0.1

0.2

0.5

1

2

5

10

Favours PT+AD

Analysis 1.12.   Comparison 1 PD+/-AGORAPHOBIA: Psychotherapy+Antidepressant vs
Antidepressant alone, Outcome 12 Global/Avoidance/Panic on continued treatment.

Study or subgroup

PT+AD

AD

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

1.12.1 Behaviour therapy

Johnston 1995

Telch 1985

Subtotal ***

5.4 (5.7)

12.6 (8.1)

12

10

22

Heterogeneity: Tau2=0; Chi2=0.7, df=1(P=0.4); I2=0%

Test for overall effect: Z=2.93(P=0)

1.12.2 Cognitive-behaviour therapy

Barlow 2000

Subtotal ***

0.8 (0.9)

65

65

Heterogeneity: Not applicable

Test for overall effect: Z=2.47(P=0.01)

1.12.3 Psychodynamic psychotherapy and others

Berger 2004

Wiborg 1996

Subtotal ***

0.5 (1)

0.5 (1.1)

21

20

41

Heterogeneity: Tau2=0.71; Chi2=8.29, df=1(P=0); I2=87.93%

Test for overall effect: Z=0.32(P=0.75)

11.3 (9.6)

23.8 (9.3)

1.1 (0.9)

0.1 (0.6)

2.4 (2.9)

16

10

26

83

83

29

20

49

Total ***

128

158

Heterogeneity: Tau2=0.21; Chi2=13.19, df=4(P=0.01); I2=69.67%

Test for overall effect: Z=1.92(P=0.06)

Test for subgroup differences: Chi2=4.2, df=1 (P=0.12), I2=52.43%

17.45%

13.97%

31.42%

-0.7[-1.47,0.07]

-1.23[-2.2,-0.26]

-0.91[-1.51,-0.3]

26.88%

26.88%

-0.41[-0.74,-0.09]

-0.41[-0.74,-0.09]

21.74%

19.97%

41.71%

0.42[-0.15,0.99]

-0.85[-1.5,-0.2]

-0.2[-1.45,1.04]

100%

-0.48[-0.98,0.01]

Favours PT+AD

-4

-2

0

2

4

Favours AD

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

55

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 1.13.   Comparison 1 PD+/-AGORAPHOBIA: Psychotherapy+Antidepressant vs
Antidepressant alone, Outcome 13 Dropouts for any reason on continued treatment.

Study or subgroup

PT+AD

n/N

AD

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

1.13.1 Behaviour therapy

Telch 1985

Subtotal (95% CI)

Total events: 1 (PT+AD), 1 (AD)

Heterogeneity: Not applicable

Test for overall effect: Not applicable

1.13.2 Cognitive-behaviour therapy

Barlow 2000

Subtotal (95% CI)

Total events: 4 (PT+AD), 7 (AD)

Heterogeneity: Not applicable

Test for overall effect: Z=0.52(P=0.6)

1/10

10

4/65

65

1.13.3 Psychodynamic psychotherapy and others

Wiborg 1996

Subtotal (95% CI)

Total events: 1 (PT+AD), 2 (AD)

Heterogeneity: Not applicable

Test for overall effect: Z=0.59(P=0.56)

1/20

20

1/10

10

7/83

83

2/20

20

13.87%

13.87%

1[0.07,13.87]

1[0.07,13.87]

68.3%

68.3%

0.73[0.22,2.39]

0.73[0.22,2.39]

17.83%

17.83%

0.5[0.05,5.08]

0.5[0.05,5.08]

Total (95% CI)

95

113

100%

0.71[0.27,1.9]

Total events: 6 (PT+AD), 10 (AD)

Heterogeneity: Tau2=0; Chi2=0.16, df=2(P=0.93); I2=0%

Test for overall effect: Z=0.68(P=0.5)

Test for subgroup differences: Not applicable

Favours PT+AD

0.1

0.2

0.5

1

2

5

10

Favours AD

Analysis 1.14.   Comparison 1 PD+/-AGORAPHOBIA: Psychotherapy+Antidepressant vs Antidepressant
alone, Outcome 14 Response/remission immediately after treatment discontinuation.

Study or subgroup

PT+AD

n/N

AD

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

1.14.1 Behaviour therapy

Subtotal (95% CI)

Total events: 0 (PT+AD), 0 (AD)

Heterogeneity: Not applicable

Test for overall effect: Not applicable

1.14.2 Cognitive-behaviour therapy

Subtotal (95% CI)

Total events: 0 (PT+AD), 0 (AD)

Heterogeneity: Not applicable

Test for overall effect: Not applicable

0

0

0

0

Not estimable

Not estimable

1.14.3 Psychodynamic psychotherapy and others

Berger 2004

16/21

26/29

100%

0.85[0.65,1.11]

Favours AD

0.1

0.2

0.5

1

2

5

10

Favours PT+AD

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

56

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

PT+AD

n/N

AD

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

Subtotal (95% CI)

21

29

100%

0.85[0.65,1.11]

Total events: 16 (PT+AD), 26 (AD)

Heterogeneity: Not applicable

Test for overall effect: Z=1.18(P=0.24)

Total (95% CI)

21

29

100%

0.85[0.65,1.11]

Total events: 16 (PT+AD), 26 (AD)

Heterogeneity: Not applicable

Test for overall effect: Z=1.18(P=0.24)

Test for subgroup differences: Not applicable

Favours AD

0.1

0.2

0.5

1

2

5

10

Favours PT+AD

Analysis 1.15.   Comparison 1 PD+/-AGORAPHOBIA: Psychotherapy+Antidepressant vs Antidepressant
alone, Outcome 15 Global/Avoidance/Panic immediately after treatment discontinuation.

Study or subgroup

PT+AD

AD

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

1.15.1 Behaviour therapy

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Not applicable

1.15.2 Cognitive-behaviour therapy

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Not applicable

0

0

1.15.3 Psychodynamic psychotherapy and others

Berger 2004

Subtotal ***

0.5 (1)

21

21

Heterogeneity: Tau2=0; Chi2=0, df=0(P<0.0001); I2=100%

Test for overall effect: Z=1.45(P=0.15)

Total ***

21

Heterogeneity: Tau2=0; Chi2=0, df=0(P<0.0001); I2=100%

Test for overall effect: Z=1.45(P=0.15)

Test for subgroup differences: Not applicable

0

0

29

29

29

Not estimable

Not estimable

0.1 (0.6)

100%

100%

0.42[-0.15,0.99]

0.42[-0.15,0.99]

100%

0.42[-0.15,0.99]

Favours PT+AD

-4

-2

0

2

4

Favours AD

Analysis 1.16.   Comparison 1 PD+/-AGORAPHOBIA: Psychotherapy+Antidepressant vs Antidepressant
alone, Outcome 16 Response/remission 6-24 months after treatment discontinuation.

Study or subgroup

1.16.1 Behaviour therapy

Zitrin 1983

Subtotal (95% CI)

PT+AD

n/N

AD

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

23/43

43

19/53

53

35.41%

35.41%

1.49[0.95,2.35]

1.49[0.95,2.35]

Favours AD

0.2

0.5

1

2

5

Favours PT+AD

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

57

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

PT+AD

n/N

AD

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

Total events: 23 (PT+AD), 19 (AD)

Heterogeneity: Not applicable

Test for overall effect: Z=1.72(P=0.09)

1.16.2 Cognitive-behaviour therapy

Barlow 2000

Loerch 1999

Sharp 1996

Subtotal (95% CI)

Total events: 41 (PT+AD), 32 (AD)

16/59

9/14

16/38

111

15/77

7/16

10/36

129

19.27%

15.93%

17.63%

52.83%

1.39[0.75,2.58]

1.47[0.75,2.9]

1.52[0.8,2.89]

1.46[1,2.11]

Heterogeneity: Tau2=0; Chi2=0.04, df=2(P=0.98); I2=0%

Test for overall effect: Z=1.97(P=0.05)

1.16.3 Other psychotherapies

Wiborg 1996

Subtotal (95% CI)

Total events: 16 (PT+AD), 5 (AD)

Heterogeneity: Not applicable

Test for overall effect: Z=2.89(P=0)

16/20

20

5/20

20

11.76%

11.76%

3.2[1.45,7.05]

3.2[1.45,7.05]

Total (95% CI)

174

202

100%

1.61[1.23,2.11]

Total events: 80 (PT+AD), 56 (AD)

Heterogeneity: Tau2=0; Chi2=3.34, df=4(P=0.5); I2=0%

Test for overall effect: Z=3.45(P=0)

Test for subgroup differences: Not applicable

Favours AD

0.2

0.5

1

2

5

Favours PT+AD

Analysis 1.17.   Comparison 1 PD+/-AGORAPHOBIA: Psychotherapy+Antidepressant vs Antidepressant
alone, Outcome 17 Global/Avoidance/Panic 6-24 months after treatment discontinuation.

Study or subgroup

PT+AD

AD

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

1.17.1 Behaviour therapy

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Not applicable

1.17.2 Cognitive-behaviour therapy

Barlow 2000

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Not applicable

0

59

59

1.5 (0.9)

1.17.3 Psychodynamic psychotherapy and others

Wiborg 1996

Subtotal ***

0.6 (1.1)

20

20

Heterogeneity: Not applicable

Test for overall effect: Z=3.54(P=0)

0

77

77

20

20

1.5 (0.8)

2.4 (1.7)

Not estimable

53%

53%

0[-0.34,0.34]

0[-0.34,0.34]

47%

47%

-1.23[-1.91,-0.55]

-1.23[-1.91,-0.55]

Favours PT+AD

-4

-2

0

2

4

Favours AD

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

58

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Total ***

PT+AD

Mean(SD)

N

79

N

97

AD

Mean(SD)

Std. Mean Difference

Weight

Std. Mean Difference

Random, 95% CI

Random, 95% CI

100%

-0.58[-1.78,0.63]

Heterogeneity: Tau2=0.68; Chi2=10.06, df=1(P=0); I2=90.06%

Test for overall effect: Z=0.94(P=0.35)

Test for subgroup differences: Chi2=10.06, df=1 (P=0), I2=90.06%

Favours PT+AD

-4

-2

0

2

4

Favours AD

Comparison 2.   PD+/-AGORAPHOBIA: Psychotherapy+Antidepressant vs Psychotherapy alone

Outcome or subgroup title

1 Response at 2-4 months

1.1 Behaviour therapy

1.2 Cognitive-behaviour therapy

2 Remission at 2-4 months

2.1 Behaviour therapy

2.2 Cognitive-behaviour therapy

3 Global severity at 2-4 months

3.1 Behaviour therapy

3.2 Cognitive-behaviour therapy

4 Frequency of panic attacks at 2-4 months

4.1 Behaviour therapy

4.2 Cognitive-behaviour therapy

5 Phobic avoidance at 2-4 months

5.1 Behaviour therapy

No. of
studies

No. of
partici-
pants

Statistical method

Effect size

6

2

4

4

2

2

3

1

2

4

2

2

4

2

366

59

307

282

59

223

238

37

201

122

48

74

150

51

Risk Ratio (M-H, Random, 95%
CI)

1.13 [0.85, 1.50]

Risk Ratio (M-H, Random, 95%
CI)

0.88 [0.11, 7.30]

Risk Ratio (M-H, Random, 95%
CI)

1.09 [0.90, 1.31]

Risk Ratio (M-H, Random, 95%
CI)

1.19 [0.97, 1.45]

Risk Ratio (M-H, Random, 95%
CI)

0.70 [0.16, 3.15]

Risk Ratio (M-H, Random, 95%
CI)

1.22 [0.98, 1.52]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.31 [-0.63, 0.02]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.68 [-1.34, -0.01]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.22 [-0.56, 0.13]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.02 [-0.45, 0.49]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.01 [-1.30, 1.28]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.13 [-0.33, 0.58]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.19 [-0.73, 0.35]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.27 [-1.77, 1.22]

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

59

 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

No. of
studies

No. of
partici-
pants

Statistical method

Effect size

Outcome or subgroup title

5.2 Cognitive-behaviour therapy

6 General anxiety at 2-4 months

6.1 Behaviour therapy

6.2 Cognitive-behaviour therapy

7 Depression at 2-4 months

7.1 Behaviour therapy

7.2 Cognitive-behaviour therapy

8 Social malfunctioning at 2-4 months

8.1 Behaviour therapy

8.2 Cognitive-behaviour therapy

2

4

2

2

4

2

2

1

0

1

9 Dropouts for any reason within 2-4 months

5

9.1 Behaviour therapy

9.2 Cognitive-behaviour therapy

10 Dropouts due to side effects within 2-4
months

10.1 Behaviour therapy

10.2 Cognitive-behaviour therapy

11 Response/remission on continued treat-
ment

11.1 Behaviour therapy

2

3

4

1

3

1

0

99

144

51

93

125

51

74

59

0

59

322

59

263

308

45

263

142

0

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.05 [-0.44, 0.35]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.17 [-0.69, 0.35]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.55 [-1.44, 0.34]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.09 [-0.32, 0.49]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.51 [-1.15, 0.12]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.94 [-1.62, -0.25]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.31 [-1.12, 0.49]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.18 [-0.69, 0.33]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.0 [0.0, 0.0]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.18 [-0.69, 0.33]

Risk Ratio (M-H, Random, 95%
CI)

1.07 [0.72, 1.59]

Risk Ratio (M-H, Random, 95%
CI)

1.46 [0.40, 5.38]

Risk Ratio (M-H, Random, 95%
CI)

1.06 [0.65, 1.72]

Risk Ratio (M-H, Random, 95%
CI)

7.46 [1.73, 32.26]

Risk Ratio (M-H, Random, 95%
CI)

4.4 [0.22, 86.78]

Risk Ratio (M-H, Random, 95%
CI)

8.82 [1.64, 47.37]

Risk Ratio (M-H, Random, 95%
CI)

1.37 [0.98, 1.92]

Risk Ratio (M-H, Random, 95%
CI)

0.0 [0.0, 0.0]

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

60

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of
studies

No. of
partici-
pants

Statistical method

Effect size

11.2 Cognitive-behaviour therapy

12 GlobalAvoidance/Panic on continued
treatment

12.1 Behaviour therapy

12.2 Cognitive-behaviour therapy

13 Dropouts for any reason on continued
treatment

13.1 Behaviour therapy

13.2 Cognitive-behaviour therapy

14 Response/remission 6-24 months after
treatment discontinuation

14.1 Behaviour therapy

14.2 Cognitive-behaviour therapy

15 Global/Avoidance/Panic 6-24 months af-
ter treatment discontinuation

15.1 Behaviour therapy

15.2 Cognitive-behaviour therapy

1

1

0

1

1

0

1

4

2

2

2

1

1

142

142

0

142

142

0

142

272

59

213

167

35

132

Risk Ratio (M-H, Random, 95%
CI)

1.37 [0.98, 1.92]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.46 [-0.80, -0.13]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.0 [0.0, 0.0]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.46 [-0.80, -0.13]

Risk Ratio (M-H, Random, 95%
CI)

0.68 [0.21, 2.21]

Risk Ratio (M-H, Random, 95%
CI)

0.0 [0.0, 0.0]

Risk Ratio (M-H, Random, 95%
CI)

0.68 [0.21, 2.21]

Risk Ratio (M-H, Random, 95%
CI)

0.97 [0.71, 1.33]

Risk Ratio (M-H, Random, 95%
CI)

0.93 [0.54, 1.60]

Risk Ratio (M-H, Random, 95%
CI)

0.99 [0.68, 1.45]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.09 [-0.21, 0.40]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.05 [-0.71, 0.61]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.13 [-0.21, 0.47]

Analysis 2.1.   Comparison 2 PD+/-AGORAPHOBIA: Psychotherapy
+Antidepressant vs Psychotherapy alone, Outcome 1 Response at 2-4 months.

PT+AD

n/N

PT

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

17/24

1/7

31

7/21

4/7

28

12.97%

2.05%

15.02%

2.13[1.1,4.1]

0.25[0.04,1.71]

0.88[0.11,7.3]

Study or subgroup

2.1.1 Behaviour therapy

de Beurs 1995

Fava 1997

Subtotal (95% CI)

Total events: 18 (PT+AD), 11 (PT)

Heterogeneity: Tau2=1.86; Chi2=4.46, df=1(P=0.03); I2=77.58%

Favours PT

0.1

0.2

0.5

1

2

5

10

Favours PT+AD

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

61

 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

PT+AD

n/N

PT

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

Test for overall effect: Z=0.12(P=0.91)

2.1.2 Cognitive-behaviour therapy

Azhar 2000

Barlow 2000

Sharp 1996

Spinhoven 1996

Subtotal (95% CI)

14/22

39/65

26/38

4/20

145

17/22

37/77

26/43

4/20

162

Total events: 83 (PT+AD), 84 (PT)

Heterogeneity: Tau2=0; Chi2=2.87, df=3(P=0.41); I2=0%

Test for overall effect: Z=0.85(P=0.4)

23.85%

28.83%

27.66%

4.64%

84.98%

0.82[0.56,1.21]

1.25[0.92,1.69]

1.13[0.82,1.56]

1[0.29,3.45]

1.09[0.9,1.31]

Total (95% CI)

176

190

100%

1.13[0.85,1.5]

Total events: 101 (PT+AD), 95 (PT)

Heterogeneity: Tau2=0.05; Chi2=8.96, df=5(P=0.11); I2=44.2%

Test for overall effect: Z=0.84(P=0.4)

Test for subgroup differences: Not applicable

Favours PT

0.1

0.2

0.5

1

2

5

10

Favours PT+AD

Analysis 2.2.   Comparison 2 PD+/-AGORAPHOBIA: Psychotherapy
+Antidepressant vs Psychotherapy alone, Outcome 2 Remission at 2-4 months.

PT+AD

n/N

PT

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

12/21

4/7

28

42/77

21/43

120

18.45%

1.08%

19.53%

1.17[0.73,1.86]

0.25[0.04,1.71]

0.7[0.16,3.15]

54.2%

26.27%

80.47%

1.18[0.9,1.55]

1.29[0.88,1.91]

1.22[0.98,1.52]

Study or subgroup

2.2.1 Behaviour therapy

de Beurs 1995

Fava 1997

Subtotal (95% CI)

16/24

1/7

31

Total events: 17 (PT+AD), 16 (PT)

Heterogeneity: Tau2=0.82; Chi2=2.6, df=1(P=0.11); I2=61.57%

Test for overall effect: Z=0.46(P=0.64)

2.2.2 Cognitive-behaviour therapy

Barlow 2000

Sharp 1996

Subtotal (95% CI)

42/65

24/38

103

Total events: 66 (PT+AD), 63 (PT)

Heterogeneity: Tau2=0; Chi2=0.13, df=1(P=0.72); I2=0%

Test for overall effect: Z=1.74(P=0.08)

Total (95% CI)

134

148

100%

1.19[0.97,1.45]

Total events: 83 (PT+AD), 79 (PT)

Heterogeneity: Tau2=0; Chi2=2.76, df=3(P=0.43); I2=0%

Test for overall effect: Z=1.69(P=0.09)

Test for subgroup differences: Not applicable

Favours PT

0.1

0.2

0.5

1

2

5

10

Favours PT+AD

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

62

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 2.3.   Comparison 2 PD+/-AGORAPHOBIA: Psychotherapy+Antidepressant
vs Psychotherapy alone, Outcome 3 Global severity at 2-4 months.

Study or subgroup

Treatment

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

2.3.1 Behaviour therapy

de Beurs 1995

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=2(P=0.05)

2.3.2 Cognitive-behaviour therapy

Barlow 2000

Sharp 1996

Subtotal ***

19

19

65

29

94

1.6 (0.8)

0.9 (0.7)

1.7 (1.1)

18

18

77

30

107

2.3 (1.2)

1.1 (0.7)

1.7 (1)

Heterogeneity: Tau2=0.02; Chi2=1.41, df=1(P=0.24); I2=29.07%

Test for overall effect: Z=1.23(P=0.22)

Total ***

113

125

Heterogeneity: Tau2=0.03; Chi2=2.84, df=2(P=0.24); I2=29.56%

Test for overall effect: Z=1.83(P=0.07)

Test for subgroup differences: Chi2=1.43, df=1 (P=0.23), I2=30.04%

19.67%

19.67%

-0.68[-1.34,-0.01]

-0.68[-1.34,-0.01]

50.71%

29.61%

80.33%

-0.35[-0.68,-0.02]

0.02[-0.49,0.53]

-0.22[-0.56,0.13]

100%

-0.31[-0.63,0.02]

Favours treatment

-4

-2

0

2

4

Favours control

Analysis 2.4.   Comparison 2 PD+/-AGORAPHOBIA: Psychotherapy+Antidepressant
vs Psychotherapy alone, Outcome 4 Frequency of panic attacks at 2-4 months.

Study or subgroup

Treatment

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

1.7 (3.5)

2 (1)

3.6 (2.2)

2.7 (2.3)

2.4.1 Behaviour therapy

de Beurs 1995

Fava 1997

Subtotal ***

0.2 (0.5)

2.7 (0.8)

18

7

25

Heterogeneity: Tau2=0.66; Chi2=4.01, df=1(P=0.05); I2=75.09%

Test for overall effect: Z=0.01(P=0.99)

2.4.2 Cognitive-behaviour therapy

Azhar 2000

Spinhoven 1996

Subtotal ***

4.1 (3.9)

3 (2.5)

17

20

37

Heterogeneity: Tau2=0; Chi2=0, df=1(P=0.98); I2=0%

Test for overall effect: Z=0.55(P=0.58)

Total ***

62

Heterogeneity: Tau2=0.09; Chi2=4.87, df=3(P=0.18); I2=38.41%

Test for overall effect: Z=0.07(P=0.95)

Test for subgroup differences: Chi2=0.86, df=1 (P=0.35), I2=0%

16

7

23

17

20

37

60

27.13%

14.37%

41.49%

-0.6[-1.29,0.09]

0.72[-0.37,1.82]

-0.01[-1.3,1.28]

27.93%

30.57%

58.51%

0.13[-0.54,0.81]

0.12[-0.5,0.74]

0.13[-0.33,0.58]

100%

0.02[-0.45,0.49]

Favours treatment

-4

-2

0

2

4

Favours control

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

63

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 2.5.   Comparison 2 PD+/-AGORAPHOBIA: Psychotherapy+Antidepressant
vs Psychotherapy alone, Outcome 5 Phobic avoidance at 2-4 months.

Study or subgroup

Treatment

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

2.5.1 Behaviour therapy

de Beurs 1995

Fava 1997

Subtotal ***

4.1 (2)

19.6 (4.7)

19

7

26

Heterogeneity: Tau2=0.96; Chi2=5.54, df=1(P=0.02); I2=81.95%

Test for overall effect: Z=0.36(P=0.72)

2.5.2 Cognitive-behaviour therapy

Sharp 1996

Spinhoven 1996

Subtotal ***

4.7 (7.8)

22.5 (12)

29

20

49

Heterogeneity: Tau2=0; Chi2=0, df=1(P=0.95); I2=0%

Test for overall effect: Z=0.24(P=0.81)

Total ***

75

Heterogeneity: Tau2=0.17; Chi2=7.42, df=3(P=0.06); I2=59.56%

Test for overall effect: Z=0.69(P=0.49)

Test for subgroup differences: Chi2=1.87, df=1 (P=0.17), I2=46.63%

6.1 (1.9)

15.6 (8.4)

5.1 (5.4)

22.9 (11.3)

18

7

25

30

20

50

75

25.41%

15.9%

41.31%

-0.98[-1.67,-0.3]

0.55[-0.52,1.63]

-0.27[-1.77,1.22]

31.17%

27.52%

58.69%

-0.06[-0.57,0.45]

-0.03[-0.65,0.59]

-0.05[-0.44,0.35]

100%

-0.19[-0.73,0.35]

Favours treatment

-4

-2

0

2

4

Favours control

Analysis 2.6.   Comparison 2 PD+/-AGORAPHOBIA: Psychotherapy+Antidepressant
vs Psychotherapy alone, Outcome 6 General anxiety at 2-4 months.

Study or subgroup

Treatment

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

2.6.1 Behaviour therapy

de Beurs 1995

Fava 1997

Subtotal ***

2.6 (1.3)

3.6 (0.5)

19

7

26

Heterogeneity: Tau2=0.22; Chi2=2.09, df=1(P=0.15); I2=52.07%

Test for overall effect: Z=1.22(P=0.22)

2.6.2 Cognitive-behaviour therapy

Azhar 2000

Sharp 1996

Subtotal ***

22.9 (4.7)

4.8 (5.7)

17

29

46

Heterogeneity: Tau2=0; Chi2=0.45, df=1(P=0.5); I2=0%

Test for overall effect: Z=0.41(P=0.68)

Total ***

72

Heterogeneity: Tau2=0.15; Chi2=6.72, df=3(P=0.08); I2=55.35%

Test for overall effect: Z=0.65(P=0.51)

Test for subgroup differences: Chi2=4.19, df=1 (P=0.04), I2=76.11%

3.9 (1.5)

3.6 (0.5)

21.5 (5.2)

4.9 (4.4)

18

7

25

17

30

47

72

25.82%

16.12%

41.93%

-0.92[-1.6,-0.24]

0[-1.05,1.05]

-0.55[-1.44,0.34]

26.02%

32.05%

58.07%

0.27[-0.41,0.94]

-0.02[-0.53,0.49]

0.09[-0.32,0.49]

100%

-0.17[-0.69,0.35]

Favours treatment

-4

-2

0

2

4

Favours control

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

64

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 2.7.   Comparison 2 PD+/-AGORAPHOBIA: Psychotherapy
+Antidepressant vs Psychotherapy alone, Outcome 7 Depression at 2-4 months.

Study or subgroup

Treatment

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

3.8 (1.5)

1.1 (0.4)

10 (0.6)

42.7 (10)

2.7.1 Behaviour therapy

de Beurs 1995

Fava 1997

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=2.68(P=0.01)

2.7.2 Cognitive-behaviour therapy

Azhar 2000

Spinhoven 1996

Subtotal ***

19

7

26

17

20

37

2.6 (1)

1 (0)

9.2 (1.4)

43.5 (8.7)

Heterogeneity: Tau2=0.23; Chi2=2.99, df=1(P=0.08); I2=66.55%

Test for overall effect: Z=0.76(P=0.45)

Total ***

63

Heterogeneity: Tau2=0.2; Chi2=5.41, df=2(P=0.07); I2=63.04%

Test for overall effect: Z=1.59(P=0.11)

Test for subgroup differences: Chi2=2.42, df=1 (P=0.12), I2=58.7%

18

7

25

17

20

37

62

32.73%

-0.94[-1.62,-0.25]

Not estimable

32.73%

-0.94[-1.62,-0.25]

32.19%

35.08%

67.27%

-0.74[-1.44,-0.04]

0.08[-0.54,0.7]

-0.31[-1.12,0.49]

100%

-0.51[-1.15,0.12]

Favours treatment

-4

-2

0

2

4

Favours control

Analysis 2.8.   Comparison 2 PD+/-AGORAPHOBIA: Psychotherapy+Antidepressant
vs Psychotherapy alone, Outcome 8 Social malfunctioning at 2-4 months.

Study or subgroup

Treatment

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

2.8.1 Behaviour therapy

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Not applicable

2.8.2 Cognitive-behaviour therapy

Sharp 1996

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=0.69(P=0.49)

Total ***

0

29

29

29

Heterogeneity: Not applicable

Test for overall effect: Z=0.69(P=0.49)

Test for subgroup differences: Not applicable

1.4 (2.8)

0

30

30

30

Not estimable

1.9 (2.6)

100%

100%

-0.18[-0.69,0.33]

-0.18[-0.69,0.33]

100%

-0.18[-0.69,0.33]

Favours treatment

-4

-2

0

2

4

Favours control

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

65

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 2.9.   Comparison 2 PD+/-AGORAPHOBIA: Psychotherapy+Antidepressant
vs Psychotherapy alone, Outcome 9 Dropouts for any reason within 2-4 months.

Study or subgroup

2.9.1 Behaviour therapy

de Beurs 1995

Fava 1997

Subtotal (95% CI)

Total events: 5 (Treatment), 3 (Control)

Heterogeneity: Not applicable

Test for overall effect: Z=0.57(P=0.57)

2.9.2 Cognitive-behaviour therapy

Barlow 2000

Sharp 1996

Spinhoven 1996

Subtotal (95% CI)

Treatment

n/N

Control

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

5/24

0/7

31

18/65

11/38

4/20

123

3/21

0/7

28

21/77

13/43

0/20

140

9.17%

9.17%

1.46[0.4,5.38]

Not estimable

1.46[0.4,5.38]

54.46%

34.45%

1.92%

90.83%

1.02[0.59,1.74]

0.96[0.49,1.88]

9[0.52,156.91]

1.06[0.65,1.72]

Total events: 33 (Treatment), 34 (Control)

Heterogeneity: Tau2=0.03; Chi2=2.37, df=2(P=0.31); I2=15.72%

Test for overall effect: Z=0.22(P=0.83)

Total (95% CI)

154

168

100%

1.07[0.72,1.59]

Total events: 38 (Treatment), 37 (Control)

Heterogeneity: Tau2=0; Chi2=2.61, df=3(P=0.46); I2=0%

Test for overall effect: Z=0.35(P=0.73)

Test for subgroup differences: Not applicable

Favours treatment

0.1

0.2

0.5

1

2

5

10

Favours control

Analysis 2.10.   Comparison 2 PD+/-AGORAPHOBIA: Psychotherapy+Antidepressant
vs Psychotherapy alone, Outcome 10 Dropouts due to side effects within 2-4 months.

Study or subgroup

2.10.1 Behaviour therapy

de Beurs 1995

Subtotal (95% CI)

Total events: 2 (Treatment), 0 (Control)

Heterogeneity: Not applicable

Test for overall effect: Z=0.97(P=0.33)

2.10.2 Cognitive-behaviour therapy

Barlow 2000

Sharp 1996

Spinhoven 1996

Subtotal (95% CI)

Treatment

n/N

Control

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

2/24

24

2/65

5/38

4/20

123

0/21

21

0/77

0/43

0/20

140

24.1%

24.1%

4.4[0.22,86.78]

4.4[0.22,86.78]

23.52%

26.15%

26.23%

75.9%

5.91[0.29,120.92]

12.41[0.71,217.31]

9[0.52,156.91]

8.82[1.64,47.37]

Total events: 11 (Treatment), 0 (Control)

Heterogeneity: Tau2=0; Chi2=0.12, df=2(P=0.94); I2=0%

Test for overall effect: Z=2.54(P=0.01)

Total (95% CI)

147

161

100%

7.46[1.73,32.26]

Total events: 13 (Treatment), 0 (Control)

Favours treatment

0.1

0.2

0.5

1

2

5

10

Favours control

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

66

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Treatment

n/N

Control

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

Heterogeneity: Tau2=0; Chi2=0.29, df=3(P=0.96); I2=0%

Test for overall effect: Z=2.69(P=0.01)

Test for subgroup differences: Not applicable

Favours treatment

0.1

0.2

0.5

1

2

5

10

Favours control

Analysis 2.11.   Comparison 2 PD+/-AGORAPHOBIA: Psychotherapy+Antidepressant
vs Psychotherapy alone, Outcome 11 Response/remission on continued treatment.

Study or subgroup

AD+PT

n/N

PT

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

2.11.1 Behaviour therapy

Subtotal (95% CI)

Total events: 0 (AD+PT), 0 (PT)

Heterogeneity: Not applicable

Test for overall effect: Not applicable

2.11.2 Cognitive-behaviour therapy

Barlow 2000

Subtotal (95% CI)

Total events: 37 (AD+PT), 32 (PT)

Heterogeneity: Not applicable

Test for overall effect: Z=1.82(P=0.07)

0

0

Not estimable

37/65

65

32/77

77

100%

100%

1.37[0.98,1.92]

1.37[0.98,1.92]

Total (95% CI)

65

77

100%

1.37[0.98,1.92]

Total events: 37 (AD+PT), 32 (PT)

Heterogeneity: Not applicable

Test for overall effect: Z=1.82(P=0.07)

Test for subgroup differences: Not applicable

Favours PT

0.1

0.2

0.5

1

2

5

10

Favours PT+AD

Analysis 2.12.   Comparison 2 PD+/-AGORAPHOBIA: Psychotherapy+Antidepressant vs
Psychotherapy alone, Outcome 12 GlobalAvoidance/Panic on continued treatment.

Study or subgroup

Treatment

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

2.12.1 Behaviour therapy

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Not applicable

2.12.2 Cognitive-behaviour therapy

Barlow 2000

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=2.71(P=0.01)

Total ***

0

65

65

65

0.8 (0.9)

0

77

77

77

Not estimable

1.2 (0.9)

100%

100%

-0.46[-0.8,-0.13]

-0.46[-0.8,-0.13]

100%

-0.46[-0.8,-0.13]

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

67

Favours treatment

-4

-2

0

2

4

Favours control

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Treatment

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

Heterogeneity: Not applicable

Test for overall effect: Z=2.71(P=0.01)

Test for subgroup differences: Not applicable

Favours treatment

-4

-2

0

2

4

Favours control

Analysis 2.13.   Comparison 2 PD+/-AGORAPHOBIA: Psychotherapy+Antidepressant vs
Psychotherapy alone, Outcome 13 Dropouts for any reason on continued treatment.

Study or subgroup

Treatment

n/N

Control

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

2.13.1 Behaviour therapy

Subtotal (95% CI)

Total events: 0 (Treatment), 0 (Control)

Heterogeneity: Not applicable

Test for overall effect: Not applicable

2.13.2 Cognitive-behaviour therapy

Barlow 2000

Subtotal (95% CI)

Total events: 4 (Treatment), 7 (Control)

Heterogeneity: Not applicable

Test for overall effect: Z=0.65(P=0.52)

0

0

Not estimable

4/65

65

7/77

77

100%

100%

0.68[0.21,2.21]

0.68[0.21,2.21]

Total (95% CI)

65

77

100%

0.68[0.21,2.21]

Total events: 4 (Treatment), 7 (Control)

Heterogeneity: Not applicable

Test for overall effect: Z=0.65(P=0.52)

Test for subgroup differences: Not applicable

Favours treatment

0.1

0.2

0.5

1

2

5

10

Favours control

Analysis 2.14.   Comparison 2 PD+/-AGORAPHOBIA: Psychotherapy+Antidepressant vs Psychotherapy
alone, Outcome 14 Response/remission 6-24 months after treatment discontinuation.

PT+AD

n/N

PT

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

Study or subgroup

2.14.1 Behaviour therapy

de Beurs 1995

Fava 1997

Subtotal (95% CI)

12/24

2/7

31

Total events: 14 (PT+AD), 14 (PT)

Heterogeneity: Tau2=0; Chi2=1, df=1(P=0.32); I2=0%

Test for overall effect: Z=0.27(P=0.79)

2.14.2 Cognitive-behaviour therapy

Barlow 2000

Sharp 1996

Subtotal (95% CI)

16/59

16/38

97

10/21

4/7

28

24/73

15/43

116

27.3%

5.53%

32.83%

1.05[0.58,1.92]

0.5[0.13,1.9]

0.93[0.54,1.6]

34.92%

32.25%

67.17%

0.82[0.48,1.4]

1.21[0.69,2.1]

0.99[0.68,1.45]

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

68

Favours PT

0.1

0.2

0.5

1

2

5

10

Favours PT+AD

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

PT+AD

n/N

PT

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

Total events: 32 (PT+AD), 39 (PT)

Heterogeneity: Tau2=0; Chi2=0.95, df=1(P=0.33); I2=0%

Test for overall effect: Z=0.05(P=0.96)

Total (95% CI)

128

144

100%

0.97[0.71,1.33]

Total events: 46 (PT+AD), 53 (PT)

Heterogeneity: Tau2=0; Chi2=1.98, df=3(P=0.58); I2=0%

Test for overall effect: Z=0.2(P=0.84)

Test for subgroup differences: Not applicable

Favours PT

0.1

0.2

0.5

1

2

5

10

Favours PT+AD

Analysis 2.15.   Comparison 2 PD+/-AGORAPHOBIA: Psychotherapy+Antidepressant vs Psychotherapy
alone, Outcome 15 Global/Avoidance/Panic 6-24 months after treatment discontinuation.

Study or subgroup

Treatment

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

3.5 (2.2)

1.3 (0.9)

2.15.1 Behaviour therapy

de Beurs 1995

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=0.15(P=0.88)

2.15.2 Cognitive-behaviour therapy

Barlow 2000

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=0.74(P=0.46)

Total ***

18

18

59

59

77

3.3 (2.4)

1.5 (0.9)

17

17

73

73

90

Heterogeneity: Tau2=0; Chi2=0.23, df=1(P=0.63); I2=0%

Test for overall effect: Z=0.59(P=0.56)

Test for subgroup differences: Chi2=0.23, df=1 (P=0.63), I2=0%

21.16%

21.16%

-0.05[-0.71,0.61]

-0.05[-0.71,0.61]

78.84%

78.84%

0.13[-0.21,0.47]

0.13[-0.21,0.47]

100%

0.09[-0.21,0.4]

Favours treatment

-4

-2

0

2

4

Favours control

Comparison 3.   PD+/-AGORAPHOBIA: Psychotherapy+Antidepressant vs Psychotherapy+Placebo

Outcome or subgroup title

1 Response at 2-4 months

1.1 Behaviour therapy

1.2 Cognitive-behaviour therapy

No. of
studies

17

10

7

No. of
partici-
pants

1032

527

505

Statistical method

Effect size

Risk Ratio (M-H, Random, 95%
CI)

1.17 [1.04, 1.32]

Risk Ratio (M-H, Random, 95%
CI)

1.24 [1.03, 1.48]

Risk Ratio (M-H, Random, 95%
CI)

1.17 [0.93, 1.47]

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

69

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of
studies

No. of
partici-
pants

Statistical method

Effect size

2 Remission at 2-4 months

15

2.1 Behaviour therapy

2.2 Cognitive-behaviour therapy

3 Global severity at 2-4 months

3.1 Behaviour therapy

3.2 Cognitive-behaviour therapy

4 Frequency of panic attacks at 2-4 months

4.1 Behaviour therapy

4.2 Cognitive-behaviour therapy

5 Phobic avoidance at 2-4 months

5.1 Behaviour therapy

5.2 Cognitive-behaviour therapy

6 General anxiety at 2-4 months

6.1 Behaviour therapy

6.2 Cognitive-behaviour therapy

7 Depression at 2-4 months

7.1 Behaviour therapy

7.2 Cognitive-behaviour therapy

8

7

8

5

3

9

7

2

15

10

5

13

7

6

12

9

3

952

447

505

477

221

256

393

248

145

582

364

218

595

270

325

436

318

118

Risk Ratio (M-H, Random, 95%
CI)

1.30 [1.10, 1.54]

Risk Ratio (M-H, Random, 95%
CI)

1.45 [1.10, 1.91]

Risk Ratio (M-H, Random, 95%
CI)

1.26 [0.99, 1.60]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.45 [-0.63, -0.26]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.61 [-0.88, -0.33]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.35 [-0.69, -0.00]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.06 [-0.27, 0.15]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.07 [-0.19, 0.32]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.29 [-0.61, 0.04]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.35 [-0.54, -0.15]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.42 [-0.72, -0.11]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.26 [-0.53, 0.01]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.47 [-0.65, -0.29]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.67 [-0.96, -0.38]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.32 [-0.54, -0.09]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.40 [-0.60, -0.19]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.41 [-0.68, -0.13]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.38 [-0.76, -0.01]

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

70

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of
studies

No. of
partici-
pants

Statistical method

Effect size

8 Social malfunctioning at 2-4 months

10

8.1 Behaviour therapy

8.2 Cognitive-behaviour therapy

9 Dropouts for any reason within 2-4
months

9.1 Behaviour therapy

9.2 Cognitive-behaviour therapy

10 Dropouts due to side effects within 2-4
months

10.1 Behaviour therapy

10.2 Cognitive-behaviour therapy

11 Response/remission on continued treat-
ment

11.1 Behaviour therapy

11.2 Cognitive-behaviour therapy

12 Global/Avoidance/Panic on continued
treatment

12.1 Behaviour therapy

12.2 Cognitive-behaviour therapy

13 Dropouts for any reason on continued
treatment

13.1 Behaviour therapy

13.2 Cognitive-behaviour therapy

7

3

15

8

7

9

4

5

3

2

1

4

3

1

2

1

1

374

260

114

950

445

505

665

221

444

229

101

128

229

101

128

147

19

128

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.37 [-0.65, -0.10]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.55 [-0.84, -0.26]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.04 [-0.41, 0.33]

Risk Ratio (M-H, Random, 95%
CI)

1.19 [0.94, 1.50]

Risk Ratio (M-H, Random, 95%
CI)

1.18 [0.88, 1.58]

Risk Ratio (M-H, Random, 95%
CI)

1.21 [0.81, 1.78]

Risk Ratio (M-H, Random, 95%
CI)

2.43 [1.23, 4.81]

Risk Ratio (M-H, Random, 95%
CI)

1.84 [0.77, 4.41]

Risk Ratio (M-H, Random, 95%
CI)

3.78 [1.26, 11.33]

Risk Ratio (M-H, Random, 95%
CI)

1.25 [0.93, 1.67]

Risk Ratio (M-H, Random, 95%
CI)

1.64 [0.74, 3.61]

Risk Ratio (M-H, Random, 95%
CI)

1.12 [0.81, 1.55]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.76 [-1.22, -0.31]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.95 [-1.37, -0.53]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.36 [-0.71, -0.01]

Risk Ratio (M-H, Random, 95%
CI)

0.78 [0.25, 2.43]

Risk Ratio (M-H, Random, 95%
CI)

2.73 [0.12, 59.57]

Risk Ratio (M-H, Random, 95%
CI)

0.65 [0.19, 2.18]

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

71

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of
studies

No. of
partici-
pants

Statistical method

Effect size

14 Response/remission 6-24 months after
treatment discontinuation

14.1 Behaviour therapy

14.2 Cognitive-behaviour therapy

15 Global/Avoidance/Panic 6-24 months
after treatment discontinuation

15.1 Behaviour therapy

15.2 Cognitive-behviour therapy

8

5

3

5

4

1

507

284

223

245

124

121

Risk Ratio (M-H, Random, 95%
CI)

0.93 [0.76, 1.15]

Risk Ratio (M-H, Random, 95%
CI)

1.03 [0.78, 1.36]

Risk Ratio (M-H, Random, 95%
CI)

0.84 [0.62, 1.13]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.16 [-0.15, 0.48]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.08 [-0.37, 0.53]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.29 [-0.06, 0.65]

Analysis 3.1.   Comparison 3 PD+/-AGORAPHOBIA: Psychotherapy
+Antidepressant vs Psychotherapy+Placebo, Outcome 1 Response at 2-4 months.

PT+AD

n/N

PT+placebo

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

Study or subgroup

3.1.1 Behaviour therapy

de Beurs 1995

Johnston 1995

Marks 1983

Mavissakalian 1986a

Mavissakalian 1986b

Sheehan 1980a

Sheehan 1980b

Telch 1985

Zitrin 1980

Zitrin 1983

Subtotal (95% CI)

17/24

7/28

20/36

11/20

8/20

16/28

16/29

5/13

25/41

25/43

282

Total events: 150 (PT+AD), 105 (PT+placebo)

Heterogeneity: Tau2=0; Chi2=3.28, df=9(P=0.95); I2=0%

Test for overall effect: Z=2.33(P=0.02)

3.1.2 Cognitive-behaviour therapy

Barlow 2000

Fahy 1992

Kampman 2002

Loerch 1999

Oehrberg 1995

Sharp 1996

Stein 2000

Subtotal (95% CI)

39/65

26/53

12/22

11/14

42/60

26/38

13/16

268

12/24

7/27

17/36

10/20

9/20

6/16

5/14

2/12

16/35

21/41

245

36/63

9/26

5/21

12/14

25/60

28/36

12/17

237

5.68%

1.71%

6.2%

3.83%

2.62%

2.72%

2.29%

0.69%

6.6%

7.93%

1.42[0.88,2.28]

0.96[0.39,2.38]

1.18[0.75,1.85]

1.1[0.61,1.99]

0.89[0.43,1.83]

1.52[0.75,3.1]

1.54[0.71,3.36]

2.31[0.55,9.74]

1.33[0.86,2.06]

1.14[0.77,1.68]

40.26%

1.24[1.03,1.48]

12.7%

3.77%

1.9%

9.68%

9.92%

13.65%

8.11%

59.74%

1.05[0.78,1.41]

1.42[0.78,2.57]

2.29[0.97,5.39]

0.92[0.65,1.3]

1.68[1.19,2.37]

0.88[0.67,1.16]

1.15[0.78,1.69]

1.17[0.93,1.47]

Favours PT+placebo

0.2

0.5

1

2

5

Favours PT+AD

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

72

 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

PT+AD

n/N

PT+placebo

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

Total events: 169 (PT+AD), 127 (PT+placebo)

Heterogeneity: Tau2=0.05; Chi2=14.48, df=6(P=0.02); I2=58.57%

Test for overall effect: Z=1.34(P=0.18)

Total (95% CI)

550

482

100%

1.17[1.04,1.32]

Total events: 319 (PT+AD), 232 (PT+placebo)

Heterogeneity: Tau2=0.01; Chi2=18.19, df=16(P=0.31); I2=12.02%

Test for overall effect: Z=2.58(P=0.01)

Test for subgroup differences: Not applicable

Favours PT+placebo

0.2

0.5

1

2

5

Favours PT+AD

Analysis 3.2.   Comparison 3 PD+/-AGORAPHOBIA: Psychotherapy
+Antidepressant vs Psychotherapy+Placebo, Outcome 2 Remission at 2-4 months.

PT+AD

n/N

PT+placebo

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

Study or subgroup

3.2.1 Behaviour therapy

de Beurs 1995

Marks 1983

Mavissakalian 1986a

Mavissakalian 1986b

Sheehan 1980a

Sheehan 1980b

Zitrin 1980

Zitrin 1983

Subtotal (95% CI)

16/24

17/36

8/20

8/20

5/28

10/29

7/41

13/43

241

Total events: 84 (PT+AD), 48 (PT+placebo)

Heterogeneity: Tau2=0; Chi2=3.84, df=7(P=0.8); I2=0%

Test for overall effect: Z=2.65(P=0.01)

3.2.2 Cognitive-behaviour therapy

Barlow 2000

Fahy 1992

Kampman 2002

Loerch 1999

Oehrberg 1995

Sharp 1996

Stein 2000

Subtotal (95% CI)

42/65

28/53

14/22

9/14

39/60

24/38

7/16

268

Total events: 163 (PT+AD), 115 (PT+placebo)

Heterogeneity: Tau2=0.05; Chi2=11.52, df=6(P=0.07); I2=47.94%

Test for overall effect: Z=1.86(P=0.06)

14/24

12/36

4/20

5/20

2/15

2/15

4/35

5/41

206

39/63

10/26

9/21

8/14

21/60

25/36

3/17

237

10.4%

6.86%

2.46%

2.97%

1.18%

1.4%

2.02%

2.92%

30.21%

19.45%

7.44%

6.68%

6.45%

12.29%

15.54%

1.94%

69.79%

1.14[0.74,1.78]

1.42[0.8,2.52]

2[0.72,5.59]

1.6[0.63,4.05]

1.34[0.29,6.09]

2.59[0.65,10.32]

1.49[0.48,4.68]

2.48[0.97,6.34]

1.45[1.1,1.91]

1.04[0.8,1.36]

1.37[0.79,2.38]

1.48[0.83,2.67]

1.13[0.62,2.05]

1.86[1.26,2.75]

0.91[0.66,1.26]

2.48[0.77,7.97]

1.26[0.99,1.6]

Total (95% CI)

509

443

100%

1.3[1.1,1.54]

Total events: 247 (PT+AD), 163 (PT+placebo)

Heterogeneity: Tau2=0.02; Chi2=17.33, df=14(P=0.24); I2=19.24%

Test for overall effect: Z=3.11(P=0)

Test for subgroup differences: Not applicable

Favours PT+placebo

0.1

0.2

0.5

1

2

5

10

Favours PT+AD

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

73

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 3.3.   Comparison 3 PD+/-AGORAPHOBIA: Psychotherapy+Antidepressant
vs Psychotherapy+Placebo, Outcome 3 Global severity at 2-4 months.

Study or subgroup

PT+AD

PT+placebo

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

3.3.1 Behaviour therapy

de Beurs 1995

Mavissakalian 1986a

Mavissakalian 1986b

Zitrin 1980

Zitrin 1983

Subtotal ***

1.6 (0.8)

2 (1.7)

2.2 (1.7)

1.9 (0.6)

3.2 (1)

19

17

14

29

34

113

Heterogeneity: Tau2=0; Chi2=0.94, df=4(P=0.92); I2=0%

Test for overall effect: Z=4.38(P<0.0001)

3.3.2 Cognitive-behaviour therapy

Barlow 2000

Fahy 1992

Sharp 1996

Subtotal ***

0.9 (0.7)

2 (1.1)

1.7 (1.1)

65

42

29

136

Heterogeneity: Tau2=0.04; Chi2=3.52, df=2(P=0.17); I2=43.19%

Test for overall effect: Z=1.97(P=0.05)

19

14

17

24

34

108

63

24

33

120

2.1 (1.1)

3 (1.9)

3.1 (1.9)

2.3 (0.9)

4 (1)

1 (0.7)

2.8 (1)

2 (1.3)

8.02%

6.47%

6.53%

11.17%

13.75%

45.94%

28.04%

12.57%

13.45%

54.06%

-0.55[-1.19,0.1]

-0.55[-1.27,0.18]

-0.49[-1.2,0.23]

-0.5[-1.05,0.05]

-0.81[-1.3,-0.31]

-0.61[-0.88,-0.33]

-0.15[-0.5,0.2]

-0.74[-1.26,-0.22]

-0.25[-0.75,0.25]

-0.35[-0.69,-0]

Total ***

249

228

100%

-0.45[-0.63,-0.26]

Heterogeneity: Tau2=0; Chi2=6.86, df=7(P=0.44); I2=0%

Test for overall effect: Z=4.78(P<0.0001)

Test for subgroup differences: Chi2=2.39, df=1 (P=0.12), I2=58.23%

Favours treatment

-4

-2

0

2

4

Favours control

Analysis 3.4.   Comparison 3 PD+/-AGORAPHOBIA: Psychotherapy+Antidepressant
vs Psychotherapy+Placebo, Outcome 4 Frequency of panic attacks at 2-4 months.

Study or subgroup

PT+AD

PT+placebo

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

3.4.1 Behaviour therapy

de Beurs 1995

Johnston 1995

Mavissakalian 1986a

Mavissakalian 1986b

Telch 1985

Zitrin 1980

Zitrin 1983

Subtotal ***

0.2 (0.5)

0.6 (0.9)

1.3 (2)

2.4 (1.9)

0.6 (1.1)

6.4 (1)

6 (1.2)

18

12

17

14

10

19

34

124

Heterogeneity: Tau2=0; Chi2=5.9, df=6(P=0.43); I2=0%

Test for overall effect: Z=0.51(P=0.61)

3.4.2 Cognitive-behaviour therapy

Kampman 2002

Oehrberg 1995

Subtotal ***

2.2 (0.6)

-16 (18.4)

19

55

74

0.5 (1.6)

1.1 (1.8)

1.6 (2.1)

2.2 (2.1)

0.8 (0.7)

6 (1)

5.4 (1.2)

2.3 (0.7)

-9.8 (18.4)

19

17

14

17

9

14

34

124

19

52

71

9.94%

7.69%

8.45%

8.46%

5.36%

8.71%

16.75%

65.36%

-0.28[-0.93,0.37]

-0.34[-1.09,0.4]

-0.14[-0.85,0.56]

0.1[-0.61,0.8]

-0.18[-1.08,0.72]

0.36[-0.33,1.06]

0.44[-0.04,0.92]

0.07[-0.19,0.32]

10.26%

24.38%

34.64%

-0.15[-0.79,0.49]

-0.33[-0.72,0.05]

-0.29[-0.61,0.04]

Favours treatment

-4

-2

0

2

4

Favours control

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

74

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

PT+AD

PT+placebo

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

Heterogeneity: Tau2=0; Chi2=0.24, df=1(P=0.63); I2=0%

Test for overall effect: Z=1.71(P=0.09)

Total ***

198

195

Heterogeneity: Tau2=0.01; Chi2=8.92, df=8(P=0.35); I2=10.28%

Test for overall effect: Z=0.55(P=0.58)

Test for subgroup differences: Chi2=2.78, df=1 (P=0.1), I2=63.99%

100%

-0.06[-0.27,0.15]

Favours treatment

-4

-2

0

2

4

Favours control

Analysis 3.5.   Comparison 3 PD+/-AGORAPHOBIA: Psychotherapy+Antidepressant
vs Psychotherapy+Placebo, Outcome 5 Phobic avoidance at 2-4 months.

Study or subgroup

PT+AD

PT+placebo

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

3.5.1 Behaviour therapy

de Beurs 1995

Johnston 1995

Marks 1983

Mavissakalian 1986a

Mavissakalian 1986b

Sheehan 1980a

Sheehan 1980b

Telch 1985

Zitrin 1980

Zitrin 1983

Subtotal ***

19

12

23

17

14

18

17

10

25

34

4.1 (2)

8.5 (8.4)

11.4 (9.4)

11.4 (8.8)

12.3 (8.8)

3 (1)

2.4 (1.2)

17.3 (10.3)

6.2 (0.8)

2.7 (1.4)

19

17

22

14

17

11

11

9

21

34

5.7 (1.3)

13.5 (9.6)

12.7 (10.5)

13.8 (9.9)

13.3 (9.9)

3.9 (1.3)

3.9 (1.3)

23.3 (7.8)

5.7 (1.1)

3.4 (1.4)

189

175

Heterogeneity: Tau2=0.12; Chi2=17.73, df=9(P=0.04); I2=49.23%

Test for overall effect: Z=2.69(P=0.01)

3.5.2 Cognitive-behaviour therapy

Fahy 1992

Kampman 2002

Loerch 1999

Sharp 1996

Stein 2000

Subtotal ***

31.4 (30.7)

1.8 (0.5)

7 (8.3)

4.7 (7.8)

-5.8 (6.7)

42

19

14

29

12

116

24

19

14

33

12

102

40.2 (25.4)

2 (0.6)

9.1 (6.3)

7.2 (10.6)

-5.9 (9.8)

Heterogeneity: Tau2=0; Chi2=0.55, df=4(P=0.97); I2=0%

Test for overall effect: Z=1.9(P=0.06)

Total ***

305

277

Heterogeneity: Tau2=0.04; Chi2=18.78, df=14(P=0.17); I2=25.44%

Test for overall effect: Z=3.46(P=0)

Test for subgroup differences: Chi2=0.49, df=1 (P=0.48), I2=0%

6.46%

5.41%

7.91%

5.93%

5.97%

5.1%

4.62%

3.83%

7.83%

-0.92[-1.59,-0.25]

-0.53[-1.29,0.22]

-0.13[-0.71,0.46]

-0.25[-0.96,0.46]

-0.1[-0.81,0.6]

-0.79[-1.57,-0.01]

-1.2[-2.03,-0.37]

-0.62[-1.55,0.31]

0.49[-0.1,1.08]

10.19%

63.25%

-0.51[-0.99,-0.02]

-0.42[-0.72,-0.11]

9.66%

6.93%

5.5%

9.74%

4.91%

-0.3[-0.81,0.2]

-0.35[-1,0.29]

-0.28[-1.03,0.46]

-0.26[-0.76,0.24]

0.01[-0.79,0.81]

36.75%

-0.26[-0.53,0.01]

100%

-0.35[-0.54,-0.15]

Favours treatment

-4

-2

0

2

4

Favours control

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

75

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 3.6.   Comparison 3 PD+/-AGORAPHOBIA: Psychotherapy+Antidepressant
vs Psychotherapy+Placebo, Outcome 6 General anxiety at 2-4 months.

Study or subgroup

PT+AD

PT+placebo

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

3.6.1 Behaviour therapy

de Beurs 1995

Marks 1983

Mavissakalian 1986a

Mavissakalian 1986b

Sheehan 1980a

Sheehan 1980b

Zitrin 1983

Subtotal ***

2.6 (1.3)

8.9 (9.4)

30.1 (7.6)

34.3 (7.6)

1 (0.7)

1 (0.6)

21.5 (9.9)

19

23

17

14

18

17

34

142

Heterogeneity: Tau2=0.04; Chi2=8.09, df=6(P=0.23); I2=25.82%

Test for overall effect: Z=4.46(P<0.0001)

3.6.2 Cognitive-behaviour therapy

Fahy 1992

Kampman 2002

Loerch 1999

Oehrberg 1995

Sharp 1996

Stein 2000

Subtotal ***

11.3 (7.6)

1.5 (1.7)

11.4 (11.1)

-6.5 (5.5)

4.8 (5.7)

-15.3 (10.6)

42

19

14

55

29

12

171

3.8 (1.4)

12.7 (9.2)

35.5 (9.3)

34.4 (9.3)

2 (1.1)

2 (1.1)

27.9 (9.9)

14.4 (6.6)

1.7 (1.3)

11.9 (8.4)

-4.3 (5.5)

6.5 (6.7)

-10 (13.1)

19

22

14

17

11

11

34

128

24

19

14

52

33

12

154

Heterogeneity: Tau2=0; Chi2=1.3, df=5(P=0.93); I2=0%

Test for overall effect: Z=2.8(P=0.01)

Total ***

313

282

Heterogeneity: Tau2=0.01; Chi2=13.46, df=12(P=0.34); I2=10.82%

Test for overall effect: Z=5.19(P<0.0001)

Test for subgroup differences: Chi2=4.06, df=1 (P=0.04), I2=75.39%

6.4%

8.02%

5.51%

5.79%

4.45%

4.17%

11.16%

45.5%

10.47%

7.02%

5.32%

16.53%

10.67%

4.49%

54.5%

-0.88[-1.55,-0.21]

-0.4[-0.99,0.19]

-0.63[-1.35,0.1]

-0.01[-0.72,0.7]

-1.15[-1.97,-0.34]

-1.31[-2.15,-0.47]

-0.64[-1.13,-0.15]

-0.67[-0.96,-0.38]

-0.42[-0.93,0.08]

-0.13[-0.77,0.51]

-0.04[-0.78,0.7]

-0.4[-0.78,-0.01]

-0.27[-0.77,0.23]

-0.43[-1.24,0.38]

-0.32[-0.54,-0.09]

100%

-0.47[-0.65,-0.29]

Favours treatment

-4

-2

0

2

4

Favours control

Analysis 3.7.   Comparison 3 PD+/-AGORAPHOBIA: Psychotherapy
+Antidepressant vs Psychotherapy+Placebo, Outcome 7 Depression at 2-4 months.

Study or subgroup

PT+AD

PT+placebo

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

3.7.1 Behaviour therapy

de Beurs 1995

Johnston 1995

Marks 1983

Mavissakalian 1986a

Mavissakalian 1986b

Sheehan 1980a

Sheehan 1980b

Telch 1985

Zitrin 1983

Subtotal ***

19

12

23

17

14

18

17

10

34

2.6 (1)

0.8 (0.5)

4 (4.9)

2.8 (8.5)

8.7 (8.5)

51.1 (9.4)

45.4 (9)

13.4 (5.7)

1.3 (0.5)

19

17

22

14

17

11

11

9

34

3.5 (1.4)

1 (0.8)

4 (2.7)

7.7 (8.7)

6.9 (8.7)

57.7 (10.1)

57.7 (10.1)

13 (11.9)

1.6 (0.5)

164

154

Heterogeneity: Tau2=0.05; Chi2=11.4, df=8(P=0.18); I2=29.81%

Test for overall effect: Z=2.89(P=0)

8.74%

7.04%

10.74%

7.4%

7.65%

6.56%

5.65%

4.94%

14.68%

73.4%

-0.72[-1.38,-0.06]

-0.28[-1.02,0.46]

0[-0.58,0.58]

-0.56[-1.28,0.17]

0.2[-0.51,0.91]

-0.66[-1.43,0.11]

-1.26[-2.1,-0.42]

0.04[-0.86,0.94]

-0.51[-1,-0.03]

-0.41[-0.68,-0.13]

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

76

Favours treatment

-4

-2

0

2

4

Favours control

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

PT+AD

PT+placebo

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

3.7.2 Cognitive-behaviour therapy

Fahy 1992

Loerch 1999

Stein 2000

Subtotal ***

5.6 (4.5)

5.6 (5.8)

-10.5 (10.4)

42

14

12

68

24

14

12

50

8.3 (5.1)

6.5 (5.2)

-8.6 (7.6)

Heterogeneity: Tau2=0; Chi2=1.02, df=2(P=0.6); I2=0%

Test for overall effect: Z=2.02(P=0.04)

Total ***

232

204

Heterogeneity: Tau2=0.02; Chi2=12.42, df=11(P=0.33); I2=11.47%

Test for overall effect: Z=3.74(P=0)

Test for subgroup differences: Chi2=0.01, df=1 (P=0.94), I2=0%

13.43%

7.05%

6.12%

26.6%

-0.56[-1.08,-0.05]

-0.16[-0.9,0.58]

-0.2[-1,0.6]

-0.38[-0.76,-0.01]

100%

-0.4[-0.6,-0.19]

Favours treatment

-4

-2

0

2

4

Favours control

Analysis 3.8.   Comparison 3 PD+/-AGORAPHOBIA: Psychotherapy+Antidepressant
vs Psychotherapy+Placebo, Outcome 8 Social malfunctioning at 2-4 months.

Study or subgroup

PT+AD

PT+placebo

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

3.8.1 Behaviour therapy

Johnston 1995

Mavissakalian 1986a

Mavissakalian 1986b

Sheehan 1980a

Sheehan 1980b

Zitrin 1980

Zitrin 1983

Subtotal ***

2.1 (0.6)

2.3 (1)

2.4 (1)

3.1 (1.1)

2.4 (1.4)

1.1 (0.8)

1.2 (0.9)

12

17

14

18

17

25

34

137

Heterogeneity: Tau2=0.03; Chi2=7.7, df=6(P=0.26); I2=22.11%

Test for overall effect: Z=3.69(P=0)

3.8.2 Cognitive-behaviour therapy

Loerch 1999

Sharp 1996

Stein 2000

Subtotal ***

2.4 (2.8)

1.4 (2.8)

-3.1 (2.5)

14

29

12

55

Heterogeneity: Tau2=0; Chi2=1.96, df=2(P=0.37); I2=0%

Test for overall effect: Z=0.2(P=0.84)

2 (0.8)

2.8 (1.1)

2.8 (1.1)

4 (1)

4 (1)

1.4 (1.1)

1.9 (0.9)

2.1 (2.2)

2.1 (2.6)

-4 (2.1)

16

14

17

11

11

20

34

123

14

33

12

59

Total ***

192

182

Heterogeneity: Tau2=0.07; Chi2=14.71, df=9(P=0.1); I2=38.81%

Test for overall effect: Z=2.7(P=0.01)

Test for subgroup differences: Chi2=5.04, df=1 (P=0.02), I2=80.17%

8.8%

9.29%

9.36%

8.31%

7.6%

11.73%

14.12%

69.21%

8.92%

13.93%

7.93%

30.79%

0.14[-0.61,0.89]

-0.49[-1.21,0.23]

-0.38[-1.1,0.33]

-0.8[-1.58,-0.02]

-1.22[-2.06,-0.39]

-0.33[-0.92,0.26]

-0.78[-1.27,-0.28]

-0.55[-0.84,-0.26]

0.11[-0.63,0.85]

-0.27[-0.77,0.23]

0.38[-0.43,1.18]

-0.04[-0.41,0.33]

100%

-0.37[-0.65,-0.1]

Favours treatment

-4

-2

0

2

4

Favours control

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

77

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 3.9.   Comparison 3 PD+/-AGORAPHOBIA: Psychotherapy+Antidepressant
vs Psychotherapy+Placebo, Outcome 9 Dropouts for any reason within 2-4 months.

PT+AD

n/N

PT+placebo

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

Study or subgroup

3.9.1 Behaviour therapy

de Beurs 1995

Johnston 1995

Marks 1983

Sheehan 1980a

Sheehan 1980b

Telch 1985

Zitrin 1980

Zitrin 1983

Subtotal (95% CI)

5/24

16/26

13/36

7/28

9/29

3/13

12/41

9/43

240

Total events: 74 (PT+AD), 55 (PT+placebo)

Heterogeneity: Tau2=0; Chi2=3.42, df=7(P=0.84); I2=0%

Test for overall effect: Z=1.13(P=0.26)

3.9.2 Cognitive-behaviour therapy

Barlow 2000

Fahy 1992

Kampman 2002

Loerch 1999

Oehrberg 1995

Sharp 1996

Stein 2000

Subtotal (95% CI)

18/65

12/53

3/22

3/14

5/60

11/38

1/16

268

Total events: 53 (PT+AD), 37 (PT+placebo)

Heterogeneity: Tau2=0; Chi2=5.6, df=6(P=0.47); I2=0%

Test for overall effect: Z=0.93(P=0.35)

5/24

10/27

14/36

3/16

2/14

3/12

11/35

7/41

205

18/63

3/26

2/21

1/14

8/60

4/36

1/17

237

4.51%

16.41%

15.38%

3.78%

2.83%

2.82%

11.77%

6.92%

64.4%

17.87%

3.97%

1.93%

1.2%

4.89%

4.98%

0.76%

35.6%

1[0.33,3.01]

1.66[0.93,2.96]

0.93[0.51,1.69]

1.33[0.4,4.45]

2.17[0.54,8.75]

0.92[0.23,3.72]

0.93[0.47,1.84]

1.23[0.5,2.99]

1.18[0.88,1.58]

0.97[0.56,1.69]

1.96[0.61,6.35]

1.43[0.27,7.73]

3[0.35,25.46]

0.63[0.22,1.8]

2.61[0.91,7.44]

1.06[0.07,15.6]

1.21[0.81,1.78]

Total (95% CI)

508

442

100%

1.19[0.94,1.5]

Total events: 127 (PT+AD), 92 (PT+placebo)

Heterogeneity: Tau2=0; Chi2=9, df=14(P=0.83); I2=0%

Test for overall effect: Z=1.46(P=0.14)

Test for subgroup differences: Not applicable

Favours treatment

0.1

0.2

0.5

1

2

5

10

Favours control

Analysis 3.10.   Comparison 3 PD+/-AGORAPHOBIA: Psychotherapy+Antidepressant vs
Psychotherapy+Placebo, Outcome 10 Dropouts due to side effects within 2-4 months.

Study or subgroup

3.10.1 Behaviour therapy

de Beurs 1995

Marks 1983

Telch 1985

Zitrin 1980

Subtotal (95% CI)

PT+AD

n/N

PT+placebo

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

2/24

2/36

3/13

8/41

114

0/24

3/36

1/12

3/35

107

5.25%

15.65%

10.37%

30.02%

61.29%

5[0.25,98.96]

0.67[0.12,3.75]

2.77[0.33,23.14]

2.28[0.65,7.93]

1.84[0.77,4.41]

Total events: 15 (PT+AD), 7 (PT+placebo)

Heterogeneity: Tau2=0; Chi2=2.01, df=3(P=0.57); I2=0%

Favours treatment

0.1

0.2

0.5

1

2

5

10

Favours control

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

78

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

PT+AD

n/N

PT+placebo

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

Test for overall effect: Z=1.37(P=0.17)

3.10.2 Cognitive-behaviour therapy

Barlow 2000

Fahy 1992

Kampman 2002

Oehrberg 1995

Sharp 1996

Subtotal (95% CI)

2/65

7/53

3/22

4/60

5/38

238

0/63

0/26

2/21

0/60

0/36

206

Total events: 21 (PT+AD), 2 (PT+placebo)

Heterogeneity: Tau2=0; Chi2=2.53, df=4(P=0.64); I2=0%

Test for overall effect: Z=2.37(P=0.02)

5.14%

5.86%

16.44%

5.56%

5.72%

38.71%

4.85[0.24,99.04]

7.5[0.44,126.48]

1.43[0.27,7.73]

9[0.5,163.58]

10.44[0.6,182.21]

3.78[1.26,11.33]

Total (95% CI)

352

313

100%

2.43[1.23,4.81]

Total events: 36 (PT+AD), 9 (PT+placebo)

Heterogeneity: Tau2=0; Chi2=5.64, df=8(P=0.69); I2=0%

Test for overall effect: Z=2.55(P=0.01)

Test for subgroup differences: Not applicable

Favours treatment

0.1

0.2

0.5

1

2

5

10

Favours control

Analysis 3.11.   Comparison 3 PD+/-AGORAPHOBIA: Psychotherapy+Antidepressant vs
Psychotherapy+Placebo, Outcome 11 Response/remission on continued treatment.

Study or subgroup

3.11.1 Behaviour therapy

Telch 1985

Zitrin 1980

Subtotal (95% CI)

PT+AD

n/N

PT+placebo

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

7/13

26/41

54

2/12

17/35

47

4.52%

39.21%

43.72%

3.23[0.83,12.61]

1.31[0.86,1.97]

1.64[0.74,3.61]

Total events: 33 (PT+AD), 19 (PT+placebo)

Heterogeneity: Tau2=0.17; Chi2=1.66, df=1(P=0.2); I2=39.69%

Test for overall effect: Z=1.22(P=0.22)

3.11.2 Cognitive-behaviour therapy

Barlow 2000

Subtotal (95% CI)

Total events: 37 (PT+AD), 32 (PT+placebo)

Heterogeneity: Not applicable

Test for overall effect: Z=0.69(P=0.49)

37/65

65

32/63

63

56.28%

56.28%

1.12[0.81,1.55]

1.12[0.81,1.55]

Total (95% CI)

119

110

100%

1.25[0.93,1.67]

Total events: 70 (PT+AD), 51 (PT+placebo)

Heterogeneity: Tau2=0.01; Chi2=2.4, df=2(P=0.3); I2=16.51%

Test for overall effect: Z=1.48(P=0.14)

Test for subgroup differences: Not applicable

Favours PT+placebo

0.1

0.2

0.5

1

2

5

10

Favours PT+AD

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

79

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 3.12.   Comparison 3 PD+/-AGORAPHOBIA: Psychotherapy+Antidepressant vs
Psychotherapy+Placebo, Outcome 12 Global/Avoidance/Panic on continued treatment.

Study or subgroup

PT+AD

PT+placebo

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

3.12.1 Behaviour therapy

Johnston 1995

Telch 1985

Zitrin 1980

Subtotal ***

5.4 (5.7)

12.6 (8.1)

1.5 (0.7)

12

10

29

51

Heterogeneity: Tau2=0; Chi2=1.84, df=2(P=0.4); I2=0%

Test for overall effect: Z=4.44(P<0.0001)

3.12.2 Cognitive-behaviour therapy

Barlow 2000

Subtotal ***

0.8 (0.9)

65

65

Heterogeneity: Not applicable

Test for overall effect: Z=2.02(P=0.04)

14.6 (9.1)

25.6 (8.8)

2 (0.9)

1.1 (0.8)

17

9

24

50

63

63

Total ***

116

113

Heterogeneity: Tau2=0.11; Chi2=6.34, df=3(P=0.1); I2=52.67%

Test for overall effect: Z=3.3(P=0)

Test for subgroup differences: Chi2=4.5, df=1 (P=0.03), I2=77.78%

19.48%

13.74%

28.36%

61.58%

-1.13[-1.94,-0.33]

-1.47[-2.51,-0.43]

-0.72[-1.27,-0.16]

-0.95[-1.37,-0.53]

38.42%

38.42%

-0.36[-0.71,-0.01]

-0.36[-0.71,-0.01]

100%

-0.76[-1.22,-0.31]

Favours treatment

-4

-2

0

2

4

Favours control

Analysis 3.13.   Comparison 3 PD+/-AGORAPHOBIA: Psychotherapy+Antidepressant vs
Psychotherapy+Placebo, Outcome 13 Dropouts for any reason on continued treatment.

Study or subgroup

3.13.1 Behaviour therapy

Telch 1985

Subtotal (95% CI)

Total events: 1 (PT+AD), 0 (PT+placebo)

Heterogeneity: Not applicable

Test for overall effect: Z=0.64(P=0.52)

3.13.2 Cognitive-behaviour therapy

Barlow 2000

Subtotal (95% CI)

Total events: 4 (PT+AD), 6 (PT+placebo)

Heterogeneity: Not applicable

Test for overall effect: Z=0.7(P=0.48)

PT+AD

n/N

PT+placebo

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

1/10

10

4/65

65

0/9

9

6/63

63

13.47%

13.47%

2.73[0.12,59.57]

2.73[0.12,59.57]

86.53%

86.53%

0.65[0.19,2.18]

0.65[0.19,2.18]

Total (95% CI)

75

72

100%

0.78[0.25,2.43]

Total events: 5 (PT+AD), 6 (PT+placebo)

Heterogeneity: Tau2=0; Chi2=0.73, df=1(P=0.39); I2=0%

Test for overall effect: Z=0.42(P=0.67)

Test for subgroup differences: Not applicable

Favours treatment

0.1

0.2

0.5

1

2

5

10

Favours control

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

80

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 3.14.   Comparison 3 PD+/-AGORAPHOBIA: Psychotherapy+Antidepressant vs Psychotherapy
+Placebo, Outcome 14 Response/remission 6-24 months after treatment discontinuation.

PT+AD

n/N

PT+placebo

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

Study or subgroup

3.14.1 Behaviour therapy

de Beurs 1995

Marks 1983

Mavissakalian 1986a

Mavissakalian 1986b

Zitrin 1983

Subtotal (95% CI)

12/24

9/36

6/20

6/20

23/43

143

Total events: 56 (PT+AD), 54 (PT+placebo)

Heterogeneity: Tau2=0; Chi2=0.55, df=4(P=0.97); I2=0%

Test for overall effect: Z=0.19(P=0.85)

3.14.2 Cognitive-behaviour therapy

Barlow 2000

Loerch 1999

Sharp 1996

Subtotal (95% CI)

16/59

9/14

16/38

111

Total events: 41 (PT+AD), 51 (PT+placebo)

Heterogeneity: Tau2=0; Chi2=1.21, df=2(P=0.55); I2=0%

Test for overall effect: Z=1.15(P=0.25)

12/24

11/36

5/20

6/20

20/41

141

25/62

9/14

17/36

112

13.25%

7.54%

4.14%

4.73%

24.09%

53.76%

15.91%

13.91%

16.42%

46.24%

1[0.57,1.76]

0.82[0.39,1.73]

1.2[0.44,3.3]

1[0.39,2.58]

1.1[0.72,1.67]

1.03[0.78,1.36]

0.67[0.4,1.13]

1[0.58,1.74]

0.89[0.54,1.48]

0.84[0.62,1.13]

Total (95% CI)

254

253

100%

0.93[0.76,1.15]

Total events: 97 (PT+AD), 105 (PT+placebo)

Heterogeneity: Tau2=0; Chi2=2.68, df=7(P=0.91); I2=0%

Test for overall effect: Z=0.64(P=0.52)

Test for subgroup differences: Not applicable

Favours PT+placebo

0.2

0.5

1

2

5

Favours PT+AD

Analysis 3.15.   Comparison 3 PD+/-AGORAPHOBIA: Psychotherapy+Antidepressant vs Psychotherapy
+Placebo, Outcome 15 Global/Avoidance/Panic 6-24 months after treatment discontinuation.

Study or subgroup

PT+AD

PT+placebo

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

3.15.1 Behaviour therapy

de Beurs 1995

Marks 1983

Mavissakalian 1986a

Mavissakalian 1986b

Subtotal ***

3.3 (2.4)

14.1 (2.7)

2.1 (1.4)

2 (1.2)

18

22

14

11

65

Heterogeneity: Tau2=0.07; Chi2=4.65, df=3(P=0.2); I2=35.44%

Test for overall effect: Z=0.34(P=0.74)

3.15.2 Cognitive-behviour therapy

Barlow 2000

Subtotal ***

1.5 (0.9)

59

59

Heterogeneity: Not applicable

Test for overall effect: Z=1.61(P=0.11)

3.2 (2.7)

13.7 (2.8)

3.3 (2.6)

1.3 (0.5)

1.2 (0.9)

19

18

11

11

59

62

62

18.23%

19.17%

12.66%

11.26%

61.32%

0.07[-0.57,0.72]

0.14[-0.48,0.77]

-0.58[-1.39,0.23]

0.71[-0.16,1.58]

0.08[-0.37,0.53]

38.68%

38.68%

0.29[-0.06,0.65]

0.29[-0.06,0.65]

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

81

Favours treatment

-10

-5

0

5

10

Favours control

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

PT+AD

PT+placebo

Std. Mean Difference

Weight

Std. Mean Difference

Total ***

Mean(SD)

N

124

N

121

Heterogeneity: Tau2=0.03; Chi2=5.36, df=4(P=0.25); I2=25.42%

Test for overall effect: Z=1(P=0.32)

Test for subgroup differences: Chi2=0.72, df=1 (P=0.4), I2=0%

Mean(SD)

Random, 95% CI

Random, 95% CI

100%

0.16[-0.15,0.48]

Favours treatment

-10

-5

0

5

10

Favours control

Comparison 4.   PD+/-AGORAPHOBIA: Psychotherapy+Antidepressant vs Psychotherapy alone or +Placebo

Outcome or subgroup title

No. of
studies

1 Response at 2-4 months

1.1 Behaviour therapy

1.2 Cognitive-behaviour therapy

2 Remission at 2-4 months

2.1 Behaviour therapy

2.2 Cognitive-behaviour therapy

3 Global severity at 2-4 months

3.1 Behaviour therapy

3.2 Cognitive-behaviour therapy

23

12

11

19

10

9

11

6

5

4 Frequency of panic attacks at 2-4 months

13

4.1 Behaviour therapy

4.2 Cognitive-behaviour therapy

5 Phobic avoidance at 2-4 months

5.1 Behaviour therapy

9

4

19

12

No. of
partici-
pants

1271

562

709

1107

482

625

602

239

363

497

278

219

684

396

Statistical method

Effect size

Risk Ratio (M-H, Random, 95%
CI)

1.17 [1.05, 1.31]

Risk Ratio (M-H, Random, 95%
CI)

1.26 [1.05, 1.50]

Risk Ratio (M-H, Random, 95%
CI)

1.13 [0.96, 1.33]

Risk Ratio (M-H, Random, 95%
CI)

1.26 [1.10, 1.44]

Risk Ratio (M-H, Random, 95%
CI)

1.37 [1.06, 1.77]

Risk Ratio (M-H, Random, 95%
CI)

1.23 [1.02, 1.47]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.43 [-0.60, -0.26]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.61 [-0.87, -0.34]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.31 [-0.54, -0.08]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.03 [-0.21, 0.16]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.06 [-0.19, 0.31]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.15 [-0.41, 0.12]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.31 [-0.49, -0.12]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.41 [-0.70, -0.11]

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

82

 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of
studies

No. of
partici-
pants

Statistical method

Effect size

5.2 Cognitive-behaviour therapy

6 General anxiety at 2-4 months

6.1 Behaviour therapy

6.2 Cognitive-behaviour therapy

7 Depression at 2-4 months

7.1 Behaviour therapy

7.2 Cognitive-behaviour therapy

8 Social malfunctioning at 2-4 months

8.1 Behaviour therapy

8.2 Cognitive-behaviour therapy

9 Dropouts for any reason within 2-4
months

9.1 Behaviour therapy

9.2 Cognitive-behaviour therapy

10 Dropouts due to side effects within 2-4
months

10.1 Behaviour therapy

10.2 Cognitive-behaviour therapy

11 Response/remission on continued treat-
ment

11.1 Behaviour therapy

7

17

9

8

16

11

5

11

7

4

20

10

10

13

5

8

4

2

288

691

302

389

542

350

192

404

260

144

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.20 [-0.44, 0.04]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.41 [-0.59, -0.23]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.64 [-0.90, -0.37]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.23 [-0.44, -0.03]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.39 [-0.59, -0.20]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.43 [-0.69, -0.17]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.34 [-0.64, -0.05]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.36 [-0.61, -0.11]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.55 [-0.84, -0.26]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.04 [-0.39, 0.30]

1145

Risk Ratio (M-H, Random, 95%
CI)

1.18 [0.95, 1.47]

480

665

846

242

604

306

101

Risk Ratio (M-H, Random, 95%
CI)

1.20 [0.90, 1.60]

Risk Ratio (M-H, Random, 95%
CI)

1.16 [0.83, 1.62]

Risk Ratio (M-H, Random, 95%
CI)

3.01 [1.61, 5.63]

Risk Ratio (M-H, Random, 95%
CI)

1.99 [0.85, 4.62]

Risk Ratio (M-H, Random, 95%
CI)

5.00 [1.96, 12.72]

Risk Ratio (M-H, Random, 95%
CI)

1.29 [1.03, 1.62]

Risk Ratio (M-H, Random, 95%
CI)

1.64 [0.74, 3.61]

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

83

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of
studies

No. of
partici-
pants

Statistical method

Effect size

11.2 Cognitive-behaviour therapy

12 Global/Avoidance/Panic on continued
treatment

12.1 Behaviour therapy

12.2 Cognitive-behaviour therapy

13 Dropouts for any reason on continued
treatment

13.1 Behaviour therapy

13.2 Cognitive-behaviour therapy

2

5

3

2

3

1

2

14 Response/remission 6-24 months after
treatment discontinuation

12

14.1 Behaviour therapy

14.2 Cognitive-behaviour therapy

15 Global/Avoidance/Panic 6-24 months
after treatment discontinuation

15.1 Behaviour therapy

15.2 Cognitive-behviour therapy

7

5

7

5

2

205

306

101

205

224

19

205

658

319

339

335

141

194

Risk Ratio (M-H, Random, 95%
CI)

1.23 [0.93, 1.63]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.65 [-0.97, -0.33]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.95 [-1.37, -0.53]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.41 [-0.71, -0.12]

Risk Ratio (M-H, Random, 95%
CI)

0.77 [0.28, 2.15]

Risk Ratio (M-H, Random, 95%
CI)

2.73 [0.12, 59.57]

Risk Ratio (M-H, Random, 95%
CI)

0.66 [0.22, 1.95]

Risk Ratio (M-H, Random, 95%
CI)

0.96 [0.79, 1.16]

Risk Ratio (M-H, Random, 95%
CI)

1.00 [0.77, 1.31]

Risk Ratio (M-H, Random, 95%
CI)

0.91 [0.69, 1.21]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.14 [-0.09, 0.37]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.05 [-0.32, 0.43]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.21 [-0.10, 0.52]

Analysis 4.1.   Comparison 4 PD+/-AGORAPHOBIA: Psychotherapy+Antidepressant
vs Psychotherapy alone or +Placebo, Outcome 1 Response at 2-4 months.

PT+AD

n/N

PT

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

Study or subgroup

4.1.1 Behaviour therapy

de Beurs 1995i

de Beurs 1995ii

Fava 1997

Johnston 1995

Marks 1983

8/12

9/12

1/7

7/28

20/36

12/24

7/21

4/7

7/27

17/36

3.49%

2.44%

0.33%

1.45%

5.18%

Favours PT

0.2

0.5

1

2

5

Favours PT+AD

1.33[0.76,2.35]

2.25[1.13,4.47]

0.25[0.04,1.71]

0.96[0.39,2.38]

1.18[0.75,1.85]

84

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

PT+AD

n/N

PT

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

Study or subgroup

Mavissakalian 1986a

Mavissakalian 1986b

Sheehan 1980a

Sheehan 1980b

Telch 1985

Zitrin 1980

Zitrin 1983

Subtotal (95% CI)

Total events: 151 (PT+AD), 116 (PT)

11/20

8/20

16/28

16/29

5/13

25/41

25/43

289

Heterogeneity: Tau2=0; Chi2=8.58, df=11(P=0.66); I2=0%

Test for overall effect: Z=2.53(P=0.01)

4.1.2 Cognitive-behaviour therapy

Azhar 2000

Barlow 2000i

Barlow 2000ii

Fahy 1992

Kampman 2002

Loerch 1999

Oehrberg 1995

Sharp 1996i

Sharp 1996ii

Spinhoven 1996

Stein 2000

Subtotal (95% CI)

14/22

19/32

20/33

26/53

12/22

11/14

42/60

13/19

13/19

4/20

13/16

310

Total events: 187 (PT+AD), 211 (PT)

Heterogeneity: Tau2=0.03; Chi2=15.9, df=10(P=0.1); I2=37.09%

Test for overall effect: Z=1.47(P=0.14)

10/20

9/20

6/16

5/14

2/12

16/35

21/41

273

17/22

36/63

37/77

9/26

5/21

12/14

25/60

28/36

26/43

4/20

12/17

399

3.23%

2.22%

2.3%

1.95%

0.59%

5.51%

6.58%

35.26%

6.67%

7.62%

7.54%

3.18%

1.62%

7.98%

8.16%

7.82%

6.64%

0.79%

6.72%

64.74%

1.1[0.61,1.99]

0.89[0.43,1.83]

1.52[0.75,3.1]

1.54[0.71,3.36]

2.31[0.55,9.74]

1.33[0.86,2.06]

1.14[0.77,1.68]

1.26[1.05,1.5]

0.82[0.56,1.21]

1.04[0.73,1.49]

1.26[0.88,1.81]

1.42[0.78,2.57]

2.29[0.97,5.39]

0.92[0.65,1.3]

1.68[1.19,2.37]

0.88[0.62,1.25]

1.13[0.77,1.67]

1[0.29,3.45]

1.15[0.78,1.69]

1.13[0.96,1.33]

Total (95% CI)

599

672

100%

1.17[1.05,1.31]

Total events: 338 (PT+AD), 327 (PT)

Heterogeneity: Tau2=0.01; Chi2=25.16, df=22(P=0.29); I2=12.57%

Test for overall effect: Z=2.75(P=0.01)

Test for subgroup differences: Not applicable

Favours PT

0.2

0.5

1

2

5

Favours PT+AD

Analysis 4.2.   Comparison 4 PD+/-AGORAPHOBIA: Psychotherapy+Antidepressant
vs Psychotherapy alone or +Placebo, Outcome 2 Remission at 2-4 months.

PT+AD

n/N

PT

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

Study or subgroup

4.2.1 Behaviour therapy

de Beurs 1995i

de Beurs 1995ii

Fava 1997

Marks 1983

Mavissakalian 1986a

Mavissakalian 1986b

Sheehan 1980a

8/12

8/12

1/7

17/36

8/20

8/20

5/28

14/24

12/21

4/7

12/36

4/20

5/20

2/15

6.3%

5.84%

0.49%

5.25%

1.71%

2.08%

0.79%

Favours PT

0.1

0.2

0.5

1

2

5

10

Favours PT+AD

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

1.14[0.68,1.93]

1.17[0.68,2.01]

0.25[0.04,1.71]

1.42[0.8,2.52]

2[0.72,5.59]

1.6[0.63,4.05]

1.34[0.29,6.09]

85

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

PT+AD

n/N

PT

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

Study or subgroup

Sheehan 1980b

Zitrin 1980

Zitrin 1983

Subtotal (95% CI)

10/29

7/41

13/43

248

Total events: 85 (PT+AD), 64 (PT)

Heterogeneity: Tau2=0; Chi2=7.02, df=9(P=0.64); I2=0%

Test for overall effect: Z=2.43(P=0.02)

4.2.2 Cognitive-behaviour therapy

Barlow 2000i

Barlow 2000ii

Fahy 1992

Kampman 2002

Loerch 1999

Oehrberg 1995

Sharp 1996i

Sharp 1996ii

Stein 2000

Subtotal (95% CI)

Total events: 160 (PT+AD), 178 (PT)

20/33

19/32

28/53

14/22

9/14

39/60

12/19

12/19

7/16

268

Heterogeneity: Tau2=0.02; Chi2=11.01, df=8(P=0.2); I2=27.36%

Test for overall effect: Z=2.2(P=0.03)

2/15

4/35

5/41

234

39/63

42/77

10/26

9/21

8/14

21/60

25/36

21/43

3/17

357

0.95%

1.39%

2.05%

26.86%

14.1%

13.05%

5.77%

5.09%

4.89%

10.78%

10.09%

8.03%

1.33%

73.14%

2.59[0.65,10.32]

1.49[0.48,4.68]

2.48[0.97,6.34]

1.37[1.06,1.77]

0.98[0.7,1.37]

1.09[0.77,1.55]

1.37[0.79,2.38]

1.48[0.83,2.67]

1.13[0.62,2.05]

1.86[1.26,2.75]

0.91[0.61,1.37]

1.29[0.82,2.05]

2.48[0.77,7.97]

1.23[1.02,1.47]

Total (95% CI)

516

591

100%

1.26[1.1,1.44]

Total events: 245 (PT+AD), 242 (PT)

Heterogeneity: Tau2=0; Chi2=18.92, df=18(P=0.4); I2=4.86%

Test for overall effect: Z=3.3(P=0)

Test for subgroup differences: Not applicable

Favours PT

0.1

0.2

0.5

1

2

5

10

Favours PT+AD

Analysis 4.3.   Comparison 4 PD+/-AGORAPHOBIA: Psychotherapy+Antidepressant
vs Psychotherapy alone or +Placebo, Outcome 3 Global severity at 2-4 months.

Study or subgroup

PT+AD

PT

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

4.3.1 Behaviour therapy

de Beurs 1995i

de Beurs 1995ii

Mavissakalian 1986a

Mavissakalian 1986b

Zitrin 1980

Zitrin 1983

Subtotal ***

10

9

17

14

29

34

113

1.6 (0.8)

1.6 (0.8)

2 (1.7)

2.2 (1.7)

1.9 (0.6)

3.2 (1)

19

18

14

17

24

34

126

2.1 (1.1)

2.3 (1.2)

3 (1.9)

3.1 (1.9)

2.3 (0.9)

4 (1)

Heterogeneity: Tau2=0; Chi2=0.96, df=5(P=0.97); I2=0%

Test for overall effect: Z=4.52(P<0.0001)

4.3.2 Cognitive-behaviour therapy

Barlow 2000i

Barlow 2000ii

33

32

0.9 (0.7)

0.9 (0.7)

63

77

1 (0.7)

1.1 (0.7)

4.75%

4.28%

5.53%

5.58%

9.54%

11.75%

41.43%

-0.52[-1.3,0.26]

-0.64[-1.46,0.19]

-0.55[-1.27,0.18]

-0.49[-1.2,0.23]

-0.5[-1.05,0.05]

-0.81[-1.3,-0.31]

-0.61[-0.87,-0.34]

16.22%

16.76%

-0.15[-0.57,0.27]

-0.35[-0.76,0.07]

Favours PT+AD

-4

-2

0

2

4

Favours PT

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

86

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

PT+AD

PT

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

Fahy 1992

Sharp 1996i

Sharp 1996ii

Subtotal ***

42

15

14

136

2 (1.1)

1.7 (1.1)

1.7 (1.1)

24

33

30

227

2.8 (1)

2 (1.3)

1.7 (1)

Heterogeneity: Tau2=0.01; Chi2=4.32, df=4(P=0.36); I2=7.49%

Test for overall effect: Z=2.6(P=0.01)

10.74%

7.69%

7.17%

58.57%

-0.74[-1.26,-0.22]

-0.24[-0.86,0.37]

0.02[-0.61,0.65]

-0.31[-0.54,-0.08]

Total ***

249

353

100%

-0.43[-0.6,-0.26]

Heterogeneity: Tau2=0; Chi2=8.21, df=10(P=0.61); I2=0%

Test for overall effect: Z=4.99(P<0.0001)

Test for subgroup differences: Chi2=2.93, df=1 (P=0.09), I2=65.86%

Favours PT+AD

-4

-2

0

2

4

Favours PT

Analysis 4.4.   Comparison 4 PD+/-AGORAPHOBIA: Psychotherapy+Antidepressant vs
Psychotherapy alone or +Placebo, Outcome 4 Frequency of panic attacks at 2-4 months.

Study or subgroup

PT+AD

PT+placebo

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

4.4.1 Behaviour therapy

de Beurs 1995i

de Beurs 1995ii

Fava 1997

Johnston 1995

Mavissakalian 1986a

Mavissakalian 1986b

Telch 1985

Zitrin 1980

Zitrin 1983

Subtotal ***

9

9

7

12

17

14

10

19

34

0.2 (0.5)

0.2 (0.5)

2.7 (0.8)

0.6 (0.9)

1.3 (2)

2.4 (1.9)

0.6 (1.1)

6.4 (1)

6 (1.2)

19

16

7

17

14

17

9

14

34

0.5 (1.6)

1.7 (3.5)

2 (1)

1.1 (1.8)

1.6 (2.1)

2.2 (2.1)

0.8 (0.7)

6 (1)

5.4 (1.2)

131

147

Heterogeneity: Tau2=0.01; Chi2=8.6, df=8(P=0.38); I2=6.93%

Test for overall effect: Z=0.47(P=0.64)

4.4.2 Cognitive-behaviour therapy

Azhar 2000

Kampman 2002

Oehrberg 1995

Spinhoven 1996

Subtotal ***

17

19

55

20

111

4.1 (3.9)

2.2 (0.6)

-16 (18.4)

3 (2.5)

3.6 (2.2)

2.3 (0.7)

-9.8 (18.4)

2.7 (2.3)

17

19

52

20

108

Heterogeneity: Tau2=0; Chi2=2.32, df=3(P=0.51); I2=0%

Test for overall effect: Z=1.07(P=0.28)

Total ***

242

255

Heterogeneity: Tau2=0; Chi2=12.28, df=12(P=0.42); I2=2.27%

Test for overall effect: Z=0.28(P=0.78)

Test for subgroup differences: Chi2=1.37, df=1 (P=0.24), I2=26.79%

5.11%

4.7%

2.73%

5.83%

6.43%

6.44%

3.99%

6.65%

13.62%

55.5%

7.11%

7.92%

21.13%

8.34%

44.5%

-0.25[-1.04,0.55]

-0.51[-1.34,0.32]

0.72[-0.37,1.82]

-0.34[-1.09,0.4]

-0.14[-0.85,0.56]

0.1[-0.61,0.8]

-0.18[-1.08,0.72]

0.36[-0.33,1.06]

0.44[-0.04,0.92]

0.06[-0.19,0.31]

0.13[-0.54,0.81]

-0.15[-0.79,0.49]

-0.33[-0.72,0.05]

0.12[-0.5,0.74]

-0.15[-0.41,0.12]

100%

-0.03[-0.21,0.16]

Favours treatment

-4

-2

0

2

4

Favours control

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

87

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 4.5.   Comparison 4 PD+/-AGORAPHOBIA: Psychotherapy+Antidepressant
vs Psychotherapy alone or +Placebo, Outcome 5 Phobic avoidance at 2-4 months.

Study or subgroup

PT+AD

PT

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

4.5.1 Behaviour therapy

de Beurs 1995i

de Beurs 1995ii

Fava 1997

Johnston 1995

Marks 1983

Mavissakalian 1986a

Mavissakalian 1986b

Sheehan 1980a

Sheehan 1980b

Telch 1985

Zitrin 1980

Zitrin 1983

Subtotal ***

10

9

7

12

23

17

14

18

17

10

25

34

4.1 (2)

4.1 (2)

19.6 (4.7)

8.5 (8.4)

11.4 (9.4)

11.4 (8.8)

12.3 (8.8)

3 (1)

2.4 (1.2)

17.3 (10.3)

6.2 (0.8)

2.7 (1.4)

19

18

7

17

22

14

17

11

11

9

21

34

5.7 (1.3)

6.1 (1.9)

15.6 (8.4)

13.5 (9.6)

12.7 (10.5)

13.8 (9.9)

13.3 (9.9)

3.9 (1.3)

3.9 (1.3)

23.3 (7.8)

5.7 (1.1)

3.4 (1.4)

4.11%

3.83%

2.58%

4.63%

6.67%

5.06%

5.09%

4.38%

3.98%

3.32%

6.6%

8.47%

-0.99[-1.8,-0.17]

-0.99[-1.84,-0.14]

0.55[-0.52,1.63]

-0.53[-1.29,0.22]

-0.13[-0.71,0.46]

-0.25[-0.96,0.46]

-0.1[-0.81,0.6]

-0.79[-1.57,-0.01]

-1.2[-2.03,-0.37]

-0.62[-1.55,0.31]

0.49[-0.1,1.08]

-0.51[-0.99,-0.02]

196

200

58.73%

-0.41[-0.7,-0.11]

Heterogeneity: Tau2=0.14; Chi2=22.21, df=11(P=0.02); I2=50.47%

Test for overall effect: Z=2.65(P=0.01)

4.5.2 Cognitive-behaviour therapy

Fahy 1992

Kampman 2002

Loerch 1999

Sharp 1996i

Sharp 1996ii

Spinhoven 1996

Stein 2000

Subtotal ***

31.4 (30.7)

1.8 (0.5)

7 (8.3)

4.7 (7.8)

4.7 (7.8)

22.5 (12)

-5.8 (6.7)

42

19

14

15

14

20

12

136

24

19

14

33

30

20

12

152

40.2 (25.4)

2 (0.6)

9.1 (6.3)

7.2 (10.6)

5.1 (5.4)

22.9 (11.3)

-5.9 (9.8)

Heterogeneity: Tau2=0; Chi2=1.17, df=6(P=0.98); I2=0%

Test for overall effect: Z=1.62(P=0.11)

Total ***

332

352

Heterogeneity: Tau2=0.04; Chi2=24.6, df=18(P=0.14); I2=26.82%

Test for overall effect: Z=3.27(P=0)

Test for subgroup differences: Chi2=1.21, df=1 (P=0.27), I2=17.4%

8.05%

5.88%

4.71%

6.27%

5.97%

6.17%

4.22%

41.27%

-0.3[-0.81,0.2]

-0.35[-1,0.29]

-0.28[-1.03,0.46]

-0.25[-0.86,0.36]

-0.06[-0.7,0.57]

-0.03[-0.65,0.59]

0.01[-0.79,0.81]

-0.2[-0.44,0.04]

100%

-0.31[-0.49,-0.12]

Favours PT+AD

-4

-2

0

2

4

Favours PT

Analysis 4.6.   Comparison 4 PD+/-AGORAPHOBIA: Psychotherapy+Antidepressant
vs Psychotherapy alone or +Placebo, Outcome 6 General anxiety at 2-4 months.

Study or subgroup

PT+AD

PT

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

4.6.1 Behaviour therapy

de Beurs 1995i

de Beurs 1995ii

Fava 1997

Marks 1983

Mavissakalian 1986a

Mavissakalian 1986b

10

9

7

23

17

14

2.6 (1.3)

2.6 (1.3)

3.6 (0.5)

8.9 (9.4)

30.1 (7.6)

34.3 (7.6)

19

18

7

22

14

17

3.8 (1.4)

3.9 (1.5)

3.6 (0.5)

12.7 (9.2)

35.5 (9.3)

34.4 (9.3)

4.25%

3.92%

2.65%

6.96%

5.01%

5.24%

-0.87[-1.67,-0.06]

-0.89[-1.73,-0.05]

0[-1.05,1.05]

-0.4[-0.99,0.19]

-0.63[-1.35,0.1]

-0.01[-0.72,0.7]

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

88

Favours PT+AD

-4

-2

0

2

4

Favours PT

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

PT+AD

PT

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

Sheehan 1980a

Sheehan 1980b

Zitrin 1983

Subtotal ***

1 (0.7)

1 (0.6)

21.5 (9.9)

18

17

34

149

Heterogeneity: Tau2=0.03; Chi2=9.68, df=8(P=0.29); I2=17.35%

Test for overall effect: Z=4.71(P<0.0001)

4.6.2 Cognitive-behaviour therapy

Azhar 2000

Fahy 1992

Kampman 2002

Loerch 1999

Oehrberg 1995

Sharp 1996i

Sharp 1996ii

Stein 2000

Subtotal ***

22.9 (4.7)

11.3 (7.6)

1.5 (1.7)

11.4 (11.1)

-6.5 (5.5)

4.8 (5.7)

4.8 (5.7)

-15.3 (10.6)

17

42

19

14

55

15

14

12

188

2 (1.1)

2 (1.1)

27.9 (9.9)

21.5 (5.2)

14.4 (6.6)

1.7 (1.3)

11.9 (8.4)

-4.3 (5.5)

6.5 (6.7)

4.9 (4.4)

-10 (13.1)

11

11

34

153

17

24

19

14

52

33

30

12

201

Heterogeneity: Tau2=0; Chi2=4.38, df=7(P=0.73); I2=0%

Test for overall effect: Z=2.23(P=0.03)

Total ***

337

354

Heterogeneity: Tau2=0.03; Chi2=20.32, df=16(P=0.21); I2=21.24%

Test for overall effect: Z=4.44(P<0.0001)

Test for subgroup differences: Chi2=6.25, df=1 (P=0.01), I2=84.01%

4.13%

3.89%

9.16%

-1.15[-1.97,-0.34]

-1.31[-2.15,-0.47]

-0.64[-1.13,-0.15]

45.22%

-0.64[-0.9,-0.37]

5.64%

8.69%

6.2%

4.86%

12.39%

6.58%

6.24%

4.17%

54.78%

0.27[-0.41,0.94]

-0.42[-0.93,0.08]

-0.13[-0.77,0.51]

-0.04[-0.78,0.7]

-0.4[-0.78,-0.01]

-0.26[-0.87,0.35]

-0.02[-0.65,0.61]

-0.43[-1.24,0.38]

-0.23[-0.44,-0.03]

100%

-0.41[-0.59,-0.23]

Favours PT+AD

-4

-2

0

2

4

Favours PT

Analysis 4.7.   Comparison 4 PD+/-AGORAPHOBIA: Psychotherapy+Antidepressant
vs Psychotherapy alone or +Placebo, Outcome 7 Depression at 2-4 months.

Study or subgroup

PT+AD

PT

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

4.7.1 Behaviour therapy

de Beurs 1995i

de Beurs 1995ii

Fava 1997

Johnston 1995

Marks 1983

Mavissakalian 1986a

Mavissakalian 1986b

Sheehan 1980a

Sheehan 1980b

Telch 1985

Zitrin 1983

Subtotal ***

10

9

7

12

23

17

14

18

17

10

34

2.6 (1)

2.6 (1)

1 (0)

0.8 (0.5)

4 (4.9)

2.8 (8.5)

8.7 (8.5)

51.1 (9.4)

45.4 (9)

13.4 (5.7)

1.3 (0.5)

19

18

7

17

22

14

17

11

11

9

34

3.5 (1.4)

3.8 (1.5)

1.1 (0.4)

1 (0.8)

4 (2.7)

7.7 (8.7)

6.9 (8.7)

57.7 (10.1)

57.7 (10.1)

13 (11.9)

1.6 (0.5)

171

179

Heterogeneity: Tau2=0.05; Chi2=12.1, df=9(P=0.21); I2=25.62%

Test for overall effect: Z=3.21(P=0)

4.7.2 Cognitive-behaviour therapy

5.3%

4.76%

5.88%

8.81%

6.17%

6.37%

5.5%

4.75%

4.17%

11.82%

63.54%

-0.68[-1.46,0.11]

-0.86[-1.7,-0.02]

Not estimable

-0.28[-1.02,0.46]

0[-0.58,0.58]

-0.56[-1.28,0.17]

0.2[-0.51,0.91]

-0.66[-1.43,0.11]

-1.26[-2.1,-0.42]

0.04[-0.86,0.94]

-0.51[-1,-0.03]

-0.43[-0.69,-0.17]

Azhar 2000

17

9.2 (1.4)

17

10 (0.6)

6.56%

-0.74[-1.44,-0.04]

Favours PT+AD

-4

-2

0

2

4

Favours PT

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

89

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

PT+AD

PT

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

Fahy 1992

Loerch 1999

Spinhoven 1996

Stein 2000

Subtotal ***

5.6 (4.5)

5.6 (5.8)

43.5 (8.7)

-10.5 (10.4)

42

14

20

12

105

24

14

20

12

87

8.3 (5.1)

6.5 (5.2)

42.7 (10)

-8.6 (7.6)

Heterogeneity: Tau2=0; Chi2=4.13, df=4(P=0.39); I2=3.15%

Test for overall effect: Z=2.27(P=0.02)

Total ***

276

266

Heterogeneity: Tau2=0.02; Chi2=16.4, df=14(P=0.29); I2=14.64%

Test for overall effect: Z=3.99(P<0.0001)

Test for subgroup differences: Chi2=0.17, df=1 (P=0.68), I2=0%

10.87%

5.89%

8%

5.13%

36.46%

-0.56[-1.08,-0.05]

-0.16[-0.9,0.58]

0.08[-0.54,0.7]

-0.2[-1,0.6]

-0.34[-0.64,-0.05]

100%

-0.39[-0.59,-0.2]

Favours PT+AD

-4

-2

0

2

4

Favours PT

Analysis 4.8.   Comparison 4 PD+/-AGORAPHOBIA: Psychotherapy+Antidepressant vs
Psychotherapy alone or +Placebo, Outcome 8 Social malfunctioning at 2-4 months.

Study or subgroup

PT+AD

PT

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

4.8.1 Behaviour therapy

Johnston 1995

Mavissakalian 1986a

Mavissakalian 1986b

Sheehan 1980a

Sheehan 1980b

Zitrin 1980

Zitrin 1983

Subtotal ***

2.1 (0.6)

2.3 (1)

2.4 (1)

3.1 (1.1)

2.4 (1.4)

1.1 (0.8)

1.2 (0.9)

12

17

14

18

17

25

34

137

Heterogeneity: Tau2=0.03; Chi2=7.7, df=6(P=0.26); I2=22.11%

Test for overall effect: Z=3.69(P=0)

4.8.2 Cognitive-behaviour therapy

Loerch 1999

Sharp 1996i

Sharp 1996ii

Stein 2000

Subtotal ***

2.4 (2.8)

1.4 (2.8)

1.4 (2.8)

-3.1 (2.5)

14

15

14

12

55

2 (0.8)

2.8 (1.1)

2.8 (1.1)

4 (1)

4 (1)

1.4 (1.1)

1.9 (0.9)

2.1 (2.2)

2.1 (2.6)

1.9 (2.6)

-4 (2.1)

16

14

17

11

11

20

34

123

14

33

30

12

89

Heterogeneity: Tau2=0; Chi2=1.9, df=3(P=0.59); I2=0%

Test for overall effect: Z=0.26(P=0.8)

Total ***

192

212

Heterogeneity: Tau2=0.06; Chi2=15.02, df=10(P=0.13); I2=33.42%

Test for overall effect: Z=2.79(P=0.01)

Test for subgroup differences: Chi2=5.42, df=1 (P=0.02), I2=81.55%

8.05%

8.53%

8.6%

7.57%

6.89%

10.97%

13.43%

64.05%

8.17%

10.52%

10.05%

7.21%

35.95%

0.14[-0.61,0.89]

-0.49[-1.21,0.23]

-0.38[-1.1,0.33]

-0.8[-1.58,-0.02]

-1.22[-2.06,-0.39]

-0.33[-0.92,0.26]

-0.78[-1.27,-0.28]

-0.55[-0.84,-0.26]

0.11[-0.63,0.85]

-0.27[-0.88,0.34]

-0.18[-0.82,0.46]

0.38[-0.43,1.18]

-0.04[-0.39,0.3]

100%

-0.36[-0.61,-0.11]

Favours PT+AD

-4

-2

0

2

4

Favours PT

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

90

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 4.9.   Comparison 4 PD+/-AGORAPHOBIA: Psychotherapy+Antidepressant vs
Psychotherapy alone or +Placebo, Outcome 9 Dropouts for any reason within 2-4 months.

PT+AD

n/N

PT

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

Study or subgroup

4.9.1 Behaviour therapy

de Beurs 1995i

de Beurs 1995ii

Fava 1997

Johnston 1995

Marks 1983

Sheehan 1980a

Sheehan 1980b

Telch 1985

Zitrin 1980

Zitrin 1983

Subtotal (95% CI)

Total events: 74 (PT+AD), 58 (PT)

3/12

2/12

0/7

16/26

13/36

7/28

9/29

3/13

12/41

9/43

247

Heterogeneity: Tau2=0; Chi2=3.32, df=8(P=0.91); I2=0%

Test for overall effect: Z=1.22(P=0.22)

4.9.2 Cognitive-behaviour therapy

Barlow 2000i

Barlow 2000ii

Fahy 1992

Kampman 2002

Loerch 1999

Oehrberg 1995

Sharp 1996i

Sharp 1996ii

Spinhoven 1996

Stein 2000

Subtotal (95% CI)

9/33

9/32

12/53

3/22

3/14

5/60

6/19

5/19

4/20

1/16

288

Total events: 57 (PT+AD), 71 (PT)

Heterogeneity: Tau2=0; Chi2=8.22, df=9(P=0.51); I2=0%

Test for overall effect: Z=0.86(P=0.39)

5/24

3/21

0/7

10/27

14/36

3/16

2/14

3/12

11/35

7/41

233

18/63

21/77

3/26

2/21

1/14

8/60

4/36

13/43

0/20

1/17

377

3.05%

1.77%

14.33%

13.43%

3.3%

2.47%

2.46%

10.28%

6.04%

57.14%

10.35%

10.89%

3.47%

1.68%

1.05%

4.27%

3.71%

6.2%

0.59%

0.66%

1.2[0.34,4.2]

1.17[0.23,6.03]

Not estimable

1.66[0.93,2.96]

0.93[0.51,1.69]

1.33[0.4,4.45]

2.17[0.54,8.75]

0.92[0.23,3.72]

0.93[0.47,1.84]

1.23[0.5,2.99]

1.2[0.9,1.6]

0.95[0.48,1.88]

1.03[0.53,2]

1.96[0.61,6.35]

1.43[0.27,7.73]

3[0.35,25.46]

0.63[0.22,1.8]

2.84[0.91,8.86]

0.87[0.36,2.1]

9[0.52,156.91]

1.06[0.07,15.6]

42.86%

1.16[0.83,1.62]

Total (95% CI)

535

610

100%

1.18[0.95,1.47]

Total events: 131 (PT+AD), 129 (PT)

Heterogeneity: Tau2=0; Chi2=11.51, df=18(P=0.87); I2=0%

Test for overall effect: Z=1.48(P=0.14)

Test for subgroup differences: Not applicable

Favours PT+AD

0.1

0.2

0.5

1

2

5

10

Favours PT

Analysis 4.10.   Comparison 4 PD+/-AGORAPHOBIA: Psychotherapy+Antidepressant vs
Psychotherapy alone or +Placebo, Outcome 10 Dropouts due to side effects within 2-4 months.

Study or subgroup

4.10.1 Behaviour therapy

de Beurs 1995i

de Beurs 1995ii

PT+AD

n/N

PT

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

1/12

1/12

0/24

0/21

4%

4.01%

5.77[0.25,131.92]

5.08[0.22,115.7]

Favours PT+AD

0.1

0.2

0.5

1

2

5

10

Favours PT

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

91

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

PT+AD

n/N

PT

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

Study or subgroup

Marks 1983

Telch 1985

Zitrin 1980

Subtotal (95% CI)

Total events: 15 (PT+AD), 7 (PT)

2/36

3/13

8/41

114

Heterogeneity: Tau2=0; Chi2=2.47, df=4(P=0.65); I2=0%

Test for overall effect: Z=1.59(P=0.11)

4.10.2 Cognitive-behaviour therapy

Barlow 2000i

Barlow 2000ii

Fahy 1992

Kampman 2002

Oehrberg 1995

Sharp 1996i

Sharp 1996ii

Spinhoven 1996

Subtotal (95% CI)

1/33

1/32

7/53

3/22

4/60

3/19

2/19

4/20

258

Total events: 25 (PT+AD), 2 (PT)

Heterogeneity: Tau2=0; Chi2=3.33, df=7(P=0.85); I2=0%

Test for overall effect: Z=3.38(P=0)

3/36

1/12

3/35

128

0/63

0/77

0/26

2/21

0/60

0/36

0/43

0/20

346

13.13%

8.7%

25.19%

55.03%

3.89%

3.89%

4.91%

13.79%

4.66%

4.62%

4.39%

4.8%

44.97%

0.67[0.12,3.75]

2.77[0.33,23.14]

2.28[0.65,7.93]

1.99[0.85,4.62]

5.65[0.24,134.91]

7.09[0.3,169.6]

7.5[0.44,126.48]

1.43[0.27,7.73]

9[0.5,163.58]

12.95[0.7,238.39]

11[0.55,218.74]

9[0.52,156.91]

5[1.96,12.72]

Total (95% CI)

372

474

100%

3.01[1.61,5.63]

Total events: 40 (PT+AD), 9 (PT)

Heterogeneity: Tau2=0; Chi2=7.96, df=12(P=0.79); I2=0%

Test for overall effect: Z=3.45(P=0)

Test for subgroup differences: Not applicable

Favours PT+AD

0.1

0.2

0.5

1

2

5

10

Favours PT

Analysis 4.11.   Comparison 4 PD+/-AGORAPHOBIA: Psychotherapy+Antidepressant vs
Psychotherapy alone or +Placebo, Outcome 11 Response/remission on continued treatment.

PT+AD

n/N

PT

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

Study or subgroup

4.11.1 Behaviour therapy

Telch 1985

Zitrin 1980

Subtotal (95% CI)

Total events: 33 (PT+AD), 19 (PT)

7/13

26/41

54

Heterogeneity: Tau2=0.17; Chi2=1.66, df=1(P=0.2); I2=39.69%

Test for overall effect: Z=1.22(P=0.22)

4.11.2 Cognitive-behaviour therapy

Barlow 2000i

Barlow 2000ii

Subtotal (95% CI)

19/33

18/32

65

Total events: 37 (PT+AD), 64 (PT)

Heterogeneity: Tau2=0; Chi2=0.39, df=1(P=0.53); I2=0%

Test for overall effect: Z=1.48(P=0.14)

2/12

17/35

47

32/63

32/77

140

2.78%

30.22%

33%

3.23[0.83,12.61]

1.31[0.86,1.97]

1.64[0.74,3.61]

35.53%

31.47%

67%

1.13[0.77,1.66]

1.35[0.9,2.03]

1.23[0.93,1.63]

Favours PT

0.1

0.2

0.5

1

2

5

10

Favours PT+AD

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

92

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

PT+AD

n/N

PT

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

Total (95% CI)

119

187

100%

1.29[1.03,1.62]

Total events: 70 (PT+AD), 83 (PT)

Heterogeneity: Tau2=0; Chi2=2.3, df=3(P=0.51); I2=0%

Test for overall effect: Z=2.19(P=0.03)

Test for subgroup differences: Not applicable

Favours PT

0.1

0.2

0.5

1

2

5

10

Favours PT+AD

Analysis 4.12.   Comparison 4 PD+/-AGORAPHOBIA: Psychotherapy+Antidepressant vs
Psychotherapy alone or +Placebo, Outcome 12 Global/Avoidance/Panic on continued treatment.

Study or subgroup

PT+AD

PT

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

4.12.1 Behaviour therapy

Johnston 1995

Telch 1985

Zitrin 1980

Subtotal ***

5.4 (5.7)

12.6 (8.1)

1.5 (0.7)

12

10

29

51

Heterogeneity: Tau2=0; Chi2=1.84, df=2(P=0.4); I2=0%

Test for overall effect: Z=4.44(P<0.0001)

4.12.2 Cognitive-behaviour therapy

Barlow 2000i

Barlow 2000ii

Subtotal ***

0.8 (0.9)

0.8 (0.9)

33

32

65

Heterogeneity: Tau2=0; Chi2=0.1, df=1(P=0.75); I2=0%

Test for overall effect: Z=2.73(P=0.01)

14.6 (9.1)

25.6 (8.8)

2 (0.9)

1.1 (0.8)

1.2 (0.9)

17

9

24

50

63

77

140

Total ***

116

190

Heterogeneity: Tau2=0.04; Chi2=6.13, df=4(P=0.19); I2=34.79%

Test for overall effect: Z=4.01(P<0.0001)

Test for subgroup differences: Chi2=4.19, df=1 (P=0.04), I2=76.16%

12.48%

8.09%

21.03%

41.6%

-1.13[-1.94,-0.33]

-1.47[-2.51,-0.43]

-0.72[-1.27,-0.16]

-0.95[-1.37,-0.53]

28.94%

29.47%

58.4%

-0.37[-0.79,0.06]

-0.46[-0.88,-0.04]

-0.41[-0.71,-0.12]

100%

-0.65[-0.97,-0.33]

Favours PT+AD

-4

-2

0

2

4

Favours PT

Analysis 4.13.   Comparison 4 PD+/-AGORAPHOBIA: Psychotherapy+Antidepressant vs
Psychotherapy alone or +Placebo, Outcome 13 Dropouts for any reason on continued treatment.

PT+AD

n/N

PT

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

1/10

10

0/9

9

10.96%

10.96%

2.73[0.12,59.57]

2.73[0.12,59.57]

Study or subgroup

4.13.1 Behaviour therapy

Telch 1985

Subtotal (95% CI)

Total events: 1 (PT+AD), 0 (PT)

Heterogeneity: Not applicable

Test for overall effect: Z=0.64(P=0.52)

4.13.2 Cognitive-behaviour therapy

Favours PT+AD

0.1

0.2

0.5

1

2

5

10

Favours PT

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

93

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Barlow 2000i

Barlow 2000ii

Subtotal (95% CI)

PT+AD

n/N

PT

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

2/33

2/32

65

6/63

7/77

140

43.72%

45.32%

89.04%

0.64[0.14,2.98]

0.69[0.15,3.13]

0.66[0.22,1.95]

Total events: 4 (PT+AD), 13 (PT)

Heterogeneity: Tau2=0; Chi2=0, df=1(P=0.94); I2=0%

Test for overall effect: Z=0.75(P=0.45)

Total (95% CI)

75

149

100%

0.77[0.28,2.15]

Total events: 5 (PT+AD), 13 (PT)

Heterogeneity: Tau2=0; Chi2=0.73, df=2(P=0.7); I2=0%

Test for overall effect: Z=0.49(P=0.62)

Test for subgroup differences: Not applicable

Favours PT+AD

0.1

0.2

0.5

1

2

5

10

Favours PT

Analysis 4.14.   Comparison 4 PD+/-AGORAPHOBIA: Psychotherapy+Antidepressant vs Psychotherapy
alone or +Placebo, Outcome 14 Response/remission 6-24 months after treatment discontinuation.

PT+AD

n/N

PT

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

Study or subgroup

4.14.1 Behaviour therapy

de Beurs 1995i

de Beurs 1995ii

Fava 1997

Marks 1983

Mavissakalian 1986a

Mavissakalian 1986b

Zitrin 1983

Subtotal (95% CI)

6/12

6/12

2/7

9/36

6/20

6/20

23/43

150

Total events: 58 (PT+AD), 68 (PT)

Heterogeneity: Tau2=0; Chi2=1.65, df=6(P=0.95); I2=0%

Test for overall effect: Z=0.03(P=0.98)

4.14.2 Cognitive-behaviour therapy

Barlow 2000i

Barlow 2000ii

Loerch 1999

Sharp 1996i

Sharp 1996ii

Subtotal (95% CI)

Total events: 41 (PT+AD), 90 (PT)

8/30

8/29

9/14

8/19

8/19

111

Heterogeneity: Tau2=0; Chi2=1.79, df=4(P=0.77); I2=0%

Test for overall effect: Z=0.66(P=0.51)

12/24

10/21

4/7

11/36

5/20

6/20

20/41

169

25/62

24/73

9/14

17/36

15/43

228

7.83%

7.21%

2.11%

6.68%

3.67%

4.19%

21.35%

53.03%

8.47%

8.26%

12.33%

9.46%

8.45%

46.97%

1[0.5,2]

1.05[0.51,2.16]

0.5[0.13,1.9]

0.82[0.39,1.73]

1.2[0.44,3.3]

1[0.39,2.58]

1.1[0.72,1.67]

1[0.77,1.31]

0.66[0.34,1.29]

0.84[0.43,1.65]

1[0.58,1.74]

0.89[0.47,1.67]

1.21[0.62,2.35]

0.91[0.69,1.21]

Total (95% CI)

261

397

100%

0.96[0.79,1.16]

Total events: 99 (PT+AD), 158 (PT)

Heterogeneity: Tau2=0; Chi2=3.68, df=11(P=0.98); I2=0%

Test for overall effect: Z=0.43(P=0.67)

Test for subgroup differences: Not applicable

Favours PT

0.2

0.5

1

2

5

Favours PT+AD

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

94

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 4.15.   Comparison 4 PD+/-AGORAPHOBIA: Psychotherapy+Antidepressant vs Psychotherapy
alone or +Placebo, Outcome 15 Global/Avoidance/Panic 6-24 months after treatment discontinuation.

Study or subgroup

PT+AD

PT

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

4.15.1 Behaviour therapy

de Beurs 1995i

de Beurs 1995ii

Marks 1983

Mavissakalian 1986a

Mavissakalian 1986b

Subtotal ***

3.3 (2.4)

3.3 (2.4)

14.1 (2.7)

2.1 (1.4)

2 (1.2)

9

9

22

14

11

65

19

17

18

11

11

76

3.2 (2.7)

3.5 (2.2)

13.7 (2.8)

3.3 (2.6)

1.3 (0.5)

Heterogeneity: Tau2=0.03; Chi2=4.73, df=4(P=0.32); I2=15.36%

Test for overall effect: Z=0.28(P=0.78)

4.15.2 Cognitive-behviour therapy

Barlow 2000i

Barlow 2000ii

Subtotal ***

30

29

59

1.5 (0.9)

1.5 (0.9)

62

73

135

1.2 (0.9)

1.3 (0.9)

Heterogeneity: Tau2=0; Chi2=0.27, df=1(P=0.6); I2=0%

Test for overall effect: Z=1.34(P=0.18)

8.3%

8%

13.42%

7.98%

6.94%

44.63%

27.21%

28.16%

55.37%

0.07[-0.72,0.86]

-0.05[-0.86,0.76]

0.14[-0.48,0.77]

-0.58[-1.39,0.23]

0.71[-0.16,1.58]

0.05[-0.32,0.43]

0.29[-0.14,0.73]

0.13[-0.3,0.56]

0.21[-0.1,0.52]

Total ***

124

211

100%

0.14[-0.09,0.37]

Heterogeneity: Tau2=0; Chi2=5.44, df=6(P=0.49); I2=0%

Test for overall effect: Z=1.2(P=0.23)

Test for subgroup differences: Chi2=0.45, df=1 (P=0.5), I2=0%

Favours PT+AD

-4

-2

0

2

4

Favours PT

Comparison 5.   SUBGROUP2: TCA: Psychotherapy+Antidepressant vs Antidepressant alone

Outcome or subgroup title

1 Response at 2-4 months

1.1 Behaviour therapy

1.2 Cognitive-behaviour therapy

1.3 Psychodynamic psychotherapy and others

2 Remission at 2-4 months

2.1 Behaviour therapy

No. of
studies

No. of
partici-
pants

Statistical method

Effect size

7

4

2

1

4

2

421

193

188

40

302

114

Risk Ratio (M-H, Random,
95% CI)

1.23 [1.04, 1.45]

Risk Ratio (M-H, Random,
95% CI)

1.06 [0.80, 1.40]

Risk Ratio (M-H, Random,
95% CI)

1.27 [0.94, 1.71]

Risk Ratio (M-H, Random,
95% CI)

1.41 [1.05, 1.90]

Risk Ratio (M-H, Random,
95% CI)

1.26 [1.06, 1.51]

Risk Ratio (M-H, Random,
95% CI)

0.97 [0.62, 1.51]

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

95

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Outcome or subgroup title

2.2 Cognitive-behaviour therapy

2.3 Psychodynamic psychotherapy and others

3 Global severity at 2-4 months

3.1 Behaviour therapy

3.2 Cognitive-behaviour therapy

3.3 Psychodynamic psychotherapy and others

4 Frequency of panic attacks at 2-4 months

4.1 Behaviour therapy

4.2 Cognitive-behaviour therapy

4.3 Psychodynamic psychotherapy and others

5 Phobic avoidance at 2-4 months

5.1 Behaviour therapy

5.2 Cognitive-behaviour therapy

5.3 Psychodynamic psychotherapy and others

6 General anxiety at 2-4 months

6.1 Behaviour therapy

6.2 Cognitive-behaviour therapy

6.3 Psychodynamic psychotherapy and others

Cochrane Database of Systematic Reviews

No. of
studies

No. of
partici-
pants

Statistical method

Effect size

1

1

4

2

1

1

6

4

1

1

7

4

2

1

3

2

0

1

148

40

278

90

148

40

217

138

39

40

275

138

97

40

130

90

0

40

Risk Ratio (M-H, Random,
95% CI)

1.34 [1.01, 1.79]

Risk Ratio (M-H, Random,
95% CI)

1.32 [1.02, 1.72]

Std. Mean Difference (IV,
Random, 95% CI)

-0.35 [-0.66, -0.04]

Std. Mean Difference (IV,
Random, 95% CI)

-0.51 [-1.45, 0.44]

Std. Mean Difference (IV,
Random, 95% CI)

-0.22 [-0.55, 0.10]

Std. Mean Difference (IV,
Random, 95% CI)

-0.69 [-1.33, -0.05]

Std. Mean Difference (IV,
Random, 95% CI)

-0.10 [-0.39, 0.20]

Std. Mean Difference (IV,
Random, 95% CI)

-0.15 [-0.49, 0.19]

Std. Mean Difference (IV,
Random, 95% CI)

0.08 [-0.55, 0.71]

Std. Mean Difference (IV,
Random, 95% CI)

0.0 [0.0, 0.0]

Std. Mean Difference (IV,
Random, 95% CI)

-0.33 [-0.65, -0.00]

Std. Mean Difference (IV,
Random, 95% CI)

-0.53 [-1.01, -0.06]

Std. Mean Difference (IV,
Random, 95% CI)

0.06 [-0.34, 0.46]

Std. Mean Difference (IV,
Random, 95% CI)

-0.60 [-1.23, 0.04]

Std. Mean Difference (IV,
Random, 95% CI)

-0.63 [-1.43, 0.17]

Std. Mean Difference (IV,
Random, 95% CI)

-0.19 [-0.60, 0.23]

Std. Mean Difference (IV,
Random, 95% CI)

0.0 [0.0, 0.0]

Std. Mean Difference (IV,
Random, 95% CI)

-1.32 [-2.01, -0.63]

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

96

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

7 Depression at 2-4 months

7.1 Behaviour therapy

7.2 Cognitive-behaviour therapy

7.3 Psychodynamic psychotherapy and others

8 Social functioning at 2-4 months

8.1 Behavour therapy

8.2 Cognitive-behaviour therapy

8.3 Psychodynamic psychotherapy and others

9 Dropouts for any reason within 2-4 months

9.1 Behaviour therapy

9.2 Cognitive-behaviour therapy

9.3 Psychodynamic psychotherapy and others

10 Dropouts due to side effects within 2-4
months

10.1 Behaviour therapy

10.2 Cognitive-behaviour therapy

10.3 Psychodynamic psychotherapy and others

11 Response/remission on continued treatment

11.1 Behaviour therapy

No. of
studies

No. of
partici-
pants

Statistical method

Effect size

6

4

1

1

4

3

0

1

7

4

2

1

5

2

2

1

4

2

217

138

39

40

158

118

0

40

421

193

188

40

271

43

188

40

309

121

Std. Mean Difference (IV,
Random, 95% CI)

-0.41 [-0.68, -0.14]

Std. Mean Difference (IV,
Random, 95% CI)

-0.35 [-0.69, -0.01]

Std. Mean Difference (IV,
Random, 95% CI)

-0.25 [-0.88, 0.38]

Std. Mean Difference (IV,
Random, 95% CI)

-0.79 [-1.44, -0.14]

Std. Mean Difference (IV,
Random, 95% CI)

-0.45 [-0.84, -0.07]

Std. Mean Difference (IV,
Random, 95% CI)

-0.30 [-0.68, 0.08]

Std. Mean Difference (IV,
Random, 95% CI)

0.0 [0.0, 0.0]

Std. Mean Difference (IV,
Random, 95% CI)

-0.81 [-1.46, -0.16]

Risk Ratio (M-H, Random,
95% CI)

0.97 [0.71, 1.32]

Risk Ratio (M-H, Random,
95% CI)

1.21 [0.78, 1.88]

Risk Ratio (M-H, Random,
95% CI)

0.75 [0.48, 1.17]

Risk Ratio (M-H, Random,
95% CI)

3.00 [0.13, 69.52]

Risk Ratio (M-H, Random,
95% CI)

0.78 [0.34, 1.83]

Risk Ratio (M-H, Random,
95% CI)

0.97 [0.27, 3.58]

Risk Ratio (M-H, Random,
95% CI)

0.57 [0.10, 3.28]

Risk Ratio (M-H, Random,
95% CI)

3.00 [0.13, 69.52]

Risk Ratio (M-H, Random,
95% CI)

1.63 [1.21, 2.19]

Risk Ratio (M-H, Random,
95% CI)

1.94 [1.10, 3.41]

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

97

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Outcome or subgroup title

11.2 Cognitive-behaviour therapy

11.3 Psychdynamic psychotherapy and others

12 Global/Avoidance/Panic on continued treat-
ment

12.1 Behaviour therapy

12.2 Cognitive-behaviour therapy

12.3 Psychodynamic psychotherapy and others

13 Dropouts for any reason on continued treat-
ment

13.1 Behaviour therapy

13.2 Cognitive-behaviour therapy

13.3 Psychodynamic psychotherapy and others

14 Response/remission immediately after treat-
ment discontinuation

14.1 Behaviour therapy

14.2 Cognitive-behaviour therapy

14.3 Psychodynamic psychotherapy and others

15 Global/Avoidance/Panic immediately after
treatment discontinuation

15.1 Behaviour therapy

15.2 Cognitive-behaviour therapy

15.3 Psychodynamic psychotherapy and others

Cochrane Database of Systematic Reviews

No. of
studies

No. of
partici-
pants

Statistical method

Effect size

1

1

4

2

1

1

3

1

1

1

0

0

0

0

0

0

0

0

148

40

236

48

148

40

208

20

148

40

0

0

0

0

0

0

0

0

Risk Ratio (M-H, Random,
95% CI)

1.52 [1.07, 2.16]

Risk Ratio (M-H, Random,
95% CI)

0.0 [0.0, 0.0]

Std. Mean Difference (IV,
Random, 95% CI)

-0.62 [-0.92, -0.31]

Std. Mean Difference (IV,
Random, 95% CI)

-0.91 [-1.51, -0.30]

Std. Mean Difference (IV,
Random, 95% CI)

-0.41 [-0.74, -0.09]

Std. Mean Difference (IV,
Random, 95% CI)

-0.85 [-1.50, -0.20]

Risk Ratio (M-H, Random,
95% CI)

0.71 [0.27, 1.90]

Risk Ratio (M-H, Random,
95% CI)

1.0 [0.07, 13.87]

Risk Ratio (M-H, Random,
95% CI)

0.73 [0.22, 2.39]

Risk Ratio (M-H, Random,
95% CI)

0.5 [0.05, 5.08]

Risk Ratio (M-H, Random,
95% CI)

0.0 [0.0, 0.0]

Risk Ratio (M-H, Random,
95% CI)

0.0 [0.0, 0.0]

Risk Ratio (M-H, Random,
95% CI)

0.0 [0.0, 0.0]

Risk Ratio (M-H, Random,
95% CI)

0.0 [0.0, 0.0]

Std. Mean Difference (IV,
Random, 95% CI)

0.0 [0.0, 0.0]

Std. Mean Difference (IV,
Random, 95% CI)

0.0 [0.0, 0.0]

Std. Mean Difference (IV,
Random, 95% CI)

0.0 [0.0, 0.0]

Std. Mean Difference (IV,
Random, 95% CI)

0.0 [0.0, 0.0]

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

98

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of
studies

No. of
partici-
pants

Statistical method

Effect size

16 Response/remission 6-24 months after treat-
ment discontinuation

16.1 Behaviour therapy

16.2 Cognitive-behaviour therapy

16.3 Psychodynamic psychotherapy and others

17 Global/Avoidance/Panic 6-24 months after
treatment discontinuation

17.1 Behaviour therapy

17.2 Cognitive-behaviour therapy

17.3 Psychodynamic psychotherapy and others

3

1

1

1

2

0

1

1

272

96

136

40

176

0

136

40

Risk Ratio (M-H, Random,
95% CI)

1.74 [1.12, 2.69]

Risk Ratio (M-H, Random,
95% CI)

1.49 [0.95, 2.35]

Risk Ratio (M-H, Random,
95% CI)

1.39 [0.75, 2.58]

Risk Ratio (M-H, Random,
95% CI)

3.2 [1.45, 7.05]

Std. Mean Difference (IV,
Random, 95% CI)

-0.58 [-1.78, 0.63]

Std. Mean Difference (IV,
Random, 95% CI)

0.0 [0.0, 0.0]

Std. Mean Difference (IV,
Random, 95% CI)

0.0 [-0.34, 0.34]

Std. Mean Difference (IV,
Random, 95% CI)

-1.23 [-1.91, -0.55]

Analysis 5.1.   Comparison 5 SUBGROUP2: TCA: Psychotherapy
+Antidepressant vs Antidepressant alone, Outcome 1 Response at 2-4 months.

PT+AD

n/N

AD

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

5/26

6/9

1/12

32/53

100

38/83

5/20

103

2.69%

8.27%

0.69%

24.78%

36.43%

1.3[0.47,3.59]

1.17[0.65,2.08]

4.62[0.63,34.05]

0.96[0.69,1.35]

1.06[0.8,1.4]

29.43%

2.06%

31.5%

1.31[0.96,1.78]

0.8[0.25,2.55]

1.27[0.94,1.71]

Study or subgroup

5.1.1 Behaviour therapy

Johnston 1995

Mavissakalian 1983

Telch 1985

Zitrin 1983

Subtotal (95% CI)

7/28

7/9

5/13

25/43

93

Total events: 44 (PT+AD), 44 (AD)

Heterogeneity: Tau2=0; Chi2=2.86, df=3(P=0.41); I2=0%

Test for overall effect: Z=0.41(P=0.68)

5.1.2 Cognitive-behaviour therapy

Barlow 2000

Spinhoven 1996

Subtotal (95% CI)

39/65

4/20

85

Total events: 43 (PT+AD), 43 (AD)

Heterogeneity: Tau2=0; Chi2=0.67, df=1(P=0.41); I2=0%

Test for overall effect: Z=1.57(P=0.12)

5.1.3 Psychodynamic psychotherapy and others

Wiborg 1996

20/20

14/20

32.07%

1.41[1.05,1.9]

Favours AD

0.1

0.2

0.5

1

2

5

10

Favours PT+AD

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

99

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

PT+AD

n/N

AD

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

Subtotal (95% CI)

20

20

32.07%

1.41[1.05,1.9]

Total events: 20 (PT+AD), 14 (AD)

Heterogeneity: Not applicable

Test for overall effect: Z=2.31(P=0.02)

Total (95% CI)

198

223

100%

1.23[1.04,1.45]

Total events: 107 (PT+AD), 101 (AD)

Heterogeneity: Tau2=0; Chi2=5.35, df=6(P=0.5); I2=0%

Test for overall effect: Z=2.44(P=0.01)

Test for subgroup differences: Not applicable

Favours AD

0.1

0.2

0.5

1

2

5

10

Favours PT+AD

Analysis 5.2.   Comparison 5 SUBGROUP2: TCA: Psychotherapy
+Antidepressant vs Antidepressant alone, Outcome 2 Remission at 2-4 months.

PT+AD

n/N

AD

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

6/9

13/43

52

6/9

17/53

62

7.39%

8.77%

16.15%

1[0.52,1.92]

0.94[0.52,1.72]

0.97[0.62,1.51]

Study or subgroup

5.2.1 Behaviour therapy

Mavissakalian 1983

Zitrin 1983

Subtotal (95% CI)

Total events: 19 (PT+AD), 23 (AD)

Heterogeneity: Tau2=0; Chi2=0.02, df=1(P=0.89); I2=0%

Test for overall effect: Z=0.14(P=0.89)

5.2.2 Cognitive-behaviour therapy

Barlow 2000

Subtotal (95% CI)

Total events: 42 (PT+AD), 40 (AD)

Heterogeneity: Not applicable

Test for overall effect: Z=2.01(P=0.04)

42/65

65

40/83

83

38.4%

38.4%

1.34[1.01,1.79]

1.34[1.01,1.79]

5.2.3 Psychodynamic psychotherapy and others

Wiborg 1996

Subtotal (95% CI)

Total events: 20 (PT+AD), 15 (AD)

Heterogeneity: Not applicable

Test for overall effect: Z=2.08(P=0.04)

20/20

20

15/20

20

45.45%

45.45%

1.32[1.02,1.72]

1.32[1.02,1.72]

Total (95% CI)

137

165

100%

1.26[1.06,1.51]

Total events: 81 (PT+AD), 78 (AD)

Heterogeneity: Tau2=0; Chi2=1.82, df=3(P=0.61); I2=0%

Test for overall effect: Z=2.59(P=0.01)

Test for subgroup differences: Not applicable

Favours AD

0.1

0.2

0.5

1

2

5

10

Favours PT+AD

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

100

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 5.3.   Comparison 5 SUBGROUP2: TCA: Psychotherapy+Antidepressant
vs Antidepressant alone, Outcome 3 Global severity at 2-4 months.

Study or subgroup

Treatment

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

3.7 (1.6)

3.3 (1)

1.1 (0.8)

2 (1.1)

5.3.1 Behaviour therapy

Mavissakalian 1983

Zitrin 1983

Subtotal ***

2.2 (0.8)

3.2 (1)

8

34

42

Heterogeneity: Tau2=0.31; Chi2=2.62, df=1(P=0.11); I2=61.84%

Test for overall effect: Z=1.05(P=0.29)

5.3.2 Cognitive-behaviour therapy

Barlow 2000

Subtotal ***

0.9 (0.7)

65

65

Heterogeneity: Not applicable

Test for overall effect: Z=1.34(P=0.18)

5.3.3 Psychodynamic psychotherapy and others

Wiborg 1996

Subtotal ***

1.4 (0.5)

20

20

Heterogeneity: Not applicable

Test for overall effect: Z=2.11(P=0.03)

7

41

48

83

83

20

20

Total ***

127

151

Heterogeneity: Tau2=0.03; Chi2=4.25, df=3(P=0.24); I2=29.4%

Test for overall effect: Z=2.2(P=0.03)

Test for subgroup differences: Chi2=1.63, df=1 (P=0.44), I2=0%

7.14%

30.25%

37.39%

-1.14[-2.26,-0.02]

-0.14[-0.6,0.31]

-0.51[-1.45,0.44]

43.99%

43.99%

-0.22[-0.55,0.1]

-0.22[-0.55,0.1]

18.62%

18.62%

-0.69[-1.33,-0.05]

-0.69[-1.33,-0.05]

100%

-0.35[-0.66,-0.04]

Favours treatment

-4

-2

0

2

4

Favours control

Analysis 5.4.   Comparison 5 SUBGROUP2: TCA: Psychotherapy+Antidepressant
vs Antidepressant alone, Outcome 4 Frequency of panic attacks at 2-4 months.

Study or subgroup

Treatment

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

5.4.1 Behaviour therapy

Johnston 1995

Mavissakalian 1983

Telch 1985

Zitrin 1983

Subtotal ***

0.6 (0.9)

1.7 (1.9)

0.6 (1.1)

6 (1.2)

12

8

10

34

64

Heterogeneity: Tau2=0; Chi2=2.22, df=3(P=0.53); I2=0%

Test for overall effect: Z=0.86(P=0.39)

5.4.2 Cognitive-behaviour therapy

Spinhoven 1996

Subtotal ***

3 (2.5)

20

20

Heterogeneity: Not applicable

Test for overall effect: Z=0.25(P=0.8)

5.4.3 Psychodynamic psychotherapy and others

0.3 (0.7)

2.1 (1.8)

0.8 (1)

6.4 (1.2)

2.8 (2.3)

16

7

10

41

74

19

19

15.49%

8.51%

11.46%

42.16%

77.62%

0.35[-0.41,1.1]

-0.22[-1.24,0.8]

-0.14[-1.01,0.74]

-0.32[-0.78,0.14]

-0.15[-0.49,0.19]

22.38%

22.38%

0.08[-0.55,0.71]

0.08[-0.55,0.71]

Wiborg 1996

20

0 (0)

20

0.8 (2.1)

Not estimable

Favours treatment

-4

-2

0

2

4

Favours control

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

101

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Treatment

Control

Std. Mean Difference

Weight

Std. Mean Difference

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Not applicable

Mean(SD)

N

20

N

20

Mean(SD)

Random, 95% CI

Random, 95% CI

Not estimable

Total ***

104

113

100%

-0.1[-0.39,0.2]

Heterogeneity: Tau2=0; Chi2=2.62, df=4(P=0.62); I2=0%

Test for overall effect: Z=0.64(P=0.52)

Test for subgroup differences: Chi2=0.4, df=1 (P=0.53), I2=0%

Favours treatment

-4

-2

0

2

4

Favours control

Analysis 5.5.   Comparison 5 SUBGROUP2: TCA: Psychotherapy+Antidepressant
vs Antidepressant alone, Outcome 5 Phobic avoidance at 2-4 months.

Study or subgroup

Treatment

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

5.5.1 Behaviour therapy

Johnston 1995

Mavissakalian 1983

Telch 1985

Zitrin 1983

Subtotal ***

8.5 (8.4)

8.6 (6.2)

17.3 (10.3)

2.7 (1.4)

12

8

10

34

64

Heterogeneity: Tau2=0.09; Chi2=4.73, df=3(P=0.19); I2=36.59%

Test for overall effect: Z=2.19(P=0.03)

5.5.2 Cognitive-behaviour therapy

Sheehan 1980a

Spinhoven 1996

Subtotal ***

4.7 (7.8)

22.5 (12)

29

20

49

Heterogeneity: Tau2=0; Chi2=0.9, df=1(P=0.34); I2=0%

Test for overall effect: Z=0.28(P=0.78)

5.5.3 Psychodynamic psychotherapy and others

Wiborg 1996

Subtotal ***

1.1 (1.1)

20

20

Heterogeneity: Not applicable

Test for overall effect: Z=1.85(P=0.07)

13.9 (9)

19.4 (12.4)

28.4 (11.2)

2.8 (1.4)

5.5 (7.9)

18.7 (13.3)

2.6 (3.3)

16

7

10

41

74

29

19

48

20

20

Total ***

133

142

Heterogeneity: Tau2=0.07; Chi2=9.94, df=6(P=0.13); I2=39.62%

Test for overall effect: Z=1.97(P=0.05)

Test for subgroup differences: Chi2=4.3, df=1 (P=0.12), I2=53.53%

12.12%

6.99%

9.04%

21.62%

49.77%

-0.6[-1.37,0.17]

-1.07[-2.18,0.04]

-0.99[-1.93,-0.05]

-0.11[-0.56,0.35]

-0.53[-1.01,-0.06]

19.31%

15.51%

34.82%

-0.1[-0.62,0.41]

0.29[-0.34,0.93]

0.06[-0.34,0.46]

15.41%

15.41%

-0.6[-1.23,0.04]

-0.6[-1.23,0.04]

100%

-0.33[-0.65,-0]

Favours treatment

-4

-2

0

2

4

Favours control

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

102

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 5.6.   Comparison 5 SUBGROUP2: TCA: Psychotherapy+Antidepressant
vs Antidepressant alone, Outcome 6 General anxiety at 2-4 months.

Study or subgroup

Treatment

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

5.6.1 Behaviour therapy

Mavissakalian 1983

Zitrin 1983

Subtotal ***

27.3 (4.8)

21.5 (9.9)

8

34

42

Heterogeneity: Tau2=0; Chi2=0.39, df=1(P=0.53); I2=0%

Test for overall effect: Z=0.88(P=0.38)

5.6.2 Cognitive-behaviour therapy

Subtotal ***

0

Heterogeneity: Not applicable

Test for overall effect: Not applicable

5.6.3 Psychodynamic psychotherapy and others

5.5 (4.7)

Wiborg 1996

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=3.74(P=0)

Total ***

20

20

62

Heterogeneity: Tau2=0.37; Chi2=7.93, df=2(P=0.02); I2=74.77%

Test for overall effect: Z=1.54(P=0.12)

Test for subgroup differences: Chi2=7.53, df=1 (P=0.01), I2=86.73%

7

41

48

0

20

20

68

32.3 (13.1)

22.8 (9.9)

25.96%

39.88%

65.84%

-0.49[-1.53,0.54]

-0.13[-0.58,0.33]

-0.19[-0.6,0.23]

Not estimable

16 (10)

34.16%

34.16%

-1.32[-2.01,-0.63]

-1.32[-2.01,-0.63]

100%

-0.63[-1.43,0.17]

Favours treatment

-4

-2

0

2

4

Favours control

Analysis 5.7.   Comparison 5 SUBGROUP2: TCA: Psychotherapy
+Antidepressant vs Antidepressant alone, Outcome 7 Depression at 2-4 months.

Study or subgroup

Treatment

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

5.7.1 Behaviour therapy

Johnston 1995

Mavissakalian 1983

Telch 1985

Zitrin 1983

Subtotal ***

0.8 (0.5)

2.4 (2)

13.4 (5.7)

1.3 (0.5)

12

8

10

34

64

Heterogeneity: Tau2=0; Chi2=2.28, df=3(P=0.52); I2=0%

Test for overall effect: Z=2.01(P=0.04)

5.7.2 Cognitive-behaviour therapy

Spinhoven 1996

Subtotal ***

43.5 (8.7)

20

20

Heterogeneity: Not applicable

Test for overall effect: Z=0.78(P=0.44)

5.7.3 Psychodynamic psychotherapy and others

Wiborg 1996

Subtotal ***

3.6 (2.7)

20

20

1 (0.9)

9.1 (7.8)

14.7 (14.1)

1.5 (0.5)

46 (10.8)

7.4 (6.1)

16

7

10

41

74

19

19

20

20

13.04%

5.88%

9.58%

35.26%

63.76%

-0.27[-1.02,0.48]

-1.14[-2.26,-0.02]

-0.12[-0.99,0.76]

-0.31[-0.77,0.15]

-0.35[-0.69,-0.01]

18.56%

18.56%

-0.25[-0.88,0.38]

-0.25[-0.88,0.38]

17.68%

17.68%

-0.79[-1.44,-0.14]

-0.79[-1.44,-0.14]

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

103

Favours treatment

-4

-2

0

2

4

Favours control

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Treatment

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

Heterogeneity: Not applicable

Test for overall effect: Z=2.4(P=0.02)

Total ***

104

113

100%

-0.41[-0.68,-0.14]

Heterogeneity: Tau2=0; Chi2=3.97, df=5(P=0.55); I2=0%

Test for overall effect: Z=2.95(P=0)

Test for subgroup differences: Chi2=1.7, df=1 (P=0.43), I2=0%

Favours treatment

-4

-2

0

2

4

Favours control

Analysis 5.8.   Comparison 5 SUBGROUP2: TCA: Psychotherapy+Antidepressant
vs Antidepressant alone, Outcome 8 Social functioning at 2-4 months.

Study or subgroup

Treatment

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

2.3 (0.7)

2.9 (0.9)

6 (0.9)

3 (2.7)

5.8.1 Behavour therapy

Johnston 1995

Mavissakalian 1983

Zitrin 1983

Subtotal ***

2.1 (0.6)

1.9 (0.9)

5.8 (0.9)

12

8

34

54

Heterogeneity: Tau2=0.01; Chi2=2.08, df=2(P=0.35); I2=3.92%

Test for overall effect: Z=1.53(P=0.13)

5.8.2 Cognitive-behaviour therapy

Subtotal ***

0

Heterogeneity: Not applicable

Test for overall effect: Not applicable

5.8.3 Psychodynamic psychotherapy and others

1.2 (1.5)

Wiborg 1996

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=2.45(P=0.01)

Total ***

20

20

74

Heterogeneity: Tau2=0.04; Chi2=3.93, df=3(P=0.27); I2=23.7%

Test for overall effect: Z=2.31(P=0.02)

Test for subgroup differences: Chi2=1.85, df=1 (P=0.17), I2=45.94%

16

7

41

64

0

20

20

84

20.82%

10.85%

42.06%

73.73%

-0.28[-1.03,0.47]

-1.05[-2.15,0.06]

-0.17[-0.62,0.29]

-0.3[-0.68,0.08]

Not estimable

26.27%

26.27%

-0.81[-1.46,-0.16]

-0.81[-1.46,-0.16]

100%

-0.45[-0.84,-0.07]

Favours treatment

-4

-2

0

2

4

Favours control

Analysis 5.9.   Comparison 5 SUBGROUP2: TCA: Psychotherapy+Antidepressant
vs Antidepressant alone, Outcome 9 Dropouts for any reason within 2-4 months.

Study or subgroup

5.9.1 Behaviour therapy

Johnston 1995

Mavissakalian 1983

Treatment

n/N

Control

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

16/28

1/9

10/26

2/9

28.39%

1.96%

1.49[0.83,2.66]

0.5[0.05,4.58]

Favours treatment

0.1

0.2

0.5

1

2

5

10

Favours control

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

104

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Treatment

n/N

Control

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

2/12

12/53

100

32/83

4/20

103

3.72%

16.46%

50.53%

1.38[0.28,6.91]

0.92[0.43,1.99]

1.21[0.78,1.88]

42.23%

6.27%

48.49%

0.72[0.45,1.16]

1[0.29,3.45]

0.75[0.48,1.17]

Study or subgroup

Telch 1985

Zitrin 1983

Subtotal (95% CI)

3/13

9/43

93

Total events: 29 (Treatment), 26 (Control)

Heterogeneity: Tau2=0; Chi2=1.63, df=3(P=0.65); I2=0%

Test for overall effect: Z=0.87(P=0.38)

5.9.2 Cognitive-behaviour therapy

Barlow 2000

Spinhoven 1996

Subtotal (95% CI)

18/65

4/20

85

Total events: 22 (Treatment), 36 (Control)

Heterogeneity: Tau2=0; Chi2=0.24, df=1(P=0.63); I2=0%

Test for overall effect: Z=1.27(P=0.21)

5.9.3 Psychodynamic psychotherapy and others

Wiborg 1996

Subtotal (95% CI)

Total events: 1 (Treatment), 0 (Control)

Heterogeneity: Not applicable

Test for overall effect: Z=0.69(P=0.49)

1/20

20

0/20

20

0.97%

0.97%

3[0.13,69.52]

3[0.13,69.52]

Total (95% CI)

198

223

100%

0.97[0.71,1.32]

Total events: 52 (Treatment), 62 (Control)

Heterogeneity: Tau2=0; Chi2=4.64, df=6(P=0.59); I2=0%

Test for overall effect: Z=0.2(P=0.84)

Test for subgroup differences: Not applicable

Favours treatment

0.1

0.2

0.5

1

2

5

10

Favours control

Analysis 5.10.   Comparison 5 SUBGROUP2: TCA: Psychotherapy+Antidepressant vs
Antidepressant alone, Outcome 10 Dropouts due to side effects within 2-4 months.

Treatment

n/N

Control

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

Study or subgroup

5.10.1 Behaviour therapy

Mavissakalian 1983

Telch 1985

Subtotal (95% CI)

1/9

3/13

22

Total events: 4 (Treatment), 4 (Control)

Heterogeneity: Tau2=0; Chi2=0.53, df=1(P=0.47); I2=0%

Test for overall effect: Z=0.04(P=0.97)

5.10.2 Cognitive-behaviour therapy

Barlow 2000

Spinhoven 1996

Subtotal (95% CI)

2/65

4/20

85

Total events: 6 (Treatment), 14 (Control)

Heterogeneity: Tau2=1.08; Chi2=3.05, df=1(P=0.08); I2=67.26%

Test for overall effect: Z=0.63(P=0.53)

2/9

2/12

21

11/83

3/20

103

13.23%

23.08%

36.31%

0.5[0.05,4.58]

1.38[0.28,6.91]

0.97[0.27,3.58]

26.67%

30.1%

56.77%

0.23[0.05,1.01]

1.33[0.34,5.21]

0.57[0.1,3.28]

Favours treatment

0.1

0.2

0.5

1

2

5

10

Favours control

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

105

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Treatment

n/N

Control

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

5.10.3 Psychodynamic psychotherapy and others

Wiborg 1996

Subtotal (95% CI)

Total events: 1 (Treatment), 0 (Control)

Heterogeneity: Not applicable

Test for overall effect: Z=0.69(P=0.49)

1/20

20

0/20

20

6.92%

6.92%

3[0.13,69.52]

3[0.13,69.52]

Total (95% CI)

127

144

100%

0.78[0.34,1.83]

Total events: 11 (Treatment), 18 (Control)

Heterogeneity: Tau2=0.14; Chi2=4.69, df=4(P=0.32); I2=14.63%

Test for overall effect: Z=0.56(P=0.57)

Test for subgroup differences: Not applicable

Favours treatment

0.1

0.2

0.5

1

2

5

10

Favours control

Analysis 5.11.   Comparison 5 SUBGROUP2: TCA: Psychotherapy+Antidepressant vs
Antidepressant alone, Outcome 11 Response/remission on continued treatment.

Study or subgroup

5.11.1 Behaviour therapy

Telch 1985

Zitrin 1983

Subtotal (95% CI)

Total events: 24 (PT+AD), 14 (AD)

PT+AD

n/N

AD

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

7/13

17/43

56

2/12

12/53

65

4.77%

23%

27.77%

3.23[0.83,12.61]

1.75[0.94,3.25]

1.94[1.1,3.41]

Heterogeneity: Tau2=0; Chi2=0.66, df=1(P=0.42); I2=0%

Test for overall effect: Z=2.3(P=0.02)

5.11.2 Cognitive-behaviour therapy

Barlow 2000

Subtotal (95% CI)

Total events: 37 (PT+AD), 31 (AD)

Heterogeneity: Not applicable

Test for overall effect: Z=2.36(P=0.02)

37/65

65

31/83

83

72.23%

72.23%

1.52[1.07,2.16]

1.52[1.07,2.16]

5.11.3 Psychdynamic psychotherapy and others

Wiborg 1996

Subtotal (95% CI)

Total events: 20 (PT+AD), 20 (AD)

Heterogeneity: Not applicable

Test for overall effect: Not applicable

20/20

20

20/20

20

Not estimable

Not estimable

Total (95% CI)

141

168

100%

1.63[1.21,2.19]

Total events: 81 (PT+AD), 65 (AD)

Heterogeneity: Tau2=0; Chi2=1.19, df=2(P=0.55); I2=0%

Test for overall effect: Z=3.22(P=0)

Test for subgroup differences: Not applicable

Favours AD

0.1

0.2

0.5

1

2

5

10

Favours PT+AD

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

106

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 5.12.   Comparison 5 SUBGROUP2: TCA: Psychotherapy+Antidepressant vs
Antidepressant alone, Outcome 12 Global/Avoidance/Panic on continued treatment.

Study or subgroup

Treatment

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

5.12.1 Behaviour therapy

Johnston 1995

Telch 1985

Subtotal ***

5.4 (5.7)

12.6 (8.1)

12

10

22

Heterogeneity: Tau2=0; Chi2=0.7, df=1(P=0.4); I2=0%

Test for overall effect: Z=2.93(P=0)

5.12.2 Cognitive-behaviour therapy

Barlow 2000

Subtotal ***

0.8 (0.9)

65

65

Heterogeneity: Not applicable

Test for overall effect: Z=2.47(P=0.01)

5.12.3 Psychodynamic psychotherapy and others

Wiborg 1996

Subtotal ***

0.5 (1.1)

20

20

Heterogeneity: Not applicable

Test for overall effect: Z=2.56(P=0.01)

11.3 (9.6)

23.8 (9.3)

1.1 (0.9)

2.4 (2.9)

16

10

26

83

83

20

20

Total ***

107

129

Heterogeneity: Tau2=0.02; Chi2=3.45, df=3(P=0.33); I2=12.97%

Test for overall effect: Z=3.94(P<0.0001)

Test for subgroup differences: Chi2=2.75, df=1 (P=0.25), I2=27.29%

14.31%

9.34%

23.64%

-0.7[-1.47,0.07]

-1.23[-2.2,-0.26]

-0.91[-1.51,-0.3]

56.78%

56.78%

-0.41[-0.74,-0.09]

-0.41[-0.74,-0.09]

19.57%

19.57%

-0.85[-1.5,-0.2]

-0.85[-1.5,-0.2]

100%

-0.62[-0.92,-0.31]

Favours treatment

-4

-2

0

2

4

Favours control

Analysis 5.13.   Comparison 5 SUBGROUP2: TCA: Psychotherapy+Antidepressant vs
Antidepressant alone, Outcome 13 Dropouts for any reason on continued treatment.

Study or subgroup

5.13.1 Behaviour therapy

Telch 1985

Subtotal (95% CI)

Total events: 1 (Treatment), 1 (Control)

Heterogeneity: Not applicable

Test for overall effect: Not applicable

5.13.2 Cognitive-behaviour therapy

Barlow 2000

Subtotal (95% CI)

Total events: 4 (Treatment), 7 (Control)

Heterogeneity: Not applicable

Test for overall effect: Z=0.52(P=0.6)

Treatment

n/N

Control

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

1/10

10

4/65

65

1/10

10

7/83

83

13.87%

13.87%

1[0.07,13.87]

1[0.07,13.87]

68.3%

68.3%

0.73[0.22,2.39]

0.73[0.22,2.39]

5.13.3 Psychodynamic psychotherapy and others

Wiborg 1996

1/20

2/20

17.83%

0.5[0.05,5.08]

Favours treatment

0.1

0.2

0.5

1

2

5

10

Favours control

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

107

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Treatment

n/N

Control

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

Subtotal (95% CI)

20

20

17.83%

0.5[0.05,5.08]

Total events: 1 (Treatment), 2 (Control)

Heterogeneity: Not applicable

Test for overall effect: Z=0.59(P=0.56)

Total (95% CI)

95

113

100%

0.71[0.27,1.9]

Total events: 6 (Treatment), 10 (Control)

Heterogeneity: Tau2=0; Chi2=0.16, df=2(P=0.93); I2=0%

Test for overall effect: Z=0.68(P=0.5)

Test for subgroup differences: Not applicable

Favours treatment

0.1

0.2

0.5

1

2

5

10

Favours control

Analysis 5.16.   Comparison 5 SUBGROUP2: TCA: Psychotherapy+Antidepressant vs Antidepressant
alone, Outcome 16 Response/remission 6-24 months after treatment discontinuation.

Study or subgroup

5.16.1 Behaviour therapy

Zitrin 1983

Subtotal (95% CI)

Total events: 23 (PT+AD), 19 (AD)

Heterogeneity: Not applicable

Test for overall effect: Z=1.72(P=0.09)

5.16.2 Cognitive-behaviour therapy

Barlow 2000

Subtotal (95% CI)

Total events: 16 (PT+AD), 15 (AD)

Heterogeneity: Not applicable

Test for overall effect: Z=1.05(P=0.29)

PT+AD

n/N

AD

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

23/43

43

19/53

53

45.17%

45.17%

1.49[0.95,2.35]

1.49[0.95,2.35]

16/59

59

15/77

77

32.04%

32.04%

1.39[0.75,2.58]

1.39[0.75,2.58]

5.16.3 Psychodynamic psychotherapy and others

Wiborg 1996

Subtotal (95% CI)

Total events: 16 (PT+AD), 5 (AD)

Heterogeneity: Not applicable

Test for overall effect: Z=2.89(P=0)

16/20

20

5/20

20

22.79%

22.79%

3.2[1.45,7.05]

3.2[1.45,7.05]

Total (95% CI)

122

150

100%

1.74[1.12,2.69]

Total events: 55 (PT+AD), 39 (AD)

Heterogeneity: Tau2=0.06; Chi2=3.18, df=2(P=0.2); I2=37.09%

Test for overall effect: Z=2.47(P=0.01)

Test for subgroup differences: Not applicable

Favours AD

0.1

0.2

0.5

1

2

5

10

Favours PT+AD

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

108

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 5.17.   Comparison 5 SUBGROUP2: TCA: Psychotherapy+Antidepressant vs Antidepressant
alone, Outcome 17 Global/Avoidance/Panic 6-24 months after treatment discontinuation.

Study or subgroup

Treatment

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

5.17.1 Behaviour therapy

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Not applicable

5.17.2 Cognitive-behaviour therapy

Barlow 2000

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Not applicable

0

59

59

1.5 (0.9)

5.17.3 Psychodynamic psychotherapy and others

0.6 (1.1)

Wiborg 1996

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=3.54(P=0)

Total ***

20

20

79

Heterogeneity: Tau2=0.68; Chi2=10.06, df=1(P=0); I2=90.06%

Test for overall effect: Z=0.94(P=0.35)

Test for subgroup differences: Chi2=10.06, df=1 (P=0), I2=90.06%

0

77

77

20

20

97

1.5 (0.8)

2.4 (1.7)

Not estimable

53%

53%

0[-0.34,0.34]

0[-0.34,0.34]

47%

47%

-1.23[-1.91,-0.55]

-1.23[-1.91,-0.55]

100%

-0.58[-1.78,0.63]

Favours treatment

-4

-2

0

2

4

Favours control

Comparison 6.   SUBGROUP2: TCA: Psychotherapy+Antidepressant vs Psychotherapy alone or +Placebo

Outcome or subgroup title

No. of
studies

No. of
partici-
pants

Statistical method

Effect size

1 Response at 2-4 months

1.1 Behaviour therapy

1.2 Cognitive-behaviour therapy

2 Remission at 2-4 months

2.1 Behaviour therapy

2.2 Cognitive-behaviour therapy

3 Global severity at 2-4 months

12

8

4

10

7

3

7

760

436

324

653

369

284

454

Risk Ratio (M-H, Random, 95%
CI)

1.17 [1.01, 1.36]

Risk Ratio (M-H, Random, 95%
CI)

1.22 [0.99, 1.50]

Risk Ratio (M-H, Random, 95%
CI)

1.12 [0.89, 1.40]

Risk Ratio (M-H, Random, 95%
CI)

1.21 [1.00, 1.45]

Risk Ratio (M-H, Random, 95%
CI)

1.38 [1.00, 1.90]

Risk Ratio (M-H, Random, 95%
CI)

1.13 [0.90, 1.42]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.48 [-0.67, -0.28]

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

109

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of
studies

No. of
partici-
pants

Statistical method

Effect size

3.1 Behaviour therapy

3.2 Cognitive-behaviour therapy

4 Frequency of panic attacks at 2-4 months

4.1 Behaviour therapy

4.2 Cognitive-behaviour therapy

4

3

8

7

1

5 Phobic avoidance at 2-4 months

11

5.1 Behaviour therapy

5.2 Cognitive-behaviour therapy

6 General anxiety at 2-4 months

6.1 Behaviour therapy

6.2 Cognitive-behaviour therapy

9

2

7

6

1

7 Depression at 2-4 months

10

7.1 Behaviour therapy

7.2 Cognitive-behaviour therapy

8 Social malfunctioning at 2-4 months

8.1 Behaviour therapy

8.2 Cognitive-behaviour therapy

8

2

6

6

0

183

271

265

225

40

418

312

106

284

218

66

372

266

106

232

232

0

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.62 [-0.92, -0.32]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.39 [-0.70, -0.07]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.16 [-0.09, 0.40]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.16 [-0.10, 0.43]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.12 [-0.50, 0.74]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.21 [-0.44, 0.02]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.22 [-0.51, 0.07]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.19 [-0.59, 0.20]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.49 [-0.73, -0.25]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.50 [-0.80, -0.21]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.42 [-0.93, 0.08]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.29 [-0.50, -0.07]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.28 [-0.53, -0.03]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.27 [-0.90, 0.37]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.48 [-0.75, -0.22]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.48 [-0.75, -0.22]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.0 [0.0, 0.0]

9 Dropouts for any reason within 2-4
months

11

692

Risk Ratio (M-H, Random, 95%
CI)

1.16 [0.90, 1.49]

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

110

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of
studies

No. of
partici-
pants

Statistical method

Effect size

9.1 Behaviour therapy

9.2 Cognitive-behaviour therapy

10 Dropouts due to side effects within 2-4
months

10.1 Behaviour therapy

10.2 Cognitive-behaviour therapy

11 Response/remission on continued treat-
ment

11.1 Behaviour therapy

11.2 Cognitive-behaviour therapy

12 Global/Avoidance/Panic on continued
treatment

12.1 Behaviour therapy

12.2 Cognitive-behaviour therapy

13 Dropouts for any reason on continued
treatment

13.1 Behaviour therapy

13.2 Cognitive-behaviour therapy

18 Response 6-24 months after treatment
discontinuation

18.1 Behaviour therapy

18.2 Cognitive-behaviour therapy

19 Global/Avoidance/Panic 6-24 months
after treatment discontinuation

7

4

7

3

4

5

3

2

5

3

2

3

1

2

7

5

2

5

368

324

497

173

324

390

185

205

306

101

205

224

19

205

444

250

194

281

Risk Ratio (M-H, Random, 95%
CI)

1.16 [0.85, 1.59]

Risk Ratio (M-H, Random, 95%
CI)

1.17 [0.73, 1.89]

Risk Ratio (M-H, Random, 95%
CI)

2.50 [1.15, 5.45]

Risk Ratio (M-H, Random, 95%
CI)

1.68 [0.67, 4.18]

Risk Ratio (M-H, Random, 95%
CI)

7.31 [1.64, 32.67]

Risk Ratio (M-H, Random, 95%
CI)

1.23 [1.00, 1.51]

Risk Ratio (M-H, Random, 95%
CI)

1.25 [0.82, 1.90]

Risk Ratio (M-H, Random, 95%
CI)

1.23 [0.93, 1.63]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.65 [-0.97, -0.33]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.95 [-1.37, -0.53]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.41 [-0.71, -0.12]

Risk Ratio (M-H, Random, 95%
CI)

0.77 [0.28, 2.15]

Risk Ratio (M-H, Random, 95%
CI)

2.73 [0.12, 59.57]

Risk Ratio (M-H, Random, 95%
CI)

0.66 [0.22, 1.95]

Risk Ratio (M-H, Random, 95%
CI)

0.91 [0.70, 1.18]

Risk Ratio (M-H, Random, 95%
CI)

1.00 [0.73, 1.36]

Risk Ratio (M-H, Random, 95%
CI)

0.74 [0.46, 1.19]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.16 [-0.14, 0.45]

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

111

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

19.1 Behaviour therapy

19.2 Cognitive-behviour therapy

No. of
studies

No. of
partici-
pants

3

2

87

194

Statistical method

Effect size

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.08 [-0.59, 0.75]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.21 [-0.10, 0.52]

Analysis 6.1.   Comparison 6 SUBGROUP2: TCA: Psychotherapy+Antidepressant
vs Psychotherapy alone or +Placebo, Outcome 1 Response at 2-4 months.

PT+AD

n/N

PT+placebo

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

Study or subgroup

6.1.1 Behaviour therapy

Johnston 1995

Marks 1983

Mavissakalian 1986a

Mavissakalian 1986b

Sheehan 1980a

Telch 1985

Zitrin 1980

Zitrin 1983

Subtotal (95% CI)

7/28

17/36

11/20

8/20

16/28

5/13

25/41

25/43

229

Total events: 114 (PT+AD), 83 (PT+placebo)

Heterogeneity: Tau2=0; Chi2=2.8, df=7(P=0.9); I2=0%

Test for overall effect: Z=1.88(P=0.06)

6.1.2 Cognitive-behaviour therapy

Barlow 2000i

Barlow 2000ii

Fahy 1992

Spinhoven 1996

Subtotal (95% CI)

19/32

20/33

26/53

4/20

138

Total events: 69 (PT+AD), 91 (PT+placebo)

Heterogeneity: Tau2=0; Chi2=0.82, df=3(P=0.84); I2=0%

Test for overall effect: Z=0.96(P=0.34)

7/27

12/36

10/20

9/20

6/16

2/12

16/35

21/41

207

36/63

42/77

9/26

4/20

186

2.84%

6.98%

6.65%

4.44%

4.62%

1.12%

12.2%

15.12%

53.97%

18.16%

19.81%

6.55%

1.51%

46.03%

0.96[0.39,2.38]

1.42[0.8,2.52]

1.1[0.61,1.99]

0.89[0.43,1.83]

1.52[0.75,3.1]

2.31[0.55,9.74]

1.33[0.86,2.06]

1.14[0.77,1.68]

1.22[0.99,1.5]

1.04[0.73,1.49]

1.11[0.79,1.56]

1.42[0.78,2.57]

1[0.29,3.45]

1.12[0.89,1.4]

Total (95% CI)

367

393

100%

1.17[1.01,1.36]

Total events: 183 (PT+AD), 174 (PT+placebo)

Heterogeneity: Tau2=0; Chi2=3.96, df=11(P=0.97); I2=0%

Test for overall effect: Z=2.03(P=0.04)

Test for subgroup differences: Not applicable

Favours PT+placebo

0.2

0.5

1

2

5

Favours PT+AD

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

112

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 6.2.   Comparison 6 SUBGROUP2: TCA: Psychotherapy+Antidepressant
vs Psychotherapy alone or +Placebo, Outcome 2 Remission at 2-4 months.

PT+AD

n/N

PT+placebo

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

Study or subgroup

6.2.1 Behaviour therapy

Fava 1997

Marks 1983

Mavissakalian 1986a

Mavissakalian 1986b

Sheehan 1980a

Zitrin 1980

Zitrin 1983

Subtotal (95% CI)

1/7

20/36

8/20

8/20

5/28

7/41

13/43

195

Total events: 62 (PT+AD), 41 (PT+placebo)

Heterogeneity: Tau2=0; Chi2=5.65, df=6(P=0.46); I2=0%

Test for overall effect: Z=1.95(P=0.05)

6.2.2 Cognitive-behaviour therapy

Barlow 2000i

Barlow 2000ii

Fahy 1992

Subtotal (95% CI)

20/33

19/32

28/53

118

Total events: 67 (PT+AD), 86 (PT+placebo)

Heterogeneity: Tau2=0; Chi2=1.44, df=2(P=0.49); I2=0%

Test for overall effect: Z=1.07(P=0.28)

4/7

17/36

4/20

5/20

2/15

4/35

5/41

174

39/63

37/77

10/26

166

0.93%

16.79%

3.25%

3.98%

1.5%

2.63%

3.9%

32.98%

30.36%

25.25%

11.41%

67.02%

0.25[0.04,1.71]

1.18[0.75,1.85]

2[0.72,5.59]

1.6[0.63,4.05]

1.34[0.29,6.09]

1.49[0.48,4.68]

2.48[0.97,6.34]

1.38[1,1.9]

0.98[0.7,1.37]

1.24[0.85,1.79]

1.37[0.79,2.38]

1.13[0.9,1.42]

Total (95% CI)

313

340

100%

1.21[1,1.45]

Total events: 129 (PT+AD), 127 (PT+placebo)

Heterogeneity: Tau2=0; Chi2=8.2, df=9(P=0.51); I2=0%

Test for overall effect: Z=2(P=0.05)

Test for subgroup differences: Not applicable

Favours PT+placebo

0.1

0.2

0.5

1

2

5

10

Favours PT+AD

Analysis 6.3.   Comparison 6 SUBGROUP2: TCA: Psychotherapy+Antidepressant
vs Psychotherapy alone or +Placebo, Outcome 3 Global severity at 2-4 months.

Study or subgroup

PT+AD

PT+placebo

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

6.3.1 Behaviour therapy

Mavissakalian 1986a

Mavissakalian 1986b

Zitrin 1980

Zitrin 1983

Subtotal ***

2 (1.7)

2.2 (1.7)

1.9 (0.6)

3.2 (1)

17

14

29

34

94

Heterogeneity: Tau2=0; Chi2=0.9, df=3(P=0.82); I2=0%

Test for overall effect: Z=4.06(P<0.0001)

6.3.2 Cognitive-behaviour therapy

Barlow 2000i

Barlow 2000ii

Fahy 1992

33

32

42

0.9 (0.7)

0.9 (0.7)

2 (1.1)

14

17

24

34

89

63

77

24

3 (1.9)

3.1 (1.9)

2.3 (0.9)

4 (1)

1 (0.7)

1.1 (0.7)

2.8 (1)

7.27%

7.33%

12.53%

15.44%

42.57%

-0.55[-1.27,0.18]

-0.49[-1.2,0.23]

-0.5[-1.05,0.05]

-0.81[-1.3,-0.31]

-0.62[-0.92,-0.32]

21.31%

22.01%

14.11%

-0.15[-0.57,0.27]

-0.35[-0.76,0.07]

-0.74[-1.26,-0.22]

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

113

Favours treatment

-4

-2

0

2

4

Favours control

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

PT+AD

PT+placebo

Std. Mean Difference

Weight

Std. Mean Difference

Subtotal ***

Mean(SD)

N

107

N

164

Heterogeneity: Tau2=0.03; Chi2=3.01, df=2(P=0.22); I2=33.55%

Test for overall effect: Z=2.38(P=0.02)

Mean(SD)

Random, 95% CI

Random, 95% CI

57.43%

-0.39[-0.7,-0.07]

Total ***

201

253

100%

-0.48[-0.67,-0.28]

Heterogeneity: Tau2=0; Chi2=5.4, df=6(P=0.49); I2=0%

Test for overall effect: Z=4.8(P<0.0001)

Test for subgroup differences: Chi2=1.49, df=1 (P=0.22), I2=32.8%

Favours treatment

-4

-2

0

2

4

Favours control

Analysis 6.4.   Comparison 6 SUBGROUP2: TCA: Psychotherapy+Antidepressant vs
Psychotherapy alone or +Placebo, Outcome 4 Frequency of panic attacks at 2-4 months.

Study or subgroup

PT+AD

PT+placebo

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

6.4.1 Behaviour therapy

Fava 1997

Johnston 1995

Mavissakalian 1986a

Mavissakalian 1986b

Telch 1985

Zitrin 1980

Zitrin 1983

Subtotal ***

7

12

17

14

10

19

34

113

2.7 (0.8)

0.6 (0.9)

1.3 (2)

2.4 (1.9)

0.6 (1.1)

6.4 (1)

6 (1.2)

7

17

14

17

9

14

34

112

2 (1)

1.1 (1.8)

1.6 (2.1)

2.2 (2.1)

0.8 (0.7)

6 (1)

5.4 (1.2)

Heterogeneity: Tau2=0; Chi2=5.68, df=6(P=0.46); I2=0%

Test for overall effect: Z=1.2(P=0.23)

6.4.2 Cognitive-behaviour therapy

Spinhoven 1996

Subtotal ***

20

20

3 (2.5)

20

20

2.7 (2.3)

Heterogeneity: Not applicable

Test for overall effect: Z=0.39(P=0.7)

4.96%

10.71%

11.84%

11.86%

7.29%

12.25%

25.65%

84.56%

0.72[-0.37,1.82]

-0.34[-1.09,0.4]

-0.14[-0.85,0.56]

0.1[-0.61,0.8]

-0.18[-1.08,0.72]

0.36[-0.33,1.06]

0.44[-0.04,0.92]

0.16[-0.1,0.43]

15.44%

15.44%

0.12[-0.5,0.74]

0.12[-0.5,0.74]

Total ***

133

132

100%

0.16[-0.09,0.4]

Heterogeneity: Tau2=0; Chi2=5.69, df=7(P=0.58); I2=0%

Test for overall effect: Z=1.25(P=0.21)

Test for subgroup differences: Chi2=0.01, df=1 (P=0.91), I2=0%

Favours treatment

-4

-2

0

2

4

Favours control

Analysis 6.5.   Comparison 6 SUBGROUP2: TCA: Psychotherapy+Antidepressant
vs Psychotherapy alone or +Placebo, Outcome 5 Phobic avoidance at 2-4 months.

Study or subgroup

PT+AD

PT+placebo

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

6.5.1 Behaviour therapy

Fava 1997

Johnston 1995

7

12

19.6 (4.7)

8.5 (8.4)

7

17

15.6 (8.4)

13.5 (9.6)

4.03%

7.44%

0.55[-0.52,1.63]

-0.53[-1.29,0.22]

Favours treatment

-4

-2

0

2

4

Favours control

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

114

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

PT+AD

PT+placebo

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

Marks 1983

Mavissakalian 1986a

Mavissakalian 1986b

Sheehan 1980a

Telch 1985

Zitrin 1980

Zitrin 1983

Subtotal ***

11.4 (9.4)

11.4 (8.8)

12.3 (8.8)

3 (1)

17.3 (10.3)

6.2 (0.8)

2.7 (1.4)

23

17

14

18

10

25

34

160

Heterogeneity: Tau2=0.07; Chi2=12.51, df=8(P=0.13); I2=36.05%

Test for overall effect: Z=1.48(P=0.14)

6.5.2 Cognitive-behaviour therapy

Fahy 1992

Spinhoven 1996

Subtotal ***

31.4 (30.7)

22.5 (12)

42

20

62

Heterogeneity: Tau2=0; Chi2=0.43, df=1(P=0.51); I2=0%

Test for overall effect: Z=0.97(P=0.33)

12.7 (10.5)

13.8 (9.9)

13.3 (9.9)

3.9 (1.3)

23.3 (7.8)

5.7 (1.1)

3.4 (1.4)

40.2 (25.4)

22.9 (11.3)

22

14

17

11

9

21

34

152

24

20

44

Total ***

222

196

Heterogeneity: Tau2=0.03; Chi2=12.95, df=10(P=0.23); I2=22.8%

Test for overall effect: Z=1.83(P=0.07)

Test for subgroup differences: Chi2=0.01, df=1 (P=0.91), I2=0%

11.01%

8.18%

8.23%

7.01%

5.24%

10.89%

14.33%

76.34%

-0.13[-0.71,0.46]

-0.25[-0.96,0.46]

-0.1[-0.81,0.6]

-0.79[-1.57,-0.01]

-0.62[-1.55,0.31]

0.49[-0.1,1.08]

-0.51[-0.99,-0.02]

-0.22[-0.51,0.07]

13.55%

10.11%

23.66%

-0.3[-0.81,0.2]

-0.03[-0.65,0.59]

-0.19[-0.59,0.2]

100%

-0.21[-0.44,0.02]

Favours treatment

-4

-2

0

2

4

Favours control

Analysis 6.6.   Comparison 6 SUBGROUP2: TCA: Psychotherapy+Antidepressant
vs Psychotherapy alone or +Placebo, Outcome 6 General anxiety at 2-4 months.

Study or subgroup

PT+AD

PT+placebo

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

6.6.1 Behaviour therapy

Fava 1997

Marks 1983

Mavissakalian 1986a

Mavissakalian 1986b

Sheehan 1980a

Zitrin 1983

Subtotal ***

3.6 (0.5)

8.9 (9.4)

30.1 (7.6)

34.3 (7.6)

1 (0.7)

21.5 (9.9)

7

23

17

14

18

34

113

Heterogeneity: Tau2=0.02; Chi2=5.71, df=5(P=0.34); I2=12.49%

Test for overall effect: Z=3.32(P=0)

6.6.2 Cognitive-behaviour therapy

Fahy 1992

Subtotal ***

11.3 (7.6)

42

42

Heterogeneity: Not applicable

Test for overall effect: Z=1.63(P=0.1)

3.6 (0.5)

12.7 (9.2)

35.5 (9.3)

34.4 (9.3)

2 (1.1)

27.9 (9.9)

14.4 (6.6)

7

22

14

17

11

34

105

24

24

5.28%

16.59%

10.97%

11.58%

8.72%

24.31%

77.46%

0[-1.05,1.05]

-0.4[-0.99,0.19]

-0.63[-1.35,0.1]

-0.01[-0.72,0.7]

-1.15[-1.97,-0.34]

-0.64[-1.13,-0.15]

-0.5[-0.8,-0.21]

22.54%

22.54%

-0.42[-0.93,0.08]

-0.42[-0.93,0.08]

Total ***

155

129

100%

-0.49[-0.73,-0.25]

Heterogeneity: Tau2=0; Chi2=5.8, df=6(P=0.45); I2=0%

Test for overall effect: Z=3.97(P<0.0001)

Favours treatment

-4

-2

0

2

4

Favours control

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

115

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

PT+AD

PT+placebo

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

Test for subgroup differences: Chi2=0.08, df=1 (P=0.77), I2=0%

Favours treatment

-4

-2

0

2

4

Favours control

Analysis 6.7.   Comparison 6 SUBGROUP2: TCA: Psychotherapy+Antidepressant
vs Psychotherapy alone or +Placebo, Outcome 7 Depression at 2-4 months.

Study or subgroup

PT+AD

PT+placebo

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

6.7.1 Behaviour therapy

Fava 1997

Johnston 1995

Marks 1983

Mavissakalian 1986a

Mavissakalian 1986b

Sheehan 1980a

Telch 1985

Zitrin 1983

Subtotal ***

1 (0)

0.8 (0.5)

4 (4.9)

2.8 (8.5)

8.7 (8.5)

51.1 (9.4)

13.4 (5.7)

1.3 (0.5)

7

12

23

17

14

18

10

34

135

Heterogeneity: Tau2=0; Chi2=5.57, df=6(P=0.47); I2=0%

Test for overall effect: Z=2.18(P=0.03)

6.7.2 Cognitive-behaviour therapy

Fahy 1992

Spinhoven 1996

Subtotal ***

5.6 (4.5)

43.5 (8.7)

42

20

62

Heterogeneity: Tau2=0.13; Chi2=2.5, df=1(P=0.11); I2=60.01%

Test for overall effect: Z=0.82(P=0.41)

1.1 (0.4)

1 (0.8)

4 (2.7)

7.7 (8.7)

6.9 (8.7)

57.7 (10.1)

13 (11.9)

1.6 (0.5)

8.3 (5.1)

42.7 (10)

7

17

22

14

17

11

9

34

131

24

20

44

8.18%

13.15%

8.64%

8.96%

7.57%

5.58%

19.1%

Not estimable

-0.28[-1.02,0.46]

0[-0.58,0.58]

-0.56[-1.28,0.17]

0.2[-0.51,0.91]

-0.66[-1.43,0.11]

0.04[-0.86,0.94]

-0.51[-1,-0.03]

71.18%

-0.28[-0.53,-0.03]

17.12%

11.7%

28.82%

-0.56[-1.08,-0.05]

0.08[-0.54,0.7]

-0.27[-0.9,0.37]

Total ***

197

175

100%

-0.29[-0.5,-0.07]

Heterogeneity: Tau2=0; Chi2=8.08, df=8(P=0.43); I2=1%

Test for overall effect: Z=2.63(P=0.01)

Test for subgroup differences: Chi2=0.01, df=1 (P=0.92), I2=0%

Favours treatment

-4

-2

0

2

4

Favours control

Analysis 6.8.   Comparison 6 SUBGROUP2: TCA: Psychotherapy+Antidepressant vs
Psychotherapy alone or +Placebo, Outcome 8 Social malfunctioning at 2-4 months.

Study or subgroup

PT+AD

PT+placebo

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

6.8.1 Behaviour therapy

Johnston 1995

Mavissakalian 1986a

Mavissakalian 1986b

Sheehan 1980a

Zitrin 1980

Zitrin 1983

Subtotal ***

12

17

14

18

25

34

120

2.1 (0.6)

2.3 (1)

2.4 (1)

3.1 (1.1)

1.1 (0.8)

1.2 (0.9)

16

14

17

11

20

34

112

2 (0.8)

2.8 (1.1)

2.8 (1.1)

4 (1)

1.4 (1.1)

1.9 (0.9)

12.49%

13.57%

13.73%

11.47%

20%

28.74%

100%

0.14[-0.61,0.89]

-0.49[-1.21,0.23]

-0.38[-1.1,0.33]

-0.8[-1.58,-0.02]

-0.33[-0.92,0.26]

-0.78[-1.27,-0.28]

-0.48[-0.75,-0.22]

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

116

Favours treatment

-4

-2

0

2

4

Favours control

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

PT+AD

PT+placebo

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

Heterogeneity: Tau2=0; Chi2=4.96, df=5(P=0.42); I2=0%

Test for overall effect: Z=3.57(P=0)

6.8.2 Cognitive-behaviour therapy

Subtotal ***

0

0

Heterogeneity: Not applicable

Test for overall effect: Not applicable

Not estimable

Total ***

120

112

100%

-0.48[-0.75,-0.22]

Heterogeneity: Tau2=0; Chi2=4.96, df=5(P=0.42); I2=0%

Test for overall effect: Z=3.57(P=0)

Test for subgroup differences: Not applicable

Favours treatment

-4

-2

0

2

4

Favours control

Analysis 6.9.   Comparison 6 SUBGROUP2: TCA: Psychotherapy+Antidepressant vs
Psychotherapy alone or +Placebo, Outcome 9 Dropouts for any reason within 2-4 months.

PT+AD

n/N

PT+placebo

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

Study or subgroup

6.9.1 Behaviour therapy

Fava 1997

Johnston 1995

Marks 1983

Sheehan 1980a

Telch 1985

Zitrin 1980

Zitrin 1983

Subtotal (95% CI)

0/7

16/26

13/36

7/28

3/13

12/41

9/43

194

Total events: 60 (PT+AD), 48 (PT+placebo)

Heterogeneity: Tau2=0; Chi2=2.59, df=5(P=0.76); I2=0%

Test for overall effect: Z=0.96(P=0.34)

6.9.2 Cognitive-behaviour therapy

Barlow 2000i

Barlow 2000ii

Fahy 1992

Spinhoven 1996

Subtotal (95% CI)

9/33

9/32

12/53

4/20

138

Total events: 34 (PT+AD), 42 (PT+placebo)

Heterogeneity: Tau2=0.03; Chi2=3.36, df=3(P=0.34); I2=10.82%

Test for overall effect: Z=0.65(P=0.52)

0/7

10/27

14/36

3/16

3/12

11/35

7/41

174

18/63

21/77

3/26

0/20

186

19.07%

17.88%

4.39%

3.28%

13.68%

8.04%

66.34%

13.77%

14.49%

4.62%

0.78%

33.66%

Not estimable

1.66[0.93,2.96]

0.93[0.51,1.69]

1.33[0.4,4.45]

0.92[0.23,3.72]

0.93[0.47,1.84]

1.23[0.5,2.99]

1.16[0.85,1.59]

0.95[0.48,1.88]

1.03[0.53,2]

1.96[0.61,6.35]

9[0.52,156.91]

1.17[0.73,1.89]

Total (95% CI)

332

360

100%

1.16[0.9,1.49]

Total events: 94 (PT+AD), 90 (PT+placebo)

Heterogeneity: Tau2=0; Chi2=5.81, df=9(P=0.76); I2=0%

Test for overall effect: Z=1.14(P=0.26)

Test for subgroup differences: Not applicable

Favours treatment

0.1

0.2

0.5

1

2

5

10

Favours control

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

117

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 6.10.   Comparison 6 SUBGROUP2: TCA: Psychotherapy+Antidepressant vs
Psychotherapy alone or +Placebo, Outcome 10 Dropouts due to side effects within 2-4 months.

PT+AD

n/N

PT+placebo

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

Study or subgroup

6.10.1 Behaviour therapy

Marks 1983

Telch 1985

Zitrin 1980

Subtotal (95% CI)

2/36

3/13

8/41

90

Total events: 13 (PT+AD), 7 (PT+placebo)

Heterogeneity: Tau2=0; Chi2=1.54, df=2(P=0.46); I2=0%

Test for overall effect: Z=1.11(P=0.27)

6.10.2 Cognitive-behaviour therapy

Barlow 2000i

Barlow 2000ii

Fahy 1992

Spinhoven 1996

Subtotal (95% CI)

1/33

1/32

7/53

4/20

138

Total events: 13 (PT+AD), 0 (PT+placebo)

Heterogeneity: Tau2=0; Chi2=0.05, df=3(P=1); I2=0%

Test for overall effect: Z=2.6(P=0.01)

3/36

1/12

3/35

83

0/63

0/77

0/26

0/20

186

20.35%

13.49%

39.04%

72.88%

0.67[0.12,3.75]

2.77[0.33,23.14]

2.28[0.65,7.93]

1.68[0.67,4.18]

6.04%

6.03%

7.62%

7.44%

5.65[0.24,134.91]

7.09[0.3,169.6]

7.5[0.44,126.48]

9[0.52,156.91]

27.12%

7.31[1.64,32.67]

Total (95% CI)

228

269

100%

2.5[1.15,5.45]

Total events: 26 (PT+AD), 7 (PT+placebo)

Heterogeneity: Tau2=0; Chi2=4.4, df=6(P=0.62); I2=0%

Test for overall effect: Z=2.3(P=0.02)

Test for subgroup differences: Not applicable

Favours treatment

0.1

0.2

0.5

1

2

5

10

Favours control

Analysis 6.11.   Comparison 6 SUBGROUP2: TCA: Psychotherapy+Antidepressant vs
Psychotherapy alone or +Placebo, Outcome 11 Response/remission on continued treatment.

PT+AD

n/N

PT+placebo

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

Study or subgroup

6.11.1 Behaviour therapy

Telch 1985

Zitrin 1980

Zitrin 1983

Subtotal (95% CI)

7/13

26/41

17/43

97

Total events: 50 (PT+AD), 36 (PT+placebo)

Heterogeneity: Tau2=0.05; Chi2=2.96, df=2(P=0.23); I2=32.38%

Test for overall effect: Z=1.02(P=0.31)

6.11.2 Cognitive-behaviour therapy

Barlow 2000i

Barlow 2000ii

Subtotal (95% CI)

19/33

18/32

65

Total events: 37 (PT+AD), 64 (PT+placebo)

Heterogeneity: Tau2=0; Chi2=0.39, df=1(P=0.53); I2=0%

2/12

17/35

17/41

88

32/63

32/77

140

2.33%

25.37%

16.06%

43.76%

3.23[0.83,12.61]

1.31[0.86,1.97]

0.95[0.57,1.6]

1.25[0.82,1.9]

29.82%

26.42%

56.24%

1.13[0.77,1.66]

1.35[0.9,2.03]

1.23[0.93,1.63]

Favours PT+placebo

0.1

0.2

0.5

1

2

5

10

Favours PT+AD

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

118

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

PT+AD

n/N

PT+placebo

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

Test for overall effect: Z=1.48(P=0.14)

Total (95% CI)

162

228

100%

1.23[1,1.51]

Total events: 87 (PT+AD), 100 (PT+placebo)

Heterogeneity: Tau2=0; Chi2=3.34, df=4(P=0.5); I2=0%

Test for overall effect: Z=1.93(P=0.05)

Test for subgroup differences: Not applicable

Favours PT+placebo

0.1

0.2

0.5

1

2

5

10

Favours PT+AD

Analysis 6.12.   Comparison 6 SUBGROUP2: TCA: Psychotherapy+Antidepressant vs
Psychotherapy alone or +Placebo, Outcome 12 Global/Avoidance/Panic on continued treatment.

Study or subgroup

PT+AD

PT+placebo

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

6.12.1 Behaviour therapy

Johnston 1995

Telch 1985

Zitrin 1980

Subtotal ***

5.4 (5.7)

12.6 (8.1)

1.5 (0.7)

12

10

29

51

Heterogeneity: Tau2=0; Chi2=1.84, df=2(P=0.4); I2=0%

Test for overall effect: Z=4.44(P<0.0001)

6.12.2 Cognitive-behaviour therapy

Barlow 2000i

Barlow 2000ii

Subtotal ***

0.8 (0.9)

0.8 (0.9)

33

32

65

Heterogeneity: Tau2=0; Chi2=0.1, df=1(P=0.75); I2=0%

Test for overall effect: Z=2.73(P=0.01)

14.6 (9.1)

25.6 (8.8)

2 (0.9)

1.1 (0.8)

1.2 (0.9)

17

9

24

50

63

77

140

Total ***

116

190

Heterogeneity: Tau2=0.04; Chi2=6.13, df=4(P=0.19); I2=34.79%

Test for overall effect: Z=4.01(P<0.0001)

Test for subgroup differences: Chi2=4.19, df=1 (P=0.04), I2=76.16%

12.48%

8.09%

21.03%

41.6%

-1.13[-1.94,-0.33]

-1.47[-2.51,-0.43]

-0.72[-1.27,-0.16]

-0.95[-1.37,-0.53]

28.94%

29.47%

58.4%

-0.37[-0.79,0.06]

-0.46[-0.88,-0.04]

-0.41[-0.71,-0.12]

100%

-0.65[-0.97,-0.33]

Favours treatment

-4

-2

0

2

4

Favours control

Analysis 6.13.   Comparison 6 SUBGROUP2: TCA: Psychotherapy+Antidepressant vs
Psychotherapy alone or +Placebo, Outcome 13 Dropouts for any reason on continued treatment.

Study or subgroup

6.13.1 Behaviour therapy

Telch 1985

Subtotal (95% CI)

Total events: 1 (PT+AD), 0 (PT+placebo)

Heterogeneity: Not applicable

Test for overall effect: Z=0.64(P=0.52)

PT+AD

n/N

PT+placebo

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

1/10

10

0/9

9

10.96%

10.96%

2.73[0.12,59.57]

2.73[0.12,59.57]

Favours treatment

0.1

0.2

0.5

1

2

5

10

Favours control

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

119

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

PT+AD

n/N

PT+placebo

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

6.13.2 Cognitive-behaviour therapy

Barlow 2000i

Barlow 2000ii

Subtotal (95% CI)

2/33

2/32

65

6/63

7/77

140

Total events: 4 (PT+AD), 13 (PT+placebo)

Heterogeneity: Tau2=0; Chi2=0, df=1(P=0.94); I2=0%

Test for overall effect: Z=0.75(P=0.45)

43.72%

45.32%

89.04%

0.64[0.14,2.98]

0.69[0.15,3.13]

0.66[0.22,1.95]

Total (95% CI)

75

149

100%

0.77[0.28,2.15]

Total events: 5 (PT+AD), 13 (PT+placebo)

Heterogeneity: Tau2=0; Chi2=0.73, df=2(P=0.7); I2=0%

Test for overall effect: Z=0.49(P=0.62)

Test for subgroup differences: Not applicable

Favours treatment

0.1

0.2

0.5

1

2

5

10

Favours control

Analysis 6.18.   Comparison 6 SUBGROUP2: TCA: Psychotherapy+Antidepressant vs Psychotherapy
alone or +Placebo, Outcome 18 Response 6-24 months after treatment discontinuation.

PT+AD

n/N

PT+placebo

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

Study or subgroup

6.18.1 Behaviour therapy

Fava 1997

Marks 1983

Mavissakalian 1986a

Mavissakalian 1986b

Zitrin 1983

Subtotal (95% CI)

2/7

9/36

6/20

6/20

23/43

126

Total events: 46 (PT+AD), 46 (PT+placebo)

Heterogeneity: Tau2=0; Chi2=1.63, df=4(P=0.8); I2=0%

Test for overall effect: Z=0.03(P=0.98)

6.18.2 Cognitive-behaviour therapy

Barlow 2000i

Barlow 2000ii

Subtotal (95% CI)

8/30

8/29

59

Total events: 16 (PT+AD), 49 (PT+placebo)

Heterogeneity: Tau2=0; Chi2=0.24, df=1(P=0.62); I2=0%

Test for overall effect: Z=1.22(P=0.22)

4/7

11/36

5/20

6/20

20/41

124

25/62

24/73

135

3.85%

12.21%

6.7%

7.66%

39.01%

69.44%

0.5[0.13,1.9]

0.82[0.39,1.73]

1.2[0.44,3.3]

1[0.39,2.58]

1.1[0.72,1.67]

1[0.73,1.36]

15.47%

15.09%

30.56%

0.66[0.34,1.29]

0.84[0.43,1.65]

0.74[0.46,1.19]

Total (95% CI)

185

259

100%

0.91[0.7,1.18]

Total events: 62 (PT+AD), 95 (PT+placebo)

Heterogeneity: Tau2=0; Chi2=2.91, df=6(P=0.82); I2=0%

Test for overall effect: Z=0.7(P=0.48)

Test for subgroup differences: Not applicable

Favours PT+placebo

0.2

0.5

1

2

5

Favours PT+AD

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

120

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 6.19.   Comparison 6 SUBGROUP2: TCA: Psychotherapy+Antidepressant vs Psychotherapy
alone or +Placebo, Outcome 19 Global/Avoidance/Panic 6-24 months after treatment discontinuation.

Study or subgroup

PT+AD

PT+placebo

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

6.19.1 Behaviour therapy

Marks 1983

Mavissakalian 1986a

Mavissakalian 1986b

Subtotal ***

14.1 (2.7)

2.1 (1.4)

2 (1.2)

22

14

11

47

Heterogeneity: Tau2=0.2; Chi2=4.65, df=2(P=0.1); I2=56.96%

Test for overall effect: Z=0.24(P=0.81)

6.19.2 Cognitive-behviour therapy

Barlow 2000i

Barlow 2000ii

Subtotal ***

1.5 (0.9)

1.5 (0.9)

30

29

59

Heterogeneity: Tau2=0; Chi2=0.27, df=1(P=0.6); I2=0%

Test for overall effect: Z=1.34(P=0.18)

13.7 (2.8)

3.3 (2.6)

1.3 (0.5)

1.2 (0.9)

1.3 (0.9)

18

11

11

40

62

73

135

Total ***

106

175

Heterogeneity: Tau2=0.03; Chi2=5.16, df=4(P=0.27); I2=22.49%

Test for overall effect: Z=1.05(P=0.29)

Test for subgroup differences: Chi2=0.24, df=1 (P=0.62), I2=0%

17.79%

11.52%

10.2%

39.51%

29.91%

30.59%

60.49%

0.14[-0.48,0.77]

-0.58[-1.39,0.23]

0.71[-0.16,1.58]

0.08[-0.59,0.75]

0.29[-0.14,0.73]

0.13[-0.3,0.56]

0.21[-0.1,0.52]

100%

0.16[-0.14,0.45]

Favours treatment

-10

-5

0

5

10

Favours control

Comparison 7.   SUBGROUP2: SSRI: Psychotherapy+Antidepressant vs Antidepressant alone

Outcome or subgroup title

1 Response at 2-4 months

1.1 Behaviour therapy

1.2 Cognitive-behaviour therapy

1.3 Psychodynamic psychotherapy and others

2 Remission at 2-4 months

2.1 Behaviour therapy

2.2 Cognitive-behaviour therapy

No. of
studies

No. of
partici-
pants

Statistical method

Effect size

3

0

2

1

2

0

1

218

0

118

100

174

0

74

Risk Ratio (M-H, Random,
95% CI)

1.23 [0.75, 2.03]

Risk Ratio (M-H, Random,
95% CI)

0.0 [0.0, 0.0]

Risk Ratio (M-H, Random,
95% CI)

1.68 [0.69, 4.05]

Risk Ratio (M-H, Random,
95% CI)

0.85 [0.63, 1.15]

Risk Ratio (M-H, Random,
95% CI)

0.80 [0.38, 1.70]

Risk Ratio (M-H, Random,
95% CI)

0.0 [0.0, 0.0]

Risk Ratio (M-H, Random,
95% CI)

1.14 [0.78, 1.66]

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

121

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of
studies

2.3 Psychodynamic psychotherapy and others

3 Global severity at 2-4 months

3.1 Behaviour therapy

3.2 Cognitive-behaviour therapy

3.3 Psychodynamic psychotherapy and others

4 Frequency of panic attacks at 2-4 months

4.1 Behaviour therapy

4.2 Cognitive-behaviour therapy

4.3 Psychodynamic psychotherapy and others

5 Phobic avoidance at 2-4 months

5.1 Behaviour therapy

5.2 Cognitive-behaviour therapy

5.3 Psychodynamic psychotherapy and others

6 General anxiety at 2-4 months

6.1 Behaviour therapy

6.2 Cognitive-behaviour therapy

6.3 Psychodynamic psychotherapy and others

7 Depression at 2-4 months

1

1

0

1

0

2

0

2

1

1

0

1

1

3

0

3

1

1

No. of
partici-
pants

100

58

0

58

0

138

0

86

52

104

0

52

52

196

0

144

52

34

Statistical method

Effect size

Risk Ratio (M-H, Random,
95% CI)

0.54 [0.32, 0.90]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.48 [-1.01, 0.04]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.0 [0.0, 0.0]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.48 [-1.01, 0.04]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.0 [0.0, 0.0]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.47 [-1.39, 0.45]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.0 [0.0, 0.0]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.76 [-2.34, 0.83]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.03 [-0.53, 0.59]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.57 [0.16, 0.97]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.0 [0.0, 0.0]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.57 [-0.00, 1.14]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.57 [-0.00, 1.14]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.22 [-0.93, 0.49]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.0 [0.0, 0.0]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.43 [-1.32, 0.45]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.39 [-0.18, 0.95]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.89 [-1.60, -0.18]

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

122

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

7.1 Behaviour therapy

7.2 Cognitive-behaviour therapy

7.3 Psychodynamic psychotherapy and others

8 Social functioning at 2-4 months

8.1 Behavour therapy

8.2 Cognitive-behaviour therapy

8.3 Psychodynamic psychotherapy and others

9 Dropouts for any reason within 2-4 months

9.1 Behaviour therapy

9.2 Cognitive-behaviour therapy

9.3 Psychodynamic psychotherapy and others

10 Dropouts due to side effects within 2-4
months

10.1 Behaviour therapy

10.2 Cognitive-behaviour therapy

10.3 Psychodynamic psychotherapy and others

11 Response/remission on continued treatment

11.1 Behaviour therapy

11.2 Cognitive-behaviour therapy

No. of
studies

No. of
partici-
pants

Statistical method

Effect size

0

1

0

1

0

1

0

3

0

2

1

1

0

1

0

1

0

0

0

34

0

58

0

58

0

218

0

118

100

74

0

74

0

73

0

0

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.0 [0.0, 0.0]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.89 [-1.60, -0.18]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.0 [0.0, 0.0]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.30 [-0.82, 0.22]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.0 [0.0, 0.0]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.30 [-0.82, 0.22]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.0 [0.0, 0.0]

Risk Ratio (M-H, Random,
95% CI)

1.04 [0.68, 1.60]

Risk Ratio (M-H, Random,
95% CI)

0.0 [0.0, 0.0]

Risk Ratio (M-H, Random,
95% CI)

0.90 [0.51, 1.61]

Risk Ratio (M-H, Random,
95% CI)

1.25 [0.65, 2.39]

Risk Ratio (M-H, Random,
95% CI)

1.58 [0.41, 6.13]

Risk Ratio (M-H, Random,
95% CI)

0.0 [0.0, 0.0]

Risk Ratio (M-H, Random,
95% CI)

1.58 [0.41, 6.13]

Risk Ratio (M-H, Random,
95% CI)

0.0 [0.0, 0.0]

Risk Ratio (M-H, Random,
95% CI)

0.67 [0.44, 1.02]

Risk Ratio (M-H, Random,
95% CI)

0.0 [0.0, 0.0]

Risk Ratio (M-H, Random,
95% CI)

0.0 [0.0, 0.0]

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

123

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of
studies

No. of
partici-
pants

Statistical method

Effect size

11.3 Psychdynamic psychotherapy and others

12 Global/Avoidance/Panic on continued treat-
ment

12.1 Behaviour therapy

12.2 Cognitive-behaviour therapy

12.3 Psychodynamic psychotherapy and others

13 Dropouts for any reason on continued treat-
ment

13.1 Behaviour therapy

13.2 Cognitive-behaviour therapy

13.3 Psychodynamic psychotherapy and others

14 Response/remission immediately after treat-
ment discontinuation

14.1 Behaviour therapy

14.2 Cognitive-behaviour therapy

14.3 Psychodynamic psychotherapy and others

15 Global/Avoidance/Panic immediately after
treatment discontinuation

15.1 Behaviour therapy

15.2 Cognitive-behaviour therapy

15.3 Psychodynamic psychotherapy and others

16 Response/remission 6-24 months after treat-
ment discontinuation

1

1

0

0

1

0

0

0

0

1

0

0

1

1

0

0

1

1

73

50

0

0

50

0

0

0

0

50

0

0

50

50

0

0

50

74

Risk Ratio (M-H, Random,
95% CI)

0.67 [0.44, 1.02]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.42 [-0.15, 0.99]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.0 [0.0, 0.0]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.0 [0.0, 0.0]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.42 [-0.15, 0.99]

Risk Ratio (M-H, Random,
95% CI)

0.0 [0.0, 0.0]

Risk Ratio (M-H, Random,
95% CI)

0.0 [0.0, 0.0]

Risk Ratio (M-H, Random,
95% CI)

0.0 [0.0, 0.0]

Risk Ratio (M-H, Random,
95% CI)

0.0 [0.0, 0.0]

Risk Ratio (M-H, Random,
95% CI)

0.85 [0.65, 1.11]

Risk Ratio (M-H, Random,
95% CI)

0.0 [0.0, 0.0]

Risk Ratio (M-H, Random,
95% CI)

0.0 [0.0, 0.0]

Risk Ratio (M-H, Random,
95% CI)

0.85 [0.65, 1.11]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.42 [-0.15, 0.99]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.0 [0.0, 0.0]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.0 [0.0, 0.0]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.42 [-0.15, 0.99]

Risk Ratio (M-H, Random,
95% CI)

1.52 [0.80, 2.89]

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

124

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

16.1 Behaviour therapy

16.2 Cognitive-behaviour therapy

16.3 Psychodynamic psychotherapy and others

17 Global/Avoidance/Panic 6-24 months after
treatment discontinuation

17.1 Behaviour therapy

17.2 Cognitive-behaviour therapy

17.3 Psychodynamic psychotherapy and others

No. of
studies

No. of
partici-
pants

Statistical method

Effect size

0

1

0

0

0

0

0

0

74

0

0

0

0

0

Risk Ratio (M-H, Random,
95% CI)

0.0 [0.0, 0.0]

Risk Ratio (M-H, Random,
95% CI)

1.52 [0.80, 2.89]

Risk Ratio (M-H, Random,
95% CI)

0.0 [0.0, 0.0]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.0 [0.0, 0.0]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.0 [0.0, 0.0]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.0 [0.0, 0.0]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.0 [0.0, 0.0]

Analysis 7.1.   Comparison 7 SUBGROUP2: SSRI: Psychotherapy
+Antidepressant vs Antidepressant alone, Outcome 1 Response at 2-4 months.

Study or subgroup

PT+AD

n/N

AD

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

7.1.1 Behaviour therapy

Subtotal (95% CI)

Total events: 0 (PT+AD), 0 (AD)

Heterogeneity: Not applicable

Test for overall effect: Not applicable

7.1.2 Cognitive-behaviour therapy

Azhar 2000

Sharp 1996

Subtotal (95% CI)

0

0

Not estimable

14/22

26/38

60

5/22

21/36

58

20.52%

38.75%

59.28%

2.8[1.22,6.44]

1.17[0.83,1.67]

1.68[0.69,4.05]

Total events: 40 (PT+AD), 26 (AD)

Heterogeneity: Tau2=0.31; Chi2=3.94, df=1(P=0.05); I2=74.61%

Test for overall effect: Z=1.15(P=0.25)

7.1.3 Psychodynamic psychotherapy and others

Berger 2004

Subtotal (95% CI)

Total events: 29 (PT+AD), 34 (AD)

Heterogeneity: Not applicable

Test for overall effect: Z=1.03(P=0.3)

29/50

50

34/50

50

40.72%

40.72%

0.85[0.63,1.15]

0.85[0.63,1.15]

Total (95% CI)

110

108

100%

1.23[0.75,2.03]

Total events: 69 (PT+AD), 60 (AD)

Favours AD

0.1

0.2

0.5

1

2

5

10

Favours PT+AD

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

125

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

PT+AD

n/N

AD

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

Heterogeneity: Tau2=0.14; Chi2=7.89, df=2(P=0.02); I2=74.66%

Test for overall effect: Z=0.82(P=0.41)

Test for subgroup differences: Not applicable

Favours AD

0.1

0.2

0.5

1

2

5

10

Favours PT+AD

Analysis 7.2.   Comparison 7 SUBGROUP2: SSRI: Psychotherapy
+Antidepressant vs Antidepressant alone, Outcome 2 Remission at 2-4 months.

Study or subgroup

PT+AD

n/N

AD

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

7.2.1 Behaviour therapy

Subtotal (95% CI)

Total events: 0 (PT+AD), 0 (AD)

Heterogeneity: Not applicable

Test for overall effect: Not applicable

7.2.2 Cognitive-behaviour therapy

Sharp 1996

Subtotal (95% CI)

Total events: 24 (PT+AD), 20 (AD)

Heterogeneity: Not applicable

Test for overall effect: Z=0.66(P=0.51)

0

0

Not estimable

24/38

38

20/36

36

52.73%

52.73%

1.14[0.78,1.66]

1.14[0.78,1.66]

7.2.3 Psychodynamic psychotherapy and others

Berger 2004

Subtotal (95% CI)

Total events: 14 (PT+AD), 26 (AD)

Heterogeneity: Not applicable

Test for overall effect: Z=2.34(P=0.02)

14/50

50

26/50

50

47.27%

47.27%

0.54[0.32,0.9]

0.54[0.32,0.9]

Total (95% CI)

88

86

100%

0.8[0.38,1.7]

Total events: 38 (PT+AD), 46 (AD)

Heterogeneity: Tau2=0.24; Chi2=5.51, df=1(P=0.02); I2=81.84%

Test for overall effect: Z=0.59(P=0.56)

Test for subgroup differences: Not applicable

Favours AD

0.1

0.2

0.5

1

2

5

10

Favours PT+AD

Analysis 7.3.   Comparison 7 SUBGROUP2: SSRI: Psychotherapy+Antidepressant
vs Antidepressant alone, Outcome 3 Global severity at 2-4 months.

Study or subgroup

Treatment

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

7.3.1 Behaviour therapy

Subtotal ***

0

0

Not estimable

Heterogeneity: Not applicable

Test for overall effect: Not applicable

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

126

Favours treatment

-4

-2

0

2

4

Favours control

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Treatment

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

7.3.2 Cognitive-behaviour therapy

Sharp 1996

Subtotal ***

1.7 (1.1)

29

29

Heterogeneity: Tau2=0; Chi2=0, df=0(P<0.0001); I2=100%

Test for overall effect: Z=1.81(P=0.07)

7.3.3 Psychodynamic psychotherapy and others

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Not applicable

Total ***

0

29

Heterogeneity: Tau2=0; Chi2=0, df=0(P<0.0001); I2=100%

Test for overall effect: Z=1.81(P=0.07)

Test for subgroup differences: Not applicable

29

29

0

29

2.3 (1.2)

100%

100%

-0.48[-1.01,0.04]

-0.48[-1.01,0.04]

Not estimable

100%

-0.48[-1.01,0.04]

Favours treatment

-4

-2

0

2

4

Favours control

Analysis 7.4.   Comparison 7 SUBGROUP2: SSRI: Psychotherapy+Antidepressant
vs Antidepressant alone, Outcome 4 Frequency of panic attacks at 2-4 months.

Study or subgroup

Treatment

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

7.4.1 Behaviour therapy

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Not applicable

7.4.2 Cognitive-behaviour therapy

Azhar 2000

Berger 2004

Subtotal ***

0

17

20

37

4.1 (3.9)

0.6 (1.1)

Heterogeneity: Tau2=1.18; Chi2=10.83, df=1(P=0); I2=90.77%

Test for overall effect: Z=0.94(P=0.35)

7.4.3 Psychodynamic psychotherapy and others

0.6 (1.1)

Berger 2004

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=0.09(P=0.92)

Total ***

20

20

57

Heterogeneity: Tau2=0.56; Chi2=13.03, df=2(P=0); I2=84.65%

Test for overall effect: Z=1(P=0.32)

Test for subgroup differences: Chi2=2.2, df=1 (P=0.14), I2=54.5%

0

17

32

49

32

32

81

9.1 (2)

0.6 (1.6)

0.6 (1.6)

Not estimable

30.81%

34.59%

65.41%

-1.59[-2.37,-0.81]

0.03[-0.53,0.59]

-0.76[-2.34,0.83]

34.59%

34.59%

0.03[-0.53,0.59]

0.03[-0.53,0.59]

100%

-0.47[-1.39,0.45]

Favours treatment

-4

-2

0

2

4

Favours control

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

127

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 7.5.   Comparison 7 SUBGROUP2: SSRI: Psychotherapy+Antidepressant
vs Antidepressant alone, Outcome 5 Phobic avoidance at 2-4 months.

Study or subgroup

Treatment

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

7.5.1 Behaviour therapy

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Not applicable

7.5.2 Cognitive-behaviour therapy

Berger 2004

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=1.95(P=0.05)

0

20

20

7.5.3 Psychodynamic psychotherapy and others

Berger 2004

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=1.95(P=0.05)

Total ***

20

20

40

Heterogeneity: Tau2=0; Chi2=0, df=1(P=1); I2=0%

Test for overall effect: Z=2.75(P=0.01)

Test for subgroup differences: Not applicable

0.5 (1)

0.5 (1)

0

32

32

32

32

64

0.1 (0.3)

0.1 (0.3)

Not estimable

0.57[-0,1.14]

0.57[-0,1.14]

0.57[-0,1.14]

0.57[-0,1.14]

50%

50%

50%

50%

100%

0.57[0.16,0.97]

Favours treatment

-4

-2

0

2

4

Favours control

Analysis 7.6.   Comparison 7 SUBGROUP2: SSRI: Psychotherapy+Antidepressant
vs Antidepressant alone, Outcome 6 General anxiety at 2-4 months.

Study or subgroup

Treatment

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

7.6.1 Behaviour therapy

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Not applicable

7.6.2 Cognitive-behaviour therapy

Azhar 2000

Berger 2004

Sharp 1996

Subtotal ***

0

17

20

29

66

22.9 (4.7)

1.8 (2)

4.8 (5.7)

Heterogeneity: Tau2=0.51; Chi2=12.84, df=2(P=0); I2=84.42%

Test for overall effect: Z=0.96(P=0.34)

7.6.3 Psychodynamic psychotherapy and others

Berger 2004

Subtotal ***

1.8 (2)

20

20

Heterogeneity: Not applicable

Test for overall effect: Z=1.35(P=0.18)

0

17

32

29

78

32

32

28.7 (4.2)

1 (2)

7.9 (7)

1 (2)

Not estimable

22.79%

25.54%

26.13%

74.46%

-1.29[-2.03,-0.54]

0.39[-0.18,0.95]

-0.48[-1,0.04]

-0.43[-1.32,0.45]

25.54%

25.54%

0.39[-0.18,0.95]

0.39[-0.18,0.95]

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

128

Favours treatment

-4

-2

0

2

4

Favours control

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Treatment

Control

Std. Mean Difference

Weight

Std. Mean Difference

Total ***

Mean(SD)

N

86

N

110

Heterogeneity: Tau2=0.43; Chi2=17.4, df=3(P=0); I2=82.76%

Test for overall effect: Z=0.61(P=0.54)

Test for subgroup differences: Chi2=4.56, df=1 (P=0.03), I2=78.08%

Mean(SD)

Random, 95% CI

Random, 95% CI

100%

-0.22[-0.93,0.49]

Favours treatment

-4

-2

0

2

4

Favours control

Analysis 7.7.   Comparison 7 SUBGROUP2: SSRI: Psychotherapy
+Antidepressant vs Antidepressant alone, Outcome 7 Depression at 2-4 months.

Study or subgroup

Treatment

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

7.7.1 Behaviour therapy

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Not applicable

7.7.2 Cognitive-behaviour therapy

Azhar 2000

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=2.45(P=0.01)

0

17

17

9.2 (1.4)

7.7.3 Psychodynamic psychotherapy and others

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Not applicable

Total ***

0

17

Heterogeneity: Not applicable

Test for overall effect: Z=2.45(P=0.01)

Test for subgroup differences: Not applicable

0

17

17

0

17

Not estimable

12.2 (4.5)

100%

100%

-0.89[-1.6,-0.18]

-0.89[-1.6,-0.18]

Not estimable

100%

-0.89[-1.6,-0.18]

Favours treatment

-4

-2

0

2

4

Favours control

Analysis 7.8.   Comparison 7 SUBGROUP2: SSRI: Psychotherapy+Antidepressant
vs Antidepressant alone, Outcome 8 Social functioning at 2-4 months.

Study or subgroup

Treatment

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

7.8.1 Behavour therapy

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Not applicable

7.8.2 Cognitive-behaviour therapy

Sharp 1996

Subtotal ***

Heterogeneity: Not applicable

0

29

29

0

29

29

1.4 (2.8)

Not estimable

2.2 (2.9)

100%

100%

-0.3[-0.82,0.22]

-0.3[-0.82,0.22]

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

129

Favours treatment

-4

-2

0

2

4

Favours control

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Treatment

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

Test for overall effect: Z=1.14(P=0.25)

7.8.3 Psychodynamic psychotherapy and others

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Not applicable

Total ***

0

29

Heterogeneity: Not applicable

Test for overall effect: Z=1.14(P=0.25)

Test for subgroup differences: Not applicable

0

29

Not estimable

100%

-0.3[-0.82,0.22]

Favours treatment

-4

-2

0

2

4

Favours control

Analysis 7.9.   Comparison 7 SUBGROUP2: SSRI: Psychotherapy+Antidepressant
vs Antidepressant alone, Outcome 9 Dropouts for any reason within 2-4 months.

Study or subgroup

7.9.1 Behaviour therapy

Subtotal (95% CI)

Total events: 0 (Treatment), 0 (Control)

Heterogeneity: Not applicable

Test for overall effect: Not applicable

7.9.2 Cognitive-behaviour therapy

Azhar 2000

Sharp 1996

Subtotal (95% CI)

Treatment

n/N

Control

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

0

0

Not estimable

5/22

11/38

60

5/22

12/36

58

15.67%

40.31%

55.97%

1[0.34,2.97]

0.87[0.44,1.71]

0.9[0.51,1.61]

Total events: 16 (Treatment), 17 (Control)

Heterogeneity: Tau2=0; Chi2=0.05, df=1(P=0.83); I2=0%

Test for overall effect: Z=0.35(P=0.73)

7.9.3 Psychodynamic psychotherapy and others

Berger 2004

Subtotal (95% CI)

15/50

50

12/50

50

Total events: 15 (Treatment), 12 (Control)

Heterogeneity: Not applicable

Test for overall effect: Z=0.67(P=0.5)

44.03%

44.03%

1.25[0.65,2.39]

1.25[0.65,2.39]

Total (95% CI)

110

108

100%

1.04[0.68,1.6]

Total events: 31 (Treatment), 29 (Control)

Heterogeneity: Tau2=0; Chi2=0.58, df=2(P=0.75); I2=0%

Test for overall effect: Z=0.19(P=0.85)

Test for subgroup differences: Not applicable

Favours treatment

0.1

0.2

0.5

1

2

5

10

Favours control

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

130

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 7.10.   Comparison 7 SUBGROUP2: SSRI: Psychotherapy+Antidepressant vs
Antidepressant alone, Outcome 10 Dropouts due to side effects within 2-4 months.

Study or subgroup

Treatment

n/N

Control

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

7.10.1 Behaviour therapy

Subtotal (95% CI)

Total events: 0 (Treatment), 0 (Control)

Heterogeneity: Not applicable

Test for overall effect: Not applicable

7.10.2 Cognitive-behaviour therapy

Sharp 1996

Subtotal (95% CI)

Total events: 5 (Treatment), 3 (Control)

Heterogeneity: Not applicable

Test for overall effect: Z=0.66(P=0.51)

0

0

Not estimable

5/38

38

3/36

36

100%

100%

1.58[0.41,6.13]

1.58[0.41,6.13]

7.10.3 Psychodynamic psychotherapy and others

Subtotal (95% CI)

0

0

Total events: 0 (Treatment), 0 (Control)

Heterogeneity: Not applicable

Test for overall effect: Not applicable

Not estimable

Total (95% CI)

38

36

100%

1.58[0.41,6.13]

Total events: 5 (Treatment), 3 (Control)

Heterogeneity: Not applicable

Test for overall effect: Z=0.66(P=0.51)

Test for subgroup differences: Not applicable

Favours treatment

0.1

0.2

0.5

1

2

5

10

Favours control

Analysis 7.11.   Comparison 7 SUBGROUP2: SSRI: Psychotherapy+Antidepressant
vs Antidepressant alone, Outcome 11 Response/remission on continued treatment.

Study or subgroup

PT+AD

n/N

AD

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

7.11.1 Behaviour therapy

Subtotal (95% CI)

Total events: 0 (PT+AD), 0 (AD)

Heterogeneity: Not applicable

Test for overall effect: Not applicable

7.11.2 Cognitive-behaviour therapy

Subtotal (95% CI)

Total events: 0 (PT+AD), 0 (AD)

Heterogeneity: Not applicable

Test for overall effect: Not applicable

0

0

0

0

7.11.3 Psychdynamic psychotherapy and others

Berger 2004

Subtotal (95% CI)

Total events: 16 (PT+AD), 26 (AD)

16/35

35

26/38

38

Not estimable

Not estimable

100%

100%

0.67[0.44,1.02]

0.67[0.44,1.02]

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

131

Favours AD

0.1

0.2

0.5

1

2

5

10

Favours PT+AD

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

PT+AD

n/N

AD

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

Heterogeneity: Not applicable

Test for overall effect: Z=1.88(P=0.06)

Total (95% CI)

35

38

100%

0.67[0.44,1.02]

Total events: 16 (PT+AD), 26 (AD)

Heterogeneity: Not applicable

Test for overall effect: Z=1.88(P=0.06)

Test for subgroup differences: Not applicable

Favours AD

0.1

0.2

0.5

1

2

5

10

Favours PT+AD

Analysis 7.12.   Comparison 7 SUBGROUP2: SSRI: Psychotherapy+Antidepressant vs
Antidepressant alone, Outcome 12 Global/Avoidance/Panic on continued treatment.

Study or subgroup

Treatment

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

7.12.1 Behaviour therapy

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Not applicable

7.12.2 Cognitive-behaviour therapy

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Not applicable

0

0

7.12.3 Psychodynamic psychotherapy and others

Berger 2004

Subtotal ***

0.5 (1)

21

21

Heterogeneity: Tau2=0; Chi2=0, df=0(P<0.0001); I2=100%

Test for overall effect: Z=1.45(P=0.15)

Total ***

21

Heterogeneity: Tau2=0; Chi2=0, df=0(P<0.0001); I2=100%

Test for overall effect: Z=1.45(P=0.15)

Test for subgroup differences: Not applicable

0

0

29

29

29

Not estimable

Not estimable

0.1 (0.6)

100%

100%

0.42[-0.15,0.99]

0.42[-0.15,0.99]

100%

0.42[-0.15,0.99]

Favours treatment

-4

-2

0

2

4

Favours control

Analysis 7.14.   Comparison 7 SUBGROUP2: SSRI: Psychotherapy+Antidepressant vs Antidepressant
alone, Outcome 14 Response/remission immediately after treatment discontinuation.

Study or subgroup

PT+AD

n/N

AD

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

7.14.1 Behaviour therapy

Subtotal (95% CI)

Total events: 0 (PT+AD), 0 (AD)

Heterogeneity: Not applicable

Test for overall effect: Not applicable

0

0

Not estimable

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

132

Favours AD

0.1

0.2

0.5

1

2

5

10

Favours PT+AD

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

PT+AD

n/N

AD

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

7.14.2 Cognitive-behaviour therapy

Subtotal (95% CI)

Total events: 0 (PT+AD), 0 (AD)

Heterogeneity: Not applicable

Test for overall effect: Not applicable

7.14.3 Psychodynamic psychotherapy and others

0

0

Not estimable

Berger 2004

Subtotal (95% CI)

Total events: 16 (PT+AD), 26 (AD)

Heterogeneity: Not applicable

Test for overall effect: Z=1.18(P=0.24)

16/21

21

26/29

29

100%

100%

0.85[0.65,1.11]

0.85[0.65,1.11]

Total (95% CI)

21

29

100%

0.85[0.65,1.11]

Total events: 16 (PT+AD), 26 (AD)

Heterogeneity: Not applicable

Test for overall effect: Z=1.18(P=0.24)

Test for subgroup differences: Not applicable

Favours AD

0.1

0.2

0.5

1

2

5

10

Favours PT+AD

Analysis 7.15.   Comparison 7 SUBGROUP2: SSRI: Psychotherapy+Antidepressant vs Antidepressant
alone, Outcome 15 Global/Avoidance/Panic immediately after treatment discontinuation.

Study or subgroup

Treatment

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

7.15.1 Behaviour therapy

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Not applicable

7.15.2 Cognitive-behaviour therapy

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Not applicable

0

0

7.15.3 Psychodynamic psychotherapy and others

Berger 2004

Subtotal ***

0.5 (1)

21

21

Heterogeneity: Tau2=0; Chi2=0, df=0(P<0.0001); I2=100%

Test for overall effect: Z=1.45(P=0.15)

Total ***

21

Heterogeneity: Tau2=0; Chi2=0, df=0(P<0.0001); I2=100%

Test for overall effect: Z=1.45(P=0.15)

Test for subgroup differences: Not applicable

0

0

29

29

29

Not estimable

Not estimable

0.1 (0.6)

100%

100%

0.42[-0.15,0.99]

0.42[-0.15,0.99]

100%

0.42[-0.15,0.99]

Favours treatment

-4

-2

0

2

4

Favours control

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

133

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 7.16.   Comparison 7 SUBGROUP2: SSRI: Psychotherapy+Antidepressant vs Antidepressant
alone, Outcome 16 Response/remission 6-24 months after treatment discontinuation.

Study or subgroup

PT+AD

n/N

AD

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

7.16.1 Behaviour therapy

Subtotal (95% CI)

Total events: 0 (PT+AD), 0 (AD)

Heterogeneity: Not applicable

Test for overall effect: Not applicable

7.16.2 Cognitive-behaviour therapy

Sharp 1996

Subtotal (95% CI)

Total events: 16 (PT+AD), 10 (AD)

Heterogeneity: Not applicable

Test for overall effect: Z=1.26(P=0.21)

0

0

Not estimable

16/38

38

10/36

36

100%

100%

1.52[0.8,2.89]

1.52[0.8,2.89]

7.16.3 Psychodynamic psychotherapy and others

Subtotal (95% CI)

Total events: 0 (PT+AD), 0 (AD)

Heterogeneity: Not applicable

Test for overall effect: Not applicable

0

0

Not estimable

Total (95% CI)

38

36

100%

1.52[0.8,2.89]

Total events: 16 (PT+AD), 10 (AD)

Heterogeneity: Not applicable

Test for overall effect: Z=1.26(P=0.21)

Test for subgroup differences: Not applicable

Favours AD

0.1

0.2

0.5

1

2

5

10

Favours PT+AD

Comparison 8.   SUBGROUP2: SSRI: Psychotherapy+Antidepressant vs Psychotherapy alone or +Placebo

Outcome or subgroup title

1 Response at 2-4 months

1.1 Behaviour therapy

1.2 Cognitive-behaviour therapy

2 Remission at 2-4 months

2.1 Behaviour therapy

2.2 Cognitive-behaviour therapy

No. of
studies

No. of
partici-
pants

Statistical method

Effect size

8

2

6

7

2

5

426

69

357

382

69

313

Risk Ratio (M-H, Random, 95%
CI)

1.24 [0.94, 1.65]

Risk Ratio (M-H, Random, 95%
CI)

2.93 [1.07, 7.99]

Risk Ratio (M-H, Random, 95%
CI)

1.16 [0.89, 1.53]

Risk Ratio (M-H, Random, 95%
CI)

1.31 [1.04, 1.65]

Risk Ratio (M-H, Random, 95%
CI)

1.15 [0.79, 1.68]

Risk Ratio (M-H, Random, 95%
CI)

1.39 [1.01, 1.92]

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

134

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

3 Global severity at 2-4 months

3.1 Behaviour therapy

3.2 Cognitive-behaviour therapy

4 Frequency of panic attacks at 2-4 months

4.1 Behaviour therapy

4.2 Cognitive-behaviour therapy

5 Phobic avoidance at 2-4 months

5.1 Behaviour therapy

5.2 Cognitive-behaviour therapy

6 General anxiety at 2-4 months

6.1 Behaviour therapy

6.2 Cognitive-behaviour therapy

7 Depression at 2-4 months

7.1 Behaviour therapy

7.2 Cognitive-behaviour therapy

8 Social malfunctioning at 2-4 months

8.1 Behaviour therapy

8.2 Cognitive-behaviour therapy

No. of
studies

No. of
partici-
pants

Statistical method

Effect size

4

2

2

5

2

3

6

2

4

8

2

6

4

2

2

3

0

3

148

56

92

232

53

179

210

56

154

351

56

295

114

56

58

116

0

116

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.29 [-0.64, 0.06]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.58 [-1.14, -0.01]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.12 [-0.56, 0.32]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.24 [-0.50, 0.02]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.37 [-0.95, 0.20]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.21 [-0.50, 0.09]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.39 [-0.71, -0.06]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.99 [-1.57, -0.40]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.18 [-0.51, 0.15]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.30 [-0.54, -0.07]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.88 [-1.46, -0.30]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.21 [-0.45, 0.02]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.62 [-1.01, -0.24]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.76 [-1.34, -0.19]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.51 [-1.03, 0.02]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.09 [-0.47, 0.30]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.0 [0.0, 0.0]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.09 [-0.47, 0.30]

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

135

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of
studies

No. of
partici-
pants

Statistical method

Effect size

9 Dropouts for any reason within 2-4 months

7

9.1 Behaviour therapy

9.2 Cognitive-behaviour therapy

10 Dropouts due to side effects within 2-4
months

10.1 Behaviour therapy

10.2 Cognitive-behaviour therapy

11 Response/remission on continued treat-
ment

11.1 Behaviour therapy

11.2 Cognitive-behaviour therapy

12 Global/Avoidance/Panic on continued
treatment

12.1 Behaviour therapy

12.2 Cognitive-behaviour therapy

13 Dropouts for any reason on continued
treatment

13.1 Behaviour therapy

13.2 Cognitive-behaviour therapy

18 Response 6-24 months after treatment
discontinuation

18.1 Behaviour therapy

18.2 Cognitive-behaviour therapy

2

5

6

2

4

0

0

0

0

0

0

1

1

0

4

2

2

382

69

313

349

69

280

0

0

0

0

0

0

38

38

0

186

69

117

Risk Ratio (M-H, Random, 95%
CI)

1.12 [0.70, 1.80]

Risk Ratio (M-H, Random, 95%
CI)

1.19 [0.44, 3.22]

Risk Ratio (M-H, Random, 95%
CI)

1.11 [0.64, 1.93]

Risk Ratio (M-H, Random, 95%
CI)

4.22 [1.47, 12.08]

Risk Ratio (M-H, Random, 95%
CI)

5.41 [0.59, 49.42]

Risk Ratio (M-H, Random, 95%
CI)

3.93 [1.19, 12.97]

Risk Ratio (M-H, Random, 95%
CI)

0.0 [0.0, 0.0]

Risk Ratio (M-H, Random, 95%
CI)

0.0 [0.0, 0.0]

Risk Ratio (M-H, Random, 95%
CI)

0.0 [0.0, 0.0]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.0 [0.0, 0.0]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.0 [0.0, 0.0]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.0 [0.0, 0.0]

Risk Ratio (M-H, Random, 95%
CI)

3.00 [0.13, 69.31]

Risk Ratio (M-H, Random, 95%
CI)

3.00 [0.13, 69.31]

Risk Ratio (M-H, Random, 95%
CI)

0.0 [0.0, 0.0]

Risk Ratio (M-H, Random, 95%
CI)

1.03 [0.73, 1.44]

Risk Ratio (M-H, Random, 95%
CI)

1.02 [0.62, 1.69]

Risk Ratio (M-H, Random, 95%
CI)

1.03 [0.65, 1.63]

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

136

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Outcome or subgroup title

19 Global/Avoidance/Panic 6-24 months af-
ter treatment discontinuation

19.1 Behaviour therapy

19.2 Cognitive-behviour therapy

Cochrane Database of Systematic Reviews

No. of
studies

No. of
partici-
pants

2

2

0

54

54

0

Statistical method

Effect size

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.01 [-0.56, 0.58]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.01 [-0.56, 0.58]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.0 [0.0, 0.0]

Analysis 8.1.   Comparison 8 SUBGROUP2: SSRI: Psychotherapy+Antidepressant
vs Psychotherapy alone or +Placebo, Outcome 1 Response at 2-4 months.

PT+AD

n/N

PT+placebo

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

Study or subgroup

8.1.1 Behaviour therapy

de Beurs 1995i

de Beurs 1995ii

Subtotal (95% CI)

4/12

4/12

24

Total events: 8 (PT+AD), 5 (PT+placebo)

Heterogeneity: Tau2=0; Chi2=0.27, df=1(P=0.6); I2=0%

Test for overall effect: Z=2.1(P=0.04)

8.1.2 Cognitive-behaviour therapy

Azhar 2000

Kampman 2002

Oehrberg 1995

Sharp 1996i

Sharp 1996ii

Stein 2000

Subtotal (95% CI)

14/22

12/22

42/60

13/19

13/19

13/16

158

Total events: 107 (PT+AD), 113 (PT+placebo)

Heterogeneity: Tau2=0.07; Chi2=13.19, df=5(P=0.02); I2=62.08%

Test for overall effect: Z=1.09(P=0.28)

2/24

3/21

45

17/22

5/21

25/60

28/36

26/43

12/17

199

2.93%

3.87%

6.8%

4[0.85,18.84]

2.33[0.62,8.72]

2.93[1.07,7.99]

16.67%

7.55%

17.94%

17.68%

16.65%

16.72%

93.2%

0.82[0.56,1.21]

2.29[0.97,5.39]

1.68[1.19,2.37]

0.88[0.62,1.25]

1.13[0.77,1.67]

1.15[0.78,1.69]

1.16[0.89,1.53]

Total (95% CI)

182

244

100%

1.24[0.94,1.65]

Total events: 115 (PT+AD), 118 (PT+placebo)

Heterogeneity: Tau2=0.09; Chi2=17.46, df=7(P=0.01); I2=59.92%

Test for overall effect: Z=1.51(P=0.13)

Test for subgroup differences: Not applicable

Favours PT+placebo

0.2

0.5

1

2

5

Favours PT+AD

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

137

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 8.2.   Comparison 8 SUBGROUP2: SSRI: Psychotherapy+Antidepressant
vs Psychotherapy alone or +Placebo, Outcome 2 Remission at 2-4 months.

PT+AD

n/N

PT+placebo

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

Study or subgroup

8.2.1 Behaviour therapy

de Beurs 1995i

de Beurs 1995ii

Subtotal (95% CI)

8/12

8/12

24

Total events: 16 (PT+AD), 26 (PT+placebo)

Heterogeneity: Tau2=0; Chi2=0, df=1(P=0.96); I2=0%

Test for overall effect: Z=0.74(P=0.46)

8.2.2 Cognitive-behaviour therapy

Kampman 2002

Oehrberg 1995

Sharp 1996i

Sharp 1996ii

Stein 2000

Subtotal (95% CI)

14/22

39/60

12/19

12/19

7/16

136

Total events: 84 (PT+AD), 79 (PT+placebo)

Heterogeneity: Tau2=0.06; Chi2=7.72, df=4(P=0.1); I2=48.15%

Test for overall effect: Z=2(P=0.05)

14/24

12/21

45

9/21

21/60

25/36

21/43

3/17

177

14.02%

13.21%

27.23%

1.14[0.68,1.93]

1.17[0.68,2.01]

1.15[0.79,1.68]

11.83%

20.7%

19.81%

16.84%

3.59%

72.77%

1.48[0.83,2.67]

1.86[1.26,2.75]

0.91[0.61,1.37]

1.29[0.82,2.05]

2.48[0.77,7.97]

1.39[1.01,1.92]

Total (95% CI)

160

222

100%

1.31[1.04,1.65]

Total events: 100 (PT+AD), 105 (PT+placebo)

Heterogeneity: Tau2=0.03; Chi2=8.32, df=6(P=0.22); I2=27.89%

Test for overall effect: Z=2.32(P=0.02)

Test for subgroup differences: Not applicable

Favours PT+placebo

0.1

0.2

0.5

1

2

5

10

Favours PT+AD

Analysis 8.3.   Comparison 8 SUBGROUP2: SSRI: Psychotherapy+Antidepressant
vs Psychotherapy alone or +Placebo, Outcome 3 Global severity at 2-4 months.

Study or subgroup

PT+AD

PT+placebo

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

8.3.1 Behaviour therapy

de Beurs 1995i

de Beurs 1995ii

Subtotal ***

1.6 (0.8)

1.6 (0.8)

10

9

19

Heterogeneity: Tau2=0; Chi2=0.04, df=1(P=0.85); I2=0%

Test for overall effect: Z=2(P=0.05)

8.3.2 Cognitive-behaviour therapy

Sharp 1996i

Sharp 1996ii

Subtotal ***

1.7 (1.1)

1.7 (1.1)

15

14

29

Heterogeneity: Tau2=0; Chi2=0.34, df=1(P=0.56); I2=0%

Test for overall effect: Z=0.52(P=0.61)

2.1 (1.1)

2.3 (1.2)

2 (1.3)

1.7 (1)

19

18

37

33

30

63

Total ***

48

100

Heterogeneity: Tau2=0; Chi2=1.96, df=3(P=0.58); I2=0%

19.88%

17.92%

37.8%

-0.52[-1.3,0.26]

-0.64[-1.46,0.19]

-0.58[-1.14,-0.01]

32.19%

30%

62.2%

-0.24[-0.86,0.37]

0.02[-0.61,0.65]

-0.12[-0.56,0.32]

100%

-0.29[-0.64,0.06]

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

138

Favours treatment

-4

-2

0

2

4

Favours control

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

PT+AD

PT+placebo

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

Test for overall effect: Z=1.64(P=0.1)

Test for subgroup differences: Chi2=1.58, df=1 (P=0.21), I2=36.84%

Favours treatment

-4

-2

0

2

4

Favours control

Analysis 8.4.   Comparison 8 SUBGROUP2: SSRI: Psychotherapy+Antidepressant vs
Psychotherapy alone or +Placebo, Outcome 4 Frequency of panic attacks at 2-4 months.

Study or subgroup

PT+AD

PT+placebo

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

8.4.1 Behaviour therapy

de Beurs 1995i

de Beurs 1995ii

Subtotal ***

0.2 (0.5)

0.2 (0.5)

9

9

18

Heterogeneity: Tau2=0; Chi2=0.19, df=1(P=0.66); I2=0%

Test for overall effect: Z=1.27(P=0.21)

8.4.2 Cognitive-behaviour therapy

Azhar 2000

Kampman 2002

Oehrberg 1995

Subtotal ***

4.1 (3.9)

2.2 (0.6)

-16 (18.4)

17

19

55

91

Heterogeneity: Tau2=0; Chi2=1.44, df=2(P=0.49); I2=0%

Test for overall effect: Z=1.37(P=0.17)

0.5 (1.6)

1.7 (3.5)

3.6 (2.2)

2.3 (0.7)

-9.8 (18.4)

19

16

35

17

19

52

88

10.84%

9.95%

20.79%

-0.25[-1.04,0.55]

-0.51[-1.34,0.32]

-0.37[-0.95,0.2]

15.16%

16.94%

47.11%

79.21%

0.13[-0.54,0.81]

-0.15[-0.79,0.49]

-0.33[-0.72,0.05]

-0.21[-0.5,0.09]

Total ***

109

123

100%

-0.24[-0.5,0.02]

Heterogeneity: Tau2=0; Chi2=1.89, df=4(P=0.76); I2=0%

Test for overall effect: Z=1.79(P=0.07)

Test for subgroup differences: Chi2=0.25, df=1 (P=0.62), I2=0%

Favours treatment

-4

-2

0

2

4

Favours control

Analysis 8.5.   Comparison 8 SUBGROUP2: SSRI: Psychotherapy+Antidepressant
vs Psychotherapy alone or +Placebo, Outcome 5 Phobic avoidance at 2-4 months.

Study or subgroup

PT+AD

PT+placebo

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

8.5.1 Behaviour therapy

de Beurs 1995i

de Beurs 1995ii

Subtotal ***

4.1 (2)

4.1 (2)

10

9

19

Heterogeneity: Tau2=0; Chi2=0, df=1(P=1); I2=0%

Test for overall effect: Z=3.29(P=0)

8.5.2 Cognitive-behaviour therapy

Kampman 2002

Sharp 1996i

Sharp 1996ii

Stein 2000

19

15

14

12

1.8 (0.5)

4.7 (7.8)

4.7 (7.8)

-5.8 (6.7)

19

18

37

19

33

30

12

5.7 (1.3)

6.1 (1.9)

2 (0.6)

7.2 (10.6)

5.1 (5.4)

-5.9 (9.8)

13.32%

12.36%

25.69%

-0.99[-1.8,-0.17]

-0.99[-1.84,-0.14]

-0.99[-1.57,-0.4]

19.62%

21.06%

19.95%

13.69%

-0.35[-1,0.29]

-0.25[-0.86,0.36]

-0.06[-0.7,0.57]

0.01[-0.79,0.81]

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

139

Favours treatment

-4

-2

0

2

4

Favours control

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

PT+AD

PT+placebo

Std. Mean Difference

Weight

Std. Mean Difference

Subtotal ***

Mean(SD)

N

60

N

94

Heterogeneity: Tau2=0; Chi2=0.69, df=3(P=0.88); I2=0%

Test for overall effect: Z=1.08(P=0.28)

Total ***

79

131

Heterogeneity: Tau2=0.03; Chi2=6.15, df=5(P=0.29); I2=18.75%

Test for overall effect: Z=2.35(P=0.02)

Test for subgroup differences: Chi2=5.47, df=1 (P=0.02), I2=81.71%

Mean(SD)

Random, 95% CI

Random, 95% CI

74.31%

-0.18[-0.51,0.15]

100%

-0.39[-0.71,-0.06]

Favours treatment

-4

-2

0

2

4

Favours control

Analysis 8.6.   Comparison 8 SUBGROUP2: SSRI: Psychotherapy+Antidepressant
vs Psychotherapy alone or +Placebo, Outcome 6 General anxiety at 2-4 months.

Study or subgroup

PT+AD

PT+placebo

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

8.6.1 Behaviour therapy

de Beurs 1995i

de Beurs 1995ii

Subtotal ***

2.6 (1.3)

2.6 (1.3)

10

9

19

Heterogeneity: Tau2=0; Chi2=0, df=1(P=0.97); I2=0%

Test for overall effect: Z=2.96(P=0)

8.6.2 Cognitive-behaviour therapy

Azhar 2000

Kampman 2002

Oehrberg 1995

Sharp 1996i

Sharp 1996ii

Stein 2000

Subtotal ***

22.9 (4.7)

1.5 (1.7)

-6.5 (5.5)

4.8 (5.7)

4.8 (5.7)

-15.3 (10.6)

17

19

55

15

14

12

132

3.8 (1.4)

3.9 (1.5)

21.5 (5.2)

1.7 (1.3)

-4.3 (5.5)

6.5 (6.7)

4.9 (4.4)

-10 (13.1)

19

18

37

17

19

52

33

30

12

163

Heterogeneity: Tau2=0; Chi2=3.56, df=5(P=0.61); I2=0%

Test for overall effect: Z=1.76(P=0.08)

Total ***

151

200

Heterogeneity: Tau2=0.01; Chi2=7.91, df=7(P=0.34); I2=11.51%

Test for overall effect: Z=2.52(P=0.01)

Test for subgroup differences: Chi2=4.35, df=1 (P=0.04), I2=76.99%

8.03%

7.38%

15.41%

-0.87[-1.67,-0.06]

-0.89[-1.73,-0.05]

-0.88[-1.46,-0.3]

10.99%

12.22%

28.12%

13.08%

12.3%

7.88%

84.59%

0.27[-0.41,0.94]

-0.13[-0.77,0.51]

-0.4[-0.78,-0.01]

-0.26[-0.87,0.35]

-0.02[-0.65,0.61]

-0.43[-1.24,0.38]

-0.21[-0.45,0.02]

100%

-0.3[-0.54,-0.07]

Favours treatment

-4

-2

0

2

4

Favours control

Analysis 8.7.   Comparison 8 SUBGROUP2: SSRI: Psychotherapy+Antidepressant
vs Psychotherapy alone or +Placebo, Outcome 7 Depression at 2-4 months.

Study or subgroup

PT+AD

PT+placebo

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

8.7.1 Behaviour therapy

de Beurs 1995i

de Beurs 1995ii

10

9

2.6 (1)

2.6 (1)

19

18

3.5 (1.4)

3.8 (1.5)

24.24%

21.46%

-0.68[-1.46,0.11]

-0.86[-1.7,-0.02]

Favours treatment

-4

-2

0

2

4

Favours control

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

140

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

PT+AD

PT+placebo

Std. Mean Difference

Weight

Std. Mean Difference

Subtotal ***

Mean(SD)

N

19

N

37

Heterogeneity: Tau2=0; Chi2=0.1, df=1(P=0.75); I2=0%

Test for overall effect: Z=2.6(P=0.01)

Mean(SD)

Random, 95% CI

Random, 95% CI

45.69%

-0.76[-1.34,-0.19]

8.7.2 Cognitive-behaviour therapy

Azhar 2000

Stein 2000

Subtotal ***

9.2 (1.4)

-10.5 (10.4)

17

12

29

Heterogeneity: Tau2=0; Chi2=0.98, df=1(P=0.32); I2=0%

Test for overall effect: Z=1.89(P=0.06)

Total ***

48

Heterogeneity: Tau2=0; Chi2=1.49, df=3(P=0.68); I2=0%

Test for overall effect: Z=3.15(P=0)

Test for subgroup differences: Chi2=0.41, df=1 (P=0.52), I2=0%

10 (0.6)

-8.6 (7.6)

17

12

29

66

30.93%

23.38%

54.31%

-0.74[-1.44,-0.04]

-0.2[-1,0.6]

-0.51[-1.03,0.02]

100%

-0.62[-1.01,-0.24]

Favours treatment

-4

-2

0

2

4

Favours control

Analysis 8.8.   Comparison 8 SUBGROUP2: SSRI: Psychotherapy+Antidepressant vs
Psychotherapy alone or +Placebo, Outcome 8 Social malfunctioning at 2-4 months.

Study or subgroup

PT+AD

PT+placebo

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

8.8.1 Behaviour therapy

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Not applicable

8.8.2 Cognitive-behaviour therapy

Sharp 1996i

Sharp 1996ii

Stein 2000

Subtotal ***

0

15

14

12

41

1.4 (2.8)

1.4 (2.8)

-3.1 (2.5)

Heterogeneity: Tau2=0; Chi2=1.68, df=2(P=0.43); I2=0%

Test for overall effect: Z=0.44(P=0.66)

Total ***

41

Heterogeneity: Tau2=0; Chi2=1.68, df=2(P=0.43); I2=0%

Test for overall effect: Z=0.44(P=0.66)

Test for subgroup differences: Not applicable

0

33

30

12

75

75

2.1 (2.6)

1.9 (2.6)

-4 (2.1)

Not estimable

39.93%

37.13%

22.94%

100%

-0.27[-0.88,0.34]

-0.18[-0.82,0.46]

0.38[-0.43,1.18]

-0.09[-0.47,0.3]

100%

-0.09[-0.47,0.3]

Favours treatment

-4

-2

0

2

4

Favours control

Analysis 8.9.   Comparison 8 SUBGROUP2: SSRI: Psychotherapy+Antidepressant vs
Psychotherapy alone or +Placebo, Outcome 9 Dropouts for any reason within 2-4 months.

Study or subgroup

8.9.1 Behaviour therapy

PT+AD

n/N

PT+placebo

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

Favours treatment

0.1

0.2

0.5

1

2

5

10

Favours control

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

141

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

PT+AD

n/N

PT+placebo

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

Study or subgroup

de Beurs 1995i

de Beurs 1995ii

Subtotal (95% CI)

Total events: 5 (PT+AD), 8 (PT+placebo)

Heterogeneity: Tau2=0; Chi2=0, df=1(P=0.98); I2=0%

Test for overall effect: Z=0.34(P=0.74)

8.9.2 Cognitive-behaviour therapy

Kampman 2002

Oehrberg 1995

Sharp 1996i

Sharp 1996ii

Stein 2000

Subtotal (95% CI)

3/22

5/60

6/19

5/19

1/16

136

Total events: 20 (PT+AD), 28 (PT+placebo)

Heterogeneity: Tau2=0.01; Chi2=4.14, df=4(P=0.39); I2=3.47%

Test for overall effect: Z=0.37(P=0.71)

5/24

3/21

45

2/21

8/60

4/36

13/43

1/17

177

14.29%

8.31%

22.6%

1.2[0.34,4.2]

1.17[0.23,6.03]

1.19[0.44,3.22]

7.88%

20.01%

17.36%

29.03%

3.11%

77.4%

1.43[0.27,7.73]

0.63[0.22,1.8]

2.84[0.91,8.86]

0.87[0.36,2.1]

1.06[0.07,15.6]

1.11[0.64,1.93]

Total (95% CI)

160

222

100%

1.12[0.7,1.8]

Total events: 25 (PT+AD), 36 (PT+placebo)

Heterogeneity: Tau2=0; Chi2=4.16, df=6(P=0.65); I2=0%

Test for overall effect: Z=0.48(P=0.63)

Test for subgroup differences: Not applicable

Favours treatment

0.1

0.2

0.5

1

2

5

10

Favours control

Analysis 8.10.   Comparison 8 SUBGROUP2: SSRI: Psychotherapy+Antidepressant vs
Psychotherapy alone or +Placebo, Outcome 10 Dropouts due to side effects within 2-4 months.

PT+AD

n/N

PT+placebo

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

3/12

2/12

24

1/12

1/12

24

0/24

0/21

45

2/21

0/60

0/36

0/43

160

11.29%

11.31%

22.59%

5.77[0.25,131.92]

5.08[0.22,115.7]

5.41[0.59,49.42]

38.87%

13.14%

13.03%

12.36%

77.41%

1.43[0.27,7.73]

9[0.5,163.58]

12.95[0.7,238.39]

11[0.55,218.74]

3.93[1.19,12.97]

Study or subgroup

8.10.1 Behaviour therapy

de Beurs 1995i

de Beurs 1995ii

Subtotal (95% CI)

Total events: 2 (PT+AD), 0 (PT+placebo)

Heterogeneity: Tau2=0; Chi2=0, df=1(P=0.95); I2=0%

Test for overall effect: Z=1.5(P=0.13)

8.10.2 Cognitive-behaviour therapy

Kampman 2002

Oehrberg 1995

Sharp 1996i

Sharp 1996ii

Subtotal (95% CI)

3/22

4/60

3/19

2/19

120

Total events: 12 (PT+AD), 2 (PT+placebo)

Heterogeneity: Tau2=0; Chi2=2.9, df=3(P=0.41); I2=0%

Test for overall effect: Z=2.24(P=0.02)

Total (95% CI)

144

205

100%

4.22[1.47,12.08]

Favours treatment

0.1

0.2

0.5

1

2

5

10

Favours control

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

142

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

PT+AD

n/N

PT+placebo

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

Total events: 14 (PT+AD), 2 (PT+placebo)

Heterogeneity: Tau2=0; Chi2=2.94, df=5(P=0.71); I2=0%

Test for overall effect: Z=2.68(P=0.01)

Test for subgroup differences: Not applicable

Favours treatment

0.1

0.2

0.5

1

2

5

10

Favours control

Analysis 8.13.   Comparison 8 SUBGROUP2: SSRI: Psychotherapy+Antidepressant vs
Psychotherapy alone or +Placebo, Outcome 13 Dropouts for any reason on continued treatment.

PT+AD

n/N

PT+placebo

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

1/19

19

0/19

19

100%

100%

3[0.13,69.31]

3[0.13,69.31]

Study or subgroup

8.13.1 Behaviour therapy

de Beurs 1995i

Subtotal (95% CI)

Total events: 1 (PT+AD), 0 (PT+placebo)

Heterogeneity: Not applicable

Test for overall effect: Z=0.69(P=0.49)

8.13.2 Cognitive-behaviour therapy

Subtotal (95% CI)

0

0

Not estimable

Total events: 0 (PT+AD), 0 (PT+placebo)

Heterogeneity: Not applicable

Test for overall effect: Not applicable

Total (95% CI)

19

19

100%

3[0.13,69.31]

Total events: 1 (PT+AD), 0 (PT+placebo)

Heterogeneity: Not applicable

Test for overall effect: Z=0.69(P=0.49)

Test for subgroup differences: Not applicable

Favours treatment

0.1

0.2

0.5

1

2

5

10

Favours control

Analysis 8.18.   Comparison 8 SUBGROUP2: SSRI: Psychotherapy+Antidepressant vs Psychotherapy
alone or +Placebo, Outcome 18 Response 6-24 months after treatment discontinuation.

Study or subgroup

8.18.1 Behaviour therapy

de Beurs 1995i

de Beurs 1995ii

Subtotal (95% CI)

PT+AD

n/N

PT+placebo

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

6/12

6/12

24

12/24

10/21

45

23.76%

21.88%

45.64%

1[0.5,2]

1.05[0.51,2.16]

1.02[0.62,1.69]

Total events: 12 (PT+AD), 22 (PT+placebo)

Heterogeneity: Tau2=0; Chi2=0.01, df=1(P=0.92); I2=0%

Test for overall effect: Z=0.09(P=0.93)

8.18.2 Cognitive-behaviour therapy

Sharp 1996i

Sharp 1996ii

8/19

8/19

17/36

15/43

28.71%

25.65%

0.89[0.47,1.67]

1.21[0.62,2.35]

Favours PT+placebo

0.2

0.5

1

2

5

Favours PT+AD

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

143

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

PT+AD

n/N

PT+placebo

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

Subtotal (95% CI)

38

79

54.36%

1.03[0.65,1.63]

Total events: 16 (PT+AD), 32 (PT+placebo)

Heterogeneity: Tau2=0; Chi2=0.42, df=1(P=0.52); I2=0%

Test for overall effect: Z=0.12(P=0.9)

Total (95% CI)

62

124

100%

1.03[0.73,1.44]

Total events: 28 (PT+AD), 54 (PT+placebo)

Heterogeneity: Tau2=0; Chi2=0.43, df=3(P=0.93); I2=0%

Test for overall effect: Z=0.15(P=0.88)

Test for subgroup differences: Not applicable

Favours PT+placebo

0.2

0.5

1

2

5

Favours PT+AD

Analysis 8.19.   Comparison 8 SUBGROUP2: SSRI: Psychotherapy+Antidepressant vs Psychotherapy
alone or +Placebo, Outcome 19 Global/Avoidance/Panic 6-24 months after treatment discontinuation.

Study or subgroup

PT+AD

PT+placebo

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

8.19.1 Behaviour therapy

de Beurs 1995i

de Beurs 1995ii

Subtotal ***

3.3 (2.4)

3.3 (2.4)

9

9

18

Heterogeneity: Tau2=0; Chi2=0.05, df=1(P=0.83); I2=0%

Test for overall effect: Z=0.04(P=0.97)

8.19.2 Cognitive-behviour therapy

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Not applicable

Total ***

0

18

Heterogeneity: Tau2=0; Chi2=0.05, df=1(P=0.83); I2=0%

Test for overall effect: Z=0.04(P=0.97)

Test for subgroup differences: Not applicable

19

17

36

0

36

3.2 (2.7)

3.5 (2.2)

50.92%

49.08%

100%

0.07[-0.72,0.86]

-0.05[-0.86,0.76]

0.01[-0.56,0.58]

Not estimable

100%

0.01[-0.56,0.58]

Favours treatment

-10

-5

0

5

10

Favours control

Comparison 9.   SUBGROUP3: 100%agoraphobia: Psychotherapy+Antidepressant vs Antidepressant alone

Outcome or subgroup title

1 Response at 2-4 months

1.1 Behaviour therapy

No. of
studies

No. of
partici-
pants

5

4

223

193

Statistical method

Effect size

Risk Ratio (M-H, Random,
95% CI)

1.35 [0.88, 2.08]

Risk Ratio (M-H, Random,
95% CI)

1.06 [0.80, 1.40]

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

144

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Outcome or subgroup title

1.2 Cognitive-behaviour therapy

1.3 Psychodynamic psychotherapy and others

2 Remission at 2-4 months

2.1 Behaviour therapy

2.2 Cognitive-behaviour therapy

2.3 Psychodynamic psychotherapy and others

3 Global severity at 2-4 months

3.1 Behaviour therapy

3.2 Cognitive-behaviour therapy

3.3 Psychodynamic psychotherapy and others

4 Frequency of panic attacks at 2-4 months

4.1 Behaviour therapy

4.2 Cognitive-behaviour therapy

4.3 Psychodynamic psychotherapy and others

5 Phobic avoidance at 2-4 months

5.1 Behaviour therapy

5.2 Cognitive-behaviour therapy

5.3 Psychodynamic psychotherapy and others

Cochrane Database of Systematic Reviews

No. of
studies

No. of
partici-
pants

Statistical method

Effect size

1

0

3

2

1

0

2

2

0

0

4

4

0

0

6

4

2

0

30

0

144

114

30

0

90

90

0

0

138

138

0

0

226

138

88

0

Risk Ratio (M-H, Random,
95% CI)

2.51 [1.16, 5.47]

Risk Ratio (M-H, Random,
95% CI)

0.0 [0.0, 0.0]

Risk Ratio (M-H, Random,
95% CI)

1.36 [0.63, 2.96]

Risk Ratio (M-H, Random,
95% CI)

0.97 [0.62, 1.51]

Risk Ratio (M-H, Random,
95% CI)

5.14 [1.33, 19.92]

Risk Ratio (M-H, Random,
95% CI)

0.0 [0.0, 0.0]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.51 [-1.45, 0.44]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.51 [-1.45, 0.44]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.0 [0.0, 0.0]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.0 [0.0, 0.0]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.15 [-0.49, 0.19]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.15 [-0.49, 0.19]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.0 [0.0, 0.0]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.0 [0.0, 0.0]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.51 [-0.89, -0.13]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.53 [-1.01, -0.06]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.53 [-1.45, 0.39]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.0 [0.0, 0.0]

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

145

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of
studies

6 General anxiety at 2-4 months

6.1 Behaviour therapy

6.2 Cognitive-behaviour therapy

6.3 Psychodynamic psychotherapy and others

7 Depression at 2-4 months

7.1 Behaviour therapy

7.2 Cognitive-behaviour therapy

7.3 Psychodynamic psychotherapy and others

8 Social functioning at 2-4 months

8.1 Behavour therapy

8.2 Cognitive-behaviour therapy

8.3 Psychodynamic psychotherapy and others

9 Dropouts for any reason within 2-4 months

9.1 Behaviour therapy

9.2 Cognitive-behaviour therapy

9.3 Psychodynamic psychotherapy and others

10 Dropouts due to side effects within 2-4
months

10.1 Behaviour therapy

3

2

1

0

5

4

1

0

4

3

1

0

5

4

1

0

2

2

No. of
partici-
pants

120

90

30

0

168

138

30

0

148

118

30

0

223

193

30

0

43

43

Statistical method

Effect size

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.36 [-0.77, 0.05]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.19 [-0.60, 0.23]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.79 [-1.54, -0.04]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.0 [0.0, 0.0]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.45 [-0.77, -0.13]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.35 [-0.69, -0.01]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.93 [-1.69, -0.17]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.0 [0.0, 0.0]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.53 [-1.02, -0.05]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.30 [-0.68, 0.08]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-1.08 [-1.85, -0.30]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.0 [0.0, 0.0]

Risk Ratio (M-H, Random,
95% CI)

1.08 [0.72, 1.63]

Risk Ratio (M-H, Random,
95% CI)

1.21 [0.78, 1.88]

Risk Ratio (M-H, Random,
95% CI)

0.49 [0.16, 1.54]

Risk Ratio (M-H, Random,
95% CI)

0.0 [0.0, 0.0]

Risk Ratio (M-H, Random,
95% CI)

0.97 [0.27, 3.58]

Risk Ratio (M-H, Random,
95% CI)

0.97 [0.27, 3.58]

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

146

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Outcome or subgroup title

10.2 Cognitive-behaviour therapy

10.3 Psychodynamic psychotherapy and others

11 Response/remission on continued treatment

11.1 Behaviour therapy

11.2 Cognitive-behaviour therapy

11.3 Psychdynamic psychotherapy and others

12 Global/Avoidance/Panic on continued treat-
ment

12.1 Behaviour therapy

12.2 Cognitive-behaviour therapy

12.3 Psychodynamic psychotherapy and others

13 Dropouts for any reason on continued treat-
ment

13.1 Behaviour therapy

13.2 Cognitive-behaviour therapy

13.3 Psychodynamic psychotherapy and others

14 Response/remission immediately after treat-
ment discontinuation

14.1 Behaviour therapy

14.2 Cognitive-behaviour therapy

14.3 Psychodynamic psychotherapy and others

Cochrane Database of Systematic Reviews

No. of
studies

No. of
partici-
pants

Statistical method

Effect size

0

0

2

2

0

0

2

2

0

0

1

1

0

0

0

0

0

0

0

0

121

121

0

0

48

48

0

0

20

20

0

0

0

0

0

0

Risk Ratio (M-H, Random,
95% CI)

0.0 [0.0, 0.0]

Risk Ratio (M-H, Random,
95% CI)

0.0 [0.0, 0.0]

Risk Ratio (M-H, Random,
95% CI)

1.94 [1.10, 3.41]

Risk Ratio (M-H, Random,
95% CI)

1.94 [1.10, 3.41]

Risk Ratio (M-H, Random,
95% CI)

0.0 [0.0, 0.0]

Risk Ratio (M-H, Random,
95% CI)

0.0 [0.0, 0.0]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.91 [-1.51, -0.30]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.91 [-1.51, -0.30]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.0 [0.0, 0.0]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.0 [0.0, 0.0]

Risk Ratio (M-H, Random,
95% CI)

1.0 [0.07, 13.87]

Risk Ratio (M-H, Random,
95% CI)

1.0 [0.07, 13.87]

Risk Ratio (M-H, Random,
95% CI)

0.0 [0.0, 0.0]

Risk Ratio (M-H, Random,
95% CI)

0.0 [0.0, 0.0]

Risk Ratio (M-H, Random,
95% CI)

0.0 [0.0, 0.0]

Risk Ratio (M-H, Random,
95% CI)

0.0 [0.0, 0.0]

Risk Ratio (M-H, Random,
95% CI)

0.0 [0.0, 0.0]

Risk Ratio (M-H, Random,
95% CI)

0.0 [0.0, 0.0]

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

147

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of
studies

No. of
partici-
pants

Statistical method

Effect size

15 Global/Avoidance/Panic immediately after
treatment discontinuation

15.1 Behaviour therapy

15.2 Cognitive-behaviour therapy

15.3 Psychodynamic psychotherapy and others

16 Response/remission 6-24 months after treat-
ment discontinuation

16.1 Behaviour therapy

16.2 Cognitive-behaviour therapy

16.3 Psychodynamic psychotherapy and others

17 Global/Avoidance/Panic 6-24 months after
treatment discontinuation

17.1 Behaviour therapy

17.2 Cognitive-behaviour therapy

17.3 Psychodynamic psychotherapy and others

0

0

0

0

2

1

1

0

0

0

0

0

0

0

0

0

126

96

30

0

0

0

0

0

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.0 [0.0, 0.0]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.0 [0.0, 0.0]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.0 [0.0, 0.0]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.0 [0.0, 0.0]

Risk Ratio (M-H, Random,
95% CI)

1.48 [1.02, 2.17]

Risk Ratio (M-H, Random,
95% CI)

1.49 [0.95, 2.35]

Risk Ratio (M-H, Random,
95% CI)

1.47 [0.75, 2.90]

Risk Ratio (M-H, Random,
95% CI)

0.0 [0.0, 0.0]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.0 [0.0, 0.0]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.0 [0.0, 0.0]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.0 [0.0, 0.0]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.0 [0.0, 0.0]

Analysis 9.1.   Comparison 9 SUBGROUP3: 100%agoraphobia: Psychotherapy
+Antidepressant vs Antidepressant alone, Outcome 1 Response at 2-4 months.

PT+AD

n/N

AD

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

7/28

7/9

5/13

25/43

93

5/26

6/9

1/12

32/53

100

13.2%

25.96%

4.27%

37.64%

81.07%

1.3[0.47,3.59]

1.17[0.65,2.08]

4.62[0.63,34.05]

0.96[0.69,1.35]

1.06[0.8,1.4]

Study or subgroup

9.1.1 Behaviour therapy

Johnston 1995

Mavissakalian 1983

Telch 1985

Zitrin 1983

Subtotal (95% CI)

Total events: 44 (PT+AD), 44 (AD)

Heterogeneity: Tau2=0; Chi2=2.86, df=3(P=0.41); I2=0%

Favours AD

0.1

0.2

0.5

1

2

5

10

Favours PT+AD

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

148

 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

PT+AD

n/N

AD

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

Test for overall effect: Z=0.41(P=0.68)

9.1.2 Cognitive-behaviour therapy

Loerch 1999

Subtotal (95% CI)

Total events: 11 (PT+AD), 5 (AD)

Heterogeneity: Not applicable

Test for overall effect: Z=2.33(P=0.02)

11/14

14

5/16

16

18.93%

18.93%

2.51[1.16,5.47]

2.51[1.16,5.47]

9.1.3 Psychodynamic psychotherapy and others

Subtotal (95% CI)

Total events: 0 (PT+AD), 0 (AD)

Heterogeneity: Not applicable

Test for overall effect: Not applicable

0

0

Not estimable

Total (95% CI)

107

116

100%

1.35[0.88,2.08]

Total events: 55 (PT+AD), 49 (AD)

Heterogeneity: Tau2=0.1; Chi2=7.29, df=4(P=0.12); I2=45.14%

Test for overall effect: Z=1.36(P=0.17)

Test for subgroup differences: Not applicable

Favours AD

0.1

0.2

0.5

1

2

5

10

Favours PT+AD

Analysis 9.2.   Comparison 9 SUBGROUP3: 100%agoraphobia: Psychotherapy
+Antidepressant vs Antidepressant alone, Outcome 2 Remission at 2-4 months.

PT+AD

n/N

AD

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

6/9

13/43

52

6/9

17/53

62

38.93%

40.69%

79.62%

1[0.52,1.92]

0.94[0.52,1.72]

0.97[0.62,1.51]

Study or subgroup

9.2.1 Behaviour therapy

Mavissakalian 1983

Zitrin 1983

Subtotal (95% CI)

Total events: 19 (PT+AD), 23 (AD)

Heterogeneity: Tau2=0; Chi2=0.02, df=1(P=0.89); I2=0%

Test for overall effect: Z=0.14(P=0.89)

9.2.2 Cognitive-behaviour therapy

Loerch 1999

Subtotal (95% CI)

Total events: 9 (PT+AD), 2 (AD)

Heterogeneity: Not applicable

Test for overall effect: Z=2.37(P=0.02)

9/14

14

2/16

16

20.38%

20.38%

5.14[1.33,19.92]

5.14[1.33,19.92]

9.2.3 Psychodynamic psychotherapy and others

Subtotal (95% CI)

Total events: 0 (PT+AD), 0 (AD)

Heterogeneity: Not applicable

Test for overall effect: Not applicable

0

0

Not estimable

Total (95% CI)

66

78

100%

1.36[0.63,2.96]

Favours AD

0.1

0.2

0.5

1

2

5

10

Favours PT+AD

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

149

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

PT+AD

n/N

AD

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

Total events: 28 (PT+AD), 25 (AD)

Heterogeneity: Tau2=0.29; Chi2=5.67, df=2(P=0.06); I2=64.75%

Test for overall effect: Z=0.78(P=0.43)

Test for subgroup differences: Not applicable

Favours AD

0.1

0.2

0.5

1

2

5

10

Favours PT+AD

Analysis 9.3.   Comparison 9 SUBGROUP3: 100%agoraphobia: Psychotherapy
+Antidepressant vs Antidepressant alone, Outcome 3 Global severity at 2-4 months.

Study or subgroup

Treatment

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

9.3.1 Behaviour therapy

Mavissakalian 1983

Zitrin 1983

Subtotal ***

2.2 (0.8)

3.2 (1)

8

34

42

Heterogeneity: Tau2=0.31; Chi2=2.62, df=1(P=0.11); I2=61.84%

Test for overall effect: Z=1.05(P=0.29)

9.3.2 Cognitive-behaviour therapy

Subtotal ***

0

Heterogeneity: Not applicable

Test for overall effect: Not applicable

9.3.3 Psychodynamic psychotherapy and others

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Not applicable

Total ***

0

42

Heterogeneity: Tau2=0.31; Chi2=2.62, df=1(P=0.11); I2=61.84%

Test for overall effect: Z=1.05(P=0.29)

Test for subgroup differences: Not applicable

7

41

48

0

0

48

3.7 (1.6)

3.3 (1)

36.33%

63.67%

100%

-1.14[-2.26,-0.02]

-0.14[-0.6,0.31]

-0.51[-1.45,0.44]

Not estimable

Not estimable

100%

-0.51[-1.45,0.44]

Favours treatment

-4

-2

0

2

4

Favours control

Analysis 9.4.   Comparison 9 SUBGROUP3: 100%agoraphobia: Psychotherapy+Antidepressant
vs Antidepressant alone, Outcome 4 Frequency of panic attacks at 2-4 months.

Study or subgroup

Treatment

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

9.4.1 Behaviour therapy

Johnston 1995

Mavissakalian 1983

Telch 1985

Zitrin 1983

Subtotal ***

12

8

10

34

64

0.6 (0.9)

1.7 (1.9)

0.6 (1.1)

6 (1.2)

16

7

10

41

74

0.3 (0.7)

2.1 (1.8)

0.8 (1)

6.4 (1.2)

Heterogeneity: Tau2=0; Chi2=2.22, df=3(P=0.53); I2=0%

Test for overall effect: Z=0.86(P=0.39)

19.96%

10.96%

14.76%

54.31%

100%

0.35[-0.41,1.1]

-0.22[-1.24,0.8]

-0.14[-1.01,0.74]

-0.32[-0.78,0.14]

-0.15[-0.49,0.19]

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

150

Favours treatment

-4

-2

0

2

4

Favours control

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Treatment

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

9.4.2 Cognitive-behaviour therapy

Subtotal ***

0

Heterogeneity: Not applicable

Test for overall effect: Not applicable

9.4.3 Psychodynamic psychotherapy and others

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Not applicable

Total ***

0

64

Heterogeneity: Tau2=0; Chi2=2.22, df=3(P=0.53); I2=0%

Test for overall effect: Z=0.86(P=0.39)

Test for subgroup differences: Not applicable

0

0

74

Not estimable

Not estimable

100%

-0.15[-0.49,0.19]

Favours treatment

-4

-2

0

2

4

Favours control

Analysis 9.5.   Comparison 9 SUBGROUP3: 100%agoraphobia: Psychotherapy
+Antidepressant vs Antidepressant alone, Outcome 5 Phobic avoidance at 2-4 months.

Study or subgroup

Treatment

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

13.9 (9)

19.4 (12.4)

28.4 (11.2)

2.8 (1.4)

19 (13.2)

5.5 (7.9)

9.5.1 Behaviour therapy

Johnston 1995

Mavissakalian 1983

Telch 1985

Zitrin 1983

Subtotal ***

8.5 (8.4)

8.6 (6.2)

17.3 (10.3)

2.7 (1.4)

12

8

10

34

64

Heterogeneity: Tau2=0.09; Chi2=4.73, df=3(P=0.19); I2=36.59%

Test for overall effect: Z=2.19(P=0.03)

9.5.2 Cognitive-behaviour therapy

Loerch 1999

Sheehan 1980a

Subtotal ***

7 (8.3)

4.7 (7.8)

14

29

43

Heterogeneity: Tau2=0.34; Chi2=4, df=1(P=0.05); I2=74.97%

Test for overall effect: Z=1.12(P=0.26)

9.5.3 Psychodynamic psychotherapy and others

Subtotal ***

0

Heterogeneity: Not applicable

Test for overall effect: Not applicable

16

7

10

41

74

16

29

45

0

Total ***

107

119

Heterogeneity: Tau2=0.09; Chi2=8.73, df=5(P=0.12); I2=42.75%

Test for overall effect: Z=2.66(P=0.01)

Test for subgroup differences: Chi2=0.01, df=1 (P=0.93), I2=0%

15.24%

9.07%

11.59%

25.7%

61.6%

-0.6[-1.37,0.17]

-1.07[-2.18,0.04]

-0.99[-1.93,-0.05]

-0.11[-0.56,0.35]

-0.53[-1.01,-0.06]

15.14%

23.26%

38.4%

-1.05[-1.82,-0.28]

-0.1[-0.62,0.41]

-0.53[-1.45,0.39]

Not estimable

100%

-0.51[-0.89,-0.13]

Favours treatment

-4

-2

0

2

4

Favours control

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

151

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 9.6.   Comparison 9 SUBGROUP3: 100%agoraphobia: Psychotherapy
+Antidepressant vs Antidepressant alone, Outcome 6 General anxiety at 2-4 months.

Study or subgroup

Treatment

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

32.3 (13.1)

22.8 (9.9)

19.9 (9.8)

9.6.1 Behaviour therapy

Mavissakalian 1983

Zitrin 1983

Subtotal ***

27.3 (4.8)

21.5 (9.9)

8

34

42

Heterogeneity: Tau2=0; Chi2=0.39, df=1(P=0.53); I2=0%

Test for overall effect: Z=0.88(P=0.38)

9.6.2 Cognitive-behaviour therapy

Loerch 1999

Subtotal ***

11.4 (11.1)

14

14

Heterogeneity: Not applicable

Test for overall effect: Z=2.07(P=0.04)

9.6.3 Psychodynamic psychotherapy and others

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Not applicable

Total ***

0

56

Heterogeneity: Tau2=0.02; Chi2=2.3, df=2(P=0.32); I2=12.95%

Test for overall effect: Z=1.71(P=0.09)

Test for subgroup differences: Chi2=1.91, df=1 (P=0.17), I2=47.51%

7

41

48

16

16

0

64

14.59%

59.12%

73.71%

-0.49[-1.53,0.54]

-0.13[-0.58,0.33]

-0.19[-0.6,0.23]

26.29%

26.29%

-0.79[-1.54,-0.04]

-0.79[-1.54,-0.04]

Not estimable

100%

-0.36[-0.77,0.05]

Favours treatment

-4

-2

0

2

4

Favours control

Analysis 9.7.   Comparison 9 SUBGROUP3: 100%agoraphobia: Psychotherapy
+Antidepressant vs Antidepressant alone, Outcome 7 Depression at 2-4 months.

Study or subgroup

Treatment

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

9.7.1 Behaviour therapy

Johnston 1995

Mavissakalian 1983

Telch 1985

Zitrin 1983

Subtotal ***

0.8 (0.5)

2.4 (2)

13.4 (5.7)

1.3 (0.5)

12

8

10

34

64

Heterogeneity: Tau2=0; Chi2=2.28, df=3(P=0.52); I2=0%

Test for overall effect: Z=2.01(P=0.04)

9.7.2 Cognitive-behaviour therapy

Loerch 1999

Subtotal ***

5.6 (5.8)

14

14

Heterogeneity: Not applicable

Test for overall effect: Z=2.4(P=0.02)

9.7.3 Psychodynamic psychotherapy and others

Subtotal ***

0

16

7

10

41

74

16

16

0

1 (0.9)

9.1 (7.8)

14.7 (14.1)

1.5 (0.5)

12 (7.4)

17.45%

8.02%

12.95%

44.5%

82.91%

-0.27[-1.02,0.48]

-1.14[-2.26,-0.02]

-0.12[-0.99,0.76]

-0.31[-0.77,0.15]

-0.35[-0.69,-0.01]

17.09%

17.09%

-0.93[-1.69,-0.17]

-0.93[-1.69,-0.17]

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Favours treatment

-4

-2

0

2

4

Favours control

Not estimable

152

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Treatment

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

Heterogeneity: Not applicable

Test for overall effect: Not applicable

Total ***

78

90

Heterogeneity: Tau2=0.01; Chi2=4.15, df=4(P=0.39); I2=3.68%

Test for overall effect: Z=2.76(P=0.01)

Test for subgroup differences: Chi2=1.88, df=1 (P=0.17), I2=46.72%

100%

-0.45[-0.77,-0.13]

Favours treatment

-4

-2

0

2

4

Favours control

Analysis 9.8.   Comparison 9 SUBGROUP3: 100%agoraphobia: Psychotherapy
+Antidepressant vs Antidepressant alone, Outcome 8 Social functioning at 2-4 months.

Study or subgroup

Treatment

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

2.3 (0.7)

2.9 (0.9)

6 (0.9)

5.9 (3.5)

9.8.1 Behavour therapy

Johnston 1995

Mavissakalian 1983

Zitrin 1983

Subtotal ***

2.1 (0.6)

1.9 (0.9)

5.8 (0.9)

12

8

34

54

Heterogeneity: Tau2=0.01; Chi2=2.08, df=2(P=0.35); I2=3.92%

Test for overall effect: Z=1.53(P=0.13)

9.8.2 Cognitive-behaviour therapy

Loerch 1999

Subtotal ***

2.4 (2.8)

14

14

Heterogeneity: Not applicable

Test for overall effect: Z=2.73(P=0.01)

9.8.3 Psychodynamic psychotherapy and others

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Not applicable

Total ***

0

68

Heterogeneity: Tau2=0.1; Chi2=5.32, df=3(P=0.15); I2=43.62%

Test for overall effect: Z=2.16(P=0.03)

Test for subgroup differences: Chi2=3.24, df=1 (P=0.07), I2=69.13%

16

7

41

64

16

16

0

80

24.08%

14.38%

38.28%

76.74%

-0.28[-1.03,0.47]

-1.05[-2.15,0.06]

-0.17[-0.62,0.29]

-0.3[-0.68,0.08]

23.26%

23.26%

-1.08[-1.85,-0.3]

-1.08[-1.85,-0.3]

Not estimable

100%

-0.53[-1.02,-0.05]

Favours treatment

-4

-2

0

2

4

Favours control

Analysis 9.9.   Comparison 9 SUBGROUP3: 100%agoraphobia: Psychotherapy+Antidepressant
vs Antidepressant alone, Outcome 9 Dropouts for any reason within 2-4 months.

Study or subgroup

9.9.1 Behaviour therapy

Johnston 1995

Mavissakalian 1983

Treatment

n/N

Control

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

16/28

1/9

10/26

2/9

49.06%

3.39%

1.49[0.83,2.66]

0.5[0.05,4.58]

Favours treatment

0.1

0.2

0.5

1

2

5

10

Favours control

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

153

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Telch 1985

Zitrin 1983

Subtotal (95% CI)

Treatment

n/N

Control

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

3/13

9/43

93

2/12

12/53

100

6.44%

28.45%

87.34%

1.38[0.28,6.91]

0.92[0.43,1.99]

1.21[0.78,1.88]

Total events: 29 (Treatment), 26 (Control)

Heterogeneity: Tau2=0; Chi2=1.63, df=3(P=0.65); I2=0%

Test for overall effect: Z=0.87(P=0.38)

9.9.2 Cognitive-behaviour therapy

Loerch 1999

Subtotal (95% CI)

Total events: 3 (Treatment), 7 (Control)

Heterogeneity: Not applicable

Test for overall effect: Z=1.22(P=0.22)

3/14

14

7/16

16

12.66%

12.66%

0.49[0.16,1.54]

0.49[0.16,1.54]

9.9.3 Psychodynamic psychotherapy and others

Subtotal (95% CI)

0

0

Total events: 0 (Treatment), 0 (Control)

Heterogeneity: Not applicable

Test for overall effect: Not applicable

Not estimable

Total (95% CI)

107

116

100%

1.08[0.72,1.63]

Total events: 32 (Treatment), 33 (Control)

Heterogeneity: Tau2=0; Chi2=3.77, df=4(P=0.44); I2=0%

Test for overall effect: Z=0.38(P=0.7)

Test for subgroup differences: Not applicable

Favours treatment

0.1

0.2

0.5

1

2

5

10

Favours control

Analysis 9.10.   Comparison 9 SUBGROUP3: 100%agoraphobia: Psychotherapy+Antidepressant
vs Antidepressant alone, Outcome 10 Dropouts due to side effects within 2-4 months.

Study or subgroup

9.10.1 Behaviour therapy

Mavissakalian 1983

Telch 1985

Subtotal (95% CI)

Treatment

n/N

Control

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

1/9

3/13

22

2/9

2/12

21

34.5%

65.5%

100%

0.5[0.05,4.58]

1.38[0.28,6.91]

0.97[0.27,3.58]

Total events: 4 (Treatment), 4 (Control)

Heterogeneity: Tau2=0; Chi2=0.53, df=1(P=0.47); I2=0%

Test for overall effect: Z=0.04(P=0.97)

9.10.2 Cognitive-behaviour therapy

Subtotal (95% CI)

Total events: 0 (Treatment), 0 (Control)

Heterogeneity: Not applicable

Test for overall effect: Not applicable

9.10.3 Psychodynamic psychotherapy and others

Subtotal (95% CI)

Total events: 0 (Treatment), 0 (Control)

0

0

0

0

Not estimable

Not estimable

Favours treatment

0.1

0.2

0.5

1

2

5

10

Favours control

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

154

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Treatment

n/N

Control

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

Heterogeneity: Not applicable

Test for overall effect: Not applicable

Total (95% CI)

22

21

100%

0.97[0.27,3.58]

Total events: 4 (Treatment), 4 (Control)

Heterogeneity: Tau2=0; Chi2=0.53, df=1(P=0.47); I2=0%

Test for overall effect: Z=0.04(P=0.97)

Test for subgroup differences: Not applicable

Favours treatment

0.1

0.2

0.5

1

2

5

10

Favours control

Analysis 9.11.   Comparison 9 SUBGROUP3: 100%agoraphobia: Psychotherapy+Antidepressant
vs Antidepressant alone, Outcome 11 Response/remission on continued treatment.

Study or subgroup

9.11.1 Behaviour therapy

Telch 1985

Zitrin 1983

Subtotal (95% CI)

Total events: 24 (PT+AD), 14 (AD)

PT+AD

n/N

AD

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

7/13

17/43

56

2/12

12/53

65

17.17%

82.83%

100%

3.23[0.83,12.61]

1.75[0.94,3.25]

1.94[1.1,3.41]

Heterogeneity: Tau2=0; Chi2=0.66, df=1(P=0.42); I2=0%

Test for overall effect: Z=2.3(P=0.02)

9.11.2 Cognitive-behaviour therapy

Subtotal (95% CI)

Total events: 0 (PT+AD), 0 (AD)

Heterogeneity: Not applicable

Test for overall effect: Not applicable

9.11.3 Psychdynamic psychotherapy and others

Subtotal (95% CI)

Total events: 0 (PT+AD), 0 (AD)

Heterogeneity: Not applicable

Test for overall effect: Not applicable

0

0

0

0

Not estimable

Not estimable

Total (95% CI)

56

65

100%

1.94[1.1,3.41]

Total events: 24 (PT+AD), 14 (AD)

Heterogeneity: Tau2=0; Chi2=0.66, df=1(P=0.42); I2=0%

Test for overall effect: Z=2.3(P=0.02)

Test for subgroup differences: Not applicable

Favours AD

0.1

0.2

0.5

1

2

5

10

Favours PT+AD

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

155

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 9.12.   Comparison 9 SUBGROUP3: 100%agoraphobia: Psychotherapy+Antidepressant
vs Antidepressant alone, Outcome 12 Global/Avoidance/Panic on continued treatment.

Study or subgroup

Treatment

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

9.12.1 Behaviour therapy

Johnston 1995

Telch 1985

Subtotal ***

5.4 (5.7)

12.6 (8.1)

12

10

22

Heterogeneity: Tau2=0; Chi2=0.7, df=1(P=0.4); I2=0%

Test for overall effect: Z=2.93(P=0)

9.12.2 Cognitive-behaviour therapy

Subtotal ***

0

Heterogeneity: Not applicable

Test for overall effect: Not applicable

9.12.3 Psychodynamic psychotherapy and others

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Not applicable

Total ***

0

22

Heterogeneity: Tau2=0; Chi2=0.7, df=1(P=0.4); I2=0%

Test for overall effect: Z=2.93(P=0)

Test for subgroup differences: Not applicable

16

10

26

0

0

26

11.3 (9.6)

23.8 (9.3)

61.3%

38.7%

100%

-0.7[-1.47,0.07]

-1.23[-2.2,-0.26]

-0.91[-1.51,-0.3]

Not estimable

Not estimable

100%

-0.91[-1.51,-0.3]

Favours treatment

-4

-2

0

2

4

Favours control

Analysis 9.13.   Comparison 9 SUBGROUP3: 100%agoraphobia: Psychotherapy+Antidepressant
vs Antidepressant alone, Outcome 13 Dropouts for any reason on continued treatment.

Treatment

n/N

Control

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

1/10

10

1/10

10

100%

100%

1[0.07,13.87]

1[0.07,13.87]

Study or subgroup

9.13.1 Behaviour therapy

Telch 1985

Subtotal (95% CI)

Total events: 1 (Treatment), 1 (Control)

Heterogeneity: Not applicable

Test for overall effect: Not applicable

9.13.2 Cognitive-behaviour therapy

Subtotal (95% CI)

Total events: 0 (Treatment), 0 (Control)

Heterogeneity: Not applicable

Test for overall effect: Not applicable

9.13.3 Psychodynamic psychotherapy and others

Subtotal (95% CI)

Total events: 0 (Treatment), 0 (Control)

Heterogeneity: Not applicable

Test for overall effect: Not applicable

0

0

0

0

Not estimable

Not estimable

Favours treatment

0.1

0.2

0.5

1

2

5

10

Favours control

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

156

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Treatment

n/N

Control

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

Total (95% CI)

10

10

100%

1[0.07,13.87]

Total events: 1 (Treatment), 1 (Control)

Heterogeneity: Not applicable

Test for overall effect: Not applicable

Test for subgroup differences: Not applicable

Favours treatment

0.1

0.2

0.5

1

2

5

10

Favours control

Analysis 9.16.   Comparison 9 SUBGROUP3: 100%agoraphobia: Psychotherapy+Antidepressant vs
Antidepressant alone, Outcome 16 Response/remission 6-24 months after treatment discontinuation.

Study or subgroup

9.16.1 Behaviour therapy

Zitrin 1983

Subtotal (95% CI)

Total events: 23 (PT+AD), 19 (AD)

Heterogeneity: Not applicable

Test for overall effect: Z=1.72(P=0.09)

9.16.2 Cognitive-behaviour therapy

Loerch 1999

Subtotal (95% CI)

Total events: 9 (PT+AD), 7 (AD)

Heterogeneity: Not applicable

Test for overall effect: Z=1.11(P=0.27)

PT+AD

n/N

AD

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

23/43

43

19/53

53

68.98%

68.98%

1.49[0.95,2.35]

1.49[0.95,2.35]

9/14

14

7/16

16

31.02%

31.02%

1.47[0.75,2.9]

1.47[0.75,2.9]

9.16.3 Psychodynamic psychotherapy and others

Subtotal (95% CI)

Total events: 0 (PT+AD), 0 (AD)

Heterogeneity: Not applicable

Test for overall effect: Not applicable

0

0

Not estimable

Total (95% CI)

57

69

100%

1.48[1.02,2.17]

Total events: 32 (PT+AD), 26 (AD)

Heterogeneity: Tau2=0; Chi2=0, df=1(P=0.97); I2=0%

Test for overall effect: Z=2.05(P=0.04)

Test for subgroup differences: Not applicable

Favours AD

0.1

0.2

0.5

1

2

5

10

Favours PT+AD

Comparison 10.   SUBGROUP3: 100%agoraphobia: Psychotherapy+Antidepressant vs Psychotherapy alone or
+Placebo

Outcome or subgroup title

No. of
studies

No. of
partici-
pants

Statistical method

Effect size

1 Response at 2-4 months

12

576

Risk Ratio (M-H, Random, 95%
CI)

1.18 [1.00, 1.40]

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

157

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

1.1 Behaviour therapy

1.2 Cognitive-behaviour therapy

2 Remission at 2-4 months

2.1 Behaviour therapy

2.2 Cognitive-behaviour therapy

3 Global severity at 2-4 months

3.1 Behaviour therapy

3.2 Cognitive-behaviour therapy

4 Frequency of panic attacks at 2-4 months

4.1 Behaviour therapy

4.2 Cognitive-behaviour therapy

5 Phobic avoidance at 2-4 months

5.1 Behaviour therapy

5.2 Cognitive-behaviour therapy

6 General anxiety at 2-4 months

6.1 Behaviour therapy

6.2 Cognitive-behaviour therapy

7 Depression at 2-4 months

No. of
studies

No. of
partici-
pants

Statistical method

Effect size

11

1

11

10

1

6

6

0

9

9

0

13

12

1

10

9

1

12

548

28

510

482

28

239

239

0

278

278

0

424

396

28

330

302

28

378

Risk Ratio (M-H, Random, 95%
CI)

1.28 [1.05, 1.56]

Risk Ratio (M-H, Random, 95%
CI)

0.92 [0.65, 1.30]

Risk Ratio (M-H, Random, 95%
CI)

1.28 [1.02, 1.60]

Risk Ratio (M-H, Random, 95%
CI)

1.31 [1.03, 1.66]

Risk Ratio (M-H, Random, 95%
CI)

1.13 [0.62, 2.05]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.61 [-0.87, -0.34]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.61 [-0.87, -0.34]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.0 [0.0, 0.0]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.06 [-0.19, 0.31]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.06 [-0.19, 0.31]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.0 [0.0, 0.0]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.39 [-0.67, -0.12]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.41 [-0.70, -0.11]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.28 [-1.03, 0.46]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.58 [-0.85, -0.32]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.64 [-0.90, -0.37]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.04 [-0.78, 0.70]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.40 [-0.65, -0.16]

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

158

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

No. of
studies

No. of
partici-
pants

Statistical method

Effect size

Outcome or subgroup title

7.1 Behaviour therapy

7.2 Cognitive-behaviour therapy

8 Social malfunctioning at 2-4 months

8.1 Behaviour therapy

8.2 Cognitive-behaviour therapy

11

1

8

7

1

9 Dropouts for any reason within 2-4 months

11

9.1 Behaviour therapy

10

9.2 Cognitive-behaviour therapy

10 Dropouts due to side effects within 2-4
months

10.1 Behaviour therapy

10.2 Cognitive-behaviour therapy

11 Response/remission on continued treat-
ment

11.1 Behaviour therapy

11.2 Cognitive-behaviour therapy

12 Global/Avoidance/Panic on continued
treatment

12.1 Behaviour therapy

12.2 Cognitive-behaviour therapy

13 Dropouts for any reason on continued
treatment

1

5

5

0

3

3

0

3

3

0

2

350

28

288

260

28

508

480

28

242

242

0

185

185

0

101

101

0

57

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.43 [-0.69, -0.17]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.16 [-0.90, 0.58]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.47 [-0.77, -0.17]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.55 [-0.84, -0.26]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.11 [-0.63, 0.85]

Risk Ratio (M-H, Random, 95%
CI)

1.22 [0.91, 1.62]

Risk Ratio (M-H, Random, 95%
CI)

1.20 [0.90, 1.60]

Risk Ratio (M-H, Random, 95%
CI)

3.00 [0.35, 25.46]

Risk Ratio (M-H, Random, 95%
CI)

1.99 [0.85, 4.62]

Risk Ratio (M-H, Random, 95%
CI)

1.99 [0.85, 4.62]

Risk Ratio (M-H, Random, 95%
CI)

0.0 [0.0, 0.0]

Risk Ratio (M-H, Random, 95%
CI)

1.25 [0.82, 1.90]

Risk Ratio (M-H, Random, 95%
CI)

1.25 [0.82, 1.90]

Risk Ratio (M-H, Random, 95%
CI)

0.0 [0.0, 0.0]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.95 [-1.37, -0.53]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.95 [-1.37, -0.53]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.0 [0.0, 0.0]

Risk Ratio (M-H, Random, 95%
CI)

2.86 [0.32, 25.80]

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

159

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of
studies

No. of
partici-
pants

Statistical method

Effect size

13.1 Behaviour therapy

13.2 Cognitive-behaviour therapy

18 Response 6-24 months after treatment
discontinuation

18.1 Behaviour therapy

18.2 Cognitive-behaviour therapy

19 Global/Avoidance/Panic 6-24 months af-
ter treatment discontinuation

19.1 Behaviour therapy

19.2 Cognitive-behviour therapy

2

0

8

7

1

5

5

0

57

0

347

319

28

141

141

0

Risk Ratio (M-H, Random, 95%
CI)

2.86 [0.32, 25.80]

Risk Ratio (M-H, Random, 95%
CI)

0.0 [0.0, 0.0]

Risk Ratio (M-H, Random, 95%
CI)

1.00 [0.79, 1.27]

Risk Ratio (M-H, Random, 95%
CI)

1.00 [0.77, 1.31]

Risk Ratio (M-H, Random, 95%
CI)

1.0 [0.58, 1.74]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.05 [-0.32, 0.43]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.05 [-0.32, 0.43]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.0 [0.0, 0.0]

Analysis 10.1.   Comparison 10 SUBGROUP3: 100%agoraphobia: Psychotherapy
+Antidepressant vs Psychotherapy alone or +Placebo, Outcome 1 Response at 2-4 months.

PT+AD

n/N

PT+placebo

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

Study or subgroup

10.1.1 Behaviour therapy

de Beurs 1995i

de Beurs 1995ii

Johnston 1995

Marks 1983

Mavissakalian 1986a

Mavissakalian 1986b

Sheehan 1980a

Sheehan 1980b

Telch 1985

Zitrin 1980

Zitrin 1983

Subtotal (95% CI)

4/12

4/12

7/28

17/36

11/20

8/20

16/28

16/29

5/13

25/41

25/43

282

2/24

3/21

7/27

12/36

10/20

9/20

6/16

5/14

2/12

16/35

21/41

266

Total events: 138 (PT+AD), 93 (PT+placebo)

Heterogeneity: Tau2=0; Chi2=6.17, df=10(P=0.8); I2=0%

Test for overall effect: Z=2.47(P=0.01)

10.1.2 Cognitive-behaviour therapy

Loerch 1999

Subtotal (95% CI)

11/14

14

12/14

14

1.22%

1.68%

3.58%

8.79%

8.38%

5.59%

5.81%

4.86%

1.41%

15.37%

19.05%

75.74%

4[0.85,18.84]

2.33[0.62,8.72]

0.96[0.39,2.38]

1.42[0.8,2.52]

1.1[0.61,1.99]

0.89[0.43,1.83]

1.52[0.75,3.1]

1.54[0.71,3.36]

2.31[0.55,9.74]

1.33[0.86,2.06]

1.14[0.77,1.68]

1.28[1.05,1.56]

24.26%

24.26%

0.92[0.65,1.3]

0.92[0.65,1.3]

Favours PT+placebo

0.2

0.5

1

2

5

Favours PT+AD

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

160

 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

PT+AD

n/N

PT+placebo

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

Total events: 11 (PT+AD), 12 (PT+placebo)

Heterogeneity: Not applicable

Test for overall effect: Z=0.49(P=0.62)

Total (95% CI)

296

280

100%

1.18[1,1.4]

Total events: 149 (PT+AD), 105 (PT+placebo)

Heterogeneity: Tau2=0; Chi2=9.54, df=11(P=0.57); I2=0%

Test for overall effect: Z=1.91(P=0.06)

Test for subgroup differences: Not applicable

Favours PT+placebo

0.2

0.5

1

2

5

Favours PT+AD

Analysis 10.2.   Comparison 10 SUBGROUP3: 100%agoraphobia: Psychotherapy
+Antidepressant vs Psychotherapy alone or +Placebo, Outcome 2 Remission at 2-4 months.

Study or subgroup

10.2.1 Behaviour therapy

de Beurs 1995i

de Beurs 1995ii

Fava 1997

Marks 1983

Mavissakalian 1986a

Mavissakalian 1986b

Sheehan 1980a

Sheehan 1980b

Zitrin 1980

Zitrin 1983

Subtotal (95% CI)

PT+AD

n/N

PT+placebo

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

8/12

8/12

1/7

20/36

8/20

8/20

5/28

10/29

7/41

13/43

248

14/24

12/21

4/7

17/36

4/20

5/20

2/15

2/15

4/35

5/41

234

18.3%

16.89%

1.36%

24.53%

4.75%

5.81%

2.19%

2.62%

3.84%

5.7%

1.14[0.68,1.93]

1.17[0.68,2.01]

0.25[0.04,1.71]

1.18[0.75,1.85]

2[0.72,5.59]

1.6[0.63,4.05]

1.34[0.29,6.09]

2.59[0.65,10.32]

1.49[0.48,4.68]

2.48[0.97,6.34]

85.99%

1.31[1.03,1.66]

Total events: 88 (PT+AD), 69 (PT+placebo)

Heterogeneity: Tau2=0; Chi2=7.34, df=9(P=0.6); I2=0%

Test for overall effect: Z=2.17(P=0.03)

10.2.2 Cognitive-behaviour therapy

Loerch 1999

Subtotal (95% CI)

Total events: 9 (PT+AD), 8 (PT+placebo)

Heterogeneity: Not applicable

Test for overall effect: Z=0.39(P=0.7)

9/14

14

8/14

14

14.01%

14.01%

1.13[0.62,2.05]

1.13[0.62,2.05]

Total (95% CI)

262

248

100%

1.28[1.02,1.6]

Total events: 97 (PT+AD), 77 (PT+placebo)

Heterogeneity: Tau2=0; Chi2=7.58, df=10(P=0.67); I2=0%

Test for overall effect: Z=2.16(P=0.03)

Test for subgroup differences: Not applicable

Favours PT+placebo

0.1

0.2

0.5

1

2

5

10

Favours PT+AD

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

161

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 10.3.   Comparison 10 SUBGROUP3: 100%agoraphobia: Psychotherapy
+Antidepressant vs Psychotherapy alone or +Placebo, Outcome 3 Global severity at 2-4 months.

Study or subgroup

PT+AD

PT+placebo

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

10.3.1 Behaviour therapy

de Beurs 1995i

de Beurs 1995ii

Mavissakalian 1986a

Mavissakalian 1986b

Zitrin 1980

Zitrin 1983

Subtotal ***

10

9

17

14

29

34

113

1.6 (0.8)

1.6 (0.8)

2 (1.7)

2.2 (1.7)

1.9 (0.6)

3.2 (1)

19

18

14

17

24

34

126

2.1 (1.1)

2.3 (1.2)

3 (1.9)

3.1 (1.9)

2.3 (0.9)

4 (1)

Heterogeneity: Tau2=0; Chi2=0.96, df=5(P=0.97); I2=0%

Test for overall effect: Z=4.52(P<0.0001)

10.3.2 Cognitive-behaviour therapy

Subtotal ***

0

0

Heterogeneity: Not applicable

Test for overall effect: Not applicable

11.47%

10.33%

13.35%

13.47%

23.03%

28.36%

100%

-0.52[-1.3,0.26]

-0.64[-1.46,0.19]

-0.55[-1.27,0.18]

-0.49[-1.2,0.23]

-0.5[-1.05,0.05]

-0.81[-1.3,-0.31]

-0.61[-0.87,-0.34]

Not estimable

Total ***

113

126

100%

-0.61[-0.87,-0.34]

Heterogeneity: Tau2=0; Chi2=0.96, df=5(P=0.97); I2=0%

Test for overall effect: Z=4.52(P<0.0001)

Test for subgroup differences: Not applicable

Favours treatment

-4

-2

0

2

4

Favours control

Analysis 10.4.   Comparison 10 SUBGROUP3: 100%agoraphobia: Psychotherapy+Antidepressant
vs Psychotherapy alone or +Placebo, Outcome 4 Frequency of panic attacks at 2-4 months.

Study or subgroup

PT+AD

PT+placebo

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

10.4.1 Behaviour therapy

de Beurs 1995i

de Beurs 1995ii

Fava 1997

Johnston 1995

Mavissakalian 1986a

Mavissakalian 1986b

Telch 1985

Zitrin 1980

Zitrin 1983

Subtotal ***

9

9

7

12

17

14

10

19

34

0.2 (0.5)

0.2 (0.5)

2.7 (0.8)

0.6 (0.9)

1.3 (2)

2.4 (1.9)

0.6 (1.1)

6.4 (1)

6 (1.2)

19

16

7

17

14

17

9

14

34

0.5 (1.6)

1.7 (3.5)

2 (1)

1.1 (1.8)

1.6 (2.1)

2.2 (2.1)

0.8 (0.7)

6 (1)

5.4 (1.2)

131

147

Heterogeneity: Tau2=0.01; Chi2=8.6, df=8(P=0.38); I2=6.93%

Test for overall effect: Z=0.47(P=0.64)

10.4.2 Cognitive-behaviour therapy

Subtotal ***

0

0

Heterogeneity: Not applicable

Test for overall effect: Not applicable

9.4%

8.67%

5.12%

10.64%

11.69%

11.71%

7.41%

12.06%

23.31%

100%

-0.25[-1.04,0.55]

-0.51[-1.34,0.32]

0.72[-0.37,1.82]

-0.34[-1.09,0.4]

-0.14[-0.85,0.56]

0.1[-0.61,0.8]

-0.18[-1.08,0.72]

0.36[-0.33,1.06]

0.44[-0.04,0.92]

0.06[-0.19,0.31]

Not estimable

Total ***

131

147

100%

0.06[-0.19,0.31]

Favours treatment

-4

-2

0

2

4

Favours control

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

162

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

PT+AD

PT+placebo

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

Heterogeneity: Tau2=0.01; Chi2=8.6, df=8(P=0.38); I2=6.93%

Test for overall effect: Z=0.47(P=0.64)

Test for subgroup differences: Not applicable

Favours treatment

-4

-2

0

2

4

Favours control

Analysis 10.5.   Comparison 10 SUBGROUP3: 100%agoraphobia: Psychotherapy+Antidepressant
vs Psychotherapy alone or +Placebo, Outcome 5 Phobic avoidance at 2-4 months.

Study or subgroup

PT+AD

PT+placebo

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

10.5.1 Behaviour therapy

de Beurs 1995i

de Beurs 1995ii

Fava 1997

Johnston 1995

Marks 1983

Mavissakalian 1986a

Mavissakalian 1986b

Sheehan 1980a

Sheehan 1980b

Telch 1985

Zitrin 1980

Zitrin 1983

Subtotal ***

10

9

7

12

23

17

14

18

17

10

25

34

4.1 (2)

4.1 (2)

19.6 (4.7)

8.5 (8.4)

11.4 (9.4)

11.4 (8.8)

12.3 (8.8)

3 (1)

2.4 (1.2)

17.3 (10.3)

6.2 (0.8)

2.7 (1.4)

19

18

7

17

22

14

17

11

11

9

21

34

5.7 (1.3)

6.1 (1.9)

15.6 (8.4)

13.5 (9.6)

12.7 (10.5)

13.8 (9.9)

13.3 (9.9)

3.9 (1.3)

3.9 (1.3)

23.3 (7.8)

5.7 (1.1)

3.4 (1.4)

196

200

Heterogeneity: Tau2=0.14; Chi2=22.21, df=11(P=0.02); I2=50.47%

Test for overall effect: Z=2.65(P=0.01)

10.5.2 Cognitive-behaviour therapy

Loerch 1999

Subtotal ***

14

14

7 (8.3)

14

14

9.1 (6.3)

Heterogeneity: Not applicable

Test for overall effect: Z=0.75(P=0.46)

Total ***

210

214

Heterogeneity: Tau2=0.11; Chi2=22.26, df=12(P=0.03); I2=46.1%

Test for overall effect: Z=2.8(P=0.01)

Test for subgroup differences: Chi2=0.05, df=1 (P=0.82), I2=0%

6.91%

6.55%

4.77%

7.54%

9.72%

8.05%

8.08%

7.24%

6.73%

5.85%

9.65%

11.28%

92.36%

-0.99[-1.8,-0.17]

-0.99[-1.84,-0.14]

0.55[-0.52,1.63]

-0.53[-1.29,0.22]

-0.13[-0.71,0.46]

-0.25[-0.96,0.46]

-0.1[-0.81,0.6]

-0.79[-1.57,-0.01]

-1.2[-2.03,-0.37]

-0.62[-1.55,0.31]

0.49[-0.1,1.08]

-0.51[-0.99,-0.02]

-0.41[-0.7,-0.11]

7.64%

7.64%

-0.28[-1.03,0.46]

-0.28[-1.03,0.46]

100%

-0.39[-0.67,-0.12]

Favours treatment

-4

-2

0

2

4

Favours control

Analysis 10.6.   Comparison 10 SUBGROUP3: 100%agoraphobia: Psychotherapy
+Antidepressant vs Psychotherapy alone or +Placebo, Outcome 6 General anxiety at 2-4 months.

Study or subgroup

PT+AD

PT+placebo

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

10.6.1 Behaviour therapy

de Beurs 1995i

de Beurs 1995ii

10

9

2.6 (1.3)

2.6 (1.3)

19

18

3.8 (1.4)

3.9 (1.5)

8.66%

8.04%

-0.87[-1.67,-0.06]

-0.89[-1.73,-0.05]

Favours treatment

-4

-2

0

2

4

Favours control

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

163

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

PT+AD

PT+placebo

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

Fava 1997

Marks 1983

Mavissakalian 1986a

Mavissakalian 1986b

Sheehan 1980a

Sheehan 1980b

Zitrin 1983

Subtotal ***

7

23

17

14

18

17

34

149

3.6 (0.5)

8.9 (9.4)

30.1 (7.6)

34.3 (7.6)

1 (0.7)

1 (0.6)

21.5 (9.9)

7

22

14

17

11

11

34

153

3.6 (0.5)

12.7 (9.2)

35.5 (9.3)

34.4 (9.3)

2 (1.1)

2 (1.1)

27.9 (9.9)

Heterogeneity: Tau2=0.03; Chi2=9.68, df=8(P=0.29); I2=17.35%

Test for overall effect: Z=4.71(P<0.0001)

10.6.2 Cognitive-behaviour therapy

Loerch 1999

Subtotal ***

11.4 (11.1)

14

14

14

14

11.9 (8.4)

Heterogeneity: Tau2=0; Chi2=0, df=0(P<0.0001); I2=100%

Test for overall effect: Z=0.11(P=0.91)

Total ***

163

167

Heterogeneity: Tau2=0.04; Chi2=11.89, df=9(P=0.22); I2=24.31%

Test for overall effect: Z=4.31(P<0.0001)

Test for subgroup differences: Chi2=2.21, df=1 (P=0.14), I2=54.78%

5.55%

13.59%

10.1%

10.52%

8.44%

7.99%

17.3%

90.19%

0[-1.05,1.05]

-0.4[-0.99,0.19]

-0.63[-1.35,0.1]

-0.01[-0.72,0.7]

-1.15[-1.97,-0.34]

-1.31[-2.15,-0.47]

-0.64[-1.13,-0.15]

-0.64[-0.9,-0.37]

9.81%

9.81%

-0.04[-0.78,0.7]

-0.04[-0.78,0.7]

100%

-0.58[-0.85,-0.32]

Favours treatment

-4

-2

0

2

4

Favours control

Analysis 10.7.   Comparison 10 SUBGROUP3: 100%agoraphobia: Psychotherapy
+Antidepressant vs Psychotherapy alone or +Placebo, Outcome 7 Depression at 2-4 months.

Study or subgroup

PT+AD

PT+placebo

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

10.7.1 Behaviour therapy

de Beurs 1995i

de Beurs 1995ii

Fava 1997

Johnston 1995

Marks 1983

Mavissakalian 1986a

Mavissakalian 1986b

Sheehan 1980a

Sheehan 1980b

Telch 1985

Zitrin 1983

Subtotal ***

10

9

7

12

23

17

14

18

17

10

34

2.6 (1)

2.6 (1)

1 (0)

0.8 (0.5)

4 (4.9)

2.8 (8.5)

8.7 (8.5)

51.1 (9.4)

45.4 (9)

13.4 (5.7)

1.3 (0.5)

19

18

7

17

22

14

17

11

11

9

34

3.5 (1.4)

3.8 (1.5)

1.1 (0.4)

1 (0.8)

4 (2.7)

7.7 (8.7)

6.9 (8.7)

57.7 (10.1)

57.7 (10.1)

13 (11.9)

1.6 (0.5)

171

179

Heterogeneity: Tau2=0.05; Chi2=12.1, df=9(P=0.21); I2=25.62%

Test for overall effect: Z=3.21(P=0)

10.7.2 Cognitive-behaviour therapy

Loerch 1999

Subtotal ***

14

14

5.6 (5.8)

14

14

6.5 (5.2)

Heterogeneity: Not applicable

Test for overall effect: Z=0.43(P=0.67)

7.78%

7.03%

8.58%

12.42%

8.97%

9.24%

8.05%

7.03%

6.21%

16.12%

91.41%

-0.68[-1.46,0.11]

-0.86[-1.7,-0.02]

Not estimable

-0.28[-1.02,0.46]

0[-0.58,0.58]

-0.56[-1.28,0.17]

0.2[-0.51,0.91]

-0.66[-1.43,0.11]

-1.26[-2.1,-0.42]

0.04[-0.86,0.94]

-0.51[-1,-0.03]

-0.43[-0.69,-0.17]

8.59%

8.59%

-0.16[-0.9,0.58]

-0.16[-0.9,0.58]

Favours treatment

-4

-2

0

2

4

Favours control

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

164

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

PT+AD

PT+placebo

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

Total ***

185

193

Heterogeneity: Tau2=0.03; Chi2=12.53, df=10(P=0.25); I2=20.16%

Test for overall effect: Z=3.28(P=0)

Test for subgroup differences: Chi2=0.43, df=1 (P=0.51), I2=0%

100%

-0.4[-0.65,-0.16]

Favours treatment

-4

-2

0

2

4

Favours control

Analysis 10.8.   Comparison 10 SUBGROUP3: 100%agoraphobia: Psychotherapy+Antidepressant
vs Psychotherapy alone or +Placebo, Outcome 8 Social malfunctioning at 2-4 months.

Study or subgroup

PT+AD

PT+placebo

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

10.8.1 Behaviour therapy

Johnston 1995

Mavissakalian 1986a

Mavissakalian 1986b

Sheehan 1980a

Sheehan 1980b

Zitrin 1980

Zitrin 1983

Subtotal ***

2.1 (0.6)

2.3 (1)

2.4 (1)

3.1 (1.1)

2.4 (1.4)

1.1 (0.8)

1.2 (0.9)

12

17

14

18

17

25

34

137

Heterogeneity: Tau2=0.03; Chi2=7.7, df=6(P=0.26); I2=22.11%

Test for overall effect: Z=3.69(P=0)

10.8.2 Cognitive-behaviour therapy

Loerch 1999

Subtotal ***

2.4 (2.8)

14

14

Heterogeneity: Not applicable

Test for overall effect: Z=0.29(P=0.77)

2 (0.8)

2.8 (1.1)

2.8 (1.1)

4 (1)

4 (1)

1.4 (1.1)

1.9 (0.9)

2.1 (2.2)

16

14

17

11

11

20

34

123

14

14

Total ***

151

137

Heterogeneity: Tau2=0.06; Chi2=10.45, df=7(P=0.16); I2=33.03%

Test for overall effect: Z=3.11(P=0)

Test for subgroup differences: Chi2=2.75, df=1 (P=0.1), I2=63.62%

11.14%

11.81%

11.91%

10.48%

9.54%

15.19%

18.61%

0.14[-0.61,0.89]

-0.49[-1.21,0.23]

-0.38[-1.1,0.33]

-0.8[-1.58,-0.02]

-1.22[-2.06,-0.39]

-0.33[-0.92,0.26]

-0.78[-1.27,-0.28]

88.69%

-0.55[-0.84,-0.26]

11.31%

11.31%

0.11[-0.63,0.85]

0.11[-0.63,0.85]

100%

-0.47[-0.77,-0.17]

Favours treatment

-4

-2

0

2

4

Favours control

Analysis 10.9.   Comparison 10 SUBGROUP3: 100%agoraphobia: Psychotherapy+Antidepressant
vs Psychotherapy alone or +Placebo, Outcome 9 Dropouts for any reason within 2-4 months.

PT+AD

n/N

PT+placebo

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

Study or subgroup

10.9.1 Behaviour therapy

de Beurs 1995i

de Beurs 1995ii

Fava 1997

Johnston 1995

Marks 1983

3/12

2/12

0/7

16/26

13/36

5/24

3/21

0/7

10/27

14/36

5.25%

3.05%

24.63%

23.09%

Favours treatment

0.1

0.2

0.5

1

2

5

10

Favours control

1.2[0.34,4.2]

1.17[0.23,6.03]

Not estimable

1.66[0.93,2.96]

0.93[0.51,1.69]

165

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Sheehan 1980a

Sheehan 1980b

Telch 1985

Zitrin 1980

Zitrin 1983

Subtotal (95% CI)

PT+AD

n/N

PT+placebo

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

7/28

9/29

3/13

12/41

9/43

247

3/16

2/14

3/12

11/35

7/41

233

5.67%

4.24%

4.23%

17.67%

10.38%

98.2%

1.33[0.4,4.45]

2.17[0.54,8.75]

0.92[0.23,3.72]

0.93[0.47,1.84]

1.23[0.5,2.99]

1.2[0.9,1.6]

Total events: 74 (PT+AD), 58 (PT+placebo)

Heterogeneity: Tau2=0; Chi2=3.32, df=8(P=0.91); I2=0%

Test for overall effect: Z=1.22(P=0.22)

10.9.2 Cognitive-behaviour therapy

Loerch 1999

Subtotal (95% CI)

Total events: 3 (PT+AD), 1 (PT+placebo)

Heterogeneity: Not applicable

Test for overall effect: Z=1.01(P=0.31)

3/14

14

1/14

14

1.8%

1.8%

3[0.35,25.46]

3[0.35,25.46]

Total (95% CI)

261

247

100%

1.22[0.91,1.62]

Total events: 77 (PT+AD), 59 (PT+placebo)

Heterogeneity: Tau2=0; Chi2=4.02, df=9(P=0.91); I2=0%

Test for overall effect: Z=1.34(P=0.18)

Test for subgroup differences: Not applicable

Favours treatment

0.1

0.2

0.5

1

2

5

10

Favours control

Analysis 10.10.   Comparison 10 SUBGROUP3: 100%agoraphobia: Psychotherapy+Antidepressant
vs Psychotherapy alone or +Placebo, Outcome 10 Dropouts due to side effects within 2-4 months.

Study or subgroup

10.10.1 Behaviour therapy

de Beurs 1995i

de Beurs 1995ii

Marks 1983

Telch 1985

Zitrin 1980

Subtotal (95% CI)

PT+AD

n/N

PT+placebo

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

1/12

1/12

2/36

3/13

8/41

114

0/24

0/21

3/36

1/12

3/35

128

7.28%

7.29%

23.85%

15.81%

45.77%

100%

5.77[0.25,131.92]

5.08[0.22,115.7]

0.67[0.12,3.75]

2.77[0.33,23.14]

2.28[0.65,7.93]

1.99[0.85,4.62]

Total events: 15 (PT+AD), 7 (PT+placebo)

Heterogeneity: Tau2=0; Chi2=2.47, df=4(P=0.65); I2=0%

Test for overall effect: Z=1.59(P=0.11)

10.10.2 Cognitive-behaviour therapy

Subtotal (95% CI)

0

0

Not estimable

Total events: 0 (PT+AD), 0 (PT+placebo)

Heterogeneity: Not applicable

Test for overall effect: Not applicable

Total (95% CI)

114

128

100%

1.99[0.85,4.62]

Total events: 15 (PT+AD), 7 (PT+placebo)

Heterogeneity: Tau2=0; Chi2=2.47, df=4(P=0.65); I2=0%

Favours treatment

0.1

0.2

0.5

1

2

5

10

Favours control

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

166

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

PT+AD

n/N

PT+placebo

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

Test for overall effect: Z=1.59(P=0.11)

Test for subgroup differences: Not applicable

Favours treatment

0.1

0.2

0.5

1

2

5

10

Favours control

Analysis 10.11.   Comparison 10 SUBGROUP3: 100%agoraphobia: Psychotherapy+Antidepressant
vs Psychotherapy alone or +Placebo, Outcome 11 Response/remission on continued treatment.

Study or subgroup

10.11.1 Behaviour therapy

Telch 1985

Zitrin 1980

Zitrin 1983

Subtotal (95% CI)

PT+AD

n/N

PT+placebo

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

7/13

26/41

17/43

97

2/12

17/35

17/41

88

8.81%

51.23%

39.96%

100%

3.23[0.83,12.61]

1.31[0.86,1.97]

0.95[0.57,1.6]

1.25[0.82,1.9]

Total events: 50 (PT+AD), 36 (PT+placebo)

Heterogeneity: Tau2=0.05; Chi2=2.96, df=2(P=0.23); I2=32.38%

Test for overall effect: Z=1.02(P=0.31)

10.11.2 Cognitive-behaviour therapy

Subtotal (95% CI)

0

0

Not estimable

Total events: 0 (PT+AD), 0 (PT+placebo)

Heterogeneity: Not applicable

Test for overall effect: Not applicable

Total (95% CI)

97

88

100%

1.25[0.82,1.9]

Total events: 50 (PT+AD), 36 (PT+placebo)

Heterogeneity: Tau2=0.05; Chi2=2.96, df=2(P=0.23); I2=32.38%

Test for overall effect: Z=1.02(P=0.31)

Test for subgroup differences: Not applicable

Favours PT+placebo

0.1

0.2

0.5

1

2

5

10

Favours PT+AD

Analysis 10.12.   Comparison 10 SUBGROUP3: 100%agoraphobia: Psychotherapy+Antidepressant
vs Psychotherapy alone or +Placebo, Outcome 12 Global/Avoidance/Panic on continued treatment.

Study or subgroup

PT+AD

PT+placebo

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

10.12.1 Behaviour therapy

Johnston 1995

Telch 1985

Zitrin 1980

Subtotal ***

5.4 (5.7)

12.6 (8.1)

1.5 (0.7)

12

10

29

51

Heterogeneity: Tau2=0; Chi2=1.84, df=2(P=0.4); I2=0%

Test for overall effect: Z=4.44(P<0.0001)

10.12.2 Cognitive-behaviour therapy

Subtotal ***

0

Heterogeneity: Not applicable

14.6 (9.1)

25.6 (8.8)

2 (0.9)

17

9

24

50

0

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Favours treatment

-4

-2

0

2

4

Favours control

27.36%

16.22%

56.42%

100%

-1.13[-1.94,-0.33]

-1.47[-2.51,-0.43]

-0.72[-1.27,-0.16]

-0.95[-1.37,-0.53]

Not estimable

167

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

PT+AD

PT+placebo

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

Test for overall effect: Not applicable

Total ***

51

50

100%

-0.95[-1.37,-0.53]

Heterogeneity: Tau2=0; Chi2=1.84, df=2(P=0.4); I2=0%

Test for overall effect: Z=4.44(P<0.0001)

Test for subgroup differences: Not applicable

Favours treatment

-4

-2

0

2

4

Favours control

Analysis 10.13.   Comparison 10 SUBGROUP3: 100%agoraphobia: Psychotherapy+Antidepressant
vs Psychotherapy alone or +Placebo, Outcome 13 Dropouts for any reason on continued treatment.

Study or subgroup

10.13.1 Behaviour therapy

de Beurs 1995i

Telch 1985

Subtotal (95% CI)

PT+AD

n/N

PT+placebo

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

1/19

1/10

29

0/19

0/9

28

49.1%

50.9%

100%

3[0.13,69.31]

2.73[0.12,59.57]

2.86[0.32,25.8]

Total events: 2 (PT+AD), 0 (PT+placebo)

Heterogeneity: Tau2=0; Chi2=0, df=1(P=0.97); I2=0%

Test for overall effect: Z=0.94(P=0.35)

10.13.2 Cognitive-behaviour therapy

Subtotal (95% CI)

0

0

Not estimable

Total events: 0 (PT+AD), 0 (PT+placebo)

Heterogeneity: Not applicable

Test for overall effect: Not applicable

Total (95% CI)

29

28

100%

2.86[0.32,25.8]

Total events: 2 (PT+AD), 0 (PT+placebo)

Heterogeneity: Tau2=0; Chi2=0, df=1(P=0.97); I2=0%

Test for overall effect: Z=0.94(P=0.35)

Test for subgroup differences: Not applicable

Favours treatment

0.1

0.2

0.5

1

2

5

10

Favours control

Analysis 10.18.   Comparison 10 SUBGROUP3: 100%agoraphobia: Psychotherapy+Antidepressant vs
Psychotherapy alone or +Placebo, Outcome 18 Response 6-24 months after treatment discontinuation.

PT+AD

n/N

PT+placebo

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

Study or subgroup

10.18.1 Behaviour therapy

de Beurs 1995i

de Beurs 1995ii

Fava 1997

Marks 1983

Mavissakalian 1986a

Mavissakalian 1986b

Zitrin 1983

6/12

6/12

2/7

9/36

6/20

6/20

23/43

12/24

10/21

4/7

11/36

5/20

6/20

20/41

11.98%

11.03%

3.22%

10.22%

5.61%

6.42%

32.66%

Favours PT+placebo

0.2

0.5

1

2

5

Favours PT+AD

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

1[0.5,2]

1.05[0.51,2.16]

0.5[0.13,1.9]

0.82[0.39,1.73]

1.2[0.44,3.3]

1[0.39,2.58]

1.1[0.72,1.67]

168

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

PT+AD

n/N

PT+placebo

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

Subtotal (95% CI)

150

169

81.14%

1[0.77,1.31]

Total events: 58 (PT+AD), 68 (PT+placebo)

Heterogeneity: Tau2=0; Chi2=1.65, df=6(P=0.95); I2=0%

Test for overall effect: Z=0.03(P=0.98)

10.18.2 Cognitive-behaviour therapy

Loerch 1999

Subtotal (95% CI)

Total events: 9 (PT+AD), 9 (PT+placebo)

Heterogeneity: Not applicable

Test for overall effect: Not applicable

9/14

14

9/14

14

18.86%

18.86%

1[0.58,1.74]

1[0.58,1.74]

Total (95% CI)

164

183

100%

1[0.79,1.27]

Total events: 67 (PT+AD), 77 (PT+placebo)

Heterogeneity: Tau2=0; Chi2=1.65, df=7(P=0.98); I2=0%

Test for overall effect: Z=0.02(P=0.98)

Test for subgroup differences: Not applicable

Favours PT+placebo

0.2

0.5

1

2

5

Favours PT+AD

Analysis 10.19.   Comparison 10 SUBGROUP3: 100%agoraphobia: Psychotherapy+Antidepressant vs Psychotherapy
alone or +Placebo, Outcome 19 Global/Avoidance/Panic 6-24 months after treatment discontinuation.

Study or subgroup

PT+AD

PT+placebo

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

3.2 (2.7)

3.5 (2.2)

13.7 (2.8)

3.3 (2.6)

1.3 (0.5)

10.19.1 Behaviour therapy

de Beurs 1995i

de Beurs 1995ii

Marks 1983

Mavissakalian 1986a

Mavissakalian 1986b

Subtotal ***

3.3 (2.4)

3.3 (2.4)

14.1 (2.7)

2.1 (1.4)

2 (1.2)

9

9

22

14

11

65

Heterogeneity: Tau2=0.03; Chi2=4.73, df=4(P=0.32); I2=15.36%

Test for overall effect: Z=0.28(P=0.78)

10.19.2 Cognitive-behviour therapy

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Not applicable

Total ***

0

65

Heterogeneity: Tau2=0.03; Chi2=4.73, df=4(P=0.32); I2=15.36%

Test for overall effect: Z=0.28(P=0.78)

Test for subgroup differences: Not applicable

19

17

18

11

11

76

0

76

18.95%

18.36%

28.11%

18.33%

16.25%

100%

0.07[-0.72,0.86]

-0.05[-0.86,0.76]

0.14[-0.48,0.77]

-0.58[-1.39,0.23]

0.71[-0.16,1.58]

0.05[-0.32,0.43]

Not estimable

100%

0.05[-0.32,0.43]

Favours treatment

-10

-5

0

5

10

Favours control

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

169

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Comparison 11.   SUBGROUP3: 0%agoraphobia: Psychotherapy+Antidepressant vs Psychotherapy alone or +Placebo

Outcome or subgroup title

1 Response at 2-4 months

1.1 Behaviour therapy

1.2 Cognitive-behaviour therapy

2 Remission at 2-4 months

2.1 Behaviour therapy

2.2 Cognitive-behaviour therapy

3 Global severity at 2-4 months

3.1 Behaviour therapy

3.2 Cognitive-behaviour therapy

4 Frequency of panic attacks at 2-4 months

4.1 Behaviour therapy

4.2 Cognitive-behaviour therapy

5 Phobic avoidance at 2-4 months

5.1 Behaviour therapy

5.2 Cognitive-behaviour therapy

6 General anxiety at 2-4 months

6.1 Behaviour therapy

6.2 Cognitive-behaviour therapy

No. of
studies

No. of
partici-
pants

Statistical method

Effect size

2

0

2

2

0

2

2

0

2

0

0

0

0

0

0

0

0

0

205

0

205

205

0

205

205

0

205

0

0

0

0

0

0

0

0

0

Risk Ratio (M-H, Random, 95%
CI)

1.08 [0.84, 1.38]

Risk Ratio (M-H, Random, 95%
CI)

0.0 [0.0, 0.0]

Risk Ratio (M-H, Random, 95%
CI)

1.08 [0.84, 1.38]

Risk Ratio (M-H, Random, 95%
CI)

1.09 [0.85, 1.40]

Risk Ratio (M-H, Random, 95%
CI)

0.0 [0.0, 0.0]

Risk Ratio (M-H, Random, 95%
CI)

1.09 [0.85, 1.40]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.25 [-0.55, 0.04]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.0 [0.0, 0.0]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.25 [-0.55, 0.04]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.0 [0.0, 0.0]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.0 [0.0, 0.0]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.0 [0.0, 0.0]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.0 [0.0, 0.0]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.0 [0.0, 0.0]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.0 [0.0, 0.0]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.0 [0.0, 0.0]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.0 [0.0, 0.0]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.0 [0.0, 0.0]

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

170

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

7 Depression at 2-4 months

7.1 Behaviour therapy

7.2 Cognitive-behaviour therapy

8 Social malfunctioning at 2-4 months

8.1 Behaviour therapy

8.2 Cognitive-behaviour therapy

9 Dropouts for any reason within 2-4 months

9.1 Behaviour therapy

9.2 Cognitive-behaviour therapy

10 Dropouts due to side effects within 2-4
months

10.1 Behaviour therapy

10.2 Cognitive-behaviour therapy

11 Response/remission on continued treat-
ment

11.1 Behaviour therapy

11.2 Cognitive-behaviour therapy

12 Global/Avoidance/Panic on continued
treatment

12.1 Behaviour therapy

12.2 Cognitive-behaviour therapy

No. of
studies

No. of
partici-
pants

Statistical method

Effect size

0

0

0

0

0

0

2

0

2

2

0

2

2

0

2

2

0

2

0

0

0

0

0

0

205

0

205

205

0

205

205

0

205

205

0

205

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.0 [0.0, 0.0]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.0 [0.0, 0.0]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.0 [0.0, 0.0]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.0 [0.0, 0.0]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.0 [0.0, 0.0]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.0 [0.0, 0.0]

Risk Ratio (M-H, Random, 95%
CI)

0.99 [0.62, 1.60]

Risk Ratio (M-H, Random, 95%
CI)

0.0 [0.0, 0.0]

Risk Ratio (M-H, Random, 95%
CI)

0.99 [0.62, 1.60]

Risk Ratio (M-H, Random, 95%
CI)

6.33 [0.67, 59.70]

Risk Ratio (M-H, Random, 95%
CI)

0.0 [0.0, 0.0]

Risk Ratio (M-H, Random, 95%
CI)

6.33 [0.67, 59.70]

Risk Ratio (M-H, Random, 95%
CI)

1.23 [0.93, 1.63]

Risk Ratio (M-H, Random, 95%
CI)

0.0 [0.0, 0.0]

Risk Ratio (M-H, Random, 95%
CI)

1.23 [0.93, 1.63]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.41 [-0.71, -0.12]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.0 [0.0, 0.0]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.41 [-0.71, -0.12]

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

171

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of
studies

No. of
partici-
pants

Statistical method

Effect size

13 Dropouts for any reason on continued
treatment

13.1 Behaviour therapy

13.2 Cognitive-behaviour therapy

18 Response 6-24 months after treatment dis-
continuation

18.1 Behaviour therapy

18.2 Cognitive-behaviour therapy

19 Global/Avoidance/Panic 6-24 months after
treatment discontinuation

19.1 Behaviour therapy

19.2 Cognitive-behviour therapy

2

0

2

2

0

2

2

0

2

205

0

205

194

0

194

194

0

194

Risk Ratio (M-H, Random, 95%
CI)

0.66 [0.22, 1.95]

Risk Ratio (M-H, Random, 95%
CI)

0.0 [0.0, 0.0]

Risk Ratio (M-H, Random, 95%
CI)

0.66 [0.22, 1.95]

Risk Ratio (M-H, Random, 95%
CI)

0.74 [0.46, 1.19]

Risk Ratio (M-H, Random, 95%
CI)

0.0 [0.0, 0.0]

Risk Ratio (M-H, Random, 95%
CI)

0.74 [0.46, 1.19]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.21 [-0.10, 0.52]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.0 [0.0, 0.0]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.21 [-0.10, 0.52]

Analysis 11.1.   Comparison 11 SUBGROUP3: 0%agoraphobia: Psychotherapy
+Antidepressant vs Psychotherapy alone or +Placebo, Outcome 1 Response at 2-4 months.

Study or subgroup

PT+AD

n/N

PT+placebo

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

11.1.1 Behaviour therapy

Subtotal (95% CI)

Total events: 0 (PT+AD), 0 (PT+placebo)

Heterogeneity: Not applicable

Test for overall effect: Not applicable

11.1.2 Cognitive-behaviour therapy

Barlow 2000i

Barlow 2000ii

Subtotal (95% CI)

0

0

Not estimable

19/32

20/33

65

36/63

42/77

140

47.83%

52.17%

100%

1.04[0.73,1.49]

1.11[0.79,1.56]

1.08[0.84,1.38]

Total events: 39 (PT+AD), 78 (PT+placebo)

Heterogeneity: Tau2=0; Chi2=0.07, df=1(P=0.79); I2=0%

Test for overall effect: Z=0.58(P=0.56)

Total (95% CI)

65

140

100%

1.08[0.84,1.38]

Total events: 39 (PT+AD), 78 (PT+placebo)

Heterogeneity: Tau2=0; Chi2=0.07, df=1(P=0.79); I2=0%

Favours PT+placebo

0.2

0.5

1

2

5

Favours PT+AD

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

172

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

PT+AD

n/N

PT+placebo

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

Test for overall effect: Z=0.58(P=0.56)

Test for subgroup differences: Not applicable

Favours PT+placebo

0.2

0.5

1

2

5

Favours PT+AD

Analysis 11.2.   Comparison 11 SUBGROUP3: 0%agoraphobia: Psychotherapy
+Antidepressant vs Psychotherapy alone or +Placebo, Outcome 2 Remission at 2-4 months.

Study or subgroup

PT+AD

n/N

PT+placebo

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

11.2.1 Behaviour therapy

Subtotal (95% CI)

Total events: 0 (PT+AD), 0 (PT+placebo)

Heterogeneity: Not applicable

Test for overall effect: Not applicable

11.2.2 Cognitive-behaviour therapy

Barlow 2000i

Barlow 2000ii

Subtotal (95% CI)

0

0

Not estimable

20/33

19/32

65

39/63

37/77

140

54.59%

45.41%

100%

0.98[0.7,1.37]

1.24[0.85,1.79]

1.09[0.85,1.4]

Total events: 39 (PT+AD), 76 (PT+placebo)

Heterogeneity: Tau2=0; Chi2=0.84, df=1(P=0.36); I2=0%

Test for overall effect: Z=0.67(P=0.51)

Total (95% CI)

65

140

100%

1.09[0.85,1.4]

Total events: 39 (PT+AD), 76 (PT+placebo)

Heterogeneity: Tau2=0; Chi2=0.84, df=1(P=0.36); I2=0%

Test for overall effect: Z=0.67(P=0.51)

Test for subgroup differences: Not applicable

Favours PT+placebo

0.1

0.2

0.5

1

2

5

10

Favours PT+AD

Analysis 11.3.   Comparison 11 SUBGROUP3: 0%agoraphobia: Psychotherapy+Antidepressant
vs Psychotherapy alone or +Placebo, Outcome 3 Global severity at 2-4 months.

Study or subgroup

PT+AD

PT+placebo

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

11.3.1 Behaviour therapy

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Not applicable

11.3.2 Cognitive-behaviour therapy

Barlow 2000i

Barlow 2000ii

Subtotal ***

0

33

32

65

0

63

77

140

0.9 (0.7)

0.9 (0.7)

Heterogeneity: Tau2=0; Chi2=0.42, df=1(P=0.52); I2=0%

Test for overall effect: Z=1.67(P=0.09)

Not estimable

1 (0.7)

1.1 (0.7)

49.18%

50.82%

100%

-0.15[-0.57,0.27]

-0.35[-0.76,0.07]

-0.25[-0.55,0.04]

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

173

Favours treatment

-4

-2

0

2

4

Favours control

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

PT+AD

PT+placebo

Std. Mean Difference

Weight

Std. Mean Difference

Total ***

Mean(SD)

N

65

N

140

Heterogeneity: Tau2=0; Chi2=0.42, df=1(P=0.52); I2=0%

Test for overall effect: Z=1.67(P=0.09)

Test for subgroup differences: Not applicable

Mean(SD)

Random, 95% CI

Random, 95% CI

100%

-0.25[-0.55,0.04]

Favours treatment

-4

-2

0

2

4

Favours control

Analysis 11.9.   Comparison 11 SUBGROUP3: 0%agoraphobia: Psychotherapy+Antidepressant
vs Psychotherapy alone or +Placebo, Outcome 9 Dropouts for any reason within 2-4 months.

Study or subgroup

PT+AD

n/N

PT+placebo

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

11.9.1 Behaviour therapy

Subtotal (95% CI)

Total events: 0 (PT+AD), 0 (PT+placebo)

Heterogeneity: Not applicable

Test for overall effect: Not applicable

11.9.2 Cognitive-behaviour therapy

Barlow 2000i

Barlow 2000ii

Subtotal (95% CI)

0

0

Not estimable

9/33

9/32

65

18/63

21/77

140

48.72%

51.28%

100%

0.95[0.48,1.88]

1.03[0.53,2]

0.99[0.62,1.6]

Total events: 18 (PT+AD), 39 (PT+placebo)

Heterogeneity: Tau2=0; Chi2=0.03, df=1(P=0.87); I2=0%

Test for overall effect: Z=0.03(P=0.98)

Total (95% CI)

65

140

100%

0.99[0.62,1.6]

Total events: 18 (PT+AD), 39 (PT+placebo)

Heterogeneity: Tau2=0; Chi2=0.03, df=1(P=0.87); I2=0%

Test for overall effect: Z=0.03(P=0.98)

Test for subgroup differences: Not applicable

Favours treatment

0.1

0.2

0.5

1

2

5

10

Favours control

Analysis 11.10.   Comparison 11 SUBGROUP3: 0%agoraphobia: Psychotherapy+Antidepressant vs
Psychotherapy alone or +Placebo, Outcome 10 Dropouts due to side effects within 2-4 months.

Study or subgroup

PT+AD

n/N

PT+placebo

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

11.10.1 Behaviour therapy

Subtotal (95% CI)

Total events: 0 (PT+AD), 0 (PT+placebo)

Heterogeneity: Not applicable

Test for overall effect: Not applicable

11.10.2 Cognitive-behaviour therapy

Barlow 2000i

Barlow 2000ii

Subtotal (95% CI)

0

0

Not estimable

1/33

1/32

65

0/63

0/77

140

50.02%

49.98%

100%

5.65[0.24,134.91]

7.09[0.3,169.6]

6.33[0.67,59.7]

Favours treatment

0.1

0.2

0.5

1

2

5

10

Favours control

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

174

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

PT+AD

n/N

PT+placebo

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

Total events: 2 (PT+AD), 0 (PT+placebo)

Heterogeneity: Tau2=0; Chi2=0.01, df=1(P=0.92); I2=0%

Test for overall effect: Z=1.61(P=0.11)

Total (95% CI)

65

140

100%

6.33[0.67,59.7]

Total events: 2 (PT+AD), 0 (PT+placebo)

Heterogeneity: Tau2=0; Chi2=0.01, df=1(P=0.92); I2=0%

Test for overall effect: Z=1.61(P=0.11)

Test for subgroup differences: Not applicable

Favours treatment

0.1

0.2

0.5

1

2

5

10

Favours control

Analysis 11.11.   Comparison 11 SUBGROUP3: 0%agoraphobia: Psychotherapy+Antidepressant
vs Psychotherapy alone or +Placebo, Outcome 11 Response/remission on continued treatment.

Study or subgroup

PT+AD

n/N

PT+placebo

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

11.11.1 Behaviour therapy

Subtotal (95% CI)

Total events: 0 (PT+AD), 0 (PT+placebo)

Heterogeneity: Not applicable

Test for overall effect: Not applicable

11.11.2 Cognitive-behaviour therapy

Barlow 2000i

Barlow 2000ii

Subtotal (95% CI)

0

0

Not estimable

19/33

18/32

65

32/63

32/77

140

53.03%

46.97%

100%

1.13[0.77,1.66]

1.35[0.9,2.03]

1.23[0.93,1.63]

Total events: 37 (PT+AD), 64 (PT+placebo)

Heterogeneity: Tau2=0; Chi2=0.39, df=1(P=0.53); I2=0%

Test for overall effect: Z=1.48(P=0.14)

Total (95% CI)

65

140

100%

1.23[0.93,1.63]

Total events: 37 (PT+AD), 64 (PT+placebo)

Heterogeneity: Tau2=0; Chi2=0.39, df=1(P=0.53); I2=0%

Test for overall effect: Z=1.48(P=0.14)

Test for subgroup differences: Not applicable

Favours PT+placebo

0.1

0.2

0.5

1

2

5

10

Favours PT+AD

Analysis 11.12.   Comparison 11 SUBGROUP3: 0%agoraphobia: Psychotherapy+Antidepressant vs
Psychotherapy alone or +Placebo, Outcome 12 Global/Avoidance/Panic on continued treatment.

Study or subgroup

PT+AD

PT+placebo

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

11.12.1 Behaviour therapy

Subtotal ***

0

0

Not estimable

Heterogeneity: Not applicable

Test for overall effect: Not applicable

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

175

Favours treatment

-4

-2

0

2

4

Favours control

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

PT+AD

PT+placebo

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

11.12.2 Cognitive-behaviour therapy

Barlow 2000i

Barlow 2000ii

Subtotal ***

33

32

65

0.8 (0.9)

0.8 (0.9)

63

77

140

1.1 (0.8)

1.2 (0.9)

Heterogeneity: Tau2=0; Chi2=0.1, df=1(P=0.75); I2=0%

Test for overall effect: Z=2.73(P=0.01)

49.11%

50.89%

100%

-0.37[-0.79,0.06]

-0.46[-0.88,-0.04]

-0.41[-0.71,-0.12]

Total ***

65

140

100%

-0.41[-0.71,-0.12]

Heterogeneity: Tau2=0; Chi2=0.1, df=1(P=0.75); I2=0%

Test for overall effect: Z=2.73(P=0.01)

Test for subgroup differences: Not applicable

Favours treatment

-4

-2

0

2

4

Favours control

Analysis 11.13.   Comparison 11 SUBGROUP3: 0%agoraphobia: Psychotherapy+Antidepressant vs
Psychotherapy alone or +Placebo, Outcome 13 Dropouts for any reason on continued treatment.

Study or subgroup

PT+AD

n/N

PT+placebo

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

11.13.1 Behaviour therapy

Subtotal (95% CI)

Total events: 0 (PT+AD), 0 (PT+placebo)

Heterogeneity: Not applicable

Test for overall effect: Not applicable

11.13.2 Cognitive-behaviour therapy

Barlow 2000i

Barlow 2000ii

Subtotal (95% CI)

0

0

Not estimable

2/33

2/32

65

6/63

7/77

140

49.1%

50.9%

100%

0.64[0.14,2.98]

0.69[0.15,3.13]

0.66[0.22,1.95]

Total events: 4 (PT+AD), 13 (PT+placebo)

Heterogeneity: Tau2=0; Chi2=0, df=1(P=0.94); I2=0%

Test for overall effect: Z=0.75(P=0.45)

Total (95% CI)

65

140

100%

0.66[0.22,1.95]

Total events: 4 (PT+AD), 13 (PT+placebo)

Heterogeneity: Tau2=0; Chi2=0, df=1(P=0.94); I2=0%

Test for overall effect: Z=0.75(P=0.45)

Test for subgroup differences: Not applicable

Favours treatment

0.1

0.2

0.5

1

2

5

10

Favours control

Analysis 11.18.   Comparison 11 SUBGROUP3: 0%agoraphobia: Psychotherapy+Antidepressant vs
Psychotherapy alone or +Placebo, Outcome 18 Response 6-24 months after treatment discontinuation.

Study or subgroup

PT+AD

n/N

PT+placebo

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

11.18.1 Behaviour therapy

Subtotal (95% CI)

Total events: 0 (PT+AD), 0 (PT+placebo)

0

0

Not estimable

Favours PT+placebo

0.2

0.5

1

2

5

Favours PT+AD

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

176

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

PT+AD

n/N

PT+placebo

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

Heterogeneity: Not applicable

Test for overall effect: Not applicable

11.18.2 Cognitive-behaviour therapy

Barlow 2000i

Barlow 2000ii

Subtotal (95% CI)

8/30

8/29

59

25/62

24/73

135

50.63%

49.37%

100%

0.66[0.34,1.29]

0.84[0.43,1.65]

0.74[0.46,1.19]

Total events: 16 (PT+AD), 49 (PT+placebo)

Heterogeneity: Tau2=0; Chi2=0.24, df=1(P=0.62); I2=0%

Test for overall effect: Z=1.22(P=0.22)

Total (95% CI)

59

135

100%

0.74[0.46,1.19]

Total events: 16 (PT+AD), 49 (PT+placebo)

Heterogeneity: Tau2=0; Chi2=0.24, df=1(P=0.62); I2=0%

Test for overall effect: Z=1.22(P=0.22)

Test for subgroup differences: Not applicable

Favours PT+placebo

0.2

0.5

1

2

5

Favours PT+AD

Analysis 11.19.   Comparison 11 SUBGROUP3: 0%agoraphobia: Psychotherapy+Antidepressant vs Psychotherapy
alone or +Placebo, Outcome 19 Global/Avoidance/Panic 6-24 months after treatment discontinuation.

Study or subgroup

PT+AD

PT+placebo

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

11.19.1 Behaviour therapy

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Not applicable

11.19.2 Cognitive-behviour therapy

Barlow 2000i

Barlow 2000ii

Subtotal ***

0

30

29

59

0

62

73

135

1.5 (0.9)

1.5 (0.9)

Heterogeneity: Tau2=0; Chi2=0.27, df=1(P=0.6); I2=0%

Test for overall effect: Z=1.34(P=0.18)

Not estimable

1.2 (0.9)

1.3 (0.9)

49.14%

50.86%

100%

0.29[-0.14,0.73]

0.13[-0.3,0.56]

0.21[-0.1,0.52]

Total ***

59

135

100%

0.21[-0.1,0.52]

Heterogeneity: Tau2=0; Chi2=0.27, df=1(P=0.6); I2=0%

Test for overall effect: Z=1.34(P=0.18)

Test for subgroup differences: Not applicable

Favours treatment

-10

-5

0

5

10

Favours control

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

177

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Comparison 12.   SUBGROUP4: without comorbidity: Psychotherapy+Antidepressant vs Antidepressant alone

Outcome or subgroup title

1 Response at 2-4 months

1.1 Behaviour therapy

1.2 Cognitive-behaviour therapy

1.3 Psychodynamic psychotherapy and others

2 Remission at 2-4 months

2.1 Behaviour therapy

2.2 Cognitive-behaviour therapy

2.3 Psychodynamic psychotherapy and others

3 Global severity at 2-4 months

3.1 Behaviour therapy

3.2 Cognitive-behaviour therapy

3.3 Psychodynamic psychotherapy and others

4 Frequency of panic attacks at 2-4 months

4.1 Behaviour therapy

4.2 Cognitive-behaviour therapy

4.3 Psychodynamic psychotherapy and others

5 Phobic avoidance at 2-4 months

5.1 Behaviour therapy

No. of
studies

No. of
partici-
pants

Statistical method

Effect size

5

2

3

0

3

1

2

0

2

1

1

0

3

2

1

0

4

2

265

121

144

0

200

96

104

0

133

75

58

0

134

95

39

0

164

95

Risk Ratio (M-H, Random,
95% CI)

1.25 [0.86, 1.82]

Risk Ratio (M-H, Random,
95% CI)

1.57 [0.35, 7.03]

Risk Ratio (M-H, Random,
95% CI)

1.37 [0.79, 2.39]

Risk Ratio (M-H, Random,
95% CI)

0.0 [0.0, 0.0]

Risk Ratio (M-H, Random,
95% CI)

1.34 [0.72, 2.51]

Risk Ratio (M-H, Random,
95% CI)

0.94 [0.52, 1.72]

Risk Ratio (M-H, Random,
95% CI)

2.13 [0.45, 10.10]

Risk Ratio (M-H, Random,
95% CI)

0.0 [0.0, 0.0]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.29 [-0.63, 0.05]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.14 [-0.60, 0.31]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.48 [-1.01, 0.04]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.0 [0.0, 0.0]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.17 [-0.51, 0.17]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.28 [-0.69, 0.13]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.08 [-0.55, 0.71]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.0 [0.0, 0.0]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.39 [1.00, 0.21]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.45 [-1.29, 0.39]

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

178

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Outcome or subgroup title

5.2 Cognitive-behaviour therapy

5.3 Psychodynamic psychotherapy and others

6 General anxiety at 2-4 months

6.1 Behaviour therapy

6.2 Cognitive-behaviour therapy

6.3 Psychodynamic psychotherapy and others

7 Depression at 2-4 months

7.1 Behaviour therapy

7.2 Cognitive-behaviour therapy

7.3 Psychodynamic psychotherapy and others

8 Social functioning at 2-4 months

8.1 Behavour therapy

8.2 Cognitive-behaviour therapy

8.3 Psychodynamic psychotherapy and others

9 Dropouts for any reason within 2-4 months

9.1 Behaviour therapy

9.2 Cognitive-behaviour therapy

9.3 Psychodynamic psychotherapy and others

Cochrane Database of Systematic Reviews

No. of
studies

No. of
partici-
pants

Statistical method

Effect size

2

0

3

1

2

0

4

2

2

0

3

1

2

0

5

2

3

0

69

0

163

75

88

0

164

95

69

0

163

75

88

0

265

121

144

0

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.36 [-1.67, 0.96]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.0 [0.0, 0.0]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.38 [-0.74, -0.03]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.13 [-0.58, 0.33]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.58 [-1.01, -0.15]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.0 [0.0, 0.0]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.37 [-0.69, -0.06]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.27 [-0.67, 0.14]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.56 [-1.22, 0.11]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.0 [0.0, 0.0]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.43 [-0.89, 0.04]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.17 [-0.62, 0.29]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.63 [-1.39, 0.12]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.0 [0.0, 0.0]

Risk Ratio (M-H, Random,
95% CI)

0.86 [0.57, 1.31]

Risk Ratio (M-H, Random,
95% CI)

1.00 [0.50, 1.99]

Risk Ratio (M-H, Random,
95% CI)

0.79 [0.46, 1.34]

Risk Ratio (M-H, Random,
95% CI)

0.0 [0.0, 0.0]

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

179

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of
studies

No. of
partici-
pants

Statistical method

Effect size

10 Dropouts due to side effects within 2-4
months

10.1 Behaviour therapy

10.2 Cognitive-behaviour therapy

10.3 Psychodynamic psychotherapy and others

11 Response/remission on continued treatment

11.1 Behaviour therapy

11.2 Cognitive-behaviour therapy

11.3 Psychdynamic psychotherapy and others

12 Global/Avoidance/Panic on continued treat-
ment

12.1 Behaviour therapy

12.2 Cognitive-behaviour therapy

12.3 Psychodynamic psychotherapy and others

13 Dropouts for any reason on continued treat-
ment

13.1 Behaviour therapy

13.2 Cognitive-behaviour therapy

13.3 Psychodynamic psychotherapy and others

14 Response/remission immediately after treat-
ment discontinuation

14.1 Behaviour therapy

3

1

2

0

2

2

0

0

1

1

0

0

1

1

0

0

0

0

139

25

114

0

121

121

0

0

20

20

0

0

20

20

0

0

0

0

Risk Ratio (M-H, Random,
95% CI)

1.43 [0.63, 3.27]

Risk Ratio (M-H, Random,
95% CI)

1.38 [0.28, 6.91]

Risk Ratio (M-H, Random,
95% CI)

1.45 [0.55, 3.80]

Risk Ratio (M-H, Random,
95% CI)

0.0 [0.0, 0.0]

Risk Ratio (M-H, Random,
95% CI)

1.94 [1.10, 3.41]

Risk Ratio (M-H, Random,
95% CI)

1.94 [1.10, 3.41]

Risk Ratio (M-H, Random,
95% CI)

0.0 [0.0, 0.0]

Risk Ratio (M-H, Random,
95% CI)

0.0 [0.0, 0.0]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-1.23 [-2.20, -0.26]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-1.23 [-2.20, -0.26]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.0 [0.0, 0.0]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.0 [0.0, 0.0]

Risk Ratio (M-H, Random,
95% CI)

1.0 [0.07, 13.87]

Risk Ratio (M-H, Random,
95% CI)

1.0 [0.07, 13.87]

Risk Ratio (M-H, Random,
95% CI)

0.0 [0.0, 0.0]

Risk Ratio (M-H, Random,
95% CI)

0.0 [0.0, 0.0]

Risk Ratio (M-H, Random,
95% CI)

0.0 [0.0, 0.0]

Risk Ratio (M-H, Random,
95% CI)

0.0 [0.0, 0.0]

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

180

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Outcome or subgroup title

14.2 Cognitive-behaviour therapy

14.3 Psychodynamic psychotherapy and others

15 Global/Avoidance/Panic immediately after
treatment discontinuation

15.1 Behaviour therapy

15.2 Cognitive-behaviour therapy

15.3 Psychodynamic psychotherapy and others

16 Response/remission 6-24 months after treat-
ment discontinuation

16.1 Behaviour therapy

16.2 Cognitive-behaviour therapy

16.3 Psychodynamic psychotherapy and others

17 Global/Avoidance/Panic 6-24 months after
treatment discontinuation

17.1 Behaviour therapy

17.2 Cognitive-behaviour therapy

17.3 Psychodynamic psychotherapy and others

Cochrane Database of Systematic Reviews

No. of
studies

No. of
partici-
pants

Statistical method

Effect size

0

0

0

0

0

0

3

1

2

0

0

0

0

0

0

0

0

0

0

0

200

96

104

0

0

0

0

0

Risk Ratio (M-H, Random,
95% CI)

0.0 [0.0, 0.0]

Risk Ratio (M-H, Random,
95% CI)

0.0 [0.0, 0.0]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.0 [0.0, 0.0]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.0 [0.0, 0.0]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.0 [0.0, 0.0]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.0 [0.0, 0.0]

Risk Ratio (M-H, Random,
95% CI)

1.49 [1.08, 2.07]

Risk Ratio (M-H, Random,
95% CI)

1.49 [0.95, 2.35]

Risk Ratio (M-H, Random,
95% CI)

1.49 [0.94, 2.38]

Risk Ratio (M-H, Random,
95% CI)

0.0 [0.0, 0.0]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.0 [0.0, 0.0]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.0 [0.0, 0.0]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.0 [0.0, 0.0]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.0 [0.0, 0.0]

Analysis 12.1.   Comparison 12 SUBGROUP4: without comorbidity: Psychotherapy
+Antidepressant vs Antidepressant alone, Outcome 1 Response at 2-4 months.

Study or subgroup

12.1.1 Behaviour therapy

Telch 1985

Zitrin 1983

PT+AD

n/N

AD

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

5/13

25/43

1/12

32/53

3.34%

36.36%

4.62[0.63,34.05]

0.96[0.69,1.35]

Favours AD

0.1

0.2

0.5

1

2

5

10

Favours PT+AD

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

181

 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

PT+AD

n/N

AD

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

Subtotal (95% CI)

56

65

39.7%

1.57[0.35,7.03]

Total events: 30 (PT+AD), 33 (AD)

Heterogeneity: Tau2=0.82; Chi2=2.53, df=1(P=0.11); I2=60.55%

Test for overall effect: Z=0.59(P=0.55)

12.1.2 Cognitive-behaviour therapy

Loerch 1999

Sharp 1996

Spinhoven 1996

Subtotal (95% CI)

11/14

26/38

4/20

72

5/16

21/36

5/20

72

Total events: 41 (PT+AD), 31 (AD)

Heterogeneity: Tau2=0.12; Chi2=3.79, df=2(P=0.15); I2=47.21%

Test for overall effect: Z=1.12(P=0.26)

16.15%

35.37%

8.78%

60.3%

2.51[1.16,5.47]

1.17[0.83,1.67]

0.8[0.25,2.55]

1.37[0.79,2.39]

12.1.3 Psychodynamic psychotherapy and others

Subtotal (95% CI)

Total events: 0 (PT+AD), 0 (AD)

Heterogeneity: Not applicable

Test for overall effect: Not applicable

0

0

Not estimable

Total (95% CI)

128

137

100%

1.25[0.86,1.82]

Total events: 71 (PT+AD), 64 (AD)

Heterogeneity: Tau2=0.07; Chi2=7.41, df=4(P=0.12); I2=46.01%

Test for overall effect: Z=1.16(P=0.25)

Test for subgroup differences: Not applicable

Favours AD

0.1

0.2

0.5

1

2

5

10

Favours PT+AD

Analysis 12.2.   Comparison 12 SUBGROUP4: without comorbidity: Psychotherapy
+Antidepressant vs Antidepressant alone, Outcome 2 Remission at 2-4 months.

Study or subgroup

12.2.1 Behaviour therapy

Zitrin 1983

Subtotal (95% CI)

Total events: 13 (PT+AD), 17 (AD)

Heterogeneity: Not applicable

Test for overall effect: Z=0.19(P=0.85)

12.2.2 Cognitive-behaviour therapy

Loerch 1999

Sharp 1996

Subtotal (95% CI)

PT+AD

n/N

AD

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

13/43

43

17/53

53

37.4%

37.4%

0.94[0.52,1.72]

0.94[0.52,1.72]

9/14

24/38

52

2/16

20/36

52

15.57%

47.03%

62.6%

5.14[1.33,19.92]

1.14[0.78,1.66]

2.13[0.45,10.1]

Total events: 33 (PT+AD), 22 (AD)

Heterogeneity: Tau2=1.04; Chi2=5.05, df=1(P=0.02); I2=80.19%

Test for overall effect: Z=0.95(P=0.34)

12.2.3 Psychodynamic psychotherapy and others

Subtotal (95% CI)

0

0

Favours AD

0.1

0.2

0.5

1

2

5

10

Favours PT+AD

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Not estimable

182

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

PT+AD

n/N

AD

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

Total events: 0 (PT+AD), 0 (AD)

Heterogeneity: Not applicable

Test for overall effect: Not applicable

Total (95% CI)

95

105

100%

1.34[0.72,2.51]

Total events: 46 (PT+AD), 39 (AD)

Heterogeneity: Tau2=0.18; Chi2=5.31, df=2(P=0.07); I2=62.36%

Test for overall effect: Z=0.92(P=0.36)

Test for subgroup differences: Not applicable

Favours AD

0.1

0.2

0.5

1

2

5

10

Favours PT+AD

Analysis 12.3.   Comparison 12 SUBGROUP4: without comorbidity: Psychotherapy
+Antidepressant vs Antidepressant alone, Outcome 3 Global severity at 2-4 months.

Study or subgroup

Treatment

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

3.3 (1)

2.3 (1.2)

12.3.1 Behaviour therapy

Zitrin 1983

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=0.61(P=0.54)

12.3.2 Cognitive-behaviour therapy

Sharp 1996

Subtotal ***

34

34

29

29

3.2 (1)

1.7 (1.1)

Heterogeneity: Tau2=0; Chi2=0, df=0(P<0.0001); I2=100%

Test for overall effect: Z=1.81(P=0.07)

12.3.3 Psychodynamic psychotherapy and others

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Not applicable

Total ***

0

63

Heterogeneity: Tau2=0; Chi2=0.93, df=1(P=0.34); I2=0%

Test for overall effect: Z=1.65(P=0.1)

Test for subgroup differences: Chi2=0.93, df=1 (P=0.34), I2=0%

41

41

29

29

0

70

56.87%

56.87%

-0.14[-0.6,0.31]

-0.14[-0.6,0.31]

43.13%

43.13%

-0.48[-1.01,0.04]

-0.48[-1.01,0.04]

Not estimable

100%

-0.29[-0.63,0.05]

Favours treatment

-4

-2

0

2

4

Favours control

Analysis 12.4.   Comparison 12 SUBGROUP4: without comorbidity: Psychotherapy
+Antidepressant vs Antidepressant alone, Outcome 4 Frequency of panic attacks at 2-4 months.

Study or subgroup

Treatment

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

12.4.1 Behaviour therapy

Telch 1985

Zitrin 1983

10

34

0.6 (1.1)

6 (1.2)

10

41

0.8 (1)

6.4 (1.2)

15.08%

55.48%

-0.14[-1.01,0.74]

-0.32[-0.78,0.14]

Favours treatment

-4

-2

0

2

4

Favours control

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

183

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Treatment

Control

Std. Mean Difference

Weight

Std. Mean Difference

Subtotal ***

Mean(SD)

N

44

N

51

Heterogeneity: Tau2=0; Chi2=0.13, df=1(P=0.72); I2=0%

Test for overall effect: Z=1.35(P=0.18)

12.4.2 Cognitive-behaviour therapy

Spinhoven 1996

Subtotal ***

3 (2.5)

20

20

Heterogeneity: Not applicable

Test for overall effect: Z=0.25(P=0.8)

12.4.3 Psychodynamic psychotherapy and others

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Not applicable

Total ***

0

64

Heterogeneity: Tau2=0; Chi2=1.03, df=2(P=0.6); I2=0%

Test for overall effect: Z=1(P=0.32)

Test for subgroup differences: Chi2=0.9, df=1 (P=0.34), I2=0%

19

19

0

70

Mean(SD)

Random, 95% CI

Random, 95% CI

70.56%

-0.28[-0.69,0.13]

2.8 (2.3)

29.44%

29.44%

0.08[-0.55,0.71]

0.08[-0.55,0.71]

Not estimable

100%

-0.17[-0.51,0.17]

Favours treatment

-4

-2

0

2

4

Favours control

Analysis 12.5.   Comparison 12 SUBGROUP4: without comorbidity: Psychotherapy
+Antidepressant vs Antidepressant alone, Outcome 5 Phobic avoidance at 2-4 months.

Study or subgroup

Treatment

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

28.4 (11.2)

2.8 (1.4)

19 (13.2)

18.7 (13.3)

12.5.1 Behaviour therapy

Telch 1985

Zitrin 1983

Subtotal ***

17.3 (10.3)

2.7 (1.4)

10

34

44

Heterogeneity: Tau2=0.24; Chi2=2.72, df=1(P=0.1); I2=63.27%

Test for overall effect: Z=1.05(P=0.3)

12.5.2 Cognitive-behaviour therapy

Loerch 1999

Spinhoven 1996

Subtotal ***

7 (8.3)

22.5 (12)

14

20

34

Heterogeneity: Tau2=0.77; Chi2=6.95, df=1(P=0.01); I2=85.61%

Test for overall effect: Z=0.53(P=0.59)

12.5.3 Psychodynamic psychotherapy and others

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Not applicable

Total ***

0

78

Heterogeneity: Tau2=0.25; Chi2=9.68, df=3(P=0.02); I2=69%

Test for overall effect: Z=1.27(P=0.2)

Test for subgroup differences: Chi2=0.01, df=1 (P=0.92), I2=0%

10

41

51

16

19

35

0

86

19.57%

30.77%

50.34%

-0.99[-1.93,-0.05]

-0.11[-0.56,0.35]

-0.45[-1.29,0.39]

23.18%

26.48%

49.66%

-1.05[-1.82,-0.28]

0.29[-0.34,0.93]

-0.36[-1.67,0.96]

Not estimable

100%

-0.39[-1,0.21]

Favours treatment

-4

-2

0

2

4

Favours control

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

184

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 12.6.   Comparison 12 SUBGROUP4: without comorbidity: Psychotherapy
+Antidepressant vs Antidepressant alone, Outcome 6 General anxiety at 2-4 months.

Study or subgroup

Treatment

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

22.8 (9.9)

19.9 (9.8)

7.9 (7)

12.6.1 Behaviour therapy

Zitrin 1983

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=0.56(P=0.58)

12.6.2 Cognitive-behaviour therapy

Loerch 1999

Sharp 1996

Subtotal ***

21.5 (9.9)

11.4 (11.1)

4.8 (5.7)

34

34

14

29

43

Heterogeneity: Tau2=0; Chi2=0.45, df=1(P=0.5); I2=0%

Test for overall effect: Z=2.66(P=0.01)

12.6.3 Psychodynamic psychotherapy and others

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Not applicable

Total ***

0

77

Heterogeneity: Tau2=0.02; Chi2=2.46, df=2(P=0.29); I2=18.62%

Test for overall effect: Z=2.14(P=0.03)

Test for subgroup differences: Chi2=2.01, df=1 (P=0.16), I2=50.2%

41

41

16

29

45

0

86

44.45%

44.45%

-0.13[-0.58,0.33]

-0.13[-0.58,0.33]

19.6%

35.95%

55.55%

-0.79[-1.54,-0.04]

-0.48[-1,0.04]

-0.58[-1.01,-0.15]

Not estimable

100%

-0.38[-0.74,-0.03]

Favours treatment

-4

-2

0

2

4

Favours control

Analysis 12.7.   Comparison 12 SUBGROUP4: without comorbidity: Psychotherapy
+Antidepressant vs Antidepressant alone, Outcome 7 Depression at 2-4 months.

Study or subgroup

Treatment

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

12.7.1 Behaviour therapy

Telch 1985

Zitrin 1983

Subtotal ***

13.4 (5.7)

1.3 (0.5)

10

34

44

Heterogeneity: Tau2=0; Chi2=0.15, df=1(P=0.7); I2=0%

Test for overall effect: Z=1.29(P=0.2)

12.7.2 Cognitive-behaviour therapy

Loerch 1999

Spinhoven 1996

Subtotal ***

5.6 (5.8)

43.5 (8.7)

14

20

34

Heterogeneity: Tau2=0.1; Chi2=1.82, df=1(P=0.18); I2=45.12%

Test for overall effect: Z=1.64(P=0.1)

12.7.3 Psychodynamic psychotherapy and others

Subtotal ***

0

10

41

51

16

19

35

0

14.7 (14.1)

1.5 (0.5)

12 (7.4)

46 (10.8)

12.58%

46.3%

58.88%

-0.12[-0.99,0.76]

-0.31[-0.77,0.15]

-0.27[-0.67,0.14]

16.75%

24.36%

41.12%

-0.93[-1.69,-0.17]

-0.25[-0.88,0.38]

-0.56[-1.22,0.11]

Favours treatment

-4

-2

0

2

4

Favours control

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Not estimable

185

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Treatment

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

Heterogeneity: Not applicable

Test for overall effect: Not applicable

Total ***

78

86

100%

-0.37[-0.69,-0.06]

Heterogeneity: Tau2=0; Chi2=2.62, df=3(P=0.45); I2=0%

Test for overall effect: Z=2.36(P=0.02)

Test for subgroup differences: Chi2=0.65, df=1 (P=0.42), I2=0%

Favours treatment

-4

-2

0

2

4

Favours control

Analysis 12.8.   Comparison 12 SUBGROUP4: without comorbidity: Psychotherapy
+Antidepressant vs Antidepressant alone, Outcome 8 Social functioning at 2-4 months.

Study or subgroup

Treatment

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

6 (0.9)

5.9 (3.5)

2.2 (2.9)

12.8.1 Behavour therapy

Zitrin 1983

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=0.72(P=0.47)

12.8.2 Cognitive-behaviour therapy

Loerch 1999

Sharp 1996

Subtotal ***

5.8 (0.9)

2.4 (2.8)

1.4 (2.8)

34

34

14

29

43

Heterogeneity: Tau2=0.19; Chi2=2.67, df=1(P=0.1); I2=62.54%

Test for overall effect: Z=1.65(P=0.1)

12.8.3 Psychodynamic psychotherapy and others

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Not applicable

Total ***

0

77

Heterogeneity: Tau2=0.08; Chi2=4.04, df=2(P=0.13); I2=50.56%

Test for overall effect: Z=1.81(P=0.07)

Test for subgroup differences: Chi2=1.38, df=1 (P=0.24), I2=27.29%

41

41

16

29

45

0

86

40.44%

40.44%

-0.17[-0.62,0.29]

-0.17[-0.62,0.29]

23.26%

36.3%

59.56%

-1.08[-1.85,-0.3]

-0.3[-0.82,0.22]

-0.63[-1.39,0.12]

Not estimable

100%

-0.43[-0.89,0.04]

Favours treatment

-4

-2

0

2

4

Favours control

Analysis 12.9.   Comparison 12 SUBGROUP4: without comorbidity: Psychotherapy
+Antidepressant vs Antidepressant alone, Outcome 9 Dropouts for any reason within 2-4 months.

Study or subgroup

12.9.1 Behaviour therapy

Telch 1985

Zitrin 1983

Subtotal (95% CI)

Treatment

n/N

Control

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

3/13

9/43

56

2/12

12/53

65

6.82%

30.12%

36.94%

1.38[0.28,6.91]

0.92[0.43,1.99]

1[0.5,1.99]

Favours treatment

0.1

0.2

0.5

1

2

5

10

Favours control

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

186

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Treatment

n/N

Control

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

Total events: 12 (Treatment), 14 (Control)

Heterogeneity: Tau2=0; Chi2=0.2, df=1(P=0.66); I2=0%

Test for overall effect: Z=0.01(P=0.99)

12.9.2 Cognitive-behaviour therapy

Loerch 1999

Sharp 1996

Spinhoven 1996

Subtotal (95% CI)

3/14

11/38

4/20

72

7/16

12/36

4/20

72

Total events: 18 (Treatment), 23 (Control)

Heterogeneity: Tau2=0; Chi2=0.88, df=2(P=0.64); I2=0%

Test for overall effect: Z=0.88(P=0.38)

12.9.3 Psychodynamic psychotherapy and others

Subtotal (95% CI)

0

0

Total events: 0 (Treatment), 0 (Control)

Heterogeneity: Not applicable

Test for overall effect: Not applicable

13.41%

38.19%

11.47%

63.06%

0.49[0.16,1.54]

0.87[0.44,1.71]

1[0.29,3.45]

0.79[0.46,1.34]

Not estimable

Total (95% CI)

128

137

100%

0.86[0.57,1.31]

Total events: 30 (Treatment), 37 (Control)

Heterogeneity: Tau2=0; Chi2=1.35, df=4(P=0.85); I2=0%

Test for overall effect: Z=0.71(P=0.48)

Test for subgroup differences: Not applicable

Favours treatment

0.1

0.2

0.5

1

2

5

10

Favours control

Analysis 12.10.   Comparison 12 SUBGROUP4: without comorbidity: Psychotherapy+Antidepressant
vs Antidepressant alone, Outcome 10 Dropouts due to side effects within 2-4 months.

Treatment

n/N

Control

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

Study or subgroup

12.10.1 Behaviour therapy

Telch 1985

Subtotal (95% CI)

Total events: 3 (Treatment), 2 (Control)

Heterogeneity: Not applicable

Test for overall effect: Z=0.4(P=0.69)

12.10.2 Cognitive-behaviour therapy

Sharp 1996

Spinhoven 1996

Subtotal (95% CI)

3/13

13

5/38

4/20

58

2/12

12

3/36

3/20

56

Total events: 9 (Treatment), 6 (Control)

Heterogeneity: Tau2=0; Chi2=0.03, df=1(P=0.86); I2=0%

Test for overall effect: Z=0.76(P=0.45)

12.10.3 Psychodynamic psychotherapy and others

Subtotal (95% CI)

0

0

Total events: 0 (Treatment), 0 (Control)

26.34%

26.34%

1.38[0.28,6.91]

1.38[0.28,6.91]

36.99%

36.68%

73.66%

1.58[0.41,6.13]

1.33[0.34,5.21]

1.45[0.55,3.8]

Not estimable

Favours treatment

0.1

0.2

0.5

1

2

5

10

Favours control

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

187

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Treatment

n/N

Control

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

Heterogeneity: Not applicable

Test for overall effect: Not applicable

Total (95% CI)

71

68

100%

1.43[0.63,3.27]

Total events: 12 (Treatment), 8 (Control)

Heterogeneity: Tau2=0; Chi2=0.03, df=2(P=0.98); I2=0%

Test for overall effect: Z=0.86(P=0.39)

Test for subgroup differences: Not applicable

Favours treatment

0.1

0.2

0.5

1

2

5

10

Favours control

Analysis 12.11.   Comparison 12 SUBGROUP4: without comorbidity: Psychotherapy
+Antidepressant vs Antidepressant alone, Outcome 11 Response/remission on continued treatment.

Study or subgroup

12.11.1 Behaviour therapy

Telch 1985

Zitrin 1983

Subtotal (95% CI)

PT+AD

n/N

AD

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

7/13

17/43

56

2/12

12/53

65

17.17%

82.83%

100%

3.23[0.83,12.61]

1.75[0.94,3.25]

1.94[1.1,3.41]

Total events: 24 (PT+AD), 14 (AD)

Heterogeneity: Tau2=0; Chi2=0.66, df=1(P=0.42); I2=0%

Test for overall effect: Z=2.3(P=0.02)

12.11.2 Cognitive-behaviour therapy

Subtotal (95% CI)

Total events: 0 (PT+AD), 0 (AD)

Heterogeneity: Not applicable

Test for overall effect: Not applicable

12.11.3 Psychdynamic psychotherapy and others

Subtotal (95% CI)

Total events: 0 (PT+AD), 0 (AD)

Heterogeneity: Not applicable

Test for overall effect: Not applicable

0

0

0

0

Not estimable

Not estimable

Total (95% CI)

56

65

100%

1.94[1.1,3.41]

Total events: 24 (PT+AD), 14 (AD)

Heterogeneity: Tau2=0; Chi2=0.66, df=1(P=0.42); I2=0%

Test for overall effect: Z=2.3(P=0.02)

Test for subgroup differences: Not applicable

Favours AD

0.1

0.2

0.5

1

2

5

10

Favours PT+AD

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

188

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 12.12.   Comparison 12 SUBGROUP4: without comorbidity: Psychotherapy+Antidepressant
vs Antidepressant alone, Outcome 12 Global/Avoidance/Panic on continued treatment.

Study or subgroup

Treatment

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

12.6 (8.1)

12.12.1 Behaviour therapy

Telch 1985

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=2.47(P=0.01)

12.12.2 Cognitive-behaviour therapy

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Not applicable

10

10

0

12.12.3 Psychodynamic psychotherapy and others

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Not applicable

Total ***

0

10

Heterogeneity: Not applicable

Test for overall effect: Z=2.47(P=0.01)

Test for subgroup differences: Not applicable

10

10

0

0

10

23.8 (9.3)

100%

100%

-1.23[-2.2,-0.26]

-1.23[-2.2,-0.26]

Not estimable

Not estimable

100%

-1.23[-2.2,-0.26]

Favours treatment

-4

-2

0

2

4

Favours control

Analysis 12.13.   Comparison 12 SUBGROUP4: without comorbidity: Psychotherapy+Antidepressant
vs Antidepressant alone, Outcome 13 Dropouts for any reason on continued treatment.

Study or subgroup

12.13.1 Behaviour therapy

Telch 1985

Subtotal (95% CI)

Total events: 1 (Treatment), 1 (Control)

Heterogeneity: Not applicable

Test for overall effect: Not applicable

Treatment

n/N

Control

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

1/10

10

1/10

10

100%

100%

1[0.07,13.87]

1[0.07,13.87]

12.13.2 Cognitive-behaviour therapy

Subtotal (95% CI)

0

Total events: 0 (Treatment), 0 (Control)

Heterogeneity: Not applicable

Test for overall effect: Not applicable

12.13.3 Psychodynamic psychotherapy and others

Subtotal (95% CI)

0

Total events: 0 (Treatment), 0 (Control)

Heterogeneity: Not applicable

Test for overall effect: Not applicable

0

0

Not estimable

Not estimable

Total (95% CI)

10

10

100%

1[0.07,13.87]

Favours treatment

0.1

0.2

0.5

1

2

5

10

Favours control

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

189

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Treatment

n/N

Control

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

Total events: 1 (Treatment), 1 (Control)

Heterogeneity: Not applicable

Test for overall effect: Not applicable

Test for subgroup differences: Not applicable

Favours treatment

0.1

0.2

0.5

1

2

5

10

Favours control

Analysis 12.16.   Comparison 12 SUBGROUP4: without comorbidity: Psychotherapy+Antidepressant vs
Antidepressant alone, Outcome 16 Response/remission 6-24 months after treatment discontinuation.

Study or subgroup

PT+AD

n/N

AD

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

12.16.1 Behaviour therapy

Zitrin 1983

Subtotal (95% CI)

Total events: 23 (PT+AD), 19 (AD)

Heterogeneity: Not applicable

Test for overall effect: Z=1.72(P=0.09)

12.16.2 Cognitive-behaviour therapy

Loerch 1999

Sharp 1996

Subtotal (95% CI)

23/43

43

19/53

53

51.34%

51.34%

1.49[0.95,2.35]

1.49[0.95,2.35]

9/14

16/38

52

7/16

10/36

52

23.09%

25.57%

48.66%

1.47[0.75,2.9]

1.52[0.8,2.89]

1.49[0.94,2.38]

Total events: 25 (PT+AD), 17 (AD)

Heterogeneity: Tau2=0; Chi2=0, df=1(P=0.95); I2=0%

Test for overall effect: Z=1.68(P=0.09)

12.16.3 Psychodynamic psychotherapy and others

Subtotal (95% CI)

Total events: 0 (PT+AD), 0 (AD)

Heterogeneity: Not applicable

Test for overall effect: Not applicable

0

0

Not estimable

Total (95% CI)

95

105

100%

1.49[1.08,2.07]

Total events: 48 (PT+AD), 36 (AD)

Heterogeneity: Tau2=0; Chi2=0, df=2(P=1); I2=0%

Test for overall effect: Z=2.41(P=0.02)

Test for subgroup differences: Not applicable

Favours AD

0.1

0.2

0.5

1

2

5

10

Favours PT+AD

Comparison 13.   SUBGROUP4: without comorbidity: Psychotherapy+Antidepressant vs Psychotherapy alone or
+Placebo

Outcome or subgroup title

No. of
studies

No. of
partici-
pants

Statistical method

Effect size

1 Response at 2-4 months

12

675

Risk Ratio (M-H, Random, 95%
CI)

1.15 [1.01, 1.32]

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

190

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

No. of
studies

No. of
partici-
pants

Statistical method

Effect size

Outcome or subgroup title

1.1 Behaviour therapy

1.2 Cognitive-behaviour therapy

2 Remission at 2-4 months

2.1 Behaviour therapy

2.2 Cognitive-behaviour therapy

3 Global severity at 2-4 months

3.1 Behaviour therapy

3.2 Cognitive-behaviour therapy

4 Frequency of panic attacks at 2-4 months

4.1 Behaviour therapy

4.2 Cognitive-behaviour therapy

6

6

10

5

5

6

4

2

7

5

2

5 Phobic avoidance at 2-4 months

11

5.1 Behaviour therapy

5.2 Cognitive-behaviour therapy

6 General anxiety at 2-4 months

6.1 Behaviour therapy

6.2 Cognitive-behaviour therapy

7 Depression at 2-4 months

6

5

9

4

5

8

337

338

610

312

298

275

183

92

329

182

147

424

240

184

426

175

251

286

Risk Ratio (M-H, Random, 95%
CI)

1.21 [0.97, 1.51]

Risk Ratio (M-H, Random, 95%
CI)

1.12 [0.89, 1.40]

Risk Ratio (M-H, Random, 95%
CI)

1.37 [1.11, 1.70]

Risk Ratio (M-H, Random, 95%
CI)

1.45 [1.04, 2.03]

Risk Ratio (M-H, Random, 95%
CI)

1.32 [0.95, 1.84]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.46 [-0.71, -0.21]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.62 [-0.92, -0.32]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.12 [-0.56, 0.32]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.04 [-0.22, 0.29]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.20 [-0.09, 0.49]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.17 [-0.60, 0.25]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.15 [-0.35, 0.04]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.16 [-0.49, 0.16]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.13 [-0.43, 0.17]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.35 [-0.55, -0.16]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.46 [-0.76, -0.16]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.27 [-0.53, -0.02]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.17 [-0.41, 0.06]

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

191

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of
studies

No. of
partici-
pants

Statistical method

Effect size

7.1 Behaviour therapy

7.2 Cognitive-behaviour therapy

8 Social functioning at 2-4 months

8.1 Behaviour therapy

8.2 Cognitive-behaviour therapy

5

3

8

4

4

9 Dropouts for any reason within 2-4 months

10

9.1 Behaviour therapy

9.2 Cognitive-behaviour therapy

10 Dropouts due to side effects within 2-4
months

10.1 Behaviour therapy

10.2 Cognitive-behaviour therapy

11 Response/remission on continued treat-
ment

11.1 Behaviour therapy

11.2 Cognitive-behaviour therapy

12 Global/Avoidance/Panic on continued
treatment

12.1 Behaviour therapy

12.2 Cognitive-behaviour therapy

13 Dropouts for any reason on continued
treatment

4

6

7

3

4

3

3

0

2

2

0

1

194

92

319

175

144

595

257

338

450

173

277

185

185

0

72

72

0

19

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.22 [-0.52, 0.09]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.07 [-0.47, 0.34]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.06 [-0.27, 0.39]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.10 [-0.51, 0.71]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.04 [-0.39, 0.30]

Risk Ratio (M-H, Random, 95%
CI)

1.06 [0.77, 1.45]

Risk Ratio (M-H, Random, 95%
CI)

0.98 [0.67, 1.44]

Risk Ratio (M-H, Random, 95%
CI)

1.35 [0.68, 2.68]

Risk Ratio (M-H, Random, 95%
CI)

2.81 [1.29, 6.11]

Risk Ratio (M-H, Random, 95%
CI)

1.68 [0.67, 4.18]

Risk Ratio (M-H, Random, 95%
CI)

10.34 [2.41, 44.39]

Risk Ratio (M-H, Random, 95%
CI)

1.25 [0.82, 1.90]

Risk Ratio (M-H, Random, 95%
CI)

1.25 [0.82, 1.90]

Risk Ratio (M-H, Random, 95%
CI)

0.0 [0.0, 0.0]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.96 [-1.65, -0.27]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.96 [-1.65, -0.27]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.0 [0.0, 0.0]

Risk Ratio (M-H, Random, 95%
CI)

2.73 [0.12, 59.57]

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

192

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Outcome or subgroup title

13.1 Behaviour therapy

13.2 Cognitive-behaviour therapy

14 Response/remission 6 months after treat-
ment discontinuation

14.1 Behaviour therapy

14.2 Cognitive-behaviour therapy

15 Global/Avoidance/Panic 6 months after
treatment discontinuation

15.1 Behaviour therapy

15.2 Cognitive-behaviour therapy

16 Response/remission 18-24 months after
treatment discontinuation

16.1 Behaviour therapy

16.2 Cognitive-behaviour therapy

17 Global/Avoidance/Panic 18-24 months af-
ter treatment discontinuation

17.1 Behaviour therapy

17.2 Cognitive-behviour therapy

Cochrane Database of Systematic Reviews

No. of
studies

No. of
partici-
pants

Statistical method

Effect size

1

0

6

3

3

3

3

0

4

4

0

3

3

0

19

0

297

152

145

90

90

0

236

236

0

87

87

0

Risk Ratio (M-H, Random, 95%
CI)

2.73 [0.12, 59.57]

Risk Ratio (M-H, Random, 95%
CI)

0.0 [0.0, 0.0]

Risk Ratio (M-H, Random, 95%
CI)

1.10 [0.80, 1.52]

Risk Ratio (M-H, Random, 95%
CI)

1.42 [0.61, 3.32]

Risk Ratio (M-H, Random, 95%
CI)

1.02 [0.71, 1.45]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.03 [-0.43, 0.49]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.03 [-0.43, 0.49]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.0 [0.0, 0.0]

Risk Ratio (M-H, Random, 95%
CI)

1.04 [0.75, 1.43]

Risk Ratio (M-H, Random, 95%
CI)

1.04 [0.75, 1.43]

Risk Ratio (M-H, Random, 95%
CI)

0.0 [0.0, 0.0]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.08 [-0.59, 0.75]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.08 [-0.59, 0.75]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.0 [0.0, 0.0]

Analysis 13.1.   Comparison 13 SUBGROUP4: without comorbidity: Psychotherapy
+Antidepressant vs Psychotherapy alone or +Placebo, Outcome 1 Response at 2-4 months.

Study or subgroup

13.1.1 Behaviour therapy

Marks 1983

Mavissakalian 1986a

PT+AD

n/N

PT+placebo

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

17/36

11/20

12/36

10/20

5.31%

5.06%

1.42[0.8,2.52]

1.1[0.61,1.99]

Favours PT+placebo

0.1

0.2

0.5

1

2

5

10

Favours PT+AD

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

193

 
 
 
 
 
 
 
8/20

5/13

25/41

25/43

173

20/36

8/20

8/20

7/41

13/43

160

Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

PT+AD

n/N

PT+placebo

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

Study or subgroup

Mavissakalian 1986b

Telch 1985

Zitrin 1980

Zitrin 1983

Subtotal (95% CI)

Total events: 91 (PT+AD), 70 (PT+placebo)

Heterogeneity: Tau2=0; Chi2=2.17, df=5(P=0.83); I2=0%

Test for overall effect: Z=1.68(P=0.09)

13.1.2 Cognitive-behaviour therapy

Loerch 1999

Oehrberg 1995

Sharp 1996i

Sharp 1996ii

Spinhoven 1996

Stein 2000

Subtotal (95% CI)

11/14

42/60

13/19

13/19

4/20

13/16

148

Total events: 96 (PT+AD), 107 (PT+placebo)

Heterogeneity: Tau2=0.04; Chi2=9.22, df=5(P=0.1); I2=45.78%

Test for overall effect: Z=0.96(P=0.34)

9/20

2/12

16/35

21/41

164

12/14

25/60

28/36

26/43

4/20

12/17

190

3.42%

0.88%

9.05%

11.06%

34.78%

13.82%

14.2%

13.49%

11.19%

1.18%

11.34%

65.22%

0.89[0.43,1.83]

2.31[0.55,9.74]

1.33[0.86,2.06]

1.14[0.77,1.68]

1.21[0.97,1.51]

0.92[0.65,1.3]

1.68[1.19,2.37]

0.88[0.62,1.25]

1.13[0.77,1.67]

1[0.29,3.45]

1.15[0.78,1.69]

1.12[0.89,1.4]

Total (95% CI)

321

354

100%

1.15[1.01,1.32]

Total events: 187 (PT+AD), 177 (PT+placebo)

Heterogeneity: Tau2=0; Chi2=11.61, df=11(P=0.39); I2=5.23%

Test for overall effect: Z=2.04(P=0.04)

Test for subgroup differences: Not applicable

Favours PT+placebo

0.1

0.2

0.5

1

2

5

10

Favours PT+AD

Analysis 13.2.   Comparison 13 SUBGROUP4: without comorbidity: Psychotherapy
+Antidepressant vs Psychotherapy alone or +Placebo, Outcome 2 Remission at 2-4 months.

PT+AD

n/N

PT+placebo

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

Study or subgroup

13.2.1 Behaviour therapy

Marks 1983

Mavissakalian 1986a

Mavissakalian 1986b

Zitrin 1980

Zitrin 1983

Subtotal (95% CI)

Total events: 56 (PT+AD), 35 (PT+placebo)

Heterogeneity: Tau2=0; Chi2=2.65, df=4(P=0.62); I2=0%

Test for overall effect: Z=2.19(P=0.03)

13.2.2 Cognitive-behaviour therapy

Loerch 1999

Oehrberg 1995

Sharp 1996i

Sharp 1996ii

9/14

39/60

12/19

12/19

17/36

4/20

5/20

4/35

5/41

152

8/14

21/60

25/36

21/43

15.98%

4%

4.81%

3.28%

4.73%

32.8%

10.37%

19.5%

18.58%

15.6%

Favours PT+placebo

0.1

0.2

0.5

1

2

5

10

Favours PT+AD

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

1.18[0.75,1.85]

2[0.72,5.59]

1.6[0.63,4.05]

1.49[0.48,4.68]

2.48[0.97,6.34]

1.45[1.04,2.03]

1.13[0.62,2.05]

1.86[1.26,2.75]

0.91[0.61,1.37]

1.29[0.82,2.05]

194

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Study or subgroup

Stein 2000

Subtotal (95% CI)

PT+AD

n/N

PT+placebo

n/N

7/16

128

3/17

170

Total events: 79 (PT+AD), 78 (PT+placebo)

Heterogeneity: Tau2=0.07; Chi2=7.97, df=4(P=0.09); I2=49.8%

Test for overall effect: Z=1.67(P=0.09)

Cochrane Database of Systematic Reviews

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

3.15%

67.2%

2.48[0.77,7.97]

1.32[0.95,1.84]

Total (95% CI)

288

322

100%

1.37[1.11,1.7]

Total events: 135 (PT+AD), 113 (PT+placebo)

Heterogeneity: Tau2=0.02; Chi2=11, df=9(P=0.28); I2=18.16%

Test for overall effect: Z=2.91(P=0)

Test for subgroup differences: Not applicable

Favours PT+placebo

0.1

0.2

0.5

1

2

5

10

Favours PT+AD

Analysis 13.3.   Comparison 13 SUBGROUP4: without comorbidity: Psychotherapy
+Antidepressant vs Psychotherapy alone or +Placebo, Outcome 3 Global severity at 2-4 months.

Study or subgroup

PT+AD

PT+placebo

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

13.3.1 Behaviour therapy

Mavissakalian 1986a

Mavissakalian 1986b

Zitrin 1980

Zitrin 1983

Subtotal ***

2 (1.7)

2.2 (1.7)

1.9 (0.6)

3.2 (1)

17

14

29

34

94

Heterogeneity: Tau2=0; Chi2=0.9, df=3(P=0.82); I2=0%

Test for overall effect: Z=4.06(P<0.0001)

13.3.2 Cognitive-behaviour therapy

Sharp 1996i

Sharp 1996ii

Subtotal ***

1.7 (1.1)

1.7 (1.1)

15

14

29

Heterogeneity: Tau2=0; Chi2=0.34, df=1(P=0.56); I2=0%

Test for overall effect: Z=0.52(P=0.61)

3 (1.9)

3.1 (1.9)

2.3 (0.9)

4 (1)

2 (1.3)

1.7 (1)

14

17

24

34

89

33

30

63

11.7%

11.81%

20.19%

24.86%

68.56%

-0.55[-1.27,0.18]

-0.49[-1.2,0.23]

-0.5[-1.05,0.05]

-0.81[-1.3,-0.31]

-0.62[-0.92,-0.32]

16.28%

15.17%

31.44%

-0.24[-0.86,0.37]

0.02[-0.61,0.65]

-0.12[-0.56,0.32]

Total ***

123

152

100%

-0.46[-0.71,-0.21]

Heterogeneity: Tau2=0; Chi2=4.66, df=5(P=0.46); I2=0%

Test for overall effect: Z=3.65(P=0)

Test for subgroup differences: Chi2=3.41, df=1 (P=0.06), I2=70.7%

Favours treatment

-4

-2

0

2

4

Favours control

Analysis 13.4.   Comparison 13 SUBGROUP4: without comorbidity: Psychotherapy+Antidepressant
vs Psychotherapy alone or +Placebo, Outcome 4 Frequency of panic attacks at 2-4 months.

Study or subgroup

PT+AD

PT+placebo

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

13.4.1 Behaviour therapy

Mavissakalian 1986a

17

1.3 (2)

14

1.6 (2.1)

10.88%

-0.14[-0.85,0.56]

Favours treatment

-4

-2

0

2

4

Favours control

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

195

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

PT+AD

PT+placebo

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

Mavissakalian 1986b

Telch 1985

Zitrin 1980

Zitrin 1983

Subtotal ***

2.4 (1.9)

0.6 (1.1)

6.4 (1)

6 (1.2)

14

10

19

34

94

Heterogeneity: Tau2=0; Chi2=2.83, df=4(P=0.59); I2=0%

Test for overall effect: Z=1.34(P=0.18)

13.4.2 Cognitive-behaviour therapy

Oehrberg 1995

Spinhoven 1996

Subtotal ***

-16 (18.4)

3 (2.5)

55

20

75

Heterogeneity: Tau2=0.04; Chi2=1.51, df=1(P=0.22); I2=33.83%

Test for overall effect: Z=0.8(P=0.42)

2.2 (2.1)

0.8 (0.7)

6 (1)

5.4 (1.2)

-9.8 (18.4)

2.7 (2.3)

17

9

14

34

88

52

20

72

Total ***

169

160

Heterogeneity: Tau2=0.03; Chi2=7.69, df=6(P=0.26); I2=22.03%

Test for overall effect: Z=0.28(P=0.78)

Test for subgroup differences: Chi2=3.35, df=1 (P=0.07), I2=70.17%

10.89%

7.15%

11.19%

19.74%

59.86%

0.1[-0.61,0.8]

-0.18[-1.08,0.72]

0.36[-0.33,1.06]

0.44[-0.04,0.92]

0.2[-0.09,0.49]

26.64%

13.5%

40.14%

-0.33[-0.72,0.05]

0.12[-0.5,0.74]

-0.17[-0.6,0.25]

100%

0.04[-0.22,0.29]

Favours treatment

-4

-2

0

2

4

Favours control

Analysis 13.5.   Comparison 13 SUBGROUP4: without comorbidity: Psychotherapy
+Antidepressant vs Psychotherapy alone or +Placebo, Outcome 5 Phobic avoidance at 2-4 months.

Study or subgroup

PT+AD

PT+placebo

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

13.5.1 Behaviour therapy

Marks 1983

Mavissakalian 1986a

Mavissakalian 1986b

Telch 1985

Zitrin 1980

Zitrin 1983

Subtotal ***

11.4 (9.4)

11.4 (8.8)

12.3 (8.8)

17.3 (10.3)

6.2 (0.8)

2.7 (1.4)

23

17

14

10

25

34

123

Heterogeneity: Tau2=0.06; Chi2=7.67, df=5(P=0.18); I2=34.79%

Test for overall effect: Z=0.99(P=0.32)

13.5.2 Cognitive-behaviour therapy

Loerch 1999

Sharp 1996i

Sharp 1996ii

Spinhoven 1996

Stein 2000

Subtotal ***

7 (8.3)

4.7 (7.8)

4.7 (7.8)

22.5 (12)

-5.8 (6.7)

14

15

14

20

12

75

12.7 (10.5)

13.8 (9.9)

13.3 (9.9)

23.3 (7.8)

5.7 (1.1)

3.4 (1.4)

9.1 (6.3)

7.2 (10.6)

5.1 (5.4)

22.9 (11.3)

-5.9 (9.8)

22

14

17

9

21

34

117

14

33

30

20

12

109

Heterogeneity: Tau2=0; Chi2=0.57, df=4(P=0.97); I2=0%

Test for overall effect: Z=0.82(P=0.41)

Total ***

198

226

Heterogeneity: Tau2=0; Chi2=8.28, df=10(P=0.6); I2=0%

11.09%

7.52%

7.58%

4.41%

10.93%

16.26%

57.79%

6.84%

10.12%

9.43%

9.88%

5.93%

42.21%

-0.13[-0.71,0.46]

-0.25[-0.96,0.46]

-0.1[-0.81,0.6]

-0.62[-1.55,0.31]

0.49[-0.1,1.08]

-0.51[-0.99,-0.02]

-0.16[-0.49,0.16]

-0.28[-1.03,0.46]

-0.25[-0.86,0.36]

-0.06[-0.7,0.57]

-0.03[-0.65,0.59]

0.01[-0.79,0.81]

-0.13[-0.43,0.17]

100%

-0.15[-0.35,0.04]

Favours treatment

-4

-2

0

2

4

Favours control

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

196

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

PT+AD

PT+placebo

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

Test for overall effect: Z=1.51(P=0.13)

Test for subgroup differences: Chi2=0.04, df=1 (P=0.84), I2=0%

Favours treatment

-4

-2

0

2

4

Favours control

Analysis 13.6.   Comparison 13 SUBGROUP4: without comorbidity: Psychotherapy
+Antidepressant vs Psychotherapy alone or +Placebo, Outcome 6 General anxiety at 2-4 months.

Study or subgroup

PT+AD

PT+placebo

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

13.6.1 Behaviour therapy

Marks 1983

Mavissakalian 1986a

Mavissakalian 1986b

Zitrin 1983

Subtotal ***

8.9 (9.4)

30.1 (7.6)

34.3 (7.6)

21.5 (9.9)

23

17

14

34

88

Heterogeneity: Tau2=0; Chi2=2.31, df=3(P=0.51); I2=0%

Test for overall effect: Z=2.99(P=0)

13.6.2 Cognitive-behaviour therapy

Loerch 1999

Oehrberg 1995

Sharp 1996i

Sharp 1996ii

Stein 2000

Subtotal ***

11.4 (11.1)

-6.5 (5.5)

4.8 (5.7)

4.8 (5.7)

-15.3 (10.6)

14

55

15

14

12

110

Heterogeneity: Tau2=0; Chi2=1.53, df=4(P=0.82); I2=0%

Test for overall effect: Z=2.1(P=0.04)

12.7 (9.2)

35.5 (9.3)

34.4 (9.3)

27.9 (9.9)

11.9 (8.4)

-4.3 (5.5)

6.5 (6.7)

4.9 (4.4)

-10 (13.1)

22

14

17

34

87

14

52

33

30

12

141

10.91%

7.21%

7.61%

15.98%

41.71%

6.94%

25.96%

10.14%

9.46%

5.79%

58.29%

-0.4[-0.99,0.19]

-0.63[-1.35,0.1]

-0.01[-0.72,0.7]

-0.64[-1.13,-0.15]

-0.46[-0.76,-0.16]

-0.04[-0.78,0.7]

-0.4[-0.78,-0.01]

-0.26[-0.87,0.35]

-0.02[-0.65,0.61]

-0.43[-1.24,0.38]

-0.27[-0.53,-0.02]

Total ***

198

228

100%

-0.35[-0.55,-0.16]

Heterogeneity: Tau2=0; Chi2=4.71, df=8(P=0.79); I2=0%

Test for overall effect: Z=3.53(P=0)

Test for subgroup differences: Chi2=0.86, df=1 (P=0.35), I2=0%

Favours treatment

-4

-2

0

2

4

Favours control

Analysis 13.7.   Comparison 13 SUBGROUP4: without comorbidity: Psychotherapy
+Antidepressant vs Psychotherapy alone or +Placebo, Outcome 7 Depression at 2-4 months.

Study or subgroup

PT+AD

PT+placebo

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

13.7.1 Behaviour therapy

Marks 1983

Mavissakalian 1986a

Mavissakalian 1986b

Telch 1985

Zitrin 1983

Subtotal ***

4 (4.9)

2.8 (8.5)

8.7 (8.5)

13.4 (5.7)

1.3 (0.5)

23

17

14

10

34

98

22

14

17

9

34

96

4 (2.7)

7.7 (8.7)

6.9 (8.7)

13 (11.9)

1.6 (0.5)

Heterogeneity: Tau2=0.01; Chi2=4.5, df=4(P=0.34); I2=11.12%

15.99%

10.46%

10.85%

6.73%

23.36%

67.39%

0[-0.58,0.58]

-0.56[-1.28,0.17]

0.2[-0.51,0.91]

0.04[-0.86,0.94]

-0.51[-1,-0.03]

-0.22[-0.52,0.09]

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

197

Favours treatment

-4

-2

0

2

4

Favours control

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

PT+AD

PT+placebo

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

Test for overall effect: Z=1.41(P=0.16)

13.7.2 Cognitive-behaviour therapy

Loerch 1999

Spinhoven 1996

Stein 2000

Subtotal ***

5.6 (5.8)

43.5 (8.7)

-10.5 (10.4)

14

20

12

46

14

20

12

46

6.5 (5.2)

42.7 (10)

-8.6 (7.6)

Heterogeneity: Tau2=0; Chi2=0.4, df=2(P=0.82); I2=0%

Test for overall effect: Z=0.31(P=0.75)

9.92%

14.21%

8.48%

32.61%

-0.16[-0.9,0.58]

0.08[-0.54,0.7]

-0.2[-1,0.6]

-0.07[-0.47,0.34]

Total ***

144

142

100%

-0.17[-0.41,0.06]

Heterogeneity: Tau2=0; Chi2=5.31, df=7(P=0.62); I2=0%

Test for overall effect: Z=1.47(P=0.14)

Test for subgroup differences: Chi2=0.41, df=1 (P=0.52), I2=0%

Favours treatment

-4

-2

0

2

4

Favours control

Analysis 13.8.   Comparison 13 SUBGROUP4: without comorbidity: Psychotherapy
+Antidepressant vs Psychotherapy alone or +Placebo, Outcome 8 Social functioning at 2-4 months.

Study or subgroup

PT+AD

PT+placebo

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

13.8.1 Behaviour therapy

Mavissakalian 1986a

Mavissakalian 1986b

Zitrin 1980

Zitrin 1983

Subtotal ***

2.3 (1)

2.4 (1)

5.9 (0.8)

5.8 (0.9)

17

14

25

34

90

Heterogeneity: Tau2=0.28; Chi2=11.49, df=3(P=0.01); I2=73.88%

Test for overall effect: Z=0.32(P=0.75)

13.8.2 Cognitive-behaviour therapy

Loerch 1999

Sharp 1996i

Sharp 1996ii

Stein 2000

Subtotal ***

2.4 (2.8)

1.4 (2.8)

1.4 (2.8)

-3.1 (2.5)

14

15

14

12

55

2.8 (1.1)

2.8 (1.1)

5.6 (1.1)

5.1 (0.9)

2.1 (2.2)

2.1 (2.6)

1.9 (2.6)

-4 (2.1)

14

17

20

34

85

14

33

30

12

89

Heterogeneity: Tau2=0; Chi2=1.9, df=3(P=0.59); I2=0%

Test for overall effect: Z=0.26(P=0.8)

Total ***

145

174

Heterogeneity: Tau2=0.12; Chi2=14.71, df=7(P=0.04); I2=52.41%

Test for overall effect: Z=0.35(P=0.73)

Test for subgroup differences: Chi2=1.33, df=1 (P=0.25), I2=24.68%

11.44%

11.51%

13.78%

15.86%

52.59%

11.07%

13.37%

12.93%

10.04%

47.41%

-0.49[-1.21,0.23]

-0.38[-1.1,0.33]

0.33[-0.26,0.92]

0.78[0.28,1.27]

0.1[-0.51,0.71]

0.11[-0.63,0.85]

-0.27[-0.88,0.34]

-0.18[-0.82,0.46]

0.38[-0.43,1.18]

-0.04[-0.39,0.3]

100%

0.06[-0.27,0.39]

Favours treatment

-4

-2

0

2

4

Favours control

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

198

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 13.9.   Comparison 13 SUBGROUP4: without comorbidity: Psychotherapy+Antidepressant
vs Psychotherapy alone or +Placebo, Outcome 9 Dropouts for any reason within 2-4 months.

PT+AD

n/N

PT+placebo

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

Study or subgroup

13.9.1 Behaviour therapy

Marks 1983

Telch 1985

Zitrin 1980

Zitrin 1983

Subtotal (95% CI)

13/36

3/13

12/41

9/43

133

Total events: 37 (PT+AD), 35 (PT+placebo)

Heterogeneity: Tau2=0; Chi2=0.31, df=3(P=0.96); I2=0%

Test for overall effect: Z=0.11(P=0.91)

13.9.2 Cognitive-behaviour therapy

Loerch 1999

Oehrberg 1995

Sharp 1996i

Sharp 1996ii

Spinhoven 1996

Stein 2000

Subtotal (95% CI)

3/14

5/60

6/19

5/19

4/20

1/16

148

Total events: 24 (PT+AD), 27 (PT+placebo)

Heterogeneity: Tau2=0.19; Chi2=6.87, df=5(P=0.23); I2=27.27%

Test for overall effect: Z=0.85(P=0.4)

14/36

3/12

11/35

7/41

124

1/14

8/60

4/36

13/43

0/20

1/17

190

27.59%

5.06%

21.11%

12.41%

66.16%

2.15%

8.78%

7.61%

12.73%

1.2%

1.36%

33.84%

0.93[0.51,1.69]

0.92[0.23,3.72]

0.93[0.47,1.84]

1.23[0.5,2.99]

0.98[0.67,1.44]

3[0.35,25.46]

0.63[0.22,1.8]

2.84[0.91,8.86]

0.87[0.36,2.1]

9[0.52,156.91]

1.06[0.07,15.6]

1.35[0.68,2.68]

Total (95% CI)

281

314

100%

1.06[0.77,1.45]

Total events: 61 (PT+AD), 62 (PT+placebo)

Heterogeneity: Tau2=0; Chi2=7.68, df=9(P=0.57); I2=0%

Test for overall effect: Z=0.36(P=0.72)

Test for subgroup differences: Not applicable

Favours treatment

0.1

0.2

0.5

1

2

5

10

Favours control

Analysis 13.10.   Comparison 13 SUBGROUP4: without comorbidity: Psychotherapy+Antidepressant
vs Psychotherapy alone or +Placebo, Outcome 10 Dropouts due to side effects within 2-4 months.

PT+AD

n/N

PT+placebo

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

Study or subgroup

13.10.1 Behaviour therapy

Marks 1983

Telch 1985

Zitrin 1980

Subtotal (95% CI)

2/36

3/13

8/41

90

Total events: 13 (PT+AD), 7 (PT+placebo)

Heterogeneity: Tau2=0; Chi2=1.54, df=2(P=0.46); I2=0%

Test for overall effect: Z=1.11(P=0.27)

13.10.2 Cognitive-behaviour therapy

Oehrberg 1995

Sharp 1996i

Sharp 1996ii

4/60

3/19

2/19

3/36

1/12

3/35

83

0/60

0/36

0/43

20.07%

13.35%

38.16%

71.58%

0.67[0.12,3.75]

2.77[0.33,23.14]

2.28[0.65,7.93]

1.68[0.67,4.18]

7.17%

7.11%

6.75%

9[0.5,163.58]

12.95[0.7,238.39]

11[0.55,218.74]

Favours treatment

0.1

0.2

0.5

1

2

5

10

Favours control

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

199

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Study or subgroup

Spinhoven 1996

Subtotal (95% CI)

PT+AD

n/N

PT+placebo

n/N

4/20

118

0/20

159

Total events: 13 (PT+AD), 0 (PT+placebo)

Heterogeneity: Tau2=0; Chi2=0.04, df=3(P=1); I2=0%

Test for overall effect: Z=3.14(P=0)

Cochrane Database of Systematic Reviews

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

7.38%

28.42%

9[0.52,156.91]

10.34[2.41,44.39]

Total (95% CI)

208

242

100%

2.81[1.29,6.11]

Total events: 26 (PT+AD), 7 (PT+placebo)

Heterogeneity: Tau2=0.01; Chi2=6.04, df=6(P=0.42); I2=0.63%

Test for overall effect: Z=2.6(P=0.01)

Test for subgroup differences: Not applicable

Favours treatment

0.1

0.2

0.5

1

2

5

10

Favours control

Analysis 13.11.   Comparison 13 SUBGROUP4: without comorbidity: Psychotherapy+Antidepressant
vs Psychotherapy alone or +Placebo, Outcome 11 Response/remission on continued treatment.

Study or subgroup

13.11.1 Behaviour therapy

Telch 1985

Zitrin 1980

Zitrin 1983

Subtotal (95% CI)

PT+AD

n/N

PT+placebo

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

7/13

26/41

17/43

97

2/12

17/35

17/41

88

8.81%

51.23%

39.96%

100%

3.23[0.83,12.61]

1.31[0.86,1.97]

0.95[0.57,1.6]

1.25[0.82,1.9]

Total events: 50 (PT+AD), 36 (PT+placebo)

Heterogeneity: Tau2=0.05; Chi2=2.96, df=2(P=0.23); I2=32.38%

Test for overall effect: Z=1.02(P=0.31)

13.11.2 Cognitive-behaviour therapy

Subtotal (95% CI)

0

0

Not estimable

Total events: 0 (PT+AD), 0 (PT+placebo)

Heterogeneity: Not applicable

Test for overall effect: Not applicable

Total (95% CI)

97

88

100%

1.25[0.82,1.9]

Total events: 50 (PT+AD), 36 (PT+placebo)

Heterogeneity: Tau2=0.05; Chi2=2.96, df=2(P=0.23); I2=32.38%

Test for overall effect: Z=1.02(P=0.31)

Test for subgroup differences: Not applicable

Favours PT+placebo

0.1

0.2

0.5

1

2

5

10

Favours PT+AD

Analysis 13.12.   Comparison 13 SUBGROUP4: without comorbidity: Psychotherapy+Antidepressant
vs Psychotherapy alone or +Placebo, Outcome 12 Global/Avoidance/Panic on continued treatment.

Study or subgroup

PT+AD

PT+placebo

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

13.12.1 Behaviour therapy

Telch 1985

10

12.6 (8.1)

9

25.6 (8.8)

32.38%

-1.47[-2.51,-0.43]

Favours treatment

-4

-2

0

2

4

Favours control

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

200

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

PT+AD

PT+placebo

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

2 (0.9)

Zitrin 1980

Subtotal ***

1.5 (0.7)

29

39

Heterogeneity: Tau2=0.1; Chi2=1.57, df=1(P=0.21); I2=36.34%

Test for overall effect: Z=2.71(P=0.01)

13.12.2 Cognitive-behaviour therapy

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Not applicable

Total ***

0

39

Heterogeneity: Tau2=0.1; Chi2=1.57, df=1(P=0.21); I2=36.34%

Test for overall effect: Z=2.71(P=0.01)

Test for subgroup differences: Not applicable

24

33

0

33

67.62%

100%

Random, 95% CI

-0.72[-1.27,-0.16]

-0.96[-1.65,-0.27]

Not estimable

100%

-0.96[-1.65,-0.27]

Favours treatment

-4

-2

0

2

4

Favours control

Analysis 13.13.   Comparison 13 SUBGROUP4: without comorbidity: Psychotherapy+Antidepressant
vs Psychotherapy alone or +Placebo, Outcome 13 Dropouts for any reason on continued treatment.

PT+AD

n/N

PT+placebo

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

1/10

10

0/9

9

100%

100%

2.73[0.12,59.57]

2.73[0.12,59.57]

Study or subgroup

13.13.1 Behaviour therapy

Telch 1985

Subtotal (95% CI)

Total events: 1 (PT+AD), 0 (PT+placebo)

Heterogeneity: Not applicable

Test for overall effect: Z=0.64(P=0.52)

13.13.2 Cognitive-behaviour therapy

Subtotal (95% CI)

Total events: 0 (PT+AD), 0 (PT+placebo)

Heterogeneity: Not applicable

Test for overall effect: Not applicable

Total (95% CI)

Total events: 1 (PT+AD), 0 (PT+placebo)

Heterogeneity: Not applicable

Test for overall effect: Z=0.64(P=0.52)

Test for subgroup differences: Not applicable

0

10

0

9

Not estimable

100%

2.73[0.12,59.57]

Favours treatment

0.1

0.2

0.5

1

2

5

10

Favours control

Analysis 13.14.   Comparison 13 SUBGROUP4: without comorbidity: Psychotherapy+Antidepressant vs
Psychotherapy alone or +Placebo, Outcome 14 Response/remission 6 months after treatment discontinuation.

Study or subgroup

13.14.1 Behaviour therapy

PT+AD

n/N

PT+placebo

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

Favours PT+placebo

0.1

0.2

0.5

1

2

5

10

Favours PT+AD

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

201

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Marks 1983

Mavissakalian 1986a

Mavissakalian 1986b

Subtotal (95% CI)

12/36

9/20

6/20

76

Total events: 27 (PT+AD), 19 (PT+placebo)

Heterogeneity: Tau2=0.32; Chi2=4.76, df=2(P=0.09); I2=57.98%

Test for overall effect: Z=0.81(P=0.42)

13.14.2 Cognitive-behaviour therapy

Loerch 1999

Sharp 1996i

Sharp 1996ii

Subtotal (95% CI)

9/14

8/19

8/19

52

Total events: 25 (PT+AD), 41 (PT+placebo)

Heterogeneity: Tau2=0; Chi2=0.42, df=2(P=0.81); I2=0%

Test for overall effect: Z=0.09(P=0.93)

PT+AD

n/N

PT+placebo

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

9/36

2/20

8/20

76

9/14

17/36

15/43

93

16.4%

4.94%

12.34%

33.67%

26.1%

21.07%

19.17%

66.33%

1.33[0.64,2.77]

4.5[1.11,18.27]

0.75[0.32,1.77]

1.42[0.61,3.32]

1[0.58,1.74]

0.89[0.47,1.67]

1.21[0.62,2.35]

1.02[0.71,1.45]

Total (95% CI)

128

169

100%

1.1[0.8,1.52]

Total events: 52 (PT+AD), 60 (PT+placebo)

Heterogeneity: Tau2=0.02; Chi2=5.77, df=5(P=0.33); I2=13.38%

Test for overall effect: Z=0.6(P=0.55)

Test for subgroup differences: Not applicable

Favours PT+placebo

0.1

0.2

0.5

1

2

5

10

Favours PT+AD

Analysis 13.15.   Comparison 13 SUBGROUP4: without comorbidity: Psychotherapy+Antidepressant vs
Psychotherapy alone or +Placebo, Outcome 15 Global/Avoidance/Panic 6 months after treatment discontinuation.

Study or subgroup

PT+AD

PT+placebo

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

12 (10.8)

2.9 (1.7)

2.1 (1.7)

13.15.1 Behaviour therapy

Marks 1983

Mavissakalian 1986a

Mavissakalian 1986b

Subtotal ***

11.8 (11.2)

2.1 (1.7)

2.9 (1.4)

23

13

11

47

Heterogeneity: Tau2=0.02; Chi2=2.31, df=2(P=0.32); I2=13.35%

Test for overall effect: Z=0.14(P=0.89)

13.15.2 Cognitive-behaviour therapy

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Not applicable

Total ***

0

47

Heterogeneity: Tau2=0.02; Chi2=2.31, df=2(P=0.32); I2=13.35%

Test for overall effect: Z=0.14(P=0.89)

Test for subgroup differences: Not applicable

22

7

14

43

0

43

49.1%

22.09%

28.8%

100%

-0.02[-0.6,0.57]

-0.45[-1.38,0.48]

0.49[-0.31,1.29]

0.03[-0.43,0.49]

Not estimable

100%

0.03[-0.43,0.49]

Favours treatment

-4

-2

0

2

4

Favours control

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

202

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 13.16.   Comparison 13 SUBGROUP4: without comorbidity: Psychotherapy+Antidepressant vs
Psychotherapy alone or +Placebo, Outcome 16 Response/remission 18-24 months after treatment discontinuation.

Study or subgroup

13.16.1 Behaviour therapy

Marks 1983

Mavissakalian 1986a

Mavissakalian 1986b

Zitrin 1983

Subtotal (95% CI)

PT+AD

n/N

PT+placebo

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

9/36

6/20

6/20

23/43

119

11/36

5/20

6/20

20/41

117

18.61%

10.22%

11.68%

59.48%

100%

0.82[0.39,1.73]

1.2[0.44,3.3]

1[0.39,2.58]

1.1[0.72,1.67]

1.04[0.75,1.43]

Total events: 44 (PT+AD), 42 (PT+placebo)

Heterogeneity: Tau2=0; Chi2=0.54, df=3(P=0.91); I2=0%

Test for overall effect: Z=0.22(P=0.83)

13.16.2 Cognitive-behaviour therapy

Subtotal (95% CI)

0

0

Not estimable

Total events: 0 (PT+AD), 0 (PT+placebo)

Heterogeneity: Not applicable

Test for overall effect: Not applicable

Total (95% CI)

119

117

100%

1.04[0.75,1.43]

Total events: 44 (PT+AD), 42 (PT+placebo)

Heterogeneity: Tau2=0; Chi2=0.54, df=3(P=0.91); I2=0%

Test for overall effect: Z=0.22(P=0.83)

Test for subgroup differences: Not applicable

Favours PT+placebo

0.1

0.2

0.5

1

2

5

10

Favours PT+AD

Analysis 13.17.   Comparison 13 SUBGROUP4: without comorbidity:
Psychotherapy+Antidepressant vs Psychotherapy alone or +Placebo, Outcome
17 Global/Avoidance/Panic 18-24 months after treatment discontinuation.

Study or subgroup

PT+AD

PT+placebo

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

13.7 (2.8)

3.3 (2.6)

1.3 (0.5)

13.17.1 Behaviour therapy

Marks 1983

Mavissakalian 1986a

Mavissakalian 1986b

Subtotal ***

14.1 (2.7)

2.1 (1.4)

2 (1.2)

22

14

11

47

Heterogeneity: Tau2=0.2; Chi2=4.65, df=2(P=0.1); I2=56.96%

Test for overall effect: Z=0.24(P=0.81)

13.17.2 Cognitive-behviour therapy

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Not applicable

Total ***

0

47

Heterogeneity: Tau2=0.2; Chi2=4.65, df=2(P=0.1); I2=56.96%

Test for overall effect: Z=0.24(P=0.81)

Test for subgroup differences: Not applicable

18

11

11

40

0

40

38.85%

31.59%

29.56%

100%

0.14[-0.48,0.77]

-0.58[-1.39,0.23]

0.71[-0.16,1.58]

0.08[-0.59,0.75]

Not estimable

100%

0.08[-0.59,0.75]

Favours treatment

-10

-5

0

5

10

Favours control

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

203

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Comparison 14.   SENSITIVITY1: blinded rater: Psychotherapy+Antidepressant vs Antidepressant alone

Outcome or subgroup title

1 Response at 2-4 months

1.1 Behaviour therapy

1.2 Cognitive-behaviour therapy

1.3 Psychodynamic psychotherapy and others

2 Remission at 2-4 months

2.1 Behaviour therapy

2.2 Cognitive-behaviour therapy

2.3 Psychodynamic psychotherapy and others

3 Global severity at 2-4 months

3.1 Behaviour therapy

3.2 Cognitive-behaviour therapy

3.3 Psychodynamic psychotherapy and others

4 Frequency of panic attacks at 2-4 months

4.1 Behaviour therapy

4.2 Cognitive-behaviour therapy

4.3 Psychodynamic psychotherapy and others

5 Phobic avoidance at 2-4 months

No. of
studies

No. of
partici-
pants

Statistical method

Effect size

7

3

3

1

5

1

3

1

4

1

2

1

4

3

0

1

6

467

175

252

40

388

96

252

40

321

75

206

40

163

123

0

40

251

Risk Ratio (M-H, Random,
95% CI)

1.32 [1.05, 1.64]

Risk Ratio (M-H, Random,
95% CI)

1.16 [0.66, 2.07]

Risk Ratio (M-H, Random,
95% CI)

1.36 [1.01, 1.84]

Risk Ratio (M-H, Random,
95% CI)

1.64 [1.07, 2.50]

Risk Ratio (M-H, Random,
95% CI)

1.28 [1.04, 1.58]

Risk Ratio (M-H, Random,
95% CI)

0.94 [0.52, 1.72]

Risk Ratio (M-H, Random,
95% CI)

1.40 [0.92, 2.14]

Risk Ratio (M-H, Random,
95% CI)

1.32 [1.02, 1.72]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.31 [-0.53, -0.09]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.14 [-0.60, 0.31]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.30 [-0.57, -0.02]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.69 [-1.33, -0.05]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.13 [-0.51, 0.26]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.13 [-0.51, 0.26]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.0 [0.0, 0.0]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.0 [0.0, 0.0]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.46 [-0.79, -0.14]

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

204

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

5.1 Behaviour therapy

5.2 Cognitive-behaviour therapy

5.3 Psychodynamic psychotherapy and others

6 General anxiety at 2-4 months

6.1 Behaviour therapy

6.2 Cognitive-behaviour therapy

6.3 Psychodynamic psychotherapy and others

7 Depression at 2-4 months

7.1 Behaviour therapy

7.2 Cognitive-behaviour therapy

7.3 Psychodynamic psychotherapy and others

8 Social functioning at 2-4 months

8.1 Behavour therapy

8.2 Cognitive-behaviour therapy

8.3 Psychodynamic psychotherapy and others

9 Dropouts for any reason within 2-4 months

9.1 Behaviour therapy

9.2 Cognitive-behaviour therapy

No. of
studies

No. of
partici-
pants

Statistical method

Effect size

3

2

1

4

1

2

1

5

3

1

1

5

2

2

1

7

3

3

123

88

40

203

75

88

40

193

123

30

40

231

103

88

40

467

175

252

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.44 [-0.95, 0.07]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.53 [-1.45, 0.39]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.60 [-1.23, 0.04]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.63 [-1.12, -0.13]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.13 [-0.58, 0.33]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.58 [-1.01, -0.15]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-1.32 [-2.01, -0.63]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.47 [-0.76, -0.18]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.27 [-0.62, 0.09]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.93 [-1.69, -0.17]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.79 [-1.44, -0.14]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.46 [-0.78, -0.14]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.20 [-0.59, 0.19]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.63 [-1.39, 0.12]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.81 [-1.46, -0.16]

Risk Ratio (M-H, Random,
95% CI)

0.92 [0.69, 1.22]

Risk Ratio (M-H, Random,
95% CI)

1.26 [0.81, 1.96]

Risk Ratio (M-H, Random,
95% CI)

0.73 [0.50, 1.06]

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

205

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of
studies

No. of
partici-
pants

Statistical method

Effect size

9.3 Psychodynamic psychotherapy and others

10 Dropouts due to side effects within 2-4
months

10.1 Behaviour therapy

10.2 Cognitive-behaviour therapy

1

4

1

2

10.3 Psychodynamic psychotherapy and others

1

11 Response/remission on continued treat-
ment

11.1 Behaviour therapy

11.2 Cognitive-behaviour therapy

11.3 Psychdynamic psychotherapy and others

12 Global/Avoidance/Panic on continued treat-
ment

12.1 Behaviour therapy

12.2 Cognitive-behaviour therapy

4

2

1

1

4

2

1

12.3 Psychodynamic psychotherapy and others

1

13 Dropouts for any reason on continued treat-
ment

13.1 Behaviour therapy

13.2 Cognitive-behaviour therapy

3

1

1

13.3 Psychodynamic psychotherapy and others

1

16 Response/remission 6-24 months after
treatment discontinuation

5

40

287

25

222

40

309

121

148

40

236

48

148

40

208

20

148

40

376

Risk Ratio (M-H, Random,
95% CI)

3.00 [0.13, 69.52]

Risk Ratio (M-H, Random,
95% CI)

0.92 [0.31, 2.73]

Risk Ratio (M-H, Random,
95% CI)

1.38 [0.28, 6.91]

Risk Ratio (M-H, Random,
95% CI)

0.62 [0.09, 4.15]

Risk Ratio (M-H, Random,
95% CI)

3.00 [0.13, 69.52]

Risk Ratio (M-H, Random,
95% CI)

1.63 [1.21, 2.19]

Risk Ratio (M-H, Random,
95% CI)

1.94 [1.10, 3.41]

Risk Ratio (M-H, Random,
95% CI)

1.52 [1.07, 2.16]

Risk Ratio (M-H, Random,
95% CI)

0.0 [0.0, 0.0]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.62 [-0.92, -0.31]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.91 [-1.51, -0.30]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.41 [-0.74, -0.09]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.85 [-1.50, -0.20]

Risk Ratio (M-H, Random,
95% CI)

0.71 [0.27, 1.90]

Risk Ratio (M-H, Random,
95% CI)

1.0 [0.07, 13.87]

Risk Ratio (M-H, Random,
95% CI)

0.73 [0.22, 2.39]

Risk Ratio (M-H, Random,
95% CI)

0.5 [0.05, 5.08]

Risk Ratio (M-H, Random,
95% CI)

1.61 [1.23, 2.11]

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

206

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of
studies

No. of
partici-
pants

Statistical method

Effect size

16.1 Behaviour therapy

16.2 Cognitive-behaviour therapy

1

3

16.3 Psychodynamic psychotherapy and others

1

17 Global/Avoidance/Panic 6-24 months after
treatment discontinuation

17.1 Behaviour therapy

17.2 Cognitive-behaviour therapy

2

0

1

17.3 Psychodynamic psychotherapy and others

1

96

240

40

176

0

136

40

Risk Ratio (M-H, Random,
95% CI)

1.49 [0.95, 2.35]

Risk Ratio (M-H, Random,
95% CI)

1.46 [1.00, 2.11]

Risk Ratio (M-H, Random,
95% CI)

3.2 [1.45, 7.05]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.58 [-1.78, 0.63]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.0 [0.0, 0.0]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.0 [-0.34, 0.34]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-1.23 [-1.91, -0.55]

Analysis 14.1.   Comparison 14 SENSITIVITY1: blinded rater: Psychotherapy
+Antidepressant vs Antidepressant alone, Outcome 1 Response at 2-4 months.

PT+AD

n/N

AD

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

5/26

1/12

32/53

91

38/83

5/16

21/36

135

4.37%

1.21%

22.97%

28.55%

25.02%

7.01%

21.86%

53.9%

1.3[0.47,3.59]

4.62[0.63,34.05]

0.96[0.69,1.35]

1.16[0.66,2.07]

1.31[0.96,1.78]

2.51[1.16,5.47]

1.17[0.83,1.67]

1.36[1.01,1.84]

Study or subgroup

14.1.1 Behaviour therapy

Johnston 1995

Telch 1985

Zitrin 1983

Subtotal (95% CI)

7/28

5/13

25/43

84

Total events: 37 (PT+AD), 38 (AD)

Heterogeneity: Tau2=0.1; Chi2=2.81, df=2(P=0.25); I2=28.73%

Test for overall effect: Z=0.52(P=0.61)

14.1.2 Cognitive-behaviour therapy

Barlow 2000

Loerch 1999

Sharp 1996

Subtotal (95% CI)

Total events: 76 (PT+AD), 64 (AD)

39/65

11/14

26/38

117

Heterogeneity: Tau2=0.03; Chi2=3.13, df=2(P=0.21); I2=36.12%

Test for overall effect: Z=2.02(P=0.04)

14.1.3 Psychodynamic psychotherapy and others

Wiborg 1996

Subtotal (95% CI)

Total events: 18 (PT+AD), 11 (AD)

Heterogeneity: Not applicable

18/20

20

11/20

20

17.56%

17.56%

1.64[1.07,2.5]

1.64[1.07,2.5]

Favours AD

0.1

0.2

0.5

1

2

5

10

Favours PT+AD

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

207

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

PT+AD

n/N

AD

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

Test for overall effect: Z=2.28(P=0.02)

Total (95% CI)

221

246

100%

1.32[1.05,1.64]

Total events: 131 (PT+AD), 113 (AD)

Heterogeneity: Tau2=0.03; Chi2=8.92, df=6(P=0.18); I2=32.71%

Test for overall effect: Z=2.42(P=0.02)

Test for subgroup differences: Not applicable

Favours AD

0.1

0.2

0.5

1

2

5

10

Favours PT+AD

Analysis 14.2.   Comparison 14 SENSITIVITY1: blinded rater: Psychotherapy
+Antidepressant vs Antidepressant alone, Outcome 2 Remission at 2-4 months.

Study or subgroup

14.2.1 Behaviour therapy

Zitrin 1983

Subtotal (95% CI)

Total events: 13 (PT+AD), 17 (AD)

Heterogeneity: Not applicable

Test for overall effect: Z=0.19(P=0.85)

14.2.2 Cognitive-behaviour therapy

Barlow 2000

Loerch 1999

Sharp 1996

Subtotal (95% CI)

Total events: 75 (PT+AD), 62 (AD)

PT+AD

n/N

AD

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

13/43

43

17/53

53

10.67%

10.67%

0.94[0.52,1.72]

0.94[0.52,1.72]

42/65

9/14

24/38

117

40/83

2/16

20/36

135

31.1%

2.38%

21.76%

55.23%

1.34[1.01,1.79]

5.14[1.33,19.92]

1.14[0.78,1.66]

1.4[0.92,2.14]

Heterogeneity: Tau2=0.07; Chi2=4.73, df=2(P=0.09); I2=57.73%

Test for overall effect: Z=1.56(P=0.12)

14.2.3 Psychodynamic psychotherapy and others

Wiborg 1996

Subtotal (95% CI)

Total events: 20 (PT+AD), 15 (AD)

Heterogeneity: Not applicable

Test for overall effect: Z=2.08(P=0.04)

20/20

20

15/20

20

34.1%

34.1%

1.32[1.02,1.72]

1.32[1.02,1.72]

Total (95% CI)

180

208

100%

1.28[1.04,1.58]

Total events: 108 (PT+AD), 94 (AD)

Heterogeneity: Tau2=0.02; Chi2=5.61, df=4(P=0.23); I2=28.73%

Test for overall effect: Z=2.28(P=0.02)

Test for subgroup differences: Not applicable

Favours AD

0.1

0.2

0.5

1

2

5

10

Favours PT+AD

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

208

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 14.3.   Comparison 14 SENSITIVITY1: blinded rater: Psychotherapy
+Antidepressant vs Antidepressant alone, Outcome 3 Global severity at 2-4 months.

Study or subgroup

Treatment

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

3.2 (1)

41

41

3.3 (1)

23.7%

23.7%

-0.14[-0.6,0.31]

-0.14[-0.6,0.31]

14.3.1 Behaviour therapy

Zitrin 1983

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=0.61(P=0.54)

14.3.2 Cognitive-behaviour therapy

Barlow 2000

Sharp 1996

Subtotal ***

34

34

65

29

94

Heterogeneity: Tau2=0; Chi2=0.68, df=1(P=0.41); I2=0%

Test for overall effect: Z=2.1(P=0.04)

14.3.3 Psychodynamic psychotherapy and others

Wiborg 1996

Subtotal ***

1.4 (0.5)

20

20

Heterogeneity: Not applicable

Test for overall effect: Z=2.11(P=0.03)

0.9 (0.7)

1.7 (1.1)

1.1 (0.8)

2.3 (1.2)

2 (1.1)

83

29

112

20

20

46.32%

17.98%

64.3%

-0.22[-0.55,0.1]

-0.48[-1.01,0.04]

-0.3[-0.57,-0.02]

12%

12%

-0.69[-1.33,-0.05]

-0.69[-1.33,-0.05]

Total ***

148

173

100%

-0.31[-0.53,-0.09]

Heterogeneity: Tau2=0; Chi2=2.56, df=3(P=0.47); I2=0%

Test for overall effect: Z=2.71(P=0.01)

Test for subgroup differences: Chi2=1.87, df=1 (P=0.39), I2=0%

Favours treatment

-4

-2

0

2

4

Favours control

Analysis 14.4.   Comparison 14 SENSITIVITY1: blinded rater: Psychotherapy+Antidepressant
vs Antidepressant alone, Outcome 4 Frequency of panic attacks at 2-4 months.

Study or subgroup

Treatment

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

14.4.1 Behaviour therapy

Johnston 1995

Telch 1985

Zitrin 1983

Subtotal ***

0.6 (0.9)

0.6 (1.1)

6 (1.2)

12

10

34

56

Heterogeneity: Tau2=0.01; Chi2=2.2, df=2(P=0.33); I2=8.91%

Test for overall effect: Z=0.64(P=0.52)

14.4.2 Cognitive-behaviour therapy

Subtotal ***

0

Heterogeneity: Not applicable

Test for overall effect: Not applicable

14.4.3 Psychodynamic psychotherapy and others

Wiborg 1996

Subtotal ***

Heterogeneity: Not applicable

20

20

0 (0)

0.3 (0.7)

0.8 (1)

6.4 (1.2)

0.8 (2.1)

16

10

41

67

0

20

20

23.99%

18.09%

57.92%

100%

0.35[-0.41,1.1]

-0.14[-1.01,0.74]

-0.32[-0.78,0.14]

-0.13[-0.51,0.26]

Not estimable

Not estimable

Not estimable

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

209

Favours treatment

-4

-2

0

2

4

Favours control

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Treatment

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

Test for overall effect: Not applicable

Total ***

76

87

Heterogeneity: Tau2=0.01; Chi2=2.2, df=2(P=0.33); I2=8.91%

Test for overall effect: Z=0.64(P=0.52)

Test for subgroup differences: Not applicable

100%

-0.13[-0.51,0.26]

Favours treatment

-4

-2

0

2

4

Favours control

Analysis 14.5.   Comparison 14 SENSITIVITY1: blinded rater: Psychotherapy
+Antidepressant vs Antidepressant alone, Outcome 5 Phobic avoidance at 2-4 months.

Study or subgroup

Treatment

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

14.5.1 Behaviour therapy

Johnston 1995

Telch 1985

Zitrin 1983

Subtotal ***

8.5 (8.4)

17.3 (10.3)

2.7 (1.4)

12

10

34

56

Heterogeneity: Tau2=0.08; Chi2=3.26, df=2(P=0.2); I2=38.7%

Test for overall effect: Z=1.7(P=0.09)

14.5.2 Cognitive-behaviour therapy

Loerch 1999

Sheehan 1980a

Subtotal ***

7 (8.3)

4.7 (7.8)

14

29

43

Heterogeneity: Tau2=0.34; Chi2=4, df=1(P=0.05); I2=74.97%

Test for overall effect: Z=1.12(P=0.26)

14.5.3 Psychodynamic psychotherapy and others

Wiborg 1996

Subtotal ***

1.1 (1.1)

20

20

Heterogeneity: Not applicable

Test for overall effect: Z=1.85(P=0.07)

13.9 (9)

28.4 (11.2)

2.8 (1.4)

19 (13.2)

5.5 (7.9)

2.6 (3.3)

16

10

41

67

16

29

45

20

20

Total ***

119

132

Heterogeneity: Tau2=0.06; Chi2=7.71, df=5(P=0.17); I2=35.17%

Test for overall effect: Z=2.78(P=0.01)

Test for subgroup differences: Chi2=0.45, df=1 (P=0.8), I2=0%

13.18%

9.65%

24.98%

47.82%

-0.6[-1.37,0.17]

-0.99[-1.93,-0.05]

-0.11[-0.56,0.35]

-0.44[-0.95,0.07]

13.08%

21.98%

35.07%

-1.05[-1.82,-0.28]

-0.1[-0.62,0.41]

-0.53[-1.45,0.39]

17.12%

17.12%

-0.6[-1.23,0.04]

-0.6[-1.23,0.04]

100%

-0.46[-0.79,-0.14]

Favours treatment

-4

-2

0

2

4

Favours control

Analysis 14.6.   Comparison 14 SENSITIVITY1: blinded rater: Psychotherapy
+Antidepressant vs Antidepressant alone, Outcome 6 General anxiety at 2-4 months.

Study or subgroup

Treatment

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

14.6.1 Behaviour therapy

Zitrin 1983

34

21.5 (9.9)

41

22.8 (9.9)

29.56%

-0.13[-0.58,0.33]

Favours treatment

-4

-2

0

2

4

Favours control

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

210

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Treatment

Control

Std. Mean Difference

Weight

Std. Mean Difference

Mean(SD)

N

34

N

41

Mean(SD)

Random, 95% CI

Random, 95% CI

29.56%

-0.13[-0.58,0.33]

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=0.56(P=0.58)

14.6.2 Cognitive-behaviour therapy

19.9 (9.8)

7.9 (7)

16 (10)

Loerch 1999

Sharp 1996

Subtotal ***

11.4 (11.1)

4.8 (5.7)

14

29

43

Heterogeneity: Tau2=0; Chi2=0.45, df=1(P=0.5); I2=0%

Test for overall effect: Z=2.66(P=0.01)

14.6.3 Psychodynamic psychotherapy and others

5.5 (4.7)

Wiborg 1996

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=3.74(P=0)

Total ***

20

20

97

16

29

45

20

20

106

Heterogeneity: Tau2=0.16; Chi2=8.48, df=3(P=0.04); I2=64.6%

Test for overall effect: Z=2.48(P=0.01)

Test for subgroup differences: Chi2=8.03, df=1 (P=0.02), I2=75.08%

20.73%

27.39%

48.12%

-0.79[-1.54,-0.04]

-0.48[-1,0.04]

-0.58[-1.01,-0.15]

22.32%

22.32%

-1.32[-2.01,-0.63]

-1.32[-2.01,-0.63]

100%

-0.63[-1.12,-0.13]

Favours treatment

-4

-2

0

2

4

Favours control

Analysis 14.7.   Comparison 14 SENSITIVITY1: blinded rater: Psychotherapy
+Antidepressant vs Antidepressant alone, Outcome 7 Depression at 2-4 months.

Study or subgroup

Treatment

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

14.7.1 Behaviour therapy

Johnston 1995

Telch 1985

Zitrin 1983

Subtotal ***

0.8 (0.5)

13.4 (5.7)

1.3 (0.5)

12

10

34

56

Heterogeneity: Tau2=0; Chi2=0.15, df=2(P=0.93); I2=0%

Test for overall effect: Z=1.47(P=0.14)

14.7.2 Cognitive-behaviour therapy

Loerch 1999

Subtotal ***

5.6 (5.8)

14

14

Heterogeneity: Not applicable

Test for overall effect: Z=2.4(P=0.02)

14.7.3 Psychodynamic psychotherapy and others

3.6 (2.7)

Wiborg 1996

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=2.4(P=0.02)

Total ***

20

20

90

16

10

41

67

16

16

20

20

103

1 (0.9)

14.7 (14.1)

1.5 (0.5)

12 (7.4)

7.4 (6.1)

14.76%

10.85%

39.92%

65.54%

-0.27[-1.02,0.48]

-0.12[-0.99,0.76]

-0.31[-0.77,0.15]

-0.27[-0.62,0.09]

14.45%

14.45%

-0.93[-1.69,-0.17]

-0.93[-1.69,-0.17]

20.02%

20.02%

-0.79[-1.44,-0.14]

-0.79[-1.44,-0.14]

100%

-0.47[-0.76,-0.18]

Favours treatment

-4

-2

0

2

4

Favours control

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

211

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Treatment

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

Heterogeneity: Tau2=0; Chi2=3.73, df=4(P=0.44); I2=0%

Test for overall effect: Z=3.17(P=0)

Test for subgroup differences: Chi2=3.58, df=1 (P=0.17), I2=44.17%

Favours treatment

-4

-2

0

2

4

Favours control

Analysis 14.8.   Comparison 14 SENSITIVITY1: blinded rater: Psychotherapy
+Antidepressant vs Antidepressant alone, Outcome 8 Social functioning at 2-4 months.

Study or subgroup

Treatment

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

2.3 (0.7)

6 (0.9)

5.9 (3.5)

2.2 (2.9)

3 (2.7)

14.8.1 Behavour therapy

Johnston 1995

Zitrin 1983

Subtotal ***

2.1 (0.6)

5.8 (0.9)

12

34

46

Heterogeneity: Tau2=0; Chi2=0.06, df=1(P=0.8); I2=0%

Test for overall effect: Z=0.99(P=0.32)

14.8.2 Cognitive-behaviour therapy

Loerch 1999

Sharp 1996

Subtotal ***

2.4 (2.8)

1.4 (2.8)

14

29

43

Heterogeneity: Tau2=0.19; Chi2=2.67, df=1(P=0.1); I2=62.54%

Test for overall effect: Z=1.65(P=0.1)

14.8.3 Psychodynamic psychotherapy and others

Wiborg 1996

Subtotal ***

1.2 (1.5)

20

20

Heterogeneity: Not applicable

Test for overall effect: Z=2.45(P=0.01)

16

41

57

16

29

45

20

20

Total ***

109

122

Heterogeneity: Tau2=0.04; Chi2=5.67, df=4(P=0.23); I2=29.47%

Test for overall effect: Z=2.79(P=0.01)

Test for subgroup differences: Chi2=2.94, df=1 (P=0.23), I2=31.91%

14.45%

28.87%

43.32%

-0.28[-1.03,0.47]

-0.17[-0.62,0.29]

-0.2[-0.59,0.19]

13.8%

24.7%

38.5%

-1.08[-1.85,-0.3]

-0.3[-0.82,0.22]

-0.63[-1.39,0.12]

18.18%

18.18%

-0.81[-1.46,-0.16]

-0.81[-1.46,-0.16]

100%

-0.46[-0.78,-0.14]

Favours treatment

-4

-2

0

2

4

Favours control

Analysis 14.9.   Comparison 14 SENSITIVITY1: blinded rater: Psychotherapy+Antidepressant
vs Antidepressant alone, Outcome 9 Dropouts for any reason within 2-4 months.

Study or subgroup

14.9.1 Behaviour therapy

Johnston 1995

Telch 1985

Zitrin 1983

Subtotal (95% CI)

Treatment

n/N

Control

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

16/28

3/13

9/43

84

10/26

2/12

12/53

91

23.66%

3.1%

13.72%

40.49%

1.49[0.83,2.66]

1.38[0.28,6.91]

0.92[0.43,1.99]

1.26[0.81,1.96]

Total events: 28 (Treatment), 24 (Control)

Favours treatment

0.1

0.2

0.5

1

2

5

10

Favours control

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

212

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Treatment

n/N

Control

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

Heterogeneity: Tau2=0; Chi2=0.97, df=2(P=0.62); I2=0%

Test for overall effect: Z=1.01(P=0.31)

14.9.2 Cognitive-behaviour therapy

Barlow 2000

Loerch 1999

Sharp 1996

Subtotal (95% CI)

18/65

3/14

11/38

117

32/83

7/16

12/36

135

Total events: 32 (Treatment), 51 (Control)

Heterogeneity: Tau2=0; Chi2=0.72, df=2(P=0.7); I2=0%

Test for overall effect: Z=1.67(P=0.1)

14.9.3 Psychodynamic psychotherapy and others

35.2%

6.11%

17.39%

58.7%

0.72[0.45,1.16]

0.49[0.16,1.54]

0.87[0.44,1.71]

0.73[0.5,1.06]

Wiborg 1996

Subtotal (95% CI)

Total events: 1 (Treatment), 0 (Control)

Heterogeneity: Not applicable

Test for overall effect: Z=0.69(P=0.49)

1/20

20

0/20

20

0.81%

0.81%

3[0.13,69.52]

3[0.13,69.52]

Total (95% CI)

221

246

100%

0.92[0.69,1.22]

Total events: 61 (Treatment), 75 (Control)

Heterogeneity: Tau2=0; Chi2=5.63, df=6(P=0.47); I2=0%

Test for overall effect: Z=0.57(P=0.57)

Test for subgroup differences: Not applicable

Favours treatment

0.1

0.2

0.5

1

2

5

10

Favours control

Analysis 14.10.   Comparison 14 SENSITIVITY1: blinded rater: Psychotherapy+Antidepressant
vs Antidepressant alone, Outcome 10 Dropouts due to side effects within 2-4 months.

Treatment

n/N

Control

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

Study or subgroup

14.10.1 Behaviour therapy

Telch 1985

Subtotal (95% CI)

Total events: 3 (Treatment), 2 (Control)

Heterogeneity: Not applicable

Test for overall effect: Z=0.4(P=0.69)

14.10.2 Cognitive-behaviour therapy

Barlow 2000

Sharp 1996

Subtotal (95% CI)

3/13

13

2/65

5/38

103

2/12

12

11/83

3/36

119

Total events: 7 (Treatment), 14 (Control)

Heterogeneity: Tau2=1.37; Chi2=3.62, df=1(P=0.06); I2=72.4%

Test for overall effect: Z=0.49(P=0.62)

14.10.3 Psychodynamic psychotherapy and others

Wiborg 1996

Subtotal (95% CI)

1/20

20

0/20

20

27.13%

27.13%

1.38[0.28,6.91]

1.38[0.28,6.91]

30%

32.65%

62.65%

0.23[0.05,1.01]

1.58[0.41,6.13]

0.62[0.09,4.15]

10.22%

10.22%

3[0.13,69.52]

3[0.13,69.52]

Favours treatment

0.1

0.2

0.5

1

2

5

10

Favours control

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

213

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Treatment

n/N

Control

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

Total events: 1 (Treatment), 0 (Control)

Heterogeneity: Not applicable

Test for overall effect: Z=0.69(P=0.49)

Total (95% CI)

136

151

100%

0.92[0.31,2.73]

Total events: 11 (Treatment), 16 (Control)

Heterogeneity: Tau2=0.47; Chi2=4.9, df=3(P=0.18); I2=38.82%

Test for overall effect: Z=0.16(P=0.87)

Test for subgroup differences: Not applicable

Favours treatment

0.1

0.2

0.5

1

2

5

10

Favours control

Analysis 14.11.   Comparison 14 SENSITIVITY1: blinded rater: Psychotherapy+Antidepressant
vs Antidepressant alone, Outcome 11 Response/remission on continued treatment.

Study or subgroup

14.11.1 Behaviour therapy

Telch 1985

Zitrin 1983

Subtotal (95% CI)

PT+AD

n/N

AD

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

7/13

17/43

56

2/12

12/53

65

4.77%

23%

27.77%

3.23[0.83,12.61]

1.75[0.94,3.25]

1.94[1.1,3.41]

Total events: 24 (PT+AD), 14 (AD)

Heterogeneity: Tau2=0; Chi2=0.66, df=1(P=0.42); I2=0%

Test for overall effect: Z=2.3(P=0.02)

14.11.2 Cognitive-behaviour therapy

Barlow 2000

Subtotal (95% CI)

Total events: 37 (PT+AD), 31 (AD)

Heterogeneity: Not applicable

Test for overall effect: Z=2.36(P=0.02)

37/65

65

31/83

83

72.23%

72.23%

1.52[1.07,2.16]

1.52[1.07,2.16]

14.11.3 Psychdynamic psychotherapy and others

Wiborg 1996

Subtotal (95% CI)

Total events: 20 (PT+AD), 20 (AD)

Heterogeneity: Not applicable

Test for overall effect: Not applicable

20/20

20

20/20

20

Not estimable

Not estimable

Total (95% CI)

141

168

100%

1.63[1.21,2.19]

Total events: 81 (PT+AD), 65 (AD)

Heterogeneity: Tau2=0; Chi2=1.19, df=2(P=0.55); I2=0%

Test for overall effect: Z=3.22(P=0)

Test for subgroup differences: Not applicable

Favours AD

0.1

0.2

0.5

1

2

5

10

Favours PT+AD

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

214

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 14.12.   Comparison 14 SENSITIVITY1: blinded rater: Psychotherapy+Antidepressant
vs Antidepressant alone, Outcome 12 Global/Avoidance/Panic on continued treatment.

Study or subgroup

Treatment

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

14.12.1 Behaviour therapy

Johnston 1995

Telch 1985

Subtotal ***

5.4 (5.7)

12.6 (8.1)

12

10

22

Heterogeneity: Tau2=0; Chi2=0.7, df=1(P=0.4); I2=0%

Test for overall effect: Z=2.93(P=0)

14.12.2 Cognitive-behaviour therapy

Barlow 2000

Subtotal ***

0.8 (0.9)

65

65

Heterogeneity: Not applicable

Test for overall effect: Z=2.47(P=0.01)

14.12.3 Psychodynamic psychotherapy and others

Wiborg 1996

Subtotal ***

0.5 (1.1)

20

20

Heterogeneity: Not applicable

Test for overall effect: Z=2.56(P=0.01)

11.3 (9.6)

23.8 (9.3)

1.1 (0.9)

2.4 (2.9)

16

10

26

83

83

20

20

Total ***

107

129

Heterogeneity: Tau2=0.02; Chi2=3.45, df=3(P=0.33); I2=12.97%

Test for overall effect: Z=3.94(P<0.0001)

Test for subgroup differences: Chi2=2.75, df=1 (P=0.25), I2=27.29%

14.31%

9.34%

23.64%

-0.7[-1.47,0.07]

-1.23[-2.2,-0.26]

-0.91[-1.51,-0.3]

56.78%

56.78%

-0.41[-0.74,-0.09]

-0.41[-0.74,-0.09]

19.57%

19.57%

-0.85[-1.5,-0.2]

-0.85[-1.5,-0.2]

100%

-0.62[-0.92,-0.31]

Favours treatment

-4

-2

0

2

4

Favours control

Analysis 14.13.   Comparison 14 SENSITIVITY1: blinded rater: Psychotherapy+Antidepressant
vs Antidepressant alone, Outcome 13 Dropouts for any reason on continued treatment.

Treatment

n/N

Control

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

Study or subgroup

14.13.1 Behaviour therapy

Telch 1985

Subtotal (95% CI)

Total events: 1 (Treatment), 1 (Control)

Heterogeneity: Not applicable

Test for overall effect: Not applicable

14.13.2 Cognitive-behaviour therapy

Barlow 2000

Subtotal (95% CI)

Total events: 4 (Treatment), 7 (Control)

Heterogeneity: Not applicable

Test for overall effect: Z=0.52(P=0.6)

1/10

10

4/65

65

14.13.3 Psychodynamic psychotherapy and others

Wiborg 1996

Subtotal (95% CI)

1/20

20

1/10

10

7/83

83

2/20

20

13.87%

13.87%

1[0.07,13.87]

1[0.07,13.87]

68.3%

68.3%

0.73[0.22,2.39]

0.73[0.22,2.39]

17.83%

17.83%

0.5[0.05,5.08]

0.5[0.05,5.08]

Favours treatment

0.1

0.2

0.5

1

2

5

10

Favours control

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

215

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Treatment

n/N

Control

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

Total events: 1 (Treatment), 2 (Control)

Heterogeneity: Not applicable

Test for overall effect: Z=0.59(P=0.56)

Total (95% CI)

95

113

100%

0.71[0.27,1.9]

Total events: 6 (Treatment), 10 (Control)

Heterogeneity: Tau2=0; Chi2=0.16, df=2(P=0.93); I2=0%

Test for overall effect: Z=0.68(P=0.5)

Test for subgroup differences: Not applicable

Favours treatment

0.1

0.2

0.5

1

2

5

10

Favours control

Analysis 14.16.   Comparison 14 SENSITIVITY1: blinded rater: Psychotherapy+Antidepressant vs
Antidepressant alone, Outcome 16 Response/remission 6-24 months after treatment discontinuation.

Study or subgroup

PT+AD

n/N

AD

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

14.16.1 Behaviour therapy

Zitrin 1983

Subtotal (95% CI)

Total events: 23 (PT+AD), 19 (AD)

Heterogeneity: Not applicable

Test for overall effect: Z=1.72(P=0.09)

14.16.2 Cognitive-behaviour therapy

Barlow 2000

Loerch 1999

Sharp 1996

Subtotal (95% CI)

Total events: 41 (PT+AD), 32 (AD)

23/43

43

19/53

53

35.41%

35.41%

1.49[0.95,2.35]

1.49[0.95,2.35]

16/59

9/14

16/38

111

15/77

7/16

10/36

129

19.27%

15.93%

17.63%

52.83%

1.39[0.75,2.58]

1.47[0.75,2.9]

1.52[0.8,2.89]

1.46[1,2.11]

Heterogeneity: Tau2=0; Chi2=0.04, df=2(P=0.98); I2=0%

Test for overall effect: Z=1.97(P=0.05)

14.16.3 Psychodynamic psychotherapy and others

Wiborg 1996

Subtotal (95% CI)

Total events: 16 (PT+AD), 5 (AD)

Heterogeneity: Not applicable

Test for overall effect: Z=2.89(P=0)

16/20

20

5/20

20

11.76%

11.76%

3.2[1.45,7.05]

3.2[1.45,7.05]

Total (95% CI)

174

202

100%

1.61[1.23,2.11]

Total events: 80 (PT+AD), 56 (AD)

Heterogeneity: Tau2=0; Chi2=3.34, df=4(P=0.5); I2=0%

Test for overall effect: Z=3.45(P=0)

Test for subgroup differences: Not applicable

Favours AD

0.1

0.2

0.5

1

2

5

10

Favours PT+AD

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

216

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 14.17.   Comparison 14 SENSITIVITY1: blinded rater: Psychotherapy+Antidepressant vs
Antidepressant alone, Outcome 17 Global/Avoidance/Panic 6-24 months after treatment discontinuation.

Study or subgroup

Treatment

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

14.17.1 Behaviour therapy

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Not applicable

14.17.2 Cognitive-behaviour therapy

Barlow 2000

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Not applicable

0

59

59

1.5 (0.9)

14.17.3 Psychodynamic psychotherapy and others

0.6 (1.1)

Wiborg 1996

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=3.54(P=0)

Total ***

20

20

79

Heterogeneity: Tau2=0.68; Chi2=10.06, df=1(P=0); I2=90.06%

Test for overall effect: Z=0.94(P=0.35)

Test for subgroup differences: Chi2=10.06, df=1 (P=0), I2=90.06%

0

77

77

20

20

97

1.5 (0.8)

2.4 (1.7)

Not estimable

53%

53%

0[-0.34,0.34]

0[-0.34,0.34]

47%

47%

-1.23[-1.91,-0.55]

-1.23[-1.91,-0.55]

100%

-0.58[-1.78,0.63]

Favours treatment

-4

-2

0

2

4

Favours control

Comparison 15.   SENSITIVITY1: blinded rater: Psychotherapy+Antidepressant vs Psychotherapy alone or +Placebo

Outcome or subgroup title

No. of
studies

1 Response at 2-4 months

1.1 Behaviour therapy

1.2 Cognitive-behaviour therapy

1.3 Psychodynamic and other therapies

2 Remission at 2-4 months

2.1 Behaviour therapy

2.2 Cognitive-behaviour therapy

20

11

9

0

19

10

9

No. of
partici-
pants

1173

548

625

0

1107

482

625

Statistical method

Effect size

Risk Ratio (M-H, Random, 95%
CI)

1.21 [1.08, 1.35]

Risk Ratio (M-H, Random, 95%
CI)

1.30 [1.09, 1.56]

Risk Ratio (M-H, Random, 95%
CI)

1.17 [0.99, 1.40]

Risk Ratio (M-H, Random, 95%
CI)

0.0 [0.0, 0.0]

Risk Ratio (M-H, Random, 95%
CI)

1.24 [1.09, 1.42]

Risk Ratio (M-H, Random, 95%
CI)

1.31 [1.03, 1.66]

Risk Ratio (M-H, Random, 95%
CI)

1.23 [1.02, 1.47]

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

217

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of
studies

No. of
partici-
pants

Statistical method

Effect size

2.3 Psychodynamic and other therapies

3 Global severity at 2-4 months

3.1 Behaviour therapy

3.2 Cognitive-behaviour therapy

3.3 Psychodynamic and other therapies

0

11

6

5

0

4 Frequency of panic attacks at 2-4 months

11

4.1 Behaviour therapy

4.2 Cognitive-behaviour therapy

5 Phobic avoidance at 2-4 months

5.1 Behaviour therapy

5.2 Cognitive-behaviour therapy

5.3 Psychodynamic and other therapies

6 General anxiety at 2-4 months

6.1 Behaviour therapy

6.2 Cognitive-behaviour therapy

6.3 Psychodynamic and other therapies

7 Depression at 2-4 months

7.1 Behaviour therapy

9

2

18

12

6

0

16

9

7

0

14

11

0

602

239

363

0

423

278

145

644

396

248

0

657

302

355

0

468

350

Risk Ratio (M-H, Random, 95%
CI)

0.0 [0.0, 0.0]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.43 [-0.60, -0.26]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.61 [-0.87, -0.34]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.31 [-0.54, -0.08]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.0 [0.0, 0.0]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.05 [-0.26, 0.17]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.06 [-0.19, 0.31]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.29 [-0.61, 0.04]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.33 [-0.52, -0.13]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.41 [-0.70, -0.11]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.23 [-0.49, 0.03]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.0 [0.0, 0.0]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.44 [-0.61, -0.27]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.64 [-0.90, -0.37]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.28 [-0.50, -0.07]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.0 [0.0, 0.0]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.41 [-0.61, -0.21]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.43 [-0.69, -0.17]

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

218

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of
studies

No. of
partici-
pants

Statistical method

Effect size

7.2 Cognitive-behaviour therapy

7.3 Psychodynamic and other therapies

8 Social functioning at 2-4 months

8.1 Behaviour therapy

8.2 Cognitive-behaviour therapy

3

0

11

7

4

118

0

404

260

144

9 Dropouts for any reason within 2-4 months

19

1105

9.1 Behaviour therapy

9.2 Cognitive-behaviour therapy

9.3 Psychodynamic and other therapies

10 Dropouts due to side effects within 2-4
months

10.1 Behaviour therapy

10.2 Cognitive-behaviour therapy

11 Response/remission on continued treat-
ment

11.1 Behaviour therapy

11.2 Cognitive-behaviour therapy

12 Global/Avoidance/Panic on continued
treatment

12.1 Behaviour therapy

12.2 Cognitive-behaviour therapy

10

9

0

12

5

7

5

3

2

5

3

2

480

625

0

806

242

564

390

185

205

306

101

205

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.38 [-0.76, -0.01]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.0 [0.0, 0.0]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.11 [-0.46, 0.23]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.19 [-0.73, 0.34]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.04 [-0.39, 0.30]

Risk Ratio (M-H, Random, 95%
CI)

1.17 [0.94, 1.45]

Risk Ratio (M-H, Random, 95%
CI)

1.20 [0.90, 1.60]

Risk Ratio (M-H, Random, 95%
CI)

1.13 [0.80, 1.58]

Risk Ratio (M-H, Random, 95%
CI)

0.0 [0.0, 0.0]

Risk Ratio (M-H, Random, 95%
CI)

2.85 [1.50, 5.41]

Risk Ratio (M-H, Random, 95%
CI)

1.99 [0.85, 4.62]

Risk Ratio (M-H, Random, 95%
CI)

4.66 [1.73, 12.52]

Risk Ratio (M-H, Random, 95%
CI)

1.23 [1.00, 1.51]

Risk Ratio (M-H, Random, 95%
CI)

1.25 [0.82, 1.90]

Risk Ratio (M-H, Random, 95%
CI)

1.23 [0.93, 1.63]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.65 [-0.97, -0.33]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.95 [-1.37, -0.53]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.41 [-0.71, -0.12]

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

219

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of
studies

No. of
partici-
pants

Statistical method

Effect size

13 Dropouts for any reason on continued
treatment

13.1 Behaviour therapy

13.2 Cognitive-behaviour therapy

4

2

2

14 Response/remission 6-24 months after
treatment discontinuation

11

14.1 Behaviour therapy

14.2 Cognitive-behaviour therapy

15 Global/Avoidance/Panic 6-24 months af-
ter treatment discontinuation

15.1 Behaviour therapy

15.2 Cognitive-behaviour therapy

6

5

7

5

2

262

57

205

644

305

339

335

141

194

Risk Ratio (M-H, Random, 95%
CI)

0.88 [0.33, 2.32]

Risk Ratio (M-H, Random, 95%
CI)

2.86 [0.32, 25.80]

Risk Ratio (M-H, Random, 95%
CI)

0.66 [0.22, 1.95]

Risk Ratio (M-H, Random, 95%
CI)

0.97 [0.80, 1.18]

Risk Ratio (M-H, Random, 95%
CI)

1.03 [0.79, 1.36]

Risk Ratio (M-H, Random, 95%
CI)

0.91 [0.69, 1.21]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.14 [-0.09, 0.37]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.05 [-0.32, 0.43]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.21 [-0.10, 0.52]

Analysis 15.1.   Comparison 15 SENSITIVITY1: blinded rater: Psychotherapy
+Antidepressant vs Psychotherapy alone or +Placebo, Outcome 1 Response at 2-4 months.

Study or subgroup

15.1.1 Behaviour therapy

de Beurs 1995i

de Beurs 1995ii

Johnston 1995

Marks 1983

Mavissakalian 1986a

Mavissakalian 1986b

Sheehan 1980a

Sheehan 1980b

Telch 1985

Zitrin 1980

Zitrin 1983

Subtotal (95% CI)

PT+AD

n/N

PT+placebo

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

8/12

9/12

7/28

17/36

11/20

8/20

16/28

16/29

5/13

25/41

25/43

282

12/24

7/21

7/27

12/36

10/20

9/20

6/16

5/14

2/12

16/35

21/41

266

3.64%

2.49%

1.45%

3.51%

3.35%

2.26%

2.34%

1.97%

0.58%

6.01%

7.37%

34.97%

1.33[0.76,2.35]

2.25[1.13,4.47]

0.96[0.39,2.38]

1.42[0.8,2.52]

1.1[0.61,1.99]

0.89[0.43,1.83]

1.52[0.75,3.1]

1.54[0.71,3.36]

2.31[0.55,9.74]

1.33[0.86,2.06]

1.14[0.77,1.68]

1.3[1.09,1.56]

Total events: 147 (PT+AD), 107 (PT+placebo)

Heterogeneity: Tau2=0; Chi2=5.8, df=10(P=0.83); I2=0%

Test for overall effect: Z=2.84(P=0)

Favours PT+placebo

0.1

0.2

0.5

1

2

5

10

Favours PT+AD

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

220

 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

PT+AD

n/N

PT+placebo

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

15.1.2 Cognitive-behaviour therapy

Barlow 2000i

Barlow 2000ii

Fahy 1992

Kampman 2002

Loerch 1999

Oehrberg 1995

Sharp 1996i

Sharp 1996ii

Stein 2000

Subtotal (95% CI)

19/32

20/33

26/53

12/22

11/14

42/60

13/19

13/19

13/16

268

36/63

37/77

9/26

5/21

12/14

25/60

28/36

26/43

12/17

357

Total events: 169 (PT+AD), 190 (PT+placebo)

Heterogeneity: Tau2=0.03; Chi2=13.15, df=8(P=0.11); I2=39.16%

Test for overall effect: Z=1.82(P=0.07)

15.1.3 Psychodynamic and other therapies

8.74%

8.63%

3.3%

1.62%

9.23%

9.49%

9.01%

7.45%

7.55%

65.03%

1.04[0.73,1.49]

1.26[0.88,1.81]

1.42[0.78,2.57]

2.29[0.97,5.39]

0.92[0.65,1.3]

1.68[1.19,2.37]

0.88[0.62,1.25]

1.13[0.77,1.67]

1.15[0.78,1.69]

1.17[0.99,1.4]

Subtotal (95% CI)

0

0

Not estimable

Total events: 0 (PT+AD), 0 (PT+placebo)

Heterogeneity: Not applicable

Test for overall effect: Not applicable

Total (95% CI)

550

623

100%

1.21[1.08,1.35]

Total events: 316 (PT+AD), 297 (PT+placebo)

Heterogeneity: Tau2=0; Chi2=19.78, df=19(P=0.41); I2=3.95%

Test for overall effect: Z=3.41(P=0)

Test for subgroup differences: Not applicable

Favours PT+placebo

0.1

0.2

0.5

1

2

5

10

Favours PT+AD

Analysis 15.2.   Comparison 15 SENSITIVITY1: blinded rater: Psychotherapy
+Antidepressant vs Psychotherapy alone or +Placebo, Outcome 2 Remission at 2-4 months.

Study or subgroup

15.2.1 Behaviour therapy

de Beurs 1995i

de Beurs 1995ii

Fava 1997

Marks 1983

Mavissakalian 1986a

Mavissakalian 1986b

Sheehan 1980a

Sheehan 1980b

Zitrin 1980

Zitrin 1983

Subtotal (95% CI)

PT+AD

n/N

PT+placebo

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

8/12

8/12

1/7

20/36

8/20

8/20

5/28

10/29

7/41

13/43

248

14/24

12/21

4/7

17/36

4/20

5/20

2/15

2/15

4/35

5/41

234

6.08%

5.63%

0.47%

8.03%

1.63%

1.99%

0.76%

0.91%

1.33%

1.96%

28.8%

1.14[0.68,1.93]

1.17[0.68,2.01]

0.25[0.04,1.71]

1.18[0.75,1.85]

2[0.72,5.59]

1.6[0.63,4.05]

1.34[0.29,6.09]

2.59[0.65,10.32]

1.49[0.48,4.68]

2.48[0.97,6.34]

1.31[1.03,1.66]

Total events: 88 (PT+AD), 69 (PT+placebo)

Heterogeneity: Tau2=0; Chi2=7.34, df=9(P=0.6); I2=0%

Test for overall effect: Z=2.17(P=0.03)

Favours PT+placebo

0.1

0.2

0.5

1

2

5

10

Favours PT+AD

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

221

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

PT+AD

n/N

PT+placebo

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

15.2.2 Cognitive-behaviour therapy

Barlow 2000i

Barlow 2000ii

Fahy 1992

Kampman 2002

Loerch 1999

Oehrberg 1995

Sharp 1996i

Sharp 1996ii

Stein 2000

Subtotal (95% CI)

20/33

19/32

28/53

14/22

9/14

39/60

12/19

12/19

7/16

268

39/63

42/77

10/26

9/21

8/14

21/60

25/36

21/43

3/17

357

Total events: 160 (PT+AD), 178 (PT+placebo)

Heterogeneity: Tau2=0.02; Chi2=11.01, df=8(P=0.2); I2=27.36%

Test for overall effect: Z=2.2(P=0.03)

15.2.3 Psychodynamic and other therapies

13.85%

12.79%

5.57%

4.9%

4.71%

10.51%

9.83%

7.79%

1.27%

71.2%

0.98[0.7,1.37]

1.09[0.77,1.55]

1.37[0.79,2.38]

1.48[0.83,2.67]

1.13[0.62,2.05]

1.86[1.26,2.75]

0.91[0.61,1.37]

1.29[0.82,2.05]

2.48[0.77,7.97]

1.23[1.02,1.47]

Subtotal (95% CI)

0

0

Not estimable

Total events: 0 (PT+AD), 0 (PT+placebo)

Heterogeneity: Not applicable

Test for overall effect: Not applicable

Total (95% CI)

516

591

100%

1.24[1.09,1.42]

Total events: 248 (PT+AD), 247 (PT+placebo)

Heterogeneity: Tau2=0; Chi2=18.73, df=18(P=0.41); I2=3.88%

Test for overall effect: Z=3.2(P=0)

Test for subgroup differences: Not applicable

Favours PT+placebo

0.1

0.2

0.5

1

2

5

10

Favours PT+AD

Analysis 15.3.   Comparison 15 SENSITIVITY1: blinded rater: Psychotherapy+Antidepressant
vs Psychotherapy alone or +Placebo, Outcome 3 Global severity at 2-4 months.

Study or subgroup

PT+AD

PT+placebo

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

15.3.1 Behaviour therapy

de Beurs 1995i

de Beurs 1995ii

Mavissakalian 1986a

Mavissakalian 1986b

Zitrin 1980

Zitrin 1983

Subtotal ***

1.6 (0.8)

1.6 (0.8)

2 (1.7)

2.2 (1.7)

1.9 (0.6)

3.2 (1)

10

9

17

14

29

34

113

Heterogeneity: Tau2=0; Chi2=0.96, df=5(P=0.97); I2=0%

Test for overall effect: Z=4.52(P<0.0001)

15.3.2 Cognitive-behaviour therapy

Barlow 2000i

Barlow 2000ii

Fahy 1992

Sharp 1996i

33

32

42

15

0.9 (0.7)

0.9 (0.7)

2 (1.1)

1.7 (1.1)

19

18

14

17

24

34

126

63

77

24

33

2.1 (1.1)

2.3 (1.2)

3 (1.9)

3.1 (1.9)

2.3 (0.9)

4 (1)

1 (0.7)

1.1 (0.7)

2.8 (1)

2 (1.3)

4.75%

4.28%

5.53%

5.58%

9.54%

11.75%

41.43%

16.22%

16.76%

10.74%

7.69%

-0.52[-1.3,0.26]

-0.64[-1.46,0.19]

-0.55[-1.27,0.18]

-0.49[-1.2,0.23]

-0.5[-1.05,0.05]

-0.81[-1.3,-0.31]

-0.61[-0.87,-0.34]

-0.15[-0.57,0.27]

-0.35[-0.76,0.07]

-0.74[-1.26,-0.22]

-0.24[-0.86,0.37]

Favours treatment

-4

-2

0

2

4

Favours control

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

222

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

PT+AD

PT+placebo

Std. Mean Difference

Weight

Std. Mean Difference

Sharp 1996ii

Subtotal ***

Mean(SD)

1.7 (1.1)

N

14

136

Mean(SD)

1.7 (1)

N

30

227

Random, 95% CI

7.17%

58.57%

Random, 95% CI

0.02[-0.61,0.65]

-0.31[-0.54,-0.08]

Heterogeneity: Tau2=0.01; Chi2=4.32, df=4(P=0.36); I2=7.49%

Test for overall effect: Z=2.6(P=0.01)

15.3.3 Psychodynamic and other therapies

Subtotal ***

0

0

Heterogeneity: Not applicable

Test for overall effect: Not applicable

Not estimable

Total ***

249

353

100%

-0.43[-0.6,-0.26]

Heterogeneity: Tau2=0; Chi2=8.21, df=10(P=0.61); I2=0%

Test for overall effect: Z=4.99(P<0.0001)

Test for subgroup differences: Chi2=2.93, df=1 (P=0.09), I2=65.86%

Favours treatment

-4

-2

0

2

4

Favours control

Analysis 15.4.   Comparison 15 SENSITIVITY1: blinded rater: Psychotherapy+Antidepressant
vs Psychotherapy alone or +Placebo, Outcome 4 Frequency of panic attacks at 2-4 months.

Study or subgroup

PT+AD

PT+placebo

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

15.4.1 Behaviour therapy

de Beurs 1995i

de Beurs 1995ii

Fava 1997

Johnston 1995

Mavissakalian 1986a

Mavissakalian 1986b

Telch 1985

Zitrin 1980

Zitrin 1983

Subtotal ***

9

9

7

12

17

14

10

19

34

0.2 (0.5)

0.2 (0.5)

2.7 (0.8)

0.6 (0.9)

1.3 (2)

2.4 (1.9)

0.6 (1.1)

6.4 (1)

6 (1.2)

19

16

7

17

14

17

9

14

34

0.5 (1.6)

1.7 (3.5)

2 (1)

1.1 (1.8)

1.6 (2.1)

2.2 (2.1)

0.8 (0.7)

6 (1)

5.4 (1.2)

131

147

Heterogeneity: Tau2=0.01; Chi2=8.6, df=8(P=0.38); I2=6.93%

Test for overall effect: Z=0.47(P=0.64)

15.4.2 Cognitive-behaviour therapy

Kampman 2002

Oehrberg 1995

Subtotal ***

2.2 (0.6)

-16 (18.4)

19

55

74

2.3 (0.7)

-9.8 (18.4)

19

52

71

Heterogeneity: Tau2=0; Chi2=0.24, df=1(P=0.63); I2=0%

Test for overall effect: Z=1.71(P=0.09)

Total ***

205

218

Heterogeneity: Tau2=0.02; Chi2=11.75, df=10(P=0.3); I2=14.93%

Test for overall effect: Z=0.43(P=0.67)

Test for subgroup differences: Chi2=2.92, df=1 (P=0.09), I2=65.77%

6.62%

6.13%

3.69%

7.45%

8.13%

8.14%

5.27%

8.37%

15.27%

69.07%

-0.25[-1.04,0.55]

-0.51[-1.34,0.32]

0.72[-0.37,1.82]

-0.34[-1.09,0.4]

-0.14[-0.85,0.56]

0.1[-0.61,0.8]

-0.18[-1.08,0.72]

0.36[-0.33,1.06]

0.44[-0.04,0.92]

0.06[-0.19,0.31]

9.76%

21.18%

30.93%

-0.15[-0.79,0.49]

-0.33[-0.72,0.05]

-0.29[-0.61,0.04]

100%

-0.05[-0.26,0.17]

Favours treatment

-4

-2

0

2

4

Favours control

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

223

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 15.5.   Comparison 15 SENSITIVITY1: blinded rater: Psychotherapy+Antidepressant
vs Psychotherapy alone or +Placebo, Outcome 5 Phobic avoidance at 2-4 months.

Study or subgroup

PT+AD

PT+placebo

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

15.5.1 Behaviour therapy

de Beurs 1995i

de Beurs 1995ii

Fava 1997

Johnston 1995

Marks 1983

Mavissakalian 1986a

Mavissakalian 1986b

Sheehan 1980a

Sheehan 1980b

Telch 1985

Zitrin 1980

Zitrin 1983

Subtotal ***

10

9

7

12

23

17

14

18

17

10

25

34

4.1 (2)

4.1 (2)

19.6 (4.7)

8.5 (8.4)

11.4 (9.4)

11.4 (8.8)

12.3 (8.8)

3 (1)

2.4 (1.2)

17.3 (10.3)

6.2 (0.8)

2.7 (1.4)

19

18

7

17

22

14

17

11

11

9

21

34

5.7 (1.3)

6.1 (1.9)

15.6 (8.4)

13.5 (9.6)

12.7 (10.5)

13.8 (9.9)

13.3 (9.9)

3.9 (1.3)

3.9 (1.3)

23.3 (7.8)

5.7 (1.1)

3.4 (1.4)

196

200

Heterogeneity: Tau2=0.14; Chi2=22.21, df=11(P=0.02); I2=50.47%

Test for overall effect: Z=2.65(P=0.01)

15.5.2 Cognitive-behaviour therapy

Fahy 1992

Kampman 2002

Loerch 1999

Sharp 1996i

Sharp 1996ii

Stein 2000

Subtotal ***

31.4 (30.7)

1.8 (0.5)

7 (8.3)

4.7 (7.8)

4.7 (7.8)

-5.8 (6.7)

42

19

14

15

14

12

116

24

19

14

33

30

12

132

40.2 (25.4)

2 (0.6)

9.1 (6.3)

7.2 (10.6)

5.1 (5.4)

-5.9 (9.8)

Heterogeneity: Tau2=0; Chi2=0.86, df=5(P=0.97); I2=0%

Test for overall effect: Z=1.71(P=0.09)

15.5.3 Psychodynamic and other therapies

Subtotal ***

0

0

Heterogeneity: Not applicable

Test for overall effect: Not applicable

Total ***

312

332

Heterogeneity: Tau2=0.05; Chi2=23.84, df=17(P=0.12); I2=28.7%

Test for overall effect: Z=3.31(P=0)

Test for subgroup differences: Chi2=0.77, df=1 (P=0.38), I2=0%

4.42%

4.13%

2.79%

4.96%

7.07%

5.41%

5.44%

4.7%

4.28%

3.58%

7%

8.89%

62.68%

8.47%

6.26%

5.05%

6.66%

6.35%

4.53%

-0.99[-1.8,-0.17]

-0.99[-1.84,-0.14]

0.55[-0.52,1.63]

-0.53[-1.29,0.22]

-0.13[-0.71,0.46]

-0.25[-0.96,0.46]

-0.1[-0.81,0.6]

-0.79[-1.57,-0.01]

-1.2[-2.03,-0.37]

-0.62[-1.55,0.31]

0.49[-0.1,1.08]

-0.51[-0.99,-0.02]

-0.41[-0.7,-0.11]

-0.3[-0.81,0.2]

-0.35[-1,0.29]

-0.28[-1.03,0.46]

-0.25[-0.86,0.36]

-0.06[-0.7,0.57]

0.01[-0.79,0.81]

37.32%

-0.23[-0.49,0.03]

Not estimable

100%

-0.33[-0.52,-0.13]

Favours treatment

-4

-2

0

2

4

Favours control

Analysis 15.6.   Comparison 15 SENSITIVITY1: blinded rater: Psychotherapy+Antidepressant
vs Psychotherapy alone or +Placebo, Outcome 6 General anxiety at 2-4 months.

Study or subgroup

PT+AD

PT+placebo

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

15.6.1 Behaviour therapy

de Beurs 1995i

de Beurs 1995ii

10

9

2.6 (1.3)

2.6 (1.3)

19

18

3.8 (1.4)

3.9 (1.5)

4.16%

3.81%

-0.87[-1.67,-0.06]

-0.89[-1.73,-0.05]

Favours treatment

-4

-2

0

2

4

Favours control

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

224

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

PT+AD

PT+placebo

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

Fava 1997

Marks 1983

Mavissakalian 1986a

Mavissakalian 1986b

Sheehan 1980a

Sheehan 1980b

Zitrin 1983

Subtotal ***

3.6 (0.5)

8.9 (9.4)

30.1 (7.6)

34.3 (7.6)

1 (0.7)

1 (0.6)

21.5 (9.9)

7

23

17

14

18

17

34

149

Heterogeneity: Tau2=0.03; Chi2=9.68, df=8(P=0.29); I2=17.35%

Test for overall effect: Z=4.71(P<0.0001)

15.6.2 Cognitive-behaviour therapy

Fahy 1992

Kampman 2002

Loerch 1999

Oehrberg 1995

Sharp 1996i

Sharp 1996ii

Stein 2000

Subtotal ***

11.3 (7.6)

1.5 (1.7)

11.4 (11.1)

-6.5 (5.5)

4.8 (5.7)

4.8 (5.7)

-15.3 (10.6)

42

19

14

55

15

14

12

171

3.6 (0.5)

12.7 (9.2)

35.5 (9.3)

34.4 (9.3)

2 (1.1)

2 (1.1)

27.9 (9.9)

14.4 (6.6)

1.7 (1.3)

11.9 (8.4)

-4.3 (5.5)

6.5 (6.7)

4.9 (4.4)

-10 (13.1)

7

22

14

17

11

11

34

153

24

19

14

52

33

30

12

184

Heterogeneity: Tau2=0; Chi2=2.05, df=6(P=0.92); I2=0%

Test for overall effect: Z=2.59(P=0.01)

15.6.3 Psychodynamic and other therapies

Subtotal ***

0

0

Heterogeneity: Not applicable

Test for overall effect: Not applicable

Total ***

320

337

Heterogeneity: Tau2=0.01; Chi2=16.3, df=15(P=0.36); I2=7.96%

Test for overall effect: Z=5.16(P<0.0001)

Test for subgroup differences: Chi2=4.57, df=1 (P=0.03), I2=78.12%

2.49%

7.34%

5.01%

5.27%

4.04%

3.78%

10.31%

46.22%

9.65%

6.41%

4.83%

15.49%

6.87%

6.45%

4.08%

53.78%

0[-1.05,1.05]

-0.4[-0.99,0.19]

-0.63[-1.35,0.1]

-0.01[-0.72,0.7]

-1.15[-1.97,-0.34]

-1.31[-2.15,-0.47]

-0.64[-1.13,-0.15]

-0.64[-0.9,-0.37]

-0.42[-0.93,0.08]

-0.13[-0.77,0.51]

-0.04[-0.78,0.7]

-0.4[-0.78,-0.01]

-0.26[-0.87,0.35]

-0.02[-0.65,0.61]

-0.43[-1.24,0.38]

-0.28[-0.5,-0.07]

Not estimable

100%

-0.44[-0.61,-0.27]

Favours treatment

-4

-2

0

2

4

Favours control

Analysis 15.7.   Comparison 15 SENSITIVITY1: blinded rater: Psychotherapy
+Antidepressant vs Psychotherapy alone or +Placebo, Outcome 7 Depression at 2-4 months.

Study or subgroup

PT+AD

PT+placebo

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

15.7.1 Behaviour therapy

de Beurs 1995i

de Beurs 1995ii

Fava 1997

Johnston 1995

Marks 1983

Mavissakalian 1986a

Mavissakalian 1986b

Sheehan 1980a

Sheehan 1980b

10

9

7

12

23

17

14

18

17

2.6 (1)

2.6 (1)

1 (0)

0.8 (0.5)

4 (4.9)

2.8 (8.5)

8.7 (8.5)

51.1 (9.4)

45.4 (9)

19

18

7

17

22

14

17

11

11

3.5 (1.4)

3.8 (1.5)

1.1 (0.4)

1 (0.8)

4 (2.7)

7.7 (8.7)

6.9 (8.7)

57.7 (10.1)

57.7 (10.1)

6.07%

5.42%

6.78%

10.45%

7.13%

7.38%

6.31%

5.42%

-0.68[-1.46,0.11]

-0.86[-1.7,-0.02]

Not estimable

-0.28[-1.02,0.46]

0[-0.58,0.58]

-0.56[-1.28,0.17]

0.2[-0.51,0.91]

-0.66[-1.43,0.11]

-1.26[-2.1,-0.42]

Favours treatment

-4

-2

0

2

4

Favours control

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

225

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

PT+AD

PT+placebo

Std. Mean Difference

Weight

Std. Mean Difference

Telch 1985

Zitrin 1983

Subtotal ***

Mean(SD)

13.4 (5.7)

1.3 (0.5)

N

10

34

171

Mean(SD)

13 (11.9)

1.6 (0.5)

N

9

34

179

Random, 95% CI

Heterogeneity: Tau2=0.05; Chi2=12.1, df=9(P=0.21); I2=25.62%

Test for overall effect: Z=3.21(P=0)

15.7.2 Cognitive-behaviour therapy

Fahy 1992

Loerch 1999

Stein 2000

Subtotal ***

5.6 (4.5)

5.6 (5.8)

-10.5 (10.4)

42

14

12

68

Heterogeneity: Tau2=0; Chi2=1.02, df=2(P=0.6); I2=0%

Test for overall effect: Z=2.02(P=0.04)

15.7.3 Psychodynamic and other therapies

Subtotal ***

0

Heterogeneity: Not applicable

Test for overall effect: Not applicable

8.3 (5.1)

6.5 (5.2)

-8.6 (7.6)

24

14

12

50

0

Total ***

239

229

Heterogeneity: Tau2=0.01; Chi2=13.15, df=12(P=0.36); I2=8.72%

Test for overall effect: Z=4(P<0.0001)

Test for subgroup differences: Chi2=0.03, df=1 (P=0.87), I2=0%

4.73%

14.48%

74.16%

13.18%

6.79%

5.87%

25.84%

Random, 95% CI

0.04[-0.86,0.94]

-0.51[-1,-0.03]

-0.43[-0.69,-0.17]

-0.56[-1.08,-0.05]

-0.16[-0.9,0.58]

-0.2[-1,0.6]

-0.38[-0.76,-0.01]

Not estimable

100%

-0.41[-0.61,-0.21]

Favours treatment

-4

-2

0

2

4

Favours control

Analysis 15.8.   Comparison 15 SENSITIVITY1: blinded rater: Psychotherapy+Antidepressant
vs Psychotherapy alone or +Placebo, Outcome 8 Social functioning at 2-4 months.

Study or subgroup

PT+AD

PT+placebo

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

15.8.1 Behaviour therapy

Johnston 1995

Mavissakalian 1986a

Mavissakalian 1986b

Sheehan 1980a

Sheehan 1980b

Zitrin 1980

Zitrin 1983

Subtotal ***

2.1 (0.6)

2.3 (1)

2.4 (1)

3.1 (1.1)

2.4 (1.4)

5.9 (0.8)

5.8 (0.9)

12

17

14

18

17

25

34

137

Heterogeneity: Tau2=0.4; Chi2=25.97, df=6(P=0); I2=76.89%

Test for overall effect: Z=0.7(P=0.48)

15.8.2 Cognitive-behaviour therapy

Loerch 1999

Sharp 1996i

Sharp 1996ii

Stein 2000

Subtotal ***

2.4 (2.8)

1.4 (2.8)

1.4 (2.8)

-3.1 (2.5)

14

15

14

12

55

Heterogeneity: Tau2=0; Chi2=1.9, df=3(P=0.59); I2=0%

16

14

17

11

11

20

34

123

14

33

30

12

89

2 (0.8)

2.8 (1.1)

2.8 (1.1)

4 (1)

4 (1)

5.6 (1.1)

5.1 (0.9)

2.1 (2.2)

2.1 (2.6)

1.9 (2.6)

-4 (2.1)

8.58%

8.86%

8.91%

8.28%

7.83%

10.12%

11.13%

63.71%

8.65%

9.91%

9.68%

8.04%

36.29%

0.14[-0.61,0.89]

-0.49[-1.21,0.23]

-0.38[-1.1,0.33]

-0.8[-1.58,-0.02]

-1.22[-2.06,-0.39]

0.33[-0.26,0.92]

0.78[0.28,1.27]

-0.19[-0.73,0.34]

0.11[-0.63,0.85]

-0.27[-0.88,0.34]

-0.18[-0.82,0.46]

0.38[-0.43,1.18]

-0.04[-0.39,0.3]

Favours treatment

-4

-2

0

2

4

Favours control

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

226

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

PT+AD

PT+placebo

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

Test for overall effect: Z=0.26(P=0.8)

Total ***

192

212

Heterogeneity: Tau2=0.21; Chi2=27.87, df=10(P=0); I2=64.12%

Test for overall effect: Z=0.63(P=0.53)

Test for subgroup differences: Chi2=0.01, df=1 (P=0.93), I2=0%

100%

-0.11[-0.46,0.23]

Favours treatment

-4

-2

0

2

4

Favours control

Analysis 15.9.   Comparison 15 SENSITIVITY1: blinded rater: Psychotherapy+Antidepressant
vs Psychotherapy alone or +Placebo, Outcome 9 Dropouts for any reason within 2-4 months.

PT+AD

n/N

PT+placebo

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

Study or subgroup

15.9.1 Behaviour therapy

de Beurs 1995i

de Beurs 1995ii

Fava 1997

Johnston 1995

Marks 1983

Sheehan 1980a

Sheehan 1980b

Telch 1985

Zitrin 1980

Zitrin 1983

Subtotal (95% CI)

3/12

2/12

0/7

16/26

13/36

7/28

9/29

3/13

12/41

9/43

247

Total events: 74 (PT+AD), 58 (PT+placebo)

Heterogeneity: Tau2=0; Chi2=3.32, df=8(P=0.91); I2=0%

Test for overall effect: Z=1.22(P=0.22)

15.9.2 Cognitive-behaviour therapy

Barlow 2000i

Barlow 2000ii

Fahy 1992

Kampman 2002

Loerch 1999

Oehrberg 1995

Sharp 1996i

Sharp 1996ii

Stein 2000

Subtotal (95% CI)

9/33

9/32

12/53

3/22

3/14

5/60

6/19

5/19

1/16

268

Total events: 53 (PT+AD), 71 (PT+placebo)

Heterogeneity: Tau2=0; Chi2=6.12, df=8(P=0.63); I2=0%

Test for overall effect: Z=0.69(P=0.49)

15.9.3 Psychodynamic and other therapies

5/24

3/21

0/7

10/27

14/36

3/16

2/14

3/12

11/35

7/41

233

18/63

21/77

3/26

2/21

1/14

8/60

4/36

13/43

1/17

357

3.07%

1.79%

14.41%

13.51%

3.32%

2.48%

2.48%

10.34%

6.08%

57.47%

10.41%

10.95%

3.49%

1.69%

1.05%

4.3%

3.73%

6.24%

0.67%

42.53%

1.2[0.34,4.2]

1.17[0.23,6.03]

Not estimable

1.66[0.93,2.96]

0.93[0.51,1.69]

1.33[0.4,4.45]

2.17[0.54,8.75]

0.92[0.23,3.72]

0.93[0.47,1.84]

1.23[0.5,2.99]

1.2[0.9,1.6]

0.95[0.48,1.88]

1.03[0.53,2]

1.96[0.61,6.35]

1.43[0.27,7.73]

3[0.35,25.46]

0.63[0.22,1.8]

2.84[0.91,8.86]

0.87[0.36,2.1]

1.06[0.07,15.6]

1.13[0.8,1.58]

Subtotal (95% CI)

0

0

Not estimable

Total events: 0 (PT+AD), 0 (PT+placebo)

Heterogeneity: Not applicable

Test for overall effect: Not applicable

Favours treatment

0.1

0.2

0.5

1

2

5

10

Favours control

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

227

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

PT+AD

n/N

PT+placebo

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

Total (95% CI)

515

590

100%

1.17[0.94,1.45]

Total events: 127 (PT+AD), 129 (PT+placebo)

Heterogeneity: Tau2=0; Chi2=9.51, df=17(P=0.92); I2=0%

Test for overall effect: Z=1.37(P=0.17)

Test for subgroup differences: Not applicable

Favours treatment

0.1

0.2

0.5

1

2

5

10

Favours control

Analysis 15.10.   Comparison 15 SENSITIVITY1: blinded rater: Psychotherapy+Antidepressant vs
Psychotherapy alone or +Placebo, Outcome 10 Dropouts due to side effects within 2-4 months.

PT+AD

n/N

PT+placebo

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

Study or subgroup

15.10.1 Behaviour therapy

de Beurs 1995i

de Beurs 1995ii

Marks 1983

Telch 1985

Zitrin 1980

Subtotal (95% CI)

1/12

1/12

2/36

3/13

8/41

114

Total events: 15 (PT+AD), 7 (PT+placebo)

Heterogeneity: Tau2=0; Chi2=2.47, df=4(P=0.65); I2=0%

Test for overall effect: Z=1.59(P=0.11)

15.10.2 Cognitive-behaviour therapy

Barlow 2000i

Barlow 2000ii

Fahy 1992

Kampman 2002

Oehrberg 1995

Sharp 1996i

Sharp 1996ii

Subtotal (95% CI)

1/33

1/32

7/53

3/22

4/60

3/19

2/19

238

Total events: 21 (PT+AD), 2 (PT+placebo)

Heterogeneity: Tau2=0; Chi2=3.15, df=6(P=0.79); I2=0%

Test for overall effect: Z=3.05(P=0)

0/24

0/21

3/36

1/12

3/35

128

0/63

0/77

0/26

2/21

0/60

0/36

0/43

326

4.21%

4.22%

13.79%

9.14%

26.46%

57.81%

4.09%

4.09%

5.16%

14.49%

4.9%

4.86%

4.61%

42.19%

5.77[0.25,131.92]

5.08[0.22,115.7]

0.67[0.12,3.75]

2.77[0.33,23.14]

2.28[0.65,7.93]

1.99[0.85,4.62]

5.65[0.24,134.91]

7.09[0.3,169.6]

7.5[0.44,126.48]

1.43[0.27,7.73]

9[0.5,163.58]

12.95[0.7,238.39]

11[0.55,218.74]

4.66[1.73,12.52]

Total (95% CI)

352

454

100%

2.85[1.5,5.41]

Total events: 36 (PT+AD), 9 (PT+placebo)

Heterogeneity: Tau2=0; Chi2=7.33, df=11(P=0.77); I2=0%

Test for overall effect: Z=3.2(P=0)

Test for subgroup differences: Not applicable

Favours treatment

0.1

0.2

0.5

1

2

5

10

Favours control

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

228

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 15.11.   Comparison 15 SENSITIVITY1: blinded rater: Psychotherapy+Antidepressant
vs Psychotherapy alone or +Placebo, Outcome 11 Response/remission on continued treatment.

PT+AD

n/N

PT+placebo

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

Study or subgroup

15.11.1 Behaviour therapy

Telch 1985

Zitrin 1980

Zitrin 1983

Subtotal (95% CI)

7/13

26/41

17/43

97

Total events: 50 (PT+AD), 36 (PT+placebo)

Heterogeneity: Tau2=0.05; Chi2=2.96, df=2(P=0.23); I2=32.38%

Test for overall effect: Z=1.02(P=0.31)

15.11.2 Cognitive-behaviour therapy

Barlow 2000i

Barlow 2000ii

Subtotal (95% CI)

19/33

18/32

65

Total events: 37 (PT+AD), 64 (PT+placebo)

Heterogeneity: Tau2=0; Chi2=0.39, df=1(P=0.53); I2=0%

Test for overall effect: Z=1.48(P=0.14)

2/12

17/35

17/41

88

32/63

32/77

140

2.33%

25.37%

16.06%

43.76%

3.23[0.83,12.61]

1.31[0.86,1.97]

0.95[0.57,1.6]

1.25[0.82,1.9]

29.82%

26.42%

56.24%

1.13[0.77,1.66]

1.35[0.9,2.03]

1.23[0.93,1.63]

Total (95% CI)

162

228

100%

1.23[1,1.51]

Total events: 87 (PT+AD), 100 (PT+placebo)

Heterogeneity: Tau2=0; Chi2=3.34, df=4(P=0.5); I2=0%

Test for overall effect: Z=1.93(P=0.05)

Test for subgroup differences: Not applicable

Favours PT+placebo

0.1

0.2

0.5

1

2

5

10

Favours PT+AD

Analysis 15.12.   Comparison 15 SENSITIVITY1: blinded rater: Psychotherapy+Antidepressant vs
Psychotherapy alone or +Placebo, Outcome 12 Global/Avoidance/Panic on continued treatment.

Study or subgroup

PT+AD

PT+placebo

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

15.12.1 Behaviour therapy

Johnston 1995

Telch 1985

Zitrin 1980

Subtotal ***

5.4 (5.7)

12.6 (8.1)

1.5 (0.7)

12

10

29

51

Heterogeneity: Tau2=0; Chi2=1.84, df=2(P=0.4); I2=0%

Test for overall effect: Z=4.44(P<0.0001)

15.12.2 Cognitive-behaviour therapy

Barlow 2000i

Barlow 2000ii

Subtotal ***

0.8 (0.9)

0.8 (0.9)

33

32

65

Heterogeneity: Tau2=0; Chi2=0.1, df=1(P=0.75); I2=0%

Test for overall effect: Z=2.73(P=0.01)

14.6 (9.1)

25.6 (8.8)

2 (0.9)

1.1 (0.8)

1.2 (0.9)

17

9

24

50

63

77

140

Total ***

116

190

Heterogeneity: Tau2=0.04; Chi2=6.13, df=4(P=0.19); I2=34.79%

Test for overall effect: Z=4.01(P<0.0001)

12.48%

8.09%

21.03%

41.6%

-1.13[-1.94,-0.33]

-1.47[-2.51,-0.43]

-0.72[-1.27,-0.16]

-0.95[-1.37,-0.53]

28.94%

29.47%

58.4%

-0.37[-0.79,0.06]

-0.46[-0.88,-0.04]

-0.41[-0.71,-0.12]

100%

-0.65[-0.97,-0.33]

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

229

Favours treatment

-4

-2

0

2

4

Favours control

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

PT+AD

PT+placebo

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

Test for subgroup differences: Chi2=4.19, df=1 (P=0.04), I2=76.16%

Favours treatment

-4

-2

0

2

4

Favours control

Analysis 15.13.   Comparison 15 SENSITIVITY1: blinded rater: Psychotherapy+Antidepressant vs
Psychotherapy alone or +Placebo, Outcome 13 Dropouts for any reason on continued treatment.

PT+AD

n/N

PT+placebo

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

Study or subgroup

15.13.1 Behaviour therapy

de Beurs 1995

Telch 1985

Subtotal (95% CI)

1/19

1/10

29

Total events: 2 (PT+AD), 0 (PT+placebo)

Heterogeneity: Tau2=0; Chi2=0, df=1(P=0.97); I2=0%

Test for overall effect: Z=0.94(P=0.35)

15.13.2 Cognitive-behaviour therapy

Barlow 2000i

Barlow 2000ii

Subtotal (95% CI)

2/33

2/32

65

Total events: 4 (PT+AD), 13 (PT+placebo)

Heterogeneity: Tau2=0; Chi2=0, df=1(P=0.94); I2=0%

Test for overall effect: Z=0.75(P=0.45)

0/19

0/9

28

6/63

7/77

140

9.56%

9.91%

19.47%

3[0.13,69.31]

2.73[0.12,59.57]

2.86[0.32,25.8]

39.54%

40.99%

80.53%

0.64[0.14,2.98]

0.69[0.15,3.13]

0.66[0.22,1.95]

Total (95% CI)

94

168

100%

0.88[0.33,2.32]

Total events: 6 (PT+AD), 13 (PT+placebo)

Heterogeneity: Tau2=0; Chi2=1.38, df=3(P=0.71); I2=0%

Test for overall effect: Z=0.26(P=0.8)

Test for subgroup differences: Not applicable

Favours treatment

0.1

0.2

0.5

1

2

5

10

Favours control

Analysis 15.14.   Comparison 15 SENSITIVITY1: blinded rater: Psychotherapy+Antidepressant vs Psychotherapy
alone or +Placebo, Outcome 14 Response/remission 6-24 months after treatment discontinuation.

Study or subgroup

15.14.1 Behaviour therapy

de Beurs 1995i

de Beurs 1995ii

Marks 1983

Mavissakalian 1986a

Mavissakalian 1986b

Zitrin 1983

Subtotal (95% CI)

PT+AD

n/N

PT+placebo

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

6/12

6/12

9/36

6/20

6/20

23/43

143

12/24

10/21

11/36

5/20

6/20

20/41

162

8%

7.36%

6.82%

3.75%

4.28%

21.81%

52.02%

1[0.5,2]

1.05[0.51,2.16]

0.82[0.39,1.73]

1.2[0.44,3.3]

1[0.39,2.58]

1.1[0.72,1.67]

1.03[0.79,1.36]

Total events: 56 (PT+AD), 64 (PT+placebo)

Heterogeneity: Tau2=0; Chi2=0.55, df=5(P=0.99); I2=0%

Test for overall effect: Z=0.23(P=0.82)

Favours PT+placebo

0.1

0.2

0.5

1

2

5

10

Favours PT+AD

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

230

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

PT+AD

n/N

PT+placebo

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

15.14.2 Cognitive-behaviour therapy

Barlow 2000i

Barlow 2000ii

Loerch 1999

Sharp 1996i

Sharp 1996ii

Subtotal (95% CI)

8/30

8/29

9/14

8/19

8/19

111

25/62

24/73

9/14

17/36

15/43

228

Total events: 41 (PT+AD), 90 (PT+placebo)

Heterogeneity: Tau2=0; Chi2=1.79, df=4(P=0.77); I2=0%

Test for overall effect: Z=0.66(P=0.51)

8.65%

8.44%

12.59%

9.66%

8.63%

47.98%

0.66[0.34,1.29]

0.84[0.43,1.65]

1[0.58,1.74]

0.89[0.47,1.67]

1.21[0.62,2.35]

0.91[0.69,1.21]

Total (95% CI)

254

390

100%

0.97[0.8,1.18]

Total events: 97 (PT+AD), 154 (PT+placebo)

Heterogeneity: Tau2=0; Chi2=2.74, df=10(P=0.99); I2=0%

Test for overall effect: Z=0.29(P=0.77)

Test for subgroup differences: Not applicable

Favours PT+placebo

0.1

0.2

0.5

1

2

5

10

Favours PT+AD

Analysis 15.15.   Comparison 15 SENSITIVITY1: blinded rater: Psychotherapy+Antidepressant vs Psychotherapy
alone or +Placebo, Outcome 15 Global/Avoidance/Panic 6-24 months after treatment discontinuation.

Study or subgroup

PT+AD

PT+placebo

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

15.15.1 Behaviour therapy

de Beurs 1995i

de Beurs 1995ii

Marks 1983

Mavissakalian 1986a

Mavissakalian 1986b

Subtotal ***

3.3 (2.4)

3.3 (2.4)

14.1 (2.7)

2.1 (1.4)

2 (1.2)

9

9

22

14

11

65

19

17

18

11

11

76

3.2 (2.7)

3.5 (2.2)

13.7 (2.8)

3.3 (2.6)

1.3 (0.5)

Heterogeneity: Tau2=0.03; Chi2=4.73, df=4(P=0.32); I2=15.36%

Test for overall effect: Z=0.28(P=0.78)

15.15.2 Cognitive-behaviour therapy

Barlow 2000i

Barlow 2000ii

Subtotal ***

30

29

59

1.5 (0.9)

1.5 (0.9)

62

73

135

1.2 (0.9)

1.3 (0.9)

Heterogeneity: Tau2=0; Chi2=0.27, df=1(P=0.6); I2=0%

Test for overall effect: Z=1.34(P=0.18)

8.3%

8%

13.42%

7.98%

6.94%

44.63%

27.21%

28.16%

55.37%

0.07[-0.72,0.86]

-0.05[-0.86,0.76]

0.14[-0.48,0.77]

-0.58[-1.39,0.23]

0.71[-0.16,1.58]

0.05[-0.32,0.43]

0.29[-0.14,0.73]

0.13[-0.3,0.56]

0.21[-0.1,0.52]

Total ***

124

211

100%

0.14[-0.09,0.37]

Heterogeneity: Tau2=0; Chi2=5.44, df=6(P=0.49); I2=0%

Test for overall effect: Z=1.2(P=0.23)

Test for subgroup differences: Chi2=0.45, df=1 (P=0.5), I2=0%

Favours treatment

-4

-2

0

2

4

Favours control

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

231

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Comparison 16.   SENSITIVITY2: demonstrated effectiveness: Psychotherapy+Antidepressant vs Antidepressant
alone

Outcome or subgroup title

1 Response at 2-4 months

1.1 Behaviour therapy

1.2 Cognitive-behaviour therapy

1.3 Psychodynamic psychotherapy and others

2 Remission at 2-4 months

2.1 Behaviour therapy

2.2 Cognitive-behaviour therapy

2.3 Psychodynamic psychotherapy and others

3 Global severity at 2-4 months

3.1 Behaviour therapy

3.2 Cognitive-behaviour therapy

3.3 Psychodynamic psychotherapy and others

4 Frequency of panic attacks at 2-4 months

4.1 Behaviour therapy

4.2 Cognitive-behaviour therapy

4.3 Psychodynamic psychotherapy and others

5 Phobic avoidance at 2-4 months

No. of
studies

No. of
partici-
pants

Statistical method

Effect size

4

1

3

0

4

1

3

0

3

1

2

0

1

1

0

0

2

348

96

252

0

348

96

252

0

281

75

206

0

75

75

0

0

Risk Ratio (M-H, Random, 95%
CI)

1.23 [0.95, 1.61]

Risk Ratio (M-H, Random, 95%
CI)

0.96 [0.69, 1.35]

Risk Ratio (M-H, Random, 95%
CI)

1.36 [1.01, 1.84]

Risk Ratio (M-H, Random, 95%
CI)

0.0 [0.0, 0.0]

Risk Ratio (M-H, Random, 95%
CI)

1.27 [0.91, 1.78]

Risk Ratio (M-H, Random, 95%
CI)

0.94 [0.52, 1.72]

Risk Ratio (M-H, Random, 95%
CI)

1.40 [0.92, 2.14]

Risk Ratio (M-H, Random, 95%
CI)

0.0 [0.0, 0.0]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.25 [-0.49, -0.02]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.14 [-0.60, 0.31]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.30 [-0.57, -0.02]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.0 [0.0, 0.0]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.32 [-0.78, 0.14]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.32 [-0.78, 0.14]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.0 [0.0, 0.0]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.0 [0.0, 0.0]

105

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.52 [-1.44, 0.39]

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

232

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

5.1 Behaviour therapy

5.2 Cognitive-behaviour therapy

5.3 Psychodynamic psychotherapy and others

6 General anxiety at 2-4 months

6.1 Behaviour therapy

6.2 Cognitive-behaviour therapy

6.3 Psychodynamic psychotherapy and others

7 Depression at 2-4 months

7.1 Behaviour therapy

7.2 Cognitive-behaviour therapy

7.3 Psychodynamic psychotherapy and others

8 Social functioning at 2-4 months

8.1 Behavour therapy

8.2 Cognitive-behaviour therapy

8.3 Psychodynamic psychotherapy and others

9 Dropouts for any reason within 2-4 months

9.1 Behaviour therapy

9.2 Cognitive-behaviour therapy

No. of
studies

No. of
partici-
pants

Statistical method

Effect size

1

1

0

3

1

2

0

2

1

1

0

3

1

2

0

4

1

3

75

30

0

163

75

88

0

105

75

30

0

163

75

88

0

348

96

252

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.11 [-0.56, 0.35]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-1.05 [-1.82, -0.28]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.0 [0.0, 0.0]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.38 [-0.74, -0.03]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.13 [-0.58, 0.33]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.58 [-1.01, -0.15]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.0 [0.0, 0.0]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.54 [-1.13, 0.05]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.31 [-0.77, 0.15]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.93 [-1.69, -0.17]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.0 [0.0, 0.0]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.43 [-0.89, 0.04]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.17 [-0.62, 0.29]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.63 [-1.39, 0.12]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.0 [0.0, 0.0]

Risk Ratio (M-H, Random, 95%
CI)

0.76 [0.55, 1.07]

Risk Ratio (M-H, Random, 95%
CI)

0.92 [0.43, 1.99]

Risk Ratio (M-H, Random, 95%
CI)

0.73 [0.50, 1.06]

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

233

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of
studies

No. of
partici-
pants

Statistical method

Effect size

9.3 Psychodynamic psychotherapy and others

10 Dropouts due to side effects within 2-4
months

10.1 Behaviour therapy

10.2 Cognitive-behaviour therapy

0

2

0

2

10.3 Psychodynamic psychotherapy and others

0

11 Response/remission on continued treat-
ment

11.1 Behaviour therapy

11.2 Cognitive-behaviour therapy

11.3 Psychdynamic psychotherapy and others

12 Global/Avoidance/Panic on continued treat-
ment

12.1 Behaviour therapy

12.2 Cognitive-behaviour therapy

2

1

1

0

1

0

1

12.3 Psychodynamic psychotherapy and others

0

13 Dropouts for any reason on continued treat-
ment

13.1 Behaviour therapy

13.2 Cognitive-behaviour therapy

1

0

1

13.3 Psychodynamic psychotherapy and others

0

16 Response/remission 6-24 months after
treatment discontinuation

4

0

222

0

222

0

244

96

148

0

148

0

148

0

148

0

148

0

336

Risk Ratio (M-H, Random, 95%
CI)

0.0 [0.0, 0.0]

Risk Ratio (M-H, Random, 95%
CI)

0.62 [0.09, 4.15]

Risk Ratio (M-H, Random, 95%
CI)

0.0 [0.0, 0.0]

Risk Ratio (M-H, Random, 95%
CI)

0.62 [0.09, 4.15]

Risk Ratio (M-H, Random, 95%
CI)

0.0 [0.0, 0.0]

Risk Ratio (M-H, Random, 95%
CI)

1.57 [1.16, 2.14]

Risk Ratio (M-H, Random, 95%
CI)

1.75 [0.94, 3.25]

Risk Ratio (M-H, Random, 95%
CI)

1.52 [1.07, 2.16]

Risk Ratio (M-H, Random, 95%
CI)

0.0 [0.0, 0.0]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.41 [-0.74, -0.09]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.0 [0.0, 0.0]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.41 [-0.74, -0.09]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.0 [0.0, 0.0]

Risk Ratio (M-H, Random, 95%
CI)

0.73 [0.22, 2.39]

Risk Ratio (M-H, Random, 95%
CI)

0.0 [0.0, 0.0]

Risk Ratio (M-H, Random, 95%
CI)

0.73 [0.22, 2.39]

Risk Ratio (M-H, Random, 95%
CI)

0.0 [0.0, 0.0]

Risk Ratio (M-H, Random, 95%
CI)

1.47 [1.10, 1.96]

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

234

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of
studies

No. of
partici-
pants

Statistical method

Effect size

16.1 Behaviour therapy

16.2 Cognitive-behaviour therapy

1

3

16.3 Psychodynamic psychotherapy and others

0

17 Global/Avoidance/Panic 6-24 months after
treatment discontinuation

17.1 Behaviour therapy

17.2 Cognitive-behaviour therapy

1

0

1

17.3 Psychodynamic psychotherapy and others

0

96

240

0

136

0

136

0

Risk Ratio (M-H, Random, 95%
CI)

1.49 [0.95, 2.35]

Risk Ratio (M-H, Random, 95%
CI)

1.46 [1.00, 2.11]

Risk Ratio (M-H, Random, 95%
CI)

0.0 [0.0, 0.0]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.0 [-0.34, 0.34]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.0 [0.0, 0.0]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.0 [-0.34, 0.34]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.0 [0.0, 0.0]

Analysis 16.1.   Comparison 16 SENSITIVITY2: demonstrated effectiveness: Psychotherapy
+Antidepressant vs Antidepressant alone, Outcome 1 Response at 2-4 months.

Study or subgroup

16.1.1 Behaviour therapy

Zitrin 1983

Subtotal (95% CI)

Total events: 25 (PT+AD), 32 (AD)

Heterogeneity: Not applicable

Test for overall effect: Z=0.22(P=0.82)

16.1.2 Cognitive-behaviour therapy

Barlow 2000

Loerch 1999

Sharp 1996

Subtotal (95% CI)

Total events: 76 (PT+AD), 64 (AD)

PT+AD

n/N

AD

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

25/43

43

32/53

53

29.75%

29.75%

0.96[0.69,1.35]

0.96[0.69,1.35]

39/65

11/14

26/38

117

38/83

5/16

21/36

135

32.16%

9.66%

28.43%

70.25%

1.31[0.96,1.78]

2.51[1.16,5.47]

1.17[0.83,1.67]

1.36[1.01,1.84]

Heterogeneity: Tau2=0.03; Chi2=3.13, df=2(P=0.21); I2=36.12%

Test for overall effect: Z=2.02(P=0.04)

16.1.3 Psychodynamic psychotherapy and others

Subtotal (95% CI)

Total events: 0 (PT+AD), 0 (AD)

Heterogeneity: Not applicable

Test for overall effect: Not applicable

0

0

Not estimable

Total (95% CI)

160

188

100%

1.23[0.95,1.61]

Favours AD

0.1

0.2

0.5

1

2

5

10

Favours PT+AD

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

235

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

PT+AD

n/N

AD

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

Total events: 101 (PT+AD), 96 (AD)

Heterogeneity: Tau2=0.03; Chi2=5.54, df=3(P=0.14); I2=45.83%

Test for overall effect: Z=1.55(P=0.12)

Test for subgroup differences: Not applicable

Favours AD

0.1

0.2

0.5

1

2

5

10

Favours PT+AD

Analysis 16.2.   Comparison 16 SENSITIVITY2: demonstrated effectiveness: Psychotherapy
+Antidepressant vs Antidepressant alone, Outcome 2 Remission at 2-4 months.

Study or subgroup

16.2.1 Behaviour therapy

Zitrin 1983

Subtotal (95% CI)

Total events: 13 (PT+AD), 17 (AD)

Heterogeneity: Not applicable

Test for overall effect: Z=0.19(P=0.85)

16.2.2 Cognitive-behaviour therapy

Barlow 2000

Loerch 1999

Sharp 1996

Subtotal (95% CI)

Total events: 75 (PT+AD), 62 (AD)

PT+AD

n/N

AD

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

13/43

43

17/53

53

20.34%

20.34%

0.94[0.52,1.72]

0.94[0.52,1.72]

42/65

9/14

24/38

117

40/83

2/16

20/36

135

40.81%

5.55%

33.3%

79.66%

1.34[1.01,1.79]

5.14[1.33,19.92]

1.14[0.78,1.66]

1.4[0.92,2.14]

Heterogeneity: Tau2=0.07; Chi2=4.73, df=2(P=0.09); I2=57.73%

Test for overall effect: Z=1.56(P=0.12)

16.2.3 Psychodynamic psychotherapy and others

Subtotal (95% CI)

Total events: 0 (PT+AD), 0 (AD)

Heterogeneity: Not applicable

Test for overall effect: Not applicable

0

0

Not estimable

Total (95% CI)

160

188

100%

1.27[0.91,1.78]

Total events: 88 (PT+AD), 79 (AD)

Heterogeneity: Tau2=0.05; Chi2=5.58, df=3(P=0.13); I2=46.24%

Test for overall effect: Z=1.41(P=0.16)

Test for subgroup differences: Not applicable

Favours AD

0.1

0.2

0.5

1

2

5

10

Favours PT+AD

Analysis 16.3.   Comparison 16 SENSITIVITY2: demonstrated effectiveness: Psychotherapy
+Antidepressant vs Antidepressant alone, Outcome 3 Global severity at 2-4 months.

Study or subgroup

Treatment

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

16.3.1 Behaviour therapy

Zitrin 1983

34

3.2 (1)

41

3.3 (1)

26.94%

-0.14[-0.6,0.31]

Favours treatment

-4

-2

0

2

4

Favours control

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

236

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Treatment

Control

Std. Mean Difference

Weight

Std. Mean Difference

Mean(SD)

N

34

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=0.61(P=0.54)

16.3.2 Cognitive-behaviour therapy

Barlow 2000

Sharp 1996

Subtotal ***

0.9 (0.7)

1.7 (1.1)

65

29

94

Heterogeneity: Tau2=0; Chi2=0.68, df=1(P=0.41); I2=0%

Test for overall effect: Z=2.1(P=0.04)

N

41

83

29

112

16.3.3 Psychodynamic psychotherapy and others

Subtotal ***

0

0

Heterogeneity: Not applicable

Test for overall effect: Not applicable

Mean(SD)

Random, 95% CI

Random, 95% CI

26.94%

-0.14[-0.6,0.31]

1.1 (0.8)

2.3 (1.2)

52.64%

20.43%

73.06%

-0.22[-0.55,0.1]

-0.48[-1.01,0.04]

-0.3[-0.57,-0.02]

Not estimable

Total ***

128

153

100%

-0.25[-0.49,-0.02]

Heterogeneity: Tau2=0; Chi2=1, df=2(P=0.61); I2=0%

Test for overall effect: Z=2.11(P=0.03)

Test for subgroup differences: Chi2=0.32, df=1 (P=0.57), I2=0%

Favours treatment

-4

-2

0

2

4

Favours control

Analysis 16.4.   Comparison 16 SENSITIVITY2: demonstrated effectiveness: Psychotherapy
+Antidepressant vs Antidepressant alone, Outcome 4 Frequency of panic attacks at 2-4 months.

Study or subgroup

Treatment

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

6 (1.2)

16.4.1 Behaviour therapy

Zitrin 1983

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=1.37(P=0.17)

16.4.2 Cognitive-behaviour therapy

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Not applicable

34

34

0

16.4.3 Psychodynamic psychotherapy and others

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Not applicable

Total ***

0

34

Heterogeneity: Not applicable

Test for overall effect: Z=1.37(P=0.17)

Test for subgroup differences: Not applicable

41

41

0

0

41

6.4 (1.2)

100%

100%

-0.32[-0.78,0.14]

-0.32[-0.78,0.14]

Not estimable

Not estimable

100%

-0.32[-0.78,0.14]

Favours treatment

-4

-2

0

2

4

Favours control

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

237

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 16.5.   Comparison 16 SENSITIVITY2: demonstrated effectiveness: Psychotherapy
+Antidepressant vs Antidepressant alone, Outcome 5 Phobic avoidance at 2-4 months.

Study or subgroup

Treatment

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

2.8 (1.4)

19 (13.2)

16.5.1 Behaviour therapy

Zitrin 1983

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=0.47(P=0.64)

16.5.2 Cognitive-behaviour therapy

Loerch 1999

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=2.66(P=0.01)

34

34

14

14

2.7 (1.4)

7 (8.3)

16.5.3 Psychodynamic psychotherapy and others

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Not applicable

Total ***

0

48

Heterogeneity: Tau2=0.34; Chi2=4.22, df=1(P=0.04); I2=76.28%

Test for overall effect: Z=1.12(P=0.26)

Test for subgroup differences: Chi2=4.22, df=1 (P=0.04), I2=76.28%

41

41

16

16

0

57

55.74%

55.74%

-0.11[-0.56,0.35]

-0.11[-0.56,0.35]

44.26%

44.26%

-1.05[-1.82,-0.28]

-1.05[-1.82,-0.28]

Not estimable

100%

-0.52[-1.44,0.39]

Favours treatment

-4

-2

0

2

4

Favours control

Analysis 16.6.   Comparison 16 SENSITIVITY2: demonstrated effectiveness: Psychotherapy
+Antidepressant vs Antidepressant alone, Outcome 6 General anxiety at 2-4 months.

Study or subgroup

Treatment

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

22.8 (9.9)

19.9 (9.8)

7.9 (7)

16.6.1 Behaviour therapy

Zitrin 1983

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=0.56(P=0.58)

16.6.2 Cognitive-behaviour therapy

Loerch 1999

Sharp 1996

Subtotal ***

21.5 (9.9)

11.4 (11.1)

4.8 (5.7)

34

34

14

29

43

Heterogeneity: Tau2=0; Chi2=0.45, df=1(P=0.5); I2=0%

Test for overall effect: Z=2.66(P=0.01)

16.6.3 Psychodynamic psychotherapy and others

Subtotal ***

0

Heterogeneity: Not applicable

Test for overall effect: Not applicable

41

41

16

29

45

0

44.45%

44.45%

-0.13[-0.58,0.33]

-0.13[-0.58,0.33]

19.6%

35.95%

55.55%

-0.79[-1.54,-0.04]

-0.48[-1,0.04]

-0.58[-1.01,-0.15]

Not estimable

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

238

Favours treatment

-4

-2

0

2

4

Favours control

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Treatment

Control

Std. Mean Difference

Weight

Std. Mean Difference

Total ***

Mean(SD)

N

77

N

86

Heterogeneity: Tau2=0.02; Chi2=2.46, df=2(P=0.29); I2=18.62%

Test for overall effect: Z=2.14(P=0.03)

Test for subgroup differences: Chi2=2.01, df=1 (P=0.16), I2=50.2%

Mean(SD)

Random, 95% CI

Random, 95% CI

100%

-0.38[-0.74,-0.03]

Favours treatment

-4

-2

0

2

4

Favours control

Analysis 16.7.   Comparison 16 SENSITIVITY2: demonstrated effectiveness: Psychotherapy
+Antidepressant vs Antidepressant alone, Outcome 7 Depression at 2-4 months.

Study or subgroup

Treatment

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

1.5 (0.5)

12 (7.4)

16.7.1 Behaviour therapy

Zitrin 1983

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=1.33(P=0.19)

16.7.2 Cognitive-behaviour therapy

Loerch 1999

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=2.4(P=0.02)

34

34

14

14

1.3 (0.5)

5.6 (5.8)

16.7.3 Psychodynamic psychotherapy and others

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Not applicable

Total ***

0

48

Heterogeneity: Tau2=0.09; Chi2=1.88, df=1(P=0.17); I2=46.93%

Test for overall effect: Z=1.8(P=0.07)

Test for subgroup differences: Chi2=1.88, df=1 (P=0.17), I2=46.93%

41

41

16

16

0

57

62.43%

62.43%

-0.31[-0.77,0.15]

-0.31[-0.77,0.15]

37.57%

37.57%

-0.93[-1.69,-0.17]

-0.93[-1.69,-0.17]

Not estimable

100%

-0.54[-1.13,0.05]

Favours treatment

-4

-2

0

2

4

Favours control

Analysis 16.8.   Comparison 16 SENSITIVITY2: demonstrated effectiveness: Psychotherapy
+Antidepressant vs Antidepressant alone, Outcome 8 Social functioning at 2-4 months.

Study or subgroup

Treatment

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

16.8.1 Behavour therapy

Zitrin 1983

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=0.72(P=0.47)

16.8.2 Cognitive-behaviour therapy

34

34

5.8 (0.9)

41

41

6 (0.9)

40.44%

40.44%

-0.17[-0.62,0.29]

-0.17[-0.62,0.29]

Loerch 1999

14

2.4 (2.8)

16

5.9 (3.5)

23.26%

-1.08[-1.85,-0.3]

Favours treatment

-4

-2

0

2

4

Favours control

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

239

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Treatment

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

2.2 (2.9)

Sharp 1996

Subtotal ***

1.4 (2.8)

29

43

Heterogeneity: Tau2=0.19; Chi2=2.67, df=1(P=0.1); I2=62.54%

Test for overall effect: Z=1.65(P=0.1)

16.8.3 Psychodynamic psychotherapy and others

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Not applicable

Total ***

0

77

Heterogeneity: Tau2=0.08; Chi2=4.04, df=2(P=0.13); I2=50.56%

Test for overall effect: Z=1.81(P=0.07)

Test for subgroup differences: Chi2=1.38, df=1 (P=0.24), I2=27.29%

29

45

0

86

36.3%

59.56%

Random, 95% CI

-0.3[-0.82,0.22]

-0.63[-1.39,0.12]

Not estimable

100%

-0.43[-0.89,0.04]

Favours treatment

-4

-2

0

2

4

Favours control

Analysis 16.9.   Comparison 16 SENSITIVITY2: demonstrated effectiveness: Psychotherapy
+Antidepressant vs Antidepressant alone, Outcome 9 Dropouts for any reason within 2-4 months.

Study or subgroup

16.9.1 Behaviour therapy

Zitrin 1983

Subtotal (95% CI)

Treatment

n/N

Control

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

9/43

43

12/53

53

18.95%

18.95%

0.92[0.43,1.99]

0.92[0.43,1.99]

Total events: 9 (Treatment), 12 (Control)

Heterogeneity: Not applicable

Test for overall effect: Z=0.2(P=0.84)

16.9.2 Cognitive-behaviour therapy

Barlow 2000

Loerch 1999

Sharp 1996

Subtotal (95% CI)

18/65

3/14

11/38

117

32/83

7/16

12/36

135

Total events: 32 (Treatment), 51 (Control)

Heterogeneity: Tau2=0; Chi2=0.72, df=2(P=0.7); I2=0%

Test for overall effect: Z=1.67(P=0.1)

16.9.3 Psychodynamic psychotherapy and others

Subtotal (95% CI)

0

0

Total events: 0 (Treatment), 0 (Control)

Heterogeneity: Not applicable

Test for overall effect: Not applicable

48.6%

8.43%

24.02%

81.05%

0.72[0.45,1.16]

0.49[0.16,1.54]

0.87[0.44,1.71]

0.73[0.5,1.06]

Not estimable

Total (95% CI)

160

188

100%

0.76[0.55,1.07]

Total events: 41 (Treatment), 63 (Control)

Heterogeneity: Tau2=0; Chi2=1.02, df=3(P=0.8); I2=0%

Test for overall effect: Z=1.59(P=0.11)

Test for subgroup differences: Not applicable

Favours treatment

0.1

0.2

0.5

1

2

5

10

Favours control

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

240

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 16.10.   Comparison 16 SENSITIVITY2: demonstrated effectiveness: Psychotherapy
+Antidepressant vs Antidepressant alone, Outcome 10 Dropouts due to side effects within 2-4 months.

Study or subgroup

Treatment

n/N

Control

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

16.10.1 Behaviour therapy

Subtotal (95% CI)

Total events: 0 (Treatment), 0 (Control)

Heterogeneity: Not applicable

Test for overall effect: Not applicable

16.10.2 Cognitive-behaviour therapy

Barlow 2000

Sharp 1996

Subtotal (95% CI)

0

0

Not estimable

2/65

5/38

103

11/83

3/36

119

48.89%

51.11%

100%

0.23[0.05,1.01]

1.58[0.41,6.13]

0.62[0.09,4.15]

Total events: 7 (Treatment), 14 (Control)

Heterogeneity: Tau2=1.37; Chi2=3.62, df=1(P=0.06); I2=72.4%

Test for overall effect: Z=0.49(P=0.62)

16.10.3 Psychodynamic psychotherapy and others

Subtotal (95% CI)

0

0

Total events: 0 (Treatment), 0 (Control)

Heterogeneity: Not applicable

Test for overall effect: Not applicable

Not estimable

Total (95% CI)

103

119

100%

0.62[0.09,4.15]

Total events: 7 (Treatment), 14 (Control)

Heterogeneity: Tau2=1.37; Chi2=3.62, df=1(P=0.06); I2=72.4%

Test for overall effect: Z=0.49(P=0.62)

Test for subgroup differences: Not applicable

Favours treatment

0.1

0.2

0.5

1

2

5

10

Favours control

Analysis 16.11.   Comparison 16 SENSITIVITY2: demonstrated effectiveness: Psychotherapy
+Antidepressant vs Antidepressant alone, Outcome 11 Response/remission on continued treatment.

Study or subgroup

PT+AD

n/N

AD

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

16.11.1 Behaviour therapy

Zitrin 1983

Subtotal (95% CI)

Total events: 17 (PT+AD), 12 (AD)

Heterogeneity: Not applicable

Test for overall effect: Z=1.76(P=0.08)

16.11.2 Cognitive-behaviour therapy

Barlow 2000

Subtotal (95% CI)

Total events: 37 (PT+AD), 31 (AD)

Heterogeneity: Not applicable

Test for overall effect: Z=2.36(P=0.02)

17/43

43

12/53

53

24.15%

24.15%

1.75[0.94,3.25]

1.75[0.94,3.25]

37/65

65

31/83

83

75.85%

75.85%

1.52[1.07,2.16]

1.52[1.07,2.16]

Favours AD

0.1

0.2

0.5

1

2

5

10

Favours PT+AD

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

241

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

PT+AD

n/N

AD

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

16.11.3 Psychdynamic psychotherapy and others

Subtotal (95% CI)

Total events: 0 (PT+AD), 0 (AD)

Heterogeneity: Not applicable

Test for overall effect: Not applicable

0

0

Not estimable

Total (95% CI)

108

136

100%

1.57[1.16,2.14]

Total events: 54 (PT+AD), 43 (AD)

Heterogeneity: Tau2=0; Chi2=0.14, df=1(P=0.71); I2=0%

Test for overall effect: Z=2.92(P=0)

Test for subgroup differences: Not applicable

Favours AD

0.1

0.2

0.5

1

2

5

10

Favours PT+AD

Analysis 16.12.   Comparison 16 SENSITIVITY2: demonstrated effectiveness: Psychotherapy
+Antidepressant vs Antidepressant alone, Outcome 12 Global/Avoidance/Panic on continued treatment.

Study or subgroup

Treatment

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

16.12.1 Behaviour therapy

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Not applicable

16.12.2 Cognitive-behaviour therapy

Barlow 2000

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=2.47(P=0.01)

0

65

65

0.8 (0.9)

16.12.3 Psychodynamic psychotherapy and others

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Not applicable

Total ***

0

65

Heterogeneity: Not applicable

Test for overall effect: Z=2.47(P=0.01)

Test for subgroup differences: Not applicable

0

83

83

0

83

Not estimable

1.1 (0.9)

100%

100%

-0.41[-0.74,-0.09]

-0.41[-0.74,-0.09]

Not estimable

100%

-0.41[-0.74,-0.09]

Favours treatment

-4

-2

0

2

4

Favours control

Analysis 16.13.   Comparison 16 SENSITIVITY2: demonstrated effectiveness: Psychotherapy
+Antidepressant vs Antidepressant alone, Outcome 13 Dropouts for any reason on continued treatment.

Study or subgroup

16.13.1 Behaviour therapy

Treatment

n/N

Control

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

Favours treatment

0.1

0.2

0.5

1

2

5

10

Favours control

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

242

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Treatment

n/N

Control

n/N

Subtotal (95% CI)

0

0

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

Not estimable

Total events: 0 (Treatment), 0 (Control)

Heterogeneity: Not applicable

Test for overall effect: Not applicable

16.13.2 Cognitive-behaviour therapy

Barlow 2000

Subtotal (95% CI)

Total events: 4 (Treatment), 7 (Control)

Heterogeneity: Not applicable

Test for overall effect: Z=0.52(P=0.6)

4/65

65

7/83

83

100%

100%

0.73[0.22,2.39]

0.73[0.22,2.39]

16.13.3 Psychodynamic psychotherapy and others

Subtotal (95% CI)

0

0

Total events: 0 (Treatment), 0 (Control)

Heterogeneity: Not applicable

Test for overall effect: Not applicable

Not estimable

Total (95% CI)

65

83

100%

0.73[0.22,2.39]

Total events: 4 (Treatment), 7 (Control)

Heterogeneity: Not applicable

Test for overall effect: Z=0.52(P=0.6)

Test for subgroup differences: Not applicable

Favours treatment

0.1

0.2

0.5

1

2

5

10

Favours control

Analysis 16.16.   Comparison 16 SENSITIVITY2: demonstrated effectiveness: Psychotherapy+Antidepressant
vs Antidepressant alone, Outcome 16 Response/remission 6-24 months after treatment discontinuation.

Study or subgroup

PT+AD

n/N

AD

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

16.16.1 Behaviour therapy

Zitrin 1983

Subtotal (95% CI)

Total events: 23 (PT+AD), 19 (AD)

Heterogeneity: Not applicable

Test for overall effect: Z=1.72(P=0.09)

16.16.2 Cognitive-behaviour therapy

Barlow 2000

Loerch 1999

Sharp 1996

Subtotal (95% CI)

Total events: 41 (PT+AD), 32 (AD)

23/43

43

19/53

53

40.13%

40.13%

1.49[0.95,2.35]

1.49[0.95,2.35]

16/59

9/14

16/38

111

15/77

7/16

10/36

129

21.83%

18.05%

19.99%

59.87%

1.39[0.75,2.58]

1.47[0.75,2.9]

1.52[0.8,2.89]

1.46[1,2.11]

Heterogeneity: Tau2=0; Chi2=0.04, df=2(P=0.98); I2=0%

Test for overall effect: Z=1.97(P=0.05)

16.16.3 Psychodynamic psychotherapy and others

Subtotal (95% CI)

Total events: 0 (PT+AD), 0 (AD)

0

0

Not estimable

Favours AD

0.1

0.2

0.5

1

2

5

10

Favours PT+AD

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

243

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

PT+AD

n/N

AD

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

Heterogeneity: Not applicable

Test for overall effect: Not applicable

Total (95% CI)

154

182

100%

1.47[1.1,1.96]

Total events: 64 (PT+AD), 51 (AD)

Heterogeneity: Tau2=0; Chi2=0.04, df=3(P=1); I2=0%

Test for overall effect: Z=2.62(P=0.01)

Test for subgroup differences: Not applicable

Favours AD

0.1

0.2

0.5

1

2

5

10

Favours PT+AD

Analysis 16.17.   Comparison 16 SENSITIVITY2: demonstrated effectiveness: Psychotherapy+Antidepressant
vs Antidepressant alone, Outcome 17 Global/Avoidance/Panic 6-24 months after treatment discontinuation.

Study or subgroup

Treatment

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

16.17.1 Behaviour therapy

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Not applicable

16.17.2 Cognitive-behaviour therapy

Barlow 2000

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Not applicable

0

59

59

1.5 (0.9)

16.17.3 Psychodynamic psychotherapy and others

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Not applicable

Total ***

Heterogeneity: Not applicable

Test for overall effect: Not applicable

0

59

Test for subgroup differences: Not applicable

0

77

77

0

77

Not estimable

1.5 (0.8)

100%

100%

0[-0.34,0.34]

0[-0.34,0.34]

Not estimable

100%

0[-0.34,0.34]

Favours treatment

-4

-2

0

2

4

Favours control

Comparison 17.   SENSITIVITY2: demonstrated effectiveness: Psychotherapy+Antidepressant vs Psychotherapy
alone or +Placebo

Outcome or subgroup title

No. of
studies

No. of
partici-
pants

Statistical method

Effect size

1 Response at 2-4 months

9

546

Risk Ratio (M-H, Random, 95%
CI)

1.14 [0.96, 1.35]

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

244

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

1.1 Behaviour therapy

1.2 Cognitive-behaviour therapy

1.3 Psychodynamic and other therapies

2 Remission at 2-4 months

2.1 Behaviour therapy

2.2 Cognitive-behaviour therapy

2.3 Psychodynamic and other therapies

3 Global severity at 2-4 months

3.1 Behaviour therapy

3.2 Cognitive-behaviour therapy

3.3 Psychodynamic and other therapies

4 Frequency of panic attacks at 2-4 months

4.1 Behaviour therapy

4.2 Cognitive-behaviour therapy

5 Phobic avoidance at 2-4 months

5.1 Behaviour therapy

5.2 Cognitive-behaviour therapy

5.3 Psychodynamic and other therapies

No. of
studies

No. of
partici-
pants

Statistical method

Effect size

3

6

0

10

4

6

0

7

3

4

0

5

4

1

8

4

4

0

153

393

0

560

167

393

0

421

124

297

0

173

135

38

296

138

158

0

Risk Ratio (M-H, Random, 95%
CI)

1.39 [0.96, 2.00]

Risk Ratio (M-H, Random, 95%
CI)

1.07 [0.89, 1.28]

Risk Ratio (M-H, Random, 95%
CI)

0.0 [0.0, 0.0]

Risk Ratio (M-H, Random, 95%
CI)

1.11 [0.95, 1.29]

Risk Ratio (M-H, Random, 95%
CI)

1.22 [0.75, 2.00]

Risk Ratio (M-H, Random, 95%
CI)

1.08 [0.91, 1.29]

Risk Ratio (M-H, Random, 95%
CI)

0.0 [0.0, 0.0]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.36 [-0.57, -0.15]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.71 [-1.08, -0.33]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.21 [-0.46, 0.04]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.0 [0.0, 0.0]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.05 [-0.36, 0.46]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.10 [-0.43, 0.63]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.15 [-0.79, 0.49]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.38 [-0.65, -0.12]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.55 [-1.10, 0.00]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.23 [-0.56, 0.09]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.0 [0.0, 0.0]

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

245

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

No. of
studies

No. of
partici-
pants

Statistical method

Effect size

Outcome or subgroup title

6 General anxiety at 2-4 months

6.1 Behaviour therapy

6.2 Cognitive-behaviour therapy

6.3 Psychodynamic and other therapies

7 Depression at 2-4 months

7.1 Behaviour therapy

7.2 Cognitive-behaviour therapy

7.3 Psychodynamic and other therapies

8 Social functioning at 2-4 months

8.1 Behaviour therapy

8.2 Cognitive-behaviour therapy

8

4

4

0

5

4

1

0

4

1

3

9 Dropouts for any reason within 2-4 months

10

9.1 Behaviour therapy

9.2 Cognitive-behaviour therapy

9.3 Psychodynamic and other therapies

10 Dropouts due to side effects within 2-4
months

10.1 Behaviour therapy

10.2 Cognitive-behaviour therapy

4

6

0

7

2

5

296

138

158

0

166

138

28

0

188

68

120

560

167

393

0

434

69

365

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.37 [-0.61, -0.12]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.66 [-1.01, -0.30]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.12 [-0.45, 0.20]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.0 [0.0, 0.0]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.53 [-0.86, -0.20]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.62 [-0.99, -0.25]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.16 [-0.90, 0.58]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.0 [0.0, 0.0]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.13 [-0.39, 0.66]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.78 [0.28, 1.27]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.14 [-0.52, 0.24]

Risk Ratio (M-H, Random, 95%
CI)

1.16 [0.84, 1.61]

Risk Ratio (M-H, Random, 95%
CI)

1.21 [0.62, 2.35]

Risk Ratio (M-H, Random, 95%
CI)

1.15 [0.79, 1.67]

Risk Ratio (M-H, Random, 95%
CI)

0.0 [0.0, 0.0]

Risk Ratio (M-H, Random, 95%
CI)

4.18 [1.53, 11.45]

Risk Ratio (M-H, Random, 95%
CI)

5.41 [0.59, 49.42]

Risk Ratio (M-H, Random, 95%
CI)

3.91 [1.26, 12.12]

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

246

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of
studies

No. of
partici-
pants

Statistical method

Effect size

11 Response/remission on continued treat-
ment

11.1 Behaviour therapy

11.2 Cognitive-behaviour therapy

12 Global/Avoidance/Panic on continued
treatment

12.1 Behaviour therapy

12.2 Cognitive-behaviour therapy

13 Dropouts for any reason on continued
treatment

13.1 Behaviour therapy

13.2 Cognitive-behaviour therapy

14 Response/remission 6-24 months after
treatment discontinuation

14.1 Behaviour therapy

14.2 Cognitive-behaviour therapy

15 Global/Avoidance/Panic 6-24 months af-
ter treatment discontinuation

15.1 Behaviour therapy

15.2 Cognitive-behaviour therapy

3

1

2

2

0

2

3

1

2

8

3

5

4

2

2

289

84

205

205

0

205

243

38

205

485

146

339

248

54

194

Risk Ratio (M-H, Random, 95%
CI)

1.16 [0.91, 1.49]

Risk Ratio (M-H, Random, 95%
CI)

0.95 [0.57, 1.60]

Risk Ratio (M-H, Random, 95%
CI)

1.23 [0.93, 1.63]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.41 [-0.71, -0.12]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.0 [0.0, 0.0]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.41 [-0.71, -0.12]

Risk Ratio (M-H, Random, 95%
CI)

0.78 [0.28, 2.16]

Risk Ratio (M-H, Random, 95%
CI)

3.00 [0.13, 69.31]

Risk Ratio (M-H, Random, 95%
CI)

0.66 [0.22, 1.95]

Risk Ratio (M-H, Random, 95%
CI)

0.95 [0.77, 1.18]

Risk Ratio (M-H, Random, 95%
CI)

1.01 [0.73, 1.41]

Risk Ratio (M-H, Random, 95%
CI)

0.91 [0.69, 1.21]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.16 [-0.11, 0.43]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.01 [-0.56, 0.58]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.21 [-0.10, 0.52]

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

247

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 17.1.   Comparison 17 SENSITIVITY2: demonstrated effectiveness: Psychotherapy
+Antidepressant vs Psychotherapy alone or +Placebo, Outcome 1 Response at 2-4 months.

PT+AD

n/N

PT+placebo

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

Study or subgroup

17.1.1 Behaviour therapy

de Beurs 1995i

de Beurs 1995ii

Zitrin 1983

Subtotal (95% CI)

8/12

9/12

25/43

67

Total events: 42 (PT+AD), 40 (PT+placebo)

Heterogeneity: Tau2=0.03; Chi2=2.87, df=2(P=0.24); I2=30.39%

Test for overall effect: Z=1.76(P=0.08)

17.1.2 Cognitive-behaviour therapy

Barlow 2000i

Barlow 2000ii

Kampman 2002

Loerch 1999

Sharp 1996i

Sharp 1996ii

Subtotal (95% CI)

19/32

20/33

12/22

11/14

13/19

13/19

139

Total events: 88 (PT+AD), 144 (PT+placebo)

Heterogeneity: Tau2=0.01; Chi2=6.41, df=5(P=0.27); I2=22.01%

Test for overall effect: Z=0.7(P=0.48)

17.1.3 Psychodynamic and other therapies

12/24

7/21

21/41

86

36/63

37/77

5/21

12/14

28/36

26/43

254

7.35%

5.3%

12.74%

25.39%

14.36%

14.24%

3.6%

14.9%

14.66%

12.84%

74.61%

1.33[0.76,2.35]

2.25[1.13,4.47]

1.14[0.77,1.68]

1.39[0.96,2]

1.04[0.73,1.49]

1.26[0.88,1.81]

2.29[0.97,5.39]

0.92[0.65,1.3]

0.88[0.62,1.25]

1.13[0.77,1.67]

1.07[0.89,1.28]

Subtotal (95% CI)

0

0

Not estimable

Total events: 0 (PT+AD), 0 (PT+placebo)

Heterogeneity: Not applicable

Test for overall effect: Not applicable

Total (95% CI)

206

340

100%

1.14[0.96,1.35]

Total events: 130 (PT+AD), 184 (PT+placebo)

Heterogeneity: Tau2=0.02; Chi2=11.29, df=8(P=0.19); I2=29.15%

Test for overall effect: Z=1.53(P=0.13)

Test for subgroup differences: Not applicable

Favours PT+placebo

0.1

0.2

0.5

1

2

5

10

Favours PT+AD

Analysis 17.2.   Comparison 17 SENSITIVITY2: demonstrated effectiveness: Psychotherapy
+Antidepressant vs Psychotherapy alone or +Placebo, Outcome 2 Remission at 2-4 months.

Study or subgroup

17.2.1 Behaviour therapy

de Beurs 1995i

de Beurs 1995ii

Fava 1997

Zitrin 1983

Subtotal (95% CI)

PT+AD

n/N

PT+placebo

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

8/12

8/12

1/7

13/43

74

14/24

12/21

4/7

5/41

93

8.71%

8.04%

0.65%

2.71%

20.12%

1.14[0.68,1.93]

1.17[0.68,2.01]

0.25[0.04,1.71]

2.48[0.97,6.34]

1.22[0.75,2]

Total events: 30 (PT+AD), 35 (PT+placebo)

Heterogeneity: Tau2=0.09; Chi2=4.94, df=3(P=0.18); I2=39.29%

Favours PT+placebo

0.1

0.2

0.5

1

2

5

10

Favours PT+AD

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

248

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

PT+AD

n/N

PT+placebo

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

Test for overall effect: Z=0.8(P=0.42)

17.2.2 Cognitive-behaviour therapy

Barlow 2000i

Barlow 2000ii

Kampman 2002

Loerch 1999

Sharp 1996i

Sharp 1996ii

Subtotal (95% CI)

20/33

19/32

14/22

9/14

12/19

12/19

139

39/63

42/77

9/21

8/14

25/36

21/43

254

Total events: 86 (PT+AD), 144 (PT+placebo)

Heterogeneity: Tau2=0; Chi2=2.77, df=5(P=0.73); I2=0%

Test for overall effect: Z=0.89(P=0.37)

17.2.3 Psychodynamic and other therapies

21.12%

19.33%

6.96%

6.67%

14.5%

11.3%

79.88%

0.98[0.7,1.37]

1.09[0.77,1.55]

1.48[0.83,2.67]

1.13[0.62,2.05]

0.91[0.61,1.37]

1.29[0.82,2.05]

1.08[0.91,1.29]

Subtotal (95% CI)

0

0

Not estimable

Total events: 0 (PT+AD), 0 (PT+placebo)

Heterogeneity: Not applicable

Test for overall effect: Not applicable

Total (95% CI)

213

347

100%

1.11[0.95,1.29]

Total events: 116 (PT+AD), 179 (PT+placebo)

Heterogeneity: Tau2=0; Chi2=8.08, df=9(P=0.53); I2=0%

Test for overall effect: Z=1.3(P=0.19)

Test for subgroup differences: Not applicable

Favours PT+placebo

0.1

0.2

0.5

1

2

5

10

Favours PT+AD

Analysis 17.3.   Comparison 17 SENSITIVITY2: demonstrated effectiveness: Psychotherapy
+Antidepressant vs Psychotherapy alone or +Placebo, Outcome 3 Global severity at 2-4 months.

Study or subgroup

PT+AD

PT+placebo

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

17.3.1 Behaviour therapy

de Beurs 1995i

de Beurs 1995ii

Zitrin 1983

Subtotal ***

1.6 (0.8)

1.6 (0.8)

3.2 (1)

10

9

34

53

Heterogeneity: Tau2=0; Chi2=0.4, df=2(P=0.82); I2=0%

Test for overall effect: Z=3.72(P=0)

17.3.2 Cognitive-behaviour therapy

Barlow 2000i

Barlow 2000ii

Sharp 1996i

Sharp 1996ii

Subtotal ***

0.9 (0.7)

0.9 (0.7)

1.7 (1.1)

1.7 (1.1)

33

32

15

14

94

Heterogeneity: Tau2=0; Chi2=1.02, df=3(P=0.8); I2=0%

Test for overall effect: Z=1.68(P=0.09)

2.1 (1.1)

2.3 (1.2)

4 (1)

1 (0.7)

1.1 (0.7)

2 (1.3)

1.7 (1)

19

18

34

71

63

77

33

30

203

7.09%

6.4%

17.14%

30.63%

23.33%

24.06%

11.37%

10.61%

69.37%

-0.52[-1.3,0.26]

-0.64[-1.46,0.19]

-0.81[-1.3,-0.31]

-0.71[-1.08,-0.33]

-0.15[-0.57,0.27]

-0.35[-0.76,0.07]

-0.24[-0.86,0.37]

0.02[-0.61,0.65]

-0.21[-0.46,0.04]

Favours treatment

-4

-2

0

2

4

Favours control

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

249

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

PT+AD

PT+placebo

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

17.3.3 Psychodynamic and other therapies

Subtotal ***

0

0

Heterogeneity: Not applicable

Test for overall effect: Not applicable

Not estimable

Total ***

147

274

100%

-0.36[-0.57,-0.15]

Heterogeneity: Tau2=0; Chi2=6.19, df=6(P=0.4); I2=3.03%

Test for overall effect: Z=3.39(P=0)

Test for subgroup differences: Chi2=4.77, df=1 (P=0.03), I2=79.03%

Favours treatment

-4

-2

0

2

4

Favours control

Analysis 17.4.   Comparison 17 SENSITIVITY2: demonstrated effectiveness: Psychotherapy+Antidepressant
vs Psychotherapy alone or +Placebo, Outcome 4 Frequency of panic attacks at 2-4 months.

Study or subgroup

PT+AD

PT+placebo

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

0.5 (1.6)

1.7 (3.5)

2 (1)

5.4 (1.2)

2.3 (0.7)

17.4.1 Behaviour therapy

de Beurs 1995i

de Beurs 1995ii

Fava 1997

Zitrin 1983

Subtotal ***

0.2 (0.5)

0.2 (0.5)

2.7 (0.8)

6 (1.2)

9

9

7

34

59

Heterogeneity: Tau2=0.14; Chi2=5.78, df=3(P=0.12); I2=48.06%

Test for overall effect: Z=0.38(P=0.7)

17.4.2 Cognitive-behaviour therapy

Kampman 2002

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=0.46(P=0.64)

Total ***

19

19

78

2.2 (0.6)

Heterogeneity: Tau2=0.08; Chi2=6.51, df=4(P=0.16); I2=38.58%

Test for overall effect: Z=0.25(P=0.81)

Test for subgroup differences: Chi2=0.74, df=1 (P=0.39), I2=0%

19

16

7

34

76

19

19

95

17.81%

16.82%

11.2%

30.77%

76.6%

-0.25[-1.04,0.55]

-0.51[-1.34,0.32]

0.72[-0.37,1.82]

0.44[-0.04,0.92]

0.1[-0.43,0.63]

23.4%

23.4%

-0.15[-0.79,0.49]

-0.15[-0.79,0.49]

100%

0.05[-0.36,0.46]

Favours treatment

-4

-2

0

2

4

Favours control

Analysis 17.5.   Comparison 17 SENSITIVITY2: demonstrated effectiveness: Psychotherapy
+Antidepressant vs Psychotherapy alone or +Placebo, Outcome 5 Phobic avoidance at 2-4 months.

Study or subgroup

PT+AD

PT+placebo

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

17.5.1 Behaviour therapy

de Beurs 1995i

de Beurs 1995ii

Fava 1997

Zitrin 1983

10

9

7

34

4.1 (2)

4.1 (2)

19.6 (4.7)

2.7 (1.4)

19

18

7

34

5.7 (1.3)

6.1 (1.9)

15.6 (8.4)

3.4 (1.4)

9.43%

8.74%

5.71%

21.64%

-0.99[-1.8,-0.17]

-0.99[-1.84,-0.14]

0.55[-0.52,1.63]

-0.51[-0.99,-0.02]

Favours treatment

-4

-2

0

2

4

Favours control

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

250

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

PT+AD

PT+placebo

Std. Mean Difference

Weight

Std. Mean Difference

Subtotal ***

Mean(SD)

N

60

N

78

Heterogeneity: Tau2=0.16; Chi2=6.17, df=3(P=0.1); I2=51.4%

Test for overall effect: Z=1.94(P=0.05)

17.5.2 Cognitive-behaviour therapy

Kampman 2002

Loerch 1999

Sharp 1996i

Sharp 1996ii

Subtotal ***

1.8 (0.5)

7 (8.3)

4.7 (7.8)

4.7 (7.8)

19

14

15

14

62

Heterogeneity: Tau2=0; Chi2=0.43, df=3(P=0.93); I2=0%

Test for overall effect: Z=1.4(P=0.16)

17.5.3 Psychodynamic and other therapies

Subtotal ***

0

Heterogeneity: Not applicable

Test for overall effect: Not applicable

19

14

33

30

96

0

Total ***

122

174

Heterogeneity: Tau2=0.03; Chi2=8.43, df=7(P=0.3); I2=16.97%

Test for overall effect: Z=2.82(P=0)

Test for subgroup differences: Chi2=1.82, df=1 (P=0.18), I2=45.16%

Mean(SD)

Random, 95% CI

Random, 95% CI

45.52%

-0.55[-1.1,0]

2 (0.6)

9.1 (6.3)

7.2 (10.6)

5.1 (5.4)

14.06%

10.96%

15.14%

14.31%

54.48%

-0.35[-1,0.29]

-0.28[-1.03,0.46]

-0.25[-0.86,0.36]

-0.06[-0.7,0.57]

-0.23[-0.56,0.09]

Not estimable

100%

-0.38[-0.65,-0.12]

Favours treatment

-4

-2

0

2

4

Favours control

Analysis 17.6.   Comparison 17 SENSITIVITY2: demonstrated effectiveness: Psychotherapy
+Antidepressant vs Psychotherapy alone or +Placebo, Outcome 6 General anxiety at 2-4 months.

Study or subgroup

PT+AD

PT+placebo

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

17.6.1 Behaviour therapy

de Beurs 1995i

de Beurs 1995ii

Fava 1997

Zitrin 1983

Subtotal ***

2.6 (1.3)

2.6 (1.3)

3.6 (0.5)

21.5 (9.9)

10

9

7

34

60

Heterogeneity: Tau2=0; Chi2=2.07, df=3(P=0.56); I2=0%

Test for overall effect: Z=3.65(P=0)

17.6.2 Cognitive-behaviour therapy

Kampman 2002

Loerch 1999

Sharp 1996i

Sharp 1996ii

Subtotal ***

1.5 (1.7)

11.4 (11.1)

4.8 (5.7)

4.8 (5.7)

19

14

15

14

62

Heterogeneity: Tau2=0; Chi2=0.34, df=3(P=0.95); I2=0%

Test for overall effect: Z=0.73(P=0.47)

17.6.3 Psychodynamic and other therapies

Subtotal ***

0

19

18

7

34

78

19

14

33

30

96

0

3.8 (1.4)

3.9 (1.5)

3.6 (0.5)

27.9 (9.9)

1.7 (1.3)

11.9 (8.4)

6.5 (6.7)

4.9 (4.4)

8.98%

8.21%

5.31%

23.49%

45.99%

14.11%

10.5%

15.19%

14.21%

54.01%

Favours treatment

-4

-2

0

2

4

Favours control

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

-0.87[-1.67,-0.06]

-0.89[-1.73,-0.05]

0[-1.05,1.05]

-0.64[-1.13,-0.15]

-0.66[-1.01,-0.3]

-0.13[-0.77,0.51]

-0.04[-0.78,0.7]

-0.26[-0.87,0.35]

-0.02[-0.65,0.61]

-0.12[-0.45,0.2]

Not estimable

251

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

PT+AD

PT+placebo

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

Heterogeneity: Not applicable

Test for overall effect: Not applicable

Total ***

122

174

Heterogeneity: Tau2=0; Chi2=7.19, df=7(P=0.41); I2=2.67%

Test for overall effect: Z=2.96(P=0)

Test for subgroup differences: Chi2=4.78, df=1 (P=0.03), I2=79.09%

100%

-0.37[-0.61,-0.12]

Favours treatment

-4

-2

0

2

4

Favours control

Analysis 17.7.   Comparison 17 SENSITIVITY2: demonstrated effectiveness: Psychotherapy
+Antidepressant vs Psychotherapy alone or +Placebo, Outcome 7 Depression at 2-4 months.

Study or subgroup

PT+AD

PT+placebo

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

3.5 (1.4)

3.8 (1.5)

1.1 (0.4)

1.6 (0.5)

6.5 (5.2)

17.7.1 Behaviour therapy

de Beurs 1995i

de Beurs 1995ii

Fava 1997

Zitrin 1983

Subtotal ***

2.6 (1)

2.6 (1)

1 (0)

1.3 (0.5)

10

9

7

34

60

Heterogeneity: Tau2=0; Chi2=0.52, df=2(P=0.77); I2=0%

Test for overall effect: Z=3.27(P=0)

17.7.2 Cognitive-behaviour therapy

Loerch 1999

Subtotal ***

5.6 (5.8)

14

14

Heterogeneity: Not applicable

Test for overall effect: Z=0.43(P=0.67)

17.7.3 Psychodynamic and other therapies

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Not applicable

Total ***

0

74

Heterogeneity: Tau2=0; Chi2=1.67, df=3(P=0.64); I2=0%

Test for overall effect: Z=3.12(P=0)

Test for subgroup differences: Chi2=1.16, df=1 (P=0.28), I2=13.48%

19

18

7

34

78

14

14

0

92

17.64%

15.62%

46.85%

80.11%

-0.68[-1.46,0.11]

-0.86[-1.7,-0.02]

Not estimable

-0.51[-1,-0.03]

-0.62[-0.99,-0.25]

19.89%

19.89%

-0.16[-0.9,0.58]

-0.16[-0.9,0.58]

Not estimable

100%

-0.53[-0.86,-0.2]

Favours treatment

-4

-2

0

2

4

Favours control

Analysis 17.8.   Comparison 17 SENSITIVITY2: demonstrated effectiveness: Psychotherapy
+Antidepressant vs Psychotherapy alone or +Placebo, Outcome 8 Social functioning at 2-4 months.

Study or subgroup

PT+AD

PT+placebo

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

17.8.1 Behaviour therapy

Zitrin 1983

34

5.8 (0.9)

34

5.1 (0.9)

28.54%

0.78[0.28,1.27]

Favours treatment

-4

-2

0

2

4

Favours control

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

252

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

PT+AD

PT+placebo

Std. Mean Difference

Weight

Std. Mean Difference

Mean(SD)

N

34

N

34

Mean(SD)

Random, 95% CI

Random, 95% CI

28.54%

0.78[0.28,1.27]

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=3.08(P=0)

17.8.2 Cognitive-behaviour therapy

Loerch 1999

Sharp 1996i

Sharp 1996ii

Subtotal ***

14

15

14

43

2.4 (2.8)

1.4 (2.8)

1.4 (2.8)

14

33

30

77

2.1 (2.2)

2.1 (2.6)

1.9 (2.6)

Heterogeneity: Tau2=0; Chi2=0.63, df=2(P=0.73); I2=0%

Test for overall effect: Z=0.71(P=0.48)

Total ***

77

111

Heterogeneity: Tau2=0.19; Chi2=8.92, df=3(P=0.03); I2=66.35%

Test for overall effect: Z=0.5(P=0.62)

Test for subgroup differences: Chi2=8.29, df=1 (P=0), I2=87.94%

21.76%

25.16%

24.54%

71.46%

0.11[-0.63,0.85]

-0.27[-0.88,0.34]

-0.18[-0.82,0.46]

-0.14[-0.52,0.24]

100%

0.13[-0.39,0.66]

Favours treatment

-4

-2

0

2

4

Favours control

Analysis 17.9.   Comparison 17 SENSITIVITY2: demonstrated effectiveness: Psychotherapy+Antidepressant
vs Psychotherapy alone or +Placebo, Outcome 9 Dropouts for any reason within 2-4 months.

PT+AD

n/N

PT+placebo

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

Study or subgroup

17.9.1 Behaviour therapy

de Beurs 1995i

de Beurs 1995ii

Fava 1997

Zitrin 1983

Subtotal (95% CI)

Total events: 14 (PT+AD), 15 (PT+placebo)

Heterogeneity: Tau2=0; Chi2=0, df=2(P=1); I2=0%

Test for overall effect: Z=0.56(P=0.58)

17.9.2 Cognitive-behaviour therapy

Barlow 2000i

Barlow 2000ii

Kampman 2002

Loerch 1999

Sharp 1996i

Sharp 1996ii

Subtotal (95% CI)

3/12

2/12

0/7

9/43

74

9/33

9/32

3/22

3/14

6/19

5/19

139

5/24

3/21

0/7

7/41

93

18/63

21/77

2/21

1/14

4/36

13/43

254

6.82%

3.97%

13.5%

24.29%

23.12%

24.33%

3.76%

2.34%

8.29%

13.86%

75.71%

1.2[0.34,4.2]

1.17[0.23,6.03]

Not estimable

1.23[0.5,2.99]

1.21[0.62,2.35]

0.95[0.48,1.88]

1.03[0.53,2]

1.43[0.27,7.73]

3[0.35,25.46]

2.84[0.91,8.86]

0.87[0.36,2.1]

1.15[0.79,1.67]

Total events: 35 (PT+AD), 59 (PT+placebo)

Heterogeneity: Tau2=0; Chi2=4.07, df=5(P=0.54); I2=0%

Test for overall effect: Z=0.71(P=0.48)

17.9.3 Psychodynamic and other therapies

Subtotal (95% CI)

0

0

Not estimable

Total events: 0 (PT+AD), 0 (PT+placebo)

Heterogeneity: Not applicable

Favours treatment

0.1

0.2

0.5

1

2

5

10

Favours control

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

253

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

PT+AD

n/N

PT+placebo

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

Test for overall effect: Not applicable

Total (95% CI)

213

347

100%

1.16[0.84,1.61]

Total events: 49 (PT+AD), 74 (PT+placebo)

Heterogeneity: Tau2=0; Chi2=4.08, df=8(P=0.85); I2=0%

Test for overall effect: Z=0.89(P=0.37)

Test for subgroup differences: Not applicable

Favours treatment

0.1

0.2

0.5

1

2

5

10

Favours control

Analysis 17.10.   Comparison 17 SENSITIVITY2: demonstrated effectiveness: Psychotherapy+Antidepressant
vs Psychotherapy alone or +Placebo, Outcome 10 Dropouts due to side effects within 2-4 months.

PT+AD

n/N

PT+placebo

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

Study or subgroup

17.10.1 Behaviour therapy

de Beurs 1995i

de Beurs 1995ii

Subtotal (95% CI)

1/12

1/12

24

Total events: 2 (PT+AD), 0 (PT+placebo)

Heterogeneity: Tau2=0; Chi2=0, df=1(P=0.95); I2=0%

Test for overall effect: Z=1.5(P=0.13)

17.10.2 Cognitive-behaviour therapy

Barlow 2000i

Barlow 2000ii

Kampman 2002

Sharp 1996i

Sharp 1996ii

Subtotal (95% CI)

1/33

1/32

3/22

3/19

2/19

125

Total events: 10 (PT+AD), 2 (PT+placebo)

Heterogeneity: Tau2=0; Chi2=2.71, df=4(P=0.61); I2=0%

Test for overall effect: Z=2.36(P=0.02)

0/24

0/21

45

0/63

0/77

2/21

0/36

0/43

240

10.37%

10.39%

20.77%

5.77[0.25,131.92]

5.08[0.22,115.7]

5.41[0.59,49.42]

10.09%

10.08%

35.73%

11.97%

11.36%

79.23%

5.65[0.24,134.91]

7.09[0.3,169.6]

1.43[0.27,7.73]

12.95[0.7,238.39]

11[0.55,218.74]

3.91[1.26,12.12]

Total (95% CI)

149

285

100%

4.18[1.53,11.45]

Total events: 12 (PT+AD), 2 (PT+placebo)

Heterogeneity: Tau2=0; Chi2=2.77, df=6(P=0.84); I2=0%

Test for overall effect: Z=2.78(P=0.01)

Test for subgroup differences: Not applicable

Favours treatment

0.1

0.2

0.5

1

2

5

10

Favours control

Analysis 17.11.   Comparison 17 SENSITIVITY2: demonstrated effectiveness: Psychotherapy+Antidepressant
vs Psychotherapy alone or +Placebo, Outcome 11 Response/remission on continued treatment.

Study or subgroup

17.11.1 Behaviour therapy

PT+AD

n/N

PT+placebo

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

Zitrin 1983

17/43

17/41

22.22%

0.95[0.57,1.6]

Favours PT+placebo

0.1

0.2

0.5

1

2

5

10

Favours PT+AD

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

254

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

PT+AD

n/N

PT+placebo

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

Subtotal (95% CI)

43

41

22.22%

0.95[0.57,1.6]

Total events: 17 (PT+AD), 17 (PT+placebo)

Heterogeneity: Tau2=0; Chi2=0, df=0(P<0.0001); I2=100%

Test for overall effect: Z=0.18(P=0.86)

17.11.2 Cognitive-behaviour therapy

Barlow 2000i

Barlow 2000ii

Subtotal (95% CI)

19/33

18/32

65

32/63

32/77

140

Total events: 37 (PT+AD), 64 (PT+placebo)

Heterogeneity: Tau2=0; Chi2=0.39, df=1(P=0.53); I2=0%

Test for overall effect: Z=1.48(P=0.14)

41.25%

36.54%

77.78%

1.13[0.77,1.66]

1.35[0.9,2.03]

1.23[0.93,1.63]

Total (95% CI)

108

181

100%

1.16[0.91,1.49]

Total events: 54 (PT+AD), 81 (PT+placebo)

Heterogeneity: Tau2=0; Chi2=1.13, df=2(P=0.57); I2=0%

Test for overall effect: Z=1.22(P=0.22)

Test for subgroup differences: Not applicable

Favours PT+placebo

0.1

0.2

0.5

1

2

5

10

Favours PT+AD

Analysis 17.12.   Comparison 17 SENSITIVITY2: demonstrated effectiveness: Psychotherapy+Antidepressant
vs Psychotherapy alone or +Placebo, Outcome 12 Global/Avoidance/Panic on continued treatment.

Study or subgroup

PT+AD

PT+placebo

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

17.12.1 Behaviour therapy

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Not applicable

17.12.2 Cognitive-behaviour therapy

Barlow 2000i

Barlow 2000ii

Subtotal ***

0

33

32

65

0

63

77

140

0.8 (0.9)

0.8 (0.9)

Heterogeneity: Tau2=0; Chi2=0.1, df=1(P=0.75); I2=0%

Test for overall effect: Z=2.73(P=0.01)

Not estimable

1.1 (0.8)

1.2 (0.9)

49.11%

50.89%

100%

-0.37[-0.79,0.06]

-0.46[-0.88,-0.04]

-0.41[-0.71,-0.12]

Total ***

65

140

100%

-0.41[-0.71,-0.12]

Heterogeneity: Tau2=0; Chi2=0.1, df=1(P=0.75); I2=0%

Test for overall effect: Z=2.73(P=0.01)

Test for subgroup differences: Not applicable

Favours treatment

-4

-2

0

2

4

Favours control

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

255

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 17.13.   Comparison 17 SENSITIVITY2: demonstrated effectiveness: Psychotherapy+Antidepressant
vs Psychotherapy alone or +Placebo, Outcome 13 Dropouts for any reason on continued treatment.

Study or subgroup

17.13.1 Behaviour therapy

de Beurs 1995

Subtotal (95% CI)

Total events: 1 (PT+AD), 0 (PT+placebo)

Heterogeneity: Not applicable

Test for overall effect: Z=0.69(P=0.49)

17.13.2 Cognitive-behaviour therapy

Barlow 2000i

Barlow 2000ii

Subtotal (95% CI)

PT+AD

n/N

PT+placebo

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

1/19

19

2/33

2/32

65

0/19

19

6/63

7/77

140

10.61%

10.61%

3[0.13,69.31]

3[0.13,69.31]

43.89%

45.5%

89.39%

0.64[0.14,2.98]

0.69[0.15,3.13]

0.66[0.22,1.95]

Total events: 4 (PT+AD), 13 (PT+placebo)

Heterogeneity: Tau2=0; Chi2=0, df=1(P=0.94); I2=0%

Test for overall effect: Z=0.75(P=0.45)

Total (95% CI)

84

159

100%

0.78[0.28,2.16]

Total events: 5 (PT+AD), 13 (PT+placebo)

Heterogeneity: Tau2=0; Chi2=0.8, df=2(P=0.67); I2=0%

Test for overall effect: Z=0.48(P=0.63)

Test for subgroup differences: Not applicable

Favours treatment

0.1

0.2

0.5

1

2

5

10

Favours control

Analysis 17.14.   Comparison 17 SENSITIVITY2: demonstrated effectiveness: Psychotherapy+Antidepressant vs
Psychotherapy alone or +Placebo, Outcome 14 Response/remission 6-24 months after treatment discontinuation.

PT+AD

n/N

PT+placebo

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

Study or subgroup

17.14.1 Behaviour therapy

de Beurs 1995

Fava 1997

Zitrin 1983

Subtotal (95% CI)

12/24

2/7

23/43

74

Total events: 37 (PT+AD), 36 (PT+placebo)

Heterogeneity: Tau2=0; Chi2=1.22, df=2(P=0.54); I2=0%

Test for overall effect: Z=0.09(P=0.93)

17.14.2 Cognitive-behaviour therapy

Barlow 2000i

Barlow 2000ii

Loerch 1999

Sharp 1996i

Sharp 1996ii

Subtotal (95% CI)

8/30

8/29

9/14

8/19

8/19

111

Total events: 41 (PT+AD), 90 (PT+placebo)

Heterogeneity: Tau2=0; Chi2=1.79, df=4(P=0.77); I2=0%

Test for overall effect: Z=0.66(P=0.51)

12/24

4/7

20/41

72

25/62

24/73

9/14

17/36

15/43

228

14.29%

2.56%

25.98%

42.84%

10.31%

10.05%

15%

11.52%

10.29%

57.16%

1[0.57,1.76]

0.5[0.13,1.9]

1.1[0.72,1.67]

1.01[0.73,1.41]

0.66[0.34,1.29]

0.84[0.43,1.65]

1[0.58,1.74]

0.89[0.47,1.67]

1.21[0.62,2.35]

0.91[0.69,1.21]

Favours PT+placebo

0.1

0.2

0.5

1

2

5

10

Favours PT+AD

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

256

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

PT+AD

n/N

PT+placebo

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

Total (95% CI)

185

300

100%

0.95[0.77,1.18]

Total events: 78 (PT+AD), 126 (PT+placebo)

Heterogeneity: Tau2=0; Chi2=3.27, df=7(P=0.86); I2=0%

Test for overall effect: Z=0.44(P=0.66)

Test for subgroup differences: Not applicable

Favours PT+placebo

0.1

0.2

0.5

1

2

5

10

Favours PT+AD

Analysis 17.15.   Comparison 17 SENSITIVITY2: demonstrated effectiveness:
Psychotherapy+Antidepressant vs Psychotherapy alone or +Placebo, Outcome
15 Global/Avoidance/Panic 6-24 months after treatment discontinuation.

Study or subgroup

PT+AD

PT+placebo

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

17.15.1 Behaviour therapy

de Beurs 1995i

de Beurs 1995ii

Subtotal ***

3.3 (2.4)

3.3 (2.4)

9

9

18

Heterogeneity: Tau2=0; Chi2=0.05, df=1(P=0.83); I2=0%

Test for overall effect: Z=0.04(P=0.97)

17.15.2 Cognitive-behaviour therapy

Barlow 2000i

Barlow 2000ii

Subtotal ***

1.5 (0.9)

1.5 (0.9)

30

29

59

Heterogeneity: Tau2=0; Chi2=0.27, df=1(P=0.6); I2=0%

Test for overall effect: Z=1.34(P=0.18)

3.2 (2.7)

3.5 (2.2)

1.2 (0.9)

1.3 (0.9)

19

17

36

62

73

135

11.58%

11.16%

22.73%

0.07[-0.72,0.86]

-0.05[-0.86,0.76]

0.01[-0.56,0.58]

37.97%

39.3%

77.27%

0.29[-0.14,0.73]

0.13[-0.3,0.56]

0.21[-0.1,0.52]

Total ***

77

171

100%

0.16[-0.11,0.43]

Heterogeneity: Tau2=0; Chi2=0.69, df=3(P=0.88); I2=0%

Test for overall effect: Z=1.19(P=0.23)

Test for subgroup differences: Chi2=0.37, df=1 (P=0.54), I2=0%

Favours treatment

-4

-2

0

2

4

Favours control

Comparison 18.   SENSITIVITY3: operationalised criteria: Psychotherapy+Antidepressant vs Antidepressant alone

Outcome or subgroup title

1 Response at 2-4 months

1.1 Behaviour therapy

1.2 Cognitive-behaviour therapy

No. of
studies

No. of
partici-
pants

Statistical method

Effect size

8

1

5

501

25

336

Risk Ratio (M-H, Random,
95% CI)

1.38 [1.03, 1.85]

Risk Ratio (M-H, Random,
95% CI)

4.62 [0.63, 34.05]

Risk Ratio (M-H, Random,
95% CI)

1.46 [1.05, 2.02]

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

257

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of
studies

No. of
partici-
pants

Statistical method

Effect size

1.3 Psychodynamic psychotherapy and others

2 Remission at 2-4 months

2.1 Behaviour therapy

2.2 Cognitive-behaviour therapy

2.3 Psychodynamic psychotherapy and others

3 Global severity at 2-4 months

3.1 Behaviour therapy

3.2 Cognitive-behaviour therapy

3.3 Psychodynamic psychotherapy and others

4 Frequency of panic attacks at 2-4 months

4.1 Behaviour therapy

4.2 Cognitive-behaviour therapy

4.3 Psychodynamic psychotherapy and others

5 Phobic avoidance at 2-4 months

5.1 Behaviour therapy

5.2 Cognitive-behaviour therapy

5.3 Psychodynamic psychotherapy and others

6 General anxiety at 2-4 months

2

5

0

3

2

3

0

2

1

5

1

3

2

5

1

3

2

5

140

392

0

252

140

246

0

206

40

237

20

125

92

233

20

121

92

266

Risk Ratio (M-H, Random,
95% CI)

1.16 [0.61, 2.20]

Risk Ratio (M-H, Random,
95% CI)

1.17 [0.82, 1.67]

Risk Ratio (M-H, Random,
95% CI)

0.0 [0.0, 0.0]

Risk Ratio (M-H, Random,
95% CI)

1.40 [0.92, 2.14]

Risk Ratio (M-H, Random,
95% CI)

0.86 [0.28, 2.61]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.36 [-0.61, -0.10]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.0 [0.0, 0.0]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.30 [-0.57, -0.02]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.69 [-1.33, -0.05]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.28 [-0.84, 0.28]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.14 [-1.01, 0.74]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.46 [-1.42, 0.50]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.03 [-0.53, 0.59]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.15 [-0.74, 0.44]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.99 [-1.93, -0.05]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.03 [-0.93, 0.87]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.01 [-1.15, 1.13]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.49 [-1.10, 0.12]

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

258

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

6.1 Behaviour therapy

6.2 Cognitive-behaviour therapy

6.3 Psychodynamic psychotherapy and others

7 Depression at 2-4 months

7.1 Behaviour therapy

7.2 Cognitive-behaviour therapy

7.3 Psychodynamic psychotherapy and others

8 Social functioning at 2-4 months

8.1 Behavour therapy

8.2 Cognitive-behaviour therapy

8.3 Psychodynamic psychotherapy and others

9 Dropouts for any reason within 2-4 months

9.1 Behaviour therapy

9.2 Cognitive-behaviour therapy

9.3 Psychodynamic psychotherapy and others

10 Dropouts due to side effects within 2-4
months

10.1 Behaviour therapy

10.2 Cognitive-behaviour therapy

No. of
studies

No. of
partici-
pants

Statistical method

Effect size

0

4

2

5

1

3

1

3

0

2

1

7

1

5

1

5

1

3

0

174

92

163

20

103

40

128

0

88

40

401

25

336

40

327

25

262

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.0 [0.0, 0.0]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.51 [-1.20, 0.18]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.45 [-2.12, 1.22]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.61 [-0.93, -0.29]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.12 [-0.99, 0.76]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.65 [-1.10, -0.20]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.79 [-1.44, -0.14]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.66 [-1.12, -0.20]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.0 [0.0, 0.0]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.63 [-1.39, 0.12]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.81 [-1.46, -0.16]

Risk Ratio (M-H, Random,
95% CI)

0.80 [0.58, 1.11]

Risk Ratio (M-H, Random,
95% CI)

1.38 [0.28, 6.91]

Risk Ratio (M-H, Random,
95% CI)

0.77 [0.55, 1.08]

Risk Ratio (M-H, Random,
95% CI)

3.00 [0.13, 69.52]

Risk Ratio (M-H, Random,
95% CI)

0.99 [0.44, 2.24]

Risk Ratio (M-H, Random,
95% CI)

1.38 [0.28, 6.91]

Risk Ratio (M-H, Random,
95% CI)

0.81 [0.25, 2.68]

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

259

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of
studies

No. of
partici-
pants

Statistical method

Effect size

10.3 Psychodynamic psychotherapy and others

1

11 Response/remission on continued treat-
ment

11.1 Behaviour therapy

11.2 Cognitive-behaviour therapy

11.3 Psychdynamic psychotherapy and others

12 Global/Avoidance/Panic on continued treat-
ment

12.1 Behaviour therapy

12.2 Cognitive-behaviour therapy

4

1

1

2

4

1

1

12.3 Psychodynamic psychotherapy and others

2

13 Dropouts for any reason on continued treat-
ment

13.1 Behaviour therapy

13.2 Cognitive-behaviour therapy

3

1

1

13.3 Psychodynamic psychotherapy and others

1

16 Response/remission 6-24 months after
treatment discontinuation

16.1 Behaviour therapy

16.2 Cognitive-behaviour therapy

4

0

3

16.3 Psychodynamic psychotherapy and others

1

17 Global/Avoidance/Panic 6-24 months after
treatment discontinuation

2

40

286

25

148

113

258

20

148

90

208

20

148

40

280

0

240

40

176

Risk Ratio (M-H, Random,
95% CI)

3.00 [0.13, 69.52]

Risk Ratio (M-H, Random,
95% CI)

1.26 [0.59, 2.67]

Risk Ratio (M-H, Random,
95% CI)

3.23 [0.83, 12.61]

Risk Ratio (M-H, Random,
95% CI)

1.52 [1.07, 2.16]

Risk Ratio (M-H, Random,
95% CI)

0.67 [0.44, 1.02]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.45 [-1.04, 0.15]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-1.23 [-2.20, -0.26]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.41 [-0.74, -0.09]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.20 [-1.45, 1.04]

Risk Ratio (M-H, Random,
95% CI)

0.71 [0.27, 1.90]

Risk Ratio (M-H, Random,
95% CI)

1.0 [0.07, 13.87]

Risk Ratio (M-H, Random,
95% CI)

0.73 [0.22, 2.39]

Risk Ratio (M-H, Random,
95% CI)

0.5 [0.05, 5.08]

Risk Ratio (M-H, Random,
95% CI)

1.68 [1.19, 2.38]

Risk Ratio (M-H, Random,
95% CI)

0.0 [0.0, 0.0]

Risk Ratio (M-H, Random,
95% CI)

1.46 [1.00, 2.11]

Risk Ratio (M-H, Random,
95% CI)

3.2 [1.45, 7.05]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.58 [-1.78, 0.63]

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

260

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of
studies

No. of
partici-
pants

Statistical method

Effect size

17.1 Behaviour therapy

17.2 Cognitive-behaviour therapy

0

1

17.3 Psychodynamic psychotherapy and others

1

0

136

40

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.0 [0.0, 0.0]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.0 [-0.34, 0.34]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-1.23 [-1.91, -0.55]

Analysis 18.1.   Comparison 18 SENSITIVITY3: operationalised criteria: Psychotherapy
+Antidepressant vs Antidepressant alone, Outcome 1 Response at 2-4 months.

Study or subgroup

PT+AD

n/N

AD

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

5/13

13

1/12

12

1.96%

1.96%

4.62[0.63,34.05]

4.62[0.63,34.05]

18.1.1 Behaviour therapy

Telch 1985

Subtotal (95% CI)

Total events: 5 (PT+AD), 1 (AD)

Heterogeneity: Not applicable

Test for overall effect: Z=1.5(P=0.13)

18.1.2 Cognitive-behaviour therapy

Azhar 2000

Barlow 2000

Loerch 1999

Sharp 1996

Spinhoven 1996

Subtotal (95% CI)

14/22

39/65

11/14

26/38

4/20

159

Total events: 94 (PT+AD), 74 (AD)

Heterogeneity: Tau2=0.05; Chi2=6.97, df=4(P=0.14); I2=42.64%

Test for overall effect: Z=2.26(P=0.02)

18.1.3 Psychodynamic psychotherapy and others

Berger 2004

Wiborg 1996

Subtotal (95% CI)

29/50

18/20

70

Total events: 47 (PT+AD), 45 (AD)

Heterogeneity: Tau2=0.18; Chi2=6.06, df=1(P=0.01); I2=83.49%

Test for overall effect: Z=0.46(P=0.65)

5/22

38/83

5/16

21/36

5/20

177

34/50

11/20

70

8.29%

20.01%

9.1%

18.74%

5.07%

61.22%

2.8[1.22,6.44]

1.31[0.96,1.78]

2.51[1.16,5.47]

1.17[0.83,1.67]

0.8[0.25,2.55]

1.46[1.05,2.02]

20.13%

16.69%

36.82%

0.85[0.63,1.15]

1.64[1.07,2.5]

1.16[0.61,2.2]

Total (95% CI)

242

259

100%

1.38[1.03,1.85]

Total events: 146 (PT+AD), 120 (AD)

Heterogeneity: Tau2=0.09; Chi2=17.18, df=7(P=0.02); I2=59.25%

Test for overall effect: Z=2.17(P=0.03)

Test for subgroup differences: Not applicable

Favours AD

0.1

0.2

0.5

1

2

5

10

Favours PT+AD

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

261

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 18.2.   Comparison 18 SENSITIVITY3: operationalised criteria: Psychotherapy
+Antidepressant vs Antidepressant alone, Outcome 2 Remission at 2-4 months.

Study or subgroup

PT+AD

n/N

AD

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

0

0

Not estimable

18.2.1 Behaviour therapy

Subtotal (95% CI)

Total events: 0 (PT+AD), 0 (AD)

Heterogeneity: Not applicable

Test for overall effect: Not applicable

18.2.2 Cognitive-behaviour therapy

Barlow 2000

Loerch 1999

Sharp 1996

Subtotal (95% CI)

Total events: 75 (PT+AD), 62 (AD)

42/65

9/14

24/38

117

Heterogeneity: Tau2=0.07; Chi2=4.73, df=2(P=0.09); I2=57.73%

Test for overall effect: Z=1.56(P=0.12)

18.2.3 Psychodynamic psychotherapy and others

Berger 2004

Wiborg 1996

Subtotal (95% CI)

14/50

20/20

70

Total events: 34 (PT+AD), 41 (AD)

Heterogeneity: Tau2=0.6; Chi2=14.64, df=1(P=0); I2=93.17%

Test for overall effect: Z=0.27(P=0.79)

40/83

2/16

20/36

135

26/50

15/20

70

25.89%

5.71%

23%

54.61%

1.34[1.01,1.79]

5.14[1.33,19.92]

1.14[0.78,1.66]

1.4[0.92,2.14]

18.82%

26.57%

45.39%

0.54[0.32,0.9]

1.32[1.02,1.72]

0.86[0.28,2.61]

Total (95% CI)

187

205

100%

1.17[0.82,1.67]

Total events: 109 (PT+AD), 103 (AD)

Heterogeneity: Tau2=0.11; Chi2=15.05, df=4(P=0); I2=73.43%

Test for overall effect: Z=0.86(P=0.39)

Test for subgroup differences: Not applicable

Favours AD

0.1

0.2

0.5

1

2

5

10

Favours PT+AD

Analysis 18.3.   Comparison 18 SENSITIVITY3: operationalised criteria: Psychotherapy
+Antidepressant vs Antidepressant alone, Outcome 3 Global severity at 2-4 months.

Study or subgroup

Treatment

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

18.3.1 Behaviour therapy

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Not applicable

18.3.2 Cognitive-behaviour therapy

Barlow 2000

Sharp 1996

Subtotal ***

0

65

29

94

0

83

29

112

0.9 (0.7)

1.7 (1.1)

Heterogeneity: Tau2=0; Chi2=0.68, df=1(P=0.41); I2=0%

Test for overall effect: Z=2.1(P=0.04)

Not estimable

1.1 (0.8)

2.3 (1.2)

60.71%

23.56%

84.27%

-0.22[-0.55,0.1]

-0.48[-1.01,0.04]

-0.3[-0.57,-0.02]

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

262

Favours treatment

-4

-2

0

2

4

Favours control

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Treatment

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

18.3.3 Psychodynamic psychotherapy and others

Wiborg 1996

Subtotal ***

20

20

1.4 (0.5)

20

20

2 (1.1)

Heterogeneity: Not applicable

Test for overall effect: Z=2.11(P=0.03)

15.73%

15.73%

-0.69[-1.33,-0.05]

-0.69[-1.33,-0.05]

Total ***

114

132

100%

-0.36[-0.61,-0.1]

Heterogeneity: Tau2=0; Chi2=1.9, df=2(P=0.39); I2=0%

Test for overall effect: Z=2.76(P=0.01)

Test for subgroup differences: Chi2=1.22, df=1 (P=0.27), I2=17.78%

Favours treatment

-4

-2

0

2

4

Favours control

Analysis 18.4.   Comparison 18 SENSITIVITY3: operationalised criteria: Psychotherapy
+Antidepressant vs Antidepressant alone, Outcome 4 Frequency of panic attacks at 2-4 months.

Study or subgroup

Treatment

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

18.4.1 Behaviour therapy

Telch 1985

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=0.31(P=0.76)

18.4.2 Cognitive-behaviour therapy

Azhar 2000

Berger 2004

Spinhoven 1996

Subtotal ***

0.6 (1.1)

4.1 (3.9)

0.6 (1.1)

3 (2.5)

10

10

17

20

20

57

Heterogeneity: Tau2=0.61; Chi2=13.13, df=2(P=0); I2=84.76%

Test for overall effect: Z=0.94(P=0.35)

18.4.3 Psychodynamic psychotherapy and others

Berger 2004

Wiborg 1996

Subtotal ***

0.6 (1.1)

0 (0)

20

20

40

Heterogeneity: Not applicable

Test for overall effect: Z=0.09(P=0.92)

0.8 (1)

9.1 (2)

0.6 (1.6)

2.8 (2.3)

0.6 (1.6)

0.8 (2.1)

10

10

17

32

19

68

32

20

52

Total ***

107

130

Heterogeneity: Tau2=0.29; Chi2=14.13, df=4(P=0.01); I2=71.7%

Test for overall effect: Z=0.99(P=0.32)

Test for subgroup differences: Chi2=1.01, df=1 (P=0.6), I2=0%

16.68%

16.68%

-0.14[-1.01,0.74]

-0.14[-1.01,0.74]

18.22%

22.11%

20.89%

61.21%

-1.59[-2.37,-0.81]

0.03[-0.53,0.59]

0.08[-0.55,0.71]

-0.46[-1.42,0.5]

22.11%

0.03[-0.53,0.59]

Not estimable

22.11%

0.03[-0.53,0.59]

100%

-0.28[-0.84,0.28]

Favours treatment

-4

-2

0

2

4

Favours control

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

263

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 18.5.   Comparison 18 SENSITIVITY3: operationalised criteria: Psychotherapy
+Antidepressant vs Antidepressant alone, Outcome 5 Phobic avoidance at 2-4 months.

Study or subgroup

Treatment

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

18.5.1 Behaviour therapy

Telch 1985

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=2.06(P=0.04)

18.5.2 Cognitive-behaviour therapy

Berger 2004

Loerch 1999

Spinhoven 1996

Subtotal ***

17.3 (10.3)

0.5 (1)

7 (8.3)

22.5 (12)

10

10

20

14

20

54

Heterogeneity: Tau2=0.52; Chi2=11.41, df=2(P=0); I2=82.48%

Test for overall effect: Z=0.07(P=0.95)

18.5.3 Psychodynamic psychotherapy and others

Berger 2004

Wiborg 1996

Subtotal ***

0.5 (1)

1.1 (1.1)

20

20

40

Heterogeneity: Tau2=0.58; Chi2=7.14, df=1(P=0.01); I2=86%

Test for overall effect: Z=0.01(P=0.99)

28.4 (11.2)

0.1 (0.3)

19 (13.2)

18.7 (13.3)

0.1 (0.3)

2.6 (3.3)

10

10

32

16

19

67

32

20

52

Total ***

104

129

Heterogeneity: Tau2=0.41; Chi2=23.11, df=5(P=0); I2=78.37%

Test for overall effect: Z=0.5(P=0.61)

Test for subgroup differences: Chi2=4.55, df=1 (P=0.1), I2=56.08%

13.88%

13.88%

-0.99[-1.93,-0.05]

-0.99[-1.93,-0.05]

17.94%

15.72%

17.27%

50.94%

0.57[-0,1.14]

-1.05[-1.82,-0.28]

0.29[-0.34,0.93]

-0.03[-0.93,0.87]

17.94%

17.24%

35.18%

0.57[-0,1.14]

-0.6[-1.23,0.04]

-0.01[-1.15,1.13]

100%

-0.15[-0.74,0.44]

Favours treatment

-4

-2

0

2

4

Favours control

Analysis 18.6.   Comparison 18 SENSITIVITY3: operationalised criteria: Psychotherapy
+Antidepressant vs Antidepressant alone, Outcome 6 General anxiety at 2-4 months.

Study or subgroup

Treatment

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

18.6.1 Behaviour therapy

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Not applicable

18.6.2 Cognitive-behaviour therapy

Azhar 2000

Berger 2004

Loerch 1999

Sharp 1996

Subtotal ***

0

17

20

14

29

80

22.9 (4.7)

1.8 (2)

11.4 (11.1)

4.8 (5.7)

0

17

32

16

29

94

28.7 (4.2)

1 (2)

19.9 (9.8)

7.9 (7)

Heterogeneity: Tau2=0.38; Chi2=14.04, df=3(P=0); I2=78.64%

Test for overall effect: Z=1.46(P=0.14)

18.6.3 Psychodynamic psychotherapy and others

Not estimable

15.64%

17.39%

15.62%

17.77%

66.42%

-1.29[-2.03,-0.54]

0.39[-0.18,0.95]

-0.79[-1.54,-0.04]

-0.48[-1,0.04]

-0.51[-1.2,0.18]

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

264

Favours treatment

-4

-2

0

2

4

Favours control

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Treatment

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

Berger 2004

Wiborg 1996

Subtotal ***

20

20

40

1.8 (2)

5.5 (4.7)

32

20

52

1 (2)

16 (10)

Heterogeneity: Tau2=1.35; Chi2=14.05, df=1(P=0); I2=92.88%

Test for overall effect: Z=0.53(P=0.6)

Total ***

120

146

Heterogeneity: Tau2=0.47; Chi2=28.27, df=5(P<0.0001); I2=82.31%

Test for overall effect: Z=1.57(P=0.12)

Test for subgroup differences: Chi2=0.18, df=1 (P=0.67), I2=0%

17.39%

16.19%

33.58%

0.39[-0.18,0.95]

-1.32[-2.01,-0.63]

-0.45[-2.12,1.22]

100%

-0.49[-1.1,0.12]

Favours treatment

-4

-2

0

2

4

Favours control

Analysis 18.7.   Comparison 18 SENSITIVITY3: operationalised criteria: Psychotherapy
+Antidepressant vs Antidepressant alone, Outcome 7 Depression at 2-4 months.

Study or subgroup

Treatment

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

14.7 (14.1)

12.2 (4.5)

12 (7.4)

46 (10.8)

7.4 (6.1)

18.7.1 Behaviour therapy

Telch 1985

Subtotal ***

13.4 (5.7)

10

10

Heterogeneity: Tau2=0; Chi2=0, df=0(P<0.0001); I2=100%

Test for overall effect: Z=0.26(P=0.8)

18.7.2 Cognitive-behaviour therapy

Azhar 2000

Loerch 1999

Spinhoven 1996

Subtotal ***

9.2 (1.4)

5.6 (5.8)

43.5 (8.7)

17

14

20

51

Heterogeneity: Tau2=0.03; Chi2=2.5, df=2(P=0.29); I2=19.85%

Test for overall effect: Z=2.85(P=0)

18.7.3 Psychodynamic psychotherapy and others

3.6 (2.7)

Wiborg 1996

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=2.4(P=0.02)

Total ***

20

20

81

Heterogeneity: Tau2=0; Chi2=4.04, df=4(P=0.4); I2=0.9%

Test for overall effect: Z=3.74(P=0)

Test for subgroup differences: Chi2=1.54, df=1 (P=0.46), I2=0%

10

10

17

16

19

52

20

20

82

13.13%

13.13%

-0.12[-0.99,0.76]

-0.12[-0.99,0.76]

20.06%

17.44%

25.27%

62.78%

-0.89[-1.6,-0.18]

-0.93[-1.69,-0.17]

-0.25[-0.88,0.38]

-0.65[-1.1,-0.2]

24.1%

24.1%

-0.79[-1.44,-0.14]

-0.79[-1.44,-0.14]

100%

-0.61[-0.93,-0.29]

Favours treatment

-4

-2

0

2

4

Favours control

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

265

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 18.8.   Comparison 18 SENSITIVITY3: operationalised criteria: Psychotherapy
+Antidepressant vs Antidepressant alone, Outcome 8 Social functioning at 2-4 months.

Study or subgroup

Treatment

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

18.8.1 Behavour therapy

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Not applicable

18.8.2 Cognitive-behaviour therapy

Loerch 1999

Sharp 1996

Subtotal ***

0

14

29

43

2.4 (2.8)

1.4 (2.8)

Heterogeneity: Tau2=0.19; Chi2=2.67, df=1(P=0.1); I2=62.54%

Test for overall effect: Z=1.65(P=0.1)

18.8.3 Psychodynamic psychotherapy and others

1.2 (1.5)

Wiborg 1996

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=2.45(P=0.01)

Total ***

20

20

63

Heterogeneity: Tau2=0.06; Chi2=3.12, df=2(P=0.21); I2=35.89%

Test for overall effect: Z=2.84(P=0)

Test for subgroup differences: Chi2=0.45, df=1 (P=0.5), I2=0%

0

16

29

45

20

20

65

5.9 (3.5)

2.2 (2.9)

3 (2.7)

Not estimable

25.32%

42.26%

67.58%

-1.08[-1.85,-0.3]

-0.3[-0.82,0.22]

-0.63[-1.39,0.12]

32.42%

32.42%

-0.81[-1.46,-0.16]

-0.81[-1.46,-0.16]

100%

-0.66[-1.12,-0.2]

Favours treatment

-4

-2

0

2

4

Favours control

Analysis 18.9.   Comparison 18 SENSITIVITY3: operationalised criteria: Psychotherapy
+Antidepressant vs Antidepressant alone, Outcome 9 Dropouts for any reason within 2-4 months.

Study or subgroup

18.9.1 Behaviour therapy

Telch 1985

Subtotal (95% CI)

Total events: 3 (Treatment), 2 (Control)

Heterogeneity: Not applicable

Test for overall effect: Z=0.4(P=0.69)

18.9.2 Cognitive-behaviour therapy

Azhar 2000

Barlow 2000

Loerch 1999

Sharp 1996

Spinhoven 1996

Subtotal (95% CI)

Treatment

n/N

Control

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

3/13

13

2/12

12

4.16%

4.16%

1.38[0.28,6.91]

1.38[0.28,6.91]

5/22

18/65

3/14

11/38

4/20

159

5/22

32/83

7/16

12/36

4/20

177

9.06%

47.18%

8.18%

23.32%

7%

94.75%

1[0.34,2.97]

0.72[0.45,1.16]

0.49[0.16,1.54]

0.87[0.44,1.71]

1[0.29,3.45]

0.77[0.55,1.08]

Total events: 41 (Treatment), 60 (Control)

Heterogeneity: Tau2=0; Chi2=1.19, df=4(P=0.88); I2=0%

Test for overall effect: Z=1.52(P=0.13)

Favours treatment

0.1

0.2

0.5

1

2

5

10

Favours control

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

266

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Treatment

n/N

Control

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

18.9.3 Psychodynamic psychotherapy and others

Wiborg 1996

Subtotal (95% CI)

Total events: 1 (Treatment), 0 (Control)

Heterogeneity: Not applicable

Test for overall effect: Z=0.69(P=0.49)

1/20

20

0/20

20

1.09%

1.09%

3[0.13,69.52]

3[0.13,69.52]

Total (95% CI)

192

209

100%

0.8[0.58,1.11]

Total events: 45 (Treatment), 62 (Control)

Heterogeneity: Tau2=0; Chi2=2.37, df=6(P=0.88); I2=0%

Test for overall effect: Z=1.33(P=0.18)

Test for subgroup differences: Not applicable

Favours treatment

0.1

0.2

0.5

1

2

5

10

Favours control

Analysis 18.10.   Comparison 18 SENSITIVITY3: operationalised criteria: Psychotherapy
+Antidepressant vs Antidepressant alone, Outcome 10 Dropouts due to side effects within 2-4 months.

Study or subgroup

18.10.1 Behaviour therapy

Telch 1985

Subtotal (95% CI)

Total events: 3 (Treatment), 2 (Control)

Heterogeneity: Not applicable

Test for overall effect: Z=0.4(P=0.69)

18.10.2 Cognitive-behaviour therapy

Barlow 2000

Sharp 1996

Spinhoven 1996

Subtotal (95% CI)

Treatment

n/N

Control

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

3/13

13

2/65

5/38

4/20

123

2/12

12

11/83

3/36

3/20

139

19.91%

19.91%

1.38[0.28,6.91]

1.38[0.28,6.91]

22.77%

25.6%

25.45%

73.82%

0.23[0.05,1.01]

1.58[0.41,6.13]

1.33[0.34,5.21]

0.81[0.25,2.68]

Total events: 11 (Treatment), 17 (Control)

Heterogeneity: Tau2=0.6; Chi2=4.38, df=2(P=0.11); I2=54.39%

Test for overall effect: Z=0.34(P=0.73)

18.10.3 Psychodynamic psychotherapy and others

Wiborg 1996

Subtotal (95% CI)

Total events: 1 (Treatment), 0 (Control)

Heterogeneity: Not applicable

Test for overall effect: Z=0.69(P=0.49)

1/20

20

0/20

20

6.27%

6.27%

3[0.13,69.52]

3[0.13,69.52]

Total (95% CI)

156

171

100%

0.99[0.44,2.24]

Total events: 15 (Treatment), 19 (Control)

Heterogeneity: Tau2=0.2; Chi2=5.19, df=4(P=0.27); I2=22.98%

Test for overall effect: Z=0.02(P=0.98)

Test for subgroup differences: Not applicable

Favours treatment

0.1

0.2

0.5

1

2

5

10

Favours control

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

267

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 18.11.   Comparison 18 SENSITIVITY3: operationalised criteria: Psychotherapy
+Antidepressant vs Antidepressant alone, Outcome 11 Response/remission on continued treatment.

Study or subgroup

PT+AD

n/N

AD

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

18.11.1 Behaviour therapy

Telch 1985

Subtotal (95% CI)

Total events: 7 (PT+AD), 2 (AD)

Heterogeneity: Not applicable

Test for overall effect: Z=1.69(P=0.09)

18.11.2 Cognitive-behaviour therapy

Barlow 2000

Subtotal (95% CI)

Total events: 37 (PT+AD), 31 (AD)

Heterogeneity: Not applicable

Test for overall effect: Z=2.36(P=0.02)

7/13

13

2/12

12

18.32%

18.32%

3.23[0.83,12.61]

3.23[0.83,12.61]

37/65

65

31/83

83

41.64%

41.64%

1.52[1.07,2.16]

1.52[1.07,2.16]

18.11.3 Psychdynamic psychotherapy and others

Berger 2004

Wiborg 1996

Subtotal (95% CI)

Total events: 36 (PT+AD), 46 (AD)

Heterogeneity: Not applicable

Test for overall effect: Z=1.88(P=0.06)

16/35

20/20

55

26/38

20/20

58

40.03%

0.67[0.44,1.02]

Not estimable

40.03%

0.67[0.44,1.02]

Total (95% CI)

133

153

100%

1.26[0.59,2.67]

Total events: 80 (PT+AD), 79 (AD)

Heterogeneity: Tau2=0.32; Chi2=11.25, df=2(P=0); I2=82.22%

Test for overall effect: Z=0.6(P=0.55)

Test for subgroup differences: Not applicable

Favours AD

0.1

0.2

0.5

1

2

5

10

Favours PT+AD

Analysis 18.12.   Comparison 18 SENSITIVITY3: operationalised criteria: Psychotherapy
+Antidepressant vs Antidepressant alone, Outcome 12 Global/Avoidance/Panic on continued treatment.

Study or subgroup

Treatment

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

18.12.1 Behaviour therapy

Telch 1985

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=2.47(P=0.01)

18.12.2 Cognitive-behaviour therapy

Barlow 2000

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=2.47(P=0.01)

12.6 (8.1)

0.8 (0.9)

10

10

65

65

23.8 (9.3)

1.1 (0.9)

10

10

83

83

17.95%

17.95%

-1.23[-2.2,-0.26]

-1.23[-2.2,-0.26]

31.28%

31.28%

-0.41[-0.74,-0.09]

-0.41[-0.74,-0.09]

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

268

Favours treatment

-4

-2

0

2

4

Favours control

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Treatment

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

18.12.3 Psychodynamic psychotherapy and others

Berger 2004

Wiborg 1996

Subtotal ***

21

20

41

0.5 (1)

0.5 (1.1)

29

20

49

0.1 (0.6)

2.4 (2.9)

Heterogeneity: Tau2=0.71; Chi2=8.29, df=1(P=0); I2=87.93%

Test for overall effect: Z=0.32(P=0.75)

Total ***

116

142

Heterogeneity: Tau2=0.27; Chi2=12.56, df=3(P=0.01); I2=76.11%

Test for overall effect: Z=1.47(P=0.14)

Test for subgroup differences: Chi2=4.27, df=1 (P=0.12), I2=53.15%

26.29%

24.48%

50.77%

0.42[-0.15,0.99]

-0.85[-1.5,-0.2]

-0.2[-1.45,1.04]

100%

-0.45[-1.04,0.15]

Favours treatment

-4

-2

0

2

4

Favours control

Analysis 18.13.   Comparison 18 SENSITIVITY3: operationalised criteria: Psychotherapy
+Antidepressant vs Antidepressant alone, Outcome 13 Dropouts for any reason on continued treatment.

Treatment

n/N

Control

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

Study or subgroup

18.13.1 Behaviour therapy

Telch 1985

Subtotal (95% CI)

Total events: 1 (Treatment), 1 (Control)

Heterogeneity: Not applicable

Test for overall effect: Not applicable

18.13.2 Cognitive-behaviour therapy

Barlow 2000

Subtotal (95% CI)

Total events: 4 (Treatment), 7 (Control)

Heterogeneity: Not applicable

Test for overall effect: Z=0.52(P=0.6)

1/10

10

4/65

65

18.13.3 Psychodynamic psychotherapy and others

Wiborg 1996

Subtotal (95% CI)

Total events: 1 (Treatment), 2 (Control)

Heterogeneity: Not applicable

Test for overall effect: Z=0.59(P=0.56)

1/20

20

1/10

10

7/83

83

2/20

20

13.87%

13.87%

1[0.07,13.87]

1[0.07,13.87]

68.3%

68.3%

0.73[0.22,2.39]

0.73[0.22,2.39]

17.83%

17.83%

0.5[0.05,5.08]

0.5[0.05,5.08]

Total (95% CI)

95

113

100%

0.71[0.27,1.9]

Total events: 6 (Treatment), 10 (Control)

Heterogeneity: Tau2=0; Chi2=0.16, df=2(P=0.93); I2=0%

Test for overall effect: Z=0.68(P=0.5)

Test for subgroup differences: Not applicable

Favours treatment

0.1

0.2

0.5

1

2

5

10

Favours control

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

269

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 18.16.   Comparison 18 SENSITIVITY3: operationalised criteria: Psychotherapy+Antidepressant
vs Antidepressant alone, Outcome 16 Response/remission 6-24 months after treatment discontinuation.

Study or subgroup

PT+AD

n/N

AD

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

18.16.1 Behaviour therapy

Subtotal (95% CI)

Total events: 0 (PT+AD), 0 (AD)

Heterogeneity: Not applicable

Test for overall effect: Not applicable

18.16.2 Cognitive-behaviour therapy

Barlow 2000

Loerch 1999

Sharp 1996

Subtotal (95% CI)

Total events: 41 (PT+AD), 32 (AD)

0

0

Not estimable

16/59

9/14

16/38

111

15/77

7/16

10/36

129

29.57%

24.71%

27.21%

81.5%

1.39[0.75,2.58]

1.47[0.75,2.9]

1.52[0.8,2.89]

1.46[1,2.11]

Heterogeneity: Tau2=0; Chi2=0.04, df=2(P=0.98); I2=0%

Test for overall effect: Z=1.97(P=0.05)

18.16.3 Psychodynamic psychotherapy and others

Wiborg 1996

Subtotal (95% CI)

Total events: 16 (PT+AD), 5 (AD)

Heterogeneity: Not applicable

Test for overall effect: Z=2.89(P=0)

16/20

20

5/20

20

18.5%

18.5%

3.2[1.45,7.05]

3.2[1.45,7.05]

Total (95% CI)

131

149

100%

1.68[1.19,2.38]

Total events: 57 (PT+AD), 37 (AD)

Heterogeneity: Tau2=0.01; Chi2=3.16, df=3(P=0.37); I2=5.19%

Test for overall effect: Z=2.95(P=0)

Test for subgroup differences: Not applicable

Favours AD

0.1

0.2

0.5

1

2

5

10

Favours PT+AD

Analysis 18.17.   Comparison 18 SENSITIVITY3: operationalised criteria: Psychotherapy+Antidepressant vs
Antidepressant alone, Outcome 17 Global/Avoidance/Panic 6-24 months after treatment discontinuation.

Study or subgroup

Treatment

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

18.17.1 Behaviour therapy

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Not applicable

18.17.2 Cognitive-behaviour therapy

Barlow 2000

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Not applicable

0

59

59

0

77

77

1.5 (0.9)

18.17.3 Psychodynamic psychotherapy and others

Not estimable

1.5 (0.8)

53%

53%

0[-0.34,0.34]

0[-0.34,0.34]

Wiborg 1996

20

0.6 (1.1)

20

2.4 (1.7)

47%

-1.23[-1.91,-0.55]

Favours treatment

-4

-2

0

2

4

Favours control

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

270

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Treatment

Control

Std. Mean Difference

Weight

Std. Mean Difference

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=3.54(P=0)

Mean(SD)

N

20

N

20

Mean(SD)

Random, 95% CI

Random, 95% CI

47%

-1.23[-1.91,-0.55]

Total ***

79

97

Heterogeneity: Tau2=0.68; Chi2=10.06, df=1(P=0); I2=90.06%

Test for overall effect: Z=0.94(P=0.35)

Test for subgroup differences: Chi2=10.06, df=1 (P=0), I2=90.06%

100%

-0.58[-1.78,0.63]

Favours treatment

-4

-2

0

2

4

Favours control

Comparison 19.   SENSITIVITY3: operationalised criteria: Psychotherapy+Antidepressant vs Psychotherapy alone or
+Placebo

Outcome or subgroup title

1 Response at 2-4 months

1.1 Behaviour therapy

1.2 Cognitive-behaviour therapy

1.3 Psychodynamic and other therapies

2 Remission at 2-4 months

2.1 Behaviour therapy

2.2 Cognitive-behaviour therapy

2.3 Psychodynamic and other therapies

3 Global severity at 2-4 months

3.1 Behaviour therapy

3.2 Cognitive-behaviour therapy

3.3 Psychodynamic and other therapies

No. of
studies

No. of
partici-
pants

Statistical method

Effect size

16

5

11

0

14

5

9

0

9

4

5

0

883

174

709

0

788

163

625

0

481

118

363

0

Risk Ratio (M-H, Random, 95%
CI)

1.16 [1.01, 1.35]

Risk Ratio (M-H, Random, 95%
CI)

1.34 [0.97, 1.86]

Risk Ratio (M-H, Random, 95%
CI)

1.13 [0.96, 1.33]

Risk Ratio (M-H, Random, 95%
CI)

0.0 [0.0, 0.0]

Risk Ratio (M-H, Random, 95%
CI)

1.22 [1.05, 1.42]

Risk Ratio (M-H, Random, 95%
CI)

1.22 [0.88, 1.68]

Risk Ratio (M-H, Random, 95%
CI)

1.23 [1.02, 1.47]

Risk Ratio (M-H, Random, 95%
CI)

0.0 [0.0, 0.0]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.37 [-0.56, -0.18]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.54 [-0.92, -0.16]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.31 [-0.54, -0.08]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.0 [0.0, 0.0]

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

271

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of
studies

No. of
partici-
pants

Statistical method

Effect size

4 Frequency of panic attacks at 2-4 months

10

4.1 Behaviour therapy

4.2 Cognitive-behaviour therapy

5 Phobic avoidance at 2-4 months

5.1 Behaviour therapy

5.2 Cognitive-behaviour therapy

5.3 Psychodynamic and other therapies

6

4

13

6

7

0

6 General anxiety at 2-4 months

13

6.1 Behaviour therapy

6.2 Cognitive-behaviour therapy

6.3 Psychodynamic and other therapies

7 Depression at 2-4 months

7.1 Behaviour therapy

7.2 Cognitive-behaviour therapy

7.3 Psychodynamic and other therapies

8 Social functioning at 2-4 months

8.1 Behaviour therapy

8.2 Cognitive-behaviour therapy

5

8

0

11

6

5

0

6

2

4

367

148

219

439

151

288

0

521

132

389

0

343

151

192

0

206

62

144

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.12 [-0.33, 0.08]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.09 [-0.42, 0.24]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.15 [-0.41, 0.12]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.28 [-0.47, -0.08]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.43 [-0.85, -0.00]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.20 [-0.44, 0.04]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.0 [0.0, 0.0]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.30 [-0.47, -0.12]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.49 [-0.87, -0.11]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.23 [-0.44, -0.03]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.0 [0.0, 0.0]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.35 [-0.58, -0.12]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.36 [-0.77, 0.05]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.34 [-0.64, -0.05]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.0 [0.0, 0.0]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.17 [-0.45, 0.12]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.44 [-0.94, 0.07]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.04 [-0.39, 0.30]

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

272

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of
studies

No. of
partici-
pants

Statistical method

Effect size

9 Dropouts for any reason within 2-4 months

14

9.1 Behaviour therapy

9.2 Cognitive-behaviour therapy

9.3 Psychodynamic and other therapies

10 Dropouts due to side effects within 2-4
months

10.1 Behaviour therapy

10.2 Cognitive-behaviour therapy

11 Response/remission on continued treat-
ment

11.1 Behaviour therapy

11.2 Cognitive-behaviour therapy

12 Global/Avoidance/Panic on continued
treatment

12.1 Behaviour therapy

12.2 Cognitive-behaviour therapy

13 Dropouts for any reason on continued
treatment

13.1 Behaviour therapy

13.2 Cognitive-behaviour therapy

14 Response/remission 6-24 months after
treatment discontinuation

14.1 Behaviour therapy

4

10

0

11

3

8

3

1

2

3

1

2

4

2

2

10

5

773

108

665

0

698

94

604

230

25

205

224

19

205

262

57

205

502

163

Risk Ratio (M-H, Random, 95%
CI)

1.15 [0.84, 1.56]

Risk Ratio (M-H, Random, 95%
CI)

1.09 [0.48, 2.45]

Risk Ratio (M-H, Random, 95%
CI)

1.16 [0.83, 1.62]

Risk Ratio (M-H, Random, 95%
CI)

0.0 [0.0, 0.0]

Risk Ratio (M-H, Random, 95%
CI)

4.65 [2.09, 10.32]

Risk Ratio (M-H, Random, 95%
CI)

3.82 [0.83, 17.66]

Risk Ratio (M-H, Random, 95%
CI)

5.00 [1.96, 12.72]

Risk Ratio (M-H, Random, 95%
CI)

1.29 [0.95, 1.76]

Risk Ratio (M-H, Random, 95%
CI)

3.23 [0.83, 12.61]

Risk Ratio (M-H, Random, 95%
CI)

1.23 [0.93, 1.63]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.56 [-0.99, -0.13]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-1.47 [-2.51, -0.43]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.41 [-0.71, -0.12]

Risk Ratio (M-H, Random, 95%
CI)

0.88 [0.33, 2.32]

Risk Ratio (M-H, Random, 95%
CI)

2.86 [0.32, 25.80]

Risk Ratio (M-H, Random, 95%
CI)

0.66 [0.22, 1.95]

Risk Ratio (M-H, Random, 95%
CI)

0.93 [0.74, 1.17]

Risk Ratio (M-H, Random, 95%
CI)

0.98 [0.67, 1.45]

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

273

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of
studies

No. of
partici-
pants

Statistical method

Effect size

14.2 Cognitive-behaviour therapy

15 Global/Avoidance/Panic 6-24 months af-
ter treatment discontinuation

15.1 Behaviour therapy

15.2 Cognitive-behaviour therapy

5

6

4

2

339

295

101

194

Risk Ratio (M-H, Random, 95%
CI)

0.91 [0.69, 1.21]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.13 [-0.13, 0.40]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.02 [-0.49, 0.53]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.21 [-0.10, 0.52]

Analysis 19.1.   Comparison 19 SENSITIVITY3: operationalised criteria: Psychotherapy
+Antidepressant vs Psychotherapy alone or +Placebo, Outcome 1 Response at 2-4 months.

PT+AD

n/N

PT+placebo

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

Study or subgroup

19.1.1 Behaviour therapy

de Beurs 1995i

de Beurs 1995ii

Mavissakalian 1986a

Mavissakalian 1986b

Telch 1985

Subtotal (95% CI)

8/12

9/12

11/20

8/20

5/13

77

Total events: 41 (PT+AD), 40 (PT+placebo)

Heterogeneity: Tau2=0.01; Chi2=4.4, df=4(P=0.35); I2=9.05%

Test for overall effect: Z=1.77(P=0.08)

19.1.2 Cognitive-behaviour therapy

Azhar 2000

Barlow 2000i

Barlow 2000ii

Fahy 1992

Kampman 2002

Loerch 1999

Oehrberg 1995

Sharp 1996i

Sharp 1996ii

Spinhoven 1996

Stein 2000

Subtotal (95% CI)

14/22

19/32

20/33

26/53

12/22

11/14

42/60

13/19

13/19

4/20

13/16

310

Total events: 187 (PT+AD), 211 (PT+placebo)

Heterogeneity: Tau2=0.03; Chi2=15.9, df=10(P=0.1); I2=37.09%

Test for overall effect: Z=1.47(P=0.14)

19.1.3 Psychodynamic and other therapies

12/24

7/21

10/20

9/20

2/12

97

17/22

36/63

37/77

9/26

5/21

12/14

25/60

28/36

26/43

4/20

12/17

399

5.05%

3.69%

4.71%

3.38%

0.96%

1.33[0.76,2.35]

2.25[1.13,4.47]

1.1[0.61,1.99]

0.89[0.43,1.83]

2.31[0.55,9.74]

17.79%

1.34[0.97,1.86]

8.54%

9.44%

9.36%

4.66%

2.53%

9.76%

9.92%

9.61%

8.52%

1.28%

8.59%

82.21%

0.82[0.56,1.21]

1.04[0.73,1.49]

1.26[0.88,1.81]

1.42[0.78,2.57]

2.29[0.97,5.39]

0.92[0.65,1.3]

1.68[1.19,2.37]

0.88[0.62,1.25]

1.13[0.77,1.67]

1[0.29,3.45]

1.15[0.78,1.69]

1.13[0.96,1.33]

Subtotal (95% CI)

0

0

Not estimable

Total events: 0 (PT+AD), 0 (PT+placebo)

Favours PT+placebo

0.1

0.2

0.5

1

2

5

10

Favours PT+AD

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

274

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

PT+AD

n/N

PT+placebo

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

Heterogeneity: Not applicable

Test for overall effect: Not applicable

Total (95% CI)

387

496

100%

1.16[1.01,1.35]

Total events: 228 (PT+AD), 251 (PT+placebo)

Heterogeneity: Tau2=0.02; Chi2=21.43, df=15(P=0.12); I2=30%

Test for overall effect: Z=2.07(P=0.04)

Test for subgroup differences: Not applicable

Favours PT+placebo

0.1

0.2

0.5

1

2

5

10

Favours PT+AD

Analysis 19.2.   Comparison 19 SENSITIVITY3: operationalised criteria: Psychotherapy
+Antidepressant vs Psychotherapy alone or +Placebo, Outcome 2 Remission at 2-4 months.

PT+AD

n/N

PT+placebo

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

Study or subgroup

19.2.1 Behaviour therapy

de Beurs 1995i

de Beurs 1995ii

Fava 1997

Mavissakalian 1986a

Mavissakalian 1986b

Subtotal (95% CI)

8/12

8/12

1/7

8/20

8/20

71

Total events: 33 (PT+AD), 39 (PT+placebo)

Heterogeneity: Tau2=0; Chi2=3.91, df=4(P=0.42); I2=0%

Test for overall effect: Z=1.17(P=0.24)

19.2.2 Cognitive-behaviour therapy

Barlow 2000i

Barlow 2000ii

Fahy 1992

Kampman 2002

Loerch 1999

Oehrberg 1995

Sharp 1996i

Sharp 1996ii

Stein 2000

Subtotal (95% CI)

20/33

19/32

28/53

14/22

9/14

39/60

12/19

12/19

7/16

268

Total events: 160 (PT+AD), 178 (PT+placebo)

Heterogeneity: Tau2=0.02; Chi2=11.01, df=8(P=0.2); I2=27.36%

Test for overall effect: Z=2.2(P=0.03)

19.2.3 Psychodynamic and other therapies

14/24

12/21

4/7

4/20

5/20

92

39/63

42/77

10/26

9/21

8/14

21/60

25/36

21/43

3/17

357

7.24%

6.75%

0.61%

2.07%

2.51%

1.14[0.68,1.93]

1.17[0.68,2.01]

0.25[0.04,1.71]

2[0.72,5.59]

1.6[0.63,4.05]

19.18%

1.22[0.88,1.68]

14.92%

13.96%

6.67%

5.93%

5.71%

11.8%

11.14%

9.06%

1.62%

80.82%

0.98[0.7,1.37]

1.09[0.77,1.55]

1.37[0.79,2.38]

1.48[0.83,2.67]

1.13[0.62,2.05]

1.86[1.26,2.75]

0.91[0.61,1.37]

1.29[0.82,2.05]

2.48[0.77,7.97]

1.23[1.02,1.47]

Subtotal (95% CI)

0

0

Not estimable

Total events: 0 (PT+AD), 0 (PT+placebo)

Heterogeneity: Not applicable

Test for overall effect: Not applicable

Total (95% CI)

339

449

100%

1.22[1.05,1.42]

Total events: 193 (PT+AD), 217 (PT+placebo)

Favours PT+placebo

0.1

0.2

0.5

1

2

5

10

Favours PT+AD

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

275

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

PT+AD

n/N

PT+placebo

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

Heterogeneity: Tau2=0.01; Chi2=14.85, df=13(P=0.32); I2=12.48%

Test for overall effect: Z=2.58(P=0.01)

Test for subgroup differences: Not applicable

Favours PT+placebo

0.1

0.2

0.5

1

2

5

10

Favours PT+AD

Analysis 19.3.   Comparison 19 SENSITIVITY3: operationalised criteria: Psychotherapy
+Antidepressant vs Psychotherapy alone or +Placebo, Outcome 3 Global severity at 2-4 months.

Study or subgroup

PT+AD

PT+placebo

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

19.3.1 Behaviour therapy

de Beurs 1995i

de Beurs 1995ii

Mavissakalian 1986a

Mavissakalian 1986b

Subtotal ***

1.6 (0.8)

1.6 (0.8)

2 (1.7)

2.2 (1.7)

10

9

17

14

50

Heterogeneity: Tau2=0; Chi2=0.08, df=3(P=0.99); I2=0%

Test for overall effect: Z=2.81(P=0)

19.3.2 Cognitive-behaviour therapy

Barlow 2000i

Barlow 2000ii

Fahy 1992

Sharp 1996i

Sharp 1996ii

Subtotal ***

0.9 (0.7)

0.9 (0.7)

2 (1.1)

1.7 (1.1)

1.7 (1.1)

33

32

42

15

14

136

2.1 (1.1)

2.3 (1.2)

3 (1.9)

3.1 (1.9)

1 (0.7)

1.1 (0.7)

2.8 (1)

2 (1.3)

1.7 (1)

19

18

14

17

68

63

77

24

33

30

227

Heterogeneity: Tau2=0.01; Chi2=4.32, df=4(P=0.36); I2=7.49%

Test for overall effect: Z=2.6(P=0.01)

19.3.3 Psychodynamic and other therapies

Subtotal ***

0

0

Heterogeneity: Not applicable

Test for overall effect: Not applicable

6.03%

5.44%

7.03%

7.09%

-0.52[-1.3,0.26]

-0.64[-1.46,0.19]

-0.55[-1.27,0.18]

-0.49[-1.2,0.23]

25.59%

-0.54[-0.92,-0.16]

20.6%

21.29%

13.65%

9.77%

9.11%

74.41%

-0.15[-0.57,0.27]

-0.35[-0.76,0.07]

-0.74[-1.26,-0.22]

-0.24[-0.86,0.37]

0.02[-0.61,0.65]

-0.31[-0.54,-0.08]

Not estimable

Total ***

186

295

100%

-0.37[-0.56,-0.18]

Heterogeneity: Tau2=0; Chi2=5.5, df=8(P=0.7); I2=0%

Test for overall effect: Z=3.77(P=0)

Test for subgroup differences: Chi2=1.1, df=1 (P=0.29), I2=9.45%

Favours treatment

-4

-2

0

2

4

Favours control

Analysis 19.4.   Comparison 19 SENSITIVITY3: operationalised criteria: Psychotherapy+Antidepressant
vs Psychotherapy alone or +Placebo, Outcome 4 Frequency of panic attacks at 2-4 months.

Study or subgroup

PT+AD

PT+placebo

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

19.4.1 Behaviour therapy

de Beurs 1995i

9

0.2 (0.5)

19

0.5 (1.6)

6.8%

-0.25[-1.04,0.55]

Favours treatment

-4

-2

0

2

4

Favours control

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

276

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

PT+AD

PT+placebo

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

de Beurs 1995ii

Fava 1997

Mavissakalian 1986a

Mavissakalian 1986b

Telch 1985

Subtotal ***

0.2 (0.5)

2.7 (0.8)

1.3 (2)

2.4 (1.9)

0.6 (1.1)

9

7

17

14

10

66

Heterogeneity: Tau2=0; Chi2=3.57, df=5(P=0.61); I2=0%

Test for overall effect: Z=0.54(P=0.59)

19.4.2 Cognitive-behaviour therapy

Azhar 2000

Kampman 2002

Oehrberg 1995

Spinhoven 1996

Subtotal ***

4.1 (3.9)

2.2 (0.6)

-16 (18.4)

3 (2.5)

17

19

55

20

111

Heterogeneity: Tau2=0; Chi2=2.32, df=3(P=0.51); I2=0%

Test for overall effect: Z=1.07(P=0.28)

1.7 (3.5)

2 (1)

1.6 (2.1)

2.2 (2.1)

0.8 (0.7)

3.6 (2.2)

2.3 (0.7)

-9.8 (18.4)

2.7 (2.3)

16

7

14

17

9

82

17

19

52

20

108

6.24%

3.6%

8.59%

8.6%

5.29%

-0.51[-1.34,0.32]

0.72[-0.37,1.82]

-0.14[-0.85,0.56]

0.1[-0.61,0.8]

-0.18[-1.08,0.72]

39.11%

-0.09[-0.42,0.24]

9.51%

10.62%

29.56%

11.19%

60.89%

0.13[-0.54,0.81]

-0.15[-0.79,0.49]

-0.33[-0.72,0.05]

0.12[-0.5,0.74]

-0.15[-0.41,0.12]

Total ***

177

190

100%

-0.12[-0.33,0.08]

Heterogeneity: Tau2=0; Chi2=5.94, df=9(P=0.75); I2=0%

Test for overall effect: Z=1.18(P=0.24)

Test for subgroup differences: Chi2=0.06, df=1 (P=0.81), I2=0%

Favours treatment

-4

-2

0

2

4

Favours control

Analysis 19.5.   Comparison 19 SENSITIVITY3: operationalised criteria: Psychotherapy
+Antidepressant vs Psychotherapy alone or +Placebo, Outcome 5 Phobic avoidance at 2-4 months.

Study or subgroup

PT+AD

PT+placebo

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

19.5.1 Behaviour therapy

de Beurs 1995i

de Beurs 1995ii

Fava 1997

Mavissakalian 1986a

Mavissakalian 1986b

Telch 1985

Subtotal ***

4.1 (2)

4.1 (2)

19.6 (4.7)

11.4 (8.8)

12.3 (8.8)

17.3 (10.3)

10

9

7

17

14

10

67

Heterogeneity: Tau2=0.1; Chi2=7.87, df=5(P=0.16); I2=36.46%

Test for overall effect: Z=1.97(P=0.05)

19.5.2 Cognitive-behaviour therapy

Fahy 1992

Kampman 2002

Loerch 1999

Sharp 1996i

Sharp 1996ii

Spinhoven 1996

Stein 2000

Subtotal ***

31.4 (30.7)

1.8 (0.5)

7 (8.3)

4.7 (7.8)

4.7 (7.8)

22.5 (12)

-5.8 (6.7)

42

19

14

15

14

20

12

136

5.7 (1.3)

6.1 (1.9)

15.6 (8.4)

13.8 (9.9)

13.3 (9.9)

23.3 (7.8)

40.2 (25.4)

2 (0.6)

9.1 (6.3)

7.2 (10.6)

5.1 (5.4)

22.9 (11.3)

-5.9 (9.8)

19

18

7

14

17

9

84

24

19

14

33

30

20

12

152

5.74%

5.25%

3.28%

7.51%

7.56%

4.41%

33.75%

14.9%

9.21%

6.83%

10.1%

9.41%

9.87%

5.92%

66.25%

-0.99[-1.8,-0.17]

-0.99[-1.84,-0.14]

0.55[-0.52,1.63]

-0.25[-0.96,0.46]

-0.1[-0.81,0.6]

-0.62[-1.55,0.31]

-0.43[-0.85,-0]

-0.3[-0.81,0.2]

-0.35[-1,0.29]

-0.28[-1.03,0.46]

-0.25[-0.86,0.36]

-0.06[-0.7,0.57]

-0.03[-0.65,0.59]

0.01[-0.79,0.81]

-0.2[-0.44,0.04]

Favours treatment

-4

-2

0

2

4

Favours control

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

277

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

PT+AD

PT+placebo

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

Heterogeneity: Tau2=0; Chi2=1.17, df=6(P=0.98); I2=0%

Test for overall effect: Z=1.62(P=0.11)

19.5.3 Psychodynamic and other therapies

Subtotal ***

0

0

Heterogeneity: Not applicable

Test for overall effect: Not applicable

Not estimable

Total ***

203

236

100%

-0.28[-0.47,-0.08]

Heterogeneity: Tau2=0; Chi2=10.25, df=12(P=0.59); I2=0%

Test for overall effect: Z=2.77(P=0.01)

Test for subgroup differences: Chi2=1.21, df=1 (P=0.27), I2=17.23%

Favours treatment

-4

-2

0

2

4

Favours control

Analysis 19.6.   Comparison 19 SENSITIVITY3: operationalised criteria: Psychotherapy
+Antidepressant vs Psychotherapy alone or +Placebo, Outcome 6 General anxiety at 2-4 months.

Study or subgroup

PT+AD

PT+placebo

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

19.6.1 Behaviour therapy

de Beurs 1995i

de Beurs 1995ii

Fava 1997

Mavissakalian 1986a

Mavissakalian 1986b

Subtotal ***

2.6 (1.3)

2.6 (1.3)

3.6 (0.5)

30.1 (7.6)

34.3 (7.6)

10

9

7

17

14

57

Heterogeneity: Tau2=0.02; Chi2=4.44, df=4(P=0.35); I2=10%

Test for overall effect: Z=2.54(P=0.01)

19.6.2 Cognitive-behaviour therapy

Azhar 2000

Fahy 1992

Kampman 2002

Loerch 1999

Oehrberg 1995

Sharp 1996i

Sharp 1996ii

Stein 2000

Subtotal ***

22.9 (4.7)

11.3 (7.6)

1.5 (1.7)

11.4 (11.1)

-6.5 (5.5)

4.8 (5.7)

4.8 (5.7)

-15.3 (10.6)

17

42

19

14

55

15

14

12

188

3.8 (1.4)

3.9 (1.5)

3.6 (0.5)

35.5 (9.3)

34.4 (9.3)

21.5 (5.2)

14.4 (6.6)

1.7 (1.3)

11.9 (8.4)

-4.3 (5.5)

6.5 (6.7)

4.9 (4.4)

-10 (13.1)

19

18

7

14

17

75

17

24

19

14

52

33

30

12

201

Heterogeneity: Tau2=0; Chi2=4.38, df=7(P=0.73); I2=0%

Test for overall effect: Z=2.23(P=0.03)

19.6.3 Psychodynamic and other therapies

Subtotal ***

0

0

Heterogeneity: Not applicable

Test for overall effect: Not applicable

Total ***

245

276

Heterogeneity: Tau2=0; Chi2=10.32, df=12(P=0.59); I2=0%

4.91%

4.48%

2.88%

5.99%

6.32%

-0.87[-1.67,-0.06]

-0.89[-1.73,-0.05]

0[-1.05,1.05]

-0.63[-1.35,0.1]

-0.01[-0.72,0.7]

24.57%

-0.49[-0.87,-0.11]

6.92%

12.3%

7.8%

5.76%

21.56%

8.42%

7.86%

4.81%

75.43%

0.27[-0.41,0.94]

-0.42[-0.93,0.08]

-0.13[-0.77,0.51]

-0.04[-0.78,0.7]

-0.4[-0.78,-0.01]

-0.26[-0.87,0.35]

-0.02[-0.65,0.61]

-0.43[-1.24,0.38]

-0.23[-0.44,-0.03]

Not estimable

100%

-0.3[-0.47,-0.12]

Favours treatment

-4

-2

0

2

4

Favours control

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

278

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

PT+AD

PT+placebo

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

Test for overall effect: Z=3.26(P=0)

Test for subgroup differences: Chi2=1.49, df=1 (P=0.22), I2=33.06%

Favours treatment

-4

-2

0

2

4

Favours control

Analysis 19.7.   Comparison 19 SENSITIVITY3: operationalised criteria: Psychotherapy
+Antidepressant vs Psychotherapy alone or +Placebo, Outcome 7 Depression at 2-4 months.

Study or subgroup

PT+AD

PT+placebo

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

3.5 (1.4)

3.8 (1.5)

1.1 (0.4)

7.7 (8.7)

6.9 (8.7)

13 (11.9)

10 (0.6)

8.3 (5.1)

6.5 (5.2)

42.7 (10)

-8.6 (7.6)

19.7.1 Behaviour therapy

de Beurs 1995i

de Beurs 1995ii

Fava 1997

Mavissakalian 1986a

Mavissakalian 1986b

Telch 1985

Subtotal ***

2.6 (1)

2.6 (1)

1 (0)

2.8 (8.5)

8.7 (8.5)

13.4 (5.7)

10

9

7

17

14

10

67

Heterogeneity: Tau2=0.06; Chi2=5.46, df=4(P=0.24); I2=26.78%

Test for overall effect: Z=1.73(P=0.08)

19.7.2 Cognitive-behaviour therapy

Azhar 2000

Fahy 1992

Loerch 1999

Spinhoven 1996

Stein 2000

Subtotal ***

9.2 (1.4)

5.6 (4.5)

5.6 (5.8)

43.5 (8.7)

-10.5 (10.4)

17

42

14

20

12

105

Heterogeneity: Tau2=0; Chi2=4.13, df=4(P=0.39); I2=3.15%

Test for overall effect: Z=2.27(P=0.02)

19.7.3 Psychodynamic and other therapies

Subtotal ***

0

Heterogeneity: Not applicable

Test for overall effect: Not applicable

19

18

7

14

17

9

84

17

24

14

20

12

87

0

Total ***

172

171

Heterogeneity: Tau2=0.01; Chi2=9.6, df=9(P=0.38); I2=6.21%

Test for overall effect: Z=2.95(P=0)

Test for subgroup differences: Chi2=0, df=1 (P=0.95), I2=0%

8.2%

7.3%

9.66%

10%

6.36%

-0.68[-1.46,0.11]

-0.86[-1.7,-0.02]

Not estimable

-0.56[-1.28,0.17]

0.2[-0.51,0.91]

0.04[-0.86,0.94]

41.52%

-0.36[-0.77,0.05]

10.32%

18.21%

9.19%

12.84%

7.92%

58.48%

-0.74[-1.44,-0.04]

-0.56[-1.08,-0.05]

-0.16[-0.9,0.58]

0.08[-0.54,0.7]

-0.2[-1,0.6]

-0.34[-0.64,-0.05]

Not estimable

100%

-0.35[-0.58,-0.12]

Favours treatment

-4

-2

0

2

4

Favours control

Analysis 19.8.   Comparison 19 SENSITIVITY3: operationalised criteria: Psychotherapy
+Antidepressant vs Psychotherapy alone or +Placebo, Outcome 8 Social functioning at 2-4 months.

Study or subgroup

PT+AD

PT+placebo

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

19.8.1 Behaviour therapy

Favours treatment

-4

-2

0

2

4

Favours control

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

279

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

PT+AD

PT+placebo

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

Mavissakalian 1986a

Mavissakalian 1986b

Subtotal ***

2.3 (1)

2.4 (1)

17

14

31

Heterogeneity: Tau2=0; Chi2=0.04, df=1(P=0.84); I2=0%

Test for overall effect: Z=1.68(P=0.09)

19.8.2 Cognitive-behaviour therapy

Loerch 1999

Sharp 1996i

Sharp 1996ii

Stein 2000

Subtotal ***

2.4 (2.8)

1.4 (2.8)

1.4 (2.8)

-3.1 (2.5)

14

15

14

12

55

Heterogeneity: Tau2=0; Chi2=1.9, df=3(P=0.59); I2=0%

Test for overall effect: Z=0.26(P=0.8)

2.8 (1.1)

2.8 (1.1)

2.1 (2.2)

2.1 (2.6)

1.9 (2.6)

-4 (2.1)

14

17

31

14

33

30

12

89

15.62%

15.82%

31.44%

-0.49[-1.21,0.23]

-0.38[-1.1,0.33]

-0.44[-0.94,0.07]

14.7%

21.51%

20%

12.36%

68.56%

0.11[-0.63,0.85]

-0.27[-0.88,0.34]

-0.18[-0.82,0.46]

0.38[-0.43,1.18]

-0.04[-0.39,0.3]

Total ***

86

120

100%

-0.17[-0.45,0.12]

Heterogeneity: Tau2=0; Chi2=3.5, df=5(P=0.62); I2=0%

Test for overall effect: Z=1.16(P=0.25)

Test for subgroup differences: Chi2=1.56, df=1 (P=0.21), I2=36.05%

Favours treatment

-4

-2

0

2

4

Favours control

Analysis 19.9.   Comparison 19 SENSITIVITY3: operationalised criteria: Psychotherapy+Antidepressant
vs Psychotherapy alone or +Placebo, Outcome 9 Dropouts for any reason within 2-4 months.

PT+AD

n/N

PT+placebo

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

Study or subgroup

19.9.1 Behaviour therapy

de Beurs 1995i

de Beurs 1995ii

Fava 1997

Telch 1985

Subtotal (95% CI)

3/12

2/12

0/7

3/13

44

Total events: 8 (PT+AD), 11 (PT+placebo)

Heterogeneity: Tau2=0; Chi2=0.08, df=2(P=0.96); I2=0%

Test for overall effect: Z=0.21(P=0.83)

19.9.2 Cognitive-behaviour therapy

Barlow 2000i

Barlow 2000ii

Fahy 1992

Kampman 2002

Loerch 1999

Oehrberg 1995

Sharp 1996i

Sharp 1996ii

Spinhoven 1996

Stein 2000

Subtotal (95% CI)

9/33

9/32

12/53

3/22

3/14

5/60

6/19

5/19

4/20

1/16

288

5/24

3/21

0/7

3/12

64

18/63

21/77

3/26

2/21

1/14

8/60

4/36

13/43

0/20

1/17

377

6.09%

3.54%

4.91%

14.53%

20.63%

21.71%

6.92%

3.36%

2.09%

8.52%

7.39%

12.36%

1.17%

1.32%

85.47%

1.2[0.34,4.2]

1.17[0.23,6.03]

Not estimable

0.92[0.23,3.72]

1.09[0.48,2.45]

0.95[0.48,1.88]

1.03[0.53,2]

1.96[0.61,6.35]

1.43[0.27,7.73]

3[0.35,25.46]

0.63[0.22,1.8]

2.84[0.91,8.86]

0.87[0.36,2.1]

9[0.52,156.91]

1.06[0.07,15.6]

1.16[0.83,1.62]

Total events: 57 (PT+AD), 71 (PT+placebo)

Favours treatment

0.1

0.2

0.5

1

2

5

10

Favours control

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

280

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

PT+AD

n/N

PT+placebo

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

Heterogeneity: Tau2=0; Chi2=8.22, df=9(P=0.51); I2=0%

Test for overall effect: Z=0.86(P=0.39)

19.9.3 Psychodynamic and other therapies

Subtotal (95% CI)

0

0

Not estimable

Total events: 0 (PT+AD), 0 (PT+placebo)

Heterogeneity: Not applicable

Test for overall effect: Not applicable

Total (95% CI)

332

441

100%

1.15[0.84,1.56]

Total events: 65 (PT+AD), 82 (PT+placebo)

Heterogeneity: Tau2=0; Chi2=8.31, df=12(P=0.76); I2=0%

Test for overall effect: Z=0.87(P=0.38)

Test for subgroup differences: Not applicable

Favours treatment

0.1

0.2

0.5

1

2

5

10

Favours control

Analysis 19.10.   Comparison 19 SENSITIVITY3: operationalised criteria: Psychotherapy+Antidepressant
vs Psychotherapy alone or +Placebo, Outcome 10 Dropouts due to side effects within 2-4 months.

PT+AD

n/N

PT+placebo

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

Study or subgroup

19.10.1 Behaviour therapy

de Beurs 1995i

de Beurs 1995ii

Telch 1985

Subtotal (95% CI)

1/12

1/12

3/13

37

Total events: 5 (PT+AD), 1 (PT+placebo)

Heterogeneity: Tau2=0; Chi2=0.19, df=2(P=0.91); I2=0%

Test for overall effect: Z=1.71(P=0.09)

19.10.2 Cognitive-behaviour therapy

Barlow 2000i

Barlow 2000ii

Fahy 1992

Kampman 2002

Oehrberg 1995

Sharp 1996i

Sharp 1996ii

Spinhoven 1996

Subtotal (95% CI)

1/33

1/32

7/53

3/22

4/60

3/19

2/19

4/20

258

Total events: 25 (PT+AD), 2 (PT+placebo)

Heterogeneity: Tau2=0; Chi2=3.33, df=7(P=0.85); I2=0%

Test for overall effect: Z=3.38(P=0)

0/24

0/21

1/12

57

0/63

0/77

0/26

2/21

0/60

0/36

0/43

0/20

346

6.49%

6.51%

14.11%

27.11%

6.31%

6.31%

7.97%

22.36%

7.56%

7.49%

7.11%

7.78%

72.89%

5.77[0.25,131.92]

5.08[0.22,115.7]

2.77[0.33,23.14]

3.82[0.83,17.66]

5.65[0.24,134.91]

7.09[0.3,169.6]

7.5[0.44,126.48]

1.43[0.27,7.73]

9[0.5,163.58]

12.95[0.7,238.39]

11[0.55,218.74]

9[0.52,156.91]

5[1.96,12.72]

Total (95% CI)

295

403

100%

4.65[2.09,10.32]

Total events: 30 (PT+AD), 3 (PT+placebo)

Heterogeneity: Tau2=0; Chi2=3.61, df=10(P=0.96); I2=0%

Test for overall effect: Z=3.78(P=0)

Test for subgroup differences: Not applicable

Favours treatment

0.1

0.2

0.5

1

2

5

10

Favours control

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

281

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 19.11.   Comparison 19 SENSITIVITY3: operationalised criteria: Psychotherapy+Antidepressant
vs Psychotherapy alone or +Placebo, Outcome 11 Response/remission on continued treatment.

Study or subgroup

19.11.1 Behaviour therapy

Telch 1985

Subtotal (95% CI)

Total events: 7 (PT+AD), 2 (PT+placebo)

Heterogeneity: Not applicable

Test for overall effect: Z=1.69(P=0.09)

19.11.2 Cognitive-behaviour therapy

Barlow 2000i

Barlow 2000ii

Subtotal (95% CI)

PT+AD

n/N

PT+placebo

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

7/13

13

2/12

12

4.96%

4.96%

3.23[0.83,12.61]

3.23[0.83,12.61]

19/33

18/32

65

32/63

32/77

140

49.76%

45.28%

95.04%

1.13[0.77,1.66]

1.35[0.9,2.03]

1.23[0.93,1.63]

Total events: 37 (PT+AD), 64 (PT+placebo)

Heterogeneity: Tau2=0; Chi2=0.39, df=1(P=0.53); I2=0%

Test for overall effect: Z=1.48(P=0.14)

Total (95% CI)

78

152

100%

1.29[0.95,1.76]

Total events: 44 (PT+AD), 66 (PT+placebo)

Heterogeneity: Tau2=0.01; Chi2=2.32, df=2(P=0.31); I2=13.88%

Test for overall effect: Z=1.65(P=0.1)

Test for subgroup differences: Not applicable

Favours PT+placebo

0.1

0.2

0.5

1

2

5

10

Favours PT+AD

Analysis 19.12.   Comparison 19 SENSITIVITY3: operationalised criteria: Psychotherapy+Antidepressant
vs Psychotherapy alone or +Placebo, Outcome 12 Global/Avoidance/Panic on continued treatment.

Study or subgroup

PT+AD

PT+placebo

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

12.6 (8.1)

25.6 (8.8)

9

9

13.83%

13.83%

-1.47[-2.51,-0.43]

-1.47[-2.51,-0.43]

19.12.1 Behaviour therapy

Telch 1985

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=2.77(P=0.01)

19.12.2 Cognitive-behaviour therapy

Barlow 2000i

Barlow 2000ii

Subtotal ***

10

10

33

32

65

0.8 (0.9)

0.8 (0.9)

63

77

140

1.1 (0.8)

1.2 (0.9)

Heterogeneity: Tau2=0; Chi2=0.1, df=1(P=0.75); I2=0%

Test for overall effect: Z=2.73(P=0.01)

Total ***

75

149

Heterogeneity: Tau2=0.07; Chi2=3.75, df=2(P=0.15); I2=46.73%

Test for overall effect: Z=2.55(P=0.01)

Test for subgroup differences: Chi2=3.65, df=1 (P=0.06), I2=72.63%

42.77%

43.4%

86.17%

-0.37[-0.79,0.06]

-0.46[-0.88,-0.04]

-0.41[-0.71,-0.12]

100%

-0.56[-0.99,-0.13]

Favours treatment

-4

-2

0

2

4

Favours control

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

282

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 19.13.   Comparison 19 SENSITIVITY3: operationalised criteria: Psychotherapy+Antidepressant
vs Psychotherapy alone or +Placebo, Outcome 13 Dropouts for any reason on continued treatment.

PT+AD

n/N

PT+placebo

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

Study or subgroup

19.13.1 Behaviour therapy

de Beurs 1995

Telch 1985

Subtotal (95% CI)

Total events: 2 (PT+AD), 0 (PT+placebo)

Heterogeneity: Tau2=0; Chi2=0, df=1(P=0.97); I2=0%

Test for overall effect: Z=0.94(P=0.35)

19.13.2 Cognitive-behaviour therapy

Barlow 2000i

Barlow 2000ii

Subtotal (95% CI)

2/33

2/32

65

Total events: 4 (PT+AD), 13 (PT+placebo)

Heterogeneity: Tau2=0; Chi2=0, df=1(P=0.94); I2=0%

Test for overall effect: Z=0.75(P=0.45)

0/19

0/9

28

6/63

7/77

140

9.56%

9.91%

19.47%

3[0.13,69.31]

2.73[0.12,59.57]

2.86[0.32,25.8]

39.54%

40.99%

80.53%

0.64[0.14,2.98]

0.69[0.15,3.13]

0.66[0.22,1.95]

Total (95% CI)

94

168

100%

0.88[0.33,2.32]

Total events: 6 (PT+AD), 13 (PT+placebo)

Heterogeneity: Tau2=0; Chi2=1.38, df=3(P=0.71); I2=0%

Test for overall effect: Z=0.26(P=0.8)

Test for subgroup differences: Not applicable

Favours treatment

0.1

0.2

0.5

1

2

5

10

Favours control

Analysis 19.14.   Comparison 19 SENSITIVITY3: operationalised criteria: Psychotherapy+Antidepressant vs
Psychotherapy alone or +Placebo, Outcome 14 Response/remission 6-24 months after treatment discontinuation.

PT+AD

n/N

PT+placebo

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

Study or subgroup

19.14.1 Behaviour therapy

de Beurs 1995i

de Beurs 1995ii

Fava 1997

Mavissakalian 1986a

Mavissakalian 1986b

Subtotal (95% CI)

Total events: 26 (PT+AD), 37 (PT+placebo)

Heterogeneity: Tau2=0; Chi2=1.17, df=4(P=0.88); I2=0%

Test for overall effect: Z=0.09(P=0.93)

19.14.2 Cognitive-behaviour therapy

Barlow 2000i

Barlow 2000ii

Loerch 1999

Sharp 1996i

Sharp 1996ii

8/30

8/29

9/14

8/19

8/19

12/24

10/21

4/7

5/20

6/20

92

25/62

24/73

9/14

17/36

15/43

10.88%

10.02%

2.93%

5.1%

5.83%

34.74%

11.77%

11.47%

17.13%

13.15%

11.74%

Favours PT+placebo

0.1

0.2

0.5

1

2

5

10

Favours PT+AD

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

1[0.5,2]

1.05[0.51,2.16]

0.5[0.13,1.9]

1.2[0.44,3.3]

1[0.39,2.58]

0.98[0.67,1.45]

0.66[0.34,1.29]

0.84[0.43,1.65]

1[0.58,1.74]

0.89[0.47,1.67]

1.21[0.62,2.35]

283

1/19

1/10

29

6/12

6/12

2/7

6/20

6/20

71

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

PT+AD

n/N

PT+placebo

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

Subtotal (95% CI)

111

228

65.26%

0.91[0.69,1.21]

Total events: 41 (PT+AD), 90 (PT+placebo)

Heterogeneity: Tau2=0; Chi2=1.79, df=4(P=0.77); I2=0%

Test for overall effect: Z=0.66(P=0.51)

Total (95% CI)

182

320

100%

0.93[0.74,1.17]

Total events: 67 (PT+AD), 127 (PT+placebo)

Heterogeneity: Tau2=0; Chi2=3.05, df=9(P=0.96); I2=0%

Test for overall effect: Z=0.58(P=0.56)

Test for subgroup differences: Not applicable

Favours PT+placebo

0.1

0.2

0.5

1

2

5

10

Favours PT+AD

Analysis 19.15.   Comparison 19 SENSITIVITY3: operationalised criteria:
Psychotherapy+Antidepressant vs Psychotherapy alone or +Placebo, Outcome
15 Global/Avoidance/Panic 6-24 months after treatment discontinuation.

Study or subgroup

PT+AD

PT+placebo

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

3.2 (2.7)

3.5 (2.2)

3.3 (2.6)

1.3 (0.5)

1.2 (0.9)

1.3 (0.9)

19.15.1 Behaviour therapy

de Beurs 1995i

de Beurs 1995ii

Mavissakalian 1986a

Mavissakalian 1986b

Subtotal ***

3.3 (2.4)

3.3 (2.4)

2.1 (1.4)

2 (1.2)

9

9

14

11

43

Heterogeneity: Tau2=0.09; Chi2=4.61, df=3(P=0.2); I2=34.96%

Test for overall effect: Z=0.08(P=0.93)

19.15.2 Cognitive-behaviour therapy

Barlow 2000i

Barlow 2000ii

Subtotal ***

1.5 (0.9)

1.5 (0.9)

30

29

59

Heterogeneity: Tau2=0; Chi2=0.27, df=1(P=0.6); I2=0%

Test for overall effect: Z=1.34(P=0.18)

19

17

11

11

58

62

73

135

Total ***

102

193

Heterogeneity: Tau2=0.01; Chi2=5.44, df=5(P=0.36); I2=8.17%

Test for overall effect: Z=1.01(P=0.31)

Test for subgroup differences: Chi2=0.56, df=1 (P=0.45), I2=0%

10.3%

9.94%

9.92%

8.69%

0.07[-0.72,0.86]

-0.05[-0.86,0.76]

-0.58[-1.39,0.23]

0.71[-0.16,1.58]

38.85%

0.02[-0.49,0.53]

30.13%

31.02%

61.15%

0.29[-0.14,0.73]

0.13[-0.3,0.56]

0.21[-0.1,0.52]

100%

0.13[-0.13,0.4]

Favours treatment

-4

-2

0

2

4

Favours control

Comparison 20.   SENSITIVITY5: without benzo: Psychotherapy+Antidepressant vs Antidepressant alone

Outcome or subgroup title

No. of
studies

No. of
partici-
pants

Statistical method

Effect size

1 Response at 2-4 months

3

122

Risk Ratio (M-H, Random,
95% CI)

1.37 [0.91, 2.05]

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

284

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

1.1 Behaviour therapy

1.2 Cognitive-behaviour therapy

1.3 Psychodynamic psychotherapy and others

2 Remission at 2-4 months

2.1 Behaviour therapy

2.2 Cognitive-behaviour therapy

2.3 Psychodynamic psychotherapy and others

3 Global severity at 2-4 months

3.1 Behaviour therapy

3.2 Cognitive-behaviour therapy

3.3 Psychodynamic psychotherapy and others

4 Frequency of panic attacks at 2-4 months

4.1 Behaviour therapy

4.2 Cognitive-behaviour therapy

4.3 Psychodynamic psychotherapy and others

5 Phobic avoidance at 2-4 months

5.1 Behaviour therapy

5.2 Cognitive-behaviour therapy

No. of
studies

No. of
partici-
pants

Statistical method

Effect size

1

2

0

3

1

2

0

2

1

1

0

1

1

0

0

3

1

2

18

104

0

122

18

104

0

73

15

58

0

15

15

0

0

103

15

88

Risk Ratio (M-H, Random,
95% CI)

1.17 [0.65, 2.08]

Risk Ratio (M-H, Random,
95% CI)

1.59 [0.75, 3.34]

Risk Ratio (M-H, Random,
95% CI)

0.0 [0.0, 0.0]

Risk Ratio (M-H, Random,
95% CI)

1.40 [0.72, 2.73]

Risk Ratio (M-H, Random,
95% CI)

1.0 [0.52, 1.92]

Risk Ratio (M-H, Random,
95% CI)

2.13 [0.45, 10.10]

Risk Ratio (M-H, Random,
95% CI)

0.0 [0.0, 0.0]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.62 [-1.14, -0.10]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-1.14 [-2.26, -0.02]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.48 [-1.01, 0.04]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.0 [0.0, 0.0]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.22 [-1.24, 0.80]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.22 [-1.24, 0.80]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.0 [0.0, 0.0]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.0 [0.0, 0.0]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.65 [-1.37, 0.07]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-1.07 [-2.18, 0.04]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.53 [-1.45, 0.39]

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

285

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of
studies

No. of
partici-
pants

Statistical method

Effect size

5.3 Psychodynamic psychotherapy and others

6 General anxiety at 2-4 months

6.1 Behaviour therapy

6.2 Cognitive-behaviour therapy

6.3 Psychodynamic psychotherapy and others

7 Depression at 2-4 months

7.1 Behaviour therapy

7.2 Cognitive-behaviour therapy

7.3 Psychodynamic psychotherapy and others

8 Social functioning at 2-4 months

8.1 Behavour therapy

8.2 Cognitive-behaviour therapy

8.3 Psychodynamic psychotherapy and others

9 Dropouts for any reason within 2-4 months

9.1 Behaviour therapy

9.2 Cognitive-behaviour therapy

9.3 Psychodynamic psychotherapy and others

10 Dropouts due to side effects within 2-4
months

0

3

1

2

0

2

1

1

0

3

1

2

0

3

1

2

0

2

0

103

15

88

0

45

15

30

0

103

15

88

0

122

18

104

0

92

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.0 [0.0, 0.0]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.57 [-0.96, -0.17]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.49 [-1.53, 0.54]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.58 [-1.01, -0.15]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.0 [0.0, 0.0]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

1.00 [-1.63, -0.37]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-1.14 [-2.26, -0.02]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.93 [-1.69, -0.17]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.0 [0.0, 0.0]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.70 [-1.26, -0.13]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-1.05 [-2.15, 0.06]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.63 [-1.39, 0.12]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.0 [0.0, 0.0]

Risk Ratio (M-H, Random,
95% CI)

0.73 [0.41, 1.28]

Risk Ratio (M-H, Random,
95% CI)

0.5 [0.05, 4.58]

Risk Ratio (M-H, Random,
95% CI)

0.75 [0.42, 1.34]

Risk Ratio (M-H, Random,
95% CI)

0.0 [0.0, 0.0]

Risk Ratio (M-H, Random,
95% CI)

1.15 [0.36, 3.67]

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

286

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

10.1 Behaviour therapy

10.2 Cognitive-behaviour therapy

10.3 Psychodynamic psychotherapy and others

11 Response/remission on continued treatment

11.1 Behaviour therapy

11.2 Cognitive-behaviour therapy

11.3 Psychdynamic psychotherapy and others

12 Global/Avoidance/Panic on continued treat-
ment

12.1 Behaviour therapy

12.2 Cognitive-behaviour therapy

12.3 Psychodynamic psychotherapy and others

13 Dropouts for any reason on continued treat-
ment

13.1 Behaviour therapy

13.2 Cognitive-behaviour therapy

13.3 Psychodynamic psychotherapy and others

16 Response/remission 6-24 months after treat-
ment discontinuation

16.1 Behaviour therapy

16.2 Cognitive-behaviour therapy

No. of
studies

No. of
partici-
pants

Statistical method

Effect size

1

1

0

0

0

0

0

0

0

0

0

0

0

0

0

2

0

2

18

74

0

0

0

0

0

0

0

0

0

0

0

0

0

104

0

104

Risk Ratio (M-H, Random,
95% CI)

0.5 [0.05, 4.58]

Risk Ratio (M-H, Random,
95% CI)

1.58 [0.41, 6.13]

Risk Ratio (M-H, Random,
95% CI)

0.0 [0.0, 0.0]

Risk Ratio (M-H, Random,
95% CI)

0.0 [0.0, 0.0]

Risk Ratio (M-H, Random,
95% CI)

0.0 [0.0, 0.0]

Risk Ratio (M-H, Random,
95% CI)

0.0 [0.0, 0.0]

Risk Ratio (M-H, Random,
95% CI)

0.0 [0.0, 0.0]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.0 [0.0, 0.0]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.0 [0.0, 0.0]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.0 [0.0, 0.0]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.0 [0.0, 0.0]

Risk Ratio (M-H, Random,
95% CI)

0.0 [0.0, 0.0]

Risk Ratio (M-H, Random,
95% CI)

0.0 [0.0, 0.0]

Risk Ratio (M-H, Random,
95% CI)

0.0 [0.0, 0.0]

Risk Ratio (M-H, Random,
95% CI)

0.0 [0.0, 0.0]

Risk Ratio (M-H, Random,
95% CI)

1.49 [0.94, 2.38]

Risk Ratio (M-H, Random,
95% CI)

0.0 [0.0, 0.0]

Risk Ratio (M-H, Random,
95% CI)

1.49 [0.94, 2.38]

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

287

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of
studies

No. of
partici-
pants

Statistical method

Effect size

16.3 Psychodynamic psychotherapy and others

17 Global/Avoidance/Panic 6-24 months after
treatment discontinuation

17.1 Behaviour therapy

17.2 Cognitive-behaviour therapy

17.3 Psychodynamic psychotherapy and others

0

0

0

0

0

0

0

0

0

0

Risk Ratio (M-H, Random,
95% CI)

0.0 [0.0, 0.0]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.0 [0.0, 0.0]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.0 [0.0, 0.0]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.0 [0.0, 0.0]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.0 [0.0, 0.0]

Analysis 20.1.   Comparison 20 SENSITIVITY5: without benzo: Psychotherapy
+Antidepressant vs Antidepressant alone, Outcome 1 Response at 2-4 months.

Study or subgroup

PT+AD

n/N

AD

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

20.1.1 Behaviour therapy

Mavissakalian 1983

Subtotal (95% CI)

Total events: 7 (PT+AD), 6 (AD)

Heterogeneity: Not applicable

Test for overall effect: Z=0.52(P=0.6)

20.1.2 Cognitive-behaviour therapy

Loerch 1999

Sharp 1996

Subtotal (95% CI)

7/9

9

6/9

9

30.17%

30.17%

1.17[0.65,2.08]

1.17[0.65,2.08]

11/14

26/38

52

5/16

21/36

52

20.2%

49.63%

69.83%

2.51[1.16,5.47]

1.17[0.83,1.67]

1.59[0.75,3.34]

Total events: 37 (PT+AD), 26 (AD)

Heterogeneity: Tau2=0.21; Chi2=3.2, df=1(P=0.07); I2=68.7%

Test for overall effect: Z=1.22(P=0.22)

20.1.3 Psychodynamic psychotherapy and others

Subtotal (95% CI)

Total events: 0 (PT+AD), 0 (AD)

Heterogeneity: Not applicable

Test for overall effect: Not applicable

0

0

Not estimable

Total (95% CI)

61

61

100%

1.37[0.91,2.05]

Total events: 44 (PT+AD), 32 (AD)

Heterogeneity: Tau2=0.05; Chi2=3.38, df=2(P=0.18); I2=40.86%

Test for overall effect: Z=1.51(P=0.13)

Test for subgroup differences: Not applicable

Favours AD

0.1

0.2

0.5

1

2

5

10

Favours PT+AD

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

288

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 20.2.   Comparison 20 SENSITIVITY5: without benzo: Psychotherapy
+Antidepressant vs Antidepressant alone, Outcome 2 Remission at 2-4 months.

Study or subgroup

PT+AD

n/N

AD

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

20.2.1 Behaviour therapy

Mavissakalian 1983

Subtotal (95% CI)

Total events: 6 (PT+AD), 6 (AD)

Heterogeneity: Not applicable

Test for overall effect: Not applicable

20.2.2 Cognitive-behaviour therapy

Loerch 1999

Sharp 1996

Subtotal (95% CI)

6/9

9

6/9

9

36.17%

36.17%

1[0.52,1.92]

1[0.52,1.92]

9/14

24/38

52

2/16

20/36

52

16.89%

46.93%

63.83%

5.14[1.33,19.92]

1.14[0.78,1.66]

2.13[0.45,10.1]

Total events: 33 (PT+AD), 22 (AD)

Heterogeneity: Tau2=1.04; Chi2=5.05, df=1(P=0.02); I2=80.19%

Test for overall effect: Z=0.95(P=0.34)

20.2.3 Psychodynamic psychotherapy and others

Subtotal (95% CI)

Total events: 0 (PT+AD), 0 (AD)

Heterogeneity: Not applicable

Test for overall effect: Not applicable

0

0

Not estimable

Total (95% CI)

61

61

100%

1.4[0.72,2.73]

Total events: 39 (PT+AD), 28 (AD)

Heterogeneity: Tau2=0.21; Chi2=5.49, df=2(P=0.06); I2=63.6%

Test for overall effect: Z=0.99(P=0.32)

Test for subgroup differences: Not applicable

Favours AD

0.1

0.2

0.5

1

2

5

10

Favours PT+AD

Analysis 20.3.   Comparison 20 SENSITIVITY5: without benzo: Psychotherapy
+Antidepressant vs Antidepressant alone, Outcome 3 Global severity at 2-4 months.

Study or subgroup

Treatment

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

20.3.1 Behaviour therapy

Mavissakalian 1983

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=2(P=0.05)

20.3.2 Cognitive-behaviour therapy

Sharp 1996

Subtotal ***

8

8

29

29

2.2 (0.8)

1.7 (1.1)

7

7

29

29

3.7 (1.6)

2.3 (1.2)

Heterogeneity: Tau2=0; Chi2=0, df=0(P<0.0001); I2=100%

Test for overall effect: Z=1.81(P=0.07)

20.3.3 Psychodynamic psychotherapy and others

20.5%

20.5%

-1.14[-2.26,-0.02]

-1.14[-2.26,-0.02]

79.5%

79.5%

-0.48[-1.01,0.04]

-0.48[-1.01,0.04]

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

289

Favours treatment

-4

-2

0

2

4

Favours control

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Treatment

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Not applicable

Total ***

0

37

0

36

Heterogeneity: Tau2=0.02; Chi2=1.09, df=1(P=0.3); I2=8.16%

Test for overall effect: Z=2.33(P=0.02)

Test for subgroup differences: Chi2=1.09, df=1 (P=0.3), I2=8.16%

Random, 95% CI

Not estimable

100%

-0.62[-1.14,-0.1]

Favours treatment

-4

-2

0

2

4

Favours control

Analysis 20.4.   Comparison 20 SENSITIVITY5: without benzo: Psychotherapy+Antidepressant
vs Antidepressant alone, Outcome 4 Frequency of panic attacks at 2-4 months.

Study or subgroup

Treatment

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

1.7 (1.9)

20.4.1 Behaviour therapy

Mavissakalian 1983

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=0.42(P=0.67)

20.4.2 Cognitive-behaviour therapy

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Not applicable

8

8

0

20.4.3 Psychodynamic psychotherapy and others

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Not applicable

Total ***

0

8

Heterogeneity: Not applicable

Test for overall effect: Z=0.42(P=0.67)

Test for subgroup differences: Not applicable

7

7

0

0

7

2.1 (1.8)

100%

100%

-0.22[-1.24,0.8]

-0.22[-1.24,0.8]

Not estimable

Not estimable

100%

-0.22[-1.24,0.8]

Favours treatment

-4

-2

0

2

4

Favours control

Analysis 20.5.   Comparison 20 SENSITIVITY5: without benzo: Psychotherapy
+Antidepressant vs Antidepressant alone, Outcome 5 Phobic avoidance at 2-4 months.

Study or subgroup

Treatment

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

20.5.1 Behaviour therapy

Mavissakalian 1983

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=1.89(P=0.06)

8.6 (6.2)

8

8

19.4 (12.4)

7

7

23.76%

23.76%

-1.07[-2.18,0.04]

-1.07[-2.18,0.04]

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

290

Favours treatment

-4

-2

0

2

4

Favours control

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Treatment

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

20.5.2 Cognitive-behaviour therapy

Loerch 1999

Sheehan 1980a

Subtotal ***

7 (8.3)

4.7 (7.8)

14

29

43

Heterogeneity: Tau2=0.34; Chi2=4, df=1(P=0.05); I2=74.97%

Test for overall effect: Z=1.12(P=0.26)

20.5.3 Psychodynamic psychotherapy and others

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Not applicable

Total ***

0

51

Heterogeneity: Tau2=0.25; Chi2=5.24, df=2(P=0.07); I2=61.82%

Test for overall effect: Z=1.77(P=0.08)

Test for subgroup differences: Chi2=1.24, df=1 (P=0.26), I2=19.56%

16

29

45

0

52

19 (13.2)

5.5 (7.9)

33.53%

42.7%

76.24%

-1.05[-1.82,-0.28]

-0.1[-0.62,0.41]

-0.53[-1.45,0.39]

Not estimable

100%

-0.65[-1.37,0.07]

Favours treatment

-4

-2

0

2

4

Favours control

Analysis 20.6.   Comparison 20 SENSITIVITY5: without benzo: Psychotherapy
+Antidepressant vs Antidepressant alone, Outcome 6 General anxiety at 2-4 months.

Study or subgroup

Treatment

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

32.3 (13.1)

19.9 (9.8)

7.9 (7)

20.6.1 Behaviour therapy

Mavissakalian 1983

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=0.93(P=0.35)

20.6.2 Cognitive-behaviour therapy

Loerch 1999

Sharp 1996

Subtotal ***

27.3 (4.8)

11.4 (11.1)

4.8 (5.7)

8

8

14

29

43

Heterogeneity: Tau2=0; Chi2=0.45, df=1(P=0.5); I2=0%

Test for overall effect: Z=2.66(P=0.01)

20.6.3 Psychodynamic psychotherapy and others

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Not applicable

Total ***

0

51

Heterogeneity: Tau2=0; Chi2=0.47, df=2(P=0.79); I2=0%

Test for overall effect: Z=2.81(P=0)

Test for subgroup differences: Chi2=0.03, df=1 (P=0.87), I2=0%

7

7

16

29

45

0

52

14.64%

14.64%

-0.49[-1.53,0.54]

-0.49[-1.53,0.54]

27.96%

57.4%

85.36%

-0.79[-1.54,-0.04]

-0.48[-1,0.04]

-0.58[-1.01,-0.15]

Not estimable

100%

-0.57[-0.96,-0.17]

Favours treatment

-4

-2

0

2

4

Favours control

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

291

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 20.7.   Comparison 20 SENSITIVITY5: without benzo: Psychotherapy
+Antidepressant vs Antidepressant alone, Outcome 7 Depression at 2-4 months.

Study or subgroup

Treatment

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

9.1 (7.8)

12 (7.4)

20.7.1 Behaviour therapy

Mavissakalian 1983

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=2(P=0.05)

20.7.2 Cognitive-behaviour therapy

Loerch 1999

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=2.4(P=0.02)

2.4 (2)

5.6 (5.8)

8

8

14

14

20.7.3 Psychodynamic psychotherapy and others

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Not applicable

Total ***

0

22

Heterogeneity: Tau2=0; Chi2=0.09, df=1(P=0.76); I2=0%

Test for overall effect: Z=3.11(P=0)

Test for subgroup differences: Chi2=0.09, df=1 (P=0.76), I2=0%

7

7

16

16

0

23

31.53%

31.53%

-1.14[-2.26,-0.02]

-1.14[-2.26,-0.02]

68.47%

68.47%

-0.93[-1.69,-0.17]

-0.93[-1.69,-0.17]

Not estimable

100%

-1[-1.63,-0.37]

Favours treatment

-4

-2

0

2

4

Favours control

Analysis 20.8.   Comparison 20 SENSITIVITY5: without benzo: Psychotherapy
+Antidepressant vs Antidepressant alone, Outcome 8 Social functioning at 2-4 months.

Study or subgroup

Treatment

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

2.9 (0.9)

5.9 (3.5)

2.2 (2.9)

20.8.1 Behavour therapy

Mavissakalian 1983

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=1.86(P=0.06)

20.8.2 Cognitive-behaviour therapy

Loerch 1999

Sharp 1996

Subtotal ***

1.9 (0.9)

2.4 (2.8)

1.4 (2.8)

8

8

14

29

43

Heterogeneity: Tau2=0.19; Chi2=2.67, df=1(P=0.1); I2=62.54%

Test for overall effect: Z=1.65(P=0.1)

20.8.3 Psychodynamic psychotherapy and others

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Not applicable

Total ***

0

51

7

7

16

29

45

0

52

19.82%

19.82%

-1.05[-2.15,0.06]

-1.05[-2.15,0.06]

32.1%

48.08%

80.18%

-1.08[-1.85,-0.3]

-0.3[-0.82,0.22]

-0.63[-1.39,0.12]

Not estimable

100%

-0.7[-1.26,-0.13]

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

292

Favours treatment

-4

-2

0

2

4

Favours control

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Treatment

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

Heterogeneity: Tau2=0.1; Chi2=3.36, df=2(P=0.19); I2=40.55%

Test for overall effect: Z=2.42(P=0.02)

Test for subgroup differences: Chi2=0.69, df=1 (P=0.4), I2=0%

Favours treatment

-4

-2

0

2

4

Favours control

Analysis 20.9.   Comparison 20 SENSITIVITY5: without benzo: Psychotherapy+Antidepressant
vs Antidepressant alone, Outcome 9 Dropouts for any reason within 2-4 months.

Study or subgroup

20.9.1 Behaviour therapy

Mavissakalian 1983

Subtotal (95% CI)

Total events: 1 (Treatment), 2 (Control)

Heterogeneity: Not applicable

Test for overall effect: Z=0.61(P=0.54)

20.9.2 Cognitive-behaviour therapy

Loerch 1999

Sharp 1996

Subtotal (95% CI)

Treatment

n/N

Control

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

1/9

9

2/9

9

6.51%

6.51%

0.5[0.05,4.58]

0.5[0.05,4.58]

3/14

11/38

52

7/16

12/36

52

24.29%

69.2%

93.49%

0.49[0.16,1.54]

0.87[0.44,1.71]

0.75[0.42,1.34]

Total events: 14 (Treatment), 19 (Control)

Heterogeneity: Tau2=0; Chi2=0.71, df=1(P=0.4); I2=0%

Test for overall effect: Z=0.97(P=0.33)

20.9.3 Psychodynamic psychotherapy and others

Subtotal (95% CI)

0

0

Total events: 0 (Treatment), 0 (Control)

Heterogeneity: Not applicable

Test for overall effect: Not applicable

Not estimable

Total (95% CI)

61

61

100%

0.73[0.41,1.28]

Total events: 15 (Treatment), 21 (Control)

Heterogeneity: Tau2=0; Chi2=0.83, df=2(P=0.66); I2=0%

Test for overall effect: Z=1.1(P=0.27)

Test for subgroup differences: Not applicable

Favours treatment

0.1

0.2

0.5

1

2

5

10

Favours control

Analysis 20.10.   Comparison 20 SENSITIVITY5: without benzo: Psychotherapy+Antidepressant
vs Antidepressant alone, Outcome 10 Dropouts due to side effects within 2-4 months.

Study or subgroup

20.10.1 Behaviour therapy

Mavissakalian 1983

Subtotal (95% CI)

Total events: 1 (Treatment), 2 (Control)

Treatment

n/N

Control

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

1/9

9

2/9

9

27.28%

27.28%

0.5[0.05,4.58]

0.5[0.05,4.58]

Favours treatment

0.1

0.2

0.5

1

2

5

10

Favours control

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

293

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Treatment

n/N

Control

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

Heterogeneity: Not applicable

Test for overall effect: Z=0.61(P=0.54)

20.10.2 Cognitive-behaviour therapy

Sharp 1996

Subtotal (95% CI)

Total events: 5 (Treatment), 3 (Control)

Heterogeneity: Not applicable

Test for overall effect: Z=0.66(P=0.51)

5/38

38

3/36

36

72.72%

72.72%

1.58[0.41,6.13]

1.58[0.41,6.13]

20.10.3 Psychodynamic psychotherapy and others

Subtotal (95% CI)

0

0

Total events: 0 (Treatment), 0 (Control)

Heterogeneity: Not applicable

Test for overall effect: Not applicable

Not estimable

Total (95% CI)

47

45

100%

1.15[0.36,3.67]

Total events: 6 (Treatment), 5 (Control)

Heterogeneity: Tau2=0; Chi2=0.75, df=1(P=0.39); I2=0%

Test for overall effect: Z=0.24(P=0.81)

Test for subgroup differences: Not applicable

Favours treatment

0.1

0.2

0.5

1

2

5

10

Favours control

Analysis 20.16.   Comparison 20 SENSITIVITY5: without benzo: Psychotherapy+Antidepressant vs
Antidepressant alone, Outcome 16 Response/remission 6-24 months after treatment discontinuation.

Study or subgroup

PT+AD

n/N

AD

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

20.16.1 Behaviour therapy

Subtotal (95% CI)

Total events: 0 (PT+AD), 0 (AD)

Heterogeneity: Not applicable

Test for overall effect: Not applicable

20.16.2 Cognitive-behaviour therapy

Loerch 1999

Sharp 1996

Subtotal (95% CI)

0

0

Not estimable

9/14

16/38

52

7/16

10/36

52

47.45%

52.55%

100%

1.47[0.75,2.9]

1.52[0.8,2.89]

1.49[0.94,2.38]

Total events: 25 (PT+AD), 17 (AD)

Heterogeneity: Tau2=0; Chi2=0, df=1(P=0.95); I2=0%

Test for overall effect: Z=1.68(P=0.09)

20.16.3 Psychodynamic psychotherapy and others

Subtotal (95% CI)

Total events: 0 (PT+AD), 0 (AD)

Heterogeneity: Not applicable

Test for overall effect: Not applicable

0

0

Not estimable

Total (95% CI)

52

52

100%

1.49[0.94,2.38]

Favours AD

0.1

0.2

0.5

1

2

5

10

Favours PT+AD

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

294

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

PT+AD

n/N

AD

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

Total events: 25 (PT+AD), 17 (AD)

Heterogeneity: Tau2=0; Chi2=0, df=1(P=0.95); I2=0%

Test for overall effect: Z=1.68(P=0.09)

Test for subgroup differences: Not applicable

Favours AD

0.1

0.2

0.5

1

2

5

10

Favours PT+AD

Comparison 21.   SENSITIVITY5: without benzo: Psychotherapy+Antidepressant vs Psychotherapy alone or +Placebo

Outcome or subgroup title

1 Response at 2-4 months

1.1 Behaviour therapy

1.2 Cognitive-behaviour therapy

1.3 Psychodynamic and other therapies

2 Remission at 2-4 months

2.1 Behaviour therapy

2.2 Cognitive-behaviour therapy

2.3 Psychodynamic and other therapies

3 Global severity at 2-4 months

3.1 Behaviour therapy

3.2 Cognitive-behaviour therapy

3.3 Psychodynamic and other therapies

4 Frequency of panic attacks at 2-4 months

4.1 Behaviour therapy

No. of
studies

No. of
partici-
pants

Statistical method

Effect size

8

3

5

0

9

3

6

0

3

0

3

0

1

0

481

159

322

0

536

159

377

0

158

0

158

0

107

0

Risk Ratio (M-H, Random, 95%
CI)

1.26 [1.06, 1.51]

Risk Ratio (M-H, Random, 95%
CI)

1.48 [1.00, 2.18]

Risk Ratio (M-H, Random, 95%
CI)

1.22 [0.96, 1.55]

Risk Ratio (M-H, Random, 95%
CI)

0.0 [0.0, 0.0]

Risk Ratio (M-H, Random, 95%
CI)

1.32 [1.08, 1.61]

Risk Ratio (M-H, Random, 95%
CI)

1.27 [0.84, 1.93]

Risk Ratio (M-H, Random, 95%
CI)

1.33 [1.02, 1.73]

Risk Ratio (M-H, Random, 95%
CI)

0.0 [0.0, 0.0]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.35 [-0.81, 0.10]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.0 [0.0, 0.0]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.35 [-0.81, 0.10]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.0 [0.0, 0.0]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.33 [-0.72, 0.05]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.0 [0.0, 0.0]

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

295

 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of
studies

No. of
partici-
pants

Statistical method

Effect size

4.2 Cognitive-behaviour therapy

5 Phobic avoidance at 2-4 months

5.1 Behaviour therapy

5.2 Cognitive-behaviour therapy

5.3 Psychodynamic and other therapies

6 General anxiety at 2-4 months

6.1 Behaviour therapy

6.2 Cognitive-behaviour therapy

6.3 Psychodynamic and other therapies

7 Depression at 2-4 months

7.1 Behaviour therapy

7.2 Cognitive-behaviour therapy

7.3 Psychodynamic and other therapies

8 Social functioning at 2-4 months

8.1 Behaviour therapy

8.2 Cognitive-behaviour therapy

9 Dropouts for any reason within 2-4 months

9.1 Behaviour therapy

1

8

3

5

0

9

3

6

0

6

3

3

0

6

2

4

9

3

107

312

102

210

0

419

102

317

0

220

102

118

0

201

57

144

536

159

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.33 [-0.72, 0.05]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.32 [-0.56, -0.08]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.65 [-1.29, -0.01]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.20 [-0.48, 0.08]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.0 [0.0, 0.0]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.43 [-0.67, -0.20]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.89 [-1.49, -0.29]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.30 [-0.53, -0.08]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.0 [0.0, 0.0]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.44 [-0.78, -0.10]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.59 [-1.33, 0.14]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.38 [-0.76, -0.01]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.0 [0.0, 0.0]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.31 [-0.74, 0.11]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

1.00 [-1.57, -0.43]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.04 [-0.39, 0.30]

Risk Ratio (M-H, Random, 95%
CI)

1.18 [0.83, 1.68]

Risk Ratio (M-H, Random, 95%
CI)

1.10 [0.67, 1.82]

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

296

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of
studies

No. of
partici-
pants

Statistical method

Effect size

9.2 Cognitive-behaviour therapy

9.3 Psychodynamic and other therapies

10 Dropouts due to side effects within 2-4
months

10.1 Behaviour therapy

10.2 Cognitive-behaviour therapy

11 Response/remission on continued treat-
ment

11.1 Behaviour therapy

11.2 Cognitive-behaviour therapy

12 Global/Avoidance/Panic on continued
treatment

12.1 Behaviour therapy

12.2 Cognitive-behaviour therapy

13 Dropouts for any reason on continued
treatment

13.1 Behaviour therapy

13.2 Cognitive-behaviour therapy

14 Response/remission 6-24 months after
treatment discontinuation

14.1 Behaviour therapy

14.2 Cognitive-behaviour therapy

15 Global/Avoidance/Panic 6-24 months after
treatment discontinuation

6

0

5

1

4

0

0

0

0

0

0

0

0

0

4

1

3

1

377

0

388

72

316

0

0

0

0

0

0

0

0

0

217

72

145

40

Risk Ratio (M-H, Random, 95%
CI)

1.28 [0.75, 2.19]

Risk Ratio (M-H, Random, 95%
CI)

0.0 [0.0, 0.0]

Risk Ratio (M-H, Random, 95%
CI)

4.09 [1.03, 16.22]

Risk Ratio (M-H, Random, 95%
CI)

0.67 [0.12, 3.75]

Risk Ratio (M-H, Random, 95%
CI)

9.84 [2.30, 42.08]

Risk Ratio (M-H, Random, 95%
CI)

0.0 [0.0, 0.0]

Risk Ratio (M-H, Random, 95%
CI)

0.0 [0.0, 0.0]

Risk Ratio (M-H, Random, 95%
CI)

0.0 [0.0, 0.0]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.0 [0.0, 0.0]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.0 [0.0, 0.0]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.0 [0.0, 0.0]

Risk Ratio (M-H, Random, 95%
CI)

0.0 [0.0, 0.0]

Risk Ratio (M-H, Random, 95%
CI)

0.0 [0.0, 0.0]

Risk Ratio (M-H, Random, 95%
CI)

0.0 [0.0, 0.0]

Risk Ratio (M-H, Random, 95%
CI)

0.98 [0.71, 1.35]

Risk Ratio (M-H, Random, 95%
CI)

0.82 [0.39, 1.73]

Risk Ratio (M-H, Random, 95%
CI)

1.02 [0.71, 1.45]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.14 [-0.48, 0.77]

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

297

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

15.1 Behaviour therapy

15.2 Cognitive-behaviour therapy

No. of
studies

No. of
partici-
pants

1

0

40

0

Statistical method

Effect size

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.14 [-0.48, 0.77]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.0 [0.0, 0.0]

Analysis 21.1.   Comparison 21 SENSITIVITY5: without benzo: Psychotherapy
+Antidepressant vs Psychotherapy alone or +Placebo, Outcome 1 Response at 2-4 months.

PT+AD

n/N

PT+placebo

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

Study or subgroup

21.1.1 Behaviour therapy

Marks 1983

Sheehan 1980a

Sheehan 1980b

Subtotal (95% CI)

17/36

16/28

16/29

93

Total events: 49 (PT+AD), 23 (PT+placebo)

Heterogeneity: Tau2=0; Chi2=0.04, df=2(P=0.98); I2=0%

Test for overall effect: Z=1.98(P=0.05)

21.1.2 Cognitive-behaviour therapy

Fahy 1992

Loerch 1999

Oehrberg 1995

Sharp 1996ii

Stein 2000

Subtotal (95% CI)

26/53

11/14

42/60

13/19

13/16

162

Total events: 105 (PT+AD), 84 (PT+placebo)

Heterogeneity: Tau2=0.03; Chi2=7.36, df=4(P=0.12); I2=45.64%

Test for overall effect: Z=1.61(P=0.11)

21.1.3 Psychodynamic and other therapies

12/36

6/16

5/14

66

9/26

12/14

25/60

26/43

12/17

160

8.46%

5.8%

4.91%

19.17%

7.99%

19.65%

20.09%

16.45%

16.64%

80.83%

1.42[0.8,2.52]

1.52[0.75,3.1]

1.54[0.71,3.36]

1.48[1,2.18]

1.42[0.78,2.57]

0.92[0.65,1.3]

1.68[1.19,2.37]

1.13[0.77,1.67]

1.15[0.78,1.69]

1.22[0.96,1.55]

Subtotal (95% CI)

0

0

Not estimable

Total events: 0 (PT+AD), 0 (PT+placebo)

Heterogeneity: Not applicable

Test for overall effect: Not applicable

Total (95% CI)

255

226

100%

1.26[1.06,1.51]

Total events: 154 (PT+AD), 107 (PT+placebo)

Heterogeneity: Tau2=0.01; Chi2=8.32, df=7(P=0.31); I2=15.84%

Test for overall effect: Z=2.58(P=0.01)

Test for subgroup differences: Not applicable

Favours PT+placebo

0.1

0.2

0.5

1

2

5

10

Favours PT+AD

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

298

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 21.2.   Comparison 21 SENSITIVITY5: without benzo: Psychotherapy
+Antidepressant vs Psychotherapy alone or +Placebo, Outcome 2 Remission at 2-4 months.

PT+AD

n/N

PT+placebo

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

Study or subgroup

21.2.1 Behaviour therapy

Marks 1983

Sheehan 1980a

Sheehan 1980b

Subtotal (95% CI)

20/36

5/28

10/29

93

Total events: 35 (PT+AD), 21 (PT+placebo)

Heterogeneity: Tau2=0; Chi2=1.23, df=2(P=0.54); I2=0%

Test for overall effect: Z=1.15(P=0.25)

21.2.2 Cognitive-behaviour therapy

Fahy 1992

Loerch 1999

Oehrberg 1995

Sharp 1996i

Sharp 1996ii

Stein 2000

Subtotal (95% CI)

28/53

9/14

39/60

12/19

12/19

7/16

181

Total events: 107 (PT+AD), 88 (PT+placebo)

Heterogeneity: Tau2=0.04; Chi2=7.92, df=5(P=0.16); I2=36.89%

Test for overall effect: Z=2.08(P=0.04)

21.2.3 Psychodynamic and other therapies

17/36

2/15

2/15

66

10/26

8/14

21/60

25/36

21/43

3/17

196

16.2%

1.73%

2.07%

20%

11.7%

10.05%

20.36%

19.25%

15.76%

2.88%

80%

1.18[0.75,1.85]

1.34[0.29,6.09]

2.59[0.65,10.32]

1.27[0.84,1.93]

1.37[0.79,2.38]

1.13[0.62,2.05]

1.86[1.26,2.75]

0.91[0.61,1.37]

1.29[0.82,2.05]

2.48[0.77,7.97]

1.33[1.02,1.73]

Subtotal (95% CI)

0

0

Not estimable

Total events: 0 (PT+AD), 0 (PT+placebo)

Heterogeneity: Not applicable

Test for overall effect: Not applicable

Total (95% CI)

274

262

100%

1.32[1.08,1.61]

Total events: 142 (PT+AD), 109 (PT+placebo)

Heterogeneity: Tau2=0.01; Chi2=9.16, df=8(P=0.33); I2=12.67%

Test for overall effect: Z=2.67(P=0.01)

Test for subgroup differences: Not applicable

Favours PT+placebo

0.1

0.2

0.5

1

2

5

10

Favours PT+AD

Analysis 21.3.   Comparison 21 SENSITIVITY5: without benzo: Psychotherapy+Antidepressant
vs Psychotherapy alone or +Placebo, Outcome 3 Global severity at 2-4 months.

Study or subgroup

PT+AD

PT+placebo

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

21.3.1 Behaviour therapy

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Not applicable

21.3.2 Cognitive-behaviour therapy

Fahy 1992

Sharp 1996i

0

42

15

0

24

33

2 (1.1)

1.7 (1.1)

Not estimable

2.8 (1)

2 (1.3)

37.91%

31.69%

-0.74[-1.26,-0.22]

-0.24[-0.86,0.37]

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

299

Favours treatment

-4

-2

0

2

4

Favours control

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

PT+AD

PT+placebo

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

1.7 (1)

Sharp 1996ii

Subtotal ***

1.7 (1.1)

14

71

Heterogeneity: Tau2=0.07; Chi2=3.6, df=2(P=0.17); I2=44.37%

Test for overall effect: Z=1.52(P=0.13)

21.3.3 Psychodynamic and other therapies

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Not applicable

Total ***

0

71

Heterogeneity: Tau2=0.07; Chi2=3.6, df=2(P=0.17); I2=44.37%

Test for overall effect: Z=1.52(P=0.13)

Test for subgroup differences: Not applicable

30

87

0

87

30.41%

100%

Random, 95% CI

0.02[-0.61,0.65]

-0.35[-0.81,0.1]

Not estimable

100%

-0.35[-0.81,0.1]

Favours treatment

-4

-2

0

2

4

Favours control

Analysis 21.4.   Comparison 21 SENSITIVITY5: without benzo: Psychotherapy+Antidepressant
vs Psychotherapy alone or +Placebo, Outcome 4 Frequency of panic attacks at 2-4 months.

Study or subgroup

PT+AD

PT+placebo

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

21.4.1 Behaviour therapy

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Not applicable

21.4.2 Cognitive-behaviour therapy

Oehrberg 1995

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=1.72(P=0.09)

Total ***

0

55

55

55

Heterogeneity: Not applicable

Test for overall effect: Z=1.72(P=0.09)

Test for subgroup differences: Not applicable

-16 (18.4)

0

52

52

52

Not estimable

-9.8 (18.4)

100%

100%

-0.33[-0.72,0.05]

-0.33[-0.72,0.05]

100%

-0.33[-0.72,0.05]

Favours treatment

-4

-2

0

2

4

Favours control

Analysis 21.5.   Comparison 21 SENSITIVITY5: without benzo: Psychotherapy+Antidepressant
vs Psychotherapy alone or +Placebo, Outcome 5 Phobic avoidance at 2-4 months.

Study or subgroup

PT+AD

PT+placebo

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

21.5.1 Behaviour therapy

Marks 1983

Sheehan 1980a

Sheehan 1980b

23

18

17

11.4 (9.4)

3 (1)

2.4 (1.2)

22

11

11

12.7 (10.5)

3.9 (1.3)

3.9 (1.3)

15.68%

9.1%

8.1%

-0.13[-0.71,0.46]

-0.79[-1.57,-0.01]

-1.2[-2.03,-0.37]

Favours treatment

-4

-2

0

2

4

Favours control

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

300

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

PT+AD

PT+placebo

Std. Mean Difference

Weight

Std. Mean Difference

Subtotal ***

Mean(SD)

N

58

Heterogeneity: Tau2=0.18; Chi2=4.69, df=2(P=0.1); I2=57.35%

Test for overall effect: Z=1.99(P=0.05)

21.5.2 Cognitive-behaviour therapy

Fahy 1992

Loerch 1999

Sharp 1996i

Sharp 1996ii

Stein 2000

Subtotal ***

31.4 (30.7)

7 (8.3)

4.7 (7.8)

4.7 (7.8)

-5.8 (6.7)

42

14

15

14

12

97

N

44

24

14

33

30

12

113

Heterogeneity: Tau2=0; Chi2=0.68, df=4(P=0.95); I2=0%

Test for overall effect: Z=1.39(P=0.17)

21.5.3 Psychodynamic and other therapies

Subtotal ***

0

0

Heterogeneity: Not applicable

Test for overall effect: Not applicable

Total ***

155

157

Heterogeneity: Tau2=0.01; Chi2=7.45, df=7(P=0.38); I2=6.04%

Test for overall effect: Z=2.62(P=0.01)

Test for subgroup differences: Chi2=2.09, df=1 (P=0.15), I2=52.05%

Mean(SD)

Random, 95% CI

Random, 95% CI

32.88%

-0.65[-1.29,-0.01]

40.2 (25.4)

9.1 (6.3)

7.2 (10.6)

5.1 (5.4)

-5.9 (9.8)

20.57%

9.96%

14.41%

13.49%

8.7%

67.12%

-0.3[-0.81,0.2]

-0.28[-1.03,0.46]

-0.25[-0.86,0.36]

-0.06[-0.7,0.57]

0.01[-0.79,0.81]

-0.2[-0.48,0.08]

Not estimable

100%

-0.32[-0.56,-0.08]

Favours treatment

-4

-2

0

2

4

Favours control

Analysis 21.6.   Comparison 21 SENSITIVITY5: without benzo: Psychotherapy+Antidepressant
vs Psychotherapy alone or +Placebo, Outcome 6 General anxiety at 2-4 months.

Study or subgroup

PT+AD

PT+placebo

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

21.6.1 Behaviour therapy

Marks 1983

Sheehan 1980a

Sheehan 1980b

Subtotal ***

8.9 (9.4)

1 (0.7)

1 (0.6)

23

18

17

58

Heterogeneity: Tau2=0.13; Chi2=3.86, df=2(P=0.14); I2=48.25%

Test for overall effect: Z=2.93(P=0)

21.6.2 Cognitive-behaviour therapy

Fahy 1992

Loerch 1999

Oehrberg 1995

Sharp 1996i

Sharp 1996ii

Stein 2000

Subtotal ***

11.3 (7.6)

11.4 (11.1)

-6.5 (5.5)

4.8 (5.7)

4.8 (5.7)

-15.3 (10.6)

42

14

55

15

14

12

152

Heterogeneity: Tau2=0; Chi2=1.79, df=5(P=0.88); I2=0%

Test for overall effect: Z=2.61(P=0.01)

12.7 (9.2)

2 (1.1)

2 (1.1)

14.4 (6.6)

11.9 (8.4)

-4.3 (5.5)

6.5 (6.7)

4.9 (4.4)

-10 (13.1)

22

11

11

44

24

14

52

33

30

12

165

11.99%

7.06%

6.65%

25.7%

15.06%

8.31%

21.74%

11.33%

10.73%

7.12%

74.3%

-0.4[-0.99,0.19]

-1.15[-1.97,-0.34]

-1.31[-2.15,-0.47]

-0.89[-1.49,-0.29]

-0.42[-0.93,0.08]

-0.04[-0.78,0.7]

-0.4[-0.78,-0.01]

-0.26[-0.87,0.35]

-0.02[-0.65,0.61]

-0.43[-1.24,0.38]

-0.3[-0.53,-0.08]

Favours treatment

-4

-2

0

2

4

Favours control

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

301

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

PT+AD

PT+placebo

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

21.6.3 Psychodynamic and other therapies

Subtotal ***

0

0

Heterogeneity: Not applicable

Test for overall effect: Not applicable

Total ***

210

209

Heterogeneity: Tau2=0.03; Chi2=10.18, df=8(P=0.25); I2=21.4%

Test for overall effect: Z=3.64(P=0)

Test for subgroup differences: Chi2=4.52, df=1 (P=0.03), I2=77.87%

Not estimable

100%

-0.43[-0.67,-0.2]

Favours treatment

-4

-2

0

2

4

Favours control

Analysis 21.7.   Comparison 21 SENSITIVITY5: without benzo: Psychotherapy
+Antidepressant vs Psychotherapy alone or +Placebo, Outcome 7 Depression at 2-4 months.

Study or subgroup

PT+AD

PT+placebo

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

4 (2.7)

57.7 (10.1)

57.7 (10.1)

8.3 (5.1)

6.5 (5.2)

-8.6 (7.6)

21.7.1 Behaviour therapy

Marks 1983

Sheehan 1980a

Sheehan 1980b

Subtotal ***

4 (4.9)

51.1 (9.4)

45.4 (9)

23

18

17

58

Heterogeneity: Tau2=0.28; Chi2=6.14, df=2(P=0.05); I2=67.42%

Test for overall effect: Z=1.58(P=0.11)

21.7.2 Cognitive-behaviour therapy

Fahy 1992

Loerch 1999

Stein 2000

Subtotal ***

5.6 (4.5)

5.6 (5.8)

-10.5 (10.4)

42

14

12

68

Heterogeneity: Tau2=0; Chi2=1.02, df=2(P=0.6); I2=0%

Test for overall effect: Z=2.02(P=0.04)

21.7.3 Psychodynamic and other therapies

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Not applicable

Total ***

0

126

Heterogeneity: Tau2=0.06; Chi2=7.28, df=5(P=0.2); I2=31.31%

Test for overall effect: Z=2.54(P=0.01)

Test for subgroup differences: Chi2=0.12, df=1 (P=0.73), I2=0%

22

11

11

44

24

14

12

50

0

94

20.68%

14.18%

12.54%

47.41%

24.18%

15.02%

13.39%

52.59%

0[-0.58,0.58]

-0.66[-1.43,0.11]

-1.26[-2.1,-0.42]

-0.59[-1.33,0.14]

-0.56[-1.08,-0.05]

-0.16[-0.9,0.58]

-0.2[-1,0.6]

-0.38[-0.76,-0.01]

Not estimable

100%

-0.44[-0.78,-0.1]

Favours treatment

-4

-2

0

2

4

Favours control

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

302

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 21.8.   Comparison 21 SENSITIVITY5: without benzo: Psychotherapy+Antidepressant
vs Psychotherapy alone or +Placebo, Outcome 8 Social functioning at 2-4 months.

Study or subgroup

PT+AD

PT+placebo

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

21.8.1 Behaviour therapy

Sheehan 1980a

Sheehan 1980b

Subtotal ***

3.1 (1.1)

2.4 (1.4)

18

17

35

Heterogeneity: Tau2=0; Chi2=0.53, df=1(P=0.47); I2=0%

Test for overall effect: Z=3.43(P=0)

21.8.2 Cognitive-behaviour therapy

Loerch 1999

Sharp 1996i

Sharp 1996ii

Stein 2000

Subtotal ***

2.4 (2.8)

1.4 (2.8)

1.4 (2.8)

-3.1 (2.5)

14

15

14

12

55

4 (1)

4 (1)

2.1 (2.2)

2.1 (2.6)

1.9 (2.6)

-4 (2.1)

11

11

22

14

33

30

12

89

Heterogeneity: Tau2=0; Chi2=1.9, df=3(P=0.59); I2=0%

Test for overall effect: Z=0.26(P=0.8)

Total ***

90

111

Heterogeneity: Tau2=0.14; Chi2=10.3, df=5(P=0.07); I2=51.44%

Test for overall effect: Z=1.44(P=0.15)

Test for subgroup differences: Chi2=7.87, df=1 (P=0.01), I2=87.3%

15.57%

14.53%

30.1%

-0.8[-1.58,-0.02]

-1.22[-2.06,-0.39]

-1[-1.57,-0.43]

16.44%

19.51%

18.93%

15.02%

69.9%

0.11[-0.63,0.85]

-0.27[-0.88,0.34]

-0.18[-0.82,0.46]

0.38[-0.43,1.18]

-0.04[-0.39,0.3]

100%

-0.31[-0.74,0.11]

Favours treatment

-4

-2

0

2

4

Favours control

Analysis 21.9.   Comparison 21 SENSITIVITY5: without benzo: Psychotherapy+Antidepressant
vs Psychotherapy alone or +Placebo, Outcome 9 Dropouts for any reason within 2-4 months.

PT+AD

n/N

PT+placebo

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

Study or subgroup

21.9.1 Behaviour therapy

Marks 1983

Sheehan 1980a

Sheehan 1980b

Subtotal (95% CI)

13/36

7/28

9/29

93

Total events: 29 (PT+AD), 19 (PT+placebo)

Heterogeneity: Tau2=0; Chi2=1.37, df=2(P=0.5); I2=0%

Test for overall effect: Z=0.38(P=0.7)

21.9.2 Cognitive-behaviour therapy

Fahy 1992

Loerch 1999

Oehrberg 1995

Sharp 1996i

Sharp 1996ii

Stein 2000

Subtotal (95% CI)

12/53

3/14

5/60

6/19

5/19

1/16

181

Total events: 32 (PT+AD), 30 (PT+placebo)

Heterogeneity: Tau2=0.04; Chi2=5.53, df=5(P=0.35); I2=9.59%

Test for overall effect: Z=0.92(P=0.36)

14/36

3/16

2/14

66

3/26

1/14

8/60

4/36

13/43

1/17

196

34.84%

8.55%

6.4%

49.79%

9%

2.72%

11.08%

9.61%

16.08%

1.72%

50.21%

0.93[0.51,1.69]

1.33[0.4,4.45]

2.17[0.54,8.75]

1.1[0.67,1.82]

1.96[0.61,6.35]

3[0.35,25.46]

0.63[0.22,1.8]

2.84[0.91,8.86]

0.87[0.36,2.1]

1.06[0.07,15.6]

1.28[0.75,2.19]

Favours treatment

0.1

0.2

0.5

1

2

5

10

Favours control

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

303

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

PT+AD

n/N

PT+placebo

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

21.9.3 Psychodynamic and other therapies

Subtotal (95% CI)

0

0

Not estimable

Total events: 0 (PT+AD), 0 (PT+placebo)

Heterogeneity: Not applicable

Test for overall effect: Not applicable

Total (95% CI)

274

262

100%

1.18[0.83,1.68]

Total events: 61 (PT+AD), 49 (PT+placebo)

Heterogeneity: Tau2=0; Chi2=7.05, df=8(P=0.53); I2=0%

Test for overall effect: Z=0.92(P=0.36)

Test for subgroup differences: Not applicable

Favours treatment

0.1

0.2

0.5

1

2

5

10

Favours control

Analysis 21.10.   Comparison 21 SENSITIVITY5: without benzo: Psychotherapy+Antidepressant vs
Psychotherapy alone or +Placebo, Outcome 10 Dropouts due to side effects within 2-4 months.

Study or subgroup

21.10.1 Behaviour therapy

Marks 1983

Subtotal (95% CI)

Total events: 2 (PT+AD), 3 (PT+placebo)

Heterogeneity: Not applicable

Test for overall effect: Z=0.46(P=0.65)

21.10.2 Cognitive-behaviour therapy

Fahy 1992

Oehrberg 1995

Sharp 1996i

Sharp 1996ii

Subtotal (95% CI)

PT+AD

n/N

PT+placebo

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

2/36

36

7/53

4/60

3/19

2/19

151

3/36

36

0/26

0/60

0/36

0/43

165

32.65%

32.65%

0.67[0.12,3.75]

0.67[0.12,3.75]

17.56%

16.89%

16.78%

16.13%

67.35%

7.5[0.44,126.48]

9[0.5,163.58]

12.95[0.7,238.39]

11[0.55,218.74]

9.84[2.3,42.08]

Total events: 16 (PT+AD), 0 (PT+placebo)

Heterogeneity: Tau2=0; Chi2=0.08, df=3(P=0.99); I2=0%

Test for overall effect: Z=3.09(P=0)

Total (95% CI)

187

201

100%

4.09[1.03,16.22]

Total events: 18 (PT+AD), 3 (PT+placebo)

Heterogeneity: Tau2=0.73; Chi2=5.69, df=4(P=0.22); I2=29.75%

Test for overall effect: Z=2(P=0.04)

Test for subgroup differences: Not applicable

Favours treatment

0.1

0.2

0.5

1

2

5

10

Favours control

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

304

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 21.14.   Comparison 21 SENSITIVITY5: without benzo: Psychotherapy+Antidepressant vs Psychotherapy
alone or +Placebo, Outcome 14 Response/remission 6-24 months after treatment discontinuation.

Study or subgroup

21.14.1 Behaviour therapy

Marks 1983

Subtotal (95% CI)

Total events: 9 (PT+AD), 11 (PT+placebo)

Heterogeneity: Not applicable

Test for overall effect: Z=0.52(P=0.6)

21.14.2 Cognitive-behaviour therapy

Loerch 1999

Sharp 1996i

Sharp 1996ii

Subtotal (95% CI)

PT+AD

n/N

PT+placebo

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

9/36

36

9/14

8/19

8/19

52

11/36

36

9/14

17/36

15/43

93

18.09%

18.09%

0.82[0.39,1.73]

0.82[0.39,1.73]

33.39%

25.63%

22.89%

81.91%

1[0.58,1.74]

0.89[0.47,1.67]

1.21[0.62,2.35]

1.02[0.71,1.45]

Total events: 25 (PT+AD), 41 (PT+placebo)

Heterogeneity: Tau2=0; Chi2=0.42, df=2(P=0.81); I2=0%

Test for overall effect: Z=0.09(P=0.93)

Total (95% CI)

88

129

100%

0.98[0.71,1.35]

Total events: 34 (PT+AD), 52 (PT+placebo)

Heterogeneity: Tau2=0; Chi2=0.69, df=3(P=0.87); I2=0%

Test for overall effect: Z=0.14(P=0.89)

Test for subgroup differences: Not applicable

Favours PT+placebo

0.1

0.2

0.5

1

2

5

10

Favours PT+AD

Analysis 21.15.   Comparison 21 SENSITIVITY5: without benzo: Psychotherapy+Antidepressant vs Psychotherapy
alone or +Placebo, Outcome 15 Global/Avoidance/Panic 6-24 months after treatment discontinuation.

Study or subgroup

PT+AD

PT+placebo

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

21.15.1 Behaviour therapy

Marks 1983

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=0.45(P=0.65)

21.15.2 Cognitive-behaviour therapy

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Not applicable

Total ***

22

22

0

22

Heterogeneity: Not applicable

Test for overall effect: Z=0.45(P=0.65)

Test for subgroup differences: Not applicable

14.1 (2.7)

18

18

0

18

13.7 (2.8)

100%

100%

0.14[-0.48,0.77]

0.14[-0.48,0.77]

Not estimable

100%

0.14[-0.48,0.77]

Favours treatment

-4

-2

0

2

4

Favours control

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

305

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Comparison 22.   SENSITIVITY5: allowed benzo: Psychotherapy+Antidepressant vs Antidepressant alone

Outcome or subgroup title

1 Response at 2-4 months

1.1 Behaviour therapy

1.2 Cognitive-behaviour therapy

1.3 Psychodynamic psychotherapy and others

2 Remission at 2-4 months

2.1 Behaviour therapy

2.2 Cognitive-behaviour therapy

2.3 Psychodynamic psychotherapy and others

3 Global severity at 2-4 months

3.1 Behaviour therapy

3.2 Cognitive-behaviour therapy

3.3 Psychodynamic psychotherapy and others

4 Frequency of panic attacks at 2-4 months

4.1 Behaviour therapy

4.2 Cognitive-behaviour therapy

4.3 Psychodynamic psychotherapy and others

5 Phobic avoidance at 2-4 months

5.1 Behaviour therapy

No. of
studies

No. of
partici-
pants

Statistical method

Effect size

4

0

2

2

3

0

1

2

2

0

1

1

3

0

2

2

3

0

328

0

188

140

288

0

148

140

188

0

148

40

183

0

91

92

183

0

Risk Ratio (M-H, Random,
95% CI)

1.14 [0.86, 1.52]

Risk Ratio (M-H, Random,
95% CI)

0.0 [0.0, 0.0]

Risk Ratio (M-H, Random,
95% CI)

1.27 [0.94, 1.71]

Risk Ratio (M-H, Random,
95% CI)

1.10 [0.65, 1.85]

Risk Ratio (M-H, Random,
95% CI)

1.04 [0.65, 1.66]

Risk Ratio (M-H, Random,
95% CI)

0.0 [0.0, 0.0]

Risk Ratio (M-H, Random,
95% CI)

1.34 [1.01, 1.79]

Risk Ratio (M-H, Random,
95% CI)

0.86 [0.28, 2.61]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.37 [-0.80, 0.05]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.0 [0.0, 0.0]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.22 [-0.55, 0.10]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.69 [-1.33, -0.05]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.04 [-0.29, 0.38]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.0 [0.0, 0.0]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.05 [-0.37, 0.47]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.03 [-0.53, 0.59]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.22 [-0.31, 0.75]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.0 [0.0, 0.0]

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

306

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Outcome or subgroup title

5.2 Cognitive-behaviour therapy

5.3 Psychodynamic psychotherapy and others

6 General anxiety at 2-4 months

6.1 Behaviour therapy

6.2 Cognitive-behaviour therapy

6.3 Psychodynamic psychotherapy and others

7 Depression at 2-4 months

7.1 Behaviour therapy

7.2 Cognitive-behaviour therapy

7.3 Psychodynamic psychotherapy and others

8 Social functioning at 2-4 months

8.1 Behavour therapy

8.2 Cognitive-behaviour therapy

8.3 Psychodynamic psychotherapy and others

9 Dropouts for any reason within 2-4 months

9.1 Behaviour therapy

9.2 Cognitive-behaviour therapy

9.3 Psychodynamic psychotherapy and others

Cochrane Database of Systematic Reviews

No. of
studies

No. of
partici-
pants

Statistical method

Effect size

2

2

2

0

1

2

2

0

1

1

1

0

0

1

4

0

2

2

91

92

144

0

52

92

79

0

39

40

40

0

0

40

328

0

188

140

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.44 [0.02, 0.87]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.01 [-1.15, 1.13]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.16 [-1.19, 0.87]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.0 [0.0, 0.0]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.39 [-0.18, 0.95]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.45 [-2.12, 1.22]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.52 [-1.04, 0.01]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.0 [0.0, 0.0]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.25 [-0.88, 0.38]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.79 [-1.44, -0.14]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.81 [-1.46, -0.16]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.0 [0.0, 0.0]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.0 [0.0, 0.0]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.81 [-1.46, -0.16]

Risk Ratio (M-H, Random,
95% CI)

0.90 [0.62, 1.29]

Risk Ratio (M-H, Random,
95% CI)

0.0 [0.0, 0.0]

Risk Ratio (M-H, Random,
95% CI)

0.75 [0.48, 1.17]

Risk Ratio (M-H, Random,
95% CI)

1.30 [0.69, 2.45]

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

307

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of
studies

No. of
partici-
pants

Statistical method

Effect size

10 Dropouts due to side effects within 2-4
months

10.1 Behaviour therapy

10.2 Cognitive-behaviour therapy

10.3 Psychodynamic psychotherapy and others

11 Response/remission on continued treatment

11.1 Behaviour therapy

11.2 Cognitive-behaviour therapy

11.3 Psychdynamic psychotherapy and others

12 Global/Avoidance/Panic on continued treat-
ment

12.1 Behaviour therapy

12.2 Cognitive-behaviour therapy

12.3 Psychodynamic psychotherapy and others

13 Dropouts for any reason on continued treat-
ment

13.1 Behaviour therapy

13.2 Cognitive-behaviour therapy

13.3 Psychodynamic psychotherapy and others

14 Response/remission immediately after treat-
ment discontinuation

14.1 Behaviour therapy

3

0

2

1

3

0

1

2

3

0

1

2

2

0

1

1

1

0

228

0

188

40

261

0

148

113

238

0

148

90

188

0

148

40

50

0

Risk Ratio (M-H, Random,
95% CI)

0.75 [0.17, 3.22]

Risk Ratio (M-H, Random,
95% CI)

0.0 [0.0, 0.0]

Risk Ratio (M-H, Random,
95% CI)

0.57 [0.10, 3.28]

Risk Ratio (M-H, Random,
95% CI)

3.00 [0.13, 69.52]

Risk Ratio (M-H, Random,
95% CI)

1.02 [0.45, 2.29]

Risk Ratio (M-H, Random,
95% CI)

0.0 [0.0, 0.0]

Risk Ratio (M-H, Random,
95% CI)

1.52 [1.07, 2.16]

Risk Ratio (M-H, Random,
95% CI)

0.67 [0.44, 1.02]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.28 [-0.91, 0.36]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.0 [0.0, 0.0]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.41 [-0.74, -0.09]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.20 [-1.45, 1.04]

Risk Ratio (M-H, Random,
95% CI)

0.67 [0.23, 1.94]

Risk Ratio (M-H, Random,
95% CI)

0.0 [0.0, 0.0]

Risk Ratio (M-H, Random,
95% CI)

0.73 [0.22, 2.39]

Risk Ratio (M-H, Random,
95% CI)

0.5 [0.05, 5.08]

Risk Ratio (M-H, Random,
95% CI)

0.85 [0.65, 1.11]

Risk Ratio (M-H, Random,
95% CI)

0.0 [0.0, 0.0]

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

308

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Outcome or subgroup title

14.2 Cognitive-behaviour therapy

14.3 Psychodynamic psychotherapy and others

15 Global/Avoidance/Panic immediately after
treatment discontinuation

15.1 Behaviour therapy

15.2 Cognitive-behaviour therapy

15.3 Psychodynamic psychotherapy and others

16 Response/remission 6-24 months after treat-
ment discontinuation

16.1 Behaviour therapy

16.2 Cognitive-behaviour therapy

16.3 Psychodynamic psychotherapy and others

17 Global/Avoidance/Panic 6-24 months after
treatment discontinuation

17.1 Behaviour therapy

17.2 Cognitive-behaviour therapy

17.3 Psychodynamic psychotherapy and others

Cochrane Database of Systematic Reviews

No. of
studies

No. of
partici-
pants

Statistical method

Effect size

0

1

1

0

0

1

2

0

1

1

2

0

1

1

0

50

50

0

0

50

176

0

136

40

176

0

136

40

Risk Ratio (M-H, Random,
95% CI)

0.0 [0.0, 0.0]

Risk Ratio (M-H, Random,
95% CI)

0.85 [0.65, 1.11]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.42 [-0.15, 0.99]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.0 [0.0, 0.0]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.0 [0.0, 0.0]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.42 [-0.15, 0.99]

Risk Ratio (M-H, Random,
95% CI)

2.03 [0.90, 4.58]

Risk Ratio (M-H, Random,
95% CI)

0.0 [0.0, 0.0]

Risk Ratio (M-H, Random,
95% CI)

1.39 [0.75, 2.58]

Risk Ratio (M-H, Random,
95% CI)

3.2 [1.45, 7.05]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.58 [-1.78, 0.63]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.0 [0.0, 0.0]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.0 [-0.34, 0.34]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-1.23 [-1.91, -0.55]

Analysis 22.1.   Comparison 22 SENSITIVITY5: allowed benzo: Psychotherapy
+Antidepressant vs Antidepressant alone, Outcome 1 Response at 2-4 months.

Study or subgroup

22.1.1 Behaviour therapy

Subtotal (95% CI)

Total events: 0 (PT+AD), 0 (AD)

PT+AD

n/N

AD

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

0

0

Not estimable

Favours AD

0.1

0.2

0.5

1

2

5

10

Favours PT+AD

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

309

 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

PT+AD

n/N

AD

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

Heterogeneity: Not applicable

Test for overall effect: Not applicable

22.1.2 Cognitive-behaviour therapy

Barlow 2000

Spinhoven 1996

Subtotal (95% CI)

39/65

4/20

85

Total events: 43 (PT+AD), 43 (AD)

Heterogeneity: Tau2=0; Chi2=0.67, df=1(P=0.41); I2=0%

Test for overall effect: Z=1.57(P=0.12)

22.1.3 Psychodynamic psychotherapy and others

Berger 2004

Wiborg 1996

Subtotal (95% CI)

29/50

20/20

70

Total events: 49 (PT+AD), 48 (AD)

Heterogeneity: Tau2=0.12; Chi2=6.07, df=1(P=0.01); I2=83.51%

Test for overall effect: Z=0.36(P=0.72)

38/83

5/20

103

34/50

14/20

70

31.12%

5.39%

36.51%

1.31[0.96,1.78]

0.8[0.25,2.55]

1.27[0.94,1.71]

31.42%

32.07%

63.49%

0.85[0.63,1.15]

1.41[1.05,1.9]

1.1[0.65,1.85]

Total (95% CI)

155

173

100%

1.14[0.86,1.52]

Total events: 92 (PT+AD), 91 (AD)

Heterogeneity: Tau2=0.04; Chi2=6.85, df=3(P=0.08); I2=56.21%

Test for overall effect: Z=0.92(P=0.36)

Test for subgroup differences: Not applicable

Favours AD

0.1

0.2

0.5

1

2

5

10

Favours PT+AD

Analysis 22.2.   Comparison 22 SENSITIVITY5: allowed benzo: Psychotherapy
+Antidepressant vs Antidepressant alone, Outcome 2 Remission at 2-4 months.

Study or subgroup

PT+AD

n/N

AD

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

22.2.1 Behaviour therapy

Subtotal (95% CI)

Total events: 0 (PT+AD), 0 (AD)

Heterogeneity: Not applicable

Test for overall effect: Not applicable

22.2.2 Cognitive-behaviour therapy

Barlow 2000

Subtotal (95% CI)

Total events: 42 (PT+AD), 40 (AD)

Heterogeneity: Not applicable

Test for overall effect: Z=2.01(P=0.04)

0

0

Not estimable

42/65

65

40/83

83

35.85%

35.85%

1.34[1.01,1.79]

1.34[1.01,1.79]

22.2.3 Psychodynamic psychotherapy and others

Berger 2004

Wiborg 1996

Subtotal (95% CI)

Total events: 34 (PT+AD), 41 (AD)

14/50

20/20

70

26/50

15/20

70

27.56%

36.6%

64.15%

0.54[0.32,0.9]

1.32[1.02,1.72]

0.86[0.28,2.61]

Favours AD

0.1

0.2

0.5

1

2

5

10

Favours PT+AD

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

310

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

PT+AD

n/N

AD

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

Heterogeneity: Tau2=0.6; Chi2=14.64, df=1(P=0); I2=93.17%

Test for overall effect: Z=0.27(P=0.79)

Total (95% CI)

135

153

100%

1.04[0.65,1.66]

Total events: 76 (PT+AD), 81 (AD)

Heterogeneity: Tau2=0.14; Chi2=11.74, df=2(P=0); I2=82.96%

Test for overall effect: Z=0.15(P=0.88)

Test for subgroup differences: Not applicable

Favours AD

0.1

0.2

0.5

1

2

5

10

Favours PT+AD

Analysis 22.3.   Comparison 22 SENSITIVITY5: allowed benzo: Psychotherapy
+Antidepressant vs Antidepressant alone, Outcome 3 Global severity at 2-4 months.

Study or subgroup

Treatment

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

22.3.1 Behaviour therapy

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Not applicable

22.3.2 Cognitive-behaviour therapy

Barlow 2000

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=1.34(P=0.18)

0

65

65

0.9 (0.7)

22.3.3 Psychodynamic psychotherapy and others

1.4 (0.5)

Wiborg 1996

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=2.11(P=0.03)

Total ***

20

20

85

Heterogeneity: Tau2=0.04; Chi2=1.61, df=1(P=0.2); I2=37.91%

Test for overall effect: Z=1.71(P=0.09)

Test for subgroup differences: Chi2=1.61, df=1 (P=0.2), I2=37.91%

0

83

83

20

20

103

1.1 (0.8)

2 (1.1)

Not estimable

68.27%

68.27%

-0.22[-0.55,0.1]

-0.22[-0.55,0.1]

31.73%

31.73%

-0.69[-1.33,-0.05]

-0.69[-1.33,-0.05]

100%

-0.37[-0.8,0.05]

Favours treatment

-4

-2

0

2

4

Favours control

Analysis 22.4.   Comparison 22 SENSITIVITY5: allowed benzo: Psychotherapy+Antidepressant
vs Antidepressant alone, Outcome 4 Frequency of panic attacks at 2-4 months.

Study or subgroup

Treatment

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

22.4.1 Behaviour therapy

Subtotal ***

0

0

Not estimable

Heterogeneity: Not applicable

Test for overall effect: Not applicable

Favours treatment

-4

-2

0

2

4

Favours control

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

311

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Treatment

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

0.6 (1.6)

2.8 (2.3)

0.6 (1.6)

0.8 (2.1)

22.4.2 Cognitive-behaviour therapy

Berger 2004

Spinhoven 1996

Subtotal ***

0.6 (1.1)

3 (2.5)

20

20

40

Heterogeneity: Tau2=0; Chi2=0.02, df=1(P=0.9); I2=0%

Test for overall effect: Z=0.24(P=0.81)

22.4.3 Psychodynamic psychotherapy and others

0.6 (1.1)

0 (0)

Berger 2004

Wiborg 1996

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=0.09(P=0.92)

Total ***

20

20

40

80

Heterogeneity: Tau2=0; Chi2=0.02, df=2(P=0.99); I2=0%

Test for overall effect: Z=0.25(P=0.8)

Test for subgroup differences: Chi2=0, df=1 (P=0.95), I2=0%

32

19

51

32

20

52

103

35.83%

28.34%

64.17%

0.03[-0.53,0.59]

0.08[-0.55,0.71]

0.05[-0.37,0.47]

35.83%

0.03[-0.53,0.59]

Not estimable

35.83%

0.03[-0.53,0.59]

100%

0.04[-0.29,0.38]

Favours treatment

-4

-2

0

2

4

Favours control

Analysis 22.5.   Comparison 22 SENSITIVITY5: allowed benzo: Psychotherapy
+Antidepressant vs Antidepressant alone, Outcome 5 Phobic avoidance at 2-4 months.

Study or subgroup

Treatment

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

22.5.1 Behaviour therapy

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Not applicable

22.5.2 Cognitive-behaviour therapy

Berger 2004

Spinhoven 1996

Subtotal ***

0

20

20

40

0.5 (1)

22.5 (12)

Heterogeneity: Tau2=0; Chi2=0.39, df=1(P=0.53); I2=0%

Test for overall effect: Z=2.06(P=0.04)

22.5.3 Psychodynamic psychotherapy and others

Berger 2004

Wiborg 1996

Subtotal ***

0.5 (1)

1.1 (1.1)

20

20

40

Heterogeneity: Tau2=0.58; Chi2=7.14, df=1(P=0.01); I2=86%

Test for overall effect: Z=0.01(P=0.99)

0

32

19

51

32

20

52

Total ***

80

103

Heterogeneity: Tau2=0.19; Chi2=9.23, df=3(P=0.03); I2=67.48%

Test for overall effect: Z=0.82(P=0.41)

Test for subgroup differences: Chi2=1.69, df=1 (P=0.19), I2=40.81%

0.1 (0.3)

18.7 (13.3)

0.1 (0.3)

2.6 (3.3)

Not estimable

25.86%

24.19%

50.04%

0.57[-0,1.14]

0.29[-0.34,0.93]

0.44[0.02,0.87]

25.86%

24.1%

49.96%

0.57[-0,1.14]

-0.6[-1.23,0.04]

-0.01[-1.15,1.13]

100%

0.22[-0.31,0.75]

Favours treatment

-4

-2

0

2

4

Favours control

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

312

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 22.6.   Comparison 22 SENSITIVITY5: allowed benzo: Psychotherapy
+Antidepressant vs Antidepressant alone, Outcome 6 General anxiety at 2-4 months.

Study or subgroup

Treatment

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

22.6.1 Behaviour therapy

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Not applicable

22.6.2 Cognitive-behaviour therapy

Berger 2004

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=1.35(P=0.18)

0

20

20

1.8 (2)

22.6.3 Psychodynamic psychotherapy and others

Berger 2004

Wiborg 1996

Subtotal ***

1.8 (2)

5.5 (4.7)

20

20

40

Heterogeneity: Tau2=1.35; Chi2=14.05, df=1(P=0); I2=92.88%

Test for overall effect: Z=0.53(P=0.6)

Total ***

60

Heterogeneity: Tau2=0.74; Chi2=17.56, df=2(P=0); I2=88.61%

Test for overall effect: Z=0.31(P=0.76)

Test for subgroup differences: Chi2=3.51, df=1 (P=0.06), I2=71.55%

0

32

32

32

20

52

84

1 (2)

1 (2)

16 (10)

Not estimable

33.87%

33.87%

0.39[-0.18,0.95]

0.39[-0.18,0.95]

33.87%

32.25%

66.13%

0.39[-0.18,0.95]

-1.32[-2.01,-0.63]

-0.45[-2.12,1.22]

100%

-0.16[-1.19,0.87]

Favours treatment

-4

-2

0

2

4

Favours control

Analysis 22.7.   Comparison 22 SENSITIVITY5: allowed benzo: Psychotherapy
+Antidepressant vs Antidepressant alone, Outcome 7 Depression at 2-4 months.

Study or subgroup

Treatment

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

22.7.1 Behaviour therapy

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Not applicable

22.7.2 Cognitive-behaviour therapy

Spinhoven 1996

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=0.78(P=0.44)

0

20

20

43.5 (8.7)

22.7.3 Psychodynamic psychotherapy and others

Wiborg 1996

Subtotal ***

3.6 (2.7)

20

20

Heterogeneity: Not applicable

Test for overall effect: Z=2.4(P=0.02)

0

19

19

20

20

46 (10.8)

7.4 (6.1)

Not estimable

50.88%

50.88%

-0.25[-0.88,0.38]

-0.25[-0.88,0.38]

49.12%

49.12%

-0.79[-1.44,-0.14]

-0.79[-1.44,-0.14]

Favours treatment

-4

-2

0

2

4

Favours control

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

313

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Treatment

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

Total ***

40

39

Heterogeneity: Tau2=0.04; Chi2=1.37, df=1(P=0.24); I2=27.01%

Test for overall effect: Z=1.91(P=0.06)

Test for subgroup differences: Chi2=1.37, df=1 (P=0.24), I2=27.01%

100%

-0.52[-1.04,0.01]

Favours treatment

-4

-2

0

2

4

Favours control

Analysis 22.8.   Comparison 22 SENSITIVITY5: allowed benzo: Psychotherapy
+Antidepressant vs Antidepressant alone, Outcome 8 Social functioning at 2-4 months.

Study or subgroup

Treatment

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

22.8.1 Behavour therapy

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Not applicable

22.8.2 Cognitive-behaviour therapy

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Not applicable

0

0

22.8.3 Psychodynamic psychotherapy and others

1.2 (1.5)

Wiborg 1996

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=2.45(P=0.01)

Total ***

20

20

20

Heterogeneity: Not applicable

Test for overall effect: Z=2.45(P=0.01)

Test for subgroup differences: Not applicable

0

0

20

20

20

Not estimable

Not estimable

3 (2.7)

100%

100%

-0.81[-1.46,-0.16]

-0.81[-1.46,-0.16]

100%

-0.81[-1.46,-0.16]

Favours treatment

-4

-2

0

2

4

Favours control

Analysis 22.9.   Comparison 22 SENSITIVITY5: allowed benzo: Psychotherapy+Antidepressant
vs Antidepressant alone, Outcome 9 Dropouts for any reason within 2-4 months.

Study or subgroup

Treatment

n/N

Control

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

22.9.1 Behaviour therapy

Subtotal (95% CI)

Total events: 0 (Treatment), 0 (Control)

Heterogeneity: Not applicable

Test for overall effect: Not applicable

22.9.2 Cognitive-behaviour therapy

0

0

Not estimable

Barlow 2000

18/65

32/83

58.44%

0.72[0.45,1.16]

Favours treatment

0.1

0.2

0.5

1

2

5

10

Favours control

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

314

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Spinhoven 1996

Subtotal (95% CI)

Treatment

n/N

Control

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

4/20

85

4/20

103

8.67%

67.11%

1[0.29,3.45]

0.75[0.48,1.17]

Total events: 22 (Treatment), 36 (Control)

Heterogeneity: Tau2=0; Chi2=0.24, df=1(P=0.63); I2=0%

Test for overall effect: Z=1.27(P=0.21)

22.9.3 Psychodynamic psychotherapy and others

Berger 2004

Wiborg 1996

Subtotal (95% CI)

15/50

1/20

70

12/50

0/20

70

Total events: 16 (Treatment), 12 (Control)

Heterogeneity: Tau2=0; Chi2=0.29, df=1(P=0.59); I2=0%

Test for overall effect: Z=0.8(P=0.43)

31.54%

1.35%

32.89%

1.25[0.65,2.39]

3[0.13,69.52]

1.3[0.69,2.45]

Total (95% CI)

155

173

100%

0.9[0.62,1.29]

Total events: 38 (Treatment), 48 (Control)

Heterogeneity: Tau2=0; Chi2=2.44, df=3(P=0.49); I2=0%

Test for overall effect: Z=0.58(P=0.56)

Test for subgroup differences: Not applicable

Favours treatment

0.1

0.2

0.5

1

2

5

10

Favours control

Analysis 22.10.   Comparison 22 SENSITIVITY5: allowed benzo: Psychotherapy+Antidepressant
vs Antidepressant alone, Outcome 10 Dropouts due to side effects within 2-4 months.

Study or subgroup

Treatment

n/N

Control

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

22.10.1 Behaviour therapy

Subtotal (95% CI)

Total events: 0 (Treatment), 0 (Control)

Heterogeneity: Not applicable

Test for overall effect: Not applicable

22.10.2 Cognitive-behaviour therapy

Barlow 2000

Spinhoven 1996

Subtotal (95% CI)

0

0

Not estimable

2/65

4/20

85

11/83

3/20

103

40.54%

43.07%

83.61%

0.23[0.05,1.01]

1.33[0.34,5.21]

0.57[0.1,3.28]

Total events: 6 (Treatment), 14 (Control)

Heterogeneity: Tau2=1.08; Chi2=3.05, df=1(P=0.08); I2=67.26%

Test for overall effect: Z=0.63(P=0.53)

22.10.3 Psychodynamic psychotherapy and others

Wiborg 1996

Subtotal (95% CI)

Total events: 1 (Treatment), 0 (Control)

Heterogeneity: Not applicable

Test for overall effect: Z=0.69(P=0.49)

1/20

20

0/20

20

16.39%

16.39%

3[0.13,69.52]

3[0.13,69.52]

Total (95% CI)

105

123

100%

0.75[0.17,3.22]

Total events: 7 (Treatment), 14 (Control)

Favours treatment

0.1

0.2

0.5

1

2

5

10

Favours control

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

315

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Treatment

n/N

Control

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

Heterogeneity: Tau2=0.8; Chi2=3.95, df=2(P=0.14); I2=49.39%

Test for overall effect: Z=0.39(P=0.7)

Test for subgroup differences: Not applicable

Favours treatment

0.1

0.2

0.5

1

2

5

10

Favours control

Analysis 22.11.   Comparison 22 SENSITIVITY5: allowed benzo: Psychotherapy+Antidepressant
vs Antidepressant alone, Outcome 11 Response/remission on continued treatment.

Study or subgroup

PT+AD

n/N

AD

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

22.11.1 Behaviour therapy

Subtotal (95% CI)

Total events: 0 (PT+AD), 0 (AD)

Heterogeneity: Not applicable

Test for overall effect: Not applicable

22.11.2 Cognitive-behaviour therapy

Barlow 2000

Subtotal (95% CI)

Total events: 37 (PT+AD), 31 (AD)

Heterogeneity: Not applicable

Test for overall effect: Z=2.36(P=0.02)

0

0

Not estimable

37/65

65

31/83

83

51.04%

51.04%

1.52[1.07,2.16]

1.52[1.07,2.16]

22.11.3 Psychdynamic psychotherapy and others

Berger 2004

Wiborg 1996

Subtotal (95% CI)

Total events: 36 (PT+AD), 46 (AD)

Heterogeneity: Not applicable

Test for overall effect: Z=1.88(P=0.06)

16/35

20/20

55

26/38

20/20

58

48.96%

0.67[0.44,1.02]

Not estimable

48.96%

0.67[0.44,1.02]

Total (95% CI)

120

141

100%

1.02[0.45,2.29]

Total events: 73 (PT+AD), 77 (AD)

Heterogeneity: Tau2=0.3; Chi2=8.76, df=1(P=0); I2=88.58%

Test for overall effect: Z=0.04(P=0.97)

Test for subgroup differences: Not applicable

Favours AD

0.1

0.2

0.5

1

2

5

10

Favours PT+AD

Analysis 22.12.   Comparison 22 SENSITIVITY5: allowed benzo: Psychotherapy+Antidepressant
vs Antidepressant alone, Outcome 12 Global/Avoidance/Panic on continued treatment.

Study or subgroup

Treatment

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

22.12.1 Behaviour therapy

Subtotal ***

0

0

Not estimable

Heterogeneity: Not applicable

Test for overall effect: Not applicable

Favours treatment

-4

-2

0

2

4

Favours control

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

316

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Treatment

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

22.12.2 Cognitive-behaviour therapy

Barlow 2000

Subtotal ***

0.8 (0.9)

65

65

Heterogeneity: Not applicable

Test for overall effect: Z=2.47(P=0.01)

22.12.3 Psychodynamic psychotherapy and others

Berger 2004

Wiborg 1996

Subtotal ***

0.5 (1)

0.5 (1.1)

21

20

41

Heterogeneity: Tau2=0.71; Chi2=8.29, df=1(P=0); I2=87.93%

Test for overall effect: Z=0.32(P=0.75)

1.1 (0.9)

0.1 (0.6)

2.4 (2.9)

83

83

29

20

49

Total ***

106

132

Heterogeneity: Tau2=0.24; Chi2=9.35, df=2(P=0.01); I2=78.61%

Test for overall effect: Z=0.86(P=0.39)

Test for subgroup differences: Chi2=1.06, df=1 (P=0.3), I2=5.91%

38.51%

38.51%

-0.41[-0.74,-0.09]

-0.41[-0.74,-0.09]

31.92%

29.57%

61.49%

0.42[-0.15,0.99]

-0.85[-1.5,-0.2]

-0.2[-1.45,1.04]

100%

-0.28[-0.91,0.36]

Favours treatment

-4

-2

0

2

4

Favours control

Analysis 22.13.   Comparison 22 SENSITIVITY5: allowed benzo: Psychotherapy+Antidepressant
vs Antidepressant alone, Outcome 13 Dropouts for any reason on continued treatment.

Study or subgroup

Treatment

n/N

Control

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

0

0

Not estimable

22.13.1 Behaviour therapy

Subtotal (95% CI)

Total events: 0 (Treatment), 0 (Control)

Heterogeneity: Not applicable

Test for overall effect: Not applicable

22.13.2 Cognitive-behaviour therapy

Barlow 2000

Subtotal (95% CI)

Total events: 4 (Treatment), 7 (Control)

Heterogeneity: Not applicable

Test for overall effect: Z=0.52(P=0.6)

4/65

65

22.13.3 Psychodynamic psychotherapy and others

Wiborg 1996

Subtotal (95% CI)

Total events: 1 (Treatment), 2 (Control)

Heterogeneity: Not applicable

Test for overall effect: Z=0.59(P=0.56)

1/20

20

7/83

83

2/20

20

79.3%

79.3%

0.73[0.22,2.39]

0.73[0.22,2.39]

20.7%

20.7%

0.5[0.05,5.08]

0.5[0.05,5.08]

Total (95% CI)

85

103

100%

0.67[0.23,1.94]

Total events: 5 (Treatment), 9 (Control)

Heterogeneity: Tau2=0; Chi2=0.08, df=1(P=0.78); I2=0%

Test for overall effect: Z=0.73(P=0.46)

Favours treatment

0.1

0.2

0.5

1

2

5

10

Favours control

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

317

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Treatment

n/N

Control

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

Test for subgroup differences: Not applicable

Favours treatment

0.1

0.2

0.5

1

2

5

10

Favours control

Analysis 22.14.   Comparison 22 SENSITIVITY5: allowed benzo: Psychotherapy+Antidepressant vs
Antidepressant alone, Outcome 14 Response/remission immediately after treatment discontinuation.

Study or subgroup

PT+AD

n/N

AD

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

22.14.1 Behaviour therapy

Subtotal (95% CI)

Total events: 0 (PT+AD), 0 (AD)

Heterogeneity: Not applicable

Test for overall effect: Not applicable

22.14.2 Cognitive-behaviour therapy

Subtotal (95% CI)

Total events: 0 (PT+AD), 0 (AD)

Heterogeneity: Not applicable

Test for overall effect: Not applicable

0

0

0

0

22.14.3 Psychodynamic psychotherapy and others

Not estimable

Not estimable

Berger 2004

Subtotal (95% CI)

Total events: 16 (PT+AD), 26 (AD)

Heterogeneity: Not applicable

Test for overall effect: Z=1.18(P=0.24)

16/21

21

26/29

29

100%

100%

0.85[0.65,1.11]

0.85[0.65,1.11]

Total (95% CI)

21

29

100%

0.85[0.65,1.11]

Total events: 16 (PT+AD), 26 (AD)

Heterogeneity: Not applicable

Test for overall effect: Z=1.18(P=0.24)

Test for subgroup differences: Not applicable

Favours AD

0.1

0.2

0.5

1

2

5

10

Favours PT+AD

Analysis 22.15.   Comparison 22 SENSITIVITY5: allowed benzo: Psychotherapy+Antidepressant vs
Antidepressant alone, Outcome 15 Global/Avoidance/Panic immediately after treatment discontinuation.

Study or subgroup

Treatment

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

22.15.1 Behaviour therapy

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Not applicable

22.15.2 Cognitive-behaviour therapy

Subtotal ***

Heterogeneity: Not applicable

0

0

0

0

Not estimable

Not estimable

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

318

Favours treatment

-4

-2

0

2

4

Favours control

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Treatment

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

Test for overall effect: Not applicable

22.15.3 Psychodynamic psychotherapy and others

Berger 2004

Subtotal ***

0.5 (1)

21

21

Heterogeneity: Tau2=0; Chi2=0, df=0(P<0.0001); I2=100%

Test for overall effect: Z=1.45(P=0.15)

Total ***

21

Heterogeneity: Tau2=0; Chi2=0, df=0(P<0.0001); I2=100%

Test for overall effect: Z=1.45(P=0.15)

Test for subgroup differences: Not applicable

0.1 (0.6)

29

29

29

100%

100%

0.42[-0.15,0.99]

0.42[-0.15,0.99]

100%

0.42[-0.15,0.99]

Favours treatment

-4

-2

0

2

4

Favours control

Analysis 22.16.   Comparison 22 SENSITIVITY5: allowed benzo: Psychotherapy+Antidepressant vs
Antidepressant alone, Outcome 16 Response/remission 6-24 months after treatment discontinuation.

Study or subgroup

PT+AD

n/N

AD

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

22.16.1 Behaviour therapy

Subtotal (95% CI)

Total events: 0 (PT+AD), 0 (AD)

Heterogeneity: Not applicable

Test for overall effect: Not applicable

22.16.2 Cognitive-behaviour therapy

Barlow 2000

Subtotal (95% CI)

Total events: 16 (PT+AD), 15 (AD)

Heterogeneity: Not applicable

Test for overall effect: Z=1.05(P=0.29)

0

0

Not estimable

16/59

59

15/77

77

54.56%

54.56%

1.39[0.75,2.58]

1.39[0.75,2.58]

22.16.3 Psychodynamic psychotherapy and others

Wiborg 1996

Subtotal (95% CI)

Total events: 16 (PT+AD), 5 (AD)

Heterogeneity: Not applicable

Test for overall effect: Z=2.89(P=0)

16/20

20

5/20

20

45.44%

45.44%

3.2[1.45,7.05]

3.2[1.45,7.05]

Total (95% CI)

79

97

100%

2.03[0.9,4.58]

Total events: 32 (PT+AD), 20 (AD)

Heterogeneity: Tau2=0.22; Chi2=2.65, df=1(P=0.1); I2=62.24%

Test for overall effect: Z=1.71(P=0.09)

Test for subgroup differences: Not applicable

Favours AD

0.1

0.2

0.5

1

2

5

10

Favours PT+AD

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

319

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 22.17.   Comparison 22 SENSITIVITY5: allowed benzo: Psychotherapy+Antidepressant vs
Antidepressant alone, Outcome 17 Global/Avoidance/Panic 6-24 months after treatment discontinuation.

Study or subgroup

Treatment

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

22.17.1 Behaviour therapy

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Not applicable

22.17.2 Cognitive-behaviour therapy

Barlow 2000

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Not applicable

0

59

59

1.5 (0.9)

22.17.3 Psychodynamic psychotherapy and others

0.6 (1.1)

Wiborg 1996

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=3.54(P=0)

Total ***

20

20

79

Heterogeneity: Tau2=0.68; Chi2=10.06, df=1(P=0); I2=90.06%

Test for overall effect: Z=0.94(P=0.35)

Test for subgroup differences: Chi2=10.06, df=1 (P=0), I2=90.06%

0

77

77

20

20

97

1.5 (0.8)

2.4 (1.7)

Not estimable

53%

53%

0[-0.34,0.34]

0[-0.34,0.34]

47%

47%

-1.23[-1.91,-0.55]

-1.23[-1.91,-0.55]

100%

-0.58[-1.78,0.63]

Favours treatment

-4

-2

0

2

4

Favours control

Comparison 23.   SENSITIVITY5: allowed benzo: Psychotherapy+Antidepressant vs Psychotherapy alone or +Placebo

Outcome or subgroup title

1 Response at 2-4 months

1.1 Behaviour therapy

1.2 Cognitive-behaviour therapy

2 Remission at 2-4 months

2.1 Behaviour therapy

2.2 Cognitive-behaviour therapy

3 Global severity at 2-4 months

No. of
studies

No. of
partici-
pants

Statistical method

Effect size

6

2

4

5

2

3

4

357

69

288

317

69

248

261

Risk Ratio (M-H, Random, 95%
CI)

1.32 [1.04, 1.68]

Risk Ratio (M-H, Random, 95%
CI)

1.67 [1.00, 2.78]

Risk Ratio (M-H, Random, 95%
CI)

1.20 [0.94, 1.53]

Risk Ratio (M-H, Random, 95%
CI)

1.10 [0.91, 1.34]

Risk Ratio (M-H, Random, 95%
CI)

1.15 [0.79, 1.68]

Risk Ratio (M-H, Random, 95%
CI)

1.09 [0.87, 1.36]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.32 [-0.58, -0.06]

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

320

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Outcome or subgroup title

3.1 Behaviour therapy

3.2 Cognitive-behaviour therapy

4 Frequency of panic attacks at 2-4 months

4.1 Behaviour therapy

4.2 Cognitive-behaviour therapy

5 Phobic avoidance at 2-4 months

5.1 Behaviour therapy

5.2 Cognitive-behaviour therapy

6 General anxiety at 2-4 months

6.1 Behaviour therapy

6.2 Cognitive-behaviour therapy

7 Depression at 2-4 months

7.1 Behaviour therapy

7.2 Cognitive-behaviour therapy

8 Social functioning at 2-4 months

8.1 Behaviour therapy

8.2 Cognitive-behaviour therapy

Cochrane Database of Systematic Reviews

No. of
studies

No. of
partici-
pants

Statistical method

Effect size

2

2

4

2

2

4

2

2

3

2

1

3

2

1

0

0

0

56

205

131

53

78

134

56

78

94

56

38

96

56

40

0

0

0

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.58 [-1.14, -0.01]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.25 [-0.55, 0.04]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.15 [-0.50, 0.21]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.37 [-0.95, 0.20]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.01 [-0.45, 0.43]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.52 [-0.99, -0.06]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.99 [-1.57, -0.40]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.19 [-0.63, 0.26]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.57 [-1.09, -0.05]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.88 [-1.46, -0.30]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.13 [-0.77, 0.51]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.43 [-1.03, 0.17]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.76 [-1.34, -0.19]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.08 [-0.54, 0.70]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.0 [0.0, 0.0]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.0 [0.0, 0.0]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.0 [0.0, 0.0]

9 Dropouts for any reason within 2-4 months

6

357

Risk Ratio (M-H, Random, 95%
CI)

1.10 [0.73, 1.65]

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

321

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Outcome or subgroup title

9.1 Behaviour therapy

9.2 Cognitive-behaviour therapy

10 Dropouts due to side effects within 2-4
months

10.1 Behaviour therapy

10.2 Cognitive-behaviour therapy

11 Response/remission on continued treat-
ment

11.1 Behaviour therapy

11.2 Cognitive-behaviour therapy

12 Global/Avoidance/Panic on continued
treatment

12.1 Behaviour therapy

12.2 Cognitive-behaviour therapy

13 Dropouts for any reason on continued
treatment

13.1 Behaviour therapy

13.2 Cognitive-behaviour therapy

14 Response/remission 6-24 months after
treatment discontinuation

14.1 Behaviour therapy

14.2 Cognitive-behaviour therapy

15 Global/Avoidance/Panic 6-24 months af-
ter treatment discontinuation

Cochrane Database of Systematic Reviews

No. of
studies

No. of
partici-
pants

Statistical method

Effect size

2

4

6

2

4

2

0

2

2

0

2

3

1

2

4

2

2

4

69

288

357

69

288

205

0

205

205

0

205

243

38

205

263

69

194

248

Risk Ratio (M-H, Random, 95%
CI)

1.19 [0.44, 3.22]

Risk Ratio (M-H, Random, 95%
CI)

1.08 [0.69, 1.69]

Risk Ratio (M-H, Random, 95%
CI)

3.53 [1.21, 10.27]

Risk Ratio (M-H, Random, 95%
CI)

5.41 [0.59, 49.42]

Risk Ratio (M-H, Random, 95%
CI)

3.10 [0.92, 10.50]

Risk Ratio (M-H, Random, 95%
CI)

1.23 [0.93, 1.63]

Risk Ratio (M-H, Random, 95%
CI)

0.0 [0.0, 0.0]

Risk Ratio (M-H, Random, 95%
CI)

1.23 [0.93, 1.63]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.41 [-0.71, -0.12]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.0 [0.0, 0.0]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.41 [-0.71, -0.12]

Risk Ratio (M-H, Random, 95%
CI)

0.78 [0.28, 2.16]

Risk Ratio (M-H, Random, 95%
CI)

3.00 [0.13, 69.31]

Risk Ratio (M-H, Random, 95%
CI)

0.66 [0.22, 1.95]

Risk Ratio (M-H, Random, 95%
CI)

0.87 [0.61, 1.22]

Risk Ratio (M-H, Random, 95%
CI)

1.02 [0.62, 1.69]

Risk Ratio (M-H, Random, 95%
CI)

0.74 [0.46, 1.19]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.16 [-0.11, 0.43]

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

322

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

15.1 Behaviour therapy

15.2 Cognitive-behaviour therapy

No. of
studies

No. of
partici-
pants

2

2

54

194

Statistical method

Effect size

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.01 [-0.56, 0.58]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.21 [-0.10, 0.52]

Analysis 23.1.   Comparison 23 SENSITIVITY5: allowed benzo: Psychotherapy
+Antidepressant vs Psychotherapy alone or +Placebo, Outcome 1 Response at 2-4 months.

PT+AD

n/N

PT+placebo

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

Study or subgroup

23.1.1 Behaviour therapy

de Beurs 1995i

de Beurs 1995ii

Subtotal (95% CI)

8/12

9/12

24

Total events: 17 (PT+AD), 19 (PT+placebo)

Heterogeneity: Tau2=0.04; Chi2=1.34, df=1(P=0.25); I2=25.38%

Test for overall effect: Z=1.97(P=0.05)

23.1.2 Cognitive-behaviour therapy

Barlow 2000i

Barlow 2000ii

Kampman 2002

Spinhoven 1996

Subtotal (95% CI)

19/32

20/33

12/22

4/20

107

Total events: 55 (PT+AD), 82 (PT+placebo)

Heterogeneity: Tau2=0; Chi2=3.04, df=3(P=0.38); I2=1.47%

Test for overall effect: Z=1.5(P=0.13)

12/24

7/21

45

36/63

37/77

5/21

4/20

181

15.34%

10.9%

26.24%

1.33[0.76,2.35]

2.25[1.13,4.47]

1.67[1,2.78]

31.57%

31.27%

7.31%

3.61%

73.76%

1.04[0.73,1.49]

1.26[0.88,1.81]

2.29[0.97,5.39]

1[0.29,3.45]

1.2[0.94,1.53]

Total (95% CI)

131

226

100%

1.32[1.04,1.68]

Total events: 72 (PT+AD), 101 (PT+placebo)

Heterogeneity: Tau2=0.01; Chi2=5.9, df=5(P=0.32); I2=15.31%

Test for overall effect: Z=2.27(P=0.02)

Test for subgroup differences: Not applicable

Favours PT+placebo

0.1

0.2

0.5

1

2

5

10

Favours PT+AD

Analysis 23.2.   Comparison 23 SENSITIVITY5: allowed benzo: Psychotherapy
+Antidepressant vs Psychotherapy alone or +Placebo, Outcome 2 Remission at 2-4 months.

Study or subgroup

23.2.1 Behaviour therapy

de Beurs 1995i

de Beurs 1995ii

Subtotal (95% CI)

PT+AD

n/N

PT+placebo

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

8/12

8/12

24

14/24

12/21

45

13.58%

12.54%

26.12%

1.14[0.68,1.93]

1.17[0.68,2.01]

1.15[0.79,1.68]

Favours PT+placebo

0.1

0.2

0.5

1

2

5

10

Favours PT+AD

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

323

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

PT+AD

n/N

PT+placebo

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

Total events: 16 (PT+AD), 26 (PT+placebo)

Heterogeneity: Tau2=0; Chi2=0, df=1(P=0.96); I2=0%

Test for overall effect: Z=0.74(P=0.46)

23.2.2 Cognitive-behaviour therapy

Barlow 2000i

Barlow 2000ii

Kampman 2002

Subtotal (95% CI)

20/33

19/32

14/22

87

39/63

42/77

9/21

161

Total events: 53 (PT+AD), 90 (PT+placebo)

Heterogeneity: Tau2=0; Chi2=1.47, df=2(P=0.48); I2=0%

Test for overall effect: Z=0.73(P=0.47)

32.92%

30.12%

10.84%

73.88%

0.98[0.7,1.37]

1.09[0.77,1.55]

1.48[0.83,2.67]

1.09[0.87,1.36]

Total (95% CI)

111

206

100%

1.1[0.91,1.34]

Total events: 69 (PT+AD), 116 (PT+placebo)

Heterogeneity: Tau2=0; Chi2=1.54, df=4(P=0.82); I2=0%

Test for overall effect: Z=1(P=0.32)

Test for subgroup differences: Not applicable

Favours PT+placebo

0.1

0.2

0.5

1

2

5

10

Favours PT+AD

Analysis 23.3.   Comparison 23 SENSITIVITY5: allowed benzo: Psychotherapy+Antidepressant
vs Psychotherapy alone or +Placebo, Outcome 3 Global severity at 2-4 months.

Study or subgroup

PT+AD

PT+placebo

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

23.3.1 Behaviour therapy

de Beurs 1995i

de Beurs 1995ii

Subtotal ***

1.6 (0.8)

1.6 (0.8)

10

9

19

Heterogeneity: Tau2=0; Chi2=0.04, df=1(P=0.85); I2=0%

Test for overall effect: Z=2(P=0.05)

23.3.2 Cognitive-behaviour therapy

Barlow 2000i

Barlow 2000ii

Subtotal ***

0.9 (0.7)

0.9 (0.7)

33

32

65

Heterogeneity: Tau2=0; Chi2=0.42, df=1(P=0.52); I2=0%

Test for overall effect: Z=1.67(P=0.09)

2.1 (1.1)

2.3 (1.2)

1 (0.7)

1.1 (0.7)

19

18

37

63

77

140

11.31%

10.19%

21.5%

-0.52[-1.3,0.26]

-0.64[-1.46,0.19]

-0.58[-1.14,-0.01]

38.61%

39.89%

78.5%

-0.15[-0.57,0.27]

-0.35[-0.76,0.07]

-0.25[-0.55,0.04]

Total ***

84

177

100%

-0.32[-0.58,-0.06]

Heterogeneity: Tau2=0; Chi2=1.45, df=3(P=0.69); I2=0%

Test for overall effect: Z=2.41(P=0.02)

Test for subgroup differences: Chi2=0.99, df=1 (P=0.32), I2=0%

Favours treatment

-4

-2

0

2

4

Favours control

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

324

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 23.4.   Comparison 23 SENSITIVITY5: allowed benzo: Psychotherapy+Antidepressant
vs Psychotherapy alone or +Placebo, Outcome 4 Frequency of panic attacks at 2-4 months.

Study or subgroup

PT+AD

PT+placebo

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

0.5 (1.6)

1.7 (3.5)

2.3 (0.7)

2.7 (2.3)

23.4.1 Behaviour therapy

de Beurs 1995i

de Beurs 1995ii

Subtotal ***

0.2 (0.5)

0.2 (0.5)

9

9

18

Heterogeneity: Tau2=0; Chi2=0.19, df=1(P=0.66); I2=0%

Test for overall effect: Z=1.27(P=0.21)

23.4.2 Cognitive-behaviour therapy

Kampman 2002

Spinhoven 1996

Subtotal ***

2.2 (0.6)

3 (2.5)

19

20

39

Heterogeneity: Tau2=0; Chi2=0.36, df=1(P=0.55); I2=0%

Test for overall effect: Z=0.05(P=0.96)

Total ***

57

Heterogeneity: Tau2=0; Chi2=1.5, df=3(P=0.68); I2=0%

Test for overall effect: Z=0.81(P=0.42)

Test for subgroup differences: Chi2=0.95, df=1 (P=0.33), I2=0%

19

16

35

19

20

39

74

19.5%

17.91%

37.41%

-0.25[-1.04,0.55]

-0.51[-1.34,0.32]

-0.37[-0.95,0.2]

30.48%

32.11%

62.59%

-0.15[-0.79,0.49]

0.12[-0.5,0.74]

-0.01[-0.45,0.43]

100%

-0.15[-0.5,0.21]

Favours treatment

-4

-2

0

2

4

Favours control

Analysis 23.5.   Comparison 23 SENSITIVITY5: allowed benzo: Psychotherapy+Antidepressant
vs Psychotherapy alone or +Placebo, Outcome 5 Phobic avoidance at 2-4 months.

Study or subgroup

PT+AD

PT+placebo

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

23.5.1 Behaviour therapy

de Beurs 1995i

de Beurs 1995ii

Subtotal ***

4.1 (2)

4.1 (2)

10

9

19

Heterogeneity: Tau2=0; Chi2=0, df=1(P=1); I2=0%

Test for overall effect: Z=3.29(P=0)

23.5.2 Cognitive-behaviour therapy

Kampman 2002

Spinhoven 1996

Subtotal ***

1.8 (0.5)

22.5 (12)

19

20

39

Heterogeneity: Tau2=0; Chi2=0.5, df=1(P=0.48); I2=0%

Test for overall effect: Z=0.83(P=0.41)

Total ***

58

Heterogeneity: Tau2=0.09; Chi2=5, df=3(P=0.17); I2=39.96%

Test for overall effect: Z=2.21(P=0.03)

Test for subgroup differences: Chi2=4.5, df=1 (P=0.03), I2=77.77%

5.7 (1.3)

6.1 (1.9)

2 (0.6)

22.9 (11.3)

19

18

37

19

20

39

76

21.49%

20.27%

41.76%

-0.99[-1.8,-0.17]

-0.99[-1.84,-0.14]

-0.99[-1.57,-0.4]

28.59%

29.65%

58.24%

-0.35[-1,0.29]

-0.03[-0.65,0.59]

-0.19[-0.63,0.26]

100%

-0.52[-0.99,-0.06]

Favours treatment

-4

-2

0

2

4

Favours control

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

325

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 23.6.   Comparison 23 SENSITIVITY5: allowed benzo: Psychotherapy+Antidepressant
vs Psychotherapy alone or +Placebo, Outcome 6 General anxiety at 2-4 months.

Study or subgroup

PT+AD

PT+placebo

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

3.8 (1.4)

3.9 (1.5)

1.7 (1.3)

23.6.1 Behaviour therapy

de Beurs 1995i

de Beurs 1995ii

Subtotal ***

2.6 (1.3)

2.6 (1.3)

10

9

19

Heterogeneity: Tau2=0; Chi2=0, df=1(P=0.97); I2=0%

Test for overall effect: Z=2.96(P=0)

23.6.2 Cognitive-behaviour therapy

Kampman 2002

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=0.4(P=0.69)

Total ***

19

19

38

1.5 (1.7)

Heterogeneity: Tau2=0.07; Chi2=2.9, df=2(P=0.23); I2=30.95%

Test for overall effect: Z=2.13(P=0.03)

Test for subgroup differences: Chi2=2.9, df=1 (P=0.09), I2=65.46%

19

18

37

19

19

56

30.34%

28.38%

58.71%

-0.87[-1.67,-0.06]

-0.89[-1.73,-0.05]

-0.88[-1.46,-0.3]

41.29%

41.29%

-0.13[-0.77,0.51]

-0.13[-0.77,0.51]

100%

-0.57[-1.09,-0.05]

Favours treatment

-4

-2

0

2

4

Favours control

Analysis 23.7.   Comparison 23 SENSITIVITY5: allowed benzo: Psychotherapy
+Antidepressant vs Psychotherapy alone or +Placebo, Outcome 7 Depression at 2-4 months.

Study or subgroup

PT+AD

PT+placebo

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

3.5 (1.4)

3.8 (1.5)

42.7 (10)

23.7.1 Behaviour therapy

de Beurs 1995i

de Beurs 1995ii

Subtotal ***

2.6 (1)

2.6 (1)

10

9

19

Heterogeneity: Tau2=0; Chi2=0.1, df=1(P=0.75); I2=0%

Test for overall effect: Z=2.6(P=0.01)

43.5 (8.7)

23.7.2 Cognitive-behaviour therapy

Spinhoven 1996

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=0.26(P=0.79)

Total ***

20

20

39

Heterogeneity: Tau2=0.14; Chi2=3.95, df=2(P=0.14); I2=49.35%

Test for overall effect: Z=1.4(P=0.16)

Test for subgroup differences: Chi2=3.85, df=1 (P=0.05), I2=74.03%

19

18

37

20

20

57

31.33%

29.3%

60.63%

-0.68[-1.46,0.11]

-0.86[-1.7,-0.02]

-0.76[-1.34,-0.19]

39.37%

39.37%

0.08[-0.54,0.7]

0.08[-0.54,0.7]

100%

-0.43[-1.03,0.17]

Favours treatment

-4

-2

0

2

4

Favours control

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

326

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 23.9.   Comparison 23 SENSITIVITY5: allowed benzo: Psychotherapy+Antidepressant
vs Psychotherapy alone or +Placebo, Outcome 9 Dropouts for any reason within 2-4 months.

PT+AD

n/N

PT+placebo

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

5/24

3/21

45

18/63

21/77

2/21

0/20

181

10.78%

6.26%

17.04%

1.2[0.34,4.2]

1.17[0.23,6.03]

1.19[0.44,3.22]

36.52%

38.43%

5.94%

2.07%

82.96%

0.95[0.48,1.88]

1.03[0.53,2]

1.43[0.27,7.73]

9[0.52,156.91]

1.08[0.69,1.69]

Total (95% CI)

131

226

100%

1.1[0.73,1.65]

Total events: 30 (PT+AD), 49 (PT+placebo)

Heterogeneity: Tau2=0; Chi2=2.51, df=5(P=0.77); I2=0%

Test for overall effect: Z=0.43(P=0.66)

Test for subgroup differences: Not applicable

Favours treatment

0.1

0.2

0.5

1

2

5

10

Favours control

Analysis 23.10.   Comparison 23 SENSITIVITY5: allowed benzo: Psychotherapy+Antidepressant vs
Psychotherapy alone or +Placebo, Outcome 10 Dropouts due to side effects within 2-4 months.

PT+AD

n/N

PT+placebo

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

Study or subgroup

23.9.1 Behaviour therapy

de Beurs 1995i

de Beurs 1995ii

Subtotal (95% CI)

3/12

2/12

24

Total events: 5 (PT+AD), 8 (PT+placebo)

Heterogeneity: Tau2=0; Chi2=0, df=1(P=0.98); I2=0%

Test for overall effect: Z=0.34(P=0.74)

23.9.2 Cognitive-behaviour therapy

Barlow 2000i

Barlow 2000ii

Kampman 2002

Spinhoven 1996

Subtotal (95% CI)

9/33

9/32

3/22

4/20

107

Total events: 25 (PT+AD), 41 (PT+placebo)

Heterogeneity: Tau2=0; Chi2=2.5, df=3(P=0.47); I2=0%

Test for overall effect: Z=0.32(P=0.75)

Study or subgroup

23.10.1 Behaviour therapy

de Beurs 1995i

de Beurs 1995ii

Subtotal (95% CI)

1/12

1/12

24

Total events: 2 (PT+AD), 0 (PT+placebo)

Heterogeneity: Tau2=0; Chi2=0, df=1(P=0.95); I2=0%

Test for overall effect: Z=1.5(P=0.13)

23.10.2 Cognitive-behaviour therapy

Barlow 2000i

Barlow 2000ii

Kampman 2002

Spinhoven 1996

Subtotal (95% CI)

1/33

1/32

3/22

4/20

107

Total events: 9 (PT+AD), 2 (PT+placebo)

Heterogeneity: Tau2=0; Chi2=1.8, df=3(P=0.62); I2=0%

Test for overall effect: Z=1.82(P=0.07)

0/24

0/21

45

0/63

0/77

2/21

0/20

181

11.64%

11.67%

23.31%

5.77[0.25,131.92]

5.08[0.22,115.7]

5.41[0.59,49.42]

11.32%

11.31%

40.1%

13.96%

76.69%

5.65[0.24,134.91]

7.09[0.3,169.6]

1.43[0.27,7.73]

9[0.52,156.91]

3.1[0.92,10.5]

Favours treatment

0.1

0.2

0.5

1

2

5

10

Favours control

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

327

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

PT+AD

n/N

PT+placebo

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

Total (95% CI)

131

226

100%

3.53[1.21,10.27]

Total events: 11 (PT+AD), 2 (PT+placebo)

Heterogeneity: Tau2=0; Chi2=1.97, df=5(P=0.85); I2=0%

Test for overall effect: Z=2.32(P=0.02)

Test for subgroup differences: Not applicable

Favours treatment

0.1

0.2

0.5

1

2

5

10

Favours control

Analysis 23.11.   Comparison 23 SENSITIVITY5: allowed benzo: Psychotherapy+Antidepressant
vs Psychotherapy alone or +Placebo, Outcome 11 Response/remission on continued treatment.

Study or subgroup

PT+AD

n/N

PT+placebo

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

23.11.1 Behaviour therapy

Subtotal (95% CI)

Total events: 0 (PT+AD), 0 (PT+placebo)

Heterogeneity: Not applicable

Test for overall effect: Not applicable

23.11.2 Cognitive-behaviour therapy

Barlow 2000i

Barlow 2000ii

Subtotal (95% CI)

0

0

Not estimable

19/33

18/32

65

32/63

32/77

140

53.03%

46.97%

100%

1.13[0.77,1.66]

1.35[0.9,2.03]

1.23[0.93,1.63]

Total events: 37 (PT+AD), 64 (PT+placebo)

Heterogeneity: Tau2=0; Chi2=0.39, df=1(P=0.53); I2=0%

Test for overall effect: Z=1.48(P=0.14)

Total (95% CI)

65

140

100%

1.23[0.93,1.63]

Total events: 37 (PT+AD), 64 (PT+placebo)

Heterogeneity: Tau2=0; Chi2=0.39, df=1(P=0.53); I2=0%

Test for overall effect: Z=1.48(P=0.14)

Test for subgroup differences: Not applicable

Favours PT+placebo

0.1

0.2

0.5

1

2

5

10

Favours PT+AD

Analysis 23.12.   Comparison 23 SENSITIVITY5: allowed benzo: Psychotherapy+Antidepressant vs
Psychotherapy alone or +Placebo, Outcome 12 Global/Avoidance/Panic on continued treatment.

Study or subgroup

PT+AD

PT+placebo

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

23.12.1 Behaviour therapy

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Not applicable

23.12.2 Cognitive-behaviour therapy

Barlow 2000i

Barlow 2000ii

0

33

32

0

63

77

0.8 (0.9)

0.8 (0.9)

Not estimable

1.1 (0.8)

1.2 (0.9)

49.11%

50.89%

-0.37[-0.79,0.06]

-0.46[-0.88,-0.04]

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

328

Favours treatment

-4

-2

0

2

4

Favours control

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

PT+AD

PT+placebo

Std. Mean Difference

Weight

Std. Mean Difference

Subtotal ***

Mean(SD)

N

65

N

140

Heterogeneity: Tau2=0; Chi2=0.1, df=1(P=0.75); I2=0%

Test for overall effect: Z=2.73(P=0.01)

Mean(SD)

Random, 95% CI

Random, 95% CI

100%

-0.41[-0.71,-0.12]

Total ***

65

140

100%

-0.41[-0.71,-0.12]

Heterogeneity: Tau2=0; Chi2=0.1, df=1(P=0.75); I2=0%

Test for overall effect: Z=2.73(P=0.01)

Test for subgroup differences: Not applicable

Favours treatment

-4

-2

0

2

4

Favours control

Analysis 23.13.   Comparison 23 SENSITIVITY5: allowed benzo: Psychotherapy+Antidepressant vs
Psychotherapy alone or +Placebo, Outcome 13 Dropouts for any reason on continued treatment.

Study or subgroup

23.13.1 Behaviour therapy

de Beurs 1995

Subtotal (95% CI)

Total events: 1 (PT+AD), 0 (PT+placebo)

Heterogeneity: Not applicable

Test for overall effect: Z=0.69(P=0.49)

23.13.2 Cognitive-behaviour therapy

Barlow 2000i

Barlow 2000ii

Subtotal (95% CI)

PT+AD

n/N

PT+placebo

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

1/19

19

2/33

2/32

65

0/19

19

6/63

7/77

140

10.61%

10.61%

3[0.13,69.31]

3[0.13,69.31]

43.89%

45.5%

89.39%

0.64[0.14,2.98]

0.69[0.15,3.13]

0.66[0.22,1.95]

Total events: 4 (PT+AD), 13 (PT+placebo)

Heterogeneity: Tau2=0; Chi2=0, df=1(P=0.94); I2=0%

Test for overall effect: Z=0.75(P=0.45)

Total (95% CI)

84

159

100%

0.78[0.28,2.16]

Total events: 5 (PT+AD), 13 (PT+placebo)

Heterogeneity: Tau2=0; Chi2=0.8, df=2(P=0.67); I2=0%

Test for overall effect: Z=0.48(P=0.63)

Test for subgroup differences: Not applicable

Favours treatment

0.1

0.2

0.5

1

2

5

10

Favours control

Analysis 23.14.   Comparison 23 SENSITIVITY5: allowed benzo: Psychotherapy+Antidepressant vs Psychotherapy
alone or +Placebo, Outcome 14 Response/remission 6-24 months after treatment discontinuation.

Study or subgroup

23.14.1 Behaviour therapy

de Beurs 1995i

de Beurs 1995ii

Subtotal (95% CI)

Total events: 12 (PT+AD), 22 (PT+placebo)

PT+AD

n/N

PT+placebo

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

6/12

6/12

24

12/24

10/21

45

24.64%

22.7%

47.34%

1[0.5,2]

1.05[0.51,2.16]

1.02[0.62,1.69]

Favours PT+placebo

0.1

0.2

0.5

1

2

5

10

Favours PT+AD

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

329

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

PT+AD

n/N

PT+placebo

n/N

Risk Ratio

Weight

Risk Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

Heterogeneity: Tau2=0; Chi2=0.01, df=1(P=0.92); I2=0%

Test for overall effect: Z=0.09(P=0.93)

23.14.2 Cognitive-behaviour therapy

Barlow 2000i

Barlow 2000ii

Subtotal (95% CI)

8/30

8/29

59

25/62

24/73

135

Total events: 16 (PT+AD), 49 (PT+placebo)

Heterogeneity: Tau2=0; Chi2=0.24, df=1(P=0.62); I2=0%

Test for overall effect: Z=1.22(P=0.22)

26.66%

26%

52.66%

0.66[0.34,1.29]

0.84[0.43,1.65]

0.74[0.46,1.19]

Total (95% CI)

83

180

100%

0.87[0.61,1.22]

Total events: 28 (PT+AD), 71 (PT+placebo)

Heterogeneity: Tau2=0; Chi2=1.11, df=3(P=0.77); I2=0%

Test for overall effect: Z=0.82(P=0.41)

Test for subgroup differences: Not applicable

Favours PT+placebo

0.1

0.2

0.5

1

2

5

10

Favours PT+AD

Analysis 23.15.   Comparison 23 SENSITIVITY5: allowed benzo: Psychotherapy+Antidepressant vs Psychotherapy
alone or +Placebo, Outcome 15 Global/Avoidance/Panic 6-24 months after treatment discontinuation.

Study or subgroup

PT+AD

PT+placebo

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

23.15.1 Behaviour therapy

de Beurs 1995i

de Beurs 1995ii

Subtotal ***

3.3 (2.4)

3.3 (2.4)

9

9

18

Heterogeneity: Tau2=0; Chi2=0.05, df=1(P=0.83); I2=0%

Test for overall effect: Z=0.04(P=0.97)

23.15.2 Cognitive-behaviour therapy

Barlow 2000i

Barlow 2000ii

Subtotal ***

1.5 (0.9)

1.5 (0.9)

30

29

59

Heterogeneity: Tau2=0; Chi2=0.27, df=1(P=0.6); I2=0%

Test for overall effect: Z=1.34(P=0.18)

3.2 (2.7)

3.5 (2.2)

1.2 (0.9)

1.3 (0.9)

19

17

36

62

73

135

11.58%

11.16%

22.73%

0.07[-0.72,0.86]

-0.05[-0.86,0.76]

0.01[-0.56,0.58]

37.97%

39.3%

77.27%

0.29[-0.14,0.73]

0.13[-0.3,0.56]

0.21[-0.1,0.52]

Total ***

77

171

100%

0.16[-0.11,0.43]

Heterogeneity: Tau2=0; Chi2=0.69, df=3(P=0.88); I2=0%

Test for overall effect: Z=1.19(P=0.23)

Test for subgroup differences: Chi2=0.37, df=1 (P=0.54), I2=0%

W H A T ' S   N E W

Favours treatment

-4

-2

0

2

4

Favours control

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

330

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Date

Event

Description

1 November 2008

Amended

Converted to new review format.

H I S T O R Y

Protocol first published: Issue 3, 2003
Review first published: Issue 1, 2007

Date

Event

Description

9 September 2006

New citation required and conclusions
have changed

Substantive amendment

C O N T R I B U T I O N S   O F   A U T H O R S

TAF, NW and RC contributed to the planning and writing of the protocol. TAF and NW selected the studies, assessed their quality and
extracted data. All contributed to the writing of the final manuscript.

D E C L A R A T I O N S   O F   I N T E R E S T

TAF has received research funding and fees for speaking from the following pharmaceutical companies:
Asahi Kasei, Astellas, Dai-Nippon, Eisai, Eli Lilly, GlaxoSmithKline, Janssen, Kyowa Hakko, Meiji, Organon, Pfizer, Tsumura and Yoshitomi.

S O U R C E S   O F   S U P P O R T

Internal sources

• No sources of support supplied

External sources

• Health and Labour Sciences Research Grants (Research on Health Technology Assessment) H13-018, Japan.

I N D E X   T E R M S

Medical Subject Headings (MeSH)

Agoraphobia  [psychology]  [*therapy];  Antidepressive Agents  [*therapeutic use];  Combined Modality Therapy  [methods];  Panic Disorder
 [psychology]  [*therapy];  Psychotherapy  [*methods];  Randomized Controlled Trials as Topic;  Treatment Outcome

MeSH check words

Humans

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

331
